Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders Sat, 12 Sep 2026 07:33:58 +0200 https://smartbiotechscientist.com en-us © 2026 Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders yes Support this Podcast bffee544-5be7-5cde-9515-5152e5d5f223 David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist episodic false The go-to CMC and biomanufacturing podcast for bioprocess development scientists and CMC leaders scaling biologics into regulatory-ready therapies with less trial and error.


Practical, execution-focused, and strategic guidance on CMC development, tech transfer, scale-up, GMP readiness, CDMO partnerships, and manufacturing economics for biologics, cell and gene therapies, cultivated meat, and biomaterials.


Hosted by Dr. David Brühlmann, CMC strategist, former Bioprocess Innovation Manager at Merck, PhD in glycoengineering, and close to 20 years of biomanufacturing experience. Smart Biotech Scientist delivers actionable insights for the people doing the hard work of turning promising molecules into scalable, regulatory-ready therapies.


This podcast is for you if:


  • You are a process development scientist or CMC lead managing a technology transfer, scale-up, or CDMO partnership


  • You are a biologics developer working on upstream or downstream process development, cell culture optimization, or GMP manufacturing readiness


  • You are a biotech founder preparing for an IND filing or Series A fundraise, and need a CMC strategy that holds up under investor and regulatory scrutiny


  • You are building or advising an early-stage biopharma team and need to make smart manufacturing decisions with limited resources


What you will learn:


CMC strategy and regulatory planning, bioprocess scale-up from lab to clinical and commercial manufacturing, cell culture process development and media optimization, technology transfer best practices, CDMO selection and partnership management, hybrid modeling, manufacturing economics, continuous manufacturing, digitization, and Industry 4.0 in biopharma.


Top 10 life sciences podcast with 200+ episodes and guests from Merck, FUJIFILM Irvine Scientific, Cytiva, KBI Biopharma, Eppendorf, and biotech innovators worldwide.


New episodes released weekly. Subscribe and join 400+ biotech leaders already using these insights to accelerate development, reduce manufacturing costs, and de-risk scale-up.


Next Steps:


Get the 5-day CMC email course: https://smartbiotechscientist.com/#cmc


Visit the website: https://smartbiotechscientist.com


Email us: hello@bruehlmann-consulting.com

]]> Buzzsprout (https://www.buzzsprout.com) bioprocessing, biotech, biologics, cell culture, development, cmc, manufacturing, scale-up, technology, scientist, innovation, biologics David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist https://storage.buzzsprout.com/s7blf8xqcqp4ci7fz1a91jav1a1x?.jpg Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders https://smartbiotechscientist.com 286: Why Your Dormant Omics Data Is Worth More Than the Data You'll Generate Next with Nathan Lewis - Part 2 286: Why Your Dormant Omics Data Is Worth More Than the Data You'll Generate Next with Nathan Lewis - Part 2 What does it take to crack the code of protein production and why do some proteins stubbornly refuse to cooperate, despite the best efforts of scientists and engineers? Biotech’s ambitions are often limited not by vision, but by the real-world bottlenecks of host cell lines and the unpredictability of post-translational modifications.

Nathan Lewis, GRA Eminent Scholar at the Center for Molecular Medicine, Complex Carbohydrate Research Center, and Department of Biochemistry and Molecular Biology at the University of Georgia, has made a career out of asking impossible questions about glycosylation, cell line selection, and the hidden machinery at work inside every productive cell. He’s moved beyond academic curiosity—translating discoveries into applications and even launching a company, Augment Biologics, that’s taking glycoengineering from theory to practice.

Topics discussed:

  • A proximity proteomics approach to identify supporting machinery for challenging-to-express proteins like rituximab (02:36)
  • Findings from expressing the full human secretome in CHO cells, and the correlation between host cell gene expression and protein productivity (05:00)
  • Clarifying when host cell characteristics matter more than the protein construct itself (05:46)
  • Emerging evidence that protein sequence and structure influence glycosylation patterns (contrary to previous dogma) (06:49)
  • Engineering point mutations to precisely tune glycan features for improved therapeutic efficacy (09:25)
  • The vision and activities of Augment Biologics in custom glycosylation control for drug discovery (10:32)
  • The importance and barriers to open data sharing in bioprocessing, and thoughts on overcoming them (11:11)
  • The shifting landscape as technology advances and the need for high-quality, annotated data (13:54)

If this got you thinking about the data already sitting in your freezer, and what it would take to actually use it, start here. These four conversations dig into AI-ready data, actionable omics, hybrid-model digital twins, and the cell-engineering biology underneath it all.

  • Episodes 263 - 264: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David Hardy
  • Episodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey
  • Episodes 169 - 170: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo Jain
  • Episodes 77 - 78: Cell Factories Explained: How Synthetic Biology and AI Revolutionize Protein Production with Mauro Torres

If you'd rather follow the glycosylation thread, check Episodes 69 - 70: Glycoanalytics Explained with Róisín O'Flaherty

Connect with Nathan Lewis:
Website: www.lewislab.uga.edu
LinkedIn: www.linkedin.com/in/nathanelewis

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> What does it take to crack the code of protein production and why do some proteins stubbornly refuse to cooperate, despite the best efforts of scientists and engineers? Biotech’s ambitions are often limited not by vision, but by the real-world bottlenecks of host cell lines and the unpredictability of post-translational modifications.

Nathan Lewis, GRA Eminent Scholar at the Center for Molecular Medicine, Complex Carbohydrate Research Center, and Department of Biochemistry and Molecular Biology at the University of Georgia, has made a career out of asking impossible questions about glycosylation, cell line selection, and the hidden machinery at work inside every productive cell. He’s moved beyond academic curiosity—translating discoveries into applications and even launching a company, Augment Biologics, that’s taking glycoengineering from theory to practice.

Topics discussed:

  • A proximity proteomics approach to identify supporting machinery for challenging-to-express proteins like rituximab (02:36)
  • Findings from expressing the full human secretome in CHO cells, and the correlation between host cell gene expression and protein productivity (05:00)
  • Clarifying when host cell characteristics matter more than the protein construct itself (05:46)
  • Emerging evidence that protein sequence and structure influence glycosylation patterns (contrary to previous dogma) (06:49)
  • Engineering point mutations to precisely tune glycan features for improved therapeutic efficacy (09:25)
  • The vision and activities of Augment Biologics in custom glycosylation control for drug discovery (10:32)
  • The importance and barriers to open data sharing in bioprocessing, and thoughts on overcoming them (11:11)
  • The shifting landscape as technology advances and the need for high-quality, annotated data (13:54)

If this got you thinking about the data already sitting in your freezer, and what it would take to actually use it, start here. These four conversations dig into AI-ready data, actionable omics, hybrid-model digital twins, and the cell-engineering biology underneath it all.

  • Episodes 263 - 264: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David Hardy
  • Episodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey
  • Episodes 169 - 170: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo Jain
  • Episodes 77 - 78: Cell Factories Explained: How Synthetic Biology and AI Revolutionize Protein Production with Mauro Torres

If you'd rather follow the glycosylation thread, check Episodes 69 - 70: Glycoanalytics Explained with Róisín O'Flaherty

Connect with Nathan Lewis:
Website: www.lewislab.uga.edu
LinkedIn: www.linkedin.com/in/nathanelewis

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19746285 Thu, 10 Sep 2026 05:00:00 +0200 1059 286 full false 285: Why Your Dormant Omics Data Is Worth More Than the Data You'll Generate Next with Nathan Lewis - Part 1 285: Why Your Dormant Omics Data Is Worth More Than the Data You'll Generate Next with Nathan Lewis - Part 1 Dormant omics data are a goldmine for CMC innovation waiting to be unlocked. But legacy structures, poor annotation, and spreadsheet chaos hold most biotech teams back from the real breakthroughs.

Nathan Lewis, GRA Eminent Scholar at the Center for Molecular Medicine, Complex Carbohydrate Research Center, and Department of Biochemistry and Molecular Biology at the University of Georgia, has a clear message: actionable data is now within reach thanks to hybrid modeling, advanced study design, and AI as a true scientific collaborator.

Topics discussed:

  • Rethinking the dogma: controlling protein glycosylation quality from the inside out, not just by bioprocess conditions (03:00)
  • Nathan Lewis’s journey into science and bioprocessing, from unexpected college choices to pivotal advances in CHO cell engineering (05:12)
  • The evolution of omics in bioprocessing: why actionable insights, not just big datasets, should be the goal (10:49)
  • Strategic advice for structuring, annotating, and making old and new datasets ready for AI and LLM analysis (17:34)
  • The balance between mechanistic and machine learning models—when each makes sense, and why hybrid modeling is gaining ground (22:20)
  • The current and future role of digital twins in process development and why foundation models and data consortia matter for scalability (26:24)

Smart insight: The real revolution isn’t in making new data, but in unlocking the value of what already exists. Advances in AI, hybrid modeling, and collaborative standards promise to turn decades-old data into a catalyst for innovation—enabling faster, smarter, and more reliable bioprocess development.

If this got you thinking about the data already sitting in your freezer — and what it would take to actually use it — start here. These four dig into AI-ready data, actionable omics, hybrid-model digital twins, and the cell-engineering biology underneath it all.

  • Episodes 263 - 264: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David Hardy
  • Episodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey
  • Episodes 169 - 170: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo Jain
  • Episodes 77 - 78: Cell Factories Explained: How Synthetic Biology and AI Revolutionize Protein Production with Mauro Torres

If you'd rather follow the glycosylation thread, check Episodes 69 - 70: Glycoanalytics Explained with Róisín O'Flaherty

Connect with Nathan Lewis:
Website: www.lewislab.uga.edu
LinkedIn: www.linkedin.com/in/nathanelewis

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Dormant omics data are a goldmine for CMC innovation waiting to be unlocked. But legacy structures, poor annotation, and spreadsheet chaos hold most biotech teams back from the real breakthroughs.

Nathan Lewis, GRA Eminent Scholar at the Center for Molecular Medicine, Complex Carbohydrate Research Center, and Department of Biochemistry and Molecular Biology at the University of Georgia, has a clear message: actionable data is now within reach thanks to hybrid modeling, advanced study design, and AI as a true scientific collaborator.

Topics discussed:

  • Rethinking the dogma: controlling protein glycosylation quality from the inside out, not just by bioprocess conditions (03:00)
  • Nathan Lewis’s journey into science and bioprocessing, from unexpected college choices to pivotal advances in CHO cell engineering (05:12)
  • The evolution of omics in bioprocessing: why actionable insights, not just big datasets, should be the goal (10:49)
  • Strategic advice for structuring, annotating, and making old and new datasets ready for AI and LLM analysis (17:34)
  • The balance between mechanistic and machine learning models—when each makes sense, and why hybrid modeling is gaining ground (22:20)
  • The current and future role of digital twins in process development and why foundation models and data consortia matter for scalability (26:24)

Smart insight: The real revolution isn’t in making new data, but in unlocking the value of what already exists. Advances in AI, hybrid modeling, and collaborative standards promise to turn decades-old data into a catalyst for innovation—enabling faster, smarter, and more reliable bioprocess development.

If this got you thinking about the data already sitting in your freezer — and what it would take to actually use it — start here. These four dig into AI-ready data, actionable omics, hybrid-model digital twins, and the cell-engineering biology underneath it all.

  • Episodes 263 - 264: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David Hardy
  • Episodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey
  • Episodes 169 - 170: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo Jain
  • Episodes 77 - 78: Cell Factories Explained: How Synthetic Biology and AI Revolutionize Protein Production with Mauro Torres

If you'd rather follow the glycosylation thread, check Episodes 69 - 70: Glycoanalytics Explained with Róisín O'Flaherty

Connect with Nathan Lewis:
Website: www.lewislab.uga.edu
LinkedIn: www.linkedin.com/in/nathanelewis

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19746282 Tue, 08 Sep 2026 05:00:00 +0200 1826 285 full false 284: Detecting 1 in 100,000 Cells: DNA Barcoding for Smarter Clone Selection with Kent Rapp - Part 2 284: Detecting 1 in 100,000 Cells: DNA Barcoding for Smarter Clone Selection with Kent Rapp - Part 2 “Does DNA barcoding actually work?” It's the first question Kent Rapp hears from prospective customers when he pitches Biolinco's DNA barcoding platform. By his own admission, the technology can sound too good to be true.

In Part 2 of this conversation, Kent rejoins the Smart Biotech Scientist Podcast to address that skepticism head-on, unpack how subclone variability and bispecific antibody purity concerns shape customer trust, and share what it actually took to move Biolinco from a Johns Hopkins postdoc project to a company with its first paying customer.

In this episode:

  • Common pushbacks and questions from industry regarding new cell line development technologies (03:18)
  • Practical advice for resource-constrained startups developing cell lines, emphasizing efficiency and data quality over brute force automation (08:42)
  • The role and value of DNA barcoding in screening and developing robust cell lines for therapeutics (08:56)
  • Lessons learned from translating scientific innovation into a commercial product, including securing early support and customer trust (10:27)
  • Insights on adapting messaging, leveraging feedback, and understanding market needs as part of the entrepreneurial process (13:52)
  • Key differences between academic research and industry requirements for reliable, repeatable biotech tools (15:26)
  • Kent’s most important takeaway for successful cell line development: focus on collecting the right data at the right scale for informed decisions (17:14)

Smart insight: Translating innovations from academia to industry brings a new wave of challenges. Kent describes the “valley of death” separating a publishable prototype from a reliable, commercial-grade product. Academic success is often tied to novelty, publications, and grants, while industry demands repeatability, robustness, and consistent performance across labs and operators. Securing early champions and funding, iterating based on tough industry feedback, and building trust with initial partners all require resilience, and a willingness to pivot as needed. Feedback, even when harsh, becomes a “gift” that helps refine the product and business model. The secret is not a single breakthrough, but adaptability and relentless customer focus.

If this got you rethinking how you screen clones, you'll want these next. We've tackled cell line development, high-throughput screening, and the art of spotting manufacturable candidates early from a few different directions — here are four worth queuing up.

  • Episodes 117 - 118 : Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea Gough
  • Episodes 09 - 10: Revolutionizing Cell-Line Development: Unleashing the Power of Nanopens and Microenvironments with Tanner Nevill
  • Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein
  • Episodes 115 - 116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti

Connect with Kent Rapp:
LinkedIn: www.linkedin.com/in/kent-rapp
Biolinco website: www.biolinco.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> “Does DNA barcoding actually work?” It's the first question Kent Rapp hears from prospective customers when he pitches Biolinco's DNA barcoding platform. By his own admission, the technology can sound too good to be true.

In Part 2 of this conversation, Kent rejoins the Smart Biotech Scientist Podcast to address that skepticism head-on, unpack how subclone variability and bispecific antibody purity concerns shape customer trust, and share what it actually took to move Biolinco from a Johns Hopkins postdoc project to a company with its first paying customer.

In this episode:

  • Common pushbacks and questions from industry regarding new cell line development technologies (03:18)
  • Practical advice for resource-constrained startups developing cell lines, emphasizing efficiency and data quality over brute force automation (08:42)
  • The role and value of DNA barcoding in screening and developing robust cell lines for therapeutics (08:56)
  • Lessons learned from translating scientific innovation into a commercial product, including securing early support and customer trust (10:27)
  • Insights on adapting messaging, leveraging feedback, and understanding market needs as part of the entrepreneurial process (13:52)
  • Key differences between academic research and industry requirements for reliable, repeatable biotech tools (15:26)
  • Kent’s most important takeaway for successful cell line development: focus on collecting the right data at the right scale for informed decisions (17:14)

Smart insight: Translating innovations from academia to industry brings a new wave of challenges. Kent describes the “valley of death” separating a publishable prototype from a reliable, commercial-grade product. Academic success is often tied to novelty, publications, and grants, while industry demands repeatability, robustness, and consistent performance across labs and operators. Securing early champions and funding, iterating based on tough industry feedback, and building trust with initial partners all require resilience, and a willingness to pivot as needed. Feedback, even when harsh, becomes a “gift” that helps refine the product and business model. The secret is not a single breakthrough, but adaptability and relentless customer focus.

If this got you rethinking how you screen clones, you'll want these next. We've tackled cell line development, high-throughput screening, and the art of spotting manufacturable candidates early from a few different directions — here are four worth queuing up.

  • Episodes 117 - 118 : Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea Gough
  • Episodes 09 - 10: Revolutionizing Cell-Line Development: Unleashing the Power of Nanopens and Microenvironments with Tanner Nevill
  • Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein
  • Episodes 115 - 116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti

Connect with Kent Rapp:
LinkedIn: www.linkedin.com/in/kent-rapp
Biolinco website: www.biolinco.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19698311 Thu, 03 Sep 2026 05:00:00 +0200 1247 284 full false 283: Detecting 1 in 100,000 Cells: DNA Barcoding for Smarter Clone Selection with Kent Rapp - Part 1 283: Detecting 1 in 100,000 Cells: DNA Barcoding for Smarter Clone Selection with Kent Rapp - Part 1 What if the bottleneck in cell line development isn’t how many clones you screen, but how you track them?

Cloning workflows have long relied on brute force: screen more cells, automate harder, and hope that small-scale performance predicts manufacturability. But too often, the “perfect” clone in a 96-well plate turns into a dud when it reaches the bioreactor. That disconnect costs time, money, and promising therapies.

This week, host David Brühlmann welcomes Kent Rapp, Co-founder and CEO of Biolinco, an entrepreneur who’s turning the classic approach to cell line development inside out. Drawing from his background in chemical engineering and his work in biomanufacturing at Johns Hopkins University, Kent teamed up with DNA barcoding experts to pioneer a new workflow: barcode every cell, pool them, and track their true performance in the environment that matters.

Topics discussed:

  • The pitfalls of brute-force screening in traditional cell line development (03:05)
  • Kent’s background and how he was drawn to combine science, startups, and biomanufacturing (04:37)
  • Overcoming discrepancies between small-scale and large-scale screening environments (08:30)
  • How DNA barcoding allows for high-resolution, pooled clone screening (10:34)
  • Sensitivity advantages of sequencing over plate-based detection (14:21)
  • Methodology for tracking and recovering individual high-performing clones from pools (15:13)
  • Impact on speed and workflow efficiency in cell line development (17:31)
  • Regulatory and safety considerations related to DNA barcodes in cell lines (19:04)

Smart insight: According to Kent, biotech as an industry has a tendency to "automate problems instead of solve them". Rather than addressing the root causes—like lack of meaningful measurements at relevant scales—companies often throw more robots and more plates at the issue, hoping brute force will finally yield the magical clone. But real process improvement requires a rethinking of what is being measured and how those insights are generated—not just a higher throughput of the same flawed assay.

If this got you rethinking how you screen clones, you'll want these next. We've tackled cell line development, high-throughput screening, and the art of spotting manufacturable candidates early from a few different directions — here are four worth queuing up.

  • Episodes 117 - 118 : Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea Gough
  • Episodes 09 - 10: Revolutionizing Cell-Line Development: Unleashing the Power of Nanopens and Microenvironments with Tanner Nevill
  • Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein
  • Episodes 115 - 116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti

Connect with Kent Rapp:
LinkedIn: www.linkedin.com/in/kent-rapp
Biolinco website: www.biolinco.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> What if the bottleneck in cell line development isn’t how many clones you screen, but how you track them?

Cloning workflows have long relied on brute force: screen more cells, automate harder, and hope that small-scale performance predicts manufacturability. But too often, the “perfect” clone in a 96-well plate turns into a dud when it reaches the bioreactor. That disconnect costs time, money, and promising therapies.

This week, host David Brühlmann welcomes Kent Rapp, Co-founder and CEO of Biolinco, an entrepreneur who’s turning the classic approach to cell line development inside out. Drawing from his background in chemical engineering and his work in biomanufacturing at Johns Hopkins University, Kent teamed up with DNA barcoding experts to pioneer a new workflow: barcode every cell, pool them, and track their true performance in the environment that matters.

Topics discussed:

  • The pitfalls of brute-force screening in traditional cell line development (03:05)
  • Kent’s background and how he was drawn to combine science, startups, and biomanufacturing (04:37)
  • Overcoming discrepancies between small-scale and large-scale screening environments (08:30)
  • How DNA barcoding allows for high-resolution, pooled clone screening (10:34)
  • Sensitivity advantages of sequencing over plate-based detection (14:21)
  • Methodology for tracking and recovering individual high-performing clones from pools (15:13)
  • Impact on speed and workflow efficiency in cell line development (17:31)
  • Regulatory and safety considerations related to DNA barcodes in cell lines (19:04)

Smart insight: According to Kent, biotech as an industry has a tendency to "automate problems instead of solve them". Rather than addressing the root causes—like lack of meaningful measurements at relevant scales—companies often throw more robots and more plates at the issue, hoping brute force will finally yield the magical clone. But real process improvement requires a rethinking of what is being measured and how those insights are generated—not just a higher throughput of the same flawed assay.

If this got you rethinking how you screen clones, you'll want these next. We've tackled cell line development, high-throughput screening, and the art of spotting manufacturable candidates early from a few different directions — here are four worth queuing up.

  • Episodes 117 - 118 : Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea Gough
  • Episodes 09 - 10: Revolutionizing Cell-Line Development: Unleashing the Power of Nanopens and Microenvironments with Tanner Nevill
  • Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein
  • Episodes 115 - 116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti

Connect with Kent Rapp:
LinkedIn: www.linkedin.com/in/kent-rapp
Biolinco website: www.biolinco.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19697952 Tue, 01 Sep 2026 05:00:00 +0200 1313 283 full false 282: When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent with Jitendra Kumar - Part 2 282: When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent with Jitendra Kumar - Part 2 Your active ingredient is the nucleic acid. So why does a proteolipid vehicle filing include viral clearance studies, stability data and full characterisation of a membrane protein that is not the drug? Because that protein sits on the particle surface, and a component nobody has filed before is the agency's problem regardless of what you call it.

Proteolipid vehicles (PLVs), the platform Jitendra Kumar works on as Lead Scientist for Chemistry and Process Development at Entos Pharmaceuticals, represent a novel frontier in drug delivery, Instead of being taken up into an endosome and having to escape it, a PLV fuses with the cell membrane and releases cargo straight into the cytosol. That opens targets and patient groups that liver-tropic lipid nanoparticles and viral vectors have struggled to reach, and it leaves Kumar building a regulatory file with nothing on the shelf to copy.

Highlights from the episode:

  • Strategies for communicating novel technology with regulatory agencies and ensuring robust science-driven submissions (02:34)
  • What differentiates the analytical characterization of PLVs compared to standard recombinant proteins or antibodies (04:03)
  • The development plan and regulatory pathway towards clinical and commercial approval for their lead leptin therapy (05:35)
  • The evolving role of advanced techniques—such as cryo-EM—in supporting regulatory filings and product understanding (06:56)
  • Jitendra Kumar's career journey: from agricultural research in India to protein science and neurodegeneration, and how these experiences inform current PLV technology development (09:00)
  • Challenges of early diagnostics and product development in neurodegenerative diseases (14:29)
  • Decision-making differences and focus in academic versus industry biotech research (15:32)
  • Practical advice on the importance of honest technology assessment, building networks, and understanding both strengths and weaknesses (16:16)

Smart insight: A persistent challenge for groundbreaking delivery systems is the lack of established regulatory playbooks. Jitendra Kumar laid out a science-first approach: let data do the talking, supported by rigorous GLP toxicology studies and transparent communication with agencies. Regulatory bodies like Health Canada are receptive to innovation, provided that sponsors demonstrate safety, efficacy, and scientific rationale for any deviation from standard criteria.

If this conversation got you thinking about how novel delivery vehicles reach the cell — and what it takes to carry one from bench through CMC, scale-up, and regulatory review — these four episodes go deeper:

  • Episodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei
  • Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
  • Episodes 89 - 90: Scale-Up Secrets: Cracking the Code of AAV Production with Ahmed Youssef
  • Episodes 71 - 72: Effective Outsourcing: How Small Biotech Companies Can Thrive with Mark Melville

Connect with Jitendra Kumar:

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Your active ingredient is the nucleic acid. So why does a proteolipid vehicle filing include viral clearance studies, stability data and full characterisation of a membrane protein that is not the drug? Because that protein sits on the particle surface, and a component nobody has filed before is the agency's problem regardless of what you call it.

Proteolipid vehicles (PLVs), the platform Jitendra Kumar works on as Lead Scientist for Chemistry and Process Development at Entos Pharmaceuticals, represent a novel frontier in drug delivery, Instead of being taken up into an endosome and having to escape it, a PLV fuses with the cell membrane and releases cargo straight into the cytosol. That opens targets and patient groups that liver-tropic lipid nanoparticles and viral vectors have struggled to reach, and it leaves Kumar building a regulatory file with nothing on the shelf to copy.

Highlights from the episode:

  • Strategies for communicating novel technology with regulatory agencies and ensuring robust science-driven submissions (02:34)
  • What differentiates the analytical characterization of PLVs compared to standard recombinant proteins or antibodies (04:03)
  • The development plan and regulatory pathway towards clinical and commercial approval for their lead leptin therapy (05:35)
  • The evolving role of advanced techniques—such as cryo-EM—in supporting regulatory filings and product understanding (06:56)
  • Jitendra Kumar's career journey: from agricultural research in India to protein science and neurodegeneration, and how these experiences inform current PLV technology development (09:00)
  • Challenges of early diagnostics and product development in neurodegenerative diseases (14:29)
  • Decision-making differences and focus in academic versus industry biotech research (15:32)
  • Practical advice on the importance of honest technology assessment, building networks, and understanding both strengths and weaknesses (16:16)

Smart insight: A persistent challenge for groundbreaking delivery systems is the lack of established regulatory playbooks. Jitendra Kumar laid out a science-first approach: let data do the talking, supported by rigorous GLP toxicology studies and transparent communication with agencies. Regulatory bodies like Health Canada are receptive to innovation, provided that sponsors demonstrate safety, efficacy, and scientific rationale for any deviation from standard criteria.

If this conversation got you thinking about how novel delivery vehicles reach the cell — and what it takes to carry one from bench through CMC, scale-up, and regulatory review — these four episodes go deeper:

  • Episodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei
  • Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
  • Episodes 89 - 90: Scale-Up Secrets: Cracking the Code of AAV Production with Ahmed Youssef
  • Episodes 71 - 72: Effective Outsourcing: How Small Biotech Companies Can Thrive with Mark Melville

Connect with Jitendra Kumar:

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19588165 Thu, 27 Aug 2026 05:00:00 +0200 1160 281 full false 281: When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent with Jitendra Kumar - Part 1 281: When Your Delivery Vehicle Contains a Membrane Protein: CMC Decisions With No Regulatory Precedent with Jitendra Kumar - Part 1 Gene therapy only works if the cargo reaches the right cells intact. Adeno-associated viruses (AAV) and lipid nanoparticles have carried the field this far, but both share a constraint: the particle is taken up into an endosome, and the payload has to escape that compartment before it is degraded. Endosomal escape is where a large share of the dose is lost, and it is why delivery, not the genetic construct, is usually the thing that limits the therapy. Lipid nanoparticles carry a second constraint, since they tend to accumulate in the liver, which narrows the diseases they can reach. What if the particle never entered that way at all?

Jitendra Kumar, Lead Scientist for Chemistry and Process Development at Entos Pharmaceuticals, works on a platform that fuses directly with the cell membrane and releases its cargo straight into the cytosol. He came to nanoparticle design the long way, through fifteen years of structural biology on the prion protein in Frankfurt and Edmonton, which is why he thinks about particle size, packaging and diffusion the way he does.

Key topics discussed:

  • Jitendra’s career background in structural biology and journey to Entos Pharmaceuticals (03:18)
  • The scientific motivation and challenges of working with prion proteins and breaking down complex diseases (04:55)
  • Genetic medicine approaches: gain-of-function vs. loss-of-function, and the role of siRNA, ASOs, and gene delivery (06:27)
  • The FAST protein platform: origins, function, and advantages for drug delivery (07:56)
  • Manufacturing differences compared to LNPs, including the introduction of recombinant membrane protein production and related CMC complexity (09:55)
  • Scale-up and production challenges for membrane proteins, and strategies for clinical supply (11:21)
  • Clinical development progress: Phase 1/2 studies with the platform, especially for COVID vaccine delivery (12:23)
  • Focus areas for the technology, including selective lung delivery and leptin therapy for lipodystrophy (13:12)
  • Lessons for small biotech companies in phase 1/2 manufacturing strategy, technology transfer, and the value of an experienced network (14:31)
  • Balancing process robustness with speed in new biotech ventures (16:02)
  • The importance of identifying “pause steps” and must-have vs. nice-to-have features in early manufacturing processes (17:15)

Smart insight: Jitendra’s takeaway for startups: for early phases, find a partner who genuinely understands your tech and can move at your pace rather than defaulting to a big CDMO, treat your network as infrastructure, and build the ability to run production in-house. The one thing that's never up for negotiation is process robustness. The real question isn't robustness vs. speed, but how many checkpoints and safe pause points you build in so you can have both.

If this conversation got you thinking about how novel delivery vehicles reach the cell — and what it takes to carry one from bench through CMC, scale-up, and regulatory review — these four episodes go deeper:

  • Episodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei
  • Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
  • Episodes 89 - 90: Scale-Up Secrets: Cracking the Code of AAV Production with Ahmed Youssef
  • Episodes 71 - 72: Effective Outsourcing: How Small Biotech Companies Can Thrive with Mark Melville

Connect with Jitendra Kumar:

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Gene therapy only works if the cargo reaches the right cells intact. Adeno-associated viruses (AAV) and lipid nanoparticles have carried the field this far, but both share a constraint: the particle is taken up into an endosome, and the payload has to escape that compartment before it is degraded. Endosomal escape is where a large share of the dose is lost, and it is why delivery, not the genetic construct, is usually the thing that limits the therapy. Lipid nanoparticles carry a second constraint, since they tend to accumulate in the liver, which narrows the diseases they can reach. What if the particle never entered that way at all?

Jitendra Kumar, Lead Scientist for Chemistry and Process Development at Entos Pharmaceuticals, works on a platform that fuses directly with the cell membrane and releases its cargo straight into the cytosol. He came to nanoparticle design the long way, through fifteen years of structural biology on the prion protein in Frankfurt and Edmonton, which is why he thinks about particle size, packaging and diffusion the way he does.

Key topics discussed:

  • Jitendra’s career background in structural biology and journey to Entos Pharmaceuticals (03:18)
  • The scientific motivation and challenges of working with prion proteins and breaking down complex diseases (04:55)
  • Genetic medicine approaches: gain-of-function vs. loss-of-function, and the role of siRNA, ASOs, and gene delivery (06:27)
  • The FAST protein platform: origins, function, and advantages for drug delivery (07:56)
  • Manufacturing differences compared to LNPs, including the introduction of recombinant membrane protein production and related CMC complexity (09:55)
  • Scale-up and production challenges for membrane proteins, and strategies for clinical supply (11:21)
  • Clinical development progress: Phase 1/2 studies with the platform, especially for COVID vaccine delivery (12:23)
  • Focus areas for the technology, including selective lung delivery and leptin therapy for lipodystrophy (13:12)
  • Lessons for small biotech companies in phase 1/2 manufacturing strategy, technology transfer, and the value of an experienced network (14:31)
  • Balancing process robustness with speed in new biotech ventures (16:02)
  • The importance of identifying “pause steps” and must-have vs. nice-to-have features in early manufacturing processes (17:15)

Smart insight: Jitendra’s takeaway for startups: for early phases, find a partner who genuinely understands your tech and can move at your pace rather than defaulting to a big CDMO, treat your network as infrastructure, and build the ability to run production in-house. The one thing that's never up for negotiation is process robustness. The real question isn't robustness vs. speed, but how many checkpoints and safe pause points you build in so you can have both.

If this conversation got you thinking about how novel delivery vehicles reach the cell — and what it takes to carry one from bench through CMC, scale-up, and regulatory review — these four episodes go deeper:

  • Episodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei
  • Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
  • Episodes 89 - 90: Scale-Up Secrets: Cracking the Code of AAV Production with Ahmed Youssef
  • Episodes 71 - 72: Effective Outsourcing: How Small Biotech Companies Can Thrive with Mark Melville

Connect with Jitendra Kumar:

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19588157 Tue, 25 Aug 2026 05:00:00 +0200 1213 280 full false 280: Why Nanovesicles Outperform Exosomes: Scalable Drug Delivery Beyond Injectable Vaccines with Christopher Locher - Part 2 280: Why Nanovesicles Outperform Exosomes: Scalable Drug Delivery Beyond Injectable Vaccines with Christopher Locher - Part 2 For decades, drug development has been saddled with costly manufacturing, stringent biosafety requirements, and the limits of conventional carriers. But a new approach—born from cell-derived nanovesicles—could democratize access to advanced therapies and open entirely new doors for oral, topical, and even global vaccine delivery.

This week, David Brühlmann welcomes Christopher Locher, CEO and Co-founder of Versatope Therapeutics. Christopher has shaped the translation of novel vesicle technology from idea to clinical pipeline, navigating both the science and the unstructured realm of first-in-class GMP manufacturing.

Topics discussed:

  • Tackling GMP manufacturing challenges and analytics development from scratch (00:34)
  • Deciding what to outsource vs. insource as a small biotech, and the value of a robust tech transfer process (02:25)
  • Perspectives on partnering with CDMOs versus managing manufacturing and analytics in-house (02:40)
  • Geographic expansion goals and considerations for delivering low-cost biologics in underserved markets (04:26)
  • Differentiators of Versatope’s platform—endotoxin-free processes and non-pathogenic strains (05:05)
  • Key advice on critical quality attributes and early regulatory planning for Phase 1 readiness (06:19)
  • Lessons learned as a biotech founder—getting support, leveraging networks, and planning cost-effectively (07:57)
  • Understanding end users, leveraging I-Corps™, and customer discovery in early product development (09:04)
  • The science and promise of engineered nanovesicles: delivery routes, biological origins, and research applications (10:12)
  • Business models for platform out-licensing and potential for co-development partnerships (12:58)
  • Practical takeaways for scientists: setting "good enough" standards and focusing on lean, regulatory-aligned development (13:28)

Smart insight: Christopher is honest about his blind spots, learning on the fly from CMC consultants, and the practical importance of “good enough” regulatory solutions delivers sharp advice for anyone charting the long road from discovery to human trials. Think monoclonal analytics, batch consistency, and the art of prioritization, all from someone who’s made it work with a small team and limited resources

If Christopher's vesicle platform has you thinking about building a novel modality on an unconventional host, these four episodes go deeper on alternative production systems, microbial scale-up, and the CMC and cost decisions that get a first-in-class biologic to patients.

  • Episodes 217 - 218: Silkworm Biomanufacturing: From Ancient Silk Production to Phase I Vaccine Trials with Masafumi Osawa
  • Episodes 239 - 240: Continuous Microbial Manufacturing: From Genetic Instability to 40-Day E. coli Processes with Juergen Mairhofer
  • Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
  • Episodes 267 - 268: Why Affordable Insulin Is a Money Problem, Not a Science Problem with Eric Moyal

Connect with Christopher Locher:
Website: www.versatope.com
LinkedIn: www.linkedin.com/in/christopher-locher-biotech

Support the show

]]> For decades, drug development has been saddled with costly manufacturing, stringent biosafety requirements, and the limits of conventional carriers. But a new approach—born from cell-derived nanovesicles—could democratize access to advanced therapies and open entirely new doors for oral, topical, and even global vaccine delivery.

This week, David Brühlmann welcomes Christopher Locher, CEO and Co-founder of Versatope Therapeutics. Christopher has shaped the translation of novel vesicle technology from idea to clinical pipeline, navigating both the science and the unstructured realm of first-in-class GMP manufacturing.

Topics discussed:

  • Tackling GMP manufacturing challenges and analytics development from scratch (00:34)
  • Deciding what to outsource vs. insource as a small biotech, and the value of a robust tech transfer process (02:25)
  • Perspectives on partnering with CDMOs versus managing manufacturing and analytics in-house (02:40)
  • Geographic expansion goals and considerations for delivering low-cost biologics in underserved markets (04:26)
  • Differentiators of Versatope’s platform—endotoxin-free processes and non-pathogenic strains (05:05)
  • Key advice on critical quality attributes and early regulatory planning for Phase 1 readiness (06:19)
  • Lessons learned as a biotech founder—getting support, leveraging networks, and planning cost-effectively (07:57)
  • Understanding end users, leveraging I-Corps™, and customer discovery in early product development (09:04)
  • The science and promise of engineered nanovesicles: delivery routes, biological origins, and research applications (10:12)
  • Business models for platform out-licensing and potential for co-development partnerships (12:58)
  • Practical takeaways for scientists: setting "good enough" standards and focusing on lean, regulatory-aligned development (13:28)

Smart insight: Christopher is honest about his blind spots, learning on the fly from CMC consultants, and the practical importance of “good enough” regulatory solutions delivers sharp advice for anyone charting the long road from discovery to human trials. Think monoclonal analytics, batch consistency, and the art of prioritization, all from someone who’s made it work with a small team and limited resources

If Christopher's vesicle platform has you thinking about building a novel modality on an unconventional host, these four episodes go deeper on alternative production systems, microbial scale-up, and the CMC and cost decisions that get a first-in-class biologic to patients.

  • Episodes 217 - 218: Silkworm Biomanufacturing: From Ancient Silk Production to Phase I Vaccine Trials with Masafumi Osawa
  • Episodes 239 - 240: Continuous Microbial Manufacturing: From Genetic Instability to 40-Day E. coli Processes with Juergen Mairhofer
  • Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
  • Episodes 267 - 268: Why Affordable Insulin Is a Money Problem, Not a Science Problem with Eric Moyal

Connect with Christopher Locher:
Website: www.versatope.com
LinkedIn: www.linkedin.com/in/christopher-locher-biotech

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19644369 Thu, 20 Aug 2026 05:00:00 +0200 981 280 full false 279: Why Nanovesicles Outperform Exosomes: Scalable Drug Delivery Beyond Injectable Vaccines with Christopher Locher - Part 1 279: Why Nanovesicles Outperform Exosomes: Scalable Drug Delivery Beyond Injectable Vaccines with Christopher Locher - Part 1 What if the best way to unlock durable, broad-spectrum immunity is to rethink the very vessels delivering our vaccines?

While much of the industry focuses on refining existing delivery systems, Christopher Locher is charting a new course—one inspired by nature’s own couriers. Imagine a future where oral vaccines and modular, on-demand manufacturing aren’t just possibilities, but standard practice.

Christopher Locher, CEO and Co-founder of Versatope Therapeutics, brings decades of experience in drug discovery from Vertex Pharmaceuticals, Opsona Therapeutics, and Maxigen. In this episode, he shares his journey from high school science classrooms to the helm of a company pioneering recombinant extracellular transport vesicles—nanovesicles that promise to transform vaccine delivery and immunomodulation.

Topics discussed:

  • How basic scientific curiosity and the inspiration from teachers sparked Christopher's career in biotechnology (03:39)
  • The unmet needs in vaccine development for infectious and parasitic diseases, especially in regions below the equator (04:17)
  • Engineering nanovesicles as immunomodulators and drug delivery vehicles, using microbial bioreactors for production (06:38)
  • Co-producing proteins and vesicles in a single process, and the flexibility of the platform (08:28)
  • Key benefits of Versatope's platform, such as cost efficiency, stability, and commercial scalability compared to mammalian exosomes (09:53)
  • Prospects for multi-specific vaccines and the future direction for scalable bioprocessing (11:47)
  • Adapting manufacturing processes and overcoming logistical challenges—from COVID-related shutdowns to supply chain bottlenecks (12:21)
  • Strategies for navigating evolving regulatory requirements with agencies like the FDA, and experience with fast IND allowance (14:53)
  • Analytical and characterization challenges of complex nanovesicle-based products versus simpler platforms like antibodies (17:30)
  • The vision for decentralized or local vaccine manufacturing, especially in resource-limited settings (19:12)

Smart insight: Christopher Locher highlighted that the FDA allowed their IND submission for a universal influenza vaccine in less than a month after review—and notably, with no hold clinical questions—when it was submitted just before the Christmas holidays and allowed on January 19th, 2025. This rapid regulatory turn-around was made possible by a strong regulatory team and collaborative CDMO efforts, showcasing how innovative platforms and well-prepared submissions can accelerate early-stage clinical development in biotech.

If Christopher's vesicle platform has you thinking about building a novel modality on an unconventional host, these four episodes go deeper on alternative production systems, microbial scale-up, and the CMC and cost decisions that get a first-in-class biologic to patients.

  • Episodes 217 - 218: Silkworm Biomanufacturing: From Ancient Silk Production to Phase I Vaccine Trials with Masafumi Osawa
  • Episodes 239 - 240: Continuous Microbial Manufacturing: From Genetic Instability to 40-Day E. coli Processes with Juergen Mairhofer
  • Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
  • Episodes 267 - 268: Why Affordable Insulin Is a Money Problem, Not a Science Problem with Eric Moyal

Connect with Christopher Locher:
Website: www.versatope.com
LinkedIn: www.linkedin.com/in/christopher-locher-biotech

Support the show

]]> What if the best way to unlock durable, broad-spectrum immunity is to rethink the very vessels delivering our vaccines?

While much of the industry focuses on refining existing delivery systems, Christopher Locher is charting a new course—one inspired by nature’s own couriers. Imagine a future where oral vaccines and modular, on-demand manufacturing aren’t just possibilities, but standard practice.

Christopher Locher, CEO and Co-founder of Versatope Therapeutics, brings decades of experience in drug discovery from Vertex Pharmaceuticals, Opsona Therapeutics, and Maxigen. In this episode, he shares his journey from high school science classrooms to the helm of a company pioneering recombinant extracellular transport vesicles—nanovesicles that promise to transform vaccine delivery and immunomodulation.

Topics discussed:

  • How basic scientific curiosity and the inspiration from teachers sparked Christopher's career in biotechnology (03:39)
  • The unmet needs in vaccine development for infectious and parasitic diseases, especially in regions below the equator (04:17)
  • Engineering nanovesicles as immunomodulators and drug delivery vehicles, using microbial bioreactors for production (06:38)
  • Co-producing proteins and vesicles in a single process, and the flexibility of the platform (08:28)
  • Key benefits of Versatope's platform, such as cost efficiency, stability, and commercial scalability compared to mammalian exosomes (09:53)
  • Prospects for multi-specific vaccines and the future direction for scalable bioprocessing (11:47)
  • Adapting manufacturing processes and overcoming logistical challenges—from COVID-related shutdowns to supply chain bottlenecks (12:21)
  • Strategies for navigating evolving regulatory requirements with agencies like the FDA, and experience with fast IND allowance (14:53)
  • Analytical and characterization challenges of complex nanovesicle-based products versus simpler platforms like antibodies (17:30)
  • The vision for decentralized or local vaccine manufacturing, especially in resource-limited settings (19:12)

Smart insight: Christopher Locher highlighted that the FDA allowed their IND submission for a universal influenza vaccine in less than a month after review—and notably, with no hold clinical questions—when it was submitted just before the Christmas holidays and allowed on January 19th, 2025. This rapid regulatory turn-around was made possible by a strong regulatory team and collaborative CDMO efforts, showcasing how innovative platforms and well-prepared submissions can accelerate early-stage clinical development in biotech.

If Christopher's vesicle platform has you thinking about building a novel modality on an unconventional host, these four episodes go deeper on alternative production systems, microbial scale-up, and the CMC and cost decisions that get a first-in-class biologic to patients.

  • Episodes 217 - 218: Silkworm Biomanufacturing: From Ancient Silk Production to Phase I Vaccine Trials with Masafumi Osawa
  • Episodes 239 - 240: Continuous Microbial Manufacturing: From Genetic Instability to 40-Day E. coli Processes with Juergen Mairhofer
  • Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
  • Episodes 267 - 268: Why Affordable Insulin Is a Money Problem, Not a Science Problem with Eric Moyal

Connect with Christopher Locher:
Website: www.versatope.com
LinkedIn: www.linkedin.com/in/christopher-locher-biotech

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19644354 Tue, 18 Aug 2026 05:00:00 +0200 1336 279 full false 278: Your Bioprocess Data Already Holds 35% More Yield: From End-to-End Models to Digital Twins with Ignasi Bofarull-Manzano - Part 2 278: Your Bioprocess Data Already Holds 35% More Yield: From End-to-End Models to Digital Twins with Ignasi Bofarull-Manzano - Part 2 How do you take a model that works in process development and get it accepted for use in GMP manufacturing? That question stalls most bioprocess modeling projects before they start. Ignasi Bofarull-Manzano, Senior Data Scientist and CMC Consultant at Körber Pharma, pushes back on the premise: the process you run today is already governed by a mathematical model, fitted once at small scale during process characterization and then left untouched for years, even as the process shifts.

Part 1 separated digital models from digital shadows and digital twins, and made the case for starting with the decision rather than the data. Part 2 goes into the plant: what regulators actually require, what the numbers looked like on a real biologics process, and where a team should start on Monday morning.

Topics covered:

  • Core differences—and surprising similarities—between modeling in development versus manufacturing (02:35)
  • Regulatory requirements: credibility assessments, model risk, and validation steps for digital twins (05:07)
  • Real-world example: How deploying an end-to-end process model led to 35% yield increase for Takeda, and considerations for ROI in manufacturing (08:34)
  • Advice for startup leaders on when to invest in modeling and how to scale efforts case-by-case (11:42)
  • Steps for scientists new to modeling: identifying bottlenecks, starting simple, and proving value offline before scaling up (12:26)
  • The importance of understanding basic statistics before relying on AI-generated models (15:22)
  • A stepwise summary for deploying digital modeling effectively in biotech (16:01)

Smart insight: The digital twin is the last step, not the first. Identify the bottleneck, build the simplest model that supports the decision, and concatenate it end to end so you can see how a parameter moves final drug substance quality rather than one unit operation's output. Prove the value offline. Only then connect interfaces, because that is where the cost and the validation burden live. Teams that lead with the twin arrive at the C-level with a proof of concept and no evidence. Teams that lead with the offline model arrive with a number.

Before a digital twin can earn its keep, you need connected data, the right model, and a clear decision for it to support. These four episodes cover that ground — data silos, hybrid and mechanistic modeling, and twins built to survive regulatory scrutiny.

  • Episodes 215 - 216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya Burkov
  • Episodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov
  • Episodes 17 - 18: How Extracting Gold From Your Data Accelerates Process Development with Ioscani Jiménez del Val
  • Episodes 263 - 264: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David Hardy

Connect with Ignasi Bofarull-Manzano:

LinkedIn: www.linkedin.com/in/ignasi-bofarull

Körber Pharma website: www.koerber-pharma.com

Support the show

]]> How do you take a model that works in process development and get it accepted for use in GMP manufacturing? That question stalls most bioprocess modeling projects before they start. Ignasi Bofarull-Manzano, Senior Data Scientist and CMC Consultant at Körber Pharma, pushes back on the premise: the process you run today is already governed by a mathematical model, fitted once at small scale during process characterization and then left untouched for years, even as the process shifts.

Part 1 separated digital models from digital shadows and digital twins, and made the case for starting with the decision rather than the data. Part 2 goes into the plant: what regulators actually require, what the numbers looked like on a real biologics process, and where a team should start on Monday morning.

Topics covered:

  • Core differences—and surprising similarities—between modeling in development versus manufacturing (02:35)
  • Regulatory requirements: credibility assessments, model risk, and validation steps for digital twins (05:07)
  • Real-world example: How deploying an end-to-end process model led to 35% yield increase for Takeda, and considerations for ROI in manufacturing (08:34)
  • Advice for startup leaders on when to invest in modeling and how to scale efforts case-by-case (11:42)
  • Steps for scientists new to modeling: identifying bottlenecks, starting simple, and proving value offline before scaling up (12:26)
  • The importance of understanding basic statistics before relying on AI-generated models (15:22)
  • A stepwise summary for deploying digital modeling effectively in biotech (16:01)

Smart insight: The digital twin is the last step, not the first. Identify the bottleneck, build the simplest model that supports the decision, and concatenate it end to end so you can see how a parameter moves final drug substance quality rather than one unit operation's output. Prove the value offline. Only then connect interfaces, because that is where the cost and the validation burden live. Teams that lead with the twin arrive at the C-level with a proof of concept and no evidence. Teams that lead with the offline model arrive with a number.

Before a digital twin can earn its keep, you need connected data, the right model, and a clear decision for it to support. These four episodes cover that ground — data silos, hybrid and mechanistic modeling, and twins built to survive regulatory scrutiny.

  • Episodes 215 - 216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya Burkov
  • Episodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov
  • Episodes 17 - 18: How Extracting Gold From Your Data Accelerates Process Development with Ioscani Jiménez del Val
  • Episodes 263 - 264: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David Hardy

Connect with Ignasi Bofarull-Manzano:

LinkedIn: www.linkedin.com/in/ignasi-bofarull

Körber Pharma website: www.koerber-pharma.com

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19588150 Thu, 13 Aug 2026 05:00:00 +0200 1124 278 full false 277: Your Bioprocess Data Already Holds 35% More Yield: From End-to-End Models to Digital Twins with Ignasi Bofarull-Manzano - Part 1 277: Your Bioprocess Data Already Holds 35% More Yield: From End-to-End Models to Digital Twins with Ignasi Bofarull-Manzano - Part 1 Most bioprocess teams believe a digital twin demands vast datasets and sophisticated models. Ignasi Bofarull-Manzano argues both assumptions are wrong, and that the data already sitting in your Excel files, historians and ELNs is probably enough to start.

Ignasi Bofarull-Manzano, Senior Data Scientist and CMC Consultant at Körber Pharma, breaks down what a digital twin actually is, where modeling pays back fastest across the product lifecycle, and how to tell a real business case from an expensive proof of concept.

In this episode:

  • Misconceptions about data requirements for digital twins—why quality and context of data matter more than sheer quantity (02:40)
  • Ignasi’s journey from curiosity in biology to a career in data science, modeling, and digital twins (04:31)
  • Clear distinctions between digital models, digital shadows, and digital twins, explained with real-world analogies (06:42)
  • How to approach digital development when faced with legacy data silos and scattered analytics (09:56)
  • The importance of starting with a focused business need instead of chasing trends or buzzwords (12:28)
  • Insights into where modeling truly delivers value in the product lifecycle—development versus manufacturing (13:11)
  • Strategies for small companies to leverage digitalization and data from the ground up (15:56)
  • An accessible overview of physics-informed AI, physical AI, and hybrid modeling—and their application in bioprocessing (18:15)
  • The comparative advantages of physics-informed AI versus hybrid models in different bioprocessing contexts (24:45)

Smart insight: Do not start with the model. Start with the bottleneck. Identify the business need first, then the decision the model must support, then the minimum data required for that context of use. Build the model offline, concatenate it end to end across unit operations rather than optimizing one in isolation, and prove the value before connecting a single interface. Teams that skip this sequence end up building models because models sound impressive, and those projects get expensive before they get useful.

Before a digital twin can earn its keep, you need connected data, the right model, and a clear decision for it to support. These four episodes cover that ground — data silos, hybrid and mechanistic modeling, and twins built to survive regulatory scrutiny.

  • Episodes 215 - 216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya Burkov
  • Episodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov
  • Episodes 17 - 18: How Extracting Gold From Your Data Accelerates Process Development with Ioscani Jiménez del Val
  • Episodes 263 - 264: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David Hardy

Connect with Ignasi Bofarull-Manzano:

LinkedIn: www.linkedin.com/in/ignasi-bofarull

Körber Pharma website: www.koerber-pharma.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Most bioprocess teams believe a digital twin demands vast datasets and sophisticated models. Ignasi Bofarull-Manzano argues both assumptions are wrong, and that the data already sitting in your Excel files, historians and ELNs is probably enough to start.

Ignasi Bofarull-Manzano, Senior Data Scientist and CMC Consultant at Körber Pharma, breaks down what a digital twin actually is, where modeling pays back fastest across the product lifecycle, and how to tell a real business case from an expensive proof of concept.

In this episode:

  • Misconceptions about data requirements for digital twins—why quality and context of data matter more than sheer quantity (02:40)
  • Ignasi’s journey from curiosity in biology to a career in data science, modeling, and digital twins (04:31)
  • Clear distinctions between digital models, digital shadows, and digital twins, explained with real-world analogies (06:42)
  • How to approach digital development when faced with legacy data silos and scattered analytics (09:56)
  • The importance of starting with a focused business need instead of chasing trends or buzzwords (12:28)
  • Insights into where modeling truly delivers value in the product lifecycle—development versus manufacturing (13:11)
  • Strategies for small companies to leverage digitalization and data from the ground up (15:56)
  • An accessible overview of physics-informed AI, physical AI, and hybrid modeling—and their application in bioprocessing (18:15)
  • The comparative advantages of physics-informed AI versus hybrid models in different bioprocessing contexts (24:45)

Smart insight: Do not start with the model. Start with the bottleneck. Identify the business need first, then the decision the model must support, then the minimum data required for that context of use. Build the model offline, concatenate it end to end across unit operations rather than optimizing one in isolation, and prove the value before connecting a single interface. Teams that skip this sequence end up building models because models sound impressive, and those projects get expensive before they get useful.

Before a digital twin can earn its keep, you need connected data, the right model, and a clear decision for it to support. These four episodes cover that ground — data silos, hybrid and mechanistic modeling, and twins built to survive regulatory scrutiny.

  • Episodes 215 - 216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya Burkov
  • Episodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov
  • Episodes 17 - 18: How Extracting Gold From Your Data Accelerates Process Development with Ioscani Jiménez del Val
  • Episodes 263 - 264: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David Hardy

Connect with Ignasi Bofarull-Manzano:

LinkedIn: www.linkedin.com/in/ignasi-bofarull

Körber Pharma website: www.koerber-pharma.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19588136 Tue, 11 Aug 2026 05:00:00 +0200 1662 277 full false 276: From Lab-Scale Molding to GMP: Manufacturing a Collagen Implant for the Clinic with Eva-Maria Balet - Part 2 276: From Lab-Scale Molding to GMP: Manufacturing a Collagen Implant for the Clinic with Eva-Maria Balet - Part 2 How do you turn a lab-born regenerative medical device into a solution that surgeons actually want to use and investors want to back? The path from academic innovation to clinical adoption is full of practical hurdles and strategic pivots, where compelling science alone isn’t enough.

David Brühlmann welcomes back Eva-Maria Balet, whose journey spans tissue engineering research at EPFL to leading Regenosca through first-in-human trials, fundraising, and an executive MBA completed while running the company. This conversation covers the practical realities behind that journey, from quality control to clinical setbacks to investor pitches.

Topics discussed:

  • Defining TissueSpan’s regulatory path and quality control as a medical device (02:49)
  • The significance of first-in-human studies and what early clinical experience reveals (04:11)
  • Selecting an initial clinical indication and opportunities for technology expansion (05:50)
  • Realistic assessment of where soft tissue repair technologies apply—and where they do not (07:18)
  • The stepwise progression from in vitro to animal models in product development (08:18)
  • Navigating setbacks, including the impact of Covid-19 on clinical trials, and the value of adaptability (10:36)
  • Bridging science and business in biotech fundraising and communication (12:15)
  • Key takeaways from pursuing an executive MBA alongside building a biotech company (13:42)
  • The importance of collaboration, mindset, and meaningful networks in driving biotech innovation (15:19)

Smart insight: The transition from scientist to founder brought its own learning curve. Eva-Maria pursued an executive MBA while running Regenosca, and points to financial and business vocabulary as the skill she'd have built earlier if she could. For a technical founder or CMC lead, the lesson isn't to become a business generalist, it's that the moment you're translating a manufacturing process or clinical dataset into an investor pitch, fluency in the language of accounting, market strategy, and cost structure becomes as load-bearing as the science itself.

This week's episode with Eva-Maria Balet steps out of bioprocessing into MedTech, following a collagen scaffold from EPFL lab bench to first-in-human implant. These back-catalog picks cover similar ground: what it takes to win investor buy-in beyond the science, the discipline of turning a lab process into GMP manufacturing, why regulatory classification shapes a product's whole trajectory, and what it really takes to commercialize a lab discovery.

  • Episodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome
  • Episodes 257 - 258: Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing with Milan Tomic
  • Episodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer
  • Episodes 183 - 184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee Ho

Connect with Eva-Maria Balet:
LinkedIn: www.linkedin.com/in/eva-maria-balet-72561737
Regenosca website: www.regenosca.com

Support the show

]]> How do you turn a lab-born regenerative medical device into a solution that surgeons actually want to use and investors want to back? The path from academic innovation to clinical adoption is full of practical hurdles and strategic pivots, where compelling science alone isn’t enough.

David Brühlmann welcomes back Eva-Maria Balet, whose journey spans tissue engineering research at EPFL to leading Regenosca through first-in-human trials, fundraising, and an executive MBA completed while running the company. This conversation covers the practical realities behind that journey, from quality control to clinical setbacks to investor pitches.

Topics discussed:

  • Defining TissueSpan’s regulatory path and quality control as a medical device (02:49)
  • The significance of first-in-human studies and what early clinical experience reveals (04:11)
  • Selecting an initial clinical indication and opportunities for technology expansion (05:50)
  • Realistic assessment of where soft tissue repair technologies apply—and where they do not (07:18)
  • The stepwise progression from in vitro to animal models in product development (08:18)
  • Navigating setbacks, including the impact of Covid-19 on clinical trials, and the value of adaptability (10:36)
  • Bridging science and business in biotech fundraising and communication (12:15)
  • Key takeaways from pursuing an executive MBA alongside building a biotech company (13:42)
  • The importance of collaboration, mindset, and meaningful networks in driving biotech innovation (15:19)

Smart insight: The transition from scientist to founder brought its own learning curve. Eva-Maria pursued an executive MBA while running Regenosca, and points to financial and business vocabulary as the skill she'd have built earlier if she could. For a technical founder or CMC lead, the lesson isn't to become a business generalist, it's that the moment you're translating a manufacturing process or clinical dataset into an investor pitch, fluency in the language of accounting, market strategy, and cost structure becomes as load-bearing as the science itself.

This week's episode with Eva-Maria Balet steps out of bioprocessing into MedTech, following a collagen scaffold from EPFL lab bench to first-in-human implant. These back-catalog picks cover similar ground: what it takes to win investor buy-in beyond the science, the discipline of turning a lab process into GMP manufacturing, why regulatory classification shapes a product's whole trajectory, and what it really takes to commercialize a lab discovery.

  • Episodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome
  • Episodes 257 - 258: Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing with Milan Tomic
  • Episodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer
  • Episodes 183 - 184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee Ho

Connect with Eva-Maria Balet:
LinkedIn: www.linkedin.com/in/eva-maria-balet-72561737
Regenosca website: www.regenosca.com

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19515285 Thu, 06 Aug 2026 05:00:00 +0200 1074 276 full false 275: From Lab-Scale Molding to GMP: Manufacturing a Collagen Implant for the Clinic with Eva-Maria Balet - Part 1 275: From Lab-Scale Molding to GMP: Manufacturing a Collagen Implant for the Clinic with Eva-Maria Balet - Part 1 Imagine a wound too large for the body to close on its own. That's the problem Eva-Maria Balet set out to solve, not with living cells, but with a structural bridge that lets the body's own healing mechanisms do the rest.

In this episode, David Brühlmann welcomes Eva-Maria Balet, Co-Founder & CEO of Regenosca. Trained at EPFL, Eva-Maria brought her fascination with cellular "factories" from academia straight into entrepreneurship. Rather than chasing elegant science for its own sake, she built her company around a single principle: start with a real clinical need and build backward, collaborating with clinicians from day one so every experiment serves a patient.

Highlights & Topics:

  • Why starting with clinical needs—not just scientific excitement—creates meaningful real-world impact in life sciences (02:38)
  • How Eva-Maria’s fascination with biotechnology guided her from cell factories to developing scaffolds for tissue repair (03:51)
  • The unmet challenges in current soft tissue repair treatments and where new solutions are needed (05:51)
  • What makes Regenosca’s fully-engineered collagen implant, TissueSpan, different from existing meshes and biological materials (07:09)
  • The biological mechanisms behind tissue regeneration using a temporary collagen scaffold (08:28)
  • Translating lab-scale research into a robust, scalable, and regulatory-compliant production process (10:34)
  • The practical realities and hurdles of navigating the medical device vs. biologic regulatory pathways (11:59)
  • Advice on building regulatory expertise into your founding team or leveraging consultants effectively (13:31)
  • The importance of interdisciplinary teams and trust when forming biotech startups (14:36)

Smart insight: Eva-Maria put it plainly: what works in the lab has to work reliably every single time you produce it for a patient. That shift, from proving a concept to controlling a process, from raw materials through in-process controls to final product testing, is the same discipline any CMC scientist recognizes: science alone doesn't get a product to patients. Reproducibility does.

This week's episode with Eva-Maria Balet steps out of bioprocessing into MedTech, following a collagen scaffold from EPFL lab bench to first-in-human implant. These back-catalog picks cover similar ground: what it takes to win investor buy-in beyond the science, the discipline of turning a lab process into GMP manufacturing, why regulatory classification shapes a product's whole trajectory, and what it really takes to commercialize a lab discovery.

  • Episodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome
  • Episodes 257 - 258: Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing with Milan Tomic
  • Episodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer
  • Episodes 183 - 184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee Ho

Connect with Eva-Maria Balet:
LinkedIn: www.linkedin.com/in/eva-maria-balet-72561737
Regenosca website: www.regenosca.com

Support the show

]]> Imagine a wound too large for the body to close on its own. That's the problem Eva-Maria Balet set out to solve, not with living cells, but with a structural bridge that lets the body's own healing mechanisms do the rest.

In this episode, David Brühlmann welcomes Eva-Maria Balet, Co-Founder & CEO of Regenosca. Trained at EPFL, Eva-Maria brought her fascination with cellular "factories" from academia straight into entrepreneurship. Rather than chasing elegant science for its own sake, she built her company around a single principle: start with a real clinical need and build backward, collaborating with clinicians from day one so every experiment serves a patient.

Highlights & Topics:

  • Why starting with clinical needs—not just scientific excitement—creates meaningful real-world impact in life sciences (02:38)
  • How Eva-Maria’s fascination with biotechnology guided her from cell factories to developing scaffolds for tissue repair (03:51)
  • The unmet challenges in current soft tissue repair treatments and where new solutions are needed (05:51)
  • What makes Regenosca’s fully-engineered collagen implant, TissueSpan, different from existing meshes and biological materials (07:09)
  • The biological mechanisms behind tissue regeneration using a temporary collagen scaffold (08:28)
  • Translating lab-scale research into a robust, scalable, and regulatory-compliant production process (10:34)
  • The practical realities and hurdles of navigating the medical device vs. biologic regulatory pathways (11:59)
  • Advice on building regulatory expertise into your founding team or leveraging consultants effectively (13:31)
  • The importance of interdisciplinary teams and trust when forming biotech startups (14:36)

Smart insight: Eva-Maria put it plainly: what works in the lab has to work reliably every single time you produce it for a patient. That shift, from proving a concept to controlling a process, from raw materials through in-process controls to final product testing, is the same discipline any CMC scientist recognizes: science alone doesn't get a product to patients. Reproducibility does.

This week's episode with Eva-Maria Balet steps out of bioprocessing into MedTech, following a collagen scaffold from EPFL lab bench to first-in-human implant. These back-catalog picks cover similar ground: what it takes to win investor buy-in beyond the science, the discipline of turning a lab process into GMP manufacturing, why regulatory classification shapes a product's whole trajectory, and what it really takes to commercialize a lab discovery.

  • Episodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome
  • Episodes 257 - 258: Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing with Milan Tomic
  • Episodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer
  • Episodes 183 - 184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee Ho

Connect with Eva-Maria Balet:
LinkedIn: www.linkedin.com/in/eva-maria-balet-72561737
Regenosca website: www.regenosca.com

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19515276 Tue, 04 Aug 2026 05:00:00 +0200 999 275 full false 274: Engineering iPSC Neurons for Parkinson's: From 3% Survival to Durable Graft with Bilal Fares - Part 2 274: Engineering iPSC Neurons for Parkinson's: From 3% Survival to Durable Graft with Bilal Fares - Part 2 Building a cell therapy company is hard. Building a genetically engineered iPSC therapy for the brain, on a preclinical budget, is one of the hardest translational problems in biotech. Every experiment has to move the program closer to an IND, or it's motion without progress.

That's the operating constraint Bilal Fares faces as CEO and co-founder of AzureCell, the University of Geneva spin-off engineering neuroprotective iPSC neurons for Parkinson's disease. In Part 2, he walks through how his team decides what to build, where AI and synthetic biology genuinely accelerate a CMC roadmap, and the four founder lessons he wishes he'd internalized earlier, including his conviction that scientists who use AI will replace those who don't.

Topics discussed include:

  • Strategies for prioritizing experiments and narrowing focus with limited resources (03:33)
  • How business opportunity validation programs helped define a product roadmap (04:08)
  • Integrating AI and synthetic biology into research programs—and where these tools do, and don’t, accelerate development (05:07)
  • Building a cell therapy platform for personalized approaches in neurological diseases beyond Parkinson’s (06:38)
  • Lessons learned in biotech leadership and why tackling big problems matters (08:08)
  • Key advice for aspiring biotech entrepreneurs: kill your own solutions quickly, and learn from others (09:27)
  • The importance of having a strong team and how a powerful mission attracts top talent (12:21)
  • AzureCell’s near-term plans and future goals, including upcoming fundraising and R&D milestones (13:30)

Smart insight: What separates successful biotech ventures from the rest? According to Bilal Fares, it is not just technical skill but mindset. First, choose a problem large enough to be worth the struggle. Second, try to “kill your solution as fast as possible”—engage experts, enter competitions, and seek brutal feedback early so you can pivot, improve, or abandon as needed. And finally, plan with the end (approval, patients, impact) always in sight.

If you enjoyed this, check out these episodes on cell therapy, where engineered cells can survive and do more than replace what's lost: Michael Rome's investor lens rounds it out for founders facing the same funding realities.

  • Episodes 269 - 270: How to Turn Mesenchymal Stem Cells into Programmable Cancer Delivery Vehicles with Jun Yung Woo
  • Episodes 253 - 254: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta Lee
  • Episodes 249 - 250: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez
  • Episodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome

Connect with Bilal Fares:
LinkedIn: www.linkedin.com/in/b-fares
AzureCell website: www.azurecell.co
Email: info@azurecell.co

Support the show

]]> Building a cell therapy company is hard. Building a genetically engineered iPSC therapy for the brain, on a preclinical budget, is one of the hardest translational problems in biotech. Every experiment has to move the program closer to an IND, or it's motion without progress.

That's the operating constraint Bilal Fares faces as CEO and co-founder of AzureCell, the University of Geneva spin-off engineering neuroprotective iPSC neurons for Parkinson's disease. In Part 2, he walks through how his team decides what to build, where AI and synthetic biology genuinely accelerate a CMC roadmap, and the four founder lessons he wishes he'd internalized earlier, including his conviction that scientists who use AI will replace those who don't.

Topics discussed include:

  • Strategies for prioritizing experiments and narrowing focus with limited resources (03:33)
  • How business opportunity validation programs helped define a product roadmap (04:08)
  • Integrating AI and synthetic biology into research programs—and where these tools do, and don’t, accelerate development (05:07)
  • Building a cell therapy platform for personalized approaches in neurological diseases beyond Parkinson’s (06:38)
  • Lessons learned in biotech leadership and why tackling big problems matters (08:08)
  • Key advice for aspiring biotech entrepreneurs: kill your own solutions quickly, and learn from others (09:27)
  • The importance of having a strong team and how a powerful mission attracts top talent (12:21)
  • AzureCell’s near-term plans and future goals, including upcoming fundraising and R&D milestones (13:30)

Smart insight: What separates successful biotech ventures from the rest? According to Bilal Fares, it is not just technical skill but mindset. First, choose a problem large enough to be worth the struggle. Second, try to “kill your solution as fast as possible”—engage experts, enter competitions, and seek brutal feedback early so you can pivot, improve, or abandon as needed. And finally, plan with the end (approval, patients, impact) always in sight.

If you enjoyed this, check out these episodes on cell therapy, where engineered cells can survive and do more than replace what's lost: Michael Rome's investor lens rounds it out for founders facing the same funding realities.

  • Episodes 269 - 270: How to Turn Mesenchymal Stem Cells into Programmable Cancer Delivery Vehicles with Jun Yung Woo
  • Episodes 253 - 254: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta Lee
  • Episodes 249 - 250: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez
  • Episodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome

Connect with Bilal Fares:
LinkedIn: www.linkedin.com/in/b-fares
AzureCell website: www.azurecell.co
Email: info@azurecell.co

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19515258 Thu, 30 Jul 2026 05:00:00 +0200 1015 274 full false 273: Engineering iPSC Neurons for Parkinson's: From 3% Survival to Durable Graft with Bilal Fares - Part 1 273: Engineering iPSC Neurons for Parkinson's: From 3% Survival to Durable Graft with Bilal Fares - Part 1 Transplant iPSC-derived neurons into a Parkinson's brain and 97% die before they can restore function. Of the 3% that survive, most face the same pathogenic environment that killed the original neurons. This is the compounded biology and CMC problem defining CNS cell therapy today.

Bilal Fares, neuroscience entrepreneur and co-founder of AzureCell, is translating a University of Geneva discovery into a genetically engineered iPSC platform built to solve it: neurons that don't just replace what Parkinson's destroyed, but survive the fire that destroyed them.

Topics discussed:

  • Why Bilal believes cell therapy is the future of medicine for brain diseases, and the limitations of other approaches (03:06)
  • Bilal’s personal story and the events that guided his commitment to Parkinson’s research and entrepreneurship (04:03)
  • How cell therapy might move beyond simply replacing lost neurons—using engineered cells to produce therapeutics directly in the brain (09:05)
  • The neuroprotective technology AzureCell is developing, designed to shield transplanted neurons from Parkinson’s disease mechanisms (11:31)
  • The platform approach: combining stem cell technologies, genetic engineering, and allogeneic off-the-shelf cell banks (12:38)
  • Why the blood-brain barrier makes cell therapy a necessary approach for certain conditions (13:26)
  • The current status of Azure’s preclinical and manufacturing development, and their plans for clinical translation (14:31)
  • Why previous therapies for Parkinson’s have fallen short, and how cell therapy might sidestep these limitations (15:57)
  • The potential and challenges of using cell therapy for other brain diseases like Alzheimer’s (18:26)

Smart insight: The next generation of CNS cell therapy isn't only about neuron replacement. Bilal's thesis reframes transplanted cells as engineered biological factories inside the brain: producing neuroprotective proteins, modulating disease mechanisms in real time, and eventually enabling preventative treatment as manufacturing costs fall and safety matures.

If you enjoyed this, check out these episodes on cell therapy, where engineered cells can survive and do more than replace what's lost: Michael Rome's investor lens rounds it out for founders facing the same funding realities.

  • Episodes 269 - 270: How to Turn Mesenchymal Stem Cells into Programmable Cancer Delivery Vehicles with Jun Yung Woo
  • Episodes 253 - 254: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta Lee
  • Episodes 249 - 250: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez
  • Episodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome

Connect with Bilal Fares:
LinkedIn: www.linkedin.com/in/b-fares
AzureCell website: www.azurecell.co
Email: info@azurecell.co

Support the show

]]> Transplant iPSC-derived neurons into a Parkinson's brain and 97% die before they can restore function. Of the 3% that survive, most face the same pathogenic environment that killed the original neurons. This is the compounded biology and CMC problem defining CNS cell therapy today.

Bilal Fares, neuroscience entrepreneur and co-founder of AzureCell, is translating a University of Geneva discovery into a genetically engineered iPSC platform built to solve it: neurons that don't just replace what Parkinson's destroyed, but survive the fire that destroyed them.

Topics discussed:

  • Why Bilal believes cell therapy is the future of medicine for brain diseases, and the limitations of other approaches (03:06)
  • Bilal’s personal story and the events that guided his commitment to Parkinson’s research and entrepreneurship (04:03)
  • How cell therapy might move beyond simply replacing lost neurons—using engineered cells to produce therapeutics directly in the brain (09:05)
  • The neuroprotective technology AzureCell is developing, designed to shield transplanted neurons from Parkinson’s disease mechanisms (11:31)
  • The platform approach: combining stem cell technologies, genetic engineering, and allogeneic off-the-shelf cell banks (12:38)
  • Why the blood-brain barrier makes cell therapy a necessary approach for certain conditions (13:26)
  • The current status of Azure’s preclinical and manufacturing development, and their plans for clinical translation (14:31)
  • Why previous therapies for Parkinson’s have fallen short, and how cell therapy might sidestep these limitations (15:57)
  • The potential and challenges of using cell therapy for other brain diseases like Alzheimer’s (18:26)

Smart insight: The next generation of CNS cell therapy isn't only about neuron replacement. Bilal's thesis reframes transplanted cells as engineered biological factories inside the brain: producing neuroprotective proteins, modulating disease mechanisms in real time, and eventually enabling preventative treatment as manufacturing costs fall and safety matures.

If you enjoyed this, check out these episodes on cell therapy, where engineered cells can survive and do more than replace what's lost: Michael Rome's investor lens rounds it out for founders facing the same funding realities.

  • Episodes 269 - 270: How to Turn Mesenchymal Stem Cells into Programmable Cancer Delivery Vehicles with Jun Yung Woo
  • Episodes 253 - 254: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta Lee
  • Episodes 249 - 250: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez
  • Episodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome

Connect with Bilal Fares:
LinkedIn: www.linkedin.com/in/b-fares
AzureCell website: www.azurecell.co
Email: info@azurecell.co

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19515241 Tue, 28 Jul 2026 05:00:00 +0200 1247 273 full false 272: From Static Scaffolds to Dynamic Matrices: Hydrogels for Animal-Free 3D Cell Culture with Jan Hunik and Matt Baker - Part 2 272: From Static Scaffolds to Dynamic Matrices: Hydrogels for Animal-Free 3D Cell Culture with Jan Hunik and Matt Baker - Part 2 How much of your research lives and dies on the bench? Not because the idea isn’t sound, but because building reproducible, scalable biomaterials remains an unsolved puzzle.

Jan Hunik and Matt Baker from MosaMatrix discuss the practical challenges and lessons learned from spinning out a biomaterials company from academia. They explore the importance of quality standards in biotech startups, building a team with complementary skills, and the realities of developing reproducible 3D culture systems for modern research.

Topics discussed:

  • The critical gap between invention and reliable biomaterial products (00:40)
  • Building company culture around quality standards from day one (02:45)
  • Balancing scientific curiosity and business direction as co-founders (03:51)
  • The impact of university partnerships on early-stage company development (06:02)
  • Funding challenges and strategies for sustaining a biotech startup (06:47)
  • Advice for scientists on addressing real market needs versus pushing technology (07:50)
  • The importance of listening to customers and investors to find product-market fit (09:19)
  • Vision for scaling technology and breaking even in the next two to three years (10:06)
  • New frontiers in engineering living materials and animal-free biomaterials (12:04)

Smart insight: The MosaMatrix team believes good materials are key to unlocking advances in drug discovery, cellular agriculture, and engineered living materials. Their story is a testament to how integrating rigorous science, business discipline, and a razor focus on real-world needs can create the foundation for lasting innovation in biotech.

If this conversation got you thinking about biomaterials, scale-out manufacturing, and what it takes to turn a chemistry breakthrough into a fundable company, these episodes explore the same ground from complementary angles.

  • Episodes 221 - 222: From 2D Cultures to Advanced 3D Cell Models for Preclinical Research with Catarina Brito
  • Episodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome
  • Episodes 265 - 266: From Human Variability to Automated Precision: Accelerating Cell and Gene Therapy Manufacturing Scale-Out with Farlan Veraitch
  • Episodes 223 - 224: From Cultivated Meat to Chocolate: Rethinking Cellular Agriculture Scale-Up with Steven Lang

Connect with Jan Hunik and Matt Baker:

Support the show

]]> How much of your research lives and dies on the bench? Not because the idea isn’t sound, but because building reproducible, scalable biomaterials remains an unsolved puzzle.

Jan Hunik and Matt Baker from MosaMatrix discuss the practical challenges and lessons learned from spinning out a biomaterials company from academia. They explore the importance of quality standards in biotech startups, building a team with complementary skills, and the realities of developing reproducible 3D culture systems for modern research.

Topics discussed:

  • The critical gap between invention and reliable biomaterial products (00:40)
  • Building company culture around quality standards from day one (02:45)
  • Balancing scientific curiosity and business direction as co-founders (03:51)
  • The impact of university partnerships on early-stage company development (06:02)
  • Funding challenges and strategies for sustaining a biotech startup (06:47)
  • Advice for scientists on addressing real market needs versus pushing technology (07:50)
  • The importance of listening to customers and investors to find product-market fit (09:19)
  • Vision for scaling technology and breaking even in the next two to three years (10:06)
  • New frontiers in engineering living materials and animal-free biomaterials (12:04)

Smart insight: The MosaMatrix team believes good materials are key to unlocking advances in drug discovery, cellular agriculture, and engineered living materials. Their story is a testament to how integrating rigorous science, business discipline, and a razor focus on real-world needs can create the foundation for lasting innovation in biotech.

If this conversation got you thinking about biomaterials, scale-out manufacturing, and what it takes to turn a chemistry breakthrough into a fundable company, these episodes explore the same ground from complementary angles.

  • Episodes 221 - 222: From 2D Cultures to Advanced 3D Cell Models for Preclinical Research with Catarina Brito
  • Episodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome
  • Episodes 265 - 266: From Human Variability to Automated Precision: Accelerating Cell and Gene Therapy Manufacturing Scale-Out with Farlan Veraitch
  • Episodes 223 - 224: From Cultivated Meat to Chocolate: Rethinking Cellular Agriculture Scale-Up with Steven Lang

Connect with Jan Hunik and Matt Baker:

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19475901 Thu, 23 Jul 2026 05:00:00 +0200 951 272 full false 271: From Static Scaffolds to Dynamic Matrices: Hydrogels for Animal-Free 3D Cell Culture with Jan Hunik and Matt Baker - Part 1 271: From Static Scaffolds to Dynamic Matrices: Hydrogels for Animal-Free 3D Cell Culture with Jan Hunik and Matt Baker - Part 1 What if the real obstacle in 3D cell culture and tissue engineering isn't the cells, but the very ground they grow on?

For years, cell culture has relied on flat plastic and passive scaffolds. But biology doesn't happen on a petri dish—cells live in three dimensions, surrounded by a dynamic environment that talks back, adapts, and shapes development in ways static gels simply cannot.

That's the premise behind MosaMatrix, a novel hydrogel platform designed to transform how we grow cells, engineer tissues, and screen new drugs created by CEO Jan Hunik and CTO Matt Baker.

Topics discussed:

  • Why traditional flat, 2D cell culture misses the biological mark and what a responsive cell environment really looks like (00:27)
  • The origins of MosaMatrix and the realization that new, adaptive hydrogels were needed for dynamic cell culture (04:45)
  • What makes the MosaMatrix hydrogel different—and why passive scaffolds fall short (06:12)
  • Mechanical and biological characteristics that define hydrogel performance, from stiffness to stress relaxation (07:48)
  • The company's pivot from 3D tissue printing to focusing on high-throughput 3D cell culture for drug discovery (08:42)
  • Advantages of a non-animal-derived, reproducible matrix for research and industry (10:20)
  • Strategies for obtaining real-world customer feedback and working in consortia with academia and industry partners (11:51)
  • Key hurdles in quality control, reproducibility, and measuring success in the emerging field (16:05)
  • Challenges with standardizing organoids and the move to smaller, more automatable culture systems (17:50)
  • The impact of automation and data consistency for scaling up 3D cell culture (18:14)

Smart insight: MosaMatrix validates its hydrogel not through internal R&D alone, but through direct collaboration with academic and industry partners — testing performance across cell types and culture media. This includes a ~50-company consortium building next-gen 3D cell culture tools and a new consortium improving kidney dialysis with living human cells. The partnerships surface real variables, like how much culture media composition affects results, that continually shape product development.

If this conversation got you thinking about biomaterials, scale-out manufacturing, and what it takes to turn a chemistry breakthrough into a fundable company, these episodes explore the same ground from complementary angles.

  • Episodes 221 - 222: From 2D Cultures to Advanced 3D Cell Models for Preclinical Research with Catarina Brito
  • Episodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome
  • Episodes 265 - 266: From Human Variability to Automated Precision: Accelerating Cell and Gene Therapy Manufacturing Scale-Out with Farlan Veraitch
  • Episodes 223 - 224: From Cultivated Meat to Chocolate: Rethinking Cellular Agriculture Scale-Up with Steven Lang

Connect with Jan Hunik and Matt Baker:

Support the show

]]> What if the real obstacle in 3D cell culture and tissue engineering isn't the cells, but the very ground they grow on?

For years, cell culture has relied on flat plastic and passive scaffolds. But biology doesn't happen on a petri dish—cells live in three dimensions, surrounded by a dynamic environment that talks back, adapts, and shapes development in ways static gels simply cannot.

That's the premise behind MosaMatrix, a novel hydrogel platform designed to transform how we grow cells, engineer tissues, and screen new drugs created by CEO Jan Hunik and CTO Matt Baker.

Topics discussed:

  • Why traditional flat, 2D cell culture misses the biological mark and what a responsive cell environment really looks like (00:27)
  • The origins of MosaMatrix and the realization that new, adaptive hydrogels were needed for dynamic cell culture (04:45)
  • What makes the MosaMatrix hydrogel different—and why passive scaffolds fall short (06:12)
  • Mechanical and biological characteristics that define hydrogel performance, from stiffness to stress relaxation (07:48)
  • The company's pivot from 3D tissue printing to focusing on high-throughput 3D cell culture for drug discovery (08:42)
  • Advantages of a non-animal-derived, reproducible matrix for research and industry (10:20)
  • Strategies for obtaining real-world customer feedback and working in consortia with academia and industry partners (11:51)
  • Key hurdles in quality control, reproducibility, and measuring success in the emerging field (16:05)
  • Challenges with standardizing organoids and the move to smaller, more automatable culture systems (17:50)
  • The impact of automation and data consistency for scaling up 3D cell culture (18:14)

Smart insight: MosaMatrix validates its hydrogel not through internal R&D alone, but through direct collaboration with academic and industry partners — testing performance across cell types and culture media. This includes a ~50-company consortium building next-gen 3D cell culture tools and a new consortium improving kidney dialysis with living human cells. The partnerships surface real variables, like how much culture media composition affects results, that continually shape product development.

If this conversation got you thinking about biomaterials, scale-out manufacturing, and what it takes to turn a chemistry breakthrough into a fundable company, these episodes explore the same ground from complementary angles.

  • Episodes 221 - 222: From 2D Cultures to Advanced 3D Cell Models for Preclinical Research with Catarina Brito
  • Episodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome
  • Episodes 265 - 266: From Human Variability to Automated Precision: Accelerating Cell and Gene Therapy Manufacturing Scale-Out with Farlan Veraitch
  • Episodes 223 - 224: From Cultivated Meat to Chocolate: Rethinking Cellular Agriculture Scale-Up with Steven Lang

Connect with Jan Hunik and Matt Baker:

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19475889 Tue, 21 Jul 2026 05:00:00 +0200 1208 271 full false 270: How to Turn Mesenchymal Stem Cells into Programmable Cancer Delivery Vehicles with Jun Yung Woo - Part 2 270: How to Turn Mesenchymal Stem Cells into Programmable Cancer Delivery Vehicles with Jun Yung Woo - Part 2 In the biotech industry, advancing cell-based therapies is not just about innovation. It's about solving real gaps where conventional treatments fall short, especially against complex, aggressive tumors.

In this episode of the Smart Biotech Scientist Podcast, host David Brühlmann welcomes Jun Yung Woo, Co-Founder of AGEM Bio, who offers an in-depth look at the science and strategy behind engineered mesenchymal stem cells (MSCs), with a focus on why glioblastoma is the right proving ground for the platform.

Topics discussed:

  • Why glioblastoma is the right Phase I indication: infiltrative growth, immunosuppression, and STING pathway deficiencies that make GBM uniquely suited to the platform (02:43)
  • The surgical workflow: intracavity MSC delivery during tumor resection, oral 5-FC administration, and how engineered cells act as local bioreactors in the resection cavity (04:05)
  • Mechanisms by which engineered MSCs target heterogeneous and invasive tumors through shared vulnerabilities rather than antigen recognition (05:58)
  • Overcoming immune rejection with allogeneic therapies and the unique immunological profile of MSCs (07:32)
  • Manufacturing and scale-up: addressing donor variability, GMP production, and building a reproducible process (09:16)
  • Why GMP manufacturing should be designed in from the earliest stages of research (10:50)
  • Beyond glioblastoma: expanding the platform to other solid tumors, regenerative medicine, and chronic inflammatory disease (11:27)
  • Strategies for international trial expansion and partnerships beyond Singapore (12:41)
  • Reframing MSCs from stem cell therapy to programmable delivery platform: the MSC 2.0 thesis (14:10)

Smart insight: The shift Jun Yung articulates is from treating stem cells as the therapy to treating them as programmable therapeutic vehicles. Once you can reliably engineer, manufacture, and preserve their function, the limitation is no longer what the cell naturally does. It becomes what biology you can encode into it. Glioblastoma is the proving ground, and the platform's reach extends to liver cancers, sarcomas, peritoneal malignancies, and chronic inflammatory disease.

These episodes expand on the same themes of MSC biology, cell engineering, and the challenges of scaling consistent, functional cell therapies:

  • Episodes 179 - 180 : How Mesenchymal Stromal Cells Are Transforming Care for Diabetes and Autoimmune Diseases with Lindsay Davies
  • Episodes 253 - 254: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta Lee
  • Episodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei
  • Episodes 129 - 130: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason Foster

Connect with Jun Yung Woo:

LinkedIn: www.linkedin.com/in/junyungwoo

AGEM Bio website: www.agem.bio

Email: yung@agem.bio

Support the show

]]> In the biotech industry, advancing cell-based therapies is not just about innovation. It's about solving real gaps where conventional treatments fall short, especially against complex, aggressive tumors.

In this episode of the Smart Biotech Scientist Podcast, host David Brühlmann welcomes Jun Yung Woo, Co-Founder of AGEM Bio, who offers an in-depth look at the science and strategy behind engineered mesenchymal stem cells (MSCs), with a focus on why glioblastoma is the right proving ground for the platform.

Topics discussed:

  • Why glioblastoma is the right Phase I indication: infiltrative growth, immunosuppression, and STING pathway deficiencies that make GBM uniquely suited to the platform (02:43)
  • The surgical workflow: intracavity MSC delivery during tumor resection, oral 5-FC administration, and how engineered cells act as local bioreactors in the resection cavity (04:05)
  • Mechanisms by which engineered MSCs target heterogeneous and invasive tumors through shared vulnerabilities rather than antigen recognition (05:58)
  • Overcoming immune rejection with allogeneic therapies and the unique immunological profile of MSCs (07:32)
  • Manufacturing and scale-up: addressing donor variability, GMP production, and building a reproducible process (09:16)
  • Why GMP manufacturing should be designed in from the earliest stages of research (10:50)
  • Beyond glioblastoma: expanding the platform to other solid tumors, regenerative medicine, and chronic inflammatory disease (11:27)
  • Strategies for international trial expansion and partnerships beyond Singapore (12:41)
  • Reframing MSCs from stem cell therapy to programmable delivery platform: the MSC 2.0 thesis (14:10)

Smart insight: The shift Jun Yung articulates is from treating stem cells as the therapy to treating them as programmable therapeutic vehicles. Once you can reliably engineer, manufacture, and preserve their function, the limitation is no longer what the cell naturally does. It becomes what biology you can encode into it. Glioblastoma is the proving ground, and the platform's reach extends to liver cancers, sarcomas, peritoneal malignancies, and chronic inflammatory disease.

These episodes expand on the same themes of MSC biology, cell engineering, and the challenges of scaling consistent, functional cell therapies:

  • Episodes 179 - 180 : How Mesenchymal Stromal Cells Are Transforming Care for Diabetes and Autoimmune Diseases with Lindsay Davies
  • Episodes 253 - 254: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta Lee
  • Episodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei
  • Episodes 129 - 130: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason Foster

Connect with Jun Yung Woo:

LinkedIn: www.linkedin.com/in/junyungwoo

AGEM Bio website: www.agem.bio

Email: yung@agem.bio

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19412225 Thu, 16 Jul 2026 05:00:00 +0200 1014 270 full false 269: How to Turn Mesenchymal Stem Cells into Programmable Cancer Delivery Vehicles with Jun Yung Woo - Part 1 269: How to Turn Mesenchymal Stem Cells into Programmable Cancer Delivery Vehicles with Jun Yung Woo - Part 1 What if the answer to solid tumor therapy isn’t about making immune cells smarter—but about rethinking what a therapeutic cell can do For years, mesenchymal stem cells (MSCs) have turned heads for their ability to home in on damaged tissue, yet their clinical utility has lagged behind the hype. What would it take to transform MSCs from passive healers into precision vehicles for next-generation cancer treatment?

This week, David Brühlmann sits down with Jun Yung Woo, Co-Founder of AGEM Bio, who’s devoted nearly two decades to decoding and reimagining the potential of MSCs. From engineering stress-resilient cells to pioneering dual-payload therapeutic platforms, Jun Yung Woo bridges fundamental biology and real-world clinical translation.

Topics discussed:

  • The case for understanding cell biology before focusing on process scale-up in bioprocessing (02:38)
  • Jun Yung Woo's personal and scientific journey toward developing engineered MSC therapeutics (04:36)
  • How MSCs sense their environment and exert therapeutic effects via secreted factors, rather than tissue replacement (08:28)
  • Key differences between MSC therapies and immune cell therapies like CAR T cells (10:35)
  • Overview of non-viral engineering platforms, and the importance of intracellular trafficking for modifying MSCs (12:23)
  • Design of AGEM Bio's dual-payload MSC product (cytosine deaminase and interferon beta) to induce highly localized tumor stress and immune activation (14:10)
  • Strategies for controlling MSC targeting and minimizing off-target effects, including the use of prodrug activation and localized cell delivery (17:23)
  • Study results from treating companion animals with engineered MSCs, and observations of tumor regression and possible signs of immune memory (20:29)
  • Open questions about the durability of antitumor responses and future directions for clinical research (22:34)

Smart insight: Jun Yung Woo challenges the rush toward bioprocess scale-up, arguing that a deeper understanding of cellular biology should come before manufacturing cells at scale. This episode explores how scaling the wrong biology can derail entire therapeutic platforms—and why aligning process development with cellular function may be critical for clinical success.

These episodes expand on the same themes of MSC biology, cell engineering, and the challenges of scaling consistent, functional cell therapies:

  • Episodes 179 - 180 : How Mesenchymal Stromal Cells Are Transforming Care for Diabetes and Autoimmune Diseases with Lindsay Davies
  • Episodes 253 - 254: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta Lee
  • Episodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei
  • Episodes 129 - 130: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason Foster

Connect with Jun Yung Woo:

LinkedIn: www.linkedin.com/in/junyungwoo

AGEM Bio website: www.agem.bio

Email: yung@agem.bio

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> What if the answer to solid tumor therapy isn’t about making immune cells smarter—but about rethinking what a therapeutic cell can do For years, mesenchymal stem cells (MSCs) have turned heads for their ability to home in on damaged tissue, yet their clinical utility has lagged behind the hype. What would it take to transform MSCs from passive healers into precision vehicles for next-generation cancer treatment?

This week, David Brühlmann sits down with Jun Yung Woo, Co-Founder of AGEM Bio, who’s devoted nearly two decades to decoding and reimagining the potential of MSCs. From engineering stress-resilient cells to pioneering dual-payload therapeutic platforms, Jun Yung Woo bridges fundamental biology and real-world clinical translation.

Topics discussed:

  • The case for understanding cell biology before focusing on process scale-up in bioprocessing (02:38)
  • Jun Yung Woo's personal and scientific journey toward developing engineered MSC therapeutics (04:36)
  • How MSCs sense their environment and exert therapeutic effects via secreted factors, rather than tissue replacement (08:28)
  • Key differences between MSC therapies and immune cell therapies like CAR T cells (10:35)
  • Overview of non-viral engineering platforms, and the importance of intracellular trafficking for modifying MSCs (12:23)
  • Design of AGEM Bio's dual-payload MSC product (cytosine deaminase and interferon beta) to induce highly localized tumor stress and immune activation (14:10)
  • Strategies for controlling MSC targeting and minimizing off-target effects, including the use of prodrug activation and localized cell delivery (17:23)
  • Study results from treating companion animals with engineered MSCs, and observations of tumor regression and possible signs of immune memory (20:29)
  • Open questions about the durability of antitumor responses and future directions for clinical research (22:34)

Smart insight: Jun Yung Woo challenges the rush toward bioprocess scale-up, arguing that a deeper understanding of cellular biology should come before manufacturing cells at scale. This episode explores how scaling the wrong biology can derail entire therapeutic platforms—and why aligning process development with cellular function may be critical for clinical success.

These episodes expand on the same themes of MSC biology, cell engineering, and the challenges of scaling consistent, functional cell therapies:

  • Episodes 179 - 180 : How Mesenchymal Stromal Cells Are Transforming Care for Diabetes and Autoimmune Diseases with Lindsay Davies
  • Episodes 253 - 254: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta Lee
  • Episodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei
  • Episodes 129 - 130: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason Foster

Connect with Jun Yung Woo:

LinkedIn: www.linkedin.com/in/junyungwoo

AGEM Bio website: www.agem.bio

Email: yung@agem.bio

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19412223 Tue, 14 Jul 2026 05:00:00 +0200 1572 269 full false 268: Why Affordable Insulin Is a Money Problem, Not a Science Problem with Eric Moyal - Part 2 268: Why Affordable Insulin Is a Money Problem, Not a Science Problem with Eric Moyal - Part 2 Why does life-saving insulin cost hundreds of dollars a month for patients, when manufacturing costs are just a fraction of that price? What if the nonprofit model could change everything for affordable access?

In the pharmaceutical industry, affordability and access remain two of the biggest hurdles for patients, especially when the economics of essential medicines seem stacked against them.

Eric Moyal, founder of Project Insulin, is rewriting the rules of biosimilar development. Coming from a fundraising and nonprofit background rather than the pharma inside track, Eric built Project Insulin not to chase profits, but to deliver an essential therapy at a price real people can afford.

Topics covered:

  • Key differences between nonprofit and for-profit models in biotech, especially around fundraising, incentives, and revenue (00:02)
  • The intricate balance between development costs, operating expenses, and setting an affordable price point (00:06)
  • Innovative distribution models to eliminate price inflation by middlemen, including direct-to-patient and clinic partnerships (00:08)
  • Major roadblocks in reinventing drug distribution and the importance of building the right partnerships early on (00:10)
  • Advice for founders and scientists exploring solutions to drug affordability, including corporate structure, fundraising, and perseverance (00:12)
  • Lessons learned after five years building Project Insulin, emphasizing the value of assembling the right team and listening to feedback (00:13)
  • Realistic expectations for Project Insulin’s next five years and the primary goals on the horizon (00:16)
  • The broader need for affordable generic drugs and the broken promise of the current patent system (00:17)
  • How to connect with Project Insulin and support its mission (00:18)

Smart insight: Generic medicines should be affordable. Ensuring low-cost, accessible generics is essential to restoring the original balance between pharmaceutical innovation and public access, and it requires collective effort beyond any single player.

If you enjoyed this episode, you might want to listen to these within a broader set of discussions on biologics affordability, CMC strategy, and bioprocessing realities — from the economic barriers blocking patient access and regulatory decision-making for biosimilars, to CDMO selection for resource-constrained teams:

  • Episode 136: 5 Roadblocks to Affordable Biologics (And How to Overcome Them)
  • Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner
  • Episodes 103 - 104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma Mostafa

Connect with Eric Moyal:

Next step: If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Support the show

]]> Why does life-saving insulin cost hundreds of dollars a month for patients, when manufacturing costs are just a fraction of that price? What if the nonprofit model could change everything for affordable access?

In the pharmaceutical industry, affordability and access remain two of the biggest hurdles for patients, especially when the economics of essential medicines seem stacked against them.

Eric Moyal, founder of Project Insulin, is rewriting the rules of biosimilar development. Coming from a fundraising and nonprofit background rather than the pharma inside track, Eric built Project Insulin not to chase profits, but to deliver an essential therapy at a price real people can afford.

Topics covered:

  • Key differences between nonprofit and for-profit models in biotech, especially around fundraising, incentives, and revenue (00:02)
  • The intricate balance between development costs, operating expenses, and setting an affordable price point (00:06)
  • Innovative distribution models to eliminate price inflation by middlemen, including direct-to-patient and clinic partnerships (00:08)
  • Major roadblocks in reinventing drug distribution and the importance of building the right partnerships early on (00:10)
  • Advice for founders and scientists exploring solutions to drug affordability, including corporate structure, fundraising, and perseverance (00:12)
  • Lessons learned after five years building Project Insulin, emphasizing the value of assembling the right team and listening to feedback (00:13)
  • Realistic expectations for Project Insulin’s next five years and the primary goals on the horizon (00:16)
  • The broader need for affordable generic drugs and the broken promise of the current patent system (00:17)
  • How to connect with Project Insulin and support its mission (00:18)

Smart insight: Generic medicines should be affordable. Ensuring low-cost, accessible generics is essential to restoring the original balance between pharmaceutical innovation and public access, and it requires collective effort beyond any single player.

If you enjoyed this episode, you might want to listen to these within a broader set of discussions on biologics affordability, CMC strategy, and bioprocessing realities — from the economic barriers blocking patient access and regulatory decision-making for biosimilars, to CDMO selection for resource-constrained teams:

  • Episode 136: 5 Roadblocks to Affordable Biologics (And How to Overcome Them)
  • Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner
  • Episodes 103 - 104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma Mostafa

Connect with Eric Moyal:

Next step: If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19412220 Thu, 09 Jul 2026 05:00:00 +0200 1246 268 full false 267: Why Affordable Insulin Is a Money Problem, Not a Science Problem with Eric Moyal - Part 1 267: Why Affordable Insulin Is a Money Problem, Not a Science Problem with Eric Moyal - Part 1 Insulin was first discovered over a century ago—yet in the United States, 1 in 5 insulin-dependent patients still ration their lifesaving supply. Why is a molecule so essential, and so well understood, still so out of reach for so many?

Eric Moyal, founder of Project Insulin, decided to challenge not just the science, but the business model itself. With a background in nonprofit fundraising—not drug development—he’s building a biosimilar insulin glargine and promising to sell it directly to patients at cost, insurance or not.

Topics discussed include:

  • The origins of the insulin affordability crisis and the impact of profit-driven healthcare systems (04:27)
  • How over a million Americans are forced to ration their insulin every month, and the broader impact on patients’ (lives 06:37)
  • The advantages and challenges of approaching drug development with a background outside of biotech (08:37)
  • The fundraising-focused strategy for overcoming scientific and technical hurdles in developing biosimilar insulin (09:17)
  • Technical details on Project Insulin’s development process, including selection of CDMOs, importance of analytical data, and process challenges like reverse-phase cleaving and crystallization (11:16)
  • The impact of recent FDA regulatory changes on the development and approval pathway for biosimilars in the U.S. (15:45)

Smart insight: A nonprofit approach to essential medicines could reshape the future for patients who depend on them. By removing shareholder expectations and focusing on affordability and access, leaders like Eric Moyal are proving new paths are possible—not through incremental science alone, but through bold re-imaginings of how science serves the public.

If you enjoyed this episode, you might want to listen to these within a broader set of discussions on biologics affordability, CMC strategy, and bioprocessing realities — from the economic barriers blocking patient access and regulatory decision-making for biosimilars, to CDMO selection for resource-constrained teams:

  • Episode 136: 5 Roadblocks to Affordable Biologics (And How to Overcome Them)
  • Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner
  • Episodes 103 - 104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma Mostafa

Connect with Eric Moyal:

Next step: If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Support the show

]]> Insulin was first discovered over a century ago—yet in the United States, 1 in 5 insulin-dependent patients still ration their lifesaving supply. Why is a molecule so essential, and so well understood, still so out of reach for so many?

Eric Moyal, founder of Project Insulin, decided to challenge not just the science, but the business model itself. With a background in nonprofit fundraising—not drug development—he’s building a biosimilar insulin glargine and promising to sell it directly to patients at cost, insurance or not.

Topics discussed include:

  • The origins of the insulin affordability crisis and the impact of profit-driven healthcare systems (04:27)
  • How over a million Americans are forced to ration their insulin every month, and the broader impact on patients’ (lives 06:37)
  • The advantages and challenges of approaching drug development with a background outside of biotech (08:37)
  • The fundraising-focused strategy for overcoming scientific and technical hurdles in developing biosimilar insulin (09:17)
  • Technical details on Project Insulin’s development process, including selection of CDMOs, importance of analytical data, and process challenges like reverse-phase cleaving and crystallization (11:16)
  • The impact of recent FDA regulatory changes on the development and approval pathway for biosimilars in the U.S. (15:45)

Smart insight: A nonprofit approach to essential medicines could reshape the future for patients who depend on them. By removing shareholder expectations and focusing on affordability and access, leaders like Eric Moyal are proving new paths are possible—not through incremental science alone, but through bold re-imaginings of how science serves the public.

If you enjoyed this episode, you might want to listen to these within a broader set of discussions on biologics affordability, CMC strategy, and bioprocessing realities — from the economic barriers blocking patient access and regulatory decision-making for biosimilars, to CDMO selection for resource-constrained teams:

  • Episode 136: 5 Roadblocks to Affordable Biologics (And How to Overcome Them)
  • Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner
  • Episodes 103 - 104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma Mostafa

Connect with Eric Moyal:

Next step: If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19412216 Tue, 07 Jul 2026 05:00:00 +0200 1112 267 full false 266: From Human Variability to Automated Precision: Accelerating Cell and Gene Therapy Manufacturing Scale-Out with Farlan Veraitch - Part 2 266: From Human Variability to Automated Precision: Accelerating Cell and Gene Therapy Manufacturing Scale-Out with Farlan Veraitch - Part 2 The cell and gene therapy industry faces massive hurdles—cost, scalability, and the need for highly skilled operators have historically limited the reach of these transformative treatments. advanced therapy medicinal products manufacturing innovation is urgently needed to overcome these challenges and unlock broader global access.

Farlan Veraitch, founder and Chief Scientific Officer at Ori Biotech, is leading the way in reimagining manufacturing platforms using automation, modularity, and digital transformation. His vision is redefining how cell and gene therapies are produced—from research labs to point-of-care hospital settings.

What’s inside:

  • The use and adaptation of the paper pull tab sterile connection system—miniaturized and multiplexed—to ensure reliable material transfer in the manufacturing process (06:36)
  • How modular and stackable system design supports scale-up and scale-out, increasing manufacturing capacity and flexibility (09:17)
  • Full digitization of the Ori platform, including setting up digital twins, integrating sample prep automation, and capturing data for QA/QC in real time (10:11)
  • Deskilling bioprocess operations, reducing the need for highly trained cell culture staff, and enabling broader use in both centralized facilities and hospitals (14:02)
  • The logistical benefits of separating material prep (like buffer and virus formulation) from the manufacturing site to streamline point-of-care applications (15:39)
  • Farlan’s vision for an accessible, profitable, globally distributed manufacturing platform to support new treatment pipelines (17:14)
  • Driving down cost and improving scalability as key challenges to unlocking the potential of cell and gene therapies (18:49)

Strategic insight:

The cell and gene therapy field needs to lower manufacturing costs and increase production. Focused, practical approaches are required to make these life-changing therapies more efficient, scalable, and accessible to more patients around the world.

Listen for practical perspectives on automation, digital tools, manufacturing infrastructure, and the future possibilities for decentralized, scalable cell and gene therapy production.

Connect with Farlan Veraitch:

LinkedIn: www.linkedin.com/in/farlan-singh-veraitch-a677112

Email: farlan.veraitch@oribiotech.com

Ori Biotech: www.oribiotech.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> The cell and gene therapy industry faces massive hurdles—cost, scalability, and the need for highly skilled operators have historically limited the reach of these transformative treatments. advanced therapy medicinal products manufacturing innovation is urgently needed to overcome these challenges and unlock broader global access.

Farlan Veraitch, founder and Chief Scientific Officer at Ori Biotech, is leading the way in reimagining manufacturing platforms using automation, modularity, and digital transformation. His vision is redefining how cell and gene therapies are produced—from research labs to point-of-care hospital settings.

What’s inside:

  • The use and adaptation of the paper pull tab sterile connection system—miniaturized and multiplexed—to ensure reliable material transfer in the manufacturing process (06:36)
  • How modular and stackable system design supports scale-up and scale-out, increasing manufacturing capacity and flexibility (09:17)
  • Full digitization of the Ori platform, including setting up digital twins, integrating sample prep automation, and capturing data for QA/QC in real time (10:11)
  • Deskilling bioprocess operations, reducing the need for highly trained cell culture staff, and enabling broader use in both centralized facilities and hospitals (14:02)
  • The logistical benefits of separating material prep (like buffer and virus formulation) from the manufacturing site to streamline point-of-care applications (15:39)
  • Farlan’s vision for an accessible, profitable, globally distributed manufacturing platform to support new treatment pipelines (17:14)
  • Driving down cost and improving scalability as key challenges to unlocking the potential of cell and gene therapies (18:49)

Strategic insight:

The cell and gene therapy field needs to lower manufacturing costs and increase production. Focused, practical approaches are required to make these life-changing therapies more efficient, scalable, and accessible to more patients around the world.

Listen for practical perspectives on automation, digital tools, manufacturing infrastructure, and the future possibilities for decentralized, scalable cell and gene therapy production.

Connect with Farlan Veraitch:

LinkedIn: www.linkedin.com/in/farlan-singh-veraitch-a677112

Email: farlan.veraitch@oribiotech.com

Ori Biotech: www.oribiotech.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19300442 Thu, 02 Jul 2026 05:00:00 +0200 1270 266 full false 265: From Human Variability to Automated Precision: Accelerating Cell and Gene Therapy Manufacturing Scale-Out with Farlan Veraitch - Part 1 265: From Human Variability to Automated Precision: Accelerating Cell and Gene Therapy Manufacturing Scale-Out with Farlan Veraitch - Part 1 What if the simple act of opening an incubator could undermine the consistency of your cell therapy manufacturing process? Unlike traditional biologics, the moment cells leave their incubator, subtle shifts in temperature, CO₂, and pH can spiral into mission-critical variability, jeopardizing everything from product yield to therapeutic potency.

This episode features Farlan Veraitch, founder and Chief Scientific Officer of Ori Biotech. Trained at UCL’s Department of Biochemical Engineering, Farlan blends a bioprocess engineer’s mindset with hands-on experience scaling monoclonal antibodies, before pioneering the first-ever automation platform for embryonic stem cell culture. His drive for eliminating variability and designing systems that scale seamlessly from bench to bedside has informed ORI’s approach to modular cell therapy manufacturing.

What you’ll hear in this episode:

  • The importance of controlling pH, temperature, and shear forces in cell therapy manufacturing (00:36)
  • Lessons learned from scaling monoclonal antibody production and its impact on biotech business models (05:23)
  • The unique sources of variability in primary and stem cells, and why automation is essential (11:16)
  • Strategies to minimize human-induced variability in sensitive cell cultures (12:59)
  • How exposure to ambient oxygen and CO₂ during manual processing affects cell viability (14:13)
  • The logic behind Ori Biotech’s modular design to solve environmental control issues (19:04)

Strategic insight:

As cell and gene therapies push boundaries, manufacturing must keep pace with exponentially tighter requirements. Farlan’s journey highlights a universal lesson for scientists and engineers: process control is not just a technicality, but a necessity for reproducible, scalable, and commercially viable therapies.

If you’re grappling with process variability or looking for fresh strategies in cell and gene therapy development, this episode offers an inside view from a scientist who’s worked at the intersection of bioprocess, automation, and commercial translation.

Connect with Farlan Veraitch:

LinkedIn: www.linkedin.com/in/farlan-singh-veraitch-a677112

Email: farlan.veraitch@oribiotech.com

Ori Biotech: www.oribiotech.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> What if the simple act of opening an incubator could undermine the consistency of your cell therapy manufacturing process? Unlike traditional biologics, the moment cells leave their incubator, subtle shifts in temperature, CO₂, and pH can spiral into mission-critical variability, jeopardizing everything from product yield to therapeutic potency.

This episode features Farlan Veraitch, founder and Chief Scientific Officer of Ori Biotech. Trained at UCL’s Department of Biochemical Engineering, Farlan blends a bioprocess engineer’s mindset with hands-on experience scaling monoclonal antibodies, before pioneering the first-ever automation platform for embryonic stem cell culture. His drive for eliminating variability and designing systems that scale seamlessly from bench to bedside has informed ORI’s approach to modular cell therapy manufacturing.

What you’ll hear in this episode:

  • The importance of controlling pH, temperature, and shear forces in cell therapy manufacturing (00:36)
  • Lessons learned from scaling monoclonal antibody production and its impact on biotech business models (05:23)
  • The unique sources of variability in primary and stem cells, and why automation is essential (11:16)
  • Strategies to minimize human-induced variability in sensitive cell cultures (12:59)
  • How exposure to ambient oxygen and CO₂ during manual processing affects cell viability (14:13)
  • The logic behind Ori Biotech’s modular design to solve environmental control issues (19:04)

Strategic insight:

As cell and gene therapies push boundaries, manufacturing must keep pace with exponentially tighter requirements. Farlan’s journey highlights a universal lesson for scientists and engineers: process control is not just a technicality, but a necessity for reproducible, scalable, and commercially viable therapies.

If you’re grappling with process variability or looking for fresh strategies in cell and gene therapy development, this episode offers an inside view from a scientist who’s worked at the intersection of bioprocess, automation, and commercial translation.

Connect with Farlan Veraitch:

LinkedIn: www.linkedin.com/in/farlan-singh-veraitch-a677112

Email: farlan.veraitch@oribiotech.com

Ori Biotech: www.oribiotech.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19300416 Tue, 30 Jun 2026 05:00:00 +0200 1346 265 full false 264: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David Hardy - Part 2 264: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David Hardy - Part 2 Digital transformation in biotech is no longer just about adopting new tools, it's about building a foundation where automation, data standardization, and AI integration actually lead to real value and long-term success.

For today’s episode, David Brühlmann is joined by David Hardy, a leader at Thermo Fisher Scientific. With years spent guiding automation and digital lab transformation projects around the globe, David’s perspective is equal parts pragmatic and visionary. He’s watched automation go from pilot to scale, advised on the messy realities of lab data, and seen firsthand what separates science fiction from science fact in fully connected labs.

In this episode:

  • Bottlenecks in lab automation, especially the challenge of scaling data volume and adapting processes (02:26)
  • Differences between machine learning (ML) and generative AI in lab contexts, and why ML remains central to value extraction (04:17)
  • The key requirements for successful AI adoption: quality data, robust data checking processes, and a cyclical approach to model training (05:25)
  • The vision for an AI-enabled, fully connected lab and the role of predictive maintenance and data quality checks (07:24)
  • Data governance strategies: balancing access and security, and the case for data democratization within organizations (09:32)
  • How data standardization paves the way for better AI and smoother connectivity (11:25)
  • The necessity of treating digital transformation as an ongoing journey, not a one-time project (12:15)

Smart insight: digital transformation is not a one-off project but a long-term journey. The most important takeaway for any scientist or leader? Prioritize good quality, standardized data; invest in the foundational work; and foster a culture of collaboration and learning.

The connectivity problem doesn't stop at the data layer. These episodes tackle the automation failures, digital infrastructure decisions, and AI readiness questions that determine whether your lab's data ever becomes an asset.

  • Episodes 215 - 216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya Burkov
  • Episodes 233 - 234: Why Most Bioprocess Automation Projects Fail Before the Robot Is Even Ordered with Anthony Catacchio
  • Episodes 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos
  • Episodes 17 - 18: How Extracting Gold From Your Data Accelerates Process Development with Ioscani Jiménez del Val - Part 1

Connect with David Hardy: LinkedIn: www.linkedin.com/in/david-hardy-46331823 Thermo Fisher Scientific website: www.thermofisher.com

Next: If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Support the show

]]> Digital transformation in biotech is no longer just about adopting new tools, it's about building a foundation where automation, data standardization, and AI integration actually lead to real value and long-term success.

For today’s episode, David Brühlmann is joined by David Hardy, a leader at Thermo Fisher Scientific. With years spent guiding automation and digital lab transformation projects around the globe, David’s perspective is equal parts pragmatic and visionary. He’s watched automation go from pilot to scale, advised on the messy realities of lab data, and seen firsthand what separates science fiction from science fact in fully connected labs.

In this episode:

  • Bottlenecks in lab automation, especially the challenge of scaling data volume and adapting processes (02:26)
  • Differences between machine learning (ML) and generative AI in lab contexts, and why ML remains central to value extraction (04:17)
  • The key requirements for successful AI adoption: quality data, robust data checking processes, and a cyclical approach to model training (05:25)
  • The vision for an AI-enabled, fully connected lab and the role of predictive maintenance and data quality checks (07:24)
  • Data governance strategies: balancing access and security, and the case for data democratization within organizations (09:32)
  • How data standardization paves the way for better AI and smoother connectivity (11:25)
  • The necessity of treating digital transformation as an ongoing journey, not a one-time project (12:15)

Smart insight: digital transformation is not a one-off project but a long-term journey. The most important takeaway for any scientist or leader? Prioritize good quality, standardized data; invest in the foundational work; and foster a culture of collaboration and learning.

The connectivity problem doesn't stop at the data layer. These episodes tackle the automation failures, digital infrastructure decisions, and AI readiness questions that determine whether your lab's data ever becomes an asset.

  • Episodes 215 - 216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya Burkov
  • Episodes 233 - 234: Why Most Bioprocess Automation Projects Fail Before the Robot Is Even Ordered with Anthony Catacchio
  • Episodes 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos
  • Episodes 17 - 18: How Extracting Gold From Your Data Accelerates Process Development with Ioscani Jiménez del Val - Part 1

Connect with David Hardy: LinkedIn: www.linkedin.com/in/david-hardy-46331823 Thermo Fisher Scientific website: www.thermofisher.com

Next: If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19355358 Thu, 25 Jun 2026 05:00:00 +0200 909 264 full false 263: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David Hardy - Part 1 263: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David Hardy - Part 1 Despite cutting-edge equipment and brilliant minds, biotech labs often find half their data trapped in difficult-to-access spreadsheets or isolated in silos, making true digital transformation a major, industry-wide hurdle.

David Hardy, a leading market and innovation strategist at Thermo Fisher Scientific with 25 years of experience at the intersection of data, automation, and laboratory science, is helping organizations bridge the gap between data chaos and actionable insight.

Topics discussed:

  • David Hardy’s early experiences managing NMR data at AstraZeneca and the origins of his interest in data management (03:46)
  • Lessons from retail analytics and returning to scientific data challenges (05:21)
  • Identifying the persistent problem of data connectivity in labs, despite growing data volumes and new technologies (06:40)
  • The most common pushbacks to digital solutions: long-term commitment and culture change (07:38)
  • What mindsets and leadership approaches support successful digital transformation (08:43)
  • Recognizing fragmentation and spotting “hidden” data silos in biotech labs (10:06)
  • Where data fragmentation hurts the most—especially for cross-disciplinary questions and CMC reporting (11:06)
  • Build vs. buy: deciding whether to create in-house digital tools or work with external vendors (13:50)
  • The importance of adaptable systems and preparing for inevitable change in biotech data management (14:43)

Smart insight: True digital transformation is not a project, but a process—a way of working that requires vision, patience, and continual adaptation. The labs that break down data silos and connect their digital resources are better positioned to unlock the full promise of biotech: faster discoveries, more robust compliance, and therapies delivered to patients without unnecessary delay.

The connectivity problem doesn't stop at the data layer. These episodes tackle the automation failures, digital infrastructure decisions, and AI readiness questions that determine whether your lab's data ever becomes an asset.

  • Episodes 215 - 216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya Burkov
  • Episodes 233 - 234: Why Most Bioprocess Automation Projects Fail Before the Robot Is Even Ordered with Anthony Catacchio
  • Episodes 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos
  • Episodes 17 - 18: How Extracting Gold From Your Data Accelerates Process Development with Ioscani Jiménez del Val

Connect with David Hardy

LinkedIn: www.linkedin.com/in/david-hardy-46331823

Thermo Fisher Scientific website: www.thermofisher.com

Next step: If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Support the show

]]> Despite cutting-edge equipment and brilliant minds, biotech labs often find half their data trapped in difficult-to-access spreadsheets or isolated in silos, making true digital transformation a major, industry-wide hurdle.

David Hardy, a leading market and innovation strategist at Thermo Fisher Scientific with 25 years of experience at the intersection of data, automation, and laboratory science, is helping organizations bridge the gap between data chaos and actionable insight.

Topics discussed:

  • David Hardy’s early experiences managing NMR data at AstraZeneca and the origins of his interest in data management (03:46)
  • Lessons from retail analytics and returning to scientific data challenges (05:21)
  • Identifying the persistent problem of data connectivity in labs, despite growing data volumes and new technologies (06:40)
  • The most common pushbacks to digital solutions: long-term commitment and culture change (07:38)
  • What mindsets and leadership approaches support successful digital transformation (08:43)
  • Recognizing fragmentation and spotting “hidden” data silos in biotech labs (10:06)
  • Where data fragmentation hurts the most—especially for cross-disciplinary questions and CMC reporting (11:06)
  • Build vs. buy: deciding whether to create in-house digital tools or work with external vendors (13:50)
  • The importance of adaptable systems and preparing for inevitable change in biotech data management (14:43)

Smart insight: True digital transformation is not a project, but a process—a way of working that requires vision, patience, and continual adaptation. The labs that break down data silos and connect their digital resources are better positioned to unlock the full promise of biotech: faster discoveries, more robust compliance, and therapies delivered to patients without unnecessary delay.

The connectivity problem doesn't stop at the data layer. These episodes tackle the automation failures, digital infrastructure decisions, and AI readiness questions that determine whether your lab's data ever becomes an asset.

  • Episodes 215 - 216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya Burkov
  • Episodes 233 - 234: Why Most Bioprocess Automation Projects Fail Before the Robot Is Even Ordered with Anthony Catacchio
  • Episodes 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos
  • Episodes 17 - 18: How Extracting Gold From Your Data Accelerates Process Development with Ioscani Jiménez del Val

Connect with David Hardy

LinkedIn: www.linkedin.com/in/david-hardy-46331823

Thermo Fisher Scientific website: www.thermofisher.com

Next step: If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19355359 Tue, 23 Jun 2026 05:00:00 +0200 995 263 full false 262: How to Stop Defaulting to CHO: An Evidence-Based Host Selection Framework for Biologics 262: How to Stop Defaulting to CHO: An Evidence-Based Host Selection Framework for Biologics Host David Brühlmann returns for a focused solo episode to provide an honest, data-driven perspective on the evolving landscape of host selection for biologics manufacturing. Building on part one, David reviews five alternative expression platforms and offers a clear, practical framework for scientists navigating host cell decisions today. David Brühlmann moves past simplistic "replacement" narratives to instead examine where each technology, from plant farming to cell-free systems, fits in today’s market and production realities.

Key topics discussed

  • Why asking if a novel host will "replace CHO" is the wrong question for scientists and manufacturers (00:11)
  • Critical dimensions to evaluate: cost structure, speed, and intrinsic product quality (01:20)
  • Review of five alternative platforms with current clinical and regulatory status: 
    • Plant farming for speed and decentralization (03:42)
    • Insect cells for VLPs and complex proteins (05:00)
    • Cell-free protein synthesis for ADCs and unique conjugation requirements (06:23)
    • Moss for monoclonal antibodies with distinct glycosylation patterns (07:50)
    • Filamentous fungi for high secretion and thermotolerance (08:47)
  • A practical host selection framework by molecule type and manufacturing context (09:59)
  • Detailed constraints and advantages of each platform, including cost, infrastructure, timeline, and product attributes (10:09)
  • Analysis of silkworm production as a disruptive possibility for future biologics manufacturing (13:09)
  • The evolving toolkit available to bioprocess scientists—and why "CHO replacement" is a distraction from more relevant questions (12:06)

Smart insight:

The real development over the past decade is that bioprocess scientists now have a credible, validated toolkit of alternatives for specific molecules in specific contexts. The practical implication: know this landscape well enough to ask the right host selection question at program initiation, before you've built months of process development around a platform you chose by default.

Here are the episodes referenced:

  • Episodes 163 - 164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf
  • Episodes 141 - 142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor
  • Episodes 235 - 236: Plant-Based Biomanufacturing: How Molecular Farming Produces Biopharmaceuticals in Weeks, Not Months with Waranyoo Phoolcharoen
  • Episodes 217 - 218: Silkworm Biomanufacturing: From Ancient Silk Production to Phase I Vaccine Trials with Masafumi Osawa
  • Episodes 229 - 230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim Corcoran

Next:

If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Support the show

]]> Host David Brühlmann returns for a focused solo episode to provide an honest, data-driven perspective on the evolving landscape of host selection for biologics manufacturing. Building on part one, David reviews five alternative expression platforms and offers a clear, practical framework for scientists navigating host cell decisions today. David Brühlmann moves past simplistic "replacement" narratives to instead examine where each technology, from plant farming to cell-free systems, fits in today’s market and production realities.

Key topics discussed

  • Why asking if a novel host will "replace CHO" is the wrong question for scientists and manufacturers (00:11)
  • Critical dimensions to evaluate: cost structure, speed, and intrinsic product quality (01:20)
  • Review of five alternative platforms with current clinical and regulatory status: 
    • Plant farming for speed and decentralization (03:42)
    • Insect cells for VLPs and complex proteins (05:00)
    • Cell-free protein synthesis for ADCs and unique conjugation requirements (06:23)
    • Moss for monoclonal antibodies with distinct glycosylation patterns (07:50)
    • Filamentous fungi for high secretion and thermotolerance (08:47)
  • A practical host selection framework by molecule type and manufacturing context (09:59)
  • Detailed constraints and advantages of each platform, including cost, infrastructure, timeline, and product attributes (10:09)
  • Analysis of silkworm production as a disruptive possibility for future biologics manufacturing (13:09)
  • The evolving toolkit available to bioprocess scientists—and why "CHO replacement" is a distraction from more relevant questions (12:06)

Smart insight:

The real development over the past decade is that bioprocess scientists now have a credible, validated toolkit of alternatives for specific molecules in specific contexts. The practical implication: know this landscape well enough to ask the right host selection question at program initiation, before you've built months of process development around a platform you chose by default.

Here are the episodes referenced:

  • Episodes 163 - 164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf
  • Episodes 141 - 142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor
  • Episodes 235 - 236: Plant-Based Biomanufacturing: How Molecular Farming Produces Biopharmaceuticals in Weeks, Not Months with Waranyoo Phoolcharoen
  • Episodes 217 - 218: Silkworm Biomanufacturing: From Ancient Silk Production to Phase I Vaccine Trials with Masafumi Osawa
  • Episodes 229 - 230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim Corcoran

Next:

If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19300329 Thu, 18 Jun 2026 05:00:00 +0200 938 262 full false 261: Why CHO Is Still Winning (and the 5 Platforms That Beat It in Specific Contexts) 261: Why CHO Is Still Winning (and the 5 Platforms That Beat It in Specific Contexts) In this solo episode, David Brühlmann explores the evolving landscape of biologic manufacturing platforms beyond CHO (Chinese hamster ovary) cells. Drawing from previous interviews with platform pioneers and rigorous data analysis, David examines where established and emerging hosts find their strengths—and their limits—in today’s biomanufacturing environment.

Topics Discussed

  • The historical dominance of CHO cells and what’s changed in the last decade (00:08)
  • Three critical areas where alternative hosts might outperform CHO: cost, speed, and intrinsic product quality (04:52)
  • Moss as a production platform: regulatory advantages, glycosylation, and oncology antibodies (05:47)
  • Microalgae’s carbon-negative potential and the current 1000-fold yield challenge (08:28)
  • Molecular farming (plant-based production): timelines, case of the Medicago COVID-19 vaccine, and overcoming political—not technical—barriers (10:41)
  • Silkworm-based production: infrastructure cost, individual variability, and progress in vaccines (13:07)
  • Cyanobacteria: promise of photosynthetic biomanufacturing and current limitations for clinical use (15:06)
  • The pattern emerging among all alternative platforms: finding niche advantages rather than universally replacing CHO (18:25)
  • A framework for evaluating novel hosts moving forward (19:14)

Part 2 examines whether “Will it replace CHO?” is the right question to be asking at all, and introduces an alternative framework for evaluating the issue more effectively.

Smart insight:

None of the “novel hosts” are universal CHO replacements. Winners emerge in narrow niches: plant farming for pandemic-scale vaccines, silkworms in veterinary and oral applications, and cyanobacteria as a long-term bet for sustainable production.

Here are the episodes referenced:

  • Episodes 163 - 164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf
  • Episodes 141 - 142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor
  • Episodes 235 - 236: Plant-Based Biomanufacturing: How Molecular Farming Produces Biopharmaceuticals in Weeks, Not Months with Waranyoo Phoolcharoen
  • Episodes 217 - 218: Silkworm Biomanufacturing: From Ancient Silk Production to Phase I Vaccine Trials with Masafumi Osawa
  • Episodes 229 - 230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim Corcoran

Next:

If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Support the show

]]> In this solo episode, David Brühlmann explores the evolving landscape of biologic manufacturing platforms beyond CHO (Chinese hamster ovary) cells. Drawing from previous interviews with platform pioneers and rigorous data analysis, David examines where established and emerging hosts find their strengths—and their limits—in today’s biomanufacturing environment.

Topics Discussed

  • The historical dominance of CHO cells and what’s changed in the last decade (00:08)
  • Three critical areas where alternative hosts might outperform CHO: cost, speed, and intrinsic product quality (04:52)
  • Moss as a production platform: regulatory advantages, glycosylation, and oncology antibodies (05:47)
  • Microalgae’s carbon-negative potential and the current 1000-fold yield challenge (08:28)
  • Molecular farming (plant-based production): timelines, case of the Medicago COVID-19 vaccine, and overcoming political—not technical—barriers (10:41)
  • Silkworm-based production: infrastructure cost, individual variability, and progress in vaccines (13:07)
  • Cyanobacteria: promise of photosynthetic biomanufacturing and current limitations for clinical use (15:06)
  • The pattern emerging among all alternative platforms: finding niche advantages rather than universally replacing CHO (18:25)
  • A framework for evaluating novel hosts moving forward (19:14)

Part 2 examines whether “Will it replace CHO?” is the right question to be asking at all, and introduces an alternative framework for evaluating the issue more effectively.

Smart insight:

None of the “novel hosts” are universal CHO replacements. Winners emerge in narrow niches: plant farming for pandemic-scale vaccines, silkworms in veterinary and oral applications, and cyanobacteria as a long-term bet for sustainable production.

Here are the episodes referenced:

  • Episodes 163 - 164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf
  • Episodes 141 - 142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor
  • Episodes 235 - 236: Plant-Based Biomanufacturing: How Molecular Farming Produces Biopharmaceuticals in Weeks, Not Months with Waranyoo Phoolcharoen
  • Episodes 217 - 218: Silkworm Biomanufacturing: From Ancient Silk Production to Phase I Vaccine Trials with Masafumi Osawa
  • Episodes 229 - 230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim Corcoran

Next:

If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19258743 Tue, 16 Jun 2026 05:00:00 +0200 1223 261 full false 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome - Part 2 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome - Part 2 Funding novel therapeutics isn’t just “harder than ever”—the rules have changed entirely. The wild rush of capital into early-stage biotech during 2020–2021 gave way to a drought, making investor priorities sharper and startup hurdles higher than most founders realize.

Michael Rome, Managing Director at Foresite Capital, joined the Smart Biotech Scientist Podcast to dissect what’s really driving funding decisions today, and what early-stage founders must do to stand out.

Key topics discussed:

  • The financial cycle of biotech investment before, during, and after the COVID-19 boom (02:47)
  • Why investors are now focused on clear pathways to approved drugs and how founders should frame their proposals (06:10)
  • The evolving importance of CMC expertise and manufacturing readiness for startups at different stages (07:44)
  • Leadership traits and execution qualities investors appreciate in biotech founders and teams (09:18)
  • Promising scientific and market areas including small molecule oncology, degraders, and heterobifunctional molecules (11:24)
  • Practical advice for founders preparing for fundraising: focusing on unmet medical needs and market analysis (14:55)
  • The impact of recent M&A activity and regulatory challenges at the FDA on the future of biotech investment (16:27)
  • The importance of open communication and collaboration between scientists and investors (18:47)

Smart insight: For those preparing their next fundraising push, Michael advised:

  • Start with the end in mind: Outline the unmet need, the clinical and market pathway, and the product vision first
  • Reverse engineer your innovation: Work backwards from market and regulatory needs to inform your technical approach, not the other way around.
  • Frame your business case: Make it obvious to investors how your solution advances value in the ecosystem

If you want to go deeper into the themes from this conversation with Michael Rome—how investors evaluate biotech companies, why CMC and execution matter, and how founders can better frame their science for funding—these episodes are a strong next listen:

  • Episodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)
  • Episodes 165 - 166: Why Your Funding Pitches Fail Despite Brilliant Science (And How to Fix It)
  • Episodes 183 - 184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee Ho
  • Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann

Connect with Michael Rome: LinkedIn: https://www.linkedin.com/in/michael-rome-5067616b/ Foresite Capital website: www.foresitecapital.com

Next: If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Support the show

]]> Funding novel therapeutics isn’t just “harder than ever”—the rules have changed entirely. The wild rush of capital into early-stage biotech during 2020–2021 gave way to a drought, making investor priorities sharper and startup hurdles higher than most founders realize.

Michael Rome, Managing Director at Foresite Capital, joined the Smart Biotech Scientist Podcast to dissect what’s really driving funding decisions today, and what early-stage founders must do to stand out.

Key topics discussed:

  • The financial cycle of biotech investment before, during, and after the COVID-19 boom (02:47)
  • Why investors are now focused on clear pathways to approved drugs and how founders should frame their proposals (06:10)
  • The evolving importance of CMC expertise and manufacturing readiness for startups at different stages (07:44)
  • Leadership traits and execution qualities investors appreciate in biotech founders and teams (09:18)
  • Promising scientific and market areas including small molecule oncology, degraders, and heterobifunctional molecules (11:24)
  • Practical advice for founders preparing for fundraising: focusing on unmet medical needs and market analysis (14:55)
  • The impact of recent M&A activity and regulatory challenges at the FDA on the future of biotech investment (16:27)
  • The importance of open communication and collaboration between scientists and investors (18:47)

Smart insight: For those preparing their next fundraising push, Michael advised:

  • Start with the end in mind: Outline the unmet need, the clinical and market pathway, and the product vision first
  • Reverse engineer your innovation: Work backwards from market and regulatory needs to inform your technical approach, not the other way around.
  • Frame your business case: Make it obvious to investors how your solution advances value in the ecosystem

If you want to go deeper into the themes from this conversation with Michael Rome—how investors evaluate biotech companies, why CMC and execution matter, and how founders can better frame their science for funding—these episodes are a strong next listen:

  • Episodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)
  • Episodes 165 - 166: Why Your Funding Pitches Fail Despite Brilliant Science (And How to Fix It)
  • Episodes 183 - 184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee Ho
  • Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann

Connect with Michael Rome: LinkedIn: https://www.linkedin.com/in/michael-rome-5067616b/ Foresite Capital website: www.foresitecapital.com

Next: If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19300239 Thu, 11 Jun 2026 06:00:00 +0200 1300 260 full false 259: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome - Part 1 259: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael Rome - Part 1 Strong science alone won’t get your biotech startup funded—investors are sizing up much more than just your molecule.

Michael Rome, who leads therapeutics investing at Foresite Capital, brings a rare dual lens as both scientist and investor. Having trained as a Caltech biochemist and incubated dozens of biotech companies, he’s seen first-hand how world-class discoveries become market-ready solutions—or get left behind.

Topics discussed:

  • Why strong science isn't always enough to secure funding (00:25)
  • Insights on diverse biotech investing strategies, time horizons, and mandate differences between venture firms (02:44)
  • The advantage of Foresite’s multi-stage and cross-sector investment model (03:32)
  • Michael’s journey from science and math enthusiast to biotech investor (04:49)
  • The importance of founding team track records and repeat entrepreneurs in early-stage company building (12:53)
  • The evolving global landscape: company formation, investment, and biotech innovation in Asia (with a focus on China) (15:56)
  • Effects of shifting geopolitical and regulatory landscapes on US, European, and Asian biotech partnerships (20:25)
  • The practicalities and tradeoffs of outsourcing drug development, R&D, and manufacturing overseas (22:04)

Smart insight: Engage with investor perspectives early: align your work to real market needs. Seek partnerships with industry leaders and proven entrepreneurs, embrace global resources, networks, and collaborations to maximize both scientific and commercial potential.

If you want to go deeper into the themes from this conversation with Michael Rome—how investors evaluate biotech companies, why CMC and execution matter, and how founders can better frame their science for funding—these episodes are a strong next listen:

  • Episodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)
  • Episodes 165 - 166: Why Your Funding Pitches Fail Despite Brilliant Science (And How to Fix It)
  • Episodes 183 - 184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee Ho
  • Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann

Connect with Michael Rome: LinkedIn: https://www.linkedin.com/in/michael-rome-5067616b/ Foresite Capital website: www.foresitecapital.com

Next: If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Strong science alone won’t get your biotech startup funded—investors are sizing up much more than just your molecule.

Michael Rome, who leads therapeutics investing at Foresite Capital, brings a rare dual lens as both scientist and investor. Having trained as a Caltech biochemist and incubated dozens of biotech companies, he’s seen first-hand how world-class discoveries become market-ready solutions—or get left behind.

Topics discussed:

  • Why strong science isn't always enough to secure funding (00:25)
  • Insights on diverse biotech investing strategies, time horizons, and mandate differences between venture firms (02:44)
  • The advantage of Foresite’s multi-stage and cross-sector investment model (03:32)
  • Michael’s journey from science and math enthusiast to biotech investor (04:49)
  • The importance of founding team track records and repeat entrepreneurs in early-stage company building (12:53)
  • The evolving global landscape: company formation, investment, and biotech innovation in Asia (with a focus on China) (15:56)
  • Effects of shifting geopolitical and regulatory landscapes on US, European, and Asian biotech partnerships (20:25)
  • The practicalities and tradeoffs of outsourcing drug development, R&D, and manufacturing overseas (22:04)

Smart insight: Engage with investor perspectives early: align your work to real market needs. Seek partnerships with industry leaders and proven entrepreneurs, embrace global resources, networks, and collaborations to maximize both scientific and commercial potential.

If you want to go deeper into the themes from this conversation with Michael Rome—how investors evaluate biotech companies, why CMC and execution matter, and how founders can better frame their science for funding—these episodes are a strong next listen:

  • Episodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)
  • Episodes 165 - 166: Why Your Funding Pitches Fail Despite Brilliant Science (And How to Fix It)
  • Episodes 183 - 184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee Ho
  • Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann

Connect with Michael Rome: LinkedIn: https://www.linkedin.com/in/michael-rome-5067616b/ Foresite Capital website: www.foresitecapital.com

Next: If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19300218 Tue, 09 Jun 2026 05:00:00 +0200 1564 259 full false 258: Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing with Milan Tomic - Part 2 258: Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing with Milan Tomic - Part 2 What happens between scientific discovery and clinical trials? For too many drug candidates, the answer is “failure”—not because the idea lacked merit, but because the critical handoff between discovery and IND-enabling studies gets overlooked, rushed, or under-resourced.

This episode features Milan Tomic, whose journey stretches from nucleic acid chemistry to leading GMP manufacturing and biodefense initiatives with hundreds of millions in US government support. Milan’s focus lies in streamlining drug development, from rapid molecule design to building manufacturing infrastructure, all grounded in holistic, systems-level thinking.

Topics discussed:

  • Why so many promising programs fail between discovery and the clinic, and how to close this gap through early, iterative design and testing (02:52)
  • The practical advantages and considerations of cell-free protein synthesis for rapid prototyping and testing during development (07:30)
  • How to decide when to deploy cell-free production versus traditional CHO systems (08:29)
  • Recommendations for resource-constrained startups: what to focus on first and why stability and documentation matter most (10:55)
  • Consistent success factors across Milan’s experiences, from government contract projects to launching his own company (13:54)
  • Candid stories of setbacks and lessons—such as the critical importance of safety in development and the impact of overlooked technical details like facility lighting (15:30)
  • The importance of linking drug design decisions to target patient needs and regulatory considerations, thinking holistically, and using target product profiles to guide development (20:22)

Smart insight: Perhaps the most powerful takeaway isn’t technical, but personal. Staying curious, open-minded, and deriving enjoyment from the process is vital for sustaining the drive necessary for biotech’s long and often unpredictable journey. The best way to bridge the valley of death in biotech is through rigorous iterative design, early testing of critical attributes, holistic planning, and a relentless commitment to learning.

If you enjoyed this episode you might also like listening to:

  • Episodes 189 - 190 : Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)
  • Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein
  • Episodes 213 - 214: From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab with Giuseppe Licari
  • Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann

Connect with Milan Tomic:

LinkedIn: www.linkedin.com/in/milan-tomic-phd

Albrem Biopharma: www.albrem.com

Next Step:

If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Support the show

]]> What happens between scientific discovery and clinical trials? For too many drug candidates, the answer is “failure”—not because the idea lacked merit, but because the critical handoff between discovery and IND-enabling studies gets overlooked, rushed, or under-resourced.

This episode features Milan Tomic, whose journey stretches from nucleic acid chemistry to leading GMP manufacturing and biodefense initiatives with hundreds of millions in US government support. Milan’s focus lies in streamlining drug development, from rapid molecule design to building manufacturing infrastructure, all grounded in holistic, systems-level thinking.

Topics discussed:

  • Why so many promising programs fail between discovery and the clinic, and how to close this gap through early, iterative design and testing (02:52)
  • The practical advantages and considerations of cell-free protein synthesis for rapid prototyping and testing during development (07:30)
  • How to decide when to deploy cell-free production versus traditional CHO systems (08:29)
  • Recommendations for resource-constrained startups: what to focus on first and why stability and documentation matter most (10:55)
  • Consistent success factors across Milan’s experiences, from government contract projects to launching his own company (13:54)
  • Candid stories of setbacks and lessons—such as the critical importance of safety in development and the impact of overlooked technical details like facility lighting (15:30)
  • The importance of linking drug design decisions to target patient needs and regulatory considerations, thinking holistically, and using target product profiles to guide development (20:22)

Smart insight: Perhaps the most powerful takeaway isn’t technical, but personal. Staying curious, open-minded, and deriving enjoyment from the process is vital for sustaining the drive necessary for biotech’s long and often unpredictable journey. The best way to bridge the valley of death in biotech is through rigorous iterative design, early testing of critical attributes, holistic planning, and a relentless commitment to learning.

If you enjoyed this episode you might also like listening to:

  • Episodes 189 - 190 : Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)
  • Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein
  • Episodes 213 - 214: From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab with Giuseppe Licari
  • Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann

Connect with Milan Tomic:

LinkedIn: www.linkedin.com/in/milan-tomic-phd

Albrem Biopharma: www.albrem.com

Next Step:

If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19258725 Thu, 04 Jun 2026 05:00:00 +0200 1477 258 full false 257: Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing with Milan Tomic - Part 1 257: Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing with Milan Tomic - Part 1 The gap between a “drug” and a true “product” is where many therapies fail.

Milan Tomic, biotech veteran, GMP manufacturing expert, and founder of Albrem, has spent 30 years turning promising science into scalable, executable products that can actually reach patients. His experience spans everything from antibody development to building large-scale GMP facilities. Today, he helps biotech teams align scientific innovation with the operational and regulatory realities needed for successful commercialization.

Topics discussed:

  • Milan’s path from curiosity-driven research in molecular biology to biotech industry leadership (05:24)
  • The importance of integrating work-life factors into career decisions, and balancing scientific depth with operational and business responsibilities (08:22)
  • The unexpected role that salesmanship plays for scientists moving into entrepreneurship (10:40)
  • Lessons from transitioning between scientific disciplines, including dealing with setbacks like unpublished graduate work (12:57)
  • How curiosity led Milan to oversee the redesign of a 2,000-liter GMP manufacturing facility (16:16)
  • Key advice for scientists on process design and scaling up, especially for those involved in CMC (20:18)

Smart insight: A promising molecule isn’t enough—successful drug development requires designing early for scalability, GMP compliance, and real patient need. Companies that align science with manufacturability and market fit are far better positioned to advance, attract investors, and secure partners.

If you enjoyed this episode you might also like listening to:

  • Episodes 189 - 190 : Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)
  • Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein
  • Episodes 213 - 214: From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab with Giuseppe Licari
  • Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann

Connect with Milan Tomic:

LinkedIn: www.linkedin.com/in/milan-tomic-phd

Albrem Biopharma: www.albrem.com

Next Step:

If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Support the show

]]> The gap between a “drug” and a true “product” is where many therapies fail.

Milan Tomic, biotech veteran, GMP manufacturing expert, and founder of Albrem, has spent 30 years turning promising science into scalable, executable products that can actually reach patients. His experience spans everything from antibody development to building large-scale GMP facilities. Today, he helps biotech teams align scientific innovation with the operational and regulatory realities needed for successful commercialization.

Topics discussed:

  • Milan’s path from curiosity-driven research in molecular biology to biotech industry leadership (05:24)
  • The importance of integrating work-life factors into career decisions, and balancing scientific depth with operational and business responsibilities (08:22)
  • The unexpected role that salesmanship plays for scientists moving into entrepreneurship (10:40)
  • Lessons from transitioning between scientific disciplines, including dealing with setbacks like unpublished graduate work (12:57)
  • How curiosity led Milan to oversee the redesign of a 2,000-liter GMP manufacturing facility (16:16)
  • Key advice for scientists on process design and scaling up, especially for those involved in CMC (20:18)

Smart insight: A promising molecule isn’t enough—successful drug development requires designing early for scalability, GMP compliance, and real patient need. Companies that align science with manufacturability and market fit are far better positioned to advance, attract investors, and secure partners.

If you enjoyed this episode you might also like listening to:

  • Episodes 189 - 190 : Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)
  • Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein
  • Episodes 213 - 214: From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab with Giuseppe Licari
  • Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann

Connect with Milan Tomic:

LinkedIn: www.linkedin.com/in/milan-tomic-phd

Albrem Biopharma: www.albrem.com

Next Step:

If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19258708 Tue, 02 Jun 2026 05:00:00 +0200 1414 257 full false 256: Is Bioprocess Education Keeping Up With New Tech? The Training Gap Industry Cannot Afford to Ignore with Steffen Kreye - Part 2 256: Is Bioprocess Education Keeping Up With New Tech? The Training Gap Industry Cannot Afford to Ignore with Steffen Kreye - Part 2 The "data lake" that was supposed to unify bioprocessing intelligence has, in most companies, become something else entirely: a data swamp, where information goes in and insight rarely comes back out. For anyone trying to deploy AI in GMP manufacturing, that is not a technical problem. It is the problem.

Steffen Kreye has seen it from both sides. As former upstream development lead at Bayer and now Professor of Industrial Biotechnology at Berliner Hochschule für Technik, he brings an unusually grounded perspective on where AI in bioprocessing actually stands, what the next generation of scientists needs to be equipped with, and what industry can do right now to help close the gap.

Key topics discussed:

  • How soft skills like teamwork and self-motivation are becoming increasingly important for scientists, and strategies to foster them in education (02:47)
  • The reality behind AI and machine learning in biotech today, including current limitations and the true state of industry adoption (05:48)
  • Envisioning bioprocessing ten years from now: the potential of continuous manufacturing, digital twins, and automation, and the evolving diversity of bioprocesses (08:09)
  • Practical ways industry professionals can support university education—from guest lectures to hands-on lab courses—and why it matters (10:09)
  • Motivating students by connecting coursework to real industry roles and contributions (12:10)
  • The importance of finding and following individual motivation in science careers (12:41)
  • Reflections on moving from industry to academia: autonomy, challenges, and the satisfaction of seeing students grow into scientists (13:22)
  • How strong collaboration between academia and industry leads to better innovation and prepares future scientists for success (15:53)

Smart Insight: Most companies talking about AI in bioprocessing are still solving a more fundamental problem: getting their data into a state where AI could use it at all. The breakthrough will not come from the algorithm. It will come from the unglamorous, years-long work of making data accessible, harmonized, and meaningful across sites, systems, and GMP boundaries.

Here are some other guests who touched on similar themes:

  • Episodes 175 – 176 : How Virtual Reality Training Solves Europe's Bioproduction Talent Shortage with Sandrine Lemoine — about training the next generation of biopharma talent.
  • Episodes 93 – 94: From Lab Coat to LinkedIn: Benjamin McLeod's Journey to Cell and Gene Therapy Influencer — another career pivot story from a scientist who stepped outside the traditional industry path.
  • Episodes 111 – 112: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén — very aligned with Steffen's nuanced take that AI is a tool but human expertise in bioprocessing still matters.

Connect with Steffen Kreye:

LinkedIn: www.linkedin.com/in/steffen-kreye-3b531183/

Berliner Hochschule für Technik: www.prof.bht-berlin.de/kreye

Next Step:

If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Support the show

]]> The "data lake" that was supposed to unify bioprocessing intelligence has, in most companies, become something else entirely: a data swamp, where information goes in and insight rarely comes back out. For anyone trying to deploy AI in GMP manufacturing, that is not a technical problem. It is the problem.

Steffen Kreye has seen it from both sides. As former upstream development lead at Bayer and now Professor of Industrial Biotechnology at Berliner Hochschule für Technik, he brings an unusually grounded perspective on where AI in bioprocessing actually stands, what the next generation of scientists needs to be equipped with, and what industry can do right now to help close the gap.

Key topics discussed:

  • How soft skills like teamwork and self-motivation are becoming increasingly important for scientists, and strategies to foster them in education (02:47)
  • The reality behind AI and machine learning in biotech today, including current limitations and the true state of industry adoption (05:48)
  • Envisioning bioprocessing ten years from now: the potential of continuous manufacturing, digital twins, and automation, and the evolving diversity of bioprocesses (08:09)
  • Practical ways industry professionals can support university education—from guest lectures to hands-on lab courses—and why it matters (10:09)
  • Motivating students by connecting coursework to real industry roles and contributions (12:10)
  • The importance of finding and following individual motivation in science careers (12:41)
  • Reflections on moving from industry to academia: autonomy, challenges, and the satisfaction of seeing students grow into scientists (13:22)
  • How strong collaboration between academia and industry leads to better innovation and prepares future scientists for success (15:53)

Smart Insight: Most companies talking about AI in bioprocessing are still solving a more fundamental problem: getting their data into a state where AI could use it at all. The breakthrough will not come from the algorithm. It will come from the unglamorous, years-long work of making data accessible, harmonized, and meaningful across sites, systems, and GMP boundaries.

Here are some other guests who touched on similar themes:

  • Episodes 175 – 176 : How Virtual Reality Training Solves Europe's Bioproduction Talent Shortage with Sandrine Lemoine — about training the next generation of biopharma talent.
  • Episodes 93 – 94: From Lab Coat to LinkedIn: Benjamin McLeod's Journey to Cell and Gene Therapy Influencer — another career pivot story from a scientist who stepped outside the traditional industry path.
  • Episodes 111 – 112: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén — very aligned with Steffen's nuanced take that AI is a tool but human expertise in bioprocessing still matters.

Connect with Steffen Kreye:

LinkedIn: www.linkedin.com/in/steffen-kreye-3b531183/

Berliner Hochschule für Technik: www.prof.bht-berlin.de/kreye

Next Step:

If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19226815 Thu, 28 May 2026 05:00:00 +0200 1109 256 full false 255: Is Bioprocess Education Keeping Up With New Tech? The Training Gap Industry Cannot Afford to Ignore with Steffen Kreye - Part 1 255: Is Bioprocess Education Keeping Up With New Tech? The Training Gap Industry Cannot Afford to Ignore with Steffen Kreye - Part 1 When AI can draft a literature review in minutes, the question bioprocess educators can no longer avoid is this: what does a student actually need to learn?

Steffen Kreye has a clear answer. As Professor of Industrial Biotechnology at Berliner Hochschule für Technik, he trains engineers who step into industry ready to run a bioreactor, not just describe one. His argument is direct: hands-on lab competence is the one thing AI cannot replicate, and it is exactly what underfunding is quietly eroding.

Topics discussed:

  • Why Steffen Kreye left his lab head role at Bayer to become a professor and how his career evolved (03:54)
  • The unique mission of universities of applied sciences and their close connection to industry needs (11:16)
  • Challenges of delivering lab-based education, including funding and equipment constraints (12:32)
  • Creative strategies for partnering with biotech companies to sustain practical lab courses (14:34)
  • How reading student theses, partnerships, and conferences help Steffen Kreye and his colleagues stay current in a rapidly changing field (17:43)
  • The impact of AI and digital tools on research, teaching methods, and student assessment (21:18)
  • Why traditional theoretical projects are less relevant, and the growing importance of problem-solving and oral examinations (22:09)

In Part 2, Steffen gives his unfiltered take on where AI in bioprocessing actually stands, which human capabilities are becoming harder to replace, and what a well-prepared bioprocess engineer will need to look like by 2035.

Smart Insight: Once AI can produce a polished report from a well-structured prompt, the only assessment that still reveals genuine understanding is the one a student has to navigate in real time, without a tool to hide behind.

Here are some other guests who touched on similar themes:

  • Episodes 175 – 176 : How Virtual Reality Training Solves Europe's Bioproduction Talent Shortage with Sandrine Lemoine — about training the next generation of biopharma talent.
  • Episodes 93 – 94: From Lab Coat to LinkedIn: Benjamin McLeod's Journey to Cell and Gene Therapy Influencer — another career pivot story from a scientist who stepped outside the traditional industry path.
  • Episodes 111 – 112: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén — very aligned with Steffen's nuanced take that AI is a tool but human expertise in bioprocessing still matters.

Connect with Steffen Kreye:

LinkedIn: www.linkedin.com/in/steffen-kreye-3b531183/

Berliner Hochschule für Technik: www.prof.bht-berlin.de/kreye

Next Step:

If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> When AI can draft a literature review in minutes, the question bioprocess educators can no longer avoid is this: what does a student actually need to learn?

Steffen Kreye has a clear answer. As Professor of Industrial Biotechnology at Berliner Hochschule für Technik, he trains engineers who step into industry ready to run a bioreactor, not just describe one. His argument is direct: hands-on lab competence is the one thing AI cannot replicate, and it is exactly what underfunding is quietly eroding.

Topics discussed:

  • Why Steffen Kreye left his lab head role at Bayer to become a professor and how his career evolved (03:54)
  • The unique mission of universities of applied sciences and their close connection to industry needs (11:16)
  • Challenges of delivering lab-based education, including funding and equipment constraints (12:32)
  • Creative strategies for partnering with biotech companies to sustain practical lab courses (14:34)
  • How reading student theses, partnerships, and conferences help Steffen Kreye and his colleagues stay current in a rapidly changing field (17:43)
  • The impact of AI and digital tools on research, teaching methods, and student assessment (21:18)
  • Why traditional theoretical projects are less relevant, and the growing importance of problem-solving and oral examinations (22:09)

In Part 2, Steffen gives his unfiltered take on where AI in bioprocessing actually stands, which human capabilities are becoming harder to replace, and what a well-prepared bioprocess engineer will need to look like by 2035.

Smart Insight: Once AI can produce a polished report from a well-structured prompt, the only assessment that still reveals genuine understanding is the one a student has to navigate in real time, without a tool to hide behind.

Here are some other guests who touched on similar themes:

  • Episodes 175 – 176 : How Virtual Reality Training Solves Europe's Bioproduction Talent Shortage with Sandrine Lemoine — about training the next generation of biopharma talent.
  • Episodes 93 – 94: From Lab Coat to LinkedIn: Benjamin McLeod's Journey to Cell and Gene Therapy Influencer — another career pivot story from a scientist who stepped outside the traditional industry path.
  • Episodes 111 – 112: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén — very aligned with Steffen's nuanced take that AI is a tool but human expertise in bioprocessing still matters.

Connect with Steffen Kreye:

LinkedIn: www.linkedin.com/in/steffen-kreye-3b531183/

Berliner Hochschule für Technik: www.prof.bht-berlin.de/kreye

Next Step:

If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19226644 Tue, 26 May 2026 05:00:00 +0200 1594 255 full false 254: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta Lee - Part 2 254: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta Lee - Part 2 Can aging be fundamentally slowed or even reversed—not by science fiction, but by harnessing the unassuming power of super-early stem cells?

In Part 1, Yuta Lee, Founder and CEO of Accelerated Bio, walked through the biology, ethical sourcing, and manufacturing profile of human trophoblast stem cells. In Part 2, the conversation shifts to the larger ambition: using those cells not just to treat disease, but to slow, stop, or reverse biological aging itself. The evidence starts with a striking finding from the National Institute on Aging, and it builds from there.

Topics discussed:

  • The science and ethics of sourcing stem cells from ectopic pregnancies (03:02)
  • Differences in differentiation potential between very early-stage cells and traditional MSCs or iPSCs (05:09)
  • The origins of the research focus, driven by NIH/NIA inquiry and lessons from Stanford parabiosis studies (07:27)
  • Explanation of senescent cells, inflammation, and disease connections (08:51)
  • Potential therapeutic scope, from neurodegeneration to autoimmune diseases, and systemic anti-inflammatory applications (09:26)
  • Vision for aging prevention—possibility of maintaining young biological age through regular secretome therapy (10:21)
  • Challenges and global differences in regulation, access, and clinical adoption (12:05)
  • The realistic limits and potential for reversing versus preventing age-related damage (13:20)
  • The future landscape of cell and gene therapy in medicine (14:20)
  • Why more investment is needed in longevity science and therapeutics (16:25)
  • Practical takeaways for listeners about improving healthspan and longevity today (18:07)

Smart insight:

Prevention is becoming the new frontier of medicine, shifting from treating disease to preserving long-term biological function. Yuta Lee highlights a future where proactive longevity strategies, from lifestyle choices to emerging biotech, could keep us healthier for longer and push toward “escape velocity” against aging.

If you’re interested in how we turn living biology into scalable, reliable, off-the-shelf therapies without losing control of the system, explore these episodes:

  • Episodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer
  • Episodes 147 - 148: Lab-Grown Blood: How Stem Cells Transform Transfusions with Ari Gargir
  • Episodes 179 - 180: How Mesenchymal Stromal Cells Are Transforming Care for Diabetes and Autoimmune Diseases with Lindsay Davies
  • Episodes 211 - 212: When the Innovator Becomes the Patient: Manufacturing Reality vs. Patient Urgency with Jesús Zurdo

Connect with Yuta Lee:

LinkedIn: www.linkedin.com/in/yuta10

Accelerated Bio website: www.acceleratedbio.com

Next:

If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Support the show

]]> Can aging be fundamentally slowed or even reversed—not by science fiction, but by harnessing the unassuming power of super-early stem cells?

In Part 1, Yuta Lee, Founder and CEO of Accelerated Bio, walked through the biology, ethical sourcing, and manufacturing profile of human trophoblast stem cells. In Part 2, the conversation shifts to the larger ambition: using those cells not just to treat disease, but to slow, stop, or reverse biological aging itself. The evidence starts with a striking finding from the National Institute on Aging, and it builds from there.

Topics discussed:

  • The science and ethics of sourcing stem cells from ectopic pregnancies (03:02)
  • Differences in differentiation potential between very early-stage cells and traditional MSCs or iPSCs (05:09)
  • The origins of the research focus, driven by NIH/NIA inquiry and lessons from Stanford parabiosis studies (07:27)
  • Explanation of senescent cells, inflammation, and disease connections (08:51)
  • Potential therapeutic scope, from neurodegeneration to autoimmune diseases, and systemic anti-inflammatory applications (09:26)
  • Vision for aging prevention—possibility of maintaining young biological age through regular secretome therapy (10:21)
  • Challenges and global differences in regulation, access, and clinical adoption (12:05)
  • The realistic limits and potential for reversing versus preventing age-related damage (13:20)
  • The future landscape of cell and gene therapy in medicine (14:20)
  • Why more investment is needed in longevity science and therapeutics (16:25)
  • Practical takeaways for listeners about improving healthspan and longevity today (18:07)

Smart insight:

Prevention is becoming the new frontier of medicine, shifting from treating disease to preserving long-term biological function. Yuta Lee highlights a future where proactive longevity strategies, from lifestyle choices to emerging biotech, could keep us healthier for longer and push toward “escape velocity” against aging.

If you’re interested in how we turn living biology into scalable, reliable, off-the-shelf therapies without losing control of the system, explore these episodes:

  • Episodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer
  • Episodes 147 - 148: Lab-Grown Blood: How Stem Cells Transform Transfusions with Ari Gargir
  • Episodes 179 - 180: How Mesenchymal Stromal Cells Are Transforming Care for Diabetes and Autoimmune Diseases with Lindsay Davies
  • Episodes 211 - 212: When the Innovator Becomes the Patient: Manufacturing Reality vs. Patient Urgency with Jesús Zurdo

Connect with Yuta Lee:

LinkedIn: www.linkedin.com/in/yuta10

Accelerated Bio website: www.acceleratedbio.com

Next:

If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19171413 Thu, 21 May 2026 05:00:00 +0200 1347 254 full false 253: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta Lee - Part 1 253: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta Lee - Part 1 What if the key to scalable, off-the-shelf cell therapy was hiding in tissue that surgeons discard every day?

Yuta Lee, Founder and CEO of Accelerated Bio, has spent two decades building a cell therapy platform on exactly that insight. Human trophoblast stem cells, sourced from ectopic pregnancy tissue that is otherwise discarded, sit at a unique biological intersection: earlier than MSCs, free from the ethical barriers of embryonic stem cells, expandable to 85 population doublings, and naturally equipped with HLA-G immune modulation that opens the door to allogeneic, off-the-shelf therapy at scale.

Topics discussed

  • Common misconceptions and challenges in bioprocess development for biological therapeutics (02:45)
  • The origin story behind Yuta Lee's interest in stem cells, including his father’s surgical discovery (04:15)
  • A look at the intellectual property strategy that protected and enabled Yuta Lee's company to develop its platform (07:26)
  • A clear explanation of different stem cell types (embryonic, trophoblast, mesenchymal, adult, and induced pluripotent) and their sources (09:37)
  • Ethical and regulatory issues involved in sourcing stem cells, and how trophoblast cells offer a unique alternative (10:59)
  • Discussion of stem cell differentiation, population doubling, and scalability for manufacturing purposes (17:03)
  • Importance of immune privilege and HLA-G expression in pre-placental cells for off-the-shelf therapies (20:20)
  • Shifts in the industry from autologous to allogeneic therapies, and the role trophoblast cells may play in future treatments (22:00)

In Part 2, Yuta Lee goes into the science of biological aging, the senescent cell secretome findings from the National Institute on Aging, and what a prevention-first therapeutic approach to healthspan extension could look like in practice.

Smart insight:

The scalability ceiling of MSCs is not just a manufacturing inconvenience, it is a strategic constraint. At 25 to 30 population doublings from birth-derived donors, every new donor batch requires revalidation as a distinct biological starting material. Trophoblast stem cells at 85 doublings from a single donor change that equation fundamentally, making true allogeneic scale not just biologically possible but manufacturable.

If you’re interested in how we turn living biology into scalable, reliable, off-the-shelf therapies without losing control of the system, explore these episodes:

  • Episodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer
  • Episodes 147 - 148: Lab-Grown Blood: How Stem Cells Transform Transfusions with Ari Gargir
  • Episodes 179 - 180: How Mesenchymal Stromal Cells Are Transforming Care for Diabetes and Autoimmune Diseases with Lindsay Davies
  • Episodes 211 - 212: When the Innovator Becomes the Patient: Manufacturing Reality vs. Patient Urgency with Jesús Zurdo

Connect with Yuta Lee:

LinkedIn: www.linkedin.com/in/yuta10

Accelerated Bio website: www.acceleratedbio.com

Next:

If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Support the show

]]> What if the key to scalable, off-the-shelf cell therapy was hiding in tissue that surgeons discard every day?

Yuta Lee, Founder and CEO of Accelerated Bio, has spent two decades building a cell therapy platform on exactly that insight. Human trophoblast stem cells, sourced from ectopic pregnancy tissue that is otherwise discarded, sit at a unique biological intersection: earlier than MSCs, free from the ethical barriers of embryonic stem cells, expandable to 85 population doublings, and naturally equipped with HLA-G immune modulation that opens the door to allogeneic, off-the-shelf therapy at scale.

Topics discussed

  • Common misconceptions and challenges in bioprocess development for biological therapeutics (02:45)
  • The origin story behind Yuta Lee's interest in stem cells, including his father’s surgical discovery (04:15)
  • A look at the intellectual property strategy that protected and enabled Yuta Lee's company to develop its platform (07:26)
  • A clear explanation of different stem cell types (embryonic, trophoblast, mesenchymal, adult, and induced pluripotent) and their sources (09:37)
  • Ethical and regulatory issues involved in sourcing stem cells, and how trophoblast cells offer a unique alternative (10:59)
  • Discussion of stem cell differentiation, population doubling, and scalability for manufacturing purposes (17:03)
  • Importance of immune privilege and HLA-G expression in pre-placental cells for off-the-shelf therapies (20:20)
  • Shifts in the industry from autologous to allogeneic therapies, and the role trophoblast cells may play in future treatments (22:00)

In Part 2, Yuta Lee goes into the science of biological aging, the senescent cell secretome findings from the National Institute on Aging, and what a prevention-first therapeutic approach to healthspan extension could look like in practice.

Smart insight:

The scalability ceiling of MSCs is not just a manufacturing inconvenience, it is a strategic constraint. At 25 to 30 population doublings from birth-derived donors, every new donor batch requires revalidation as a distinct biological starting material. Trophoblast stem cells at 85 doublings from a single donor change that equation fundamentally, making true allogeneic scale not just biologically possible but manufacturable.

If you’re interested in how we turn living biology into scalable, reliable, off-the-shelf therapies without losing control of the system, explore these episodes:

  • Episodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer
  • Episodes 147 - 148: Lab-Grown Blood: How Stem Cells Transform Transfusions with Ari Gargir
  • Episodes 179 - 180: How Mesenchymal Stromal Cells Are Transforming Care for Diabetes and Autoimmune Diseases with Lindsay Davies
  • Episodes 211 - 212: When the Innovator Becomes the Patient: Manufacturing Reality vs. Patient Urgency with Jesús Zurdo

Connect with Yuta Lee:

LinkedIn: www.linkedin.com/in/yuta10

Accelerated Bio website: www.acceleratedbio.com

Next:

If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19171398 Tue, 19 May 2026 05:00:00 +0200 1430 253 full false 252: How to Use Media Supplements to Tailor Biosimilar Glycan Quality to Your Reference Product in Two Rounds 252: How to Use Media Supplements to Tailor Biosimilar Glycan Quality to Your Reference Product in Two Rounds Are you still using one-factor-at-a-time experiments for biosimilar development, losing months, missing interactions, and risking costly dead-ends?

In this episode, David Brühlmann, host of the Smart Biotech Scientist Podcast, reveals how traditional "one factor at a time" screening in biosimilar development can take over 12 months, while the parallel group design massively accelerates discovery by grouping up to five factors per experiment and applying a multivariate analysis pipeline.

Topics discussed:

  • The limitations of traditional and large DoE designs and the advantages of parallel group design (00:08)
  • Best practices for grouping compounds by biological mechanism with four essential rules (00:53)
  • The importance of anchor compounds, separating strong modulators, and initial univariate screens for unknown compounds (01:43)
  • Guidance on managing practical issues, including evaporation, liquid handling, osmolality, and replicating production processes (06:42)
  • The use of multivariate analysis tools: Principal Component Analysis, Mahalanobis distance, and decision trees for candidate selection (10:14)
  • Key results and outcomes from applying the parallel group method, including faster and more cost-effective quality modulator identification (12:46)
  • Three improvements David would recommend today: prequalifying compounds, broader quality analytics, and hybrid modeling integration (13:49)
  • The shift in mindset from “time problem” to “information problem” in process development (16:50)
  • Extending the parallel group and multivariate approach to other areas like clone selection and scale-up decisions (17:52)

Smart insight:

Process development is fundamentally about generating actionable information, not just running more experiments. The parallel group, multivariate pipeline lets teams ask better questions, in parallel, with dramatically improved data yield. This mindset and methodology extend well beyond biosimilar media development into clone selection, feed design, and process characterization, wherever complexity would paralyze traditional approaches.

If you want more detail, you can read the full article “Parallel experimental design and multivariate analysis provides efficient screening of cell culture media supplements to improve biosimilar product quality” published in Biotechnology and Bioengineering, which outlines the methods and findings behind this approach.

If you’re interested in hybrid modeling, here’s what previous podcast guests have shared on the topic, offering perspectives from fundamentals to real-world applications.

  • Episodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov
  • Episodes 99 - 100: From Raw Data to Actionable Insights: Unlocking the Power of Process Models with Fabian Feidl
  • Episodes 137 - 138: Skip 90% of Bioreactor Runs: The In Silico Revolution in Bioprocess Development with Yossi Quint
  • Episodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey

Next step: If this was useful, leave a review on Apple Podcasts or Spotify. It helps other scientists find this content, and it genuinely matters.

Support the show

]]> Are you still using one-factor-at-a-time experiments for biosimilar development, losing months, missing interactions, and risking costly dead-ends?

In this episode, David Brühlmann, host of the Smart Biotech Scientist Podcast, reveals how traditional "one factor at a time" screening in biosimilar development can take over 12 months, while the parallel group design massively accelerates discovery by grouping up to five factors per experiment and applying a multivariate analysis pipeline.

Topics discussed:

  • The limitations of traditional and large DoE designs and the advantages of parallel group design (00:08)
  • Best practices for grouping compounds by biological mechanism with four essential rules (00:53)
  • The importance of anchor compounds, separating strong modulators, and initial univariate screens for unknown compounds (01:43)
  • Guidance on managing practical issues, including evaporation, liquid handling, osmolality, and replicating production processes (06:42)
  • The use of multivariate analysis tools: Principal Component Analysis, Mahalanobis distance, and decision trees for candidate selection (10:14)
  • Key results and outcomes from applying the parallel group method, including faster and more cost-effective quality modulator identification (12:46)
  • Three improvements David would recommend today: prequalifying compounds, broader quality analytics, and hybrid modeling integration (13:49)
  • The shift in mindset from “time problem” to “information problem” in process development (16:50)
  • Extending the parallel group and multivariate approach to other areas like clone selection and scale-up decisions (17:52)

Smart insight:

Process development is fundamentally about generating actionable information, not just running more experiments. The parallel group, multivariate pipeline lets teams ask better questions, in parallel, with dramatically improved data yield. This mindset and methodology extend well beyond biosimilar media development into clone selection, feed design, and process characterization, wherever complexity would paralyze traditional approaches.

If you want more detail, you can read the full article “Parallel experimental design and multivariate analysis provides efficient screening of cell culture media supplements to improve biosimilar product quality” published in Biotechnology and Bioengineering, which outlines the methods and findings behind this approach.

If you’re interested in hybrid modeling, here’s what previous podcast guests have shared on the topic, offering perspectives from fundamentals to real-world applications.

  • Episodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov
  • Episodes 99 - 100: From Raw Data to Actionable Insights: Unlocking the Power of Process Models with Fabian Feidl
  • Episodes 137 - 138: Skip 90% of Bioreactor Runs: The In Silico Revolution in Bioprocess Development with Yossi Quint
  • Episodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey

Next step: If this was useful, leave a review on Apple Podcasts or Spotify. It helps other scientists find this content, and it genuinely matters.

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19171376 Thu, 14 May 2026 05:00:00 +0200 1098 252 full false 251: Why a Single Large DoE Fails Biosimilar Glycan Optimization — And the Parallel Screening Method That Actually Works 251: Why a Single Large DoE Fails Biosimilar Glycan Optimization — And the Parallel Screening Method That Actually Works Are you stuck screening endless compounds in biosimilar development and still not hitting your quality targets? Efficient compound screening is one of the toughest bottlenecks in biopharma, with outdated methods slowing progress and risking critical quality attributes in monoclonal antibody development.

David Brühlmann breaks down a practical, parallel framework for rapid compound screening that addresses interaction effects, masking, and data quality. Methods proven in challenging biosimilar development programs.

Topics discussed:

  • The historical bottleneck of one-at-a-time screening in drug discovery and the impact of high throughput methods (01:04)
  • Problems with both one-factor-at-a-time and large design of experiments approaches when handling many variables (02:10)
  • Description of the parallel group method: splitting 17 quality modulating compounds into five biologically relevant groups and running experiments in parallel (06:09)
  • How grouping compounds by biological mechanism improves interpretability and experimental design (06:43)
  • Strategies for minimizing dilution effects, toxicity risks, and masking in multi-factor screens (08:24)
  • The importance of multivariate analysis: using principal component analysis (PCA), Mahalanobis distance, and decision trees to interpret and select optimal experimental conditions (10:31)
  • Real-world outcomes: identifying optimal compound combinations in just two rounds of screening (15:20)
  • Reflections on the evolving role of hybrid modeling and machine learning in biosimilar process optimization (15:54)

In Part 2, the focus shifts to a hands-on approach, covering how to design compound groups based on biology, set concentration ranges without compromising data quality, and execute a 96-well screen with the rigor the method demands. It also highlights three key aspects that would be approached differently if the study were conducted today.

Strategic insight:

Effective compound screening shifts from one-at-a-time testing to biology-driven parallel grouping combined with multivariate analytics, enabling faster identification of optimal combinations while preserving data quality and capturing interaction effects.

If you want more detail, you can read the full article “Parallel experimental design and multivariate analysis provides efficient screening of cell culture media supplements to improve biosimilar product quality” published in Biotechnology and Bioengineering, which outlines the methods and findings behind this approach.

If you’re interested in hybrid modeling, here’s what previous podcast guests have shared on the topic, offering perspectives from fundamentals to real-world applications.

  • Episodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov
  • Episodes 99 - 100: From Raw Data to Actionable Insights: Unlocking the Power of Process Models with Fabian Feidl
  • Episodes 137 - 138: Skip 90% of Bioreactor Runs: The In Silico Revolution in Bioprocess Development with Yossi Quint
  • Episodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey

Next step: If this was useful, leave a review on Apple Podcasts or Spotify. It helps other scientists find this content, and it genuinely matters.

Support the show

]]> Are you stuck screening endless compounds in biosimilar development and still not hitting your quality targets? Efficient compound screening is one of the toughest bottlenecks in biopharma, with outdated methods slowing progress and risking critical quality attributes in monoclonal antibody development.

David Brühlmann breaks down a practical, parallel framework for rapid compound screening that addresses interaction effects, masking, and data quality. Methods proven in challenging biosimilar development programs.

Topics discussed:

  • The historical bottleneck of one-at-a-time screening in drug discovery and the impact of high throughput methods (01:04)
  • Problems with both one-factor-at-a-time and large design of experiments approaches when handling many variables (02:10)
  • Description of the parallel group method: splitting 17 quality modulating compounds into five biologically relevant groups and running experiments in parallel (06:09)
  • How grouping compounds by biological mechanism improves interpretability and experimental design (06:43)
  • Strategies for minimizing dilution effects, toxicity risks, and masking in multi-factor screens (08:24)
  • The importance of multivariate analysis: using principal component analysis (PCA), Mahalanobis distance, and decision trees to interpret and select optimal experimental conditions (10:31)
  • Real-world outcomes: identifying optimal compound combinations in just two rounds of screening (15:20)
  • Reflections on the evolving role of hybrid modeling and machine learning in biosimilar process optimization (15:54)

In Part 2, the focus shifts to a hands-on approach, covering how to design compound groups based on biology, set concentration ranges without compromising data quality, and execute a 96-well screen with the rigor the method demands. It also highlights three key aspects that would be approached differently if the study were conducted today.

Strategic insight:

Effective compound screening shifts from one-at-a-time testing to biology-driven parallel grouping combined with multivariate analytics, enabling faster identification of optimal combinations while preserving data quality and capturing interaction effects.

If you want more detail, you can read the full article “Parallel experimental design and multivariate analysis provides efficient screening of cell culture media supplements to improve biosimilar product quality” published in Biotechnology and Bioengineering, which outlines the methods and findings behind this approach.

If you’re interested in hybrid modeling, here’s what previous podcast guests have shared on the topic, offering perspectives from fundamentals to real-world applications.

  • Episodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov
  • Episodes 99 - 100: From Raw Data to Actionable Insights: Unlocking the Power of Process Models with Fabian Feidl
  • Episodes 137 - 138: Skip 90% of Bioreactor Runs: The In Silico Revolution in Bioprocess Development with Yossi Quint
  • Episodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey

Next step: If this was useful, leave a review on Apple Podcasts or Spotify. It helps other scientists find this content, and it genuinely matters.

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19135728 Tue, 12 May 2026 05:00:00 +0200 1091 251 full false 250: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez - Part 2 250: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez - Part 2 When every batch belongs to a single patient, a single centralized facility cannot serve the world. In Part 2, Chantale Bernatchez moves from process development into the broader consequences of that reality: the manufacturing model built around clinical proximity, the global alliance bringing TIL production to regions with no current access, and the next-generation engineered approaches redefining what these therapies can do.

Chantale Bernatchez is Head of Process Development at CTMC, a joint venture between Resilience and MD Anderson Cancer Center. If you missed Part 1, she explained how specific activation changes recovered a failing TIL process from 50% to 95% success in heavily pre-treated patients.

Topics discussed:

  • How close collaboration with MD Anderson accelerates clinical development and regulatory readiness (03:08)
  • CTMC’s approach to process development and adapting to innovative technologies (05:15)
  • The value of partnership-based models versus traditional CDMO-driven approaches (06:24)
  • Global technology transfer: building alliances to expand access to cell therapies, with a case study in Brazil (07:35)
  • Key barriers and solutions for cell therapy manufacturing in new regions (09:41)
  • Practical advice for scientists starting in GMP manufacturing and process development (10:46)
  • Future directions in CAR T and TIL, including logic-gated CARs, engineered TILs, and in vivo therapies (12:24)
  • The importance of continued innovation and collaboration to expand global patient access (17:39)

Smart insight:

The choice of manufacturing partner in cell therapy is not a logistics decision. It is a process development decision. CTMC's collaboration-based model exists because many early-stage developers arrive without a process robust enough to hand over. For scientists in small or mid-sized companies, engaging that kind of partnership too late, or on purely transactional terms, is one of the most avoidable risks in early clinical development.

If you’re interested in exploring further the concepts we touched on, such as cell therapy manufacturing, process control, and scaling living therapies—take a look at these related discussions:

  • Episodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei
  • Episodes 109 - 110: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier Detournay
  • Episodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren’t Just Complex Biologics with Oliver Kraemer

Connect with Chantale Bernatchez:

LinkedIn: www.linkedin.com/in/chantale-bernatchez-22b09511

CTMC website: www.ctmc.com

Support the show

]]> When every batch belongs to a single patient, a single centralized facility cannot serve the world. In Part 2, Chantale Bernatchez moves from process development into the broader consequences of that reality: the manufacturing model built around clinical proximity, the global alliance bringing TIL production to regions with no current access, and the next-generation engineered approaches redefining what these therapies can do.

Chantale Bernatchez is Head of Process Development at CTMC, a joint venture between Resilience and MD Anderson Cancer Center. If you missed Part 1, she explained how specific activation changes recovered a failing TIL process from 50% to 95% success in heavily pre-treated patients.

Topics discussed:

  • How close collaboration with MD Anderson accelerates clinical development and regulatory readiness (03:08)
  • CTMC’s approach to process development and adapting to innovative technologies (05:15)
  • The value of partnership-based models versus traditional CDMO-driven approaches (06:24)
  • Global technology transfer: building alliances to expand access to cell therapies, with a case study in Brazil (07:35)
  • Key barriers and solutions for cell therapy manufacturing in new regions (09:41)
  • Practical advice for scientists starting in GMP manufacturing and process development (10:46)
  • Future directions in CAR T and TIL, including logic-gated CARs, engineered TILs, and in vivo therapies (12:24)
  • The importance of continued innovation and collaboration to expand global patient access (17:39)

Smart insight:

The choice of manufacturing partner in cell therapy is not a logistics decision. It is a process development decision. CTMC's collaboration-based model exists because many early-stage developers arrive without a process robust enough to hand over. For scientists in small or mid-sized companies, engaging that kind of partnership too late, or on purely transactional terms, is one of the most avoidable risks in early clinical development.

If you’re interested in exploring further the concepts we touched on, such as cell therapy manufacturing, process control, and scaling living therapies—take a look at these related discussions:

  • Episodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei
  • Episodes 109 - 110: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier Detournay
  • Episodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren’t Just Complex Biologics with Oliver Kraemer

Connect with Chantale Bernatchez:

LinkedIn: www.linkedin.com/in/chantale-bernatchez-22b09511

CTMC website: www.ctmc.com

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19066999 Thu, 07 May 2026 05:00:00 +0200 1249 250 full false 249: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez - Part 1 249: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez - Part 1 The most underappreciated parameter in cell therapy process development is not your bioreactor, your media, or your activation protocol. It is the patient. Chantale Bernatchez has spent 20 years learning that lesson the hard way, watching the same manufacturing process succeed brilliantly with one donor and fail completely with the next. In this episode, she explains why starting material variability is the defining challenge of cell therapy manufacturing, and what it actually takes to build a process robust enough to survive it.

Chantale Bernatchez is Head of Process Development at CTMC, a joint venture between Resilience and MD Anderson Cancer Center. She holds a PhD in immunology and has spent two decades advancing T cell therapy from early research programs at MD Anderson to GMP-compliant clinical manufacturing. She holds four patents in adoptive cell therapy.

Key topics discussed:

  • Personal journey: from immunology PhD in Quebec to cell therapy leadership in Houston (04:25)
  • Evolution of TIL therapy at MD Anderson, including manufacturing innovations to overcome declining T cell yields (06:14)
  • The fundamental differences between traditional medicines and cell-based immunotherapies (10:01)
  • Unique manufacturing complexities for autologous therapies, including batch variability and process standardization (11:19)
  • Strategies to address decreased cell fitness in heavily pretreated patients, including changes in cell activation and culture conditions (13:57)
  • Key learnings from the CAR T and TIL manufacturing process: balancing process duration, cell fitness, and product yield (16:28)
  • Mechanistic differences between CAR T and TIL therapies and their implications for efficacy and resistance (17:58)
  • The limits and risks of automation in cell therapy manufacturing—balancing manual vs. automated processes (24:04)
  • Why moving between manufacturing platforms raises challenges in comparability and clinical outcomes (25:44)
  • The ongoing search for critical cell quality attributes that correlate with patient response (27:00)

In part two, Chantale goes deeper into next-generation approaches, technology transfer, and what needs to change to broadly expand patient access.

Smart insight: In cell therapy, manufacturing isn’t just a production step. It defines the therapy itself. Because each patient’s starting cells are unique, even subtle changes in the process can significantly alter clinical outcomes.

If you’re interested in exploring further the concepts we touched on—such as cell therapy manufacturing, process control, and scaling living therapies—take a look at these related discussions:

  • Episodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei
  • Episodes 109 - 110: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier Detournay
  • Episodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren’t Just Complex Biologics with Oliver Kraemer

Connect with Chantale Bernatchez:

LinkedIn: www.linkedin.com/in/chantale-bernatchez-22b09511

CTMC website: www.ctmc.com

Support the show

]]> The most underappreciated parameter in cell therapy process development is not your bioreactor, your media, or your activation protocol. It is the patient. Chantale Bernatchez has spent 20 years learning that lesson the hard way, watching the same manufacturing process succeed brilliantly with one donor and fail completely with the next. In this episode, she explains why starting material variability is the defining challenge of cell therapy manufacturing, and what it actually takes to build a process robust enough to survive it.

Chantale Bernatchez is Head of Process Development at CTMC, a joint venture between Resilience and MD Anderson Cancer Center. She holds a PhD in immunology and has spent two decades advancing T cell therapy from early research programs at MD Anderson to GMP-compliant clinical manufacturing. She holds four patents in adoptive cell therapy.

Key topics discussed:

  • Personal journey: from immunology PhD in Quebec to cell therapy leadership in Houston (04:25)
  • Evolution of TIL therapy at MD Anderson, including manufacturing innovations to overcome declining T cell yields (06:14)
  • The fundamental differences between traditional medicines and cell-based immunotherapies (10:01)
  • Unique manufacturing complexities for autologous therapies, including batch variability and process standardization (11:19)
  • Strategies to address decreased cell fitness in heavily pretreated patients, including changes in cell activation and culture conditions (13:57)
  • Key learnings from the CAR T and TIL manufacturing process: balancing process duration, cell fitness, and product yield (16:28)
  • Mechanistic differences between CAR T and TIL therapies and their implications for efficacy and resistance (17:58)
  • The limits and risks of automation in cell therapy manufacturing—balancing manual vs. automated processes (24:04)
  • Why moving between manufacturing platforms raises challenges in comparability and clinical outcomes (25:44)
  • The ongoing search for critical cell quality attributes that correlate with patient response (27:00)

In part two, Chantale goes deeper into next-generation approaches, technology transfer, and what needs to change to broadly expand patient access.

Smart insight: In cell therapy, manufacturing isn’t just a production step. It defines the therapy itself. Because each patient’s starting cells are unique, even subtle changes in the process can significantly alter clinical outcomes.

If you’re interested in exploring further the concepts we touched on—such as cell therapy manufacturing, process control, and scaling living therapies—take a look at these related discussions:

  • Episodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei
  • Episodes 109 - 110: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier Detournay
  • Episodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren’t Just Complex Biologics with Oliver Kraemer

Connect with Chantale Bernatchez:

LinkedIn: www.linkedin.com/in/chantale-bernatchez-22b09511

CTMC website: www.ctmc.com

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19066973 Tue, 05 May 2026 05:00:00 +0200 1751 249 full false 248: Nitrosamine Risk Assessment and CRO Selection: The $6 Million Mistake CMC Teams Must Avoid with Ron Najafi - Part 2 248: Nitrosamine Risk Assessment and CRO Selection: The $6 Million Mistake CMC Teams Must Avoid with Ron Najafi - Part 2 Getting an NDA signed shouldn't take weeks. If your CRO needs more than 48 hours to start the paperwork, your project timeline is already moving in the wrong direction.

Ron Najafi knows what rigorous analytical work actually looks like under pressure. As founder and CEO of Emery Pharma, he led the investigation that identified NDMA as a degradation product of ranitidine — findings the FDA formally validated and that reshaped how the industry approaches nitrosamine risk assessment. In Part 2, he moves from that scientific foundation into the operational questions that determine whether a CRO partnership accelerates your program or quietly slows it down.

If you haven't heard Part 1, it covers Ron's career arc and the technical details of nitrosamine contamination in pharmaceutical development. This episode stands on its own for anyone focused on CRO selection, bioanalytical strategy, and what three decades of building analytical companies actually teaches you.

Topics discussed:

  • How to tell if a CRO’s workflow is robust—or just rigid (05:51)
  • The importance of method validation and product stability testing (07:27)
  • Managing expectations and trust-building in client relationships (08:29)
  • Entrepreneurial lessons: raising capital, team-building, and finding the right partners (10:00)
  • The hidden costs of public vs. private biotech ventures (12:31)
  • Reducing bioanalytical costs in biologics through mass spectrometry (13:23)
  • The future of analytical workflows and personalized medicine (14:48)

Smart insight:

In biotech, success isn’t just about the science—it’s about strategic discipline. Ron emphasizes a few hard-earned principles: raise more capital than you think you’ll need, don’t fixate on valuation, and invest in smart, creative talent. Just as important, real value is unlocked through strong partnerships and the ability to manage collaborations and acquisitions with intention.

If this topic resonates with you, here are a few related episodes on building strong CMC foundations and avoiding costly development mistakes:

  • Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
  • Episodes 203 - 204: Mastering CRO Selection: Essential Questions for CMC Analytical Development with Daniel Galbraith
  • Episodes 199 - 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC Development
  • Episodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)
  • Episodes 139 - 140: Regulatory Secrets Revealed: Why Your CMC Strategy Could Make or Break Your Biotech Startup with Rivka Zaibel
  • Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner
  • Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene Lee

Connect with Ron Najafi:

LinkedIn: www.linkedin.com/in/ronnajafi

Emery Pharma: www.emerypharma.com

Support the show

]]> Getting an NDA signed shouldn't take weeks. If your CRO needs more than 48 hours to start the paperwork, your project timeline is already moving in the wrong direction.

Ron Najafi knows what rigorous analytical work actually looks like under pressure. As founder and CEO of Emery Pharma, he led the investigation that identified NDMA as a degradation product of ranitidine — findings the FDA formally validated and that reshaped how the industry approaches nitrosamine risk assessment. In Part 2, he moves from that scientific foundation into the operational questions that determine whether a CRO partnership accelerates your program or quietly slows it down.

If you haven't heard Part 1, it covers Ron's career arc and the technical details of nitrosamine contamination in pharmaceutical development. This episode stands on its own for anyone focused on CRO selection, bioanalytical strategy, and what three decades of building analytical companies actually teaches you.

Topics discussed:

  • How to tell if a CRO’s workflow is robust—or just rigid (05:51)
  • The importance of method validation and product stability testing (07:27)
  • Managing expectations and trust-building in client relationships (08:29)
  • Entrepreneurial lessons: raising capital, team-building, and finding the right partners (10:00)
  • The hidden costs of public vs. private biotech ventures (12:31)
  • Reducing bioanalytical costs in biologics through mass spectrometry (13:23)
  • The future of analytical workflows and personalized medicine (14:48)

Smart insight:

In biotech, success isn’t just about the science—it’s about strategic discipline. Ron emphasizes a few hard-earned principles: raise more capital than you think you’ll need, don’t fixate on valuation, and invest in smart, creative talent. Just as important, real value is unlocked through strong partnerships and the ability to manage collaborations and acquisitions with intention.

If this topic resonates with you, here are a few related episodes on building strong CMC foundations and avoiding costly development mistakes:

  • Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
  • Episodes 203 - 204: Mastering CRO Selection: Essential Questions for CMC Analytical Development with Daniel Galbraith
  • Episodes 199 - 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC Development
  • Episodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)
  • Episodes 139 - 140: Regulatory Secrets Revealed: Why Your CMC Strategy Could Make or Break Your Biotech Startup with Rivka Zaibel
  • Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner
  • Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene Lee

Connect with Ron Najafi:

LinkedIn: www.linkedin.com/in/ronnajafi

Emery Pharma: www.emerypharma.com

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19006335 Thu, 30 Apr 2026 05:00:00 +0200 1148 248 full false 247: Nitrosamine Risk Assessment and CRO Selection: The $6 Million Mistake CMC Teams Must Avoid with Ron Najafi - Part 1 247: Nitrosamine Risk Assessment and CRO Selection: The $6 Million Mistake CMC Teams Must Avoid with Ron Najafi - Part 1 When drug safety fails, patients and entire markets pay the price. Understanding your CMC isn't just compliance — it's the line between therapeutic promise and product recall.

Ron Najafi has lived that reality firsthand. As founder of NovaBay Pharmaceuticals and Emery Pharma, he spent decades building companies at the intersection of analytical chemistry and drug development. His investigation into nitrosamine contamination in ranitidine — which led the FDA to formally validate Emery Pharma's findings — remains one of the most consequential episodes in recent pharmaceutical quality history.

In Part 1, Ron traces the scientific and entrepreneurial path that led him there, and shares what CMC teams working in drug development need to understand about impurity risk before it becomes a regulatory crisis.

Episode highlights:

  • Early academic experiences and inspirations that Ron Najafi to a science career (05:46)
  • Challenges and milestones in building companies like CP Lab Safety and NovaBay Pharmaceuticals (07:59)
  • The invention and impact of the ECO Funnel® on lab safety and environmental responsibility (12:01)
  • The formation of Emery Pharma following industry setbacks and lessons in adaptation (17:03)
  • The fundamentals of impurity risk analysis, especially nitrosamine contamination in pharmaceuticals (20:56)
  • The ranitidine (Zantac) NDMA discovery, its investigation, and consequences for drug regulation (23:33)
  • Common sources of nitrosamine and practical advice for bioprocess risk management (27:51)
  • Differences in impurity risk between small molecule and biologic drug processes (28:03)
  • The necessity and regulatory expectation of impurity and leachable/extractable analysis (30:07)

Smart insight:

One of Ron's clients conducted a superficial nitrosamine risk assessment, proceeded to manufacturing, and spent approximately $6 million producing three batches. At final FDA-required testing, NDMA came back at 11,000 nanograms per pill against an acceptable daily intake limit of 96 nanograms. The batches were unusable.

A thorough risk assessment run earlier would have cost a fraction of that. If you are developing a drug with secondary or tertiary amines in your process and have not yet conducted a formal nitrosamine risk assessment, that is the one action to take after listening to this episode.

If this topic resonates with you, here are a few related episodes on building strong CMC foundations and avoiding costly development mistakes:

  • Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
  • Episodes 203 - 204: Mastering CRO Selection: Essential Questions for CMC Analytical Development with Daniel Galbraith
  • Episodes 199 - 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC Development
  • Episodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)
  • Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner
  • Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene Lee

Connect with Ron Najafi:

LinkedIn: www.linkedin.com/in/ronnajafi

Emery Pharma: www.emerypharma.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> When drug safety fails, patients and entire markets pay the price. Understanding your CMC isn't just compliance — it's the line between therapeutic promise and product recall.

Ron Najafi has lived that reality firsthand. As founder of NovaBay Pharmaceuticals and Emery Pharma, he spent decades building companies at the intersection of analytical chemistry and drug development. His investigation into nitrosamine contamination in ranitidine — which led the FDA to formally validate Emery Pharma's findings — remains one of the most consequential episodes in recent pharmaceutical quality history.

In Part 1, Ron traces the scientific and entrepreneurial path that led him there, and shares what CMC teams working in drug development need to understand about impurity risk before it becomes a regulatory crisis.

Episode highlights:

  • Early academic experiences and inspirations that Ron Najafi to a science career (05:46)
  • Challenges and milestones in building companies like CP Lab Safety and NovaBay Pharmaceuticals (07:59)
  • The invention and impact of the ECO Funnel® on lab safety and environmental responsibility (12:01)
  • The formation of Emery Pharma following industry setbacks and lessons in adaptation (17:03)
  • The fundamentals of impurity risk analysis, especially nitrosamine contamination in pharmaceuticals (20:56)
  • The ranitidine (Zantac) NDMA discovery, its investigation, and consequences for drug regulation (23:33)
  • Common sources of nitrosamine and practical advice for bioprocess risk management (27:51)
  • Differences in impurity risk between small molecule and biologic drug processes (28:03)
  • The necessity and regulatory expectation of impurity and leachable/extractable analysis (30:07)

Smart insight:

One of Ron's clients conducted a superficial nitrosamine risk assessment, proceeded to manufacturing, and spent approximately $6 million producing three batches. At final FDA-required testing, NDMA came back at 11,000 nanograms per pill against an acceptable daily intake limit of 96 nanograms. The batches were unusable.

A thorough risk assessment run earlier would have cost a fraction of that. If you are developing a drug with secondary or tertiary amines in your process and have not yet conducted a formal nitrosamine risk assessment, that is the one action to take after listening to this episode.

If this topic resonates with you, here are a few related episodes on building strong CMC foundations and avoiding costly development mistakes:

  • Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
  • Episodes 203 - 204: Mastering CRO Selection: Essential Questions for CMC Analytical Development with Daniel Galbraith
  • Episodes 199 - 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC Development
  • Episodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)
  • Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner
  • Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene Lee

Connect with Ron Najafi:

LinkedIn: www.linkedin.com/in/ronnajafi

Emery Pharma: www.emerypharma.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19006315 Tue, 28 Apr 2026 05:00:00 +0200 1979 247 full false 246: Why Your Shake Flask Culture Doesn't Scale: OTR, Shaking Diameter, and How to Fix It with Tibor Anderlei - Part 2 246: Why Your Shake Flask Culture Doesn't Scale: OTR, Shaking Diameter, and How to Fix It with Tibor Anderlei - Part 2 Shear sensitivity is the silent challenge behind many advanced biomanufacturing modalities. Orbital-shaken bioreactors—often underestimated—may be a key enabler your CMC development is missing.

Tibor Anderlei, CSO at Kühner Shaker, joined David Brühlmann on the Smart Biotech Scientist Podcast to unpack the hidden physics behind bioprocess reproducibility and next-generation shaking technology. He has seen firsthand how overlooking fundamental parameters can derail scale-up and delay development timelines. In his role, Tibor is responsible for the customer interface—spanning sales, service, support, GMP topics, troubleshooting, marketing, and applied technology—with a focus on orbital shaking technology and small-scale cultivation support.

Topics discussed:

  • The importance of measuring oxygen transfer rate (OTR) and carbon dioxide transfer rate (CTR) for reproducible bioprocesses—why DO is not sufficient (02:55)
  • Real-time process analytical technology (PAT) for small-scale bioreactors, including microtiter plates and shake flasks (06:47)
  • Pre-culture reproducibility: transferring at the right OTR and its impact on main cultures (07:56)
  • Price sensitivity and scale-up challenges in cultivated meat—implications for media and equipment selection (10:36)
  • Expansion of shaking technology to fields such as mixing, storage, and thawing, including applications in liquid crystal production (12:10)
  • Leadership lessons from competing with bigger players: how smaller companies stay innovative, agile, and close to their customers (14:20)
  • The significance of strong business partner relationships and trusting gut feeling in decision-making (16:32)
  • Key advice for smart biotech scientists: careful definition of screening conditions and the use of online measurement tools at small scale (18:09)
  • Accessible resources for mastering shaken bioreactor techniques, including webinars and direct contact with Tibor Anderlei (19:38)

Smart insight:

Treat small-scale shaken systems as real bioreactors and define screening conditions carefully from the start. Using online measurement tools even at early stages provides critical visibility and helps ensure that results are reproducible and scalable.

Building a robust scale-up strategy requires looking at the process from multiple angles—regulatory, digital, and operational. Listen to those previous episodes:

  • Episode 03 - 04: How to Master Biotech Scale-up Without Guesswork with Leonardo Sibilio
  • Episode 25 - 26: 9 Critical Steps for a Seamless Transition to Large-Scale Production
  • Episode 231-232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
  • Episode 233-234: Why Most Bioprocess Automation Projects Fail with Anthony Catacchio
  • Episode 237-238: High-Throughput Microbial Screening with Sebastian Blum

Connect with Tibor Anderlei:

LinkedIn: www.linkedin.com/in/tibor-anderlei-66342411/

Kühner Shaker website: www.kuhner.com

Shaking Technology Forum: www.shakingtechnology.com

Support the show

]]> Shear sensitivity is the silent challenge behind many advanced biomanufacturing modalities. Orbital-shaken bioreactors—often underestimated—may be a key enabler your CMC development is missing.

Tibor Anderlei, CSO at Kühner Shaker, joined David Brühlmann on the Smart Biotech Scientist Podcast to unpack the hidden physics behind bioprocess reproducibility and next-generation shaking technology. He has seen firsthand how overlooking fundamental parameters can derail scale-up and delay development timelines. In his role, Tibor is responsible for the customer interface—spanning sales, service, support, GMP topics, troubleshooting, marketing, and applied technology—with a focus on orbital shaking technology and small-scale cultivation support.

Topics discussed:

  • The importance of measuring oxygen transfer rate (OTR) and carbon dioxide transfer rate (CTR) for reproducible bioprocesses—why DO is not sufficient (02:55)
  • Real-time process analytical technology (PAT) for small-scale bioreactors, including microtiter plates and shake flasks (06:47)
  • Pre-culture reproducibility: transferring at the right OTR and its impact on main cultures (07:56)
  • Price sensitivity and scale-up challenges in cultivated meat—implications for media and equipment selection (10:36)
  • Expansion of shaking technology to fields such as mixing, storage, and thawing, including applications in liquid crystal production (12:10)
  • Leadership lessons from competing with bigger players: how smaller companies stay innovative, agile, and close to their customers (14:20)
  • The significance of strong business partner relationships and trusting gut feeling in decision-making (16:32)
  • Key advice for smart biotech scientists: careful definition of screening conditions and the use of online measurement tools at small scale (18:09)
  • Accessible resources for mastering shaken bioreactor techniques, including webinars and direct contact with Tibor Anderlei (19:38)

Smart insight:

Treat small-scale shaken systems as real bioreactors and define screening conditions carefully from the start. Using online measurement tools even at early stages provides critical visibility and helps ensure that results are reproducible and scalable.

Building a robust scale-up strategy requires looking at the process from multiple angles—regulatory, digital, and operational. Listen to those previous episodes:

  • Episode 03 - 04: How to Master Biotech Scale-up Without Guesswork with Leonardo Sibilio
  • Episode 25 - 26: 9 Critical Steps for a Seamless Transition to Large-Scale Production
  • Episode 231-232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
  • Episode 233-234: Why Most Bioprocess Automation Projects Fail with Anthony Catacchio
  • Episode 237-238: High-Throughput Microbial Screening with Sebastian Blum

Connect with Tibor Anderlei:

LinkedIn: www.linkedin.com/in/tibor-anderlei-66342411/

Kühner Shaker website: www.kuhner.com

Shaking Technology Forum: www.shakingtechnology.com

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19006301 Thu, 23 Apr 2026 05:00:00 +0200 1351 246 full false 245: Why Your Shake Flask Culture Doesn't Scale: OTR, Shaking Diameter, and How to Fix It with Tibor Anderlei - Part 1 245: Why Your Shake Flask Culture Doesn't Scale: OTR, Shaking Diameter, and How to Fix It with Tibor Anderlei - Part 1 Why do small-scale bioprocess experiments often fail to translate in scale-up despite “perfect” results on paper?

Tibor Anderlei, Chief Scientific Officer and leader of customer support at Kühner Shaker, has spent three decades solving an issue that frustrates CMC leaders and biomanufacturing teams worldwide. He pioneered online monitoring in shake flasks, co-founded AC Biotec, and now helps organizations avoid costly trial-and-error with high-throughput screening and orbital shaken bioreactors.

Topics discussed:

  • Why orbital shaken bioreactors are fundamental to successful bioprocess development (03:11)
  • The gap between educational practices and real-world bioreactor expertise (04:00)
  • Tibor Anderlei’s journey from the Technical University of Aachen to pioneering online monitoring technology in shake flasks (04:27)
  • Reasons why published shake flask and microtiter plate experiments often fail to be reproduced in other labs (09:47)
  • Key parameters frequently omitted from publications—including shaking diameter—and their impact on experiment reproducibility (13:10)
  • Practical considerations for using microtiter plates and tubes, including automation compatibility and critical shaking speeds (14:13)
  • Common scale-up failures due to oxygen limitation and mismatched aeration rates between small-scale and bioreactor systems (22:22)
  • The effect of bioreactor geometry, such as neck shape, on process ventilation and performance (24:49)

Smart insight: If scientists want scalable, reproducible success, the path starts with getting the details right—and keeping a sharp eye on both automation trends and the fundamentals of shaken cultures.

Listen to the full episode with Tibor Anderlei to unpack the real “missing links” in bioprocess reproducibility and how to bridge small-scale insight to CMC scale-up.

Building a robust scale-up strategy requires looking at the process from multiple angles—regulatory, digital, and operational. Listen to those previous episodes:

  • Episode 03 - 04: How to Master Biotech Scale-up Without Guesswork with Leonardo Sibilio
  • Episode 25-26: 9 Critical Steps for a Seamless Transition to Large-Scale Production
  • Episode 231-232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
  • Episode 233-234: Why Most Bioprocess Automation Projects Fail with Anthony Catacchio
  • Episode 237-238: High-Throughput Microbial Screening with Sebastian Blum

Connect with Tibor Anderlei:

LinkedIn: www.linkedin.com/in/tibor-anderlei-66342411/

Kühner Shaker website: www.kuhner.com

Shaking Technology Forum: www.shakingtechnology.com

Support the show

]]> Why do small-scale bioprocess experiments often fail to translate in scale-up despite “perfect” results on paper?

Tibor Anderlei, Chief Scientific Officer and leader of customer support at Kühner Shaker, has spent three decades solving an issue that frustrates CMC leaders and biomanufacturing teams worldwide. He pioneered online monitoring in shake flasks, co-founded AC Biotec, and now helps organizations avoid costly trial-and-error with high-throughput screening and orbital shaken bioreactors.

Topics discussed:

  • Why orbital shaken bioreactors are fundamental to successful bioprocess development (03:11)
  • The gap between educational practices and real-world bioreactor expertise (04:00)
  • Tibor Anderlei’s journey from the Technical University of Aachen to pioneering online monitoring technology in shake flasks (04:27)
  • Reasons why published shake flask and microtiter plate experiments often fail to be reproduced in other labs (09:47)
  • Key parameters frequently omitted from publications—including shaking diameter—and their impact on experiment reproducibility (13:10)
  • Practical considerations for using microtiter plates and tubes, including automation compatibility and critical shaking speeds (14:13)
  • Common scale-up failures due to oxygen limitation and mismatched aeration rates between small-scale and bioreactor systems (22:22)
  • The effect of bioreactor geometry, such as neck shape, on process ventilation and performance (24:49)

Smart insight: If scientists want scalable, reproducible success, the path starts with getting the details right—and keeping a sharp eye on both automation trends and the fundamentals of shaken cultures.

Listen to the full episode with Tibor Anderlei to unpack the real “missing links” in bioprocess reproducibility and how to bridge small-scale insight to CMC scale-up.

Building a robust scale-up strategy requires looking at the process from multiple angles—regulatory, digital, and operational. Listen to those previous episodes:

  • Episode 03 - 04: How to Master Biotech Scale-up Without Guesswork with Leonardo Sibilio
  • Episode 25-26: 9 Critical Steps for a Seamless Transition to Large-Scale Production
  • Episode 231-232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann
  • Episode 233-234: Why Most Bioprocess Automation Projects Fail with Anthony Catacchio
  • Episode 237-238: High-Throughput Microbial Screening with Sebastian Blum

Connect with Tibor Anderlei:

LinkedIn: www.linkedin.com/in/tibor-anderlei-66342411/

Kühner Shaker website: www.kuhner.com

Shaking Technology Forum: www.shakingtechnology.com

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-19006274 Tue, 21 Apr 2026 05:00:00 +0200 1541 245 full false 244: Prevent the Delays That Derail Biologics Tech Transfer: 12-Week Protocol for CMC 244: Prevent the Delays That Derail Biologics Tech Transfer: 12-Week Protocol for CMC When a single mismanaged tech transfer threatens an entire development program, pressure on CMC leaders and bioprocess teams is intense. The truth? Tech transfers aren’t a black box. They’re complex, but solvable with the right mindset and playbook.

In this episode, David Brühlmann explores the practical side of tech transfer and scale-up within the biotech industry. With more than 15 years of experience, he shares personal stories and industry-tested frameworks that help demystify the complexities of transferring technologies between sites or organizations. Instead of focusing solely on technical details, he emphasizes the crucial human and organizational factors that often decide project success or failure.

Key topics discussed:

  • How mapping and managing stakeholders can resolve hidden issues and accelerate projects (01:55)
  • Case studies highlighting the importance of environmental factors — like light exposure — in process performance and troubleshooting (05:50)
  • A mass transfer checklist for bioprocess scale-up, with specific focus on equipment-related parameters (07:09)
  • The build vs. outsource dilemma: how to choose what to keep in-house and what to partner out, depending on company strategy and project phase (08:05)
  • A 12-week tech transfer preparation protocol, covering foundations, risk mitigation, and execution readiness (10:16)
  • Lessons on leadership, prioritization, and effective delegation to avoid personal and organizational bottlenecks (13:28)

Whether you're overseeing a complex CMC program, navigating CDMO relationships, or planning your next scale-up, this episode offers concrete steps to cut through confusion and deliver results.

If you’re interested in the ideas discussed, here are some of the guests David referenced in this episode.

  • Episodes 91 - 92: Mass Transfer Secrets: Mastering Bubbles and kLa from Bench to Large-Scale Production with Lars Puiman & Rik Volger
  • Episodes 79 - 80: Think Before You Build: Holistic Approaches to Biotech Facility Design with Alfredo Martínez Mogarra
  • Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner
  • Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene Lee

Support the show

]]> When a single mismanaged tech transfer threatens an entire development program, pressure on CMC leaders and bioprocess teams is intense. The truth? Tech transfers aren’t a black box. They’re complex, but solvable with the right mindset and playbook.

In this episode, David Brühlmann explores the practical side of tech transfer and scale-up within the biotech industry. With more than 15 years of experience, he shares personal stories and industry-tested frameworks that help demystify the complexities of transferring technologies between sites or organizations. Instead of focusing solely on technical details, he emphasizes the crucial human and organizational factors that often decide project success or failure.

Key topics discussed:

  • How mapping and managing stakeholders can resolve hidden issues and accelerate projects (01:55)
  • Case studies highlighting the importance of environmental factors — like light exposure — in process performance and troubleshooting (05:50)
  • A mass transfer checklist for bioprocess scale-up, with specific focus on equipment-related parameters (07:09)
  • The build vs. outsource dilemma: how to choose what to keep in-house and what to partner out, depending on company strategy and project phase (08:05)
  • A 12-week tech transfer preparation protocol, covering foundations, risk mitigation, and execution readiness (10:16)
  • Lessons on leadership, prioritization, and effective delegation to avoid personal and organizational bottlenecks (13:28)

Whether you're overseeing a complex CMC program, navigating CDMO relationships, or planning your next scale-up, this episode offers concrete steps to cut through confusion and deliver results.

If you’re interested in the ideas discussed, here are some of the guests David referenced in this episode.

  • Episodes 91 - 92: Mass Transfer Secrets: Mastering Bubbles and kLa from Bench to Large-Scale Production with Lars Puiman & Rik Volger
  • Episodes 79 - 80: Think Before You Build: Holistic Approaches to Biotech Facility Design with Alfredo Martínez Mogarra
  • Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner
  • Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene Lee

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-18956663 Thu, 16 Apr 2026 05:00:00 +0200 1065 244 full false 243: Turn Tech Transfer from a Gamble into a Managed Process: The 6-Pillar Biologics Scale-Up Framework 243: Turn Tech Transfer from a Gamble into a Managed Process: The 6-Pillar Biologics Scale-Up Framework What if the hidden cost of your bioprocess lies not in the technology, but in what you don’t document?

Too often, biotech teams discover too late that their “proven” process is just an illusion, propped up by undocumented tricks and missing critical parameters. In this episode, David Brühlmann strips down the assumptions behind scale-up and tech transfer, exposing the silent risks that threaten CMC milestones and market launches alike. After 15 years guiding biotech projects from bench to clinic, he’s felt the pain of process gaps, regulatory curveballs, and million-dollar mistakes. Here, he turns that experience into a tactical guide designed to save you from the same pitfalls.

In this episode, you’ll learn about:

  • The 6-pillar approach to turning tech transfer into a managed process, rather than a gamble (03:09)
  • Why mass transfer physics and factors like kLA are critical—and how they can make or break a process at scale (05:12)
  • The importance of analytical comparability, including the common blind spots in sampling plans and method validation (07:19)
  • Establishing a solid Quality by Design (QbD) foundation and defining critical quality attributes before transfer, not after failures (08:33)
  • Stakeholder management and why non-technical challenges often derail projects (with more on this in Part 2) (10:09)
  • Evaluating CDMO partners: What selection criteria really matter for long-term success and risk mitigation (11:03)
  • Strategic decision-making: Building core capabilities versus outsourcing, and how to avoid unnecessary costs and delays (12:22)

This episode sets the stage for Part 2, where David Brühlmann will share practical stories and detailed frameworks for real-world implementation. If you manage bioprocess scale-up, tech transfer, or CMC development, you’ll find plenty of actionable insights to apply in your own work.

If you’re interested in the ideas discussed, here are some of the guests David referenced in this episode.

  • Episodes 91 - 92: Mass Transfer Secrets: Mastering Bubbles and kLa from Bench to Large-Scale Production with Lars Puiman & Rik Volger
  • Episodes 79 - 80: Think Before You Build: Holistic Approaches to Biotech Facility Design with Alfredo Martínez Mogarra
  • Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner
  • Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene Lee

Support the show

]]> What if the hidden cost of your bioprocess lies not in the technology, but in what you don’t document?

Too often, biotech teams discover too late that their “proven” process is just an illusion, propped up by undocumented tricks and missing critical parameters. In this episode, David Brühlmann strips down the assumptions behind scale-up and tech transfer, exposing the silent risks that threaten CMC milestones and market launches alike. After 15 years guiding biotech projects from bench to clinic, he’s felt the pain of process gaps, regulatory curveballs, and million-dollar mistakes. Here, he turns that experience into a tactical guide designed to save you from the same pitfalls.

In this episode, you’ll learn about:

  • The 6-pillar approach to turning tech transfer into a managed process, rather than a gamble (03:09)
  • Why mass transfer physics and factors like kLA are critical—and how they can make or break a process at scale (05:12)
  • The importance of analytical comparability, including the common blind spots in sampling plans and method validation (07:19)
  • Establishing a solid Quality by Design (QbD) foundation and defining critical quality attributes before transfer, not after failures (08:33)
  • Stakeholder management and why non-technical challenges often derail projects (with more on this in Part 2) (10:09)
  • Evaluating CDMO partners: What selection criteria really matter for long-term success and risk mitigation (11:03)
  • Strategic decision-making: Building core capabilities versus outsourcing, and how to avoid unnecessary costs and delays (12:22)

This episode sets the stage for Part 2, where David Brühlmann will share practical stories and detailed frameworks for real-world implementation. If you manage bioprocess scale-up, tech transfer, or CMC development, you’ll find plenty of actionable insights to apply in your own work.

If you’re interested in the ideas discussed, here are some of the guests David referenced in this episode.

  • Episodes 91 - 92: Mass Transfer Secrets: Mastering Bubbles and kLa from Bench to Large-Scale Production with Lars Puiman & Rik Volger
  • Episodes 79 - 80: Think Before You Build: Holistic Approaches to Biotech Facility Design with Alfredo Martínez Mogarra
  • Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner
  • Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene Lee

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-18956651 Tue, 14 Apr 2026 05:00:00 +0200 886 243 full false 242: DMSO in Cell Therapy: Why Viability Scores Hide the Real Toxicity with Steve Oh - Part 2 242: DMSO in Cell Therapy: Why Viability Scores Hide the Real Toxicity with Steve Oh - Part 2 What if the solution to cell therapy’s biggest cold-chain challenge comes from the biology of Arctic fish?

This conversation features Steve Oh, a leader in advanced bioprocessing, whose career has placed him at the intersection of stem cell biology, process engineering, and clinical translation. Steve Oh joins David Brühlmann to share how XT Thrive®—a next-generation cryopreservation solution drawing from nature’s antifreeze proteins—lets cells survive, thrive, and simplify manufacturing from the bench to the clinic.

Episode highlights:

  • Biological insights from Arctic fish and their translation into synthetic peptide chemistry for cell preservation (00:23)
  • The effect of ice crystal formation on cellular damage, and how XT Thrive® minimizes this compared to DMSO (05:32)
  • Simplified logistics: reduced risk of contamination, elimination of post-thaw wash steps, and implications for therapy delivery to remote locations (07:23)
  • Applicability beyond single cells—preserving organoids and potential implications for tissue engineering (09:50)
  • The ease of transitioning from DMSO to the new solution in established lab protocols (10:49)
  • Broader industry challenges: maintaining purity, process optimization, and reducing cost of goods in cell therapy manufacturing (12:03)
  • Promising innovations in rapid cell type differentiation and barriers to scaling transformative biotech (12:50)
  • The importance of supporting innovative therapies beyond short-term ROI (14:17)

Smart insight:

Next-generation cryopreservation solutions address more than just viability—they simplify transport, reduce costs, lower hands-on time, and help ensure therapy reaches patients in remote locations in optimal condition. As Steve Oh observes, these advances are critical for reducing the cost of goods, improving consistency, and enabling truly scalable cell therapy manufacturing.

If you’re interested in this topic, check out these episodes, where we explore how Minnesota’s frozen forests inspired a new wave of biotech innovation—transforming how life-saving cells are frozen, stored, and shipped.

  • Episodes 161 - 162: How to Achieve 85%+ Cell Recovery Without DMSO's Toxic Side Effects with Jeffrey Allen

This is Steve’s second appearance on the podcast. You can also catch his earlier conversation with David, where they explored the challenges and opportunities of cell and gene therapy.

  • Episodes 11 - 12: From Lab to Patient: Steve Oh’s Guide to Mastering Cell Therapy Process Development.

Connect with Steve Oh:

Email: skwohso@gmail.com

LinkedIn: www.linkedin.com/in/steve-oh-4946261/

Support the show

]]> What if the solution to cell therapy’s biggest cold-chain challenge comes from the biology of Arctic fish?

This conversation features Steve Oh, a leader in advanced bioprocessing, whose career has placed him at the intersection of stem cell biology, process engineering, and clinical translation. Steve Oh joins David Brühlmann to share how XT Thrive®—a next-generation cryopreservation solution drawing from nature’s antifreeze proteins—lets cells survive, thrive, and simplify manufacturing from the bench to the clinic.

Episode highlights:

  • Biological insights from Arctic fish and their translation into synthetic peptide chemistry for cell preservation (00:23)
  • The effect of ice crystal formation on cellular damage, and how XT Thrive® minimizes this compared to DMSO (05:32)
  • Simplified logistics: reduced risk of contamination, elimination of post-thaw wash steps, and implications for therapy delivery to remote locations (07:23)
  • Applicability beyond single cells—preserving organoids and potential implications for tissue engineering (09:50)
  • The ease of transitioning from DMSO to the new solution in established lab protocols (10:49)
  • Broader industry challenges: maintaining purity, process optimization, and reducing cost of goods in cell therapy manufacturing (12:03)
  • Promising innovations in rapid cell type differentiation and barriers to scaling transformative biotech (12:50)
  • The importance of supporting innovative therapies beyond short-term ROI (14:17)

Smart insight:

Next-generation cryopreservation solutions address more than just viability—they simplify transport, reduce costs, lower hands-on time, and help ensure therapy reaches patients in remote locations in optimal condition. As Steve Oh observes, these advances are critical for reducing the cost of goods, improving consistency, and enabling truly scalable cell therapy manufacturing.

If you’re interested in this topic, check out these episodes, where we explore how Minnesota’s frozen forests inspired a new wave of biotech innovation—transforming how life-saving cells are frozen, stored, and shipped.

  • Episodes 161 - 162: How to Achieve 85%+ Cell Recovery Without DMSO's Toxic Side Effects with Jeffrey Allen

This is Steve’s second appearance on the podcast. You can also catch his earlier conversation with David, where they explored the challenges and opportunities of cell and gene therapy.

  • Episodes 11 - 12: From Lab to Patient: Steve Oh’s Guide to Mastering Cell Therapy Process Development.

Connect with Steve Oh:

Email: skwohso@gmail.com

LinkedIn: www.linkedin.com/in/steve-oh-4946261/

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-18917181 Thu, 09 Apr 2026 05:00:00 +0200 1066 242 full false 241: DMSO in Cell Therapy: Why Viability Scores Hide the Real Toxicity with Steve Oh - Part 1 241: DMSO in Cell Therapy: Why Viability Scores Hide the Real Toxicity with Steve Oh - Part 1 Arctic fish survive in waters that would freeze most life solid. Not because they tolerate ice, but because their biology prevents crystals from forming in the first place. That same principle, translated into synthetic peptide chemistry, is now showing performance data that DMSO cannot match. Part 2 is where the science becomes practical.

Steve Oh spent 22 years at Singapore's A*STAR accumulating 43 patents across stem cell bioprocessing, microcarrier technologies, and serum-free media. He now advises XTherma, where he has been stress-testing their DMSO-free cryopreservation solution across T cells, MSCs, organoids, and beyond. In Part 2, he brings the data.

Key topics discussed:

  • How antifreeze protein-inspired peptide chemistry reduces ice crystal size and protects cells during freezing and thawing (00:23)
  • T cell and MSC performance data comparing XT Thrive to DMSO and CryoStor CS10, including a 2.5-fold increase in cell yield on microcarriers post-thaw (02:23-05:00)
  • Why ice crystal formation causes more damage during thawing than freezing, and how XT Thrive addresses this (05:32)
  • Elimination of the post-thaw wash step and what that means for contamination risk and manufacturing simplicity (07:00)
  • Hold time extended to 24 hours and storage performance across 4°C, -80°C, and -196°C (08:01)
  • Applicability beyond single cells: organoids, islets, and potential implications for organ preservation (09:50)
  • How to transition from DMSO to XT Thrive: GMP grade, Drug Master File, same concentration, no protocol overhaul required (10:49)
  • Broader cell therapy challenges: differentiation time, cell population consistency, and cost of goods (12:03)

Smart insight:

The transition away from DMSO is more accessible than most scientists assume. XT Thrive is GMP-grade, carries a Drug Master File, and is used at the same 5-10% concentration as DMSO, making it a plug-and-play substitution for most cell types. The manufacturing implications go further: no wash step, extended hold times, and storage stability across all standard temperature ranges simplify both production workflows and cold-chain logistics to remote treatment sites.

If you’re interested in this topic, check out these episodes, where we explore how Minnesota’s frozen forests inspired a new wave of biotech innovation, transforming how life-saving cells are frozen, stored, and shipped.

  • Episodes 161 - 162: How to Achieve 85%+ Cell Recovery Without DMSO's Toxic Side Effects with Jeffrey Allen

This is Steve’s second appearance on the podcast. You can also catch his earlier conversation with David, where they explored the challenges and opportunities of cell and gene therapy.

  • Episodes 11 - 12: From Lab to Patient: Steve Oh’s Guide to Mastering Cell Therapy Process Development.

Connect with Steve Oh:

Email: skwohso@gmail.com

LinkedIn: www.linkedin.com/in/steve-oh-4946261/

Support the show

]]> Arctic fish survive in waters that would freeze most life solid. Not because they tolerate ice, but because their biology prevents crystals from forming in the first place. That same principle, translated into synthetic peptide chemistry, is now showing performance data that DMSO cannot match. Part 2 is where the science becomes practical.

Steve Oh spent 22 years at Singapore's A*STAR accumulating 43 patents across stem cell bioprocessing, microcarrier technologies, and serum-free media. He now advises XTherma, where he has been stress-testing their DMSO-free cryopreservation solution across T cells, MSCs, organoids, and beyond. In Part 2, he brings the data.

Key topics discussed:

  • How antifreeze protein-inspired peptide chemistry reduces ice crystal size and protects cells during freezing and thawing (00:23)
  • T cell and MSC performance data comparing XT Thrive to DMSO and CryoStor CS10, including a 2.5-fold increase in cell yield on microcarriers post-thaw (02:23-05:00)
  • Why ice crystal formation causes more damage during thawing than freezing, and how XT Thrive addresses this (05:32)
  • Elimination of the post-thaw wash step and what that means for contamination risk and manufacturing simplicity (07:00)
  • Hold time extended to 24 hours and storage performance across 4°C, -80°C, and -196°C (08:01)
  • Applicability beyond single cells: organoids, islets, and potential implications for organ preservation (09:50)
  • How to transition from DMSO to XT Thrive: GMP grade, Drug Master File, same concentration, no protocol overhaul required (10:49)
  • Broader cell therapy challenges: differentiation time, cell population consistency, and cost of goods (12:03)

Smart insight:

The transition away from DMSO is more accessible than most scientists assume. XT Thrive is GMP-grade, carries a Drug Master File, and is used at the same 5-10% concentration as DMSO, making it a plug-and-play substitution for most cell types. The manufacturing implications go further: no wash step, extended hold times, and storage stability across all standard temperature ranges simplify both production workflows and cold-chain logistics to remote treatment sites.

If you’re interested in this topic, check out these episodes, where we explore how Minnesota’s frozen forests inspired a new wave of biotech innovation, transforming how life-saving cells are frozen, stored, and shipped.

  • Episodes 161 - 162: How to Achieve 85%+ Cell Recovery Without DMSO's Toxic Side Effects with Jeffrey Allen

This is Steve’s second appearance on the podcast. You can also catch his earlier conversation with David, where they explored the challenges and opportunities of cell and gene therapy.

  • Episodes 11 - 12: From Lab to Patient: Steve Oh’s Guide to Mastering Cell Therapy Process Development.

Connect with Steve Oh:

Email: skwohso@gmail.com

LinkedIn: www.linkedin.com/in/steve-oh-4946261/

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-18885962 Tue, 07 Apr 2026 05:00:00 +0200 1226 241 full false 240: Continuous Microbial Manufacturing: From Genetic Instability to 40-Day E. coli Processes with Juergen Mairhofer - Part 2 240: Continuous Microbial Manufacturing: From Genetic Instability to 40-Day E. coli Processes with Juergen Mairhofer - Part 2 Why do CDMOs keep building bigger stainless-steel facilities while their margins erode and Asian competitors undercut them on price? And what happens when big pharma decides to stop outsourcing altogether? The business model that sustained the industry for two decades is under pressure from every direction, and for many CDMOs, standing still is no longer a neutral position.

In Part 2, Juergen Mairhofer, CEO of enGenes Biotech, shifts from the science to the stakes. Having spent over a decade building a company on licensing proprietary microbial technology rather than selling fermentation capacity, he brings a distinctive vantage point on where the CDMO industry is headed and what it will take to stay relevant.

Here are some of the topics discussed:

  • The need for innovation to stay competitive against lower-cost regions, and why capacity-focused business models are running out of road (03:08)
  • How continuous manufacturing creates a competitive edge for CDMOs operating in high-cost regions (05:49)
  • Practical advice for piloting continuous processing, building partnerships, and taking calculated risks before competitors do (06:36)
  • The parallel universe of batch and continuous manufacturing, and how this duality will shape the industry over the next decade (08:24)
  • What scientists need to know before spinning out a technology company: customer focus, cash discipline, and why the team is everything (09:49)
  • Big pharma's return to in-house manufacturing and vertical supply chain integration, and why this creates opportunity for innovation-focused partners (12:12)

Smart insight: Technology excellence is necessary but not sufficient. Juergen's closing word was simply "don't be afraid" and it carried weight precisely because it was not a platitude. The companies that will matter in ten years are those that start the hard work of innovation now, before the window closes.

If you’re interested in exploring more breakthroughs in continuous bioprocessing and the future of biotech manufacturing, check out these past episodes from the Smart Biotech Scientist Podcast:

  • Episodes 85 - 86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli
  • Episodes 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos
  • Episode 155: From Process Bottlenecks to Seamless Production: How Continuous Bioprocessing Changes Everything
  • Episode 156: The Hidden Economics of Continuous Processing That Most Biotech Companies Overlook
  • Episodes 181 - 182: Innovating Continuous Bioprocessing with Vibrating Membrane Filtration with Jarno Robin
  • Episodes 209 - 210: From Batch to Continuous: Building Innovation Culture in Conservative Biotech Environments with Irina Ramos

Connect with Juergen Mairhofer:

LinkedIn: www.linkedin.com/in/juergen-mairhofer-ab27a5b

enGenes Biotech GmbH website: www.engenes.cc

Support the show

]]> Why do CDMOs keep building bigger stainless-steel facilities while their margins erode and Asian competitors undercut them on price? And what happens when big pharma decides to stop outsourcing altogether? The business model that sustained the industry for two decades is under pressure from every direction, and for many CDMOs, standing still is no longer a neutral position.

In Part 2, Juergen Mairhofer, CEO of enGenes Biotech, shifts from the science to the stakes. Having spent over a decade building a company on licensing proprietary microbial technology rather than selling fermentation capacity, he brings a distinctive vantage point on where the CDMO industry is headed and what it will take to stay relevant.

Here are some of the topics discussed:

  • The need for innovation to stay competitive against lower-cost regions, and why capacity-focused business models are running out of road (03:08)
  • How continuous manufacturing creates a competitive edge for CDMOs operating in high-cost regions (05:49)
  • Practical advice for piloting continuous processing, building partnerships, and taking calculated risks before competitors do (06:36)
  • The parallel universe of batch and continuous manufacturing, and how this duality will shape the industry over the next decade (08:24)
  • What scientists need to know before spinning out a technology company: customer focus, cash discipline, and why the team is everything (09:49)
  • Big pharma's return to in-house manufacturing and vertical supply chain integration, and why this creates opportunity for innovation-focused partners (12:12)

Smart insight: Technology excellence is necessary but not sufficient. Juergen's closing word was simply "don't be afraid" and it carried weight precisely because it was not a platitude. The companies that will matter in ten years are those that start the hard work of innovation now, before the window closes.

If you’re interested in exploring more breakthroughs in continuous bioprocessing and the future of biotech manufacturing, check out these past episodes from the Smart Biotech Scientist Podcast:

  • Episodes 85 - 86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli
  • Episodes 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos
  • Episode 155: From Process Bottlenecks to Seamless Production: How Continuous Bioprocessing Changes Everything
  • Episode 156: The Hidden Economics of Continuous Processing That Most Biotech Companies Overlook
  • Episodes 181 - 182: Innovating Continuous Bioprocessing with Vibrating Membrane Filtration with Jarno Robin
  • Episodes 209 - 210: From Batch to Continuous: Building Innovation Culture in Conservative Biotech Environments with Irina Ramos

Connect with Juergen Mairhofer:

LinkedIn: www.linkedin.com/in/juergen-mairhofer-ab27a5b

enGenes Biotech GmbH website: www.engenes.cc

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-18885955 Thu, 02 Apr 2026 05:00:00 +0200 1127 240 full false 239: Continuous Microbial Manufacturing: From Genetic Instability to 40-Day E. coli Processes with Juergen Mairhofer - Part 1 239: Continuous Microbial Manufacturing: From Genetic Instability to 40-Day E. coli Processes with Juergen Mairhofer - Part 1 What if continuous microbial manufacturing wasn't a pipe dream, but a reality quietly reshaping the foundations of bioprocessing?

Meet Juergen Mairhofer, CEO of enGenes Biotech GmbH and a scientist with a rare dual fluency in molecular biology and bioprocess engineering. He's not just optimizing at the margins. He's devised a proprietary E. coli platform that radically stabilizes genetic stability and splits cell growth from protein production. Instead of stretching out fermentation for a few more days, he's running continuous E. coli processes for up to 40 days; something most believed impossible.

Here's why this conversation is worth your notebook and a second listen:

  • Why the commodity CDMO model struggles with innovation and how enGenes Biotech's model aligns business incentives with process improvement (02:37)
  • Juergen Mairhofer's early experiences blending molecular biology and bioprocess engineering, and how a "DIY" mentality led to entrepreneurship (04:42)
  • Strategy behind developing a proprietary E. coli strain that decouples protein production from cell growth (10:01)
  • The benefits of continuous manufacturing: running up to 40-day E. coli processes, and how this compares to mammalian (CHO) systems (13:57)
  • Economic and operational advantages: reducing facility footprint, lowering CAPEX/OPEX, and the necessity for innovation in global competition (19:25)
  • How enGenes Biotech integrates upstream and downstream operations for fully end-to-end continuous production (17:50)
  • Specific technical challenges: managing genetic drift, sterility, equipment, and process modeling in continuous systems (21:10)

Smart insight: Technology excellence is the entry ticket, but it won't sell itself. The companies that will lead the next decade of bioprocessing are those willing to align their business model with process innovation, not just capacity utilization.

If you’re interested in exploring more breakthroughs in continuous bioprocessing and the future of biotech manufacturing, check out these past episodes from the Smart Biotech Scientist Podcast:

  • Episodes 85 - 86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli
  • Episodes 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos
  • Episode 155: From Process Bottlenecks to Seamless Production: How Continuous Bioprocessing Changes Everything
  • Episode 156: The Hidden Economics of Continuous Processing That Most Biotech Companies Overlook
  • Episodes 181 - 182: Innovating Continuous Bioprocessing with Vibrating Membrane Filtration with Jarno Robin
  • Episodes 209 - 210: From Batch to Continuous: Building Innovation Culture in Conservative Biotech Environments with Irina Ramos

Connect with Juergen Mairhofer:

LinkedIn: www.linkedin.com/in/juergen-mairhofer-ab27a5b

enGenes Biotech GmbH website: www.engenes.cc

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> What if continuous microbial manufacturing wasn't a pipe dream, but a reality quietly reshaping the foundations of bioprocessing?

Meet Juergen Mairhofer, CEO of enGenes Biotech GmbH and a scientist with a rare dual fluency in molecular biology and bioprocess engineering. He's not just optimizing at the margins. He's devised a proprietary E. coli platform that radically stabilizes genetic stability and splits cell growth from protein production. Instead of stretching out fermentation for a few more days, he's running continuous E. coli processes for up to 40 days; something most believed impossible.

Here's why this conversation is worth your notebook and a second listen:

  • Why the commodity CDMO model struggles with innovation and how enGenes Biotech's model aligns business incentives with process improvement (02:37)
  • Juergen Mairhofer's early experiences blending molecular biology and bioprocess engineering, and how a "DIY" mentality led to entrepreneurship (04:42)
  • Strategy behind developing a proprietary E. coli strain that decouples protein production from cell growth (10:01)
  • The benefits of continuous manufacturing: running up to 40-day E. coli processes, and how this compares to mammalian (CHO) systems (13:57)
  • Economic and operational advantages: reducing facility footprint, lowering CAPEX/OPEX, and the necessity for innovation in global competition (19:25)
  • How enGenes Biotech integrates upstream and downstream operations for fully end-to-end continuous production (17:50)
  • Specific technical challenges: managing genetic drift, sterility, equipment, and process modeling in continuous systems (21:10)

Smart insight: Technology excellence is the entry ticket, but it won't sell itself. The companies that will lead the next decade of bioprocessing are those willing to align their business model with process innovation, not just capacity utilization.

If you’re interested in exploring more breakthroughs in continuous bioprocessing and the future of biotech manufacturing, check out these past episodes from the Smart Biotech Scientist Podcast:

  • Episodes 85 - 86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli
  • Episodes 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos
  • Episode 155: From Process Bottlenecks to Seamless Production: How Continuous Bioprocessing Changes Everything
  • Episode 156: The Hidden Economics of Continuous Processing That Most Biotech Companies Overlook
  • Episodes 181 - 182: Innovating Continuous Bioprocessing with Vibrating Membrane Filtration with Jarno Robin
  • Episodes 209 - 210: From Batch to Continuous: Building Innovation Culture in Conservative Biotech Environments with Irina Ramos

Connect with Juergen Mairhofer:

LinkedIn: www.linkedin.com/in/juergen-mairhofer-ab27a5b

enGenes Biotech GmbH website: www.engenes.cc

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-18885948 Tue, 31 Mar 2026 05:00:00 +0200 1589 239 full false 238: High-Throughput Microbial Screening: Avoiding Early Mistakes That Derail Scale-Up with Sebastian Blum - Part 2 238: High-Throughput Microbial Screening: Avoiding Early Mistakes That Derail Scale-Up with Sebastian Blum - Part 2 For many biotech innovators, high-throughput screening platforms promise faster discoveries and streamlined workflows. Yet beneath the surface, the reality is more demanding, requiring hands-on expertise, careful assay design, and a sharp understanding of microbial physiology to avoid mistakes that become expensive to fix downstream.

David Brühlmann continues his conversation with Sebastian Blum, Market Development Manager in Europe at Beckman Coulter Life Sciences, who brings a practical, unvarnished perspective to high-throughput screening. Drawing on conversations with startups, pharma, and CDMOs, Sebastian digs into what separates "push-button" automation myths from hard-won bioprocess mastery. From evaluating technical fit to troubleshooting real-world applications, he advocates for a nuanced approach, one focused on fit-for-purpose tools and critical thinking over technology hype.

In this episode, we discuss:

  • Practical advice for startups considering systems like the BioLector XT Microbioreactor, including the need for technical expertise and tailored applications (02:34)
  • Scenarios where the BioLector XT Microbioreactor is the best fit (flexibility, multiple microorganisms, modular upgrades) (04:22)
  • The most common mistakes scientists make with screening technologies, and why specialized personnel are still essential (06:45)
  • How automation, robotics, and AI are shaping the future of early-stage bioprocess development, and why core engineering principles remain vital (08:14)
  • Tips for evaluating screening tool placement in your process and aligning technology with your application needs (11:13)

If you're making decisions about high-throughput screening platforms and want to avoid costly missteps before scale-up, this episode delivers the clarity you need.

Connect with Sebastian Blum:

LinkedIn: www.de.linkedin.com/in/sebastian-blum-76240b3b

Beckman Coulter Life Sciences: www.beckman.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> For many biotech innovators, high-throughput screening platforms promise faster discoveries and streamlined workflows. Yet beneath the surface, the reality is more demanding, requiring hands-on expertise, careful assay design, and a sharp understanding of microbial physiology to avoid mistakes that become expensive to fix downstream.

David Brühlmann continues his conversation with Sebastian Blum, Market Development Manager in Europe at Beckman Coulter Life Sciences, who brings a practical, unvarnished perspective to high-throughput screening. Drawing on conversations with startups, pharma, and CDMOs, Sebastian digs into what separates "push-button" automation myths from hard-won bioprocess mastery. From evaluating technical fit to troubleshooting real-world applications, he advocates for a nuanced approach, one focused on fit-for-purpose tools and critical thinking over technology hype.

In this episode, we discuss:

  • Practical advice for startups considering systems like the BioLector XT Microbioreactor, including the need for technical expertise and tailored applications (02:34)
  • Scenarios where the BioLector XT Microbioreactor is the best fit (flexibility, multiple microorganisms, modular upgrades) (04:22)
  • The most common mistakes scientists make with screening technologies, and why specialized personnel are still essential (06:45)
  • How automation, robotics, and AI are shaping the future of early-stage bioprocess development, and why core engineering principles remain vital (08:14)
  • Tips for evaluating screening tool placement in your process and aligning technology with your application needs (11:13)

If you're making decisions about high-throughput screening platforms and want to avoid costly missteps before scale-up, this episode delivers the clarity you need.

Connect with Sebastian Blum:

LinkedIn: www.de.linkedin.com/in/sebastian-blum-76240b3b

Beckman Coulter Life Sciences: www.beckman.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18506546 Thu, 26 Mar 2026 05:00:00 +0100 839 238 full false 237: High-Throughput Microbial Screening: Avoiding Early Mistakes That Derail Scale-Up with Sebastian Blum - Part 1 237: High-Throughput Microbial Screening: Avoiding Early Mistakes That Derail Scale-Up with Sebastian Blum - Part 1 Why do so many promising biotech ideas stall long before they reach the clinic or marketplace? For many, the answer lies hidden in the earliest phase of bioprocess development: upstream processing. It’s where strain selection, media optimization, and culture conditions set the stage for everything that follows. Yet, the smallest missteps here can snowball into expensive roadblocks downstream. This episode of Smart Biotech Scientist Podcast zeros in on why smart screening strategies and the right bioreactor choices early on are the difference between breakthrough and bottleneck.

Joining host David Brühlmann is Sebastian Blum, a microbiologist with more than two decades in the life sciences. As Market Development Manager at Beckman Coulter Life Sciences, Sebastian Blum brings firsthand knowledge from collaborating with startups, pharma giants, and CDMOs, bridging theory with the practical realities of modern process development. From commercializing micro-fermentation systems to guiding clients through high-throughput data, his insights come not just from research but real-world applications.

Key Topics & Insights:

  • How startups versus large pharma companies differ in process development strategies, including the role of budget, resources, and risk management. (04:27)
  • The importance of designing screening experiments that mirror end-process conditions, and misconceptions around batch versus fed-batch modes. (07:49)
  • Overview of available small-scale bioreactor systems: shake flasks, benchtop reactors, and high-throughput platforms—pros, cons, and ideal use cases. (09:17)
  • Detailed comparison of BioLector XT Microbioreactor, ambr® 15, and ambr® 250 systems, including working volumes, experiment throughput, measurement technology, and cell types suited for each. (13:24)
  • Practical guidance on making the most of high-throughput screening tools and how training, scripting, and collaboration help new users get value from systems like the BioLector XT Microbioreactor. (17:00)

This episode offers grounded advice for scientists and founders navigating early-stage bioprocess development, plus a clear look at the technology landscape for microbial screening and optimization. Perfect for those looking to streamline process development and avoid common pitfalls.

Connect with Sebastian Blum:

LinkedIn: www.de.linkedin.com/in/sebastian-blum-76240b3b

Beckman Coulter Life Sciences: www.beckman.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> Why do so many promising biotech ideas stall long before they reach the clinic or marketplace? For many, the answer lies hidden in the earliest phase of bioprocess development: upstream processing. It’s where strain selection, media optimization, and culture conditions set the stage for everything that follows. Yet, the smallest missteps here can snowball into expensive roadblocks downstream. This episode of Smart Biotech Scientist Podcast zeros in on why smart screening strategies and the right bioreactor choices early on are the difference between breakthrough and bottleneck.

Joining host David Brühlmann is Sebastian Blum, a microbiologist with more than two decades in the life sciences. As Market Development Manager at Beckman Coulter Life Sciences, Sebastian Blum brings firsthand knowledge from collaborating with startups, pharma giants, and CDMOs, bridging theory with the practical realities of modern process development. From commercializing micro-fermentation systems to guiding clients through high-throughput data, his insights come not just from research but real-world applications.

Key Topics & Insights:

  • How startups versus large pharma companies differ in process development strategies, including the role of budget, resources, and risk management. (04:27)
  • The importance of designing screening experiments that mirror end-process conditions, and misconceptions around batch versus fed-batch modes. (07:49)
  • Overview of available small-scale bioreactor systems: shake flasks, benchtop reactors, and high-throughput platforms—pros, cons, and ideal use cases. (09:17)
  • Detailed comparison of BioLector XT Microbioreactor, ambr® 15, and ambr® 250 systems, including working volumes, experiment throughput, measurement technology, and cell types suited for each. (13:24)
  • Practical guidance on making the most of high-throughput screening tools and how training, scripting, and collaboration help new users get value from systems like the BioLector XT Microbioreactor. (17:00)

This episode offers grounded advice for scientists and founders navigating early-stage bioprocess development, plus a clear look at the technology landscape for microbial screening and optimization. Perfect for those looking to streamline process development and avoid common pitfalls.

Connect with Sebastian Blum:

LinkedIn: www.de.linkedin.com/in/sebastian-blum-76240b3b

Beckman Coulter Life Sciences: www.beckman.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18506534 Tue, 24 Mar 2026 05:00:00 +0100 1182 237 full false 236: Plant-Based Biomanufacturing: How Molecular Farming Produces Biopharmaceuticals in Weeks, Not Months with Waranyoo Phoolcharoen - Part 2 236: Plant-Based Biomanufacturing: How Molecular Farming Produces Biopharmaceuticals in Weeks, Not Months with Waranyoo Phoolcharoen - Part 2 For years, mammalian cells and microbial systems have dominated the biotech landscape, shaping the economics and access to life-saving biologics. Yet, in countries where capital and infrastructure are limited, those gold-standard systems bring hefty price tags and daunting complexity. The answer isn't bigger bioreactors; it's alternative biomanufacturing approaches, such as molecular farming. Imagine medicines grown like crops, ready for harvest in days, not months.

Meet Waranyoo Phoolcharoen, Co-Founder and CTO of Baiya Phytopharm and Professor at Chulalongkorn University in Bangkok, a scientist who didn't settle for the status quo. As the driving force behind the company, she led the charge to cut through process bottlenecks: navigating regulatory hurdles, scaling plant-based vaccine manufacturing to 5 million doses per month, and reshaping the approach to antibody production for oncology and infectious diseases. Her work proved that plants aren't an alternative. They're a platform.

Topics discussed include:

  • How plant-based molecular farming compares to traditional microbial and mammalian cell systems (02:44)
  • The flexibility and rapid scalability of using plants for biomanufacturing (05:06)
  • Speeding up process development with transient expression versus transgenic plants (05:45)
  • Regulatory perspectives and the approval process for plant-produced biologics (06:52)
  • An overview of the ongoing oncology and infectious disease antibody pipeline (08:08)
  • Strategic challenges: balancing product development, revenue, and market-ready innovations through subsidiary companies (09:51)
  • Lessons learned from building a GMP facility capable of 5 million doses per month during the pandemic, with supply chain as the biggest bottleneck (12:50)
  • Future innovations in molecular farming and the role of plant platforms in medicine production (14:47)

Smart insight:

Platform choice matters. If you're struggling with long development timelines or scale-up challenges, it may not always be the molecule. It may be the system you're using. Molecular farming offers a different set of trade-offs: faster development, flexible scaling, and a practical alternative worth considering before defaulting to a single platform.

If you’re interested in other unconventional biological platforms reshaping biomanufacturing, don’t miss these episodes exploring emerging production technologies:

  • Episodes 141 - 142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor
  • Episodes 163 - 164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf
  • Episodes 229 - 230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim Corcoran

Connect with Waranyoo Phoolcharoen:

Email: Waranyoo.P@baiyaphytopharm.com

Baiya Phytopharm website: www.baiyaphytopharm.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> For years, mammalian cells and microbial systems have dominated the biotech landscape, shaping the economics and access to life-saving biologics. Yet, in countries where capital and infrastructure are limited, those gold-standard systems bring hefty price tags and daunting complexity. The answer isn't bigger bioreactors; it's alternative biomanufacturing approaches, such as molecular farming. Imagine medicines grown like crops, ready for harvest in days, not months.

Meet Waranyoo Phoolcharoen, Co-Founder and CTO of Baiya Phytopharm and Professor at Chulalongkorn University in Bangkok, a scientist who didn't settle for the status quo. As the driving force behind the company, she led the charge to cut through process bottlenecks: navigating regulatory hurdles, scaling plant-based vaccine manufacturing to 5 million doses per month, and reshaping the approach to antibody production for oncology and infectious diseases. Her work proved that plants aren't an alternative. They're a platform.

Topics discussed include:

  • How plant-based molecular farming compares to traditional microbial and mammalian cell systems (02:44)
  • The flexibility and rapid scalability of using plants for biomanufacturing (05:06)
  • Speeding up process development with transient expression versus transgenic plants (05:45)
  • Regulatory perspectives and the approval process for plant-produced biologics (06:52)
  • An overview of the ongoing oncology and infectious disease antibody pipeline (08:08)
  • Strategic challenges: balancing product development, revenue, and market-ready innovations through subsidiary companies (09:51)
  • Lessons learned from building a GMP facility capable of 5 million doses per month during the pandemic, with supply chain as the biggest bottleneck (12:50)
  • Future innovations in molecular farming and the role of plant platforms in medicine production (14:47)

Smart insight:

Platform choice matters. If you're struggling with long development timelines or scale-up challenges, it may not always be the molecule. It may be the system you're using. Molecular farming offers a different set of trade-offs: faster development, flexible scaling, and a practical alternative worth considering before defaulting to a single platform.

If you’re interested in other unconventional biological platforms reshaping biomanufacturing, don’t miss these episodes exploring emerging production technologies:

  • Episodes 141 - 142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor
  • Episodes 163 - 164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf
  • Episodes 229 - 230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim Corcoran

Connect with Waranyoo Phoolcharoen:

Email: Waranyoo.P@baiyaphytopharm.com

Baiya Phytopharm website: www.baiyaphytopharm.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-18802101 Thu, 19 Mar 2026 05:00:00 +0100 1130 236 full false 235: Plant-Based Biomanufacturing: How Molecular Farming Produces Biopharmaceuticals in Weeks, Not Months with Waranyoo Phoolcharoen - Part 1 235: Plant-Based Biomanufacturing: How Molecular Farming Produces Biopharmaceuticals in Weeks, Not Months with Waranyoo Phoolcharoen - Part 1 Imagine producing life-saving antibodies or vaccines not in sprawling stainless steel facilities, but in sunlit greenhouses, inside living, breathing plants.

Waranyoo Phoolcharoen, Co-Founder and CTO of Baiya Phytopharm and Professor at Chulalongkorn University in Bangkok, leads the charge in molecular farming in Thailand, pioneering a shift from traditional biomanufacturing toward using whole plants as responsive biofactories. With a unique background in both pharmaceutical sciences and plant biotechnology, she has taken her research out of the academic silo and into the world, founding a clinical-stage company determined to make vaccines and therapeutic proteins accessible where they're needed most.

In this episode, we cover:

  • Waranyoo Phoolcharoen's personal journey: from an accidental start in plant biotechnology to making a global impact with molecular farming (03:57)
  • The pivotal moment that shifted her focus from publishing papers to translating research into real-world solutions (06:12)
  • The initial steps and uncertainties of co-founding Baiya Phytopharm in Thailand (07:12)
  • How 'the plant of life' philosophy drives their biopharma platform, and why whole plants (not just cell cultures) are used as biofactories (09:56)
  • Key mindset shifts when transitioning from academia to entrepreneurship, including the importance of teamwork and commercial thinking (12:55)
  • Strategies for making impact-driven biotech startups in resource-constrained environments, and why courage and speed matter (15:50)
  • Insights into the biotech and pharmaceutical landscape in Southeast Asia, including opportunities and challenges for innovators (19:27)

Smart insight:

The most important mindset shift from scientist to entrepreneur isn't technical; it's learning to ask different questions. Not "is this interesting?" but "who will pay for this, and does it make commercial sense?" As Waranyoo puts it, when you have the right question, it leads to the right answer.

Stay tuned for Part 2, where we'll explore platform capabilities and Asia's first plant-derived COVID-19 vaccine to enter clinical trials.

If you’re interested in other unconventional biological platforms reshaping biomanufacturing, don’t miss these episodes exploring emerging production technologies:

  • Episodes 141 - 142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor
  • Episodes 163 - 164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf
  • Episodes 229 - 230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim Corcoran

Connect with Waranyoo Phoolcharoen:

Email: Waranyoo.P@baiyaphytopharm.com

Baiya Phytopharm website: www.baiyaphytopharm.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Imagine producing life-saving antibodies or vaccines not in sprawling stainless steel facilities, but in sunlit greenhouses, inside living, breathing plants.

Waranyoo Phoolcharoen, Co-Founder and CTO of Baiya Phytopharm and Professor at Chulalongkorn University in Bangkok, leads the charge in molecular farming in Thailand, pioneering a shift from traditional biomanufacturing toward using whole plants as responsive biofactories. With a unique background in both pharmaceutical sciences and plant biotechnology, she has taken her research out of the academic silo and into the world, founding a clinical-stage company determined to make vaccines and therapeutic proteins accessible where they're needed most.

In this episode, we cover:

  • Waranyoo Phoolcharoen's personal journey: from an accidental start in plant biotechnology to making a global impact with molecular farming (03:57)
  • The pivotal moment that shifted her focus from publishing papers to translating research into real-world solutions (06:12)
  • The initial steps and uncertainties of co-founding Baiya Phytopharm in Thailand (07:12)
  • How 'the plant of life' philosophy drives their biopharma platform, and why whole plants (not just cell cultures) are used as biofactories (09:56)
  • Key mindset shifts when transitioning from academia to entrepreneurship, including the importance of teamwork and commercial thinking (12:55)
  • Strategies for making impact-driven biotech startups in resource-constrained environments, and why courage and speed matter (15:50)
  • Insights into the biotech and pharmaceutical landscape in Southeast Asia, including opportunities and challenges for innovators (19:27)

Smart insight:

The most important mindset shift from scientist to entrepreneur isn't technical; it's learning to ask different questions. Not "is this interesting?" but "who will pay for this, and does it make commercial sense?" As Waranyoo puts it, when you have the right question, it leads to the right answer.

Stay tuned for Part 2, where we'll explore platform capabilities and Asia's first plant-derived COVID-19 vaccine to enter clinical trials.

If you’re interested in other unconventional biological platforms reshaping biomanufacturing, don’t miss these episodes exploring emerging production technologies:

  • Episodes 141 - 142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor
  • Episodes 163 - 164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf
  • Episodes 229 - 230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim Corcoran

Connect with Waranyoo Phoolcharoen:

Email: Waranyoo.P@baiyaphytopharm.com

Baiya Phytopharm website: www.baiyaphytopharm.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-18802079 Tue, 17 Mar 2026 05:00:00 +0100 1543 235 full false 234: Why Most Bioprocess Automation Projects Fail Before the Robot Is Even Ordered with Anthony Catacchio - Part 2 234: Why Most Bioprocess Automation Projects Fail Before the Robot Is Even Ordered with Anthony Catacchio - Part 2 Picture a new bioprocess automation project: ambitious, expensive, and packed with promise. But after months of development, your team discovers a flaw that could have been caught with a simple mockup and a few sticky notes on a whiteboard. This episode confronts the real cost of skipping discovery, premature automation, and the myth that faster engineering always means faster solutions.

Anthony Catacchio, CEO of Product Insight, continues his conversation with David Brühlmann to untangle the realities of automation strategy in biotech. Drawing from years of building robotics for high-stakes labs, Anthony explores why "minimum testable product" consistently outperforms "minimum viable product" when budgets, timelines, and patient outcomes are on the line.

Highlights from the episode:

  • When custom robotics development is genuinely justified — and the conditions that determine whether a large-scale automation investment makes sense for your organization (02:59).
  • Tech demos and usability demos: how to test the hardest parts of your system concept in isolation before committing to full development (06:37).
  • Minimum testable product vs. minimum viable product: why rushing to viable in hardware development is a costly mistake, and how controlled pilot deployments generate the learning that actually accelerates your program (07:37).
  • Why testing in the real operating environment — not a simulated lab setting — is the only way to surface the hidden requirements that will determine whether your automation succeeds or fails (08:29).
  • The "go fever" trap: why problems discovered late in development get buried rather than fixed, and how front-loading validation protects both your timeline and your budget (10:16).
  • The single most practical question a biotech scientist can ask to determine whether a process is a genuine automation candidate: how much are you thinking while you do it? (16:02).
  • Where AI and machine learning deliver real value in bioprocess research — and why the more urgent question is not how to automate a process, but how to redesign it to produce better data (17:59).
  • Why capital equipment in biotech labs will need to change fundamentally to collect the volume and quality of data required to make AI-driven insights meaningful (19:01).

Smart insight: Automation is not a technology problem, it is a systems development and requirements development problem. The teams that deeply understand their process and environment before touching a line of code or a line of engineering will always outperform those that do not. As Anthony puts it: you need to look at the whole picture.

Connect with Anthony Catacchio:

LinkedIn: www.linkedin.com/in/anthony-catacchio-b881581b

Product Insight website: www.productinsight.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> Picture a new bioprocess automation project: ambitious, expensive, and packed with promise. But after months of development, your team discovers a flaw that could have been caught with a simple mockup and a few sticky notes on a whiteboard. This episode confronts the real cost of skipping discovery, premature automation, and the myth that faster engineering always means faster solutions.

Anthony Catacchio, CEO of Product Insight, continues his conversation with David Brühlmann to untangle the realities of automation strategy in biotech. Drawing from years of building robotics for high-stakes labs, Anthony explores why "minimum testable product" consistently outperforms "minimum viable product" when budgets, timelines, and patient outcomes are on the line.

Highlights from the episode:

  • When custom robotics development is genuinely justified — and the conditions that determine whether a large-scale automation investment makes sense for your organization (02:59).
  • Tech demos and usability demos: how to test the hardest parts of your system concept in isolation before committing to full development (06:37).
  • Minimum testable product vs. minimum viable product: why rushing to viable in hardware development is a costly mistake, and how controlled pilot deployments generate the learning that actually accelerates your program (07:37).
  • Why testing in the real operating environment — not a simulated lab setting — is the only way to surface the hidden requirements that will determine whether your automation succeeds or fails (08:29).
  • The "go fever" trap: why problems discovered late in development get buried rather than fixed, and how front-loading validation protects both your timeline and your budget (10:16).
  • The single most practical question a biotech scientist can ask to determine whether a process is a genuine automation candidate: how much are you thinking while you do it? (16:02).
  • Where AI and machine learning deliver real value in bioprocess research — and why the more urgent question is not how to automate a process, but how to redesign it to produce better data (17:59).
  • Why capital equipment in biotech labs will need to change fundamentally to collect the volume and quality of data required to make AI-driven insights meaningful (19:01).

Smart insight: Automation is not a technology problem, it is a systems development and requirements development problem. The teams that deeply understand their process and environment before touching a line of code or a line of engineering will always outperform those that do not. As Anthony puts it: you need to look at the whole picture.

Connect with Anthony Catacchio:

LinkedIn: www.linkedin.com/in/anthony-catacchio-b881581b

Product Insight website: www.productinsight.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-18802065 Thu, 12 Mar 2026 05:00:00 +0100 1326 234 full false 233: Why Most Bioprocess Automation Projects Fail Before the Robot Is Even Ordered with Anthony Catacchio - Part 1 233: Why Most Bioprocess Automation Projects Fail Before the Robot Is Even Ordered with Anthony Catacchio - Part 1 Many bioprocess automation projects fail, not because the technology is wrong, but because no one clearly defined the problem before buying the robot.

In this episode, David Brühlmann sits down with Anthony Catacchio, CEO of Product Insight, to explore why rigorous system design and honest problem definition matter more than any individual technology, and how industrial robotics expertise translates directly into smarter lab automation.

Highlights from the episode:

  • Why biotech's "special case" mindset around automation is costing companies time and money — and what industrial robotics already has figured out (02:45).
  • How Anthony's cross-industry career — from surgical devices to warehouse robotics — shaped a process-first approach to system design (05:05).
  • The automation paradox: how to increase throughput and reduce errors without eliminating the expert human judgment your process depends on (09:13).
  • Vision-guided robotics, AGVs, and quadrupeds: what has genuinely changed in capability and what that means for bioprocess applications (11:21).
  • Human-bot testing: the low-cost validation method that reveals workflow flaws before a single robot is purchased (15:07).
  • The $1M vs. $10K decision: a real case study where the right answer was walking away from automation entirely (15:54).
  • Why talking a client out of an expensive project is sometimes the highest-value service a technical consultant can deliver (17:38).
  • Building long-term credibility by recommending the simplest solution that actually solves the problem (19:24).

Smart insight: The most expensive automation mistake happens at the whiteboard, not on the manufacturing floor. Define the problem with surgical precision before you ever evaluate a solution.

In Part 2, the conversation continues with a deeper look at building automation systems that deliver practical solutions to bioprocessing challenges without overengineering.

Tune in for practical strategies and honest reflections on automation, system design, and the importance of clear problem definition in biotech hardware development.

Connect with Anthony Catacchio:

LinkedIn: www.linkedin.com/in/anthony-catacchio-b881581b

Product Insight website: www.productinsight.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> Many bioprocess automation projects fail, not because the technology is wrong, but because no one clearly defined the problem before buying the robot.

In this episode, David Brühlmann sits down with Anthony Catacchio, CEO of Product Insight, to explore why rigorous system design and honest problem definition matter more than any individual technology, and how industrial robotics expertise translates directly into smarter lab automation.

Highlights from the episode:

  • Why biotech's "special case" mindset around automation is costing companies time and money — and what industrial robotics already has figured out (02:45).
  • How Anthony's cross-industry career — from surgical devices to warehouse robotics — shaped a process-first approach to system design (05:05).
  • The automation paradox: how to increase throughput and reduce errors without eliminating the expert human judgment your process depends on (09:13).
  • Vision-guided robotics, AGVs, and quadrupeds: what has genuinely changed in capability and what that means for bioprocess applications (11:21).
  • Human-bot testing: the low-cost validation method that reveals workflow flaws before a single robot is purchased (15:07).
  • The $1M vs. $10K decision: a real case study where the right answer was walking away from automation entirely (15:54).
  • Why talking a client out of an expensive project is sometimes the highest-value service a technical consultant can deliver (17:38).
  • Building long-term credibility by recommending the simplest solution that actually solves the problem (19:24).

Smart insight: The most expensive automation mistake happens at the whiteboard, not on the manufacturing floor. Define the problem with surgical precision before you ever evaluate a solution.

In Part 2, the conversation continues with a deeper look at building automation systems that deliver practical solutions to bioprocessing challenges without overengineering.

Tune in for practical strategies and honest reflections on automation, system design, and the importance of clear problem definition in biotech hardware development.

Connect with Anthony Catacchio:

LinkedIn: www.linkedin.com/in/anthony-catacchio-b881581b

Product Insight website: www.productinsight.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist Buzzsprout-18802051 Tue, 10 Mar 2026 05:00:00 +0100 1267 233 full false 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann - Part 2 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann - Part 2 How solid is your CMC foundation—and what happens if it cracks under pressure?

David Brühlmann welcomes Henri Kornmann, former Head of Biologics Innovation Centre at Ferring Pharmaceuticals. From junior CMC scientist at Merck to leading Ferring Pharmaceuticals' first gene therapy approval for bladder cancer, Henri has moved repeatedly between CMC development, GMP manufacturing, and due diligence across some of the industry's most complex programs.

His “house building” approach demystifies CMC’s complexity, showing why early diligence paired with regulatory fluency and scientific insight pays dividends for years.

Tune in to hear Henri’s practical wisdom distilled through real-world analogies:

  • Building a strong CMC foundation in early phases and why later fixes can be costly or impossible (02:45)
  • Scaling up: supplying Phase 3 with the final commercial process, including robustness and supply chain strategies such as dual sourcing critical raw materials (03:23)
  • Process validation explained: FDA’s three stages, from control strategy justification to continued verification (05:15)
  • Process Performance Qualification (PPQ): what it is, how many batches are needed, and optimizing timing (07:43)
  • Handling lifecycle changes: maintaining process control, adapting to deviations, and improving systems after regulatory approval (09:34)
  • Managing teams, stakeholders, and cross-functional collaboration in CMC programs (11:49)
  • Importance of good project management, access to scientific expertise, and interpreting guidelines for your specific program (12:27)
  • The “half scientist, half lawyer” analogy for mastering both technical and regulatory aspects (15:08)

Smart insight:

Never underestimate CMC. If you do, you will pay for it later.

If this topic resonates with you, here are a few related episodes where we dive deeper into building strong CMC foundations and avoiding costly development mistakes:

  • Episodes 199 - 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC Development
  • Episodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)
  • Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene Lee
  • Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner

Connect with Henri Kornmann:

LinkedIn: www.linkedin.com/in/henri-kornmann-9b6869

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> How solid is your CMC foundation—and what happens if it cracks under pressure?

David Brühlmann welcomes Henri Kornmann, former Head of Biologics Innovation Centre at Ferring Pharmaceuticals. From junior CMC scientist at Merck to leading Ferring Pharmaceuticals' first gene therapy approval for bladder cancer, Henri has moved repeatedly between CMC development, GMP manufacturing, and due diligence across some of the industry's most complex programs.

His “house building” approach demystifies CMC’s complexity, showing why early diligence paired with regulatory fluency and scientific insight pays dividends for years.

Tune in to hear Henri’s practical wisdom distilled through real-world analogies:

  • Building a strong CMC foundation in early phases and why later fixes can be costly or impossible (02:45)
  • Scaling up: supplying Phase 3 with the final commercial process, including robustness and supply chain strategies such as dual sourcing critical raw materials (03:23)
  • Process validation explained: FDA’s three stages, from control strategy justification to continued verification (05:15)
  • Process Performance Qualification (PPQ): what it is, how many batches are needed, and optimizing timing (07:43)
  • Handling lifecycle changes: maintaining process control, adapting to deviations, and improving systems after regulatory approval (09:34)
  • Managing teams, stakeholders, and cross-functional collaboration in CMC programs (11:49)
  • Importance of good project management, access to scientific expertise, and interpreting guidelines for your specific program (12:27)
  • The “half scientist, half lawyer” analogy for mastering both technical and regulatory aspects (15:08)

Smart insight:

Never underestimate CMC. If you do, you will pay for it later.

If this topic resonates with you, here are a few related episodes where we dive deeper into building strong CMC foundations and avoiding costly development mistakes:

  • Episodes 199 - 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC Development
  • Episodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)
  • Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene Lee
  • Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner

Connect with Henri Kornmann:

LinkedIn: www.linkedin.com/in/henri-kornmann-9b6869

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18749693 Thu, 05 Mar 2026 05:00:00 +0100 1096 232 full false 231: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann - Part 1 231: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri Kornmann - Part 1 Seventy percent of FDA Complete Response Letters have a CMC root cause. Most of those failures trace back to decisions made years earlier. Decisions that felt minor at the time and proved impossible to fix later.

Henri Kornmann has spent two decades making those decisions the right way. From junior CMC scientist at Merck to leading Ferring Pharmaceuticals' first gene therapy approval for bladder cancer, Henri has crossed between CMC development, GMP manufacturing, and due diligence across some of the industry's most complex programs. His conclusion: a CMC program is like building a house. Get the foundation wrong and no amount of late-stage effort will save you.

In Part 1, Henri reveals the decisions that cannot be undone and how to get them right from the start.

What you will learn:

  • Evolution of cell bank technology and regulatory expectations (00:33)
  • The impact of weak CMC foundations on late-stage failure (00:51)
  • Lessons learned from Ferring’s gene therapy approval and CMC gap analysis (06:51)
  • FDA statistics on CMC issues in INDs and response letters (08:07)
  • Critical early decisions: cell bank clonality and proper storage practices (10:22)
  • The importance of comprehensive raw material documentation (12:29)
  • Early analytical characterization and discovering molecular “funkiness” before phase trials (13:41)
  • Supply strategy for phase 2—why stability and batch knowledge matter (14:49)
  • Introduction to critical quality attributes (CQA), process parameters, and quality-by-design principles (15:52)
  • Common pitfalls in CQA identification and continued process verification (17:01)

Smart insight:

The therapies that reach patients aren't built on heroic late-stage rescues. They're built on disciplined early decisions: the right cell bank, the right analytics, the right documentation. Henri's message is unambiguous: there are CMC mistakes you can fix later, and there are CMC mistakes you cannot. Knowing the difference is the foundation of every successful biologics program.

In Part 2, Henri walks through scale-up to commercial manufacturing, process validation stages 1 through 3, post-approval control strategy, and the project management and regulatory fluency that separate successful CMC leaders from the rest.

If this topic resonates with you, here are a few related episodes where we dive deeper into building strong CMC foundations and avoiding costly development mistakes:

  • Episodes 199 - 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC Development
  • Episodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)
  • Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene Lee
  • Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner

Connect with Henri Kornmann:

LinkedIn: www.linkedin.com/in/henri-kornmann-9b6869

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> Seventy percent of FDA Complete Response Letters have a CMC root cause. Most of those failures trace back to decisions made years earlier. Decisions that felt minor at the time and proved impossible to fix later.

Henri Kornmann has spent two decades making those decisions the right way. From junior CMC scientist at Merck to leading Ferring Pharmaceuticals' first gene therapy approval for bladder cancer, Henri has crossed between CMC development, GMP manufacturing, and due diligence across some of the industry's most complex programs. His conclusion: a CMC program is like building a house. Get the foundation wrong and no amount of late-stage effort will save you.

In Part 1, Henri reveals the decisions that cannot be undone and how to get them right from the start.

What you will learn:

  • Evolution of cell bank technology and regulatory expectations (00:33)
  • The impact of weak CMC foundations on late-stage failure (00:51)
  • Lessons learned from Ferring’s gene therapy approval and CMC gap analysis (06:51)
  • FDA statistics on CMC issues in INDs and response letters (08:07)
  • Critical early decisions: cell bank clonality and proper storage practices (10:22)
  • The importance of comprehensive raw material documentation (12:29)
  • Early analytical characterization and discovering molecular “funkiness” before phase trials (13:41)
  • Supply strategy for phase 2—why stability and batch knowledge matter (14:49)
  • Introduction to critical quality attributes (CQA), process parameters, and quality-by-design principles (15:52)
  • Common pitfalls in CQA identification and continued process verification (17:01)

Smart insight:

The therapies that reach patients aren't built on heroic late-stage rescues. They're built on disciplined early decisions: the right cell bank, the right analytics, the right documentation. Henri's message is unambiguous: there are CMC mistakes you can fix later, and there are CMC mistakes you cannot. Knowing the difference is the foundation of every successful biologics program.

In Part 2, Henri walks through scale-up to commercial manufacturing, process validation stages 1 through 3, post-approval control strategy, and the project management and regulatory fluency that separate successful CMC leaders from the rest.

If this topic resonates with you, here are a few related episodes where we dive deeper into building strong CMC foundations and avoiding costly development mistakes:

  • Episodes 199 - 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC Development
  • Episodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)
  • Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene Lee
  • Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias Müllner

Connect with Henri Kornmann:

LinkedIn: www.linkedin.com/in/henri-kornmann-9b6869

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18749683 Tue, 03 Mar 2026 05:00:00 +0100 1179 231 full false 230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim Corcoran - Part 2 230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim Corcoran - Part 2 What if the future of sustainable manufacturing required no sugar feedstocks, generated minimal waste, and operated carbon-neutral from day one? Ocean-derived cyanobacteria are making this possible—but the path from promising strain to profitable business is littered with synthetic biology casualties. This episode reveals the strategic decisions that separate winners from failures.

In Part 2, Tim Corcoran, CEO and Co-Founder of Deep Blue Biotech, exposes the hard truths about commercializing photosynthetic manufacturing: why most synthetic biology companies died when capital dried up in 2023, which infrastructure gaps nearly derail cyanobacteria scale-up, and why building one facility beats building ten. With three decades navigating commercial biotech and operations, Tim shares the disciplined commercialization framework that transforms scientific breakthroughs into economically viable platforms.

Topics covered:

  • The strategic advantage of B2B commercialization in consumer care biotech (02:46)
  • Overcoming infrastructure limitations for photobioreactor scale-up and partnering with specialized CMOs (04:50)
  • Building a pilot facility and moving toward technology licensing for global reach (05:33)
  • Location choices for production facilities—comparing natural light, skilled labor, and electricity costs in Portugal and Iceland (08:57)
  • Impact of electricity usage for LED-supported photosynthesis on business viability (10:45)
  • What distinguishes successful laboratory-to-market biotech companies from those that fail, especially in challenging financial environments (11:53)
  • Practical advice for scientists considering entrepreneurship, including partnering with business-minded collaborators and exploring university innovation programs (14:08)
  • Speculation on the broader applications and future of synthetic biology, from biofuels to biodegradable materials and CO₂-absorbing products (15:27)
  • The importance of aligning technical innovation with commercial expertise to create enduring impact (16:38)

Strategic insight:

Breakthrough science needs disciplined commercialization. Align what your technology naturally excels at with market needs, start where value is highest, and leverage partnerships to scale. As Deep Blue Biotech shows, this is how innovations move from the lab to making a real-world impact.

Explore the full story and hear Tim’s advice for both founders and innovators.

If you’re interested in other unconventional biological platforms reshaping biomanufacturing, don’t miss:

  • Episode 163-164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf
  • Episodes 141-142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor

Connect with Tim Corcoran:

LinkedIn: www.linkedin.com/in/tim-corcoran-5b10121/

Deep Blue Biotech: www.deepbluebiotech.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> What if the future of sustainable manufacturing required no sugar feedstocks, generated minimal waste, and operated carbon-neutral from day one? Ocean-derived cyanobacteria are making this possible—but the path from promising strain to profitable business is littered with synthetic biology casualties. This episode reveals the strategic decisions that separate winners from failures.

In Part 2, Tim Corcoran, CEO and Co-Founder of Deep Blue Biotech, exposes the hard truths about commercializing photosynthetic manufacturing: why most synthetic biology companies died when capital dried up in 2023, which infrastructure gaps nearly derail cyanobacteria scale-up, and why building one facility beats building ten. With three decades navigating commercial biotech and operations, Tim shares the disciplined commercialization framework that transforms scientific breakthroughs into economically viable platforms.

Topics covered:

  • The strategic advantage of B2B commercialization in consumer care biotech (02:46)
  • Overcoming infrastructure limitations for photobioreactor scale-up and partnering with specialized CMOs (04:50)
  • Building a pilot facility and moving toward technology licensing for global reach (05:33)
  • Location choices for production facilities—comparing natural light, skilled labor, and electricity costs in Portugal and Iceland (08:57)
  • Impact of electricity usage for LED-supported photosynthesis on business viability (10:45)
  • What distinguishes successful laboratory-to-market biotech companies from those that fail, especially in challenging financial environments (11:53)
  • Practical advice for scientists considering entrepreneurship, including partnering with business-minded collaborators and exploring university innovation programs (14:08)
  • Speculation on the broader applications and future of synthetic biology, from biofuels to biodegradable materials and CO₂-absorbing products (15:27)
  • The importance of aligning technical innovation with commercial expertise to create enduring impact (16:38)

Strategic insight:

Breakthrough science needs disciplined commercialization. Align what your technology naturally excels at with market needs, start where value is highest, and leverage partnerships to scale. As Deep Blue Biotech shows, this is how innovations move from the lab to making a real-world impact.

Explore the full story and hear Tim’s advice for both founders and innovators.

If you’re interested in other unconventional biological platforms reshaping biomanufacturing, don’t miss:

  • Episode 163-164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf
  • Episodes 141-142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor

Connect with Tim Corcoran:

LinkedIn: www.linkedin.com/in/tim-corcoran-5b10121/

Deep Blue Biotech: www.deepbluebiotech.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18712173 Thu, 26 Feb 2026 05:00:00 +0100 1140 230 full false 229: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim Corcoran - Part 1 229: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim Corcoran - Part 1 The chemicals industry remains locked into carbon-intensive, fossil-based manufacturing. Even engineered microbes like yeast or E. coli depend on expensive sugar feedstocks while generating significant waste. What if a photosynthetic organism could eliminate those constraints entirely—while commanding premium pricing as "ocean-derived"?

On the Smart Biotech Scientist Podcast, Tim Corcoran, CEO and Co-Founder of Deep Blue Biotech, reveals how a recently discovered fast-growing marine cyanobacteria strain is unlocking carbon-neutral chemical production at costs below conventional fermentation. With his background spanning economics, operations, and innovation commercialization, Tim challenges conventional assumptions about synthetic biology scale-up, market entry strategy, and what actually separates successful biotechs from valley-of-death casualties.

Key topics discussed:

  • Tim Corcoran’s background in commercial roles, his pivot to biotech, and the founding story of Deep Blue Biotech (03:41)
  • Overview of cyanobacteria biology: photosynthetic efficiency and its legacy in Earth's atmosphere (07:22)
  • What makes the discovered ocean-based strain unique—and its advantages in robustness, growth rate, and use in personal care (08:27)
  • Commercial challenges and scientific limitations that have made cyanobacteria difficult to industrialize—plus recent breakthroughs (9:38)
  • Comparison with legacy hosts such as E. coli, yeast, microalgae: efficiency, feedstocks, genetic tractability, and downstream processing
  • (11:02)
  • The significance of direct secretion for lowering production costs and reducing CO₂ footprint (14:38)
  • Scale-up strategies with photobioreactors: modularity, light and CO₂ management, and future tech improvements (15:17)
  • Commercial strategy: starting with high-value personal care hyaluronic acid, regulatory considerations, and the rationale for this approach (17:17)
  • The importance of aligning scientific innovation with market needs and early customer discovery (20:31)
  • Long-term vision: potential for cyanobacteria in sustainable production of commodity chemicals like biofuels and the impact on global emissions (22:04)

Strategic insight:

Deep Blue Biotech's "premium-first commercialization" mirrors Tesla's playbook: start with high-margin applications ($2,000/kg hyaluronic acid for personal care) to generate immediate revenue and prove the platform. These early profits fund continuous strain engineering and process optimization, progressively driving down cost-of-goods while improving volumetric productivity. Only after establishing economic viability at premium pricing does the company target large-volume commodity markets—sustainable fuels, industrial chemicals—where success requires demonstration of competitive economics at industrial scale.

Discover how this photosynthetic organisms could decarbonize entire chemical supply chains while improving manufacturing economics. Part 2 reveals the strategic decisions separating synthetic biology winners from failures, photobioreactor infrastructure challenges, and why licensing beats building multiple facilities.

If you’re interested in other unconventional biological platforms reshaping biomanufacturing, don’t miss:

  • Episode 163-164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf
  • Episodes 141-142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor

Connect with Tim Corcoran:

LinkedIn: www.linkedin.com/in/tim-corcoran-5b10121/

Deep Blue Biotech: www.deepbluebiotech.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support 

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> The chemicals industry remains locked into carbon-intensive, fossil-based manufacturing. Even engineered microbes like yeast or E. coli depend on expensive sugar feedstocks while generating significant waste. What if a photosynthetic organism could eliminate those constraints entirely—while commanding premium pricing as "ocean-derived"?

On the Smart Biotech Scientist Podcast, Tim Corcoran, CEO and Co-Founder of Deep Blue Biotech, reveals how a recently discovered fast-growing marine cyanobacteria strain is unlocking carbon-neutral chemical production at costs below conventional fermentation. With his background spanning economics, operations, and innovation commercialization, Tim challenges conventional assumptions about synthetic biology scale-up, market entry strategy, and what actually separates successful biotechs from valley-of-death casualties.

Key topics discussed:

  • Tim Corcoran’s background in commercial roles, his pivot to biotech, and the founding story of Deep Blue Biotech (03:41)
  • Overview of cyanobacteria biology: photosynthetic efficiency and its legacy in Earth's atmosphere (07:22)
  • What makes the discovered ocean-based strain unique—and its advantages in robustness, growth rate, and use in personal care (08:27)
  • Commercial challenges and scientific limitations that have made cyanobacteria difficult to industrialize—plus recent breakthroughs (9:38)
  • Comparison with legacy hosts such as E. coli, yeast, microalgae: efficiency, feedstocks, genetic tractability, and downstream processing
  • (11:02)
  • The significance of direct secretion for lowering production costs and reducing CO₂ footprint (14:38)
  • Scale-up strategies with photobioreactors: modularity, light and CO₂ management, and future tech improvements (15:17)
  • Commercial strategy: starting with high-value personal care hyaluronic acid, regulatory considerations, and the rationale for this approach (17:17)
  • The importance of aligning scientific innovation with market needs and early customer discovery (20:31)
  • Long-term vision: potential for cyanobacteria in sustainable production of commodity chemicals like biofuels and the impact on global emissions (22:04)

Strategic insight:

Deep Blue Biotech's "premium-first commercialization" mirrors Tesla's playbook: start with high-margin applications ($2,000/kg hyaluronic acid for personal care) to generate immediate revenue and prove the platform. These early profits fund continuous strain engineering and process optimization, progressively driving down cost-of-goods while improving volumetric productivity. Only after establishing economic viability at premium pricing does the company target large-volume commodity markets—sustainable fuels, industrial chemicals—where success requires demonstration of competitive economics at industrial scale.

Discover how this photosynthetic organisms could decarbonize entire chemical supply chains while improving manufacturing economics. Part 2 reveals the strategic decisions separating synthetic biology winners from failures, photobioreactor infrastructure challenges, and why licensing beats building multiple facilities.

If you’re interested in other unconventional biological platforms reshaping biomanufacturing, don’t miss:

  • Episode 163-164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf
  • Episodes 141-142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor

Connect with Tim Corcoran:

LinkedIn: www.linkedin.com/in/tim-corcoran-5b10121/

Deep Blue Biotech: www.deepbluebiotech.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support 

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18712115 Tue, 24 Feb 2026 05:00:00 +0100 1563 229 full false 228: Media-Based Glycan Engineering for Biosimilars: Your Rapid Implementation Guide 228: Media-Based Glycan Engineering for Biosimilars: Your Rapid Implementation Guide How early in process development should you address glycosylation? This episode presents the case for co-optimizing glycan profiles with productivity from initial process characterization. Deferring glycosylation characterization until after titer targets are met introduces risk: quality attribute gaps discovered late in development force process re-optimization, extended timelines, and potential cell line reselection. Media supplementation enables earlier intervention—tuning glycan distribution as a process parameter from the beginning of cell line and media development rather than as a remediation strategy.

David Brühlmann outlines the experimental protocol for validating raffinose supplementation, including decision criteria for proceeding or terminating at each development stage. The discussion addresses process design space requirements, analytical monitoring strategy, and the experimental variables that determine when media-based glycan tuning is appropriate versus when alternative approaches are needed.

Highlights from the episode:

  • When to use (and not use) raffinose in your development program, including limitations and effectiveness windows (00:30)
  • Essential protocol: three experiments over eight weeks to validate raffinose for your process, with clear go/no-go criteria (04:09)
  • Why individualized mannose tracking (Man5, Man6, Man7, Man8) is crucial for meaningful results (01:06)
  • Managing osmolality: why it matters and how to control it in your experiment (04:36)
  • Advice on scaling up: moving from small-scale screens to benchtop bioreactors and stress-testing your process (07:48)
  • Three key mistakes to avoid when implementing raffinose, including lessons from analytical oversight, incomplete design mapping, and feed interference (09:08)
  • Integrating glycosylation as a core part of process design, not just a secondary consideration after titer optimization (13:10)

Strategic insight:

Sequential optimization of productivity followed by glycosylation introduces development risk: quality attribute deviations discovered after process lockdown require costly re-optimization cycles. Parallel development of titer and glycan specifications from initial cell line characterization reduces this risk by establishing feasible operating windows early in the development timeline.

Are you planning your next recombinant protein scale-up? Hear how David’s rule-of-three protocol and battle-tested lessons can help you optimize faster and avoid painful late-stage surprises.

Resources: Journal of Biotechnology, 2017, volume 252, pages 32 to 42

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> How early in process development should you address glycosylation? This episode presents the case for co-optimizing glycan profiles with productivity from initial process characterization. Deferring glycosylation characterization until after titer targets are met introduces risk: quality attribute gaps discovered late in development force process re-optimization, extended timelines, and potential cell line reselection. Media supplementation enables earlier intervention—tuning glycan distribution as a process parameter from the beginning of cell line and media development rather than as a remediation strategy.

David Brühlmann outlines the experimental protocol for validating raffinose supplementation, including decision criteria for proceeding or terminating at each development stage. The discussion addresses process design space requirements, analytical monitoring strategy, and the experimental variables that determine when media-based glycan tuning is appropriate versus when alternative approaches are needed.

Highlights from the episode:

  • When to use (and not use) raffinose in your development program, including limitations and effectiveness windows (00:30)
  • Essential protocol: three experiments over eight weeks to validate raffinose for your process, with clear go/no-go criteria (04:09)
  • Why individualized mannose tracking (Man5, Man6, Man7, Man8) is crucial for meaningful results (01:06)
  • Managing osmolality: why it matters and how to control it in your experiment (04:36)
  • Advice on scaling up: moving from small-scale screens to benchtop bioreactors and stress-testing your process (07:48)
  • Three key mistakes to avoid when implementing raffinose, including lessons from analytical oversight, incomplete design mapping, and feed interference (09:08)
  • Integrating glycosylation as a core part of process design, not just a secondary consideration after titer optimization (13:10)

Strategic insight:

Sequential optimization of productivity followed by glycosylation introduces development risk: quality attribute deviations discovered after process lockdown require costly re-optimization cycles. Parallel development of titer and glycan specifications from initial cell line characterization reduces this risk by establishing feasible operating windows early in the development timeline.

Are you planning your next recombinant protein scale-up? Hear how David’s rule-of-three protocol and battle-tested lessons can help you optimize faster and avoid painful late-stage surprises.

Resources: Journal of Biotechnology, 2017, volume 252, pages 32 to 42

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18647690 Tue, 17 Feb 2026 05:00:00 +0100 952 228 full false 227: Media-Based Glycan Engineering for Biosimilars: Achieving Reference Product Match 227: Media-Based Glycan Engineering for Biosimilars: Achieving Reference Product Match When your biosimilar analytical data shows 1.4% high mannose against a 6% reference product specification, you face limited options: process temperature shifts that compromise titer, kifunensine supplementation that requires extensive regulatory justification, or 12-18 months to reclone and revalidate. Media supplementation offers an alternative pathway—tuning glycan profiles through formulation adjustments rather than cell line or process re-engineering.

In this episode, David Brühlmann presents the experimental development of a media supplementation strategy that achieved 2.8-fold increases in high mannose glycans across multiple CHO cell lines. Drawing from research published in the Journal of Biotechnology (2017, 252:32-42), the discussion covers the mechanism of raffinose-mediated glycan processing arrest, the experimental variables that initially obscured the effect, and the process development considerations for implementing media-based glycan tuning.

The episode examines N-glycan biosynthesis in CHO cells, regulatory comparability requirements for biosimilar glycosylation profiles, and the experimental framework for evaluating media supplementation as a glycan control strategy.

Highlights from the episode:

  • The unexpected link between dietary raffinose and reduced athletic performance, and its connection to bioprocessing (01:11)
  • A clear primer on the importance of glycosylation for biosimilar drugs and regulatory approval (02:43)
  • Common challenges when glycan profiles don't match reference products, and why high mannose glycans matter (04:19)
  • A review of industry strategies (temperature shifts, enzyme inhibitors, cell line reengineering) and their pitfalls (05:33)
  • Mechanistic insights into how raffinose alters glycan processing in CHO cells (07:05)
  • Key experimental findings on raffinose concentration, osmolality control, and practical lab troubleshooting (09:48)
  • Application stories and regulatory considerations for implementing raffinose-based media adjustments (13:47)
  • Closing thoughts on process optimization, regulatory impact, and what to expect in Part 2 (15:11)

Strategic insight:

Implementing raffinose as a media supplement is straightforward, regulatory-friendly, and cost-effective. It does not involve genetic engineering or enzyme inhibitors and is easily sourced as a GMP-grade material. For programs approaching submission with glycan comparability gaps, media-based tuning offers a process optimization pathway that maintains existing cell lines and manufacturing platforms while addressing critical quality attribute specifications.

Listen to this episode of the Smart Biotech Scientist Podcast to learn David’s best strategies for rapid, regulatory-friendly glycosylation control.

If you want to transform your glycoengineering workflow, keep an eye (and ear) out for the next episode of the Smart Biotech Scientist Podcast. Your path to regulatory success might be as simple as a pinch of raffinose.

Resources: Journal of Biotechnology, 2017, volume 252, pages 32 to 42

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> When your biosimilar analytical data shows 1.4% high mannose against a 6% reference product specification, you face limited options: process temperature shifts that compromise titer, kifunensine supplementation that requires extensive regulatory justification, or 12-18 months to reclone and revalidate. Media supplementation offers an alternative pathway—tuning glycan profiles through formulation adjustments rather than cell line or process re-engineering.

In this episode, David Brühlmann presents the experimental development of a media supplementation strategy that achieved 2.8-fold increases in high mannose glycans across multiple CHO cell lines. Drawing from research published in the Journal of Biotechnology (2017, 252:32-42), the discussion covers the mechanism of raffinose-mediated glycan processing arrest, the experimental variables that initially obscured the effect, and the process development considerations for implementing media-based glycan tuning.

The episode examines N-glycan biosynthesis in CHO cells, regulatory comparability requirements for biosimilar glycosylation profiles, and the experimental framework for evaluating media supplementation as a glycan control strategy.

Highlights from the episode:

  • The unexpected link between dietary raffinose and reduced athletic performance, and its connection to bioprocessing (01:11)
  • A clear primer on the importance of glycosylation for biosimilar drugs and regulatory approval (02:43)
  • Common challenges when glycan profiles don't match reference products, and why high mannose glycans matter (04:19)
  • A review of industry strategies (temperature shifts, enzyme inhibitors, cell line reengineering) and their pitfalls (05:33)
  • Mechanistic insights into how raffinose alters glycan processing in CHO cells (07:05)
  • Key experimental findings on raffinose concentration, osmolality control, and practical lab troubleshooting (09:48)
  • Application stories and regulatory considerations for implementing raffinose-based media adjustments (13:47)
  • Closing thoughts on process optimization, regulatory impact, and what to expect in Part 2 (15:11)

Strategic insight:

Implementing raffinose as a media supplement is straightforward, regulatory-friendly, and cost-effective. It does not involve genetic engineering or enzyme inhibitors and is easily sourced as a GMP-grade material. For programs approaching submission with glycan comparability gaps, media-based tuning offers a process optimization pathway that maintains existing cell lines and manufacturing platforms while addressing critical quality attribute specifications.

Listen to this episode of the Smart Biotech Scientist Podcast to learn David’s best strategies for rapid, regulatory-friendly glycosylation control.

If you want to transform your glycoengineering workflow, keep an eye (and ear) out for the next episode of the Smart Biotech Scientist Podcast. Your path to regulatory success might be as simple as a pinch of raffinose.

Resources: Journal of Biotechnology, 2017, volume 252, pages 32 to 42

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18647679 Tue, 10 Feb 2026 05:00:00 +0100 994 227 full false 226: Mastering Radiopharmaceutical Development: Preclinical Model Selection for Clinical Success with Bryan Miller - Part 2 226: Mastering Radiopharmaceutical Development: Preclinical Model Selection for Clinical Success with Bryan Miller - Part 2 Hard-to-treat cancers like pancreatic ductal adenocarcinoma (PDAC) have long defied conventional therapies. Radiopharmaceuticals, combining targeted therapy with diagnostic power, are creating new opportunities in precision oncology.

Host David Brühlmann speaks with Bryan Miller of Crown Bioscience, who explains how Crown's strategic partnerships, rigorous quality standards, and adaptive study design are shaping radiopharmaceutical development—delivering speed, safety, and real clinical impact.

In this episode, you'll learn:

  • The promise and practical implications of theranostics—agents used for both diagnosis and treatment (02:44)
  • Definitions and distinctions between CDX (cell line-derived xenograft) and PDX (patient-derived xenograft) models, and why PDX models better recapitulate tumor heterogeneity (05:11)
  • Strategies for building more predictive, clinically relevant research models (06:09)
  • Balancing rapid innovation with rigorous quality standards—why robust QC systems enable speed without compromising safety (08:01)
  • Key advice for scientists entering radiopharmaceutical development, including how to choose the right research partners (09:53)
  • Why effective collaboration between biotech companies and CROs is akin to a well-chosen partnership (10:50)
  • The future outlook for radiopharmaceuticals and their impact on hard-to-treat cancers (12:21)

Strategic insight:

Focusing on theranostic radiopharmaceuticals—agents that combine diagnostics and therapy—offers a high-impact strategy for hard-to-treat cancers like PDAC. By enabling simultaneous patient stratification and targeted treatment, theranostics can accelerate development, improve clinical outcomes, and create a competitive advantage in areas where traditional therapies are limited.

Where do you see radiopharmaceuticals and advanced preclinical models making the biggest impact in oncology or beyond?

Explore the full conversation to learn how Bryan Miller and Crown Bioscience are scaling innovation for the next generation of cancer therapies.

Connect with Bryan Miller:

LinkedIn: www.linkedin.com/in/bryan-miller-148344aa

Crown Bioscience: www.crownbio.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> Hard-to-treat cancers like pancreatic ductal adenocarcinoma (PDAC) have long defied conventional therapies. Radiopharmaceuticals, combining targeted therapy with diagnostic power, are creating new opportunities in precision oncology.

Host David Brühlmann speaks with Bryan Miller of Crown Bioscience, who explains how Crown's strategic partnerships, rigorous quality standards, and adaptive study design are shaping radiopharmaceutical development—delivering speed, safety, and real clinical impact.

In this episode, you'll learn:

  • The promise and practical implications of theranostics—agents used for both diagnosis and treatment (02:44)
  • Definitions and distinctions between CDX (cell line-derived xenograft) and PDX (patient-derived xenograft) models, and why PDX models better recapitulate tumor heterogeneity (05:11)
  • Strategies for building more predictive, clinically relevant research models (06:09)
  • Balancing rapid innovation with rigorous quality standards—why robust QC systems enable speed without compromising safety (08:01)
  • Key advice for scientists entering radiopharmaceutical development, including how to choose the right research partners (09:53)
  • Why effective collaboration between biotech companies and CROs is akin to a well-chosen partnership (10:50)
  • The future outlook for radiopharmaceuticals and their impact on hard-to-treat cancers (12:21)

Strategic insight:

Focusing on theranostic radiopharmaceuticals—agents that combine diagnostics and therapy—offers a high-impact strategy for hard-to-treat cancers like PDAC. By enabling simultaneous patient stratification and targeted treatment, theranostics can accelerate development, improve clinical outcomes, and create a competitive advantage in areas where traditional therapies are limited.

Where do you see radiopharmaceuticals and advanced preclinical models making the biggest impact in oncology or beyond?

Explore the full conversation to learn how Bryan Miller and Crown Bioscience are scaling innovation for the next generation of cancer therapies.

Connect with Bryan Miller:

LinkedIn: www.linkedin.com/in/bryan-miller-148344aa

Crown Bioscience: www.crownbio.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18592860 Thu, 05 Feb 2026 05:00:00 +0100 960 226 full false 225: Mastering Radiopharmaceutical Development: Preclinical Model Selection for Clinical Success with Bryan Miller - Part 1 225: Mastering Radiopharmaceutical Development: Preclinical Model Selection for Clinical Success with Bryan Miller - Part 1 Imagine treating cancer with the precision of a guided missile—delivering radioactive payloads directly to tumor cells. Radiopharmaceuticals are reshaping cancer diagnostics and therapy by pairing tumor-targeting molecules with radioisotopes for diagnosis or therapy. But what does it really take to develop these therapies, and why is interest from scientists, biotech companies, and pharma accelerating?

In this episode, we're joined by Bryan Miller, Director of Scientific and Technical Operations at Crown Bioscience UK. From a PhD in cardiac disease to leading preclinical oncology and radiopharmaceutical programs, Bryan brings hands-on insight into building advanced cancer models and translating innovative therapies from bench to clinic.

Topics discussed include:

  • Bryan Miller's path from cardiac disease research to leading preclinical cancer model development (03:03)
  • Crown Bioscience's comprehensive cancer model platforms, from organoids to PDX and humanized in vivo models (04:05)
  • How radiopharmaceuticals differ from traditional chemotherapies in terms of safety and speed, including the concept of theranostics (07:32)
  • The reasons behind the surge of interest in radiopharmaceuticals within science and industry (09:04)
  • The importance of selecting the right preclinical model for success—and how AI and data-driven approaches will shape future workflows (10:11)
  • Critical pitfalls and unique technical challenges in radiopharmaceutical drug development (12:46)
  • Crown Bioscience's collaborative approach with Medicines Discovery Catapult to navigate the complexities of radiopharmaceutical research (13:35)
  • The diverse client needs, from small startups to global pharma companies, and how mature their development programs can be (14:20)
  • Strategies for scaling preclinical and translational capabilities to meet growing demand in radiopharmaceutical studies (16:04)

Strategic insight:

Radiopharmaceutical success requires integrated design from the start—combining precise model selection, targeting strategy, isotope choice, linker chemistry, and rigorous QC. Programs that establish this comprehensive foundation early move faster and with higher translational confidence than those addressing these elements sequentially or treating any aspect as a downstream refinement.

If you're curious about the real challenges of drug development, the rise of theranostics, and how data-driven approaches (including AI) are shaping preclinical workflows, this episode delivers actionable strategies and insider perspectives for scientists and biotech innovators alike.

Connect with Bryan Miller:

LinkedIn: www.linkedin.com/in/bryan-miller-148344aa

Crown Bioscience: www.crownbio.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> Imagine treating cancer with the precision of a guided missile—delivering radioactive payloads directly to tumor cells. Radiopharmaceuticals are reshaping cancer diagnostics and therapy by pairing tumor-targeting molecules with radioisotopes for diagnosis or therapy. But what does it really take to develop these therapies, and why is interest from scientists, biotech companies, and pharma accelerating?

In this episode, we're joined by Bryan Miller, Director of Scientific and Technical Operations at Crown Bioscience UK. From a PhD in cardiac disease to leading preclinical oncology and radiopharmaceutical programs, Bryan brings hands-on insight into building advanced cancer models and translating innovative therapies from bench to clinic.

Topics discussed include:

  • Bryan Miller's path from cardiac disease research to leading preclinical cancer model development (03:03)
  • Crown Bioscience's comprehensive cancer model platforms, from organoids to PDX and humanized in vivo models (04:05)
  • How radiopharmaceuticals differ from traditional chemotherapies in terms of safety and speed, including the concept of theranostics (07:32)
  • The reasons behind the surge of interest in radiopharmaceuticals within science and industry (09:04)
  • The importance of selecting the right preclinical model for success—and how AI and data-driven approaches will shape future workflows (10:11)
  • Critical pitfalls and unique technical challenges in radiopharmaceutical drug development (12:46)
  • Crown Bioscience's collaborative approach with Medicines Discovery Catapult to navigate the complexities of radiopharmaceutical research (13:35)
  • The diverse client needs, from small startups to global pharma companies, and how mature their development programs can be (14:20)
  • Strategies for scaling preclinical and translational capabilities to meet growing demand in radiopharmaceutical studies (16:04)

Strategic insight:

Radiopharmaceutical success requires integrated design from the start—combining precise model selection, targeting strategy, isotope choice, linker chemistry, and rigorous QC. Programs that establish this comprehensive foundation early move faster and with higher translational confidence than those addressing these elements sequentially or treating any aspect as a downstream refinement.

If you're curious about the real challenges of drug development, the rise of theranostics, and how data-driven approaches (including AI) are shaping preclinical workflows, this episode delivers actionable strategies and insider perspectives for scientists and biotech innovators alike.

Connect with Bryan Miller:

LinkedIn: www.linkedin.com/in/bryan-miller-148344aa

Crown Bioscience: www.crownbio.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18592832 Tue, 03 Feb 2026 05:00:00 +0100 1075 225 full false 224: From Cultivated Meat to Chocolate: Rethinking Cellular Agriculture Scale-Up with Steven Lang - Part 2 224: From Cultivated Meat to Chocolate: Rethinking Cellular Agriculture Scale-Up with Steven Lang - Part 2 The cultivated meat industry has captured headlines and struggled with economics. Meanwhile, plant cell biomanufacturing is quietly solving the cost equation and approaching commercial launch. The question isn't whether cellular agriculture can work at scale. It's which applications will get there first, and what bioprocessing innovations will make it possible.

In Part 2, we dive into the commercialization challenges that separate laboratory curiosity from market-ready products. Steven Lang tackles the hard questions: How do you replicate chocolate's complex flavor profile without traditional fermentation? What analytical infrastructure ensures product consistency and safety? And how do you build the right team and data foundation to navigate the journey from premium launch to commodity-scale production?

Steven's background spanning Johnson & Johnson, Genentech, and Upside Foods gives him a unique perspective on what works and what doesn't when translating biopharma rigor to food applications. At California Cultured, he's applying those lessons to launch high-flavanol cocoa powder in 2026, with a clear roadmap to commodity cocoa and coffee thereafter.

In this episode:

  • The challenge of replicating chocolate’s taste and fermentation in the lab (02:39)
  • How plant cell culture differs from conventional farming and its advantages for safety and scalability (03:03)
  • Analytical methods and equipment needed for consistent, safe, and high-quality cultured cocoa products (05:05)
  • The potential for cell-based food to minimize heavy metals and other contaminants in chocolate (06:09)
  • Environmental implications: tackling climate change, deforestation, and the realistic timeline for widespread adoption of lab-grown foods (06:50)
  • Emerging opportunities beyond cocoa and coffee—saffron, ginseng, echinacea, and even lab-grown wood (08:40)
  • Key advice for scientists and entrepreneurs interested in entering the cellular agriculture field (10:12)
  • Building successful teams and robust data foundations in biotech startups (11:43)

Key takeaway:

Cellular agriculture's future isn't a single technology replacing conventional food production. It's multiple parallel approaches creating resilience in global food systems. The opportunity is clear: the technical principles you've mastered in biopharma translate directly to food applications, but the faster commercialization timelines and novel business models require rethinking what "stage-appropriate development" means.

The question for bioprocess leaders is whether you'll help build the solutions to bridge the food production gap, or watch from the sidelines as food security becomes the defining challenge of our generation.

Here is the previous conversation with Steven Lang:

  • Episodes 55-56: Cultivated Meat: A Promising Future or an Inevitable Bubble? with Steven Lang

Connect with Steven Lang:

LinkedIn: www.linkedin.com/in/steven-lang-b003406

California Cultured Inc.: www.cacultured.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> The cultivated meat industry has captured headlines and struggled with economics. Meanwhile, plant cell biomanufacturing is quietly solving the cost equation and approaching commercial launch. The question isn't whether cellular agriculture can work at scale. It's which applications will get there first, and what bioprocessing innovations will make it possible.

In Part 2, we dive into the commercialization challenges that separate laboratory curiosity from market-ready products. Steven Lang tackles the hard questions: How do you replicate chocolate's complex flavor profile without traditional fermentation? What analytical infrastructure ensures product consistency and safety? And how do you build the right team and data foundation to navigate the journey from premium launch to commodity-scale production?

Steven's background spanning Johnson & Johnson, Genentech, and Upside Foods gives him a unique perspective on what works and what doesn't when translating biopharma rigor to food applications. At California Cultured, he's applying those lessons to launch high-flavanol cocoa powder in 2026, with a clear roadmap to commodity cocoa and coffee thereafter.

In this episode:

  • The challenge of replicating chocolate’s taste and fermentation in the lab (02:39)
  • How plant cell culture differs from conventional farming and its advantages for safety and scalability (03:03)
  • Analytical methods and equipment needed for consistent, safe, and high-quality cultured cocoa products (05:05)
  • The potential for cell-based food to minimize heavy metals and other contaminants in chocolate (06:09)
  • Environmental implications: tackling climate change, deforestation, and the realistic timeline for widespread adoption of lab-grown foods (06:50)
  • Emerging opportunities beyond cocoa and coffee—saffron, ginseng, echinacea, and even lab-grown wood (08:40)
  • Key advice for scientists and entrepreneurs interested in entering the cellular agriculture field (10:12)
  • Building successful teams and robust data foundations in biotech startups (11:43)

Key takeaway:

Cellular agriculture's future isn't a single technology replacing conventional food production. It's multiple parallel approaches creating resilience in global food systems. The opportunity is clear: the technical principles you've mastered in biopharma translate directly to food applications, but the faster commercialization timelines and novel business models require rethinking what "stage-appropriate development" means.

The question for bioprocess leaders is whether you'll help build the solutions to bridge the food production gap, or watch from the sidelines as food security becomes the defining challenge of our generation.

Here is the previous conversation with Steven Lang:

  • Episodes 55-56: Cultivated Meat: A Promising Future or an Inevitable Bubble? with Steven Lang

Connect with Steven Lang:

LinkedIn: www.linkedin.com/in/steven-lang-b003406

California Cultured Inc.: www.cacultured.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18559985 Thu, 29 Jan 2026 05:00:00 +0100 1000 224 full false 223: From Cultivated Meat to Chocolate: Rethinking Cellular Agriculture Scale-Up with Steven Lang - Part 1 223: From Cultivated Meat to Chocolate: Rethinking Cellular Agriculture Scale-Up with Steven Lang - Part 1 What if the chocolate industry's reliance on equatorial farms—and the deforestation that comes with it—could be eliminated entirely? Plant cell bioreactors are doing that, producing real cacao without a single tree. But this isn't just about chocolate. It's about fundamentally rethinking how we manufacture food at scale, and the bioprocessing innovations emerging from this shift have implications far beyond the food industry.

Steven Lang, Head of R&D at California Cultured, spent two decades mastering mammalian cell culture at biopharma giants like Johnson & Johnson and Genentech. Then he made a radical pivot: applying those same bioprocessing principles to cultivate plant cells for food production. His mission? Prove that cellular agriculture extends far beyond the cultivated meat narrative, and that plant cell manufacturing offers a faster, more economical path to market.

At California Cultured, Steven's team is scaling cacao and coffee production using innovative low-cost plastic bioreactors instead of expensive stainless steel vessels. They've engineered plant cell media formulations that operate at a fraction of typical bioprocessing costs. And they're preparing to launch their first commercial product—high-flavanol cocoa powder—in 2026.

What you'll discover in this episode:

  • Why cellular agriculture ≠ cultivated meat (07:16) – Steven's frustration with the narrow definition that's holding the industry back, and why plant cell culture deserves equal attention
  • Plant vs. animal cell culture fundamentals (09:26) – Technical comparison: totipotent plant cells, callus formation, adaptation to suspension culture, and how cacao cell lines are developed from explants
  • Achieving 30-40% pack cell volume in 7-day batches (11:14) – Process parameters: ambient temperature growth, low pH environments, minimal downstream processing, and maintaining product consistency without genetic modification
  • The economics that change everything (14:38) – How plant cell media costs and simple raw material requirements create commodity-scale economics
  • The Tesla model for biotech (15:58) – Strategic rationale for launching with premium high-flavanol cocoa powder first, then using that revenue runway to optimize for commodity pricing
  • Low-cost bioreactor innovation (18:23) – Why plastic vessels beat stainless steel, contamination management in low-pH cultures, and scale-out strategy over traditional scale-up
  • Decentralized biomanufacturing (23:10) – Converting underutilized office space into production facilities, onshoring food ingredient production, and what this means for emerging markets and supply chain resilience
  • The bigger picture beyond cacao (24:23) – Four approved drugs already produced via plant cell culture, the expanding landscape of ingredients (saffron, ginseng, echinacea), and why stage-appropriate models matter for cellular agriculture's future

The strategic insight:

While the cultivated meat industry struggles with cost structures and consumer acceptance, plant cell manufacturing is quietly proving the business model. The lesson for bioprocessing professionals? Sometimes the fastest path to commercialization isn't the most obvious one, and the innovations happening in food manufacturing today could reshape how we think about bioproduction economics across industries.

Here is the previous conversation with Steven Lang:

  • Episodes 55-56: Cultivated Meat: A Promising Future or an Inevitable Bubble? with Steven Lang

Connect with Steven Lang:

LinkedIn: www.linkedin.com/in/steven-lang-b003406

California Cultured Inc.: www.cacultured.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> What if the chocolate industry's reliance on equatorial farms—and the deforestation that comes with it—could be eliminated entirely? Plant cell bioreactors are doing that, producing real cacao without a single tree. But this isn't just about chocolate. It's about fundamentally rethinking how we manufacture food at scale, and the bioprocessing innovations emerging from this shift have implications far beyond the food industry.

Steven Lang, Head of R&D at California Cultured, spent two decades mastering mammalian cell culture at biopharma giants like Johnson & Johnson and Genentech. Then he made a radical pivot: applying those same bioprocessing principles to cultivate plant cells for food production. His mission? Prove that cellular agriculture extends far beyond the cultivated meat narrative, and that plant cell manufacturing offers a faster, more economical path to market.

At California Cultured, Steven's team is scaling cacao and coffee production using innovative low-cost plastic bioreactors instead of expensive stainless steel vessels. They've engineered plant cell media formulations that operate at a fraction of typical bioprocessing costs. And they're preparing to launch their first commercial product—high-flavanol cocoa powder—in 2026.

What you'll discover in this episode:

  • Why cellular agriculture ≠ cultivated meat (07:16) – Steven's frustration with the narrow definition that's holding the industry back, and why plant cell culture deserves equal attention
  • Plant vs. animal cell culture fundamentals (09:26) – Technical comparison: totipotent plant cells, callus formation, adaptation to suspension culture, and how cacao cell lines are developed from explants
  • Achieving 30-40% pack cell volume in 7-day batches (11:14) – Process parameters: ambient temperature growth, low pH environments, minimal downstream processing, and maintaining product consistency without genetic modification
  • The economics that change everything (14:38) – How plant cell media costs and simple raw material requirements create commodity-scale economics
  • The Tesla model for biotech (15:58) – Strategic rationale for launching with premium high-flavanol cocoa powder first, then using that revenue runway to optimize for commodity pricing
  • Low-cost bioreactor innovation (18:23) – Why plastic vessels beat stainless steel, contamination management in low-pH cultures, and scale-out strategy over traditional scale-up
  • Decentralized biomanufacturing (23:10) – Converting underutilized office space into production facilities, onshoring food ingredient production, and what this means for emerging markets and supply chain resilience
  • The bigger picture beyond cacao (24:23) – Four approved drugs already produced via plant cell culture, the expanding landscape of ingredients (saffron, ginseng, echinacea), and why stage-appropriate models matter for cellular agriculture's future

The strategic insight:

While the cultivated meat industry struggles with cost structures and consumer acceptance, plant cell manufacturing is quietly proving the business model. The lesson for bioprocessing professionals? Sometimes the fastest path to commercialization isn't the most obvious one, and the innovations happening in food manufacturing today could reshape how we think about bioproduction economics across industries.

Here is the previous conversation with Steven Lang:

  • Episodes 55-56: Cultivated Meat: A Promising Future or an Inevitable Bubble? with Steven Lang

Connect with Steven Lang:

LinkedIn: www.linkedin.com/in/steven-lang-b003406

California Cultured Inc.: www.cacultured.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18559946 Tue, 27 Jan 2026 05:00:00 +0100 1618 223 full false 222: From 2D Cultures to Advanced 3D Cell Models for Preclinical Research with Catarina Brito - Part 2 222: From 2D Cultures to Advanced 3D Cell Models for Preclinical Research with Catarina Brito - Part 2 What happens when we move beyond oversimplified cell cultures and truly embrace the complexity of human biology? In this episode of the Smart Biotech Scientist Podcast, we explore how advanced 3D cell models are reshaping preclinical research—recreating human tissue microenvironments to better understand tumors, immunotherapies, and gene and cell therapies.

David’s guest is Catarina Brito, Principal Investigator at ITQB NOVA and Head of the Advanced Cell Models Laboratory at iBET and ITQB NOVA (Portugal). Her work bridges academia and industry through iBET, a unique partnering organization that integrates cell engineering, bioprocessing, and translational modeling.

Catarina’s pioneering models help both pharma leaders and startups predict drug resistance and immunogenicity earlier and more reliably, accelerating the path to safer, more effective therapies—well before clinical trials begin.

Topics discussed:

  • Understanding the contribution of stromal and immune cells to therapy outcomes in tumor microenvironments (03:42)
  • Studying immune responses to gene therapy vectors with advanced neural models (04:31)
  • Combining multi-omics and spatial data with AI for predictive biology and patient-specific digital twins (05:16)
  • Catarina’s advice: Start simple, let the biological question dictate model design, and avoid premature overengineering (06:53)
  • Importance of reproducibility, process controls, and standardization in advanced models (08:10)
  • How academic-industry collaborations drive model development, scalability, and real-world relevance (08:42)
  • Common pitfalls: Overengineering, poor cell source selection, insufficient system validation (11:03)
  • Next steps for precision medicine and translational research using advanced cell models (13:08)

Want to know how leading scientists make advanced cell models actionable and collaborative for pharma breakthroughs? Tune in for practical strategies, real-world collaborations, and pitfalls to avoid as you scale your own translational research.

Connect with Catarina Brito:

LinkedIn: www.linkedin.com/in/catarina-brito-ibet

Advanced Cell Models Lab – iBET: www.ibet.pt/laboratories/advanced-cell-models-lab

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> What happens when we move beyond oversimplified cell cultures and truly embrace the complexity of human biology? In this episode of the Smart Biotech Scientist Podcast, we explore how advanced 3D cell models are reshaping preclinical research—recreating human tissue microenvironments to better understand tumors, immunotherapies, and gene and cell therapies.

David’s guest is Catarina Brito, Principal Investigator at ITQB NOVA and Head of the Advanced Cell Models Laboratory at iBET and ITQB NOVA (Portugal). Her work bridges academia and industry through iBET, a unique partnering organization that integrates cell engineering, bioprocessing, and translational modeling.

Catarina’s pioneering models help both pharma leaders and startups predict drug resistance and immunogenicity earlier and more reliably, accelerating the path to safer, more effective therapies—well before clinical trials begin.

Topics discussed:

  • Understanding the contribution of stromal and immune cells to therapy outcomes in tumor microenvironments (03:42)
  • Studying immune responses to gene therapy vectors with advanced neural models (04:31)
  • Combining multi-omics and spatial data with AI for predictive biology and patient-specific digital twins (05:16)
  • Catarina’s advice: Start simple, let the biological question dictate model design, and avoid premature overengineering (06:53)
  • Importance of reproducibility, process controls, and standardization in advanced models (08:10)
  • How academic-industry collaborations drive model development, scalability, and real-world relevance (08:42)
  • Common pitfalls: Overengineering, poor cell source selection, insufficient system validation (11:03)
  • Next steps for precision medicine and translational research using advanced cell models (13:08)

Want to know how leading scientists make advanced cell models actionable and collaborative for pharma breakthroughs? Tune in for practical strategies, real-world collaborations, and pitfalls to avoid as you scale your own translational research.

Connect with Catarina Brito:

LinkedIn: www.linkedin.com/in/catarina-brito-ibet

Advanced Cell Models Lab – iBET: www.ibet.pt/laboratories/advanced-cell-models-lab

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18506524 Thu, 22 Jan 2026 05:00:00 +0100 923 222 full false 221: From 2D Cultures to Advanced 3D Cell Models for Preclinical Research with Catarina Brito - Part 1 221: From 2D Cultures to Advanced 3D Cell Models for Preclinical Research with Catarina Brito - Part 1 What if the failure rate in clinical trials isn't about picking the wrong drug candidates—but about testing them in the wrong models?

When you move cells from a 2D culture plate into a bioreactor, you're not simply scaling volume. You're fundamentally changing the biological context. Cell density shifts. Mass transfer dynamics evolve. Mechanical cues emerge. The cells sense these changes and respond—often in ways that derail strategies built on oversimplified assumptions.

Most preclinical research still relies on flat plastic surfaces and animal models that miss critical aspects of human biology. The result? Therapeutics fail late in development because the models couldn't predict how human tissues would actually respond.

In this episode, David Brühlmann speaks with Catarina Brito, Principal Investigator at ITQB NOVA and Head of the Advanced Cell Models Laboratory at iBET and ITQB NOVA in Portugal. Catarina's career-defining insight came early: studying glycan-protein interactions in murine versus human cells revealed that species differences weren't just nuances—they were fundamental gaps that could mislead entire research programs.

Catarina and her team have developed neural, liver, and tumor models that capture the multicellular complexity and microenvironmental cues that 2D cultures cannot replicate. Her work creates preclinical models sophisticated enough to predict human responses while remaining scalable for drug development workflows.

Highlights of the episode:

  • Limitations of traditional 2D cell cultures and animal models in capturing realistic tissue behavior and therapeutic responses (06:27)
  • Catarina Brito's personal scientific journey: from discovering model limitations to pioneering 3D culture systems in neural and liver tissues (04:19)
  • How advanced 3D models recreate cell-to-cell interactions, tissue-specific microenvironments, diffusion gradients, and multicellular complexity (10:35)
  • Regulatory movements toward reducing animal models, and the challenge of validating advanced alternatives for systemic biology studies (09:10)
  • Key differences in designing bioreactors for various cell types, with practical examples from liver and neural models (15:16)
  • The impact of scalable, robust 3D models on accelerating drug development and improving selection of candidate therapies (17:22)

Key Takeaway:

Bioprocess development starts when you choose the model that validates your therapeutic approach. If that model can't capture the biology that matters, every downstream optimization is built on a flawed foundation.

In Part 2, Catarina reveals how 3D tumor microenvironments expose drug resistance mechanisms invisible in 2D cultures, and her vision for AI-powered digital twins enabling personalized medicine.

Subscribe & Review:

If this conversation changed how you think about preclinical model selection, leave a review on Apple Podcasts. Your reviews help other biotech scientists discover these insights.

For more CMC development insights, visit smartbiotechscientist.com.

Connect with Catarina Brito:

LinkedIn: www.linkedin.com/in/catarina-brito-ibet

Advanced Cell Models Lab – iBET: www.ibet.pt/laboratories/advanced-cell-models-lab

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> What if the failure rate in clinical trials isn't about picking the wrong drug candidates—but about testing them in the wrong models?

When you move cells from a 2D culture plate into a bioreactor, you're not simply scaling volume. You're fundamentally changing the biological context. Cell density shifts. Mass transfer dynamics evolve. Mechanical cues emerge. The cells sense these changes and respond—often in ways that derail strategies built on oversimplified assumptions.

Most preclinical research still relies on flat plastic surfaces and animal models that miss critical aspects of human biology. The result? Therapeutics fail late in development because the models couldn't predict how human tissues would actually respond.

In this episode, David Brühlmann speaks with Catarina Brito, Principal Investigator at ITQB NOVA and Head of the Advanced Cell Models Laboratory at iBET and ITQB NOVA in Portugal. Catarina's career-defining insight came early: studying glycan-protein interactions in murine versus human cells revealed that species differences weren't just nuances—they were fundamental gaps that could mislead entire research programs.

Catarina and her team have developed neural, liver, and tumor models that capture the multicellular complexity and microenvironmental cues that 2D cultures cannot replicate. Her work creates preclinical models sophisticated enough to predict human responses while remaining scalable for drug development workflows.

Highlights of the episode:

  • Limitations of traditional 2D cell cultures and animal models in capturing realistic tissue behavior and therapeutic responses (06:27)
  • Catarina Brito's personal scientific journey: from discovering model limitations to pioneering 3D culture systems in neural and liver tissues (04:19)
  • How advanced 3D models recreate cell-to-cell interactions, tissue-specific microenvironments, diffusion gradients, and multicellular complexity (10:35)
  • Regulatory movements toward reducing animal models, and the challenge of validating advanced alternatives for systemic biology studies (09:10)
  • Key differences in designing bioreactors for various cell types, with practical examples from liver and neural models (15:16)
  • The impact of scalable, robust 3D models on accelerating drug development and improving selection of candidate therapies (17:22)

Key Takeaway:

Bioprocess development starts when you choose the model that validates your therapeutic approach. If that model can't capture the biology that matters, every downstream optimization is built on a flawed foundation.

In Part 2, Catarina reveals how 3D tumor microenvironments expose drug resistance mechanisms invisible in 2D cultures, and her vision for AI-powered digital twins enabling personalized medicine.

Subscribe & Review:

If this conversation changed how you think about preclinical model selection, leave a review on Apple Podcasts. Your reviews help other biotech scientists discover these insights.

For more CMC development insights, visit smartbiotechscientist.com.

Connect with Catarina Brito:

LinkedIn: www.linkedin.com/in/catarina-brito-ibet

Advanced Cell Models Lab – iBET: www.ibet.pt/laboratories/advanced-cell-models-lab

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18506516 Tue, 20 Jan 2026 05:00:00 +0100 1185 221 full false 220: From 10,000 Structures to 1.8 Billion Interactions: Breaking the Data Bottleneck to Engineer Efficacious Therapeutics with Troy Lionberger - Part 2 220: From 10,000 Structures to 1.8 Billion Interactions: Breaking the Data Bottleneck to Engineer Efficacious Therapeutics with Troy Lionberger - Part 2 The biotech industry stands on the verge of a radical transformation thanks to artificial intelligence (AI) and machine learning (ML). But even the most sophisticated algorithms are only as smart as the data feeding them.

David Brühlmann sits down with Troy Lionberger, Chief Business Officer at A-Alpha Bio, whose team has quietly shattered the data ceiling by measuring and curating more than 1.8 billion protein interactions. Troy Lionberger brings an insider’s perspective from the frontlines of machine learning-powered drug discovery. From partnering with leading biotechs to redesigning classic antibodies for previously “impossible” targets, Troy’s work pushes the edges of what’s tractable in biologic therapeutics.

What you'll hear in this episode:

  • Limitations of public data sources like the Protein Data Bank and their impact on current protein engineering approaches (03:11)
  • Why combining energetic (ΔG) and structural data matters for building predictive protein engineering models (05:43)
  • A-Alpha Bio’s approach to generating 1.8 billion protein interaction measurements for machine learning—what this enables today and what’s possible next (06:30)
  • Examples of how A-Alpha Bio’s platform solves challenging therapeutic problems, such as optimizing molecules for 800+ HIV variants and engineering dual-specific antibodies (07:36)
  • The ongoing debate: What capabilities should biotech companies keep in-house, and what works best outsourced to service providers? (09:59)
  • The potential of synthetic epitopes as vital tools for training models beyond the Protein Data Bank—introducing the Synthetic Epitope Atlas (12:09)
  • Key takeaways for scientists: the importance of diligence amidst rapidly evolving AI claims, and advice for accelerating R&D with the right data (14:57)

Wondering how to move protein therapeutics from “interesting” to “impactful” without waiting for years of crystal structures? Listen in to learn how you can harness next-gen machine learning tools and custom datasets for your development projects.

Connect with Troy Lionberger:

LinkedIn: www.linkedin.com/in/troylionberger

A-Alpha Bio website: www.aalphabio.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> The biotech industry stands on the verge of a radical transformation thanks to artificial intelligence (AI) and machine learning (ML). But even the most sophisticated algorithms are only as smart as the data feeding them.

David Brühlmann sits down with Troy Lionberger, Chief Business Officer at A-Alpha Bio, whose team has quietly shattered the data ceiling by measuring and curating more than 1.8 billion protein interactions. Troy Lionberger brings an insider’s perspective from the frontlines of machine learning-powered drug discovery. From partnering with leading biotechs to redesigning classic antibodies for previously “impossible” targets, Troy’s work pushes the edges of what’s tractable in biologic therapeutics.

What you'll hear in this episode:

  • Limitations of public data sources like the Protein Data Bank and their impact on current protein engineering approaches (03:11)
  • Why combining energetic (ΔG) and structural data matters for building predictive protein engineering models (05:43)
  • A-Alpha Bio’s approach to generating 1.8 billion protein interaction measurements for machine learning—what this enables today and what’s possible next (06:30)
  • Examples of how A-Alpha Bio’s platform solves challenging therapeutic problems, such as optimizing molecules for 800+ HIV variants and engineering dual-specific antibodies (07:36)
  • The ongoing debate: What capabilities should biotech companies keep in-house, and what works best outsourced to service providers? (09:59)
  • The potential of synthetic epitopes as vital tools for training models beyond the Protein Data Bank—introducing the Synthetic Epitope Atlas (12:09)
  • Key takeaways for scientists: the importance of diligence amidst rapidly evolving AI claims, and advice for accelerating R&D with the right data (14:57)

Wondering how to move protein therapeutics from “interesting” to “impactful” without waiting for years of crystal structures? Listen in to learn how you can harness next-gen machine learning tools and custom datasets for your development projects.

Connect with Troy Lionberger:

LinkedIn: www.linkedin.com/in/troylionberger

A-Alpha Bio website: www.aalphabio.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18469582 Thu, 15 Jan 2026 05:00:00 +0100 1063 220 full false 219: From 10,000 Structures to 1.8 Billion Interactions: Breaking the Data Bottleneck to Engineer Efficacious Therapeutics with Troy Lionberger - Part 1 219: From 10,000 Structures to 1.8 Billion Interactions: Breaking the Data Bottleneck to Engineer Efficacious Therapeutics with Troy Lionberger - Part 1 Antibody therapeutics have transformed modern medicine, but for many scientists, developing new candidates still feels like searching for a needle in a haystack—a slow, expensive, and unpredictable process. Structural biology and high-throughput data generation are now collapsing that haystack, offering unprecedented visibility into the molecular handshake that drives life: protein-protein interactions.

In this episode, David Brühlmann sits down with Troy Lionberger, Chief Business Officer at A-Alpha Bio, for an in-depth discussion on protein-protein interactions and how advances in data generation and machine learning are transforming antibody discovery and drug development.

Troy Lionberger shares his journey into biotechnology, challenges long-held beliefs about antibody development, and explains how Alphabio's high-throughput affinity measurements are shortening timelines and improving outcomes for therapeutic development.

In this episode, you’ll learn about:

  • The historical and current challenges in characterizing these interactions at scale (06:22)
  • How new technologies—especially high-throughput platforms—are changing the needle-in-the-haystack approach (08:40)
  • A comparison of traditional in vivo and in vitro antibody discovery methods, along with their strengths and limitations (09:06)
  • The evolving role of AI and machine learning in antibody discovery and lead optimization (12:11)
  • Real-world examples of how A-Alpha Bio’s approach is compressing years of work into months without sacrificing quality (13:58)
  • The science behind A-Alpha Bio’s AlphaSeq technology and how it leverages yeast display and genomics for large-scale affinity measurements (20:43)
  • The practical affinity range the technology can measure, covering most therapeutic applications (23:25)

Whether you’re a scientist navigating CMC or a biotech professional curious about next-generation workflows, this episode offers practical insights into both traditional and emerging methodologies in the field.

Connect with Troy Lionberger:

LinkedIn: www.linkedin.com/in/troylionberger

A-Alpha Bio website: www.aalphabio.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Antibody therapeutics have transformed modern medicine, but for many scientists, developing new candidates still feels like searching for a needle in a haystack—a slow, expensive, and unpredictable process. Structural biology and high-throughput data generation are now collapsing that haystack, offering unprecedented visibility into the molecular handshake that drives life: protein-protein interactions.

In this episode, David Brühlmann sits down with Troy Lionberger, Chief Business Officer at A-Alpha Bio, for an in-depth discussion on protein-protein interactions and how advances in data generation and machine learning are transforming antibody discovery and drug development.

Troy Lionberger shares his journey into biotechnology, challenges long-held beliefs about antibody development, and explains how Alphabio's high-throughput affinity measurements are shortening timelines and improving outcomes for therapeutic development.

In this episode, you’ll learn about:

  • The historical and current challenges in characterizing these interactions at scale (06:22)
  • How new technologies—especially high-throughput platforms—are changing the needle-in-the-haystack approach (08:40)
  • A comparison of traditional in vivo and in vitro antibody discovery methods, along with their strengths and limitations (09:06)
  • The evolving role of AI and machine learning in antibody discovery and lead optimization (12:11)
  • Real-world examples of how A-Alpha Bio’s approach is compressing years of work into months without sacrificing quality (13:58)
  • The science behind A-Alpha Bio’s AlphaSeq technology and how it leverages yeast display and genomics for large-scale affinity measurements (20:43)
  • The practical affinity range the technology can measure, covering most therapeutic applications (23:25)

Whether you’re a scientist navigating CMC or a biotech professional curious about next-generation workflows, this episode offers practical insights into both traditional and emerging methodologies in the field.

Connect with Troy Lionberger:

LinkedIn: www.linkedin.com/in/troylionberger

A-Alpha Bio website: www.aalphabio.com

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18469551 Tue, 13 Jan 2026 05:00:00 +0100 1563 219 full false 218: Silkworm Biomanufacturing: From Ancient Silk Production to Phase I Vaccine Trials with Masafumi Osawa - Part 2 218: Silkworm Biomanufacturing: From Ancient Silk Production to Phase I Vaccine Trials with Masafumi Osawa - Part 2 For generations, silkworm pupae were discarded as waste from silk production. Now, KAICO is proving these organisms can function as highly efficient protein factories—producing complex vaccine antigens at yields and costs that challenge conventional bioreactor-based manufacturing. With a PCV2 oral vaccine already registered in Vietnam and a human norovirus vaccine preparing for Phase I clinical trials, the silkworm platform is moving from proof-of-concept to commercial reality.

In Part 2, Masafumi Osawa, Business Development Lead at KAICO, walks us through the company's product pipeline, the regulatory landscape for this unprecedented platform, and why silkworm-based manufacturing could reshape global vaccine accessibility. From farm-scale validation to regulatory dialogue with Japan's PMDA, this episode bridges platform science with product development.

Stops along our Silk Road to biomanufacturing

  • KAICO’s approach to expressing complex proteins, including oral and injectable vaccines for animals and clinical-stage human health products (00:40)
  • Immune-enhancing feed additive for pigs against PCV2 (registered in Vietnam), companion animal products, and human norovirus vaccine entering Phase 1 trials (02:50)
  • Advantages of silkworm-produced antigens for both injectable and oral vaccines, and comparison to plant-based systems (04:57)
  • How silkworm production enables rapid scale-out and high-yield protein expression for global accessibility (05:34)
  • Speed of vaccine development with the silkworm platform—example with SARS-CoV-2 recombinant protein produced in three months (08:08)
  • Key regulatory differences between animal and human vaccine development, including country-specific classification and global harmonization efforts (09:14)
  • Sustainability and distributed manufacturing potential of silkworm-based systems (11:10)
  • Milestones toward the first human biologic produced in silkworms, with phase 1 trials starting soon (12:27)
  • Protein yield per silkworm pupae—scalability advantages compared to conventional bioreactor approaches (14:04)
  • Masafumi Osawa’s thoughts on the future of silkworm-based biologics: from democratized therapies to personalized medicines (15:15)

Want to know if silkworms can solve your tough protein expression problems? Tune in now to learn how KAICO’s biotech is set to redefine what’s possible for vaccine development, and how their distributed, cost-effective approach could open doors across sectors.

Connect with Masafumi Osawa,:

LinkedIn: www.linkedin.com/in/masa-osawa

KAICO Ltd.: www.kaicoltd.jp/en

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> For generations, silkworm pupae were discarded as waste from silk production. Now, KAICO is proving these organisms can function as highly efficient protein factories—producing complex vaccine antigens at yields and costs that challenge conventional bioreactor-based manufacturing. With a PCV2 oral vaccine already registered in Vietnam and a human norovirus vaccine preparing for Phase I clinical trials, the silkworm platform is moving from proof-of-concept to commercial reality.

In Part 2, Masafumi Osawa, Business Development Lead at KAICO, walks us through the company's product pipeline, the regulatory landscape for this unprecedented platform, and why silkworm-based manufacturing could reshape global vaccine accessibility. From farm-scale validation to regulatory dialogue with Japan's PMDA, this episode bridges platform science with product development.

Stops along our Silk Road to biomanufacturing

  • KAICO’s approach to expressing complex proteins, including oral and injectable vaccines for animals and clinical-stage human health products (00:40)
  • Immune-enhancing feed additive for pigs against PCV2 (registered in Vietnam), companion animal products, and human norovirus vaccine entering Phase 1 trials (02:50)
  • Advantages of silkworm-produced antigens for both injectable and oral vaccines, and comparison to plant-based systems (04:57)
  • How silkworm production enables rapid scale-out and high-yield protein expression for global accessibility (05:34)
  • Speed of vaccine development with the silkworm platform—example with SARS-CoV-2 recombinant protein produced in three months (08:08)
  • Key regulatory differences between animal and human vaccine development, including country-specific classification and global harmonization efforts (09:14)
  • Sustainability and distributed manufacturing potential of silkworm-based systems (11:10)
  • Milestones toward the first human biologic produced in silkworms, with phase 1 trials starting soon (12:27)
  • Protein yield per silkworm pupae—scalability advantages compared to conventional bioreactor approaches (14:04)
  • Masafumi Osawa’s thoughts on the future of silkworm-based biologics: from democratized therapies to personalized medicines (15:15)

Want to know if silkworms can solve your tough protein expression problems? Tune in now to learn how KAICO’s biotech is set to redefine what’s possible for vaccine development, and how their distributed, cost-effective approach could open doors across sectors.

Connect with Masafumi Osawa,:

LinkedIn: www.linkedin.com/in/masa-osawa

KAICO Ltd.: www.kaicoltd.jp/en

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18394573 Thu, 08 Jan 2026 05:00:00 +0100 1077 218 full false 217: Silkworm Biomanufacturing: From Ancient Silk Production to Phase I Vaccine Trials with Masafumi Osawa - Part 1 217: Silkworm Biomanufacturing: From Ancient Silk Production to Phase I Vaccine Trials with Masafumi Osawa - Part 1 For over 4,000 years, silkworms have connected civilizations through ancient trade routes. Now, KAICO Ltd., a Japanese biotech spin-off from Kyushu University, is transforming these creatures into living bioreactors capable of producing complex recombinant proteins and vaccine antigens—without the bioreactors, expensive media, or massive water consumption of conventional platforms.

Masafumi Osawa, Business Development Lead at KAICO, brings an unconventional path to biotech. Trained in cultural anthropology with fieldwork experience in Indonesia, he witnessed firsthand the healthcare disparities that drive his current mission. After years in pharmaceutical business development at Towa Pharmaceutical, he joined KAICO to help scale a technology he believes could reshape global vaccine accessibility. His cross-cultural expertise now proves invaluable as KAICO expands internationally, with active partnerships in Vietnam and Thailand and growing interest from other regions.

Episode highlights:

  • Masafumi’s transition from anthropology to biotech, and how cross-cultural expertise benefits global health collaborations. (04:15)
  • The founding story of KAICO, spun out from Kyushu University and focused on recombinant proteins and vaccine antigen production (08:45)
  • Step-by-step overview of the silkworm baculovirus expression system, including pupae handling and bioprocessing basics. (10:28)
  • Practical differences between silkworms, E. coli, mammalian, and insect cell culture platforms—exploring advantages and drawbacks. (13:10)
  • Strategies KAICO uses to control silkworm variability, including SPF grade sourcing, diet, environment, and documentation for pharmaceutical acceptance. (15:08)
  • Production scalability: a single pupa can match 100–1000 ml of insect cell culture, with major implications for cost and environmental footprint. (16:42)
  • Downstream harvesting and purification—how KAICO extracts and processes proteins from silkworm pupae, keeping methods largely familiar to traditional systems. (19:31)
  • Regulatory and GMP challenges of using live organisms, and KAICO’s approach to satisfying authorities and ensuring product consistency. (21:43)

Whether you’re curious about alternative biomanufacturing methods or want a transparent look at silkworm-based protein expression from research to the clinic, this episode delivers practical insights and thoughtful discussion.

Connect with Masafumi Osawa:

LinkedIn: www.linkedin.com/in/masa-osawa

KAICO Ltd.: www.kaicoltd.jp/en

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> For over 4,000 years, silkworms have connected civilizations through ancient trade routes. Now, KAICO Ltd., a Japanese biotech spin-off from Kyushu University, is transforming these creatures into living bioreactors capable of producing complex recombinant proteins and vaccine antigens—without the bioreactors, expensive media, or massive water consumption of conventional platforms.

Masafumi Osawa, Business Development Lead at KAICO, brings an unconventional path to biotech. Trained in cultural anthropology with fieldwork experience in Indonesia, he witnessed firsthand the healthcare disparities that drive his current mission. After years in pharmaceutical business development at Towa Pharmaceutical, he joined KAICO to help scale a technology he believes could reshape global vaccine accessibility. His cross-cultural expertise now proves invaluable as KAICO expands internationally, with active partnerships in Vietnam and Thailand and growing interest from other regions.

Episode highlights:

  • Masafumi’s transition from anthropology to biotech, and how cross-cultural expertise benefits global health collaborations. (04:15)
  • The founding story of KAICO, spun out from Kyushu University and focused on recombinant proteins and vaccine antigen production (08:45)
  • Step-by-step overview of the silkworm baculovirus expression system, including pupae handling and bioprocessing basics. (10:28)
  • Practical differences between silkworms, E. coli, mammalian, and insect cell culture platforms—exploring advantages and drawbacks. (13:10)
  • Strategies KAICO uses to control silkworm variability, including SPF grade sourcing, diet, environment, and documentation for pharmaceutical acceptance. (15:08)
  • Production scalability: a single pupa can match 100–1000 ml of insect cell culture, with major implications for cost and environmental footprint. (16:42)
  • Downstream harvesting and purification—how KAICO extracts and processes proteins from silkworm pupae, keeping methods largely familiar to traditional systems. (19:31)
  • Regulatory and GMP challenges of using live organisms, and KAICO’s approach to satisfying authorities and ensuring product consistency. (21:43)

Whether you’re curious about alternative biomanufacturing methods or want a transparent look at silkworm-based protein expression from research to the clinic, this episode delivers practical insights and thoughtful discussion.

Connect with Masafumi Osawa:

LinkedIn: www.linkedin.com/in/masa-osawa

KAICO Ltd.: www.kaicoltd.jp/en

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18394552 Tue, 06 Jan 2026 05:00:00 +0100 1477 217 full false 216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya Burkov - Part 2 216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya Burkov - Part 2 Biomanufacturing has always dealt with the challenge of turning vast, complex datasets and intricate production steps into life-changing therapies. But when batch records multiply and process deviations loom, how do biotech teams make sense of it all? In this episode, we move beyond theory to the nuts and bolts of how AI - when thoughtfully deployed - can turn bioprocessing chaos into actionable intelligence, paving the way for the factory of the future.

Our guest, Ilya Burkov, Global Head of Healthcare and Life Sciences Growth at Nebius AI, doesn’t just talk about data wrangling and algorithms—he’s spent years building tools and strategies to help scientists organize, contextualize, and leverage real-world datasets. Having worked across tech innovation and pharmaceuticals, Ilya Burkov bridges cutting-edge computation with the practical realities of CMC development and manufacturing, making him a trusted voice on how bioprocessing is rapidly changing.

Highlights from the episode:

  • Advice for biotech scientists on learning from innovations in other industries (00:02:21)
  • Tackling the complexities of organizing huge and often unstructured datasets in bioprocessing (03:08)
  • Techniques and tools to structure, label, and prepare data for AI—including Nebius’s in-house tool, Tracto AI (06:24)
  • Strategies for startups and small teams—how to begin implementing AI and what areas of bioprocessing to focus on first (10:12)
  • The vision for the “factory of the future”: AI-driven, interconnected, and self-learning manufacturing environments (08:11)
  • Navigating the decision between on-premise and cloud computing for scalable, cost-effective AI workloads (12:32)
  • The importance of partnership between scientists and AI, emphasizing collaboration and data-driven decisions (00:15:47)

Wondering how to kick off your own AI-enabled bioprocessing project, or what to insource versus outsource as you scale? This episode gives you a grounded starting point—minus the buzzwords and empty promises.

Connect with Ilya Burkov:

LinkedIn: www.linkedin.com/in/ilyaburkov

Contact email: ilya.burkov@nebius.com

Nebius: www.nebius.com

If this topic grabbed you, you'll love these related episodes focusing on advanced modeling, continuous manufacturing, and Digital Twins

  • Episodes 213 - 214: From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab with Giuseppe Licari
  • Episodes 85 - 86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli
  • Episodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov
  • Episode 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos
  • Episodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> Biomanufacturing has always dealt with the challenge of turning vast, complex datasets and intricate production steps into life-changing therapies. But when batch records multiply and process deviations loom, how do biotech teams make sense of it all? In this episode, we move beyond theory to the nuts and bolts of how AI - when thoughtfully deployed - can turn bioprocessing chaos into actionable intelligence, paving the way for the factory of the future.

Our guest, Ilya Burkov, Global Head of Healthcare and Life Sciences Growth at Nebius AI, doesn’t just talk about data wrangling and algorithms—he’s spent years building tools and strategies to help scientists organize, contextualize, and leverage real-world datasets. Having worked across tech innovation and pharmaceuticals, Ilya Burkov bridges cutting-edge computation with the practical realities of CMC development and manufacturing, making him a trusted voice on how bioprocessing is rapidly changing.

Highlights from the episode:

  • Advice for biotech scientists on learning from innovations in other industries (00:02:21)
  • Tackling the complexities of organizing huge and often unstructured datasets in bioprocessing (03:08)
  • Techniques and tools to structure, label, and prepare data for AI—including Nebius’s in-house tool, Tracto AI (06:24)
  • Strategies for startups and small teams—how to begin implementing AI and what areas of bioprocessing to focus on first (10:12)
  • The vision for the “factory of the future”: AI-driven, interconnected, and self-learning manufacturing environments (08:11)
  • Navigating the decision between on-premise and cloud computing for scalable, cost-effective AI workloads (12:32)
  • The importance of partnership between scientists and AI, emphasizing collaboration and data-driven decisions (00:15:47)

Wondering how to kick off your own AI-enabled bioprocessing project, or what to insource versus outsource as you scale? This episode gives you a grounded starting point—minus the buzzwords and empty promises.

Connect with Ilya Burkov:

LinkedIn: www.linkedin.com/in/ilyaburkov

Contact email: ilya.burkov@nebius.com

Nebius: www.nebius.com

If this topic grabbed you, you'll love these related episodes focusing on advanced modeling, continuous manufacturing, and Digital Twins

  • Episodes 213 - 214: From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab with Giuseppe Licari
  • Episodes 85 - 86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli
  • Episodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov
  • Episode 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos
  • Episodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18303821 Thu, 18 Dec 2025 05:00:00 +0100 1113 216 full false 215: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya Burkov - Part 1 215: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya Burkov - Part 1 Across biotech labs, researchers swim in oceans of process data: sensor streams, run records, engineering logs, and still, crucial decisions get stuck in spreadsheets or scribbled into fading notebooks. The challenge isn’t having enough information, it's knowing which actions actually move the needle in cell culture productivity, process stability, and faster timelines.

This episode, David Brühlmann brings on Ilya Burkov, Global Head of Healthcare and Life Sciences Growth at Nebius AI. With a career spanning NHS medicine, regenerative research, and cloud infrastructure, Ilya Burkov has lived the leap from microscope to server room. He’s seen firsthand how digital twins, autonomous experimentation, and cloud-first strategies are shifting the way biologics are developed and scaled.

Topics discussed:

  • Shifting from experimental-based to computational bioprocess development, and the evolving role of human expertise vs. AI (02:48)
  • Ilya Burkov's journey from medicine and orthopedics to AI and cloud infrastructure (04:15)
  • Solving data silos and making real-time decisions with digital twins and automated analytics (06:36)
  • The impact of AI-driven lab automation and robotics on drug discovery timelines (08:51)
  • Using AI to accelerate cell line selection, cloning, and protein sequence optimization (10:12)
  • Why wet lab experimentation is still essential, and how predictive modelling can reduce failure rates (11:15)
  • Reducing costs and accelerating development by leveraging AI in process screening and optimization (12:32)
  • Strategies for smaller companies to effectively store and manage bioprocess data, including practical advice on cloud adoption and security (14:30)
  • Application of AI and digital twins in scale-up processes, and connecting diverse data types like CFD simulations and process data (17:18)
  • The ongoing need for human expertise in interpreting and qualifying data, even as machine learning advances (19:09)

Wondering how to stop your own data from gathering dust? This episode unpacks practical strategies for storing and leveraging your experimental records - whether you’re in a major pharma or a small startup with limited tech resources.

Connect with Ilya Burkov:

LinkedIn: www.linkedin.com/in/ilyaburkov

Contact email: ilya.burkov@nebius.com

Nebius: www.nebius.com

If this topic grabbed you, you'll love these related episodes focusing on advanced modeling, continuous manufacturing, and Digital Twins

  • Episodes 213 - 214: From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab with Giuseppe Licari
  • Episodes 85 - 86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli
  • Episodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov
  • Episode 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos
  • Episodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> Across biotech labs, researchers swim in oceans of process data: sensor streams, run records, engineering logs, and still, crucial decisions get stuck in spreadsheets or scribbled into fading notebooks. The challenge isn’t having enough information, it's knowing which actions actually move the needle in cell culture productivity, process stability, and faster timelines.

This episode, David Brühlmann brings on Ilya Burkov, Global Head of Healthcare and Life Sciences Growth at Nebius AI. With a career spanning NHS medicine, regenerative research, and cloud infrastructure, Ilya Burkov has lived the leap from microscope to server room. He’s seen firsthand how digital twins, autonomous experimentation, and cloud-first strategies are shifting the way biologics are developed and scaled.

Topics discussed:

  • Shifting from experimental-based to computational bioprocess development, and the evolving role of human expertise vs. AI (02:48)
  • Ilya Burkov's journey from medicine and orthopedics to AI and cloud infrastructure (04:15)
  • Solving data silos and making real-time decisions with digital twins and automated analytics (06:36)
  • The impact of AI-driven lab automation and robotics on drug discovery timelines (08:51)
  • Using AI to accelerate cell line selection, cloning, and protein sequence optimization (10:12)
  • Why wet lab experimentation is still essential, and how predictive modelling can reduce failure rates (11:15)
  • Reducing costs and accelerating development by leveraging AI in process screening and optimization (12:32)
  • Strategies for smaller companies to effectively store and manage bioprocess data, including practical advice on cloud adoption and security (14:30)
  • Application of AI and digital twins in scale-up processes, and connecting diverse data types like CFD simulations and process data (17:18)
  • The ongoing need for human expertise in interpreting and qualifying data, even as machine learning advances (19:09)

Wondering how to stop your own data from gathering dust? This episode unpacks practical strategies for storing and leveraging your experimental records - whether you’re in a major pharma or a small startup with limited tech resources.

Connect with Ilya Burkov:

LinkedIn: www.linkedin.com/in/ilyaburkov

Contact email: ilya.burkov@nebius.com

Nebius: www.nebius.com

If this topic grabbed you, you'll love these related episodes focusing on advanced modeling, continuous manufacturing, and Digital Twins

  • Episodes 213 - 214: From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab with Giuseppe Licari
  • Episodes 85 - 86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli
  • Episodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov
  • Episode 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos
  • Episodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18303816 Tue, 16 Dec 2025 05:00:00 +0100 1294 215 full false 214: From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab with Giuseppe Licari - Part 2 214: From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab with Giuseppe Licari - Part 2 Computational methods can predict stability issues before the lab. But how do you actually implement these approaches in your formulation workflow? From excipient selection to long-term stability prediction, in silico tools are transforming how biotech teams develop robust formulations while reducing costly trial-and-error cycles.

In Part 2, Giuseppe Licari, Principal Scientist in Computational Structural Biology at Merck KGaA, returns to share practical implementation strategies for integrating computational methods into biologics formulation development. Giuseppe reveals how molecular dynamics simulations guide excipient selection, where current methods hit their limits, and how emerging AI capabilities are expanding what's possible in formulation prediction.

Whether you're at a well-resourced pharma company or a lean startup, Giuseppe offers actionable guidance for leveraging computational tools to predict protein behavior, optimize formulations, and accelerate your development timeline.

Topics covered:

  • Predicting protein aggregation and excipient interactions before manufacturing (00:45)
  • Using molecular dynamics to understand protein behavior over time and in different environments (03:03)
  • The interplay between computational predictions and experimental stability studies (04:49)
  • The limitations of current in silico methods for predicting long-term stability (05:08)
  • Emerging use of AI and machine learning to predict protein properties and improve developability (06:36)
  • Future possibilities: Generative AI for protein design and formulation prediction (08:06)
  • Advice for small companies: leveraging software-as-a-service and external partners to access computational tools (09:55)
  • The impact of increasing computational power on the field's evolution (11:12)
  • Most important takeaway: being open and curious about new computational techniques in biotech formulation (12:08)

Discover how to bridge computational predictions with experimental validation, navigate the current limitations of in silico stability forecasting, and position your organization to benefit from AI-driven formulation development, regardless of your resource constraints.

Connect with Giuseppe Licari to continue the conversation and explore how computational approaches can solve your formulation challenges before you ever step into the lab.

Connect with Giuseppe Licari:

LinkedIn: www.linkedin.com/in/giuseppe-licari

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> Computational methods can predict stability issues before the lab. But how do you actually implement these approaches in your formulation workflow? From excipient selection to long-term stability prediction, in silico tools are transforming how biotech teams develop robust formulations while reducing costly trial-and-error cycles.

In Part 2, Giuseppe Licari, Principal Scientist in Computational Structural Biology at Merck KGaA, returns to share practical implementation strategies for integrating computational methods into biologics formulation development. Giuseppe reveals how molecular dynamics simulations guide excipient selection, where current methods hit their limits, and how emerging AI capabilities are expanding what's possible in formulation prediction.

Whether you're at a well-resourced pharma company or a lean startup, Giuseppe offers actionable guidance for leveraging computational tools to predict protein behavior, optimize formulations, and accelerate your development timeline.

Topics covered:

  • Predicting protein aggregation and excipient interactions before manufacturing (00:45)
  • Using molecular dynamics to understand protein behavior over time and in different environments (03:03)
  • The interplay between computational predictions and experimental stability studies (04:49)
  • The limitations of current in silico methods for predicting long-term stability (05:08)
  • Emerging use of AI and machine learning to predict protein properties and improve developability (06:36)
  • Future possibilities: Generative AI for protein design and formulation prediction (08:06)
  • Advice for small companies: leveraging software-as-a-service and external partners to access computational tools (09:55)
  • The impact of increasing computational power on the field's evolution (11:12)
  • Most important takeaway: being open and curious about new computational techniques in biotech formulation (12:08)

Discover how to bridge computational predictions with experimental validation, navigate the current limitations of in silico stability forecasting, and position your organization to benefit from AI-driven formulation development, regardless of your resource constraints.

Connect with Giuseppe Licari to continue the conversation and explore how computational approaches can solve your formulation challenges before you ever step into the lab.

Connect with Giuseppe Licari:

LinkedIn: www.linkedin.com/in/giuseppe-licari

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18303785 Thu, 11 Dec 2025 05:00:00 +0100 889 214 full false 213: From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab with Giuseppe Licari - Part 1 213: From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab with Giuseppe Licari - Part 1 What if you could predict formulation failures before ever touching a pipette? Computational approaches are revolutionizing biologics development, replacing trial-and-error experimentation with predictive intelligence that catches stability issues early and accelerates your path from candidate selection to clinic.

In this episode, David Brühlmann welcomes Giuseppe Licari, Principal Scientist in Computational Structural Biology at Merck KGaA. A chemist by training, Giuseppe transitioned from wet lab experimentation to the predictive power of in silico modeling. Today, he operates at the intersection of computational biology and CMC development, using digital tools to screen candidates for developability, predict formulation challenges, and de-risk development programs before committing resources to the lab.

Discover how computational methods are transforming the way biotech companies approach developability assessment and formulation strategy:

  • Why maximizing shelf life isn’t always necessary in early development phases (02:56)
  • The critical role of communication between computational and bench scientists (06:46)
  • Core properties to assess for developability, including hydrophobicity, aggregation, charge, and immunogenicity (11:06)
  • How accurate are in silico predictions, and where do they add the most value? (13:23)
  • The limitations and strengths of machine learning and physics-based models in predicting protein behavior (15:19)
  • The differences between developability, formulation development, and formulatability, and the value of early cross-functional collaboration (17:17)
  • When to use platform formulations and when tailored approaches are needed for complex molecules (19:25)
  • The advantages of using computational methods at any stage, especially for de-risking strategies (20:13)

Listen in for practical strategies for integrating in silico predictions into your developability and CMC workflows, catching stability issues before the lab, and making smarter development decisions that save time, material, and money.

Connect with Giuseppe Licari:

LinkedIn: www.linkedin.com/in/giuseppe-licari

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> What if you could predict formulation failures before ever touching a pipette? Computational approaches are revolutionizing biologics development, replacing trial-and-error experimentation with predictive intelligence that catches stability issues early and accelerates your path from candidate selection to clinic.

In this episode, David Brühlmann welcomes Giuseppe Licari, Principal Scientist in Computational Structural Biology at Merck KGaA. A chemist by training, Giuseppe transitioned from wet lab experimentation to the predictive power of in silico modeling. Today, he operates at the intersection of computational biology and CMC development, using digital tools to screen candidates for developability, predict formulation challenges, and de-risk development programs before committing resources to the lab.

Discover how computational methods are transforming the way biotech companies approach developability assessment and formulation strategy:

  • Why maximizing shelf life isn’t always necessary in early development phases (02:56)
  • The critical role of communication between computational and bench scientists (06:46)
  • Core properties to assess for developability, including hydrophobicity, aggregation, charge, and immunogenicity (11:06)
  • How accurate are in silico predictions, and where do they add the most value? (13:23)
  • The limitations and strengths of machine learning and physics-based models in predicting protein behavior (15:19)
  • The differences between developability, formulation development, and formulatability, and the value of early cross-functional collaboration (17:17)
  • When to use platform formulations and when tailored approaches are needed for complex molecules (19:25)
  • The advantages of using computational methods at any stage, especially for de-risking strategies (20:13)

Listen in for practical strategies for integrating in silico predictions into your developability and CMC workflows, catching stability issues before the lab, and making smarter development decisions that save time, material, and money.

Connect with Giuseppe Licari:

LinkedIn: www.linkedin.com/in/giuseppe-licari

Next step:

Need fast CMC guidance? → Get rapid CMC decision support here

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18277242 Tue, 09 Dec 2025 05:00:00 +0100 1469 213 full false 212: When the Innovator Becomes the Patient: Manufacturing Reality vs. Patient Urgency with Jesús Zurdo - Part 2 212: When the Innovator Becomes the Patient: Manufacturing Reality vs. Patient Urgency with Jesús Zurdo - Part 2 What happens when cell therapy innovation meets real patient urgency? In this conversation, the barriers between scientist and patient all but vanish, bringing clarity—and a new sense of mission—to some of the biggest problems facing advanced therapy manufacturing and delivery.

Meet Jesús Zurdo, a biotech leader whose three decades of experience in innovation took on a whole new perspective when he became a leukemia patient himself. Seamlessly straddling the worlds of industry and patient care, Jesús Zurdo brings a refreshingly honest, systems-level view to cell therapies, manufacturing bottlenecks, and the realities of getting therapies from the lab to bedside.

Topics discussed:

  • Experiences and lessons from stem cell registries and point-of-care manufacturing models (03:15)
  • Challenges and potential of autologous and allogeneic cell therapies, including scalability and accessibility (06:08)
  • The promise and limitations of in vivo cell therapy, delivery risks and patient safety (07:06)
  • Reflections on current trends in manufacturing automation, delivery platforms, and the risk of overengineering (09:49)
  • Barriers to wider adoption of advanced cell therapies, including hospital infrastructure and economic constraints (13:31)
  • The case for earlier lines of treatment with new modalities and value in learning from actual patient experiences (14:30)
  • The importance of integrating voices of patients, clinicians, and developers when solving complex problems (17:31)
  • Why urgency and remembering our future roles as patients should guide therapy development (18:51)

Ready for bioprocessing to serve patients, yours included? For more insights and hands-on support, please subscribe so you never miss the next perspective-shifting episode.

Connect with Jesús Zurdo:

LinkedIn: https://www.linkedin.com/in/jesuszurdo

Email: jesus.zurdo@gmail.com

Next step:

Need fast CMC guidance? New on-demand CMC advisory → Learn more here

Support the show

]]> What happens when cell therapy innovation meets real patient urgency? In this conversation, the barriers between scientist and patient all but vanish, bringing clarity—and a new sense of mission—to some of the biggest problems facing advanced therapy manufacturing and delivery.

Meet Jesús Zurdo, a biotech leader whose three decades of experience in innovation took on a whole new perspective when he became a leukemia patient himself. Seamlessly straddling the worlds of industry and patient care, Jesús Zurdo brings a refreshingly honest, systems-level view to cell therapies, manufacturing bottlenecks, and the realities of getting therapies from the lab to bedside.

Topics discussed:

  • Experiences and lessons from stem cell registries and point-of-care manufacturing models (03:15)
  • Challenges and potential of autologous and allogeneic cell therapies, including scalability and accessibility (06:08)
  • The promise and limitations of in vivo cell therapy, delivery risks and patient safety (07:06)
  • Reflections on current trends in manufacturing automation, delivery platforms, and the risk of overengineering (09:49)
  • Barriers to wider adoption of advanced cell therapies, including hospital infrastructure and economic constraints (13:31)
  • The case for earlier lines of treatment with new modalities and value in learning from actual patient experiences (14:30)
  • The importance of integrating voices of patients, clinicians, and developers when solving complex problems (17:31)
  • Why urgency and remembering our future roles as patients should guide therapy development (18:51)

Ready for bioprocessing to serve patients, yours included? For more insights and hands-on support, please subscribe so you never miss the next perspective-shifting episode.

Connect with Jesús Zurdo:

LinkedIn: https://www.linkedin.com/in/jesuszurdo

Email: jesus.zurdo@gmail.com

Next step:

Need fast CMC guidance? New on-demand CMC advisory → Learn more here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18272307 Thu, 04 Dec 2025 05:00:00 +0100 1333 212 full false 211: When the Innovator Becomes the Patient: Manufacturing Reality vs. Patient Urgency with Jesús Zurdo - Part 1 211: When the Innovator Becomes the Patient: Manufacturing Reality vs. Patient Urgency with Jesús Zurdo - Part 1 Real progress in cell and gene therapy shouldn’t be measured solely by scientific innovation, but by whether those innovations actually reach the patients who need them most.

In this episode, David Brühlmann sits down with Jesús Zurdo, a scientist who’s spent three decades engineering life-changing biotechnologies, but whose outlook on the field shifted dramatically after becoming a leukemia patient himself.

With experience on both sides of the system, Jesús Zurdo brings a rare, unfiltered perspective to the persistent gap between scientific promise and real-world patient access.

Here’s why this conversation will reshape the way you think about bioprocessing, scale-up, and the meaning of “patient-centric” innovation:

  • The challenges of scaling up advanced therapies beyond just volume: shifting from “how much can we make” to “how many patients can we reach?” (00:21)
  • Jesús Zurdo’s personal journey—from biotech innovator to patient—and how it reshaped his thinking on product design and patient needs (04:12)
  • How the biotech industry often overemphasizes automation, cost of goods, and new technologies at the expense of true patient access (08:02)
  • The importance of designing products and manufacturing processes with patients’ lived experience in mind—not just clinical metrics (05:43)
  • Why the business model and value proposition of therapies may need to change to address the high cost and limited accessibility of new treatments (12:09)
  • Lessons from point-of-care manufacturing and real-world delivery of cell therapies—speed versus perfection (09:11)
  • How patient involvement in both development and long-term outcome tracking could drive better treatments and wider adoption (15:10)
  • The limitations of current clinical trial endpoints and the need to integrate patient-reported outcomes and new data sources like wearables (17:10)

Real progress in biotech isn’t just about scientific breakthroughs, it’s about ensuring those advances reach the millions who need them most.

Let’s rethink our business models and deployment strategies to bridge this gap for real-world impact

Connect with Jesús Zurdo:

LinkedIn: https://www.linkedin.com/in/jesuszurdo

Email: jesus.zurdo@gmail.com

Next step:

Need fast CMC guidance? New on-demand CMC advisory → Learn more here

Support the show

]]> Real progress in cell and gene therapy shouldn’t be measured solely by scientific innovation, but by whether those innovations actually reach the patients who need them most.

In this episode, David Brühlmann sits down with Jesús Zurdo, a scientist who’s spent three decades engineering life-changing biotechnologies, but whose outlook on the field shifted dramatically after becoming a leukemia patient himself.

With experience on both sides of the system, Jesús Zurdo brings a rare, unfiltered perspective to the persistent gap between scientific promise and real-world patient access.

Here’s why this conversation will reshape the way you think about bioprocessing, scale-up, and the meaning of “patient-centric” innovation:

  • The challenges of scaling up advanced therapies beyond just volume: shifting from “how much can we make” to “how many patients can we reach?” (00:21)
  • Jesús Zurdo’s personal journey—from biotech innovator to patient—and how it reshaped his thinking on product design and patient needs (04:12)
  • How the biotech industry often overemphasizes automation, cost of goods, and new technologies at the expense of true patient access (08:02)
  • The importance of designing products and manufacturing processes with patients’ lived experience in mind—not just clinical metrics (05:43)
  • Why the business model and value proposition of therapies may need to change to address the high cost and limited accessibility of new treatments (12:09)
  • Lessons from point-of-care manufacturing and real-world delivery of cell therapies—speed versus perfection (09:11)
  • How patient involvement in both development and long-term outcome tracking could drive better treatments and wider adoption (15:10)
  • The limitations of current clinical trial endpoints and the need to integrate patient-reported outcomes and new data sources like wearables (17:10)

Real progress in biotech isn’t just about scientific breakthroughs, it’s about ensuring those advances reach the millions who need them most.

Let’s rethink our business models and deployment strategies to bridge this gap for real-world impact

Connect with Jesús Zurdo:

LinkedIn: https://www.linkedin.com/in/jesuszurdo

Email: jesus.zurdo@gmail.com

Next step:

Need fast CMC guidance? New on-demand CMC advisory → Learn more here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18272304 Tue, 02 Dec 2025 05:00:00 +0100 1285 211 full false 210: From Batch to Continuous: Building Innovation Culture in Conservative Biotech Environments with Irina Ramos - Part 2 210: From Batch to Continuous: Building Innovation Culture in Conservative Biotech Environments with Irina Ramos - Part 2 From pandemic-speed vaccine deployment to AI-powered process control, what separates hype from real manufacturing transformation?

The biotech industry faces a fundamental challenge: how do you maintain rigorous quality standards while accelerating development timelines, personalizing therapies, and adopting transformative technologies? The answer isn't found in chasing every innovation trend, it's in understanding which changes create genuine value and when to implement them across the product lifecycle.

Irina Ramos brings a perspective earned through high-stakes execution. After leading the global technology transfer of AstraZeneca's COVID-19 vaccine, a project that compressed typical timelines while maintaining uncompromising quality standards, she's applying those lessons to the industry's next wave of challenges: phase-appropriate CMC strategy, the practical realities of AI integration, and building teams that bridge generational experience gaps in an era of rapid technological change.

This conversation cuts through the noise. Irina discusses when continuous processing actually makes strategic sense (hint: it's not always the right answer), why AI in bioprocessing requires more human expertise rather than less, and the collaborative frameworks that enabled one of the fastest vaccine rollouts in history—lessons directly applicable to your current CMC challenges.

Episode highlights:

  • How the biotech community is constantly changing, and the importance of adaptability for future scientists (00:00)
  • Navigating phase-appropriate CMC strategy: What to focus on in early clinical phases and which decisions set the foundation for compliance (02:36)
  • Scenarios for switching from batch to continuous processing, including barriers and benefits for early-stage vs. established products (02:58)
  • Lessons from leading AstraZeneca's COVID-19 vaccine technology transfer: Collaboration, rapid regulatory communication, and mission-driven teams (05:20)
  • Adapting lessons from the pandemic for ongoing drug development—balancing speed and risk while maintaining quality (08:24)
  • Realistic perspectives on integrating AI in bioprocessing: demystifying its applications, emphasizing human-critical oversight, and practical use cases in manufacturing (10:40)
  • Key skills for scientists in a biotech world shaped by AI—why foundational understanding and strong mentorship matter (13:51)
  • Bridging experience gaps: How to foster collaboration and creativity between new and established professionals in regulated environments (15:45)
  • Final takeaway: Start small, remain mission-driven, and remember that one size does not fit all in continuous manufacturing (17:15)

Whether you're evaluating process platform decisions for Phase I programs, building cross-functional teams for tech transfer, or determining which digital tools deserve investment beyond the buzzword, this episode provides decision frameworks grounded in real-world execution at global scale.

Connect with Irina Ramos:

LinkedIn: www.linkedin.com/in/irinaramos

Next step:

Need fast CMC guidance? New on-demand CMC advisory → Learn more here

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> From pandemic-speed vaccine deployment to AI-powered process control, what separates hype from real manufacturing transformation?

The biotech industry faces a fundamental challenge: how do you maintain rigorous quality standards while accelerating development timelines, personalizing therapies, and adopting transformative technologies? The answer isn't found in chasing every innovation trend, it's in understanding which changes create genuine value and when to implement them across the product lifecycle.

Irina Ramos brings a perspective earned through high-stakes execution. After leading the global technology transfer of AstraZeneca's COVID-19 vaccine, a project that compressed typical timelines while maintaining uncompromising quality standards, she's applying those lessons to the industry's next wave of challenges: phase-appropriate CMC strategy, the practical realities of AI integration, and building teams that bridge generational experience gaps in an era of rapid technological change.

This conversation cuts through the noise. Irina discusses when continuous processing actually makes strategic sense (hint: it's not always the right answer), why AI in bioprocessing requires more human expertise rather than less, and the collaborative frameworks that enabled one of the fastest vaccine rollouts in history—lessons directly applicable to your current CMC challenges.

Episode highlights:

  • How the biotech community is constantly changing, and the importance of adaptability for future scientists (00:00)
  • Navigating phase-appropriate CMC strategy: What to focus on in early clinical phases and which decisions set the foundation for compliance (02:36)
  • Scenarios for switching from batch to continuous processing, including barriers and benefits for early-stage vs. established products (02:58)
  • Lessons from leading AstraZeneca's COVID-19 vaccine technology transfer: Collaboration, rapid regulatory communication, and mission-driven teams (05:20)
  • Adapting lessons from the pandemic for ongoing drug development—balancing speed and risk while maintaining quality (08:24)
  • Realistic perspectives on integrating AI in bioprocessing: demystifying its applications, emphasizing human-critical oversight, and practical use cases in manufacturing (10:40)
  • Key skills for scientists in a biotech world shaped by AI—why foundational understanding and strong mentorship matter (13:51)
  • Bridging experience gaps: How to foster collaboration and creativity between new and established professionals in regulated environments (15:45)
  • Final takeaway: Start small, remain mission-driven, and remember that one size does not fit all in continuous manufacturing (17:15)

Whether you're evaluating process platform decisions for Phase I programs, building cross-functional teams for tech transfer, or determining which digital tools deserve investment beyond the buzzword, this episode provides decision frameworks grounded in real-world execution at global scale.

Connect with Irina Ramos:

LinkedIn: www.linkedin.com/in/irinaramos

Next step:

Need fast CMC guidance? New on-demand CMC advisory → Learn more here

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18207674 Thu, 27 Nov 2025 05:00:00 +0100 1256 210 full false 209: From Batch to Continuous: Building Innovation Culture in Conservative Biotech Environments with Irina Ramos - Part 1 209: From Batch to Continuous: Building Innovation Culture in Conservative Biotech Environments with Irina Ramos - Part 1 The biotech industry operates under constant tension: we work with products that directly impact human lives, demanding rigorous controls and validation at every step. Yet standing still means falling behind. The question isn't whether to innovate, it's how to do it without compromising the quality and safety standards that define our industry.

Irina Ramos has lived this paradox throughout her career. As a downstream processing leader who's guided CMC programs from early development through global regulatory filings, she helped orchestrate the worldwide transfer of AstraZeneca's COVID-19 vaccine—a masterclass in balancing speed, scale, and uncompromising quality standards. Now, she's championing a vision that sounds almost radical: lights-out biomanufacturing facilities where continuous processes run at steady state with minimal human intervention.

In this conversation, Irina shares the unfiltered reality of building innovation cultures in conservative environments, the surprising drivers behind continuous processing adoption, and why the industry's careful nature isn't a barrier to transformation. It's the foundation for sustainable innovation.

Discussion highlights:

  • Why conservatism is vital in biotech—and how to balance it with innovation (00:00)
  • The vision for "lights-out" manufacturing and if bioprocess facilities could run with minimal human intervention (02:50)
  • Irina Ramos's career story and the lessons her "happy accidents" teach junior scientists (03:53)
  • Mindset shifts: Transitioning from scientist to innovation leader in CMC development (06:29)
  • Building an innovation culture in a conservative, highly regulated industry (08:07)
  • Essential mindsets for scientists to thrive and innovate in biotech environments (11:22)
  • Coordination strategies for effective communication across stakeholders, departments, and geographies (13:52)
  • The misconceptions of continuous manufacturing and what actually drives its adoption (17:09)
  • What's hot in continuous biomanufacturing: trends, global perspectives, and how real-time analytics can change process control (21:12)
  • Guiding principles for choosing between hybrid or end-to-end continuous processes (23:46)
  • Practical tips on implementing control strategies and real-time monitoring in manufacturing (25:01)

If you're navigating the shift from batch to continuous processing, leading cross-functional innovation initiatives, or wondering how to advocate for new technologies without disrupting validated processes, this episode offers practical frameworks you can apply immediately.

Connect with Irina Ramos:

LinkedIn: www.linkedin.com/in/irinaramos

Next step:

Need fast CMC guidance? New on-demand CMC advisory → Learn more here

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> The biotech industry operates under constant tension: we work with products that directly impact human lives, demanding rigorous controls and validation at every step. Yet standing still means falling behind. The question isn't whether to innovate, it's how to do it without compromising the quality and safety standards that define our industry.

Irina Ramos has lived this paradox throughout her career. As a downstream processing leader who's guided CMC programs from early development through global regulatory filings, she helped orchestrate the worldwide transfer of AstraZeneca's COVID-19 vaccine—a masterclass in balancing speed, scale, and uncompromising quality standards. Now, she's championing a vision that sounds almost radical: lights-out biomanufacturing facilities where continuous processes run at steady state with minimal human intervention.

In this conversation, Irina shares the unfiltered reality of building innovation cultures in conservative environments, the surprising drivers behind continuous processing adoption, and why the industry's careful nature isn't a barrier to transformation. It's the foundation for sustainable innovation.

Discussion highlights:

  • Why conservatism is vital in biotech—and how to balance it with innovation (00:00)
  • The vision for "lights-out" manufacturing and if bioprocess facilities could run with minimal human intervention (02:50)
  • Irina Ramos's career story and the lessons her "happy accidents" teach junior scientists (03:53)
  • Mindset shifts: Transitioning from scientist to innovation leader in CMC development (06:29)
  • Building an innovation culture in a conservative, highly regulated industry (08:07)
  • Essential mindsets for scientists to thrive and innovate in biotech environments (11:22)
  • Coordination strategies for effective communication across stakeholders, departments, and geographies (13:52)
  • The misconceptions of continuous manufacturing and what actually drives its adoption (17:09)
  • What's hot in continuous biomanufacturing: trends, global perspectives, and how real-time analytics can change process control (21:12)
  • Guiding principles for choosing between hybrid or end-to-end continuous processes (23:46)
  • Practical tips on implementing control strategies and real-time monitoring in manufacturing (25:01)

If you're navigating the shift from batch to continuous processing, leading cross-functional innovation initiatives, or wondering how to advocate for new technologies without disrupting validated processes, this episode offers practical frameworks you can apply immediately.

Connect with Irina Ramos:

LinkedIn: www.linkedin.com/in/irinaramos

Next step:

Need fast CMC guidance? New on-demand CMC advisory → Learn more here

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18207654 Tue, 25 Nov 2025 05:00:00 +0100 1702 209 full false 208: Cryogenic Infrared Ion Spectroscopy: From Mass Spec Limitations to Molecular Precision with Tom Rizzo - Part 2 208: Cryogenic Infrared Ion Spectroscopy: From Mass Spec Limitations to Molecular Precision with Tom Rizzo - Part 2 What if you could analyze every metabolite, glycan variant, and unknown impurity in your bioprocess sample—not just the targets you're looking for, but everything that's actually there? Cryogenic infrared ion spectroscopy combined (CIRIS) with AI-powered analysis transforms untargeted screening from aspiration to reality.

This episode moves from fundamental principles to practical applications. While Part 1 established how CIRIS overcomes mass spectrometry's structural limitations, Part 2 reveals what becomes possible when you can definitively identify complex mixtures: better mAb characterization, earlier disease detection, and process decisions based on complete data rather than educated guesses.

Professor Tom Rizzo returns to discuss Isospec Analytics' path from laboratory innovation to commercial service platform. His transition from academic leadership at EPFL to biotech entrepreneurship offers insights for any scientist considering whether breakthrough research deserves a startup—and what that journey actually requires.

For bioprocess scientists drowning in unidentified peaks, struggling with glycan heterogeneity, or making critical manufacturing decisions with incomplete analytical data, this conversation demonstrates how next-generation analytics powered by quantum chemistry and machine learning can illuminate what's been hidden in your samples all along.

Episode Highlights:

  • Why targeted metabolomics creates a "streetlight effect"—and how untargeted CIRIS analysis reveals the complete molecular landscape (00:00)
  • Isomer-specific glycan characterization for mAbs: distinguishing structural variants that impact efficacy and immunogenicity (03:17)
  • Advanced disease detection and biomarker discovery: identifying diagnostic signatures in complex biological matrices (05:21)
  • AI meets quantum chemistry: automated spectral library building and machine learning algorithms that accelerate molecule identification from hours to seconds (06:05)
  • From data generation to decision-making: how comprehensive analytics and AI transform bioprocess development workflows (09:23)
  • Isospec's commercial roadmap: service platform for comprehensive sample analysis and projected timeline for benchtop instrumentation (10:09)
  • Academic to entrepreneur: Tom Rizzo's perspective on leaving tenure for a startup, with practical advice for scientists evaluating the leap (12:05)
  • Personal motivation behind early diagnostics: cancer and leukemia experiences that drive Isospec's clinical applications (14:11)
  • Technical deep dive: messenger tagging methodology and achieving single-ion infrared detection sensitivity (15:41)
  • The transformative capability: adding a structural dimension to mass spec data that eliminates ambiguity in complex mixture analysis (17:55)

Mass spectrometry tells you what masses are present. Cryogenic infrared ion spectroscopy tells you what molecules they actually are. When coupled with AI-powered analysis, this combination enables truly comprehensive characterization—from process impurity identification to critical quality attribute assessment to early disease biomarker discovery.

Connect with Tom Rizzo:

LinkedIn: www.linkedin.com/in/thomas-rizzo-4a0a6314/

Contact email: tom@isospec.ch

Isospec Analytics website: www.isospecanalytics.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> What if you could analyze every metabolite, glycan variant, and unknown impurity in your bioprocess sample—not just the targets you're looking for, but everything that's actually there? Cryogenic infrared ion spectroscopy combined (CIRIS) with AI-powered analysis transforms untargeted screening from aspiration to reality.

This episode moves from fundamental principles to practical applications. While Part 1 established how CIRIS overcomes mass spectrometry's structural limitations, Part 2 reveals what becomes possible when you can definitively identify complex mixtures: better mAb characterization, earlier disease detection, and process decisions based on complete data rather than educated guesses.

Professor Tom Rizzo returns to discuss Isospec Analytics' path from laboratory innovation to commercial service platform. His transition from academic leadership at EPFL to biotech entrepreneurship offers insights for any scientist considering whether breakthrough research deserves a startup—and what that journey actually requires.

For bioprocess scientists drowning in unidentified peaks, struggling with glycan heterogeneity, or making critical manufacturing decisions with incomplete analytical data, this conversation demonstrates how next-generation analytics powered by quantum chemistry and machine learning can illuminate what's been hidden in your samples all along.

Episode Highlights:

  • Why targeted metabolomics creates a "streetlight effect"—and how untargeted CIRIS analysis reveals the complete molecular landscape (00:00)
  • Isomer-specific glycan characterization for mAbs: distinguishing structural variants that impact efficacy and immunogenicity (03:17)
  • Advanced disease detection and biomarker discovery: identifying diagnostic signatures in complex biological matrices (05:21)
  • AI meets quantum chemistry: automated spectral library building and machine learning algorithms that accelerate molecule identification from hours to seconds (06:05)
  • From data generation to decision-making: how comprehensive analytics and AI transform bioprocess development workflows (09:23)
  • Isospec's commercial roadmap: service platform for comprehensive sample analysis and projected timeline for benchtop instrumentation (10:09)
  • Academic to entrepreneur: Tom Rizzo's perspective on leaving tenure for a startup, with practical advice for scientists evaluating the leap (12:05)
  • Personal motivation behind early diagnostics: cancer and leukemia experiences that drive Isospec's clinical applications (14:11)
  • Technical deep dive: messenger tagging methodology and achieving single-ion infrared detection sensitivity (15:41)
  • The transformative capability: adding a structural dimension to mass spec data that eliminates ambiguity in complex mixture analysis (17:55)

Mass spectrometry tells you what masses are present. Cryogenic infrared ion spectroscopy tells you what molecules they actually are. When coupled with AI-powered analysis, this combination enables truly comprehensive characterization—from process impurity identification to critical quality attribute assessment to early disease biomarker discovery.

Connect with Tom Rizzo:

LinkedIn: www.linkedin.com/in/thomas-rizzo-4a0a6314/

Contact email: tom@isospec.ch

Isospec Analytics website: www.isospecanalytics.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18176683 Thu, 20 Nov 2025 05:00:00 +0100 1305 208 full false 207: Cryogenic Infrared Ion Spectroscopy: From Mass Spec Limitations to Molecular Precision with Tom Rizzo - Part 1 207: Cryogenic Infrared Ion Spectroscopy: From Mass Spec Limitations to Molecular Precision with Tom Rizzo - Part 1 What if you could identify every structural variant in your biologics—without ambiguity, without massive sample requirements, and without the guesswork that plagues traditional mass spectrometry? Cryogenic infrared ion spectroscopy (CIRIS) makes it possible, transforming molecular characterization from frustrating puzzle to precise science.

Today's guest, Professor Tom Rizzo, bridges the gap between academic innovation and industrial application. As former Dean of the School of Basic Sciences at EPFL in Lausanne and now Chief Scientific Officer at Isospec Analytics, Tom has spent over two decades developing analytical techniques that solve problems conventional methods can't touch.

His journey from a childhood fascination sparked by chemistry demonstrations at the 1964 New York World's Fair to pioneering a breakthrough technology reveals both the persistence required for true innovation and the pathway from laboratory curiosity to commercial reality. For bioprocess scientists struggling with glycan characterization, isomer identification, or any structural puzzle where mass spec alone falls short, this conversation offers both validation and solutions.

Episode Highlights:

  • The fundamental limitations of current biomolecular analysis methods and why innovation is critical (02:51)
  • From World's Fair chemistry demos to laser spectroscopy: Tom Rizzo's path to analytical innovation (03:31)
  • The two-decade quest to combine mass spectrometry sensitivity with laser spectroscopy precision—and the machine that finally made it work (04:26)
  • Why Tom transitioned from academic leadership to Isospec Analytics: bringing lab techniques to production environments (09:17)
  • CIRIS fundamentals: how cooling ions to 10 Kelvin unlocks molecular fingerprints that room-temperature methods miss (11:14)
  • CIRIS advantages for biologics: single-ion sensitivity, isomer discrimination, and unique molecular "fingerprints" for definitive identification (14:25)
  • Integrating CIRIS into existing bioprocess workflows: LC-MS compatibility and the path to commercial instrumentation (17:29)
  • Hard-won lessons from translating academic breakthroughs into industrial tools (17:43)

When mass spectrometry hits its limits—distinguishing isomers, characterizing glycans, identifying unknowns in complex mixtures—cryogenic infrared ion spectroscopy provides the structural resolution you need. This isn't incremental improvement; it's a fundamental expansion of what's analytically possible.

If you're facing molecular identification challenges that conventional methods can't solve, or if you're curious how next-generation analytical techniques will transform bioprocess development, this episode delivers actionable insights from a scientist who's lived both the innovation and implementation journey.

Connect with Tom Rizzo:

LinkedIn: www.linkedin.com/in/thomas-rizzo-4a0a6314/

Contact email: tom@isospec.ch

Isospec Analytics website: www.isospecanalytics.com

Next step:

Need fast CMC guidance? New on-demand CMC advisory: Get 20 expert answers/month in 1 day + monthly strategy call. → Learn more: https://stan.store/SmartBiotech/p/ondemand-cmc-expertise-for-biotech-founders

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> What if you could identify every structural variant in your biologics—without ambiguity, without massive sample requirements, and without the guesswork that plagues traditional mass spectrometry? Cryogenic infrared ion spectroscopy (CIRIS) makes it possible, transforming molecular characterization from frustrating puzzle to precise science.

Today's guest, Professor Tom Rizzo, bridges the gap between academic innovation and industrial application. As former Dean of the School of Basic Sciences at EPFL in Lausanne and now Chief Scientific Officer at Isospec Analytics, Tom has spent over two decades developing analytical techniques that solve problems conventional methods can't touch.

His journey from a childhood fascination sparked by chemistry demonstrations at the 1964 New York World's Fair to pioneering a breakthrough technology reveals both the persistence required for true innovation and the pathway from laboratory curiosity to commercial reality. For bioprocess scientists struggling with glycan characterization, isomer identification, or any structural puzzle where mass spec alone falls short, this conversation offers both validation and solutions.

Episode Highlights:

  • The fundamental limitations of current biomolecular analysis methods and why innovation is critical (02:51)
  • From World's Fair chemistry demos to laser spectroscopy: Tom Rizzo's path to analytical innovation (03:31)
  • The two-decade quest to combine mass spectrometry sensitivity with laser spectroscopy precision—and the machine that finally made it work (04:26)
  • Why Tom transitioned from academic leadership to Isospec Analytics: bringing lab techniques to production environments (09:17)
  • CIRIS fundamentals: how cooling ions to 10 Kelvin unlocks molecular fingerprints that room-temperature methods miss (11:14)
  • CIRIS advantages for biologics: single-ion sensitivity, isomer discrimination, and unique molecular "fingerprints" for definitive identification (14:25)
  • Integrating CIRIS into existing bioprocess workflows: LC-MS compatibility and the path to commercial instrumentation (17:29)
  • Hard-won lessons from translating academic breakthroughs into industrial tools (17:43)

When mass spectrometry hits its limits—distinguishing isomers, characterizing glycans, identifying unknowns in complex mixtures—cryogenic infrared ion spectroscopy provides the structural resolution you need. This isn't incremental improvement; it's a fundamental expansion of what's analytically possible.

If you're facing molecular identification challenges that conventional methods can't solve, or if you're curious how next-generation analytical techniques will transform bioprocess development, this episode delivers actionable insights from a scientist who's lived both the innovation and implementation journey.

Connect with Tom Rizzo:

LinkedIn: www.linkedin.com/in/thomas-rizzo-4a0a6314/

Contact email: tom@isospec.ch

Isospec Analytics website: www.isospecanalytics.com

Next step:

Need fast CMC guidance? New on-demand CMC advisory: Get 20 expert answers/month in 1 day + monthly strategy call. → Learn more: https://stan.store/SmartBiotech/p/ondemand-cmc-expertise-for-biotech-founders

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18176674 Tue, 18 Nov 2025 05:00:00 +0100 1303 207 full false 206: Process Economics Decoded: How to Model Biomanufacturing Costs From Clinical to Commercial Scale with Niklas Jungnelius - Part 2 206: Process Economics Decoded: How to Model Biomanufacturing Costs From Clinical to Commercial Scale with Niklas Jungnelius - Part 2 Carbon neutrality goals are everywhere in biopharma. But how do you actually measure and reduce your true environmental impact when data gaps and baseline differences make comparisons so tough?

In this episode, David Brühlmann talks with Niklas Jungnelius, Cytiva’s expert in process modeling and sustainability, who’s spent years uncovering what really drives emissions and how small process tweaks can deliver big results.

Niklas goes beyond the numbers, challenging assumptions and showing how sustainability becomes a strategic, data-driven advantage. From real-world cases at Cytiva, he explains why recycling plastics may not move the needle and why the real gains often lie in hotspots like cleanroom energy use and raw material choices.

Here’s why this episode will make you rethink your next facility upgrade:

  • Understanding life cycle assessment and the key damage categories in environmental sustainability, including carbon emissions, water usage, and resource depletion. (00:00)
  • The challenge of defining carbon emissions baselines and why it’s harder, and often more expensive, to achieve deep reductions if your operations already use clean energy sources. (03:06)
  • Why the focus on recycling single-use plastics may not be the most effective route for lowering emissions, and what truly drives carbon footprint in bioprocessing. (05:54)
  • The impact of production scale, consumables, and obscure chemicals on the overall environmental impact and how these surprises can shift sustainability strategies. (06:20)
  • Practical advice for scientists and engineers: How to start monitoring and modeling environmental impact in process development and manufacturing. (08:00)
  • The importance of involving manufacturing perspectives early in process development, and choosing the right level of detail and ambition for process modeling. (08:18)
  • There’s no one-size-fits-all in manufacturing technology—whether fed-batch, continuous, or hybrid and decisions must fit each organization’s needs, resources, and ambitions. (10:13)
  • Industry trends that could transform the field, from intensified fed-batch production to future technologies like cell-free expression systems. (11:22)
  • Where to connect with Niklas for further questions or collaboration. (14:03]

Whether you’re an early-stage startup, a strategic advisor, or on the front lines of bioprocess development, this episode invites you to rethink your sustainability strategy and modeling approach. Check out the below links to connect with Niklas Jungnelius and additional resources.

Connect with Niklas Jungnelius:

LinkedIn: www.linkedin.com/in/niklas-jungnelius

Cytiva website: www.cytivalifesciences.com/en/us

Next step:

Need fast CMC guidance? New on-demand CMC advisory: Get 20 expert answers/month in 1 day + monthly strategy call. → Learn more: https://stan.store/SmartBiotech/p/ondemand-cmc-expertise-for-biotech-founders

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Carbon neutrality goals are everywhere in biopharma. But how do you actually measure and reduce your true environmental impact when data gaps and baseline differences make comparisons so tough?

In this episode, David Brühlmann talks with Niklas Jungnelius, Cytiva’s expert in process modeling and sustainability, who’s spent years uncovering what really drives emissions and how small process tweaks can deliver big results.

Niklas goes beyond the numbers, challenging assumptions and showing how sustainability becomes a strategic, data-driven advantage. From real-world cases at Cytiva, he explains why recycling plastics may not move the needle and why the real gains often lie in hotspots like cleanroom energy use and raw material choices.

Here’s why this episode will make you rethink your next facility upgrade:

  • Understanding life cycle assessment and the key damage categories in environmental sustainability, including carbon emissions, water usage, and resource depletion. (00:00)
  • The challenge of defining carbon emissions baselines and why it’s harder, and often more expensive, to achieve deep reductions if your operations already use clean energy sources. (03:06)
  • Why the focus on recycling single-use plastics may not be the most effective route for lowering emissions, and what truly drives carbon footprint in bioprocessing. (05:54)
  • The impact of production scale, consumables, and obscure chemicals on the overall environmental impact and how these surprises can shift sustainability strategies. (06:20)
  • Practical advice for scientists and engineers: How to start monitoring and modeling environmental impact in process development and manufacturing. (08:00)
  • The importance of involving manufacturing perspectives early in process development, and choosing the right level of detail and ambition for process modeling. (08:18)
  • There’s no one-size-fits-all in manufacturing technology—whether fed-batch, continuous, or hybrid and decisions must fit each organization’s needs, resources, and ambitions. (10:13)
  • Industry trends that could transform the field, from intensified fed-batch production to future technologies like cell-free expression systems. (11:22)
  • Where to connect with Niklas for further questions or collaboration. (14:03]

Whether you’re an early-stage startup, a strategic advisor, or on the front lines of bioprocess development, this episode invites you to rethink your sustainability strategy and modeling approach. Check out the below links to connect with Niklas Jungnelius and additional resources.

Connect with Niklas Jungnelius:

LinkedIn: www.linkedin.com/in/niklas-jungnelius

Cytiva website: www.cytivalifesciences.com/en/us

Next step:

Need fast CMC guidance? New on-demand CMC advisory: Get 20 expert answers/month in 1 day + monthly strategy call. → Learn more: https://stan.store/SmartBiotech/p/ondemand-cmc-expertise-for-biotech-founders

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18123553 Thu, 13 Nov 2025 05:00:00 +0100 1013 206 full false 205: Process Economics Decoded: How to Model Biomanufacturing Costs From Clinical to Commercial Scale with Niklas Jungnelius - Part 1 205: Process Economics Decoded: How to Model Biomanufacturing Costs From Clinical to Commercial Scale with Niklas Jungnelius - Part 1 Your Manufacturing Decisions Are Costing You More Than You Think

Every bioreactor decision. Every scale-up choice. Every facility investment. They're all silently writing checks your process might not be able to cash.

The difference between a profitable biologics program and one that bleeds capital? Process economic modeling, the analytical framework that reveals exactly where your money goes and why.

In this episode of the Smart Biotech Scientist Podcast, David Brühlmann talks with Niklas Jungnelius, Process Modeling Leader at Cytiva, who has spent 25+ years decoding the economics of biologics manufacturing for biotech companies navigating billion-dollar decisions.

Niklas reveals the hidden cost drivers most teams miss, the surprising economics behind fed-batch vs. continuous processing, and why your facility choice at intermediate scale could make or break your business case.

Episode Highlights:

  • What process economic modeling is and how it differs from mechanistic modeling (06:40)
  • Main cost drivers in biologics and biosimilars manufacturing, and their direct and indirect impacts on patient pricing (09:21)
  • The role of manufacturing scale and productivity in driving down costs, and how facility type (stainless steel vs single-use) affects labor, flexibility, and investment (11:51)
  • Trade-offs between single-use and stainless steel facilities at intermediate production scales (15:07)
  • Key differences in cost and efficiency between fed-batch and fully continuous manufacturing, including productivity limitations and capital/expenditure implications (16:20)
  • The impact of resin lifetime and under-utilization on clinical manufacturing costs (19:51)
  • Hidden or less quantifiable costs such as facility flexibility, excess capacity, safety margins, and the importance of realistic assumptions in economic modeling (20:20)

This is a grounded discussion with practical takeaways for biotech scientists seeking clarity in the complex terrain of process economics. Part two of this conversation will focus on sustainability modeling and the latest technologies reshaping bioprocessing economics.

Ready to see how process modeling could transform your approach and protect your bottom line? Listen to the episode and rethink your next investment.

Connect with Niklas Jungnelius:

LinkedIn: www.linkedin.com/in/niklas-jungnelius

Cytiva website: www.cytivalifesciences.com/en/us

Next step:

Need fast CMC guidance? New on-demand CMC advisory: Get 20 expert answers/month in 1 day + monthly strategy call. → Learn more: https://stan.store/SmartBiotech/p/ondemand-cmc-expertise-for-biotech-founders

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Your Manufacturing Decisions Are Costing You More Than You Think

Every bioreactor decision. Every scale-up choice. Every facility investment. They're all silently writing checks your process might not be able to cash.

The difference between a profitable biologics program and one that bleeds capital? Process economic modeling, the analytical framework that reveals exactly where your money goes and why.

In this episode of the Smart Biotech Scientist Podcast, David Brühlmann talks with Niklas Jungnelius, Process Modeling Leader at Cytiva, who has spent 25+ years decoding the economics of biologics manufacturing for biotech companies navigating billion-dollar decisions.

Niklas reveals the hidden cost drivers most teams miss, the surprising economics behind fed-batch vs. continuous processing, and why your facility choice at intermediate scale could make or break your business case.

Episode Highlights:

  • What process economic modeling is and how it differs from mechanistic modeling (06:40)
  • Main cost drivers in biologics and biosimilars manufacturing, and their direct and indirect impacts on patient pricing (09:21)
  • The role of manufacturing scale and productivity in driving down costs, and how facility type (stainless steel vs single-use) affects labor, flexibility, and investment (11:51)
  • Trade-offs between single-use and stainless steel facilities at intermediate production scales (15:07)
  • Key differences in cost and efficiency between fed-batch and fully continuous manufacturing, including productivity limitations and capital/expenditure implications (16:20)
  • The impact of resin lifetime and under-utilization on clinical manufacturing costs (19:51)
  • Hidden or less quantifiable costs such as facility flexibility, excess capacity, safety margins, and the importance of realistic assumptions in economic modeling (20:20)

This is a grounded discussion with practical takeaways for biotech scientists seeking clarity in the complex terrain of process economics. Part two of this conversation will focus on sustainability modeling and the latest technologies reshaping bioprocessing economics.

Ready to see how process modeling could transform your approach and protect your bottom line? Listen to the episode and rethink your next investment.

Connect with Niklas Jungnelius:

LinkedIn: www.linkedin.com/in/niklas-jungnelius

Cytiva website: www.cytivalifesciences.com/en/us

Next step:

Need fast CMC guidance? New on-demand CMC advisory: Get 20 expert answers/month in 1 day + monthly strategy call. → Learn more: https://stan.store/SmartBiotech/p/ondemand-cmc-expertise-for-biotech-founders

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18123539 Tue, 11 Nov 2025 05:00:00 +0100 1483 205 full false 204: Mastering CRO Selection: Essential Questions for CMC Analytical Development with Daniel Galbraith - Part 2 204: Mastering CRO Selection: Essential Questions for CMC Analytical Development with Daniel Galbraith - Part 2 Cell and gene therapies are transforming modern medicine, but their path to market is fast and complex. They often jump from small trials to global launch at record speed, putting pressure on analytics, supply chains, and partnerships. Success depends on making smart choices about what to build in-house and what to entrust to expert partners.

Daniel Galbraith knows these challenges intimately. With decades of hands-on experience and as Chief Scientific Officer at Solvias, Daniel has witnessed firsthand the seismic shifts in analytical development for advanced therapies. He’s been on every side of the table: troubleshooting manufacturing snags, scaling up from a single batch to hundreds per month, and guiding companies as they choose between in-house development and relying on a CRO’s muscle.

In this episode:

  • How evolving cell and gene therapy timelines are driving the need for true CRO-drug developer partnerships (00:00)
  • The unique challenges of scaling CMC analytics from early trials to global commercialization (02:51)
  • Key pitfalls to avoid when outsourcing to CROs—especially around communication, scheduling, and troubleshooting (06:26)
  • Deciding whether to build capabilities in-house or outsource to a CRO, and how to find the right balance for your team (08:41)
  • The critical importance of strong project management for juggling relationships between developer, CRO, and CDMO (09:51)
  • Daniel's perspective on the future of combination therapies and what the analytical landscape will demand of CROs (13:33)
  • Practical advice for building transparent, open CRO partnerships that support your goals (15:21)

Facing scale-up challenges or a first CGT launch? This conversation shares practical strategies to advance therapies efficiently.

Tune in for actionable insights on CMC, outsourcing, and analytical development.

Connect with Daniel Galbraith:

LinkedIn: www.linkedin.com/in/daniel-galbraith-26a6138

Solvias website: www.solvias.com

Email: daniel.galbraith@solvias.com

Next steps:

Need fast CMC guidance? New on-demand CMC advisory: Get 20 expert answers/month in 1 day + monthly strategy call. → Learn more: https://stan.store/SmartBiotech/p/ondemand-cmc-expertise-for-biotech-founders

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Preparing for your IND? Grab our Startup Founder CMC Dashboard in Notion to help you track tasks, timelines, and risks in one place at https://stan.store/SmartBiotech/p/discovertoind-cmc-dashboard-for-startup-founders

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Cell and gene therapies are transforming modern medicine, but their path to market is fast and complex. They often jump from small trials to global launch at record speed, putting pressure on analytics, supply chains, and partnerships. Success depends on making smart choices about what to build in-house and what to entrust to expert partners.

Daniel Galbraith knows these challenges intimately. With decades of hands-on experience and as Chief Scientific Officer at Solvias, Daniel has witnessed firsthand the seismic shifts in analytical development for advanced therapies. He’s been on every side of the table: troubleshooting manufacturing snags, scaling up from a single batch to hundreds per month, and guiding companies as they choose between in-house development and relying on a CRO’s muscle.

In this episode:

  • How evolving cell and gene therapy timelines are driving the need for true CRO-drug developer partnerships (00:00)
  • The unique challenges of scaling CMC analytics from early trials to global commercialization (02:51)
  • Key pitfalls to avoid when outsourcing to CROs—especially around communication, scheduling, and troubleshooting (06:26)
  • Deciding whether to build capabilities in-house or outsource to a CRO, and how to find the right balance for your team (08:41)
  • The critical importance of strong project management for juggling relationships between developer, CRO, and CDMO (09:51)
  • Daniel's perspective on the future of combination therapies and what the analytical landscape will demand of CROs (13:33)
  • Practical advice for building transparent, open CRO partnerships that support your goals (15:21)

Facing scale-up challenges or a first CGT launch? This conversation shares practical strategies to advance therapies efficiently.

Tune in for actionable insights on CMC, outsourcing, and analytical development.

Connect with Daniel Galbraith:

LinkedIn: www.linkedin.com/in/daniel-galbraith-26a6138

Solvias website: www.solvias.com

Email: daniel.galbraith@solvias.com

Next steps:

Need fast CMC guidance? New on-demand CMC advisory: Get 20 expert answers/month in 1 day + monthly strategy call. → Learn more: https://stan.store/SmartBiotech/p/ondemand-cmc-expertise-for-biotech-founders

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Preparing for your IND? Grab our Startup Founder CMC Dashboard in Notion to help you track tasks, timelines, and risks in one place at https://stan.store/SmartBiotech/p/discovertoind-cmc-dashboard-for-startup-founders

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18073631 Thu, 06 Nov 2025 05:00:00 +0100 1161 204 full false 203: Mastering CRO Selection: Essential Questions for CMC Analytical Development with Daniel Galbraith - Part 1 203: Mastering CRO Selection: Essential Questions for CMC Analytical Development with Daniel Galbraith - Part 1 Finding an analytical CRO that's truly invested in your success, not just processing samples, makes all the difference in CMC development. In this episode, host David Brühlmann talks with Daniel Galbraith, Chief Scientific Officer at Solvias, about the essential questions and mindset that lead to breakthrough CRO partnerships.

With nearly three decades in analytical development, spanning monoclonal antibodies, biosimilars, and cell and gene therapies, Daniel reveals what separates CROs who become true partners from those who just run methods. His insights can save your program months of delays and costly missteps.

Key Topics Discussed:

  • Why cell and gene therapies face unique challenges compared to the progression seen with monoclonal antibodies (03:04)
  • Daniel’s career path: from entering biotech in 1996 to CSO at Solvias, and the rapid evolution of the industry (05:00)
  • The analytical hurdles in characterizing cell-based products and how their inherent variability impacts development (09:46)
  • Approaches to analytical method requirements for autologous cell therapies, and how data is gathered iteratively in these cases (13:02)
  • The biggest obstacles to scaling up cell and gene therapies, and why innovative cell manipulation technologies are needed (16:06)
  • Current trends in therapeutic modalities: why antibody-drug conjugates stand out, and whether mRNA therapies are losing momentum (18:37)
  • Practical advice on choosing an analytical CRO as a strategic partner - what to look for, what questions to ask, and why enthusiasm and standardization matter (21:55)

Wondering how to streamline your own analytical strategy, or navigate the parallel universe of cell and gene therapy development? Dig into this episode for Daniel’s insider perspective. Then consider how the right analytical partnership could accelerate your path to clinic.

Connect with Daniel Galbraith:

LinkedIn: www.linkedin.com/in/daniel-galbraith-26a6138

Solvias website: www.solvias.com

Email: daniel.galbraith@solvias.com

Next steps:

Need fast CMC guidance? New on-demand CMC advisory: Get 20 expert answers/month in 1 day + monthly strategy call. → Learn more: https://stan.store/SmartBiotech/p/ondemand-cmc-expertise-for-biotech-founders

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Preparing for your IND? Grab our Startup Founder CMC Dashboard in Notion to help you track tasks, timelines, and risks in one place at https://stan.store/SmartBiotech/p/discovertoind-cmc-dashboard-for-startup-founders

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Finding an analytical CRO that's truly invested in your success, not just processing samples, makes all the difference in CMC development. In this episode, host David Brühlmann talks with Daniel Galbraith, Chief Scientific Officer at Solvias, about the essential questions and mindset that lead to breakthrough CRO partnerships.

With nearly three decades in analytical development, spanning monoclonal antibodies, biosimilars, and cell and gene therapies, Daniel reveals what separates CROs who become true partners from those who just run methods. His insights can save your program months of delays and costly missteps.

Key Topics Discussed:

  • Why cell and gene therapies face unique challenges compared to the progression seen with monoclonal antibodies (03:04)
  • Daniel’s career path: from entering biotech in 1996 to CSO at Solvias, and the rapid evolution of the industry (05:00)
  • The analytical hurdles in characterizing cell-based products and how their inherent variability impacts development (09:46)
  • Approaches to analytical method requirements for autologous cell therapies, and how data is gathered iteratively in these cases (13:02)
  • The biggest obstacles to scaling up cell and gene therapies, and why innovative cell manipulation technologies are needed (16:06)
  • Current trends in therapeutic modalities: why antibody-drug conjugates stand out, and whether mRNA therapies are losing momentum (18:37)
  • Practical advice on choosing an analytical CRO as a strategic partner - what to look for, what questions to ask, and why enthusiasm and standardization matter (21:55)

Wondering how to streamline your own analytical strategy, or navigate the parallel universe of cell and gene therapy development? Dig into this episode for Daniel’s insider perspective. Then consider how the right analytical partnership could accelerate your path to clinic.

Connect with Daniel Galbraith:

LinkedIn: www.linkedin.com/in/daniel-galbraith-26a6138

Solvias website: www.solvias.com

Email: daniel.galbraith@solvias.com

Next steps:

Need fast CMC guidance? New on-demand CMC advisory: Get 20 expert answers/month in 1 day + monthly strategy call. → Learn more: https://stan.store/SmartBiotech/p/ondemand-cmc-expertise-for-biotech-founders

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Preparing for your IND? Grab our Startup Founder CMC Dashboard in Notion to help you track tasks, timelines, and risks in one place at https://stan.store/SmartBiotech/p/discovertoind-cmc-dashboard-for-startup-founders

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18073627 Tue, 04 Nov 2025 05:00:00 +0100 1668 203 full false 202: Fighting Antimicrobial Resistance: How AI Cuts Phage Therapy Access from 6 Months to 5 Days with José Bila - Part 2 202: Fighting Antimicrobial Resistance: How AI Cuts Phage Therapy Access from 6 Months to 5 Days with José Bila - Part 2 What if the answer to battling antibiotic-resistant infections isn’t a new antibiotic, but harnessing viruses that have been quietly dominating bacterial populations?

Bacteriophages, viruses that target and kill bacteria, have been saving lives for a century, but their true potential is only now being unlocked by modern machine learning. The race isn’t just about discovering effective phages; it’s about deploying the right therapy, personalized to the patient, before time runs out.

On this episode, David Brühlmann welcomes José Luis Bila, Co-Founder and CEO of Precise Health. Driven by personal tragedy and an engineer’s mindset, José is shaping a future where AI-powered phage therapy isn’t a niche solution, but a scalable, accessible weapon against the superbugs that evade antibiotics. From building bioreactor capacity to navigating regulatory gray zones, José brings a rare blend of technical vision and practical urgency to a problem that affects families and health systems worldwide.

Key topics discussed:

  • The challenge of evolving bacteria and phages, and the question of whether it’s possible to keep up with nature’s pace through engineering new phages in silico (00:00)
  • Overview of bacteriophage production: complexity, types of bioreactors used, and comparison with chemical synthesis (02:54)
  • Bioproduction logistics: using CDMOs vs. in-house hospital production and the real-world timescales for manufacturing (02:32)
  • Barriers for smaller or less funded hospitals, especially in low- and middle-income countries, with thoughts on hospital infrastructure differences worldwide (04:41)
  • Creative solutions for cost-effective phage production in remote and underserved regions, such as the potential for single-use or mobile bioreactors (06:01)
  • Why downstream processing and ensuring product purity is a bottleneck; the need for miniaturization and economic scalability (06:40)
  • Parallels and differences in downstream processing between bacteriophages and viral vectors (09:15)
  • The vital role of stability and shelf life for phage therapy logistics and economic viability (09:15)
  • Regulatory pathways for phage therapy in Europe and beyond, including magistral preparations, ethical approvals, and adapting to digital tools for selection (12:39)
  • The future vision: routine clinic entry through matching existing phage libraries, with longer-term goals of engineering bespoke phages via AI when necessary (15:52)
  • José’s perspective on building global infrastructure and making phage therapy cost-effective and universally accessible (18:08)

José Bila’s message: solutions to antimicrobial resistance are within reach. The biotech community must build accessible infrastructure, using AI and innovative systems to ensure phage therapy benefits reach every patient, everywhere.

Connect with José Luis Bila:

LinkedIn: www.linkedin.com/in/josé-luis-bila-phd-3b08a5a7

Precise Health SA: www.precisehealth.io

Interested in how scientists are fighting superbugs? Learn how phage therapy and smart bioprocess design are helping outmaneuver drug-resistant pathogens. Check out this interview with one of our previous guests!

Episodes 187-188: From Biology Is Messy to Designable: The Smart Bioprocessing Transformation with Carmen Jungo Rhême

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> What if the answer to battling antibiotic-resistant infections isn’t a new antibiotic, but harnessing viruses that have been quietly dominating bacterial populations?

Bacteriophages, viruses that target and kill bacteria, have been saving lives for a century, but their true potential is only now being unlocked by modern machine learning. The race isn’t just about discovering effective phages; it’s about deploying the right therapy, personalized to the patient, before time runs out.

On this episode, David Brühlmann welcomes José Luis Bila, Co-Founder and CEO of Precise Health. Driven by personal tragedy and an engineer’s mindset, José is shaping a future where AI-powered phage therapy isn’t a niche solution, but a scalable, accessible weapon against the superbugs that evade antibiotics. From building bioreactor capacity to navigating regulatory gray zones, José brings a rare blend of technical vision and practical urgency to a problem that affects families and health systems worldwide.

Key topics discussed:

  • The challenge of evolving bacteria and phages, and the question of whether it’s possible to keep up with nature’s pace through engineering new phages in silico (00:00)
  • Overview of bacteriophage production: complexity, types of bioreactors used, and comparison with chemical synthesis (02:54)
  • Bioproduction logistics: using CDMOs vs. in-house hospital production and the real-world timescales for manufacturing (02:32)
  • Barriers for smaller or less funded hospitals, especially in low- and middle-income countries, with thoughts on hospital infrastructure differences worldwide (04:41)
  • Creative solutions for cost-effective phage production in remote and underserved regions, such as the potential for single-use or mobile bioreactors (06:01)
  • Why downstream processing and ensuring product purity is a bottleneck; the need for miniaturization and economic scalability (06:40)
  • Parallels and differences in downstream processing between bacteriophages and viral vectors (09:15)
  • The vital role of stability and shelf life for phage therapy logistics and economic viability (09:15)
  • Regulatory pathways for phage therapy in Europe and beyond, including magistral preparations, ethical approvals, and adapting to digital tools for selection (12:39)
  • The future vision: routine clinic entry through matching existing phage libraries, with longer-term goals of engineering bespoke phages via AI when necessary (15:52)
  • José’s perspective on building global infrastructure and making phage therapy cost-effective and universally accessible (18:08)

José Bila’s message: solutions to antimicrobial resistance are within reach. The biotech community must build accessible infrastructure, using AI and innovative systems to ensure phage therapy benefits reach every patient, everywhere.

Connect with José Luis Bila:

LinkedIn: www.linkedin.com/in/josé-luis-bila-phd-3b08a5a7

Precise Health SA: www.precisehealth.io

Interested in how scientists are fighting superbugs? Learn how phage therapy and smart bioprocess design are helping outmaneuver drug-resistant pathogens. Check out this interview with one of our previous guests!

Episodes 187-188: From Biology Is Messy to Designable: The Smart Bioprocessing Transformation with Carmen Jungo Rhême

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18042971 Thu, 30 Oct 2025 05:00:00 +0100 1388 202 full false 201: Fighting Antimicrobial Resistance: How AI Cuts Phage Therapy Access from 6 Months to 5 Days with José Bila - Part 1 201: Fighting Antimicrobial Resistance: How AI Cuts Phage Therapy Access from 6 Months to 5 Days with José Bila - Part 1 Antibiotic resistance isn’t just a looming problem. It’s a global crisis. Every year, more than one million people die directly from resistant infections, and another 5 million die indirectly. Routine infections are becoming life-threatening, and healthcare systems worldwide are under pressure.

Despite decades of warnings, pharmaceutical solutions are falling behind, while “superbugs” continue to outpace new drug development. If trends continue, by 2050, antibiotic resistance could claim 10 million lives annually and cost the world $1 trillion.

Meet José Luis Bila, a chemist-turned-biotech-founder, who transformed personal tragedy into a mission to disrupt this deadly status quo. After losing both parents to antibiotic-resistant infections, José dedicated his career to the search for targeted, effective alternatives. Now, as Co-Founder and CEO of Precise Health SA, he’s building AI-powered bacteriophage therapy platforms that promise to revolutionize personalized infection treatments and outmaneuver today’s most stubborn bacteria.

Why tune into this episode? Here are three standouts from José’s story and his technical playbook:

  • José's personal story: Losing both parents to antibiotic resistance and its impact on his career path. (00:00)
  • Scope of the antibiotic resistance crisis: Global deaths, indirect impacts, and economic cost projections. (06:29)
  • Why big pharma is pulling out of antibiotic development and why innovation may come from smaller startups. (07:29)
  • Why antibiotic resistance persists: Static nature of antibiotics versus adaptable bacteria, and misuse of antibiotics. (09:45)
  • Introduction to bacteriophage therapy and its specificity challenges. (11:46)
  • The current slow, manual process for matching phages to infections and its limitations in urgent clinical settings. (13:08)
  • How machine learning is being used at Precise Health to rapidly identify and source the right phages using genetic information. (16:58)
  • The potential to reduce phage matching and delivery time from months to just days, and how smart batching and regional surveillance improve economics. (17:23)

José Luis Bila’s journey shows the power of science driven by purpose. Through persistence, he’s pioneering AI-driven phage therapy - offering precision, hope, and a potential lifeline in the fight against antibiotic-resistant infections.

Connect with José Luis Bila:

LinkedIn: www.linkedin.com/in/josé-luis-bila-phd-3b08a5a7

Precise Health SA: www.precisehealth.io

Interested in how scientists are fighting superbugs? Learn how phage therapy and smart bioprocess design are helping outmaneuver drug-resistant pathogens. Check out this interview with one of our previous guests!

Episodes 187-188: From Biology Is Messy to Designable: The Smart Bioprocessing Transformation with Carmen Jungo Rhême

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Antibiotic resistance isn’t just a looming problem. It’s a global crisis. Every year, more than one million people die directly from resistant infections, and another 5 million die indirectly. Routine infections are becoming life-threatening, and healthcare systems worldwide are under pressure.

Despite decades of warnings, pharmaceutical solutions are falling behind, while “superbugs” continue to outpace new drug development. If trends continue, by 2050, antibiotic resistance could claim 10 million lives annually and cost the world $1 trillion.

Meet José Luis Bila, a chemist-turned-biotech-founder, who transformed personal tragedy into a mission to disrupt this deadly status quo. After losing both parents to antibiotic-resistant infections, José dedicated his career to the search for targeted, effective alternatives. Now, as Co-Founder and CEO of Precise Health SA, he’s building AI-powered bacteriophage therapy platforms that promise to revolutionize personalized infection treatments and outmaneuver today’s most stubborn bacteria.

Why tune into this episode? Here are three standouts from José’s story and his technical playbook:

  • José's personal story: Losing both parents to antibiotic resistance and its impact on his career path. (00:00)
  • Scope of the antibiotic resistance crisis: Global deaths, indirect impacts, and economic cost projections. (06:29)
  • Why big pharma is pulling out of antibiotic development and why innovation may come from smaller startups. (07:29)
  • Why antibiotic resistance persists: Static nature of antibiotics versus adaptable bacteria, and misuse of antibiotics. (09:45)
  • Introduction to bacteriophage therapy and its specificity challenges. (11:46)
  • The current slow, manual process for matching phages to infections and its limitations in urgent clinical settings. (13:08)
  • How machine learning is being used at Precise Health to rapidly identify and source the right phages using genetic information. (16:58)
  • The potential to reduce phage matching and delivery time from months to just days, and how smart batching and regional surveillance improve economics. (17:23)

José Luis Bila’s journey shows the power of science driven by purpose. Through persistence, he’s pioneering AI-driven phage therapy - offering precision, hope, and a potential lifeline in the fight against antibiotic-resistant infections.

Connect with José Luis Bila:

LinkedIn: www.linkedin.com/in/josé-luis-bila-phd-3b08a5a7

Precise Health SA: www.precisehealth.io

Interested in how scientists are fighting superbugs? Learn how phage therapy and smart bioprocess design are helping outmaneuver drug-resistant pathogens. Check out this interview with one of our previous guests!

Episodes 187-188: From Biology Is Messy to Designable: The Smart Bioprocessing Transformation with Carmen Jungo Rhême

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-18042945 Tue, 28 Oct 2025 05:00:00 +0100 1434 201 full false 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC Development - Part 2 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC Development - Part 2 Your process works perfectly at two-liter bench scale. Then you hit fifty liters and titer drops 20%. By two hundred liters, aggregation appears and charge variants shift. Your management team asks: "How long to fix this?" The honest answer? Three to twelve month, because you're flying blind.

In Part 2 of this Quality by Design Master Class, David Brühlmann reveals why scale-up chaos isn't inevitable. It's a solvable engineering problem. Drawing on experience leading bioprocess innovation at Merck and guiding biotech companies through CMC development, David delivers the process control framework that transforms reactive troubleshooting into predictive manufacturing.

The core truth: eighty percent of quality problems stem from twenty percent of your process variables. David shows how to identify Critical Process Parameters, implement intelligent control strategies, and leverage hybrid modeling that reduces experiments by 60-80%. With case studies from Genentech and Amgen, you'll gain the blueprint that turns QbD requirements into competitive advantage.

Part 1 taught you what to build and measure. Part 2 shows you how to control your process to consistently deliver commercial-scale quality.

Topics Discussed:

  • The common pitfalls of scaling up manufacturing from bench to production, and why process control must go beyond end-product testing (02:10)
  • Overview of the QbD framework: Quality Target Product Profile (QTPP), Critical Quality Attributes (CQAs), and the focus of this episode - Control Strategies for manufacturing (05:00)
  • Identifying and monitoring Critical Process Parameters (CPPs) and their impact on quality, with real-world examples from Genentech’s monoclonal antibody platform (08:20)
  • Structure of an effective manufacturing control strategy: Input, process, and output controls - including practical details on real-time monitoring and release testing (11:00)
  • The role of hybrid modeling and machine learning in accelerating process optimization, and how this approach can dramatically reduce the experimental burden (13:30)
  • Real examples of improved outcomes and efficiency through model-based control strategies, and why training and process understanding are essential for team success (16:10)
  • A quick, actionable exercise biotech teams can use to map process risks and identify critical control points (16:55)

Whether you’re part of a start-up or a large biotech firm, this episode offers clear, strategic steps for implementing QbD and improving process reliability. Don’t forget to listen to Part 1 for more on QTPP and CQA, and visit www.bruehlmann-consulting.com for additional resources.

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Preparing for your IND? We’re building a CMC Dashboard in Excel to help biotech founders track tasks, timelines, and risks in one place. Join the waitlist for early access at https://scale-your-impact.notion.site/27dd9c6ba679804b80a7ce439d56c91a?pvs=105

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Your process works perfectly at two-liter bench scale. Then you hit fifty liters and titer drops 20%. By two hundred liters, aggregation appears and charge variants shift. Your management team asks: "How long to fix this?" The honest answer? Three to twelve month, because you're flying blind.

In Part 2 of this Quality by Design Master Class, David Brühlmann reveals why scale-up chaos isn't inevitable. It's a solvable engineering problem. Drawing on experience leading bioprocess innovation at Merck and guiding biotech companies through CMC development, David delivers the process control framework that transforms reactive troubleshooting into predictive manufacturing.

The core truth: eighty percent of quality problems stem from twenty percent of your process variables. David shows how to identify Critical Process Parameters, implement intelligent control strategies, and leverage hybrid modeling that reduces experiments by 60-80%. With case studies from Genentech and Amgen, you'll gain the blueprint that turns QbD requirements into competitive advantage.

Part 1 taught you what to build and measure. Part 2 shows you how to control your process to consistently deliver commercial-scale quality.

Topics Discussed:

  • The common pitfalls of scaling up manufacturing from bench to production, and why process control must go beyond end-product testing (02:10)
  • Overview of the QbD framework: Quality Target Product Profile (QTPP), Critical Quality Attributes (CQAs), and the focus of this episode - Control Strategies for manufacturing (05:00)
  • Identifying and monitoring Critical Process Parameters (CPPs) and their impact on quality, with real-world examples from Genentech’s monoclonal antibody platform (08:20)
  • Structure of an effective manufacturing control strategy: Input, process, and output controls - including practical details on real-time monitoring and release testing (11:00)
  • The role of hybrid modeling and machine learning in accelerating process optimization, and how this approach can dramatically reduce the experimental burden (13:30)
  • Real examples of improved outcomes and efficiency through model-based control strategies, and why training and process understanding are essential for team success (16:10)
  • A quick, actionable exercise biotech teams can use to map process risks and identify critical control points (16:55)

Whether you’re part of a start-up or a large biotech firm, this episode offers clear, strategic steps for implementing QbD and improving process reliability. Don’t forget to listen to Part 1 for more on QTPP and CQA, and visit www.bruehlmann-consulting.com for additional resources.

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Preparing for your IND? We’re building a CMC Dashboard in Excel to help biotech founders track tasks, timelines, and risks in one place. Join the waitlist for early access at https://scale-your-impact.notion.site/27dd9c6ba679804b80a7ce439d56c91a?pvs=105

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17993686 Thu, 23 Oct 2025 05:00:00 +0200 1180 200 full false 199: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC Development - Part 1 199: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC Development - Part 1 Over 40% of biotherapeutic failures during clinical development stem from stability problems—and most trace back to protein aggregation that could have been prevented. In this episode of the Smart Biotech Scientist Podcast, David Brühlmann exposes the hidden manufacturing crisis that derails promising biologics programs and delivers the systematic Quality by Design framework that elite biotech companies use to build quality into every process step.

David brings two decades of bioprocess expertise from his time leading technology innovation at Merck and now guiding emerging biotech companies through CMC development as Managing Director of Brühlmann Consulting. Drawing on FDA and EMA regulatory guidance as well as landmark industry case studies he transforms complex QbD principles into an actionable roadmap for IND submission.

This isn't theoretical regulatory compliance. It's competitive survival. Companies implementing these QbD foundations achieve predictable manufacturing scale-up, accelerated regulatory approval, and significant cost advantages. If your team is navigating CMC development for the first time or struggling with scale-up challenges, this episode provides the blueprint to transform process uncertainty into manufacturing confidence.

What You’ll Learn in This Episode:

  • The high clinical failure rate for biologics due to protein aggregation and stability problems, and one company’s costly lesson in the scale-up phase. (00:00)
  • An introduction to Quality by Design (QbD)—how it differs from traditional development and why “the process is the product” in biologics. (03:09)
  • The three foundational pillars of QbD, with today’s focus on product understanding and quality requirements. (05:46)
  • Constructing your Quality Target Product Profile (QTPP): what to include and why starting with the patient is key. (07:05)
  • A real-world QTPP example—the AMAP case study—and how it shaped formulation, packaging, and critical quality standards. (09:45)
  • Defining and prioritizing Critical Quality Attributes (CQAs): measuring what truly matters for safety and efficacy. (11:50)
  • Lessons from Roche/Genentech’s QbD journey: regulatory insights and the business value of robust CQA identification. (15:55)
  • The “CQA Reality Check” exercise: a step-by-step method to focus your team on attributes that impact patients. (21:05)
  • How early, candid dialogue with regulators and using management tools like the Notion CMC Dashboard can streamline the development roadmap and reassure investors. (23:30)

Ready to flip the odds in your favor and make QbD your competitive edge? Stream this episode to catch actionable strategies and real-world cautionary tales that could change your CMC development playbook for good.

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Preparing for your IND? We’re building a CMC Dashboard in Excel to help biotech founders track tasks, timelines, and risks in one place. Join the waitlist for early access at https://scale-your-impact.notion.site/27dd9c6ba679804b80a7ce439d56c91a?pvs=105

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Over 40% of biotherapeutic failures during clinical development stem from stability problems—and most trace back to protein aggregation that could have been prevented. In this episode of the Smart Biotech Scientist Podcast, David Brühlmann exposes the hidden manufacturing crisis that derails promising biologics programs and delivers the systematic Quality by Design framework that elite biotech companies use to build quality into every process step.

David brings two decades of bioprocess expertise from his time leading technology innovation at Merck and now guiding emerging biotech companies through CMC development as Managing Director of Brühlmann Consulting. Drawing on FDA and EMA regulatory guidance as well as landmark industry case studies he transforms complex QbD principles into an actionable roadmap for IND submission.

This isn't theoretical regulatory compliance. It's competitive survival. Companies implementing these QbD foundations achieve predictable manufacturing scale-up, accelerated regulatory approval, and significant cost advantages. If your team is navigating CMC development for the first time or struggling with scale-up challenges, this episode provides the blueprint to transform process uncertainty into manufacturing confidence.

What You’ll Learn in This Episode:

  • The high clinical failure rate for biologics due to protein aggregation and stability problems, and one company’s costly lesson in the scale-up phase. (00:00)
  • An introduction to Quality by Design (QbD)—how it differs from traditional development and why “the process is the product” in biologics. (03:09)
  • The three foundational pillars of QbD, with today’s focus on product understanding and quality requirements. (05:46)
  • Constructing your Quality Target Product Profile (QTPP): what to include and why starting with the patient is key. (07:05)
  • A real-world QTPP example—the AMAP case study—and how it shaped formulation, packaging, and critical quality standards. (09:45)
  • Defining and prioritizing Critical Quality Attributes (CQAs): measuring what truly matters for safety and efficacy. (11:50)
  • Lessons from Roche/Genentech’s QbD journey: regulatory insights and the business value of robust CQA identification. (15:55)
  • The “CQA Reality Check” exercise: a step-by-step method to focus your team on attributes that impact patients. (21:05)
  • How early, candid dialogue with regulators and using management tools like the Notion CMC Dashboard can streamline the development roadmap and reassure investors. (23:30)

Ready to flip the odds in your favor and make QbD your competitive edge? Stream this episode to catch actionable strategies and real-world cautionary tales that could change your CMC development playbook for good.

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Preparing for your IND? We’re building a CMC Dashboard in Excel to help biotech founders track tasks, timelines, and risks in one place. Join the waitlist for early access at https://scale-your-impact.notion.site/27dd9c6ba679804b80a7ce439d56c91a?pvs=105

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17993669 Tue, 21 Oct 2025 05:00:00 +0200 1236 199 full false 198: Mastering ADC Development: CDMO Strategies for Analytics and Scale-Up with Amanda Hoertz - Part 2 198: Mastering ADC Development: CDMO Strategies for Analytics and Scale-Up with Amanda Hoertz - Part 2 What happens when the most complex molecules in biotech meet the organizational challenge of managing 300+ analytical scientists? The answer lies not just in the science, but in building systems that turn technical complexity into reliable delivery.

In Part 2 of our deep dive with Amanda Hoertz, VP of Analytical and Formulation Sciences at KBI Biopharma, we shift focus from the molecular intricacies of ADCs to the operational mastery required to scale analytical development across multiple sites. Amanda reveals how her team achieves consistency across hundreds of scientists while maintaining the agility to pivot priorities in real time when critical programs need emergency support.

This isn't just about managing people; it's about architecting systems that preserve institutional knowledge, accelerate method transfer, and deliver results when regulatory deadlines loom.

What you'll discover:

  • Seamless Project Handoffs Without Knowledge Loss: How KBI's stable team assignments eliminate the costly learning curves that plague most CDMO relationships, ensuring your molecule expertise stays with your program from development through commercial manufacturing.
  • Organizational Scale Without Operational Chaos: The decision tree and layered reporting structure that allows 200+ analysts at a single site to function as a coordinated force, capable of rapid reprioritization and flood-level resource deployment when programs reach critical status.
  • Digital Transformation That Actually Works: Beyond the automation buzzwords, Amanda walks through the practical realities of LIMS/ELN implementation, audit-compliant systems, and machine learning databases that transform raw data into defensible, actionable insights for complex biologics.

Whether you're evaluating how analytical capabilities scale with program complexity, or seeking practical insights into leading technical teams through digital transformation, this episode delivers the operational intelligence that separates successful ADC programs from expensive failures.

Connect with Amanda Hoertz:

LinkedIn: www.linkedin.com/in/amanda-hoertz-3aba605

KBI Biopharma: www.kbibiopharma.com

KBI Portal: www.standalone.kbi.bio

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> What happens when the most complex molecules in biotech meet the organizational challenge of managing 300+ analytical scientists? The answer lies not just in the science, but in building systems that turn technical complexity into reliable delivery.

In Part 2 of our deep dive with Amanda Hoertz, VP of Analytical and Formulation Sciences at KBI Biopharma, we shift focus from the molecular intricacies of ADCs to the operational mastery required to scale analytical development across multiple sites. Amanda reveals how her team achieves consistency across hundreds of scientists while maintaining the agility to pivot priorities in real time when critical programs need emergency support.

This isn't just about managing people; it's about architecting systems that preserve institutional knowledge, accelerate method transfer, and deliver results when regulatory deadlines loom.

What you'll discover:

  • Seamless Project Handoffs Without Knowledge Loss: How KBI's stable team assignments eliminate the costly learning curves that plague most CDMO relationships, ensuring your molecule expertise stays with your program from development through commercial manufacturing.
  • Organizational Scale Without Operational Chaos: The decision tree and layered reporting structure that allows 200+ analysts at a single site to function as a coordinated force, capable of rapid reprioritization and flood-level resource deployment when programs reach critical status.
  • Digital Transformation That Actually Works: Beyond the automation buzzwords, Amanda walks through the practical realities of LIMS/ELN implementation, audit-compliant systems, and machine learning databases that transform raw data into defensible, actionable insights for complex biologics.

Whether you're evaluating how analytical capabilities scale with program complexity, or seeking practical insights into leading technical teams through digital transformation, this episode delivers the operational intelligence that separates successful ADC programs from expensive failures.

Connect with Amanda Hoertz:

LinkedIn: www.linkedin.com/in/amanda-hoertz-3aba605

KBI Biopharma: www.kbibiopharma.com

KBI Portal: www.standalone.kbi.bio

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17914851 Thu, 16 Oct 2025 05:00:00 +0200 1265 198 full false 197: Mastering ADC Development: CDMO Strategies for Analytics and Scale-Up with Amanda Hoertz - Part 1 197: Mastering ADC Development: CDMO Strategies for Analytics and Scale-Up with Amanda Hoertz - Part 1 What if the key to unlocking ADC manufacturing success lies in abandoning the platform mindset entirely?

Antibody-drug conjugates represent biotech's most promising weapon against cancer: precision-targeted therapeutics that deliver cytotoxic payloads directly to tumor cells while sparing healthy tissue. But beneath the clinical promise lies a manufacturing reality that's rewriting the rules of bioprocess development, demanding analytical strategies that most CDMOs simply aren't equipped to handle.

In this deep-dive episode, David Brühlmann sits down with Amanda Hoertz, Vice President of Analytical and Formulation Sciences at KBI Biopharma, where she oversees 300+ scientists across the mammalian network. Amanda's team has cracked the code on some of the industry's most challenging ADC programs, achieving a remarkable 93% batch success rate by rejecting cookie-cutter approaches in favor of molecule-specific development strategies.

What you'll discover:

  • The Platform Fallacy: Why treating ADCs like standard monoclonals is costing companies millions and months of development time, and the bespoke analytical framework that's changing everything.
  • Cytotoxic Payload Management: From free drug analysis to employee safety protocols, Amanda reveals the hidden complexities of handling molecules designed to kill cells, including the specialized facilities and analytical methods required for GMP manufacturing.
  • Charge Heterogeneity Mastery: The analytical method that "keeps Amanda up at night," and the development strategies her team uses to achieve robust separation and qualification across multiple sites and analysts.

This episode delivers the technical depth and strategic insights that bioprocess engineers need to navigate ADC development successfully. Whether you're evaluating CDMO partnerships, optimizing analytical methods, or scaling complex conjugates, Amanda's proven strategies will transform your approach to these game-changing therapeutics.

Ready to master the analytical complexities that make or break ADC programs?

Connect with Amanda Hoertz:

LinkedIn: www.linkedin.com/in/amanda-hoertz-3aba605

KBI Biopharma: www.kbibiopharma.com

KBI Portal: www.standalone.kbi.bio

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> What if the key to unlocking ADC manufacturing success lies in abandoning the platform mindset entirely?

Antibody-drug conjugates represent biotech's most promising weapon against cancer: precision-targeted therapeutics that deliver cytotoxic payloads directly to tumor cells while sparing healthy tissue. But beneath the clinical promise lies a manufacturing reality that's rewriting the rules of bioprocess development, demanding analytical strategies that most CDMOs simply aren't equipped to handle.

In this deep-dive episode, David Brühlmann sits down with Amanda Hoertz, Vice President of Analytical and Formulation Sciences at KBI Biopharma, where she oversees 300+ scientists across the mammalian network. Amanda's team has cracked the code on some of the industry's most challenging ADC programs, achieving a remarkable 93% batch success rate by rejecting cookie-cutter approaches in favor of molecule-specific development strategies.

What you'll discover:

  • The Platform Fallacy: Why treating ADCs like standard monoclonals is costing companies millions and months of development time, and the bespoke analytical framework that's changing everything.
  • Cytotoxic Payload Management: From free drug analysis to employee safety protocols, Amanda reveals the hidden complexities of handling molecules designed to kill cells, including the specialized facilities and analytical methods required for GMP manufacturing.
  • Charge Heterogeneity Mastery: The analytical method that "keeps Amanda up at night," and the development strategies her team uses to achieve robust separation and qualification across multiple sites and analysts.

This episode delivers the technical depth and strategic insights that bioprocess engineers need to navigate ADC development successfully. Whether you're evaluating CDMO partnerships, optimizing analytical methods, or scaling complex conjugates, Amanda's proven strategies will transform your approach to these game-changing therapeutics.

Ready to master the analytical complexities that make or break ADC programs?

Connect with Amanda Hoertz:

LinkedIn: www.linkedin.com/in/amanda-hoertz-3aba605

KBI Biopharma: www.kbibiopharma.com

KBI Portal: www.standalone.kbi.bio

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17914845 Tue, 14 Oct 2025 05:00:00 +0200 1506 197 full false 196: Monolithic Chromatography Innovations: Solving High-Capacity Purification for Gene Therapy Vectors with Alois Jungbauer - Part 2 196: Monolithic Chromatography Innovations: Solving High-Capacity Purification for Gene Therapy Vectors with Alois Jungbauer - Part 2 What if solving tomorrow’s bioprocessing challenges meant questioning the very physics of chromatography and reimagining downstream processing from the ground up?

For years, large biomolecules like viral vectors and exosomes have squeezed through the limitations of traditional chromatography, leaving scientists to wrestle with capacity trade-offs and slow mass transfer. But what if a fundamental shift could unlock breakthroughs for gene therapies, vaccines, and advanced biologics?

In this thought-provoking episode, host David Brühlmann sits down with Alois Jungbauer, professor emeritus of downstream processing at BOKU University (Vienna) and scientific advisor at BioChromatographix International. Together, they examine the future of chromatography and downstream processing, exploring innovations that tackle the challenges of modern gene therapy, advanced therapeutics, and sustainability in manufacturing.

Alois shares his perspective on anticipating industry needs, the importance of mentorship, and why the physical limits for purification of large biomolecules are yet to be reached.

Episode Highlights:

  • The difference between solving current problems and anticipating the needs of the next generation in biotech (00:00)
  • The promise and technical details of monolithic chromatography and its application for large modalities like gene therapy vectors and exosomes (03:01)
  • Explanation of “inverted morphology" and AXISFLOW™ in new chromatography materials (03:18)
  • Challenges and opportunities in continuous gene therapy vector production, and why it’s not widespread yet (07:40)
  • The critical role of sustainability in downstream processing, particularly water usage and its impact on the viability and costs of distributed manufacturing (10:30)
  • The relationship between reducing water consumption, manufacturing footprint, and cost of goods (12:16)
  • Advice on scientific career development: listening, reading, understanding future industry needs, finding a mentor, and having persistence (13:50)
  • Broader reflections on the value of science, societal perceptions, and science communication in today’s world (17:34)
  • Alois’s key takeaway: downstream processing for gene therapy has not yet reached its physical limits—there is still significant room for improvement (20:26)

If you’re looking for fresh strategies to tackle the bottlenecks of large-molecule purification - and a candid perspective on where the real opportunities and societal responsibilities lie - you won’t want to miss this conversation.

Connect with Alois Jungbauer at leading conferences, including Bioprocessing Summit and Bioprocessing International, or find the next integrated continuous biomanufacturing event where he’s co-chairing.

Connect with Alois Jungbauer:

LinkedIn: www.linkedin.com/in/alois-jungbauer-14984811

Website : www.biochromatographix.com

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Preparing for your IND? We’re building a CMC Dashboard in Excel to help biotech founders track tasks, timelines, and risks in one place. Join the waitlist for early access at https://scale-your-impact.notion.site/27dd9c6ba679804b80a7ce439d56c91a?pvs=105

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> What if solving tomorrow’s bioprocessing challenges meant questioning the very physics of chromatography and reimagining downstream processing from the ground up?

For years, large biomolecules like viral vectors and exosomes have squeezed through the limitations of traditional chromatography, leaving scientists to wrestle with capacity trade-offs and slow mass transfer. But what if a fundamental shift could unlock breakthroughs for gene therapies, vaccines, and advanced biologics?

In this thought-provoking episode, host David Brühlmann sits down with Alois Jungbauer, professor emeritus of downstream processing at BOKU University (Vienna) and scientific advisor at BioChromatographix International. Together, they examine the future of chromatography and downstream processing, exploring innovations that tackle the challenges of modern gene therapy, advanced therapeutics, and sustainability in manufacturing.

Alois shares his perspective on anticipating industry needs, the importance of mentorship, and why the physical limits for purification of large biomolecules are yet to be reached.

Episode Highlights:

  • The difference between solving current problems and anticipating the needs of the next generation in biotech (00:00)
  • The promise and technical details of monolithic chromatography and its application for large modalities like gene therapy vectors and exosomes (03:01)
  • Explanation of “inverted morphology" and AXISFLOW™ in new chromatography materials (03:18)
  • Challenges and opportunities in continuous gene therapy vector production, and why it’s not widespread yet (07:40)
  • The critical role of sustainability in downstream processing, particularly water usage and its impact on the viability and costs of distributed manufacturing (10:30)
  • The relationship between reducing water consumption, manufacturing footprint, and cost of goods (12:16)
  • Advice on scientific career development: listening, reading, understanding future industry needs, finding a mentor, and having persistence (13:50)
  • Broader reflections on the value of science, societal perceptions, and science communication in today’s world (17:34)
  • Alois’s key takeaway: downstream processing for gene therapy has not yet reached its physical limits—there is still significant room for improvement (20:26)

If you’re looking for fresh strategies to tackle the bottlenecks of large-molecule purification - and a candid perspective on where the real opportunities and societal responsibilities lie - you won’t want to miss this conversation.

Connect with Alois Jungbauer at leading conferences, including Bioprocessing Summit and Bioprocessing International, or find the next integrated continuous biomanufacturing event where he’s co-chairing.

Connect with Alois Jungbauer:

LinkedIn: www.linkedin.com/in/alois-jungbauer-14984811

Website : www.biochromatographix.com

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Preparing for your IND? We’re building a CMC Dashboard in Excel to help biotech founders track tasks, timelines, and risks in one place. Join the waitlist for early access at https://scale-your-impact.notion.site/27dd9c6ba679804b80a7ce439d56c91a?pvs=105

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17935031 Thu, 09 Oct 2025 05:00:00 +0200 1452 196 full false 195: Monolithic Chromatography Innovations: Solving High-Capacity Purification for Gene Therapy Vectors with Alois Jungbauer - Part 1 195: Monolithic Chromatography Innovations: Solving High-Capacity Purification for Gene Therapy Vectors with Alois Jungbauer - Part 1 In this episode, host David Brühlmann is joined by Alois Jungbauer, Professor Emeritus at BOKU University, Vienna, and Scientific Advisor at BioChromatographix International. With over 40 years in bioprocess engineering and more than 400 published papers, Jungbauer offers a unique perspective on how downstream processing and purification technologies have evolved and where they’re headed next.

Alois shares his unconventional journey into the world of biotech, starting from humble beginnings on an Austrian farm, and discusses key turning points that have shaped the industry. Together, they explore the latest challenges triggered by high cell culture titers, new therapeutic modalities, and the drive for automation and process integration in manufacturing.

In this episode:

  • Why the gap between upstream and downstream processes remains a core bottleneck (03:27)
  • How rigid and convective chromatography materials changed throughput and efficiency (06:56)
  • The shift in purification strategies with skyrocketing titers in cell culture (08:43)
  • Automation and integrated biomanufacturing: their role in making processes more robust and continuous (10:20)
  • Misconceptions around resin costs in full-scale versus clinical-scale manufacturing (12:10)
  • What automation and process monitoring mean for real-time release and factory scheduling (14:05)
  • The resurgence and application of displacement chromatography for gene therapy vectors (15:49)

Whether you’re deep into process development or just curious about the next wave in biotech manufacturing, Alois Jungbauer’s insights offer valuable context for the road ahead.

Connect with Alois Jungbauer:

LinkedIn: www.linkedin.com/in/alois-jungbauer-14984811

Website : www.biochromatographix.com

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Preparing for your IND? We’re building a CMC Dashboard in Excel to help biotech founders track tasks, timelines, and risks in one place. Join the waitlist for early access at https://scale-your-impact.notion.site/27dd9c6ba679804b80a7ce439d56c91a?pvs=105

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> In this episode, host David Brühlmann is joined by Alois Jungbauer, Professor Emeritus at BOKU University, Vienna, and Scientific Advisor at BioChromatographix International. With over 40 years in bioprocess engineering and more than 400 published papers, Jungbauer offers a unique perspective on how downstream processing and purification technologies have evolved and where they’re headed next.

Alois shares his unconventional journey into the world of biotech, starting from humble beginnings on an Austrian farm, and discusses key turning points that have shaped the industry. Together, they explore the latest challenges triggered by high cell culture titers, new therapeutic modalities, and the drive for automation and process integration in manufacturing.

In this episode:

  • Why the gap between upstream and downstream processes remains a core bottleneck (03:27)
  • How rigid and convective chromatography materials changed throughput and efficiency (06:56)
  • The shift in purification strategies with skyrocketing titers in cell culture (08:43)
  • Automation and integrated biomanufacturing: their role in making processes more robust and continuous (10:20)
  • Misconceptions around resin costs in full-scale versus clinical-scale manufacturing (12:10)
  • What automation and process monitoring mean for real-time release and factory scheduling (14:05)
  • The resurgence and application of displacement chromatography for gene therapy vectors (15:49)

Whether you’re deep into process development or just curious about the next wave in biotech manufacturing, Alois Jungbauer’s insights offer valuable context for the road ahead.

Connect with Alois Jungbauer:

LinkedIn: www.linkedin.com/in/alois-jungbauer-14984811

Website : www.biochromatographix.com

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Preparing for your IND? We’re building a CMC Dashboard in Excel to help biotech founders track tasks, timelines, and risks in one place. Join the waitlist for early access at https://scale-your-impact.notion.site/27dd9c6ba679804b80a7ce439d56c91a?pvs=105

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17935014 Tue, 07 Oct 2025 05:00:00 +0200 1196 195 full false 194: Viral Vector CDMO Mastery: Singapore's Answer to Cell and Gene Therapy Supply Shortages with Lucas Chan - Part 2 194: Viral Vector CDMO Mastery: Singapore's Answer to Cell and Gene Therapy Supply Shortages with Lucas Chan - Part 2 What if the future of affordable, life-changing cell and gene therapies comes down to one critical yet often overlooked factor: manufacturing efficiency?

In advanced therapy medicinal products (ATMPs), groundbreaking science abounds, but the path to the clinic is still strewn with bottlenecks, especially when it comes to cost, complexity, and safety. While the promise is enormous, most therapies remain out of reach for many patients due to high cost of goods and logistical hurdles. What can actually break down these barriers and democratize access?

In this episode, David Brühlmann welcomes Lucas Chan, celebrated Fellow of the Royal Society of Biology, advisor to Singapore's Ministry of Health, and a true pioneer in viral vector manufacturing. In Singapore, he founded CellVec Pte Ltd – APAC’s first regulatory accredited Viral Vector specialist CDMO.

Lucas's leadership spans founding ventures in emerging markets to championing game-changing innovations in gene transfer, always with an eye toward efficiency, safety, and accessibility. Having returned “back to the bench” in collaboration with the National University of Singapore while launching his consultancy, Lucas brings both visionary perspective and hands-on experience to one of biotech’s toughest challenges.

Here are three reasons why you need to listen to this episode:

  • Efficiency is Everything: Lucas dissects how complex processes and outdated manufacturing paradigms are driving up the cost of cell and gene therapies and shares real-world advances, from transitioning viral vector production to stable producer cell lines to the emergence of non-viral gene transfer modalities, that are poised to rewrite the rulebook on scalability and affordability.
  • Leadership Amid Complexity: Learn from Lucas’s top leadership advice drawn from his CSO and CDMO tenure: inspire teams by connecting every task to the larger mission. In a multidisciplinary, high-stakes environment, alignment and motivation aren’t just nice, they’re essential for innovation.
  • Entrepreneurship and Community: Thinking of turning your biotech expertise into a startup? Lucas underscores the value of learning from others’ journeys, collaboration, and the insight that “it takes a village” when translating advanced therapies from bench to bedside, especially in emerging markets with unique affordability challenges.

Want to transform your approach to cell and gene therapy manufacturing or just need inspiration to push your biotech project to the next level?

Tune into this episode for practical insights, candid leadership lessons, and a renewed sense of what’s possible when we challenge the status quo together.

Connect with Lucas Chan:

LinkedIn: www.linkedin.com/in/lucaschangt

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Preparing for your IND? We’re building a CMC Dashboard in Excel to help biotech founders track tasks, timelines, and risks in one place. Join the waitlist for early access at https://scale-your-impact.notion.site/27dd9c6ba679804b80a7ce439d56c91a?pvs=105

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> What if the future of affordable, life-changing cell and gene therapies comes down to one critical yet often overlooked factor: manufacturing efficiency?

In advanced therapy medicinal products (ATMPs), groundbreaking science abounds, but the path to the clinic is still strewn with bottlenecks, especially when it comes to cost, complexity, and safety. While the promise is enormous, most therapies remain out of reach for many patients due to high cost of goods and logistical hurdles. What can actually break down these barriers and democratize access?

In this episode, David Brühlmann welcomes Lucas Chan, celebrated Fellow of the Royal Society of Biology, advisor to Singapore's Ministry of Health, and a true pioneer in viral vector manufacturing. In Singapore, he founded CellVec Pte Ltd – APAC’s first regulatory accredited Viral Vector specialist CDMO.

Lucas's leadership spans founding ventures in emerging markets to championing game-changing innovations in gene transfer, always with an eye toward efficiency, safety, and accessibility. Having returned “back to the bench” in collaboration with the National University of Singapore while launching his consultancy, Lucas brings both visionary perspective and hands-on experience to one of biotech’s toughest challenges.

Here are three reasons why you need to listen to this episode:

  • Efficiency is Everything: Lucas dissects how complex processes and outdated manufacturing paradigms are driving up the cost of cell and gene therapies and shares real-world advances, from transitioning viral vector production to stable producer cell lines to the emergence of non-viral gene transfer modalities, that are poised to rewrite the rulebook on scalability and affordability.
  • Leadership Amid Complexity: Learn from Lucas’s top leadership advice drawn from his CSO and CDMO tenure: inspire teams by connecting every task to the larger mission. In a multidisciplinary, high-stakes environment, alignment and motivation aren’t just nice, they’re essential for innovation.
  • Entrepreneurship and Community: Thinking of turning your biotech expertise into a startup? Lucas underscores the value of learning from others’ journeys, collaboration, and the insight that “it takes a village” when translating advanced therapies from bench to bedside, especially in emerging markets with unique affordability challenges.

Want to transform your approach to cell and gene therapy manufacturing or just need inspiration to push your biotech project to the next level?

Tune into this episode for practical insights, candid leadership lessons, and a renewed sense of what’s possible when we challenge the status quo together.

Connect with Lucas Chan:

LinkedIn: www.linkedin.com/in/lucaschangt

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Preparing for your IND? We’re building a CMC Dashboard in Excel to help biotech founders track tasks, timelines, and risks in one place. Join the waitlist for early access at https://scale-your-impact.notion.site/27dd9c6ba679804b80a7ce439d56c91a?pvs=105

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17885762 Thu, 02 Oct 2025 05:00:00 +0200 1106 194 full false 193: Viral Vector CDMO Mastery: Singapore's Answer to Cell and Gene Therapy Supply Shortages with Lucas Chan - Part 1 193: Viral Vector CDMO Mastery: Singapore's Answer to Cell and Gene Therapy Supply Shortages with Lucas Chan - Part 1 Viral vectors are the backbone of cutting-edge cell and gene therapies, delivering life-altering treatments to patients with genetic diseases. But making these biological delivery vehicles is a high-wire act: unpredictable, complex, and fraught with hurdles that traditional biologics manufacturers have never faced.

While the world races toward next-generation therapies, the challenge of producing viral vectors at clinical and commercial scale threatens to leave patients waiting on the sidelines.

Our guest on the Smart Biotech Scientist Podcast is Lucas Chan, a molecular and cell biologist with over two decades of hands-on experience in cell and gene therapy development. From his formative research at Imperial College London, where he pioneered novel viral vector cell lines, to building the UK’s first GMP clinical viral vector core and later founding CellVec Pte Ltd Asia Pacific CDMO in Singapore, Lucas is the go-to architect for manufacturing viral vectors where infrastructure barely exists.

Along the way, he’s faced and overcome challenges few others could imagine.

Here are three reasons this episode is a must-listen:

  • Viral Vectors Demystified: Lucas breaks down a common misconception: viral vectors aren’t malignant viruses, but genetically disarmed delivery vehicles that can’t revert or replicate, making them safe tools for gene therapy.
  • Manufacturing Mayhem Made Manageable: Unlike monoclonal antibodies and other biologics, viral vectors (and other cell and gene therapies) are made in living cells, leading to a level of process unpredictability and complexity where “everything, everywhere, all at once” applies. Success hinges on scientific acumen and attention to even the smallest detail, from raw materials to equipment parameters, to ensure patient safety and product quality.
  • Pioneering in Uncharted Territory: Moving from London to Singapore, Lucas faced not just technical but regulatory and logistical challenges to founding Asia-Pacific’s first CDMO dedicated to viral vectors. His advice: engage regulators early, leverage local biomanufacturing strengths, and build multidisciplinary teams to transfer and scale bioprocess know-how.

Curious how viral vector manufacturing can be reimagined to unlock the full promise of cell and gene therapies? Listen to this episode and gain unique insights into the science, strategy, and sheer determination needed to bring advanced therapies out of the lab and into the clinic.

Connect with Lucas Chan:

LinkedIn: www.linkedin.com/in/lucaschangt

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Preparing for your IND? We’re building a CMC Dashboard in Excel to help biotech founders track tasks, timelines, and risks in one place. Join the waitlist for early access at https://scale-your-impact.notion.site/27dd9c6ba679804b80a7ce439d56c91a?pvs=105

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Viral vectors are the backbone of cutting-edge cell and gene therapies, delivering life-altering treatments to patients with genetic diseases. But making these biological delivery vehicles is a high-wire act: unpredictable, complex, and fraught with hurdles that traditional biologics manufacturers have never faced.

While the world races toward next-generation therapies, the challenge of producing viral vectors at clinical and commercial scale threatens to leave patients waiting on the sidelines.

Our guest on the Smart Biotech Scientist Podcast is Lucas Chan, a molecular and cell biologist with over two decades of hands-on experience in cell and gene therapy development. From his formative research at Imperial College London, where he pioneered novel viral vector cell lines, to building the UK’s first GMP clinical viral vector core and later founding CellVec Pte Ltd Asia Pacific CDMO in Singapore, Lucas is the go-to architect for manufacturing viral vectors where infrastructure barely exists.

Along the way, he’s faced and overcome challenges few others could imagine.

Here are three reasons this episode is a must-listen:

  • Viral Vectors Demystified: Lucas breaks down a common misconception: viral vectors aren’t malignant viruses, but genetically disarmed delivery vehicles that can’t revert or replicate, making them safe tools for gene therapy.
  • Manufacturing Mayhem Made Manageable: Unlike monoclonal antibodies and other biologics, viral vectors (and other cell and gene therapies) are made in living cells, leading to a level of process unpredictability and complexity where “everything, everywhere, all at once” applies. Success hinges on scientific acumen and attention to even the smallest detail, from raw materials to equipment parameters, to ensure patient safety and product quality.
  • Pioneering in Uncharted Territory: Moving from London to Singapore, Lucas faced not just technical but regulatory and logistical challenges to founding Asia-Pacific’s first CDMO dedicated to viral vectors. His advice: engage regulators early, leverage local biomanufacturing strengths, and build multidisciplinary teams to transfer and scale bioprocess know-how.

Curious how viral vector manufacturing can be reimagined to unlock the full promise of cell and gene therapies? Listen to this episode and gain unique insights into the science, strategy, and sheer determination needed to bring advanced therapies out of the lab and into the clinic.

Connect with Lucas Chan:

LinkedIn: www.linkedin.com/in/lucaschangt

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Preparing for your IND? We’re building a CMC Dashboard in Excel to help biotech founders track tasks, timelines, and risks in one place. Join the waitlist for early access at https://scale-your-impact.notion.site/27dd9c6ba679804b80a7ce439d56c91a?pvs=105

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17885740 Tue, 30 Sep 2025 05:00:00 +0200 1699 193 full false 192: Process Intensification Secrets: A Process Engineer's Decision Framework with Andreas Castan - Part 2 192: Process Intensification Secrets: A Process Engineer's Decision Framework with Andreas Castan - Part 2 Is continuous manufacturing delivering the transformative results everyone promised, or are you being sold an expensive solution to the wrong problem? While industry headlines tout revolutionary productivity gains, the economic reality behind continuous bioprocessing tells a more nuanced story that every process engineer needs to understand before making capital investment decisions.

In this episode, host David Brühlmann continues his conversation with Andreas Castan, Strategic Technology and Business Development Leader at Cytiva, diving deep into the hard economics and operational realities of next-generation manufacturing strategies. Andreas brings over 25 years of bioprocess expertise from upstream innovation to cGMP manufacturing scale-up.

Here are three critical takeaways from this conversation:

  • Continuous vs Fed-Batch Economics Are Closer Than Expected: Andreas reveals real process economic modeling data showing that while continuous reduces capital costs through smaller bioreactors and facilities, higher media consumption (20-25% of COGS) and operational complexity often balance out the savings. The deciding factor isn't technology elegance but your specific production volume and pipeline needs.
  • Regulatory Approval Isn't Easier Despite FDA Support: Even with regulatory enthusiasm for continuous processing, QA teams still demand the same fundamentals: traceability, batch definition, viral clearance validation, and process characterization. The technology choice should be driven by your business case, not regulatory preferences.
  • Sustainability Benefits Are Modest: Contrary to industry hype, Andreas shares findings showing continuous manufacturing delivers only 20% carbon footprint reduction compared to optimized fed-batch. Real environmental gains come from HVAC efficiency and smaller cleanroom footprints, not inherent process advantages.

Ready to cut through the marketing noise and make data-driven manufacturing decisions? This conversation delivers the unvarnished truth about when continuous processing creates real value and when intensified fed-batch might be your smartest investment.

Connect with Andreas Castan:

LinkedIn: www.linkedin.com/in/andreas-castan-91570b1

Cytiva landing page: Process intensification

Online tool: Process intensifier

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Preparing for your IND? We’re building a CMC Dashboard in Excel to help biotech founders track tasks, timelines, and risks in one place. Join the waitlist for early access at https://scale-your-impact.notion.site/27dd9c6ba679804b80a7ce439d56c91a?pvs=105

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Is continuous manufacturing delivering the transformative results everyone promised, or are you being sold an expensive solution to the wrong problem? While industry headlines tout revolutionary productivity gains, the economic reality behind continuous bioprocessing tells a more nuanced story that every process engineer needs to understand before making capital investment decisions.

In this episode, host David Brühlmann continues his conversation with Andreas Castan, Strategic Technology and Business Development Leader at Cytiva, diving deep into the hard economics and operational realities of next-generation manufacturing strategies. Andreas brings over 25 years of bioprocess expertise from upstream innovation to cGMP manufacturing scale-up.

Here are three critical takeaways from this conversation:

  • Continuous vs Fed-Batch Economics Are Closer Than Expected: Andreas reveals real process economic modeling data showing that while continuous reduces capital costs through smaller bioreactors and facilities, higher media consumption (20-25% of COGS) and operational complexity often balance out the savings. The deciding factor isn't technology elegance but your specific production volume and pipeline needs.
  • Regulatory Approval Isn't Easier Despite FDA Support: Even with regulatory enthusiasm for continuous processing, QA teams still demand the same fundamentals: traceability, batch definition, viral clearance validation, and process characterization. The technology choice should be driven by your business case, not regulatory preferences.
  • Sustainability Benefits Are Modest: Contrary to industry hype, Andreas shares findings showing continuous manufacturing delivers only 20% carbon footprint reduction compared to optimized fed-batch. Real environmental gains come from HVAC efficiency and smaller cleanroom footprints, not inherent process advantages.

Ready to cut through the marketing noise and make data-driven manufacturing decisions? This conversation delivers the unvarnished truth about when continuous processing creates real value and when intensified fed-batch might be your smartest investment.

Connect with Andreas Castan:

LinkedIn: www.linkedin.com/in/andreas-castan-91570b1

Cytiva landing page: Process intensification

Online tool: Process intensifier

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Preparing for your IND? We’re building a CMC Dashboard in Excel to help biotech founders track tasks, timelines, and risks in one place. Join the waitlist for early access at https://scale-your-impact.notion.site/27dd9c6ba679804b80a7ce439d56c91a?pvs=105

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17808340 Thu, 25 Sep 2025 05:00:00 +0200 1131 192 full false 191: Process Intensification Secrets: A Process Engineer's Decision Framework with Andreas Castan - Part 1 191: Process Intensification Secrets: A Process Engineer's Decision Framework with Andreas Castan - Part 1 What if process intensification could transform your bioprocessing economics without the complexity most engineers fear? Getting 3x productivity gains and 30-150% titer increases once seemed reserved for Big Pharma's endless R&D budgets, but a strategic approach to technology selection is making these results achievable for companies of any size.

In this episode, David Brühlmann speaks with Andreas Castan, a bioprocess veteran with over 25 years of industry experience who provides leadership and support to Cytiva's bioprocess business. Andreas brings deep expertise from directing upstream development at Swedish Orphan Biovitrum and extensive work in expression systems, process development, scale-up, and cGMP manufacturing across multiple therapeutic modalities.

Why tune in? Here's your process engineer's roadmap:

  • Process Intensification Economics Decoded: Andreas reveals the cost-benefit reality behind continuous vs fed-batch manufacturing, including real process economic modeling data showing why the differences aren't as dramatic as you'd expect and what factors actually drive your business case.
  • Low-Hanging Fruit That Delivers: Skip the overhyped AI solutions. Andreas shares the strategic fundamentals that work: high-producing cell line development, N-1 perfusion for rapid productivity gains, and smart bioreactor turndown strategies that eliminate process steps without adding complexity.
  • Decision Framework for Technology Selection: Learn when continuous processing makes economic sense (and when it doesn't), how media costs impact your COGS analysis, and why understanding your bottlenecks, not following industry trends, should drive your intensification strategy.
  • Industry Insider Strategies: Get the inside track on what AstraZeneca, Sanofi, Merck, Lonza, and Takeda are actually implementing, plus Andreas's perspective on why human expertise and mechanistic insights still outweigh AI in real-world process decisions.

Ready to make smarter technology investments and achieve measurable productivity gains? This isn't theory. It's a practical guide to process intensification economics that you can apply whether you're preparing for Phase I or scaling for commercial manufacturing.

Connect with Andreas Castan:

LinkedIn: www.linkedin.com/in/andreas-castan-91570b1

Cytiva landing page: Process intensification

Online tool: Process intensifier

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Preparing for your IND? We’re building a CMC Dashboard in Excel to help biotech founders track tasks, timelines, and risks in one place. Join the waitlist for early access at https://scale-your-impact.notion.site/27dd9c6ba679804b80a7ce439d56c91a?pvs=105

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> What if process intensification could transform your bioprocessing economics without the complexity most engineers fear? Getting 3x productivity gains and 30-150% titer increases once seemed reserved for Big Pharma's endless R&D budgets, but a strategic approach to technology selection is making these results achievable for companies of any size.

In this episode, David Brühlmann speaks with Andreas Castan, a bioprocess veteran with over 25 years of industry experience who provides leadership and support to Cytiva's bioprocess business. Andreas brings deep expertise from directing upstream development at Swedish Orphan Biovitrum and extensive work in expression systems, process development, scale-up, and cGMP manufacturing across multiple therapeutic modalities.

Why tune in? Here's your process engineer's roadmap:

  • Process Intensification Economics Decoded: Andreas reveals the cost-benefit reality behind continuous vs fed-batch manufacturing, including real process economic modeling data showing why the differences aren't as dramatic as you'd expect and what factors actually drive your business case.
  • Low-Hanging Fruit That Delivers: Skip the overhyped AI solutions. Andreas shares the strategic fundamentals that work: high-producing cell line development, N-1 perfusion for rapid productivity gains, and smart bioreactor turndown strategies that eliminate process steps without adding complexity.
  • Decision Framework for Technology Selection: Learn when continuous processing makes economic sense (and when it doesn't), how media costs impact your COGS analysis, and why understanding your bottlenecks, not following industry trends, should drive your intensification strategy.
  • Industry Insider Strategies: Get the inside track on what AstraZeneca, Sanofi, Merck, Lonza, and Takeda are actually implementing, plus Andreas's perspective on why human expertise and mechanistic insights still outweigh AI in real-world process decisions.

Ready to make smarter technology investments and achieve measurable productivity gains? This isn't theory. It's a practical guide to process intensification economics that you can apply whether you're preparing for Phase I or scaling for commercial manufacturing.

Connect with Andreas Castan:

LinkedIn: www.linkedin.com/in/andreas-castan-91570b1

Cytiva landing page: Process intensification

Online tool: Process intensifier

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Preparing for your IND? We’re building a CMC Dashboard in Excel to help biotech founders track tasks, timelines, and risks in one place. Join the waitlist for early access at https://scale-your-impact.notion.site/27dd9c6ba679804b80a7ce439d56c91a?pvs=105

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17808322 Tue, 23 Sep 2025 05:00:00 +0200 1224 191 full false 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later) - Part 2 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later) - Part 2 Still think you can "figure out CMC later"? Your competitors just implemented a systematic framework that cuts their IND timeline in half while you're still debating whether CMC matters.

The founders who file INDs predictably aren't smarter than you. They just stopped gambling with ad-hoc CMC approaches and started executing proven systems. While you're wrestling with technical details in crisis mode, they built systematic advantages that turn regulatory complexity into competitive weapons.

In this episode, host David Brühlmann delivers the complete five-step framework that transforms CMC from startup-killer into market advantage. This isn't theory. These are the exact systematic approaches helping founders file INDs in 10-12 months while competitors struggle with preventable delays.

The strategic reality: Systematic CMC isn't about becoming a technical expert. It's about becoming strategically smart about expert partnerships and execution frameworks. Smart founders focus on "WHO not HOW," building the right team while maintaining strategic control.

Three key takeaways that will transform your approach:

  • Start Early, Think Strategically: Early, deliberate CMC planning isn't just for big pharma. Linking your product's clinical goals to quality, process, and regulatory milestones from day one eliminates expensive delays later. Smart founders build systematic CMC advantages while competitors treat it as an afterthought.
  • Quality by Design as Competitive Weapon: Pinpointing critical quality attributes and mapping them to real patient outcomes creates scientific credibility that accelerates every downstream decision. This isn't regulatory box-checking. This is building the foundation that impresses investors, satisfies regulators, and prevents costly manufacturing surprises.
  • Systematic Risk Management as Submission Insurance: A living, well-documented risk register can be the difference between confident IND filing and regulatory rejection. Poor risk tracking is cited by FDA and EMA as a recurring deficiency that leads to clinical holds and expensive delays. Don't become the cautionary tale.

This five-step framework creates predictable execution that transforms CMC from crisis management into strategic capability. Instead of reacting to problems, you prevent them. Rather than scrambling under pressure, you scale smoothly from development to commercialization.

Ready to bring structure and confidence to your own CMC program? Explore David’s CMC dashboard via the link below , and catch his walkthrough to see the system in action.

Solid CMC execution starts with the right conversation.

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Preparing for your IND? We’re building a CMC Dashboard in Excel to help biotech founders track tasks, timelines, and risks in one place. Join the waitlist for early access at https://scale-your-impact.notion.site/27dd9c6ba679804b80a7ce439d56c91a?pvs=105

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Still think you can "figure out CMC later"? Your competitors just implemented a systematic framework that cuts their IND timeline in half while you're still debating whether CMC matters.

The founders who file INDs predictably aren't smarter than you. They just stopped gambling with ad-hoc CMC approaches and started executing proven systems. While you're wrestling with technical details in crisis mode, they built systematic advantages that turn regulatory complexity into competitive weapons.

In this episode, host David Brühlmann delivers the complete five-step framework that transforms CMC from startup-killer into market advantage. This isn't theory. These are the exact systematic approaches helping founders file INDs in 10-12 months while competitors struggle with preventable delays.

The strategic reality: Systematic CMC isn't about becoming a technical expert. It's about becoming strategically smart about expert partnerships and execution frameworks. Smart founders focus on "WHO not HOW," building the right team while maintaining strategic control.

Three key takeaways that will transform your approach:

  • Start Early, Think Strategically: Early, deliberate CMC planning isn't just for big pharma. Linking your product's clinical goals to quality, process, and regulatory milestones from day one eliminates expensive delays later. Smart founders build systematic CMC advantages while competitors treat it as an afterthought.
  • Quality by Design as Competitive Weapon: Pinpointing critical quality attributes and mapping them to real patient outcomes creates scientific credibility that accelerates every downstream decision. This isn't regulatory box-checking. This is building the foundation that impresses investors, satisfies regulators, and prevents costly manufacturing surprises.
  • Systematic Risk Management as Submission Insurance: A living, well-documented risk register can be the difference between confident IND filing and regulatory rejection. Poor risk tracking is cited by FDA and EMA as a recurring deficiency that leads to clinical holds and expensive delays. Don't become the cautionary tale.

This five-step framework creates predictable execution that transforms CMC from crisis management into strategic capability. Instead of reacting to problems, you prevent them. Rather than scrambling under pressure, you scale smoothly from development to commercialization.

Ready to bring structure and confidence to your own CMC program? Explore David’s CMC dashboard via the link below , and catch his walkthrough to see the system in action.

Solid CMC execution starts with the right conversation.

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Preparing for your IND? We’re building a CMC Dashboard in Excel to help biotech founders track tasks, timelines, and risks in one place. Join the waitlist for early access at https://scale-your-impact.notion.site/27dd9c6ba679804b80a7ce439d56c91a?pvs=105

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17825749 Thu, 18 Sep 2025 05:00:00 +0200 1075 190 full false 189: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later) - Part 1 189: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later) - Part 1 Think you can crack the science first and worry about CMC when you "need it"? That's exactly how promising therapies die in regulatory limbo while patients keep waiting.

Your breakthrough discovery means nothing if it's trapped in CMC chaos. While you're perfecting your molecular mechanism, competitors with inferior science but superior CMC strategy are racing past you to IND filing and ultimately, to patients.

In this episode, I, David Brühlmann, your usual host, expose the dangerous delusion that's quietly bankrupting biotech startups: the belief that brilliant science automatically translates to successful drug development. Drawing from years of watching founders burn through millions because they treated CMC as an afterthought, I reveal why the smartest scientific minds often make the most catastrophic business decisions.

Here's the hard truth you'll confront in this episode:

  • The $50M Misconception: Why "CMC is just manufacturing" thinking destroys companies before they ever reach Phase II. While you're debating molecular targets, smart founders are building systematic CMC advantages that compress timelines and slash costs. The FDA doesn't care how elegant your science is if you can't demonstrate consistent, scalable manufacturing.
  • The Brutal Mathematics of Delay: Systematic CMC approach: 10-12 months to IND, 85% hit timelines. "Figure it out later" approach: 15 months or more, and a much lower success rate. Every month you delay isn't just burning cash. If your therapy could help 10,000 patients annually, that's 833 people per month who don't get treatment because of preventable delays.
  • Three Founder Myths That Kill Programs: The misconceptions about CMC being "basically just manufacturing," bringing in experts "when we need them," and CDMOs handling "the complicated stuff." Each myth leads to the same outcome: brilliant science trapped by business incompetence.
  • Your Four-Action Emergency Protocol: Stop hoping CMC will work out. Start implementing systematic approaches. I give you four specific actions to execute this week, not someday when you're "ready," but right now while you can still prevent the crisis that kills 40% of biotech programs.

The competitive reality: While you're listening to this episode, your biggest competitor just moved closer to IND filing. Maybe they completed process validation. Maybe they locked in analytical methods. The question isn't whether CMC matters. It's whether you'll master it before your competitors do.

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Preparing for your IND? We’re building a CMC Dashboard in Excel to help biotech founders track tasks, timelines, and risks in one place. Join the waitlist for early access at https://scale-your-impact.notion.site/27dd9c6ba679804b80a7ce439d56c91a?pvs=105

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Think you can crack the science first and worry about CMC when you "need it"? That's exactly how promising therapies die in regulatory limbo while patients keep waiting.

Your breakthrough discovery means nothing if it's trapped in CMC chaos. While you're perfecting your molecular mechanism, competitors with inferior science but superior CMC strategy are racing past you to IND filing and ultimately, to patients.

In this episode, I, David Brühlmann, your usual host, expose the dangerous delusion that's quietly bankrupting biotech startups: the belief that brilliant science automatically translates to successful drug development. Drawing from years of watching founders burn through millions because they treated CMC as an afterthought, I reveal why the smartest scientific minds often make the most catastrophic business decisions.

Here's the hard truth you'll confront in this episode:

  • The $50M Misconception: Why "CMC is just manufacturing" thinking destroys companies before they ever reach Phase II. While you're debating molecular targets, smart founders are building systematic CMC advantages that compress timelines and slash costs. The FDA doesn't care how elegant your science is if you can't demonstrate consistent, scalable manufacturing.
  • The Brutal Mathematics of Delay: Systematic CMC approach: 10-12 months to IND, 85% hit timelines. "Figure it out later" approach: 15 months or more, and a much lower success rate. Every month you delay isn't just burning cash. If your therapy could help 10,000 patients annually, that's 833 people per month who don't get treatment because of preventable delays.
  • Three Founder Myths That Kill Programs: The misconceptions about CMC being "basically just manufacturing," bringing in experts "when we need them," and CDMOs handling "the complicated stuff." Each myth leads to the same outcome: brilliant science trapped by business incompetence.
  • Your Four-Action Emergency Protocol: Stop hoping CMC will work out. Start implementing systematic approaches. I give you four specific actions to execute this week, not someday when you're "ready," but right now while you can still prevent the crisis that kills 40% of biotech programs.

The competitive reality: While you're listening to this episode, your biggest competitor just moved closer to IND filing. Maybe they completed process validation. Maybe they locked in analytical methods. The question isn't whether CMC matters. It's whether you'll master it before your competitors do.

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Preparing for your IND? We’re building a CMC Dashboard in Excel to help biotech founders track tasks, timelines, and risks in one place. Join the waitlist for early access at https://scale-your-impact.notion.site/27dd9c6ba679804b80a7ce439d56c91a?pvs=105

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17825739 Tue, 16 Sep 2025 05:00:00 +0200 912 189 full false 188: From Biology Is Messy to Designable: The Smart Bioprocessing Transformation with Carmen Jungo Rhême - Part 2 188: From Biology Is Messy to Designable: The Smart Bioprocessing Transformation with Carmen Jungo Rhême - Part 2 For too long, biotech innovators have viewed biological systems as inherently messy, unpredictable, and full of “black box” mysteries. But what if, armed with the latest digital tools, AI, and cross-disciplinary thinking, you could transform bioprocessing from a series of trial-and-error experiments to a streamlined, proactive design process?

Carmen Jungo Rhême is Full Professor at the University of Applied Sciences in Fribourg (HEIA-FR) and Director of the Biofactory Competence Center (BCC). With 17 years in the pharmaceutical industry at companies like Lonza, Merck Serono, UCB Farchim, and CSL Behring, she specializes in bioprocess development, protein purification, scale-up, and technology transfer. Since joining HEIA-FR in late 2023, she has launched research projects tackling antimicrobial resistance, sustainable food production, and bioprocess digitalization.

Here are three reasons why this episode is a must-listen:

  • A Blueprint for Scalable Bioprocessing: Carmen reveals the structured, four-phase approach the BCC uses to help startups and established companies alike, from feasibility and risk assessment, to scalable process design, tailored analytics, and seamless tech transfer to GMP manufacturing.
  • The Future-Proof Skill Set: Discover why data management, digital tool adaptability, and systems thinking are non-negotiable skills for biotech professionals in the next five years and how both newcomers and seasoned scientists can level up.
  • Bioprocessing as Design, Not Chaos: Learn how shifting your mindset from reactive to proactive, and from “biology is messy” to “biology is designable,” can unlock robust processes, faster innovation, and truly sustainable solutions.

Ready to smarten up your biotech game? Listen in as Carmen and David unpack practical, actionable strategies for mastering modern bioprocessing—no matter your starting point.

Connect with Carmen Jungo Rhême:

LinkedIn: www.linkedin.com/in/carmenjungo

Website: www.heia-fr.ch/en/applied-research/bcc/

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> For too long, biotech innovators have viewed biological systems as inherently messy, unpredictable, and full of “black box” mysteries. But what if, armed with the latest digital tools, AI, and cross-disciplinary thinking, you could transform bioprocessing from a series of trial-and-error experiments to a streamlined, proactive design process?

Carmen Jungo Rhême is Full Professor at the University of Applied Sciences in Fribourg (HEIA-FR) and Director of the Biofactory Competence Center (BCC). With 17 years in the pharmaceutical industry at companies like Lonza, Merck Serono, UCB Farchim, and CSL Behring, she specializes in bioprocess development, protein purification, scale-up, and technology transfer. Since joining HEIA-FR in late 2023, she has launched research projects tackling antimicrobial resistance, sustainable food production, and bioprocess digitalization.

Here are three reasons why this episode is a must-listen:

  • A Blueprint for Scalable Bioprocessing: Carmen reveals the structured, four-phase approach the BCC uses to help startups and established companies alike, from feasibility and risk assessment, to scalable process design, tailored analytics, and seamless tech transfer to GMP manufacturing.
  • The Future-Proof Skill Set: Discover why data management, digital tool adaptability, and systems thinking are non-negotiable skills for biotech professionals in the next five years and how both newcomers and seasoned scientists can level up.
  • Bioprocessing as Design, Not Chaos: Learn how shifting your mindset from reactive to proactive, and from “biology is messy” to “biology is designable,” can unlock robust processes, faster innovation, and truly sustainable solutions.

Ready to smarten up your biotech game? Listen in as Carmen and David unpack practical, actionable strategies for mastering modern bioprocessing—no matter your starting point.

Connect with Carmen Jungo Rhême:

LinkedIn: www.linkedin.com/in/carmenjungo

Website: www.heia-fr.ch/en/applied-research/bcc/

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17754387 Thu, 11 Sep 2025 05:00:00 +0200 1428 188 full false 187: From Biology Is Messy to Designable: The Smart Bioprocessing Transformation with Carmen Jungo Rhême - Part 1 187: From Biology Is Messy to Designable: The Smart Bioprocessing Transformation with Carmen Jungo Rhême - Part 1 Almost every corner of modern medicine and sustainable food production today is facing a massive challenge: how do we outpace drug-resistant “superbugs” and create food for a growing population using fewer resources? The answer, it turns out, may come down to how well we understand and control the biomanufacturing processes underpinning these biomaterials and biomolecules.

In this episode, David Brühlmann speaks with Carmen Jungo Rhême, Full Professor at the University of Applied Sciences in Fribourg, Switzerland and Director of the Biofactory Competence Center. With years in the pharmaceutical industry at Lonza, Merck Serono, UCB Farchim, and CSL Behring, she now tackles global challenges like antimicrobial resistance, sustainable food, and digitalization. From her beginnings in chemical engineering at EPFL to leading at the nexus of academia and industry, Carmen is helping shape the future of smarter, more robust biotech.

Here are three reasons why this episode is a must-listen:

  • Antimicrobial Resistance - Smarter Solutions: Carmen explains how phage therapy, recombinant proteins like endolysins, and smart bioprocess design are helping outmanoeuvre drug-resistant pathogens. In partnership with the University Hospital in Lausanne, her team is developing GMP-ready phage production using quality-by-design methods from mainstream recombinant protein manufacturing, bringing phages back into clinical relevance.
  • From Cheese Whey to Microalgae: Applying pharma-grade principles to food, BCC is turning Swiss cheese by-products into nutrient-rich microalgae, offering a new path for sustainable protein and lipid production while transforming food waste into valuable resources.
  • Digitalization - The Connecting Thread: Mapping and controlling hundreds of process parameters is key to robust, reproducible innovation. Carmen shows how data-driven process characterization links antimicrobial strategies and sustainable food production through the power of digital analytics.

Curious about how smarter bioprocesses could help you solve tomorrow’s biggest biotech challenges? Tune in to hear how Carmen’s approach could transform your perspective on both health and food security.

Connect with Carmen Jungo Rhême:

LinkedIn: www.linkedin.com/in/carmenjungo

Website: www.heia-fr.ch/en/applied-research/bcc/

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Almost every corner of modern medicine and sustainable food production today is facing a massive challenge: how do we outpace drug-resistant “superbugs” and create food for a growing population using fewer resources? The answer, it turns out, may come down to how well we understand and control the biomanufacturing processes underpinning these biomaterials and biomolecules.

In this episode, David Brühlmann speaks with Carmen Jungo Rhême, Full Professor at the University of Applied Sciences in Fribourg, Switzerland and Director of the Biofactory Competence Center. With years in the pharmaceutical industry at Lonza, Merck Serono, UCB Farchim, and CSL Behring, she now tackles global challenges like antimicrobial resistance, sustainable food, and digitalization. From her beginnings in chemical engineering at EPFL to leading at the nexus of academia and industry, Carmen is helping shape the future of smarter, more robust biotech.

Here are three reasons why this episode is a must-listen:

  • Antimicrobial Resistance - Smarter Solutions: Carmen explains how phage therapy, recombinant proteins like endolysins, and smart bioprocess design are helping outmanoeuvre drug-resistant pathogens. In partnership with the University Hospital in Lausanne, her team is developing GMP-ready phage production using quality-by-design methods from mainstream recombinant protein manufacturing, bringing phages back into clinical relevance.
  • From Cheese Whey to Microalgae: Applying pharma-grade principles to food, BCC is turning Swiss cheese by-products into nutrient-rich microalgae, offering a new path for sustainable protein and lipid production while transforming food waste into valuable resources.
  • Digitalization - The Connecting Thread: Mapping and controlling hundreds of process parameters is key to robust, reproducible innovation. Carmen shows how data-driven process characterization links antimicrobial strategies and sustainable food production through the power of digital analytics.

Curious about how smarter bioprocesses could help you solve tomorrow’s biggest biotech challenges? Tune in to hear how Carmen’s approach could transform your perspective on both health and food security.

Connect with Carmen Jungo Rhême:

LinkedIn: www.linkedin.com/in/carmenjungo

Website: www.heia-fr.ch/en/applied-research/bcc/

Next step:

Book a 20-minute call to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17754371 Tue, 09 Sep 2025 05:00:00 +0200 1227 187 full false 186: How Generative AI Accelerates Protein Design for Biotech Discovery with Elise de Reus - Part 2 186: How Generative AI Accelerates Protein Design for Biotech Discovery with Elise de Reus - Part 2 Imagine unlocking a world where designing custom proteins is not only feasible - but faster, smarter, and more powerful than ever before, thanks to artificial intelligence.

As the promise of programmable biology takes center stage, AI-driven protein engineering is rapidly moving from theoretical dream to industry standard.

In this episode, David Brühlmann sits down with Elise de Reus, co-founder of Cradle, whose ground-breaking platform has become a go-to for luminaries at pharma giants, as well as leaders in agriculture and industrial biotech. Elise’s journey bridges hands-on scientific discovery with entrepreneurial vision, and she’s on a mission to make biology a foundational pillar of a more sustainable and equitable world.

Here are three reasons you can’t miss this episode:

  • AI Unmasks the Black Box: Elise explains how Cradle’s platform isn’t just about predictive power - it offers transparency and actionable insights, allowing scientists to see why models perform as they do, and how to interpret and trust their outputs.
  • From Hype to Real-World Impact: You’ll hear real examples of AI accelerating everything from pandemic preparedness and antivenom development, to sustainable raw materials - plus candid advice on scaling AI adoption across diverse project teams.
  • Blueprints for Biotech Founders: Elise shares hard-won lessons on transforming scientific innovation into a thriving company, including the counterintuitive power of targeting “mission impossible” challenges and the priceless value of early, unfiltered feedback.

Ready to future-proof your protein engineering with generative AI? Press play to take home Elise’s practical framework for evaluating tools, overcoming organizational hurdles, and crafting a winning adoption strategy, before the innovation curve pulls away.

Wondering how Generative AI is transforming the biotech landscape? From accelerating regulatory workflows to reinventing protein purification, AI is driving breakthroughs across the industry. Explore these standout episodes to hear from experts leading the charge:

  • Episodes 77-78: Cell Factories Explained: How Synthetic Biology and AI Revolutionize Protein Production with Mauro Torres
  • Episodes 119-120: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian Guo
  • Episodes 123-124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein
  • Episodes 167-168: How Generative AI Is Revolutionizing Biotech Regulatory Compliance with Abhijeet Satwekar

Connect with Elise de Reus:

LinkedIn: www.linkedin.com/in/elise-de-reus-77b83a24

Website: www.cradle.bio

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

🧬 Ready to eliminate CMC chaos and hit your IND timeline with absolute certainty? Get the complete Notion CMC Dashboard at https://stan.store/SmartBiotech/p/cmc-dashboard-for-biotech-founders - the proven roadmap that's guided successful mAb programs to hit their IND submission deadlines.

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Imagine unlocking a world where designing custom proteins is not only feasible - but faster, smarter, and more powerful than ever before, thanks to artificial intelligence.

As the promise of programmable biology takes center stage, AI-driven protein engineering is rapidly moving from theoretical dream to industry standard.

In this episode, David Brühlmann sits down with Elise de Reus, co-founder of Cradle, whose ground-breaking platform has become a go-to for luminaries at pharma giants, as well as leaders in agriculture and industrial biotech. Elise’s journey bridges hands-on scientific discovery with entrepreneurial vision, and she’s on a mission to make biology a foundational pillar of a more sustainable and equitable world.

Here are three reasons you can’t miss this episode:

  • AI Unmasks the Black Box: Elise explains how Cradle’s platform isn’t just about predictive power - it offers transparency and actionable insights, allowing scientists to see why models perform as they do, and how to interpret and trust their outputs.
  • From Hype to Real-World Impact: You’ll hear real examples of AI accelerating everything from pandemic preparedness and antivenom development, to sustainable raw materials - plus candid advice on scaling AI adoption across diverse project teams.
  • Blueprints for Biotech Founders: Elise shares hard-won lessons on transforming scientific innovation into a thriving company, including the counterintuitive power of targeting “mission impossible” challenges and the priceless value of early, unfiltered feedback.

Ready to future-proof your protein engineering with generative AI? Press play to take home Elise’s practical framework for evaluating tools, overcoming organizational hurdles, and crafting a winning adoption strategy, before the innovation curve pulls away.

Wondering how Generative AI is transforming the biotech landscape? From accelerating regulatory workflows to reinventing protein purification, AI is driving breakthroughs across the industry. Explore these standout episodes to hear from experts leading the charge:

  • Episodes 77-78: Cell Factories Explained: How Synthetic Biology and AI Revolutionize Protein Production with Mauro Torres
  • Episodes 119-120: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian Guo
  • Episodes 123-124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein
  • Episodes 167-168: How Generative AI Is Revolutionizing Biotech Regulatory Compliance with Abhijeet Satwekar

Connect with Elise de Reus:

LinkedIn: www.linkedin.com/in/elise-de-reus-77b83a24

Website: www.cradle.bio

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

🧬 Ready to eliminate CMC chaos and hit your IND timeline with absolute certainty? Get the complete Notion CMC Dashboard at https://stan.store/SmartBiotech/p/cmc-dashboard-for-biotech-founders - the proven roadmap that's guided successful mAb programs to hit their IND submission deadlines.

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17676506 Thu, 04 Sep 2025 05:00:00 +0200 1001 186 full false 185: How Generative AI Accelerates Protein Design for Biotech Discovery with Elise de Reus - Part 1 185: How Generative AI Accelerates Protein Design for Biotech Discovery with Elise de Reus - Part 1 For decades, protein design has hinged on painstaking rounds of wet lab mutagenesis and trial-and-error, a process limited not by human ingenuity, but by time and complexity. Yet as the biotech field seeks faster, greener, and more effective solutions for therapeutics and industrial applications, the next leap might not come solely from the lab bench.

In this episode, host David Brühlmann explores the frontiers of AI-driven protein engineering with Elise de Reus, co-founder of Cradle. Elise’s journey weaves together a passion for DNA, real-world impact from the dairy industry to synthetic biology, and high-throughput experience at Zymergen. Now, at the helm of Cradle, she is bridging cutting-edge computational models with experimental validation, making biology programmable and accelerating the path from idea to functional protein.

Here are three reasons this episode is essential listening:

  • AI Makes Biology Programmable: Generative AI platforms like Cradle can intelligently design protein variants by learning from evolutionary trends and your own project data, enabling smarter, faster iterations and optimizing for stability, activity, and manufacturability - simultaneously.
  • Limited Data? No Problem: While traditional approaches have stumbled over small, “short and fat” datasets, new generative AI models can effectively update their understanding with as little as a 96-well plate per round, democratizing high-impact protein design for startups, academia, and industry alike.
  • The Future is Human + Machine: Even as algorithms advance, Elise stresses the irreplaceable value of wet lab validation. Cradle’s hybrid approach, integrating experimental feedback with algorithmic prediction, ensures reliable, scalable results and empowers multidisciplinary teams to unlock first- and best-in-class solutions.

Want to see how you can leverage AI to simplify and accelerate your own protein engineering projects? Don’t miss this episode to hear how Elise and Cradle are transforming the pace - and possibilities - of biotech.

Curious how Generative AI is reshaping biotech? From streamlining regulatory compliance to transforming protein purification, AI is changing the game. Dive into these standout episodes to explore the cutting edge of innovation in biotech:

  • Episodes 77-78: Cell Factories Explained: How Synthetic Biology and AI Revolutionize Protein Production with Mauro Torres
  • Episodes 119-120: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian Guo
  • Episodes 123-124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein
  • Episodes 167-168: How Generative AI Is Revolutionizing Biotech Regulatory Compliance with Abhijeet Satwekar

Connect with Elise de Reus:

LinkedIn: www.linkedin.com/in/elise-de-reus-77b83a24

Website: www.cradle.bio

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

🧬 Ready to eliminate CMC chaos and hit your IND timeline with absolute certainty? Get the complete Notion CMC Dashboard at https://stan.store/SmartBiotech/p/cmc-dashboard-for-biotech-founders - the proven roadmap that's guided successful mAb programs to hit their IND submission deadlines.

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> For decades, protein design has hinged on painstaking rounds of wet lab mutagenesis and trial-and-error, a process limited not by human ingenuity, but by time and complexity. Yet as the biotech field seeks faster, greener, and more effective solutions for therapeutics and industrial applications, the next leap might not come solely from the lab bench.

In this episode, host David Brühlmann explores the frontiers of AI-driven protein engineering with Elise de Reus, co-founder of Cradle. Elise’s journey weaves together a passion for DNA, real-world impact from the dairy industry to synthetic biology, and high-throughput experience at Zymergen. Now, at the helm of Cradle, she is bridging cutting-edge computational models with experimental validation, making biology programmable and accelerating the path from idea to functional protein.

Here are three reasons this episode is essential listening:

  • AI Makes Biology Programmable: Generative AI platforms like Cradle can intelligently design protein variants by learning from evolutionary trends and your own project data, enabling smarter, faster iterations and optimizing for stability, activity, and manufacturability - simultaneously.
  • Limited Data? No Problem: While traditional approaches have stumbled over small, “short and fat” datasets, new generative AI models can effectively update their understanding with as little as a 96-well plate per round, democratizing high-impact protein design for startups, academia, and industry alike.
  • The Future is Human + Machine: Even as algorithms advance, Elise stresses the irreplaceable value of wet lab validation. Cradle’s hybrid approach, integrating experimental feedback with algorithmic prediction, ensures reliable, scalable results and empowers multidisciplinary teams to unlock first- and best-in-class solutions.

Want to see how you can leverage AI to simplify and accelerate your own protein engineering projects? Don’t miss this episode to hear how Elise and Cradle are transforming the pace - and possibilities - of biotech.

Curious how Generative AI is reshaping biotech? From streamlining regulatory compliance to transforming protein purification, AI is changing the game. Dive into these standout episodes to explore the cutting edge of innovation in biotech:

  • Episodes 77-78: Cell Factories Explained: How Synthetic Biology and AI Revolutionize Protein Production with Mauro Torres
  • Episodes 119-120: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian Guo
  • Episodes 123-124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein
  • Episodes 167-168: How Generative AI Is Revolutionizing Biotech Regulatory Compliance with Abhijeet Satwekar

Connect with Elise de Reus:

LinkedIn: www.linkedin.com/in/elise-de-reus-77b83a24

Website: www.cradle.bio

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

🧬 Ready to eliminate CMC chaos and hit your IND timeline with absolute certainty? Get the complete Notion CMC Dashboard at https://stan.store/SmartBiotech/p/cmc-dashboard-for-biotech-founders - the proven roadmap that's guided successful mAb programs to hit their IND submission deadlines.

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17676477 Tue, 02 Sep 2025 05:00:00 +0200 1423 185 full false 184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee Ho - Part 2 184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee Ho - Part 2 What’s the secret to turning a cutting-edge scientific breakthrough into a commercial biotech success?

For every inspiring lab discovery, countless prototypes stall before ever reaching the market. The barriers? Securing the right beta testers, outmanoeuvring industry giants, and building teams who understand not just the science, but the user experience from bench to bedside.

In this episode of the Smart Biotech Scientist Podcast, David Brühlmann welcomes Chervee Ho, CEO & Co-Founder of BioChromatographix International. Chervee isn’t just developing breakthrough column technologies - she’s navigating the trenches of commercialization, from resource-stretched startups to partnering with risk-averse manufacturers. With hands-on experience turning innovative science into robust data and real-world adoption, Chervee shares candid lessons from her journey building a biotech company from the ground up.

Here are three reasons you can’t miss this episode:

  • From Lab Bench to Market: Learn why finding the right beta testing partner is less about luck and more about networking, shared goals, and mutual resource investment - and why a methodical, step-by-step approach beats wishful thinking every time.
  • Winning Against the Big Players: Discover how niche focus, third-party validation, and scientific partnership allow startups like BioChromatographix International to carve out space - even when competing against chromatography industry giants.
  • The Human Factor: Chervee reveals why startup success is all about mindset - resilience, adaptability, and startup “muscle” - far more than specific credentials. If you want to build a team ready for the marathon of commercialization, don’t miss these culture insights.

Ready to level up your biotech commercialization strategy? Tune in and hear how to accelerate your technology from concept to clinic - without losing focus, funds, or your sanity.

Connect with Chervee Ho:

LinkedIn: www.linkedin.com/in/cherveeho

Website: www.biochromatographix.com

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

Speaking of innovative tools to solve bioprocess development challenges, we're building an AI platform that transforms CMC overwhelm into predictable development success (launching early 2026). Join the waitlist here: https://david-jkhjdoje.scoreapp.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> What’s the secret to turning a cutting-edge scientific breakthrough into a commercial biotech success?

For every inspiring lab discovery, countless prototypes stall before ever reaching the market. The barriers? Securing the right beta testers, outmanoeuvring industry giants, and building teams who understand not just the science, but the user experience from bench to bedside.

In this episode of the Smart Biotech Scientist Podcast, David Brühlmann welcomes Chervee Ho, CEO & Co-Founder of BioChromatographix International. Chervee isn’t just developing breakthrough column technologies - she’s navigating the trenches of commercialization, from resource-stretched startups to partnering with risk-averse manufacturers. With hands-on experience turning innovative science into robust data and real-world adoption, Chervee shares candid lessons from her journey building a biotech company from the ground up.

Here are three reasons you can’t miss this episode:

  • From Lab Bench to Market: Learn why finding the right beta testing partner is less about luck and more about networking, shared goals, and mutual resource investment - and why a methodical, step-by-step approach beats wishful thinking every time.
  • Winning Against the Big Players: Discover how niche focus, third-party validation, and scientific partnership allow startups like BioChromatographix International to carve out space - even when competing against chromatography industry giants.
  • The Human Factor: Chervee reveals why startup success is all about mindset - resilience, adaptability, and startup “muscle” - far more than specific credentials. If you want to build a team ready for the marathon of commercialization, don’t miss these culture insights.

Ready to level up your biotech commercialization strategy? Tune in and hear how to accelerate your technology from concept to clinic - without losing focus, funds, or your sanity.

Connect with Chervee Ho:

LinkedIn: www.linkedin.com/in/cherveeho

Website: www.biochromatographix.com

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

Speaking of innovative tools to solve bioprocess development challenges, we're building an AI platform that transforms CMC overwhelm into predictable development success (launching early 2026). Join the waitlist here: https://david-jkhjdoje.scoreapp.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17651954 Thu, 28 Aug 2025 05:00:00 +0200 1109 184 full false 183: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee Ho - Part 1 183: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee Ho - Part 1 Every year, cutting-edge biomedical technologies are left stranded in the lab, not for lack of innovation, but because they miss the crucial leap from technical performance to genuine industry adoption. The gap between scientific brilliance and commercial success is deceptively simple: deeply understanding and building for your customer’s real-world pain points.

In this episode, David Brühlmann welcomes Chervee Ho, CEO & Co-Founder of BioChromatographix International. With a background at the intersection of biotechnology and commercial strategy, Chervee has helped reshape how startups approach product development to actually get adopted in conservative markets. From her early days in biotech to launching Singapore’s next-generation monolithic chromatography company, Chervee advocates for honest conversations, real customer feedback, and an unflinching commitment to building solutions that people want - not just what scientists think they need.

Here are three reasons you can’t afford to miss this conversation:

  • Commercial Thinking from Day One: Technical superiority is just the start; Chervee reveals how embedding commercial strategy from the earliest stages, long before the product is ‘perfect’, ensures your innovation will actually be used. Start with end-user needs and map backward.
  • Designing for Adoption, Not Just Performance: Don’t fall in love with your tech. Discover how BioChromatographix adopted a customer-centric “design for adoption” approach, integrating products into current workflows, minimizing disruption, and collecting real-life feedback that shaped commercial-ready solutions.
  • Bridging the Science-to-Market Divide: Learn how continuous customer engagement, ruthless validation of pain points, and smart use of public data (even while protecting IP) can transform a great idea into a market-ready, trust-building product.

Ready to close the gap between invention and adoption? Tune in to discover why commercial thinking isn’t just for the sales team and how it’s the secret weapon for any biotech scientist wanting to make a lasting impact.

Don’t just innovate - get your technology into the hands of those who need it most.

Connect with Chervee Ho:

LinkedIn: www.linkedin.com/in/cherveeho

Website: www.biochromatographix.com

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

Speaking of innovative tools to solve bioprocess development challenges, we're building an AI platform that transforms CMC overwhelm into predictable development success (launching early 2026). Join the waitlist here: https://david-jkhjdoje.scoreapp.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Every year, cutting-edge biomedical technologies are left stranded in the lab, not for lack of innovation, but because they miss the crucial leap from technical performance to genuine industry adoption. The gap between scientific brilliance and commercial success is deceptively simple: deeply understanding and building for your customer’s real-world pain points.

In this episode, David Brühlmann welcomes Chervee Ho, CEO & Co-Founder of BioChromatographix International. With a background at the intersection of biotechnology and commercial strategy, Chervee has helped reshape how startups approach product development to actually get adopted in conservative markets. From her early days in biotech to launching Singapore’s next-generation monolithic chromatography company, Chervee advocates for honest conversations, real customer feedback, and an unflinching commitment to building solutions that people want - not just what scientists think they need.

Here are three reasons you can’t afford to miss this conversation:

  • Commercial Thinking from Day One: Technical superiority is just the start; Chervee reveals how embedding commercial strategy from the earliest stages, long before the product is ‘perfect’, ensures your innovation will actually be used. Start with end-user needs and map backward.
  • Designing for Adoption, Not Just Performance: Don’t fall in love with your tech. Discover how BioChromatographix adopted a customer-centric “design for adoption” approach, integrating products into current workflows, minimizing disruption, and collecting real-life feedback that shaped commercial-ready solutions.
  • Bridging the Science-to-Market Divide: Learn how continuous customer engagement, ruthless validation of pain points, and smart use of public data (even while protecting IP) can transform a great idea into a market-ready, trust-building product.

Ready to close the gap between invention and adoption? Tune in to discover why commercial thinking isn’t just for the sales team and how it’s the secret weapon for any biotech scientist wanting to make a lasting impact.

Don’t just innovate - get your technology into the hands of those who need it most.

Connect with Chervee Ho:

LinkedIn: www.linkedin.com/in/cherveeho

Website: www.biochromatographix.com

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

Speaking of innovative tools to solve bioprocess development challenges, we're building an AI platform that transforms CMC overwhelm into predictable development success (launching early 2026). Join the waitlist here: https://david-jkhjdoje.scoreapp.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17651940 Tue, 26 Aug 2025 05:00:00 +0200 1442 183 full false 182: Innovating Continuous Bioprocessing with Vibrating Membrane Filtration with Jarno Robin - Part 2 182: Innovating Continuous Bioprocessing with Vibrating Membrane Filtration with Jarno Robin - Part 2 What if the secret to making continuous bioprocessing practical, sustainable, and far simpler has been shaking - literally - just beneath our feet?

For years, the industry has grappled with the complexities of continuous manufacturing, with technologies like ATF (alternating tangential flow) steadily dominating the perfusion landscape. But what if there's a game-changer right around the corner - a technology that vibrates membranes, not workflows, promising both higher performance and a greener footprint?

Enter Jarno Robin, a pioneering force in membrane filtration and Pharma Business Development Director at Sani Membranes. With two decades of experience implementing ATF and championing continuous innovation in bioprocessing, Jarno isn’t just speculating about change—he’s building it. In this episode, host David Brühlmann gets hands-on with Jarno as they unpack Sani’s patented Vibro Membrane Filtration (VMF) technology and its bold promise to transform upstream and downstream bioprocessing.

Here are three reasons you can’t afford to miss this conversation:

  • Vibration Over Crossflow: Sani’s VMF system shakes up conventional wisdom by using vibration to generate turbulence, achieving uniform transmembrane pressure, reducing cell damage, and enabling robust, scalable separations across applications from mAbs to cultivated meat and even challenging mRNA workflows.
  • Seamless Tech Swap (and Sustainability): Transitioning from ATF or TFF to VMF? Jarno explains how the setup is surprisingly straightforward, requires fewer connections at scale, dramatically cuts chemical use, and can slash your environmental footprint, as membranes last years instead of months.
  • Innovation Demands Resilience: Beyond equipment specs, Jarno pulls back the curtain on what it really takes to drive innovation in pharma: relentless belief, hours of extra work, and the patience to let good data - and internal advocates - build momentum for change.

Ready to see bioprocessing through a new lens? Tune in to discover how vibrating membranes may help you simplify your CMC development pipeline, reduce waste, and position your organization for a more continuous, efficient future.

Connect with Jarno Robin:

LinkedIn: www.linkedin.com/in/jarno-robin

Website: www.sanimembranes.com

Curious about continuous processing challenges and breakthroughs? Don’t miss these previous episodes.

  • Episodes 39-40: Balancing Perfusion Process Development and Sustainability with Jochen Sieck
  • Episodes 85-86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli
  • Episodes 153-154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

🧬 Ready to eliminate CMC chaos and hit your IND timeline with absolute certainty? Get the complete Notion CMC Dashboard at https://stan.store/SmartBiotech/p/cmc-dashboard-for-biotech-founders - the proven roadmap that's guided successful mAb programs to hit their IND submission deadlines.

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> What if the secret to making continuous bioprocessing practical, sustainable, and far simpler has been shaking - literally - just beneath our feet?

For years, the industry has grappled with the complexities of continuous manufacturing, with technologies like ATF (alternating tangential flow) steadily dominating the perfusion landscape. But what if there's a game-changer right around the corner - a technology that vibrates membranes, not workflows, promising both higher performance and a greener footprint?

Enter Jarno Robin, a pioneering force in membrane filtration and Pharma Business Development Director at Sani Membranes. With two decades of experience implementing ATF and championing continuous innovation in bioprocessing, Jarno isn’t just speculating about change—he’s building it. In this episode, host David Brühlmann gets hands-on with Jarno as they unpack Sani’s patented Vibro Membrane Filtration (VMF) technology and its bold promise to transform upstream and downstream bioprocessing.

Here are three reasons you can’t afford to miss this conversation:

  • Vibration Over Crossflow: Sani’s VMF system shakes up conventional wisdom by using vibration to generate turbulence, achieving uniform transmembrane pressure, reducing cell damage, and enabling robust, scalable separations across applications from mAbs to cultivated meat and even challenging mRNA workflows.
  • Seamless Tech Swap (and Sustainability): Transitioning from ATF or TFF to VMF? Jarno explains how the setup is surprisingly straightforward, requires fewer connections at scale, dramatically cuts chemical use, and can slash your environmental footprint, as membranes last years instead of months.
  • Innovation Demands Resilience: Beyond equipment specs, Jarno pulls back the curtain on what it really takes to drive innovation in pharma: relentless belief, hours of extra work, and the patience to let good data - and internal advocates - build momentum for change.

Ready to see bioprocessing through a new lens? Tune in to discover how vibrating membranes may help you simplify your CMC development pipeline, reduce waste, and position your organization for a more continuous, efficient future.

Connect with Jarno Robin:

LinkedIn: www.linkedin.com/in/jarno-robin

Website: www.sanimembranes.com

Curious about continuous processing challenges and breakthroughs? Don’t miss these previous episodes.

  • Episodes 39-40: Balancing Perfusion Process Development and Sustainability with Jochen Sieck
  • Episodes 85-86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli
  • Episodes 153-154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

🧬 Ready to eliminate CMC chaos and hit your IND timeline with absolute certainty? Get the complete Notion CMC Dashboard at https://stan.store/SmartBiotech/p/cmc-dashboard-for-biotech-founders - the proven roadmap that's guided successful mAb programs to hit their IND submission deadlines.

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17628942 Thu, 21 Aug 2025 05:00:00 +0200 972 182 full false 181: Innovating Continuous Bioprocessing with Vibrating Membrane Filtration with Jarno Robin - Part 1 181: Innovating Continuous Bioprocessing with Vibrating Membrane Filtration with Jarno Robin - Part 1 What if one of biotech’s biggest production breakthroughs was hiding in plain sight? Not in a new gene or a wonder drug, but in the way we process and purify biologics.

Perfusion technology, once dismissed as a pipedream in top biopharma boardrooms, is now quietly powering some of the industry’s most efficient and productive manufacturing platforms. Yet, transforming perfusion from controversial buzzword to gold standard required timing, vision, and a willingness to break from tradition.

In this episode, host David Brühlmann sits down with Jarno Robin, a bioprocessing pioneer whose 20+ year journey spans industry giants like Novo Nordisk, Sanofi, and Leo Pharma. Jarno has championed upstream continuous processes, including ATF and TFF, for decades, and now, as a leader at Sani Membranes, he’s unleashing the next evolution: Vibro® Membrane Filtration, an innovation set to upend conventional wisdom about fouling, pressure loss, scalability, energy usage, and more.

Here are three reasons you’ll want to listen to Jarno’s journey:

  • Innovation Versus Industry Inertia: Behind every platform shift are years of resistance. Jarno recounts how timing, advocacy, and matching the right data with the right decision-makers finally made perfusion mainstream, even after company leaders proclaimed, “We will never ever run perfusion.”
  • State-of-the-Art and the Next Frontier: ATF and TFF remain dominant, but their limitations, like membrane fouling, scale-up headaches, and high energy needs, are real. Jarno explains how Vibro® Membrane Filtration addresses these pain points with a radically new design, offering lower pressure loss, less fouling, higher cell densities, and surprisingly low energy consumption.
  • Practical Wisdom for Bioprocess Developers: Should you always run a control in process development? How do you translate lab-scale wins to robust, money-earning production? Jarno shares counterintuitive advice based on decades of hands-on success and mistakes.

Curious how you can optimize your process technology and sidestep costly pitfalls? Listen to this episode and discover how “timing is everything” in bioprocessing innovation and whether new filtration methods could help you leap ahead.

Connect with Jarno Robin:

LinkedIn: www.linkedin.com/in/jarno-robin

Website: www.sanimembranes.com

Curious about continuous processing challenges and breakthroughs? Don’t miss these previous episodes.

  • Episodes 39-40: Balancing Perfusion Process Development and Sustainability with Jochen Sieck
  • Episodes 85-86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli
  • Episodes 153-154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

🧬 Ready to eliminate CMC chaos and hit your IND timeline with absolute certainty? Get the complete Notion CMC Dashboard at https://stan.store/SmartBiotech/p/cmc-dashboard-for-biotech-founders

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> What if one of biotech’s biggest production breakthroughs was hiding in plain sight? Not in a new gene or a wonder drug, but in the way we process and purify biologics.

Perfusion technology, once dismissed as a pipedream in top biopharma boardrooms, is now quietly powering some of the industry’s most efficient and productive manufacturing platforms. Yet, transforming perfusion from controversial buzzword to gold standard required timing, vision, and a willingness to break from tradition.

In this episode, host David Brühlmann sits down with Jarno Robin, a bioprocessing pioneer whose 20+ year journey spans industry giants like Novo Nordisk, Sanofi, and Leo Pharma. Jarno has championed upstream continuous processes, including ATF and TFF, for decades, and now, as a leader at Sani Membranes, he’s unleashing the next evolution: Vibro® Membrane Filtration, an innovation set to upend conventional wisdom about fouling, pressure loss, scalability, energy usage, and more.

Here are three reasons you’ll want to listen to Jarno’s journey:

  • Innovation Versus Industry Inertia: Behind every platform shift are years of resistance. Jarno recounts how timing, advocacy, and matching the right data with the right decision-makers finally made perfusion mainstream, even after company leaders proclaimed, “We will never ever run perfusion.”
  • State-of-the-Art and the Next Frontier: ATF and TFF remain dominant, but their limitations, like membrane fouling, scale-up headaches, and high energy needs, are real. Jarno explains how Vibro® Membrane Filtration addresses these pain points with a radically new design, offering lower pressure loss, less fouling, higher cell densities, and surprisingly low energy consumption.
  • Practical Wisdom for Bioprocess Developers: Should you always run a control in process development? How do you translate lab-scale wins to robust, money-earning production? Jarno shares counterintuitive advice based on decades of hands-on success and mistakes.

Curious how you can optimize your process technology and sidestep costly pitfalls? Listen to this episode and discover how “timing is everything” in bioprocessing innovation and whether new filtration methods could help you leap ahead.

Connect with Jarno Robin:

LinkedIn: www.linkedin.com/in/jarno-robin

Website: www.sanimembranes.com

Curious about continuous processing challenges and breakthroughs? Don’t miss these previous episodes.

  • Episodes 39-40: Balancing Perfusion Process Development and Sustainability with Jochen Sieck
  • Episodes 85-86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli
  • Episodes 153-154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

🧬 Ready to eliminate CMC chaos and hit your IND timeline with absolute certainty? Get the complete Notion CMC Dashboard at https://stan.store/SmartBiotech/p/cmc-dashboard-for-biotech-founders

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17628933 Tue, 19 Aug 2025 05:00:00 +0200 1493 181 full false 180: How Mesenchymal Stromal Cells Are Transforming Care for Diabetes and Autoimmune Diseases with Lindsay Davies - Part 2 180: How Mesenchymal Stromal Cells Are Transforming Care for Diabetes and Autoimmune Diseases with Lindsay Davies - Part 2 The promise of advanced cell therapies is undeniable, but as demand skyrockets, the challenges of taking a living drug from bench to bedside have never been greater. Each batch brings variability, each jurisdiction adds regulatory hurdles, and every strategic decision can determine whether a lifesaving therapy reaches patients or fizzles out behind clinical barriers.

Lindsay Davies is a leading figure in the cell and gene therapy field, serving as Vice President-Elect for Europe at the International Society of Cell and Gene Therapy (ISCT). She is Chief Scientific Officer at NextCell Pharma, co-founder of QVance, and founder of the consultancy CellTherEx. With over 20 years of experience across academia and industry, she brings deep expertise in MSC manufacturing, process development, and commercialization of advanced therapies. Here are three reasons this episode is a must-listen:

  • Manufacturing at Scale, Without Compromise: Lindsay shares why NextCell Pharma has stuck with large-scale 2D manufacturing for MSCs, leveraging cell morphology and a patented donor selection algorithm to reduce batch-to-batch variability while maximizing reproducibility and safety, even when treating hundreds from a single batch.
  • Smart Scaling: Up, Out, or Both? The debate isn’t just academic. Lindsay explores when it makes sense to scale up processes versus scaling out to multiple manufacturing sites. She highlights how harmonizing global regulatory expectations and moving to closed 2D systems can lower costs, de-risk production, and bring life-changing therapies to more patients worldwide.
  • Network or Nowhere: Lindsay calls out the myth of the lone innovator, championing the crucial role of strategic networking, partnership models, including “sweat equity”, and early regulatory engagement as keys to avoiding the common commercialization pitfalls that stall so many promising ATMPs.

Wondering how to navigate the twin challenges of process control and commercial viability in ATMP development? This episode offers a rare, candid roadmap from the front lines.

Connect with Lindsay Davis:

LinkedIn: www.linkedin.com/in/lindsay-c-davies

Website: www.nextcellpharma.com

If you're interested in breakthroughs in cell therapy, here's what some of our previous guests have shared from the front lines of innovation:

  • Episodes 105-106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer
  • Episodes 109-110: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier Detournay
  • Episodes 125-126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

🧬 Ready to eliminate CMC chaos and hit your IND timeline with absolute certainty? Get the complete Notion CMC Dashboard at https://stan.store/SmartBiotech/p/cmc-dashboard-for-biotech-founders - the proven roadmap that's guided successful mAb programs to hit their IND submission deadlines.

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> The promise of advanced cell therapies is undeniable, but as demand skyrockets, the challenges of taking a living drug from bench to bedside have never been greater. Each batch brings variability, each jurisdiction adds regulatory hurdles, and every strategic decision can determine whether a lifesaving therapy reaches patients or fizzles out behind clinical barriers.

Lindsay Davies is a leading figure in the cell and gene therapy field, serving as Vice President-Elect for Europe at the International Society of Cell and Gene Therapy (ISCT). She is Chief Scientific Officer at NextCell Pharma, co-founder of QVance, and founder of the consultancy CellTherEx. With over 20 years of experience across academia and industry, she brings deep expertise in MSC manufacturing, process development, and commercialization of advanced therapies. Here are three reasons this episode is a must-listen:

  • Manufacturing at Scale, Without Compromise: Lindsay shares why NextCell Pharma has stuck with large-scale 2D manufacturing for MSCs, leveraging cell morphology and a patented donor selection algorithm to reduce batch-to-batch variability while maximizing reproducibility and safety, even when treating hundreds from a single batch.
  • Smart Scaling: Up, Out, or Both? The debate isn’t just academic. Lindsay explores when it makes sense to scale up processes versus scaling out to multiple manufacturing sites. She highlights how harmonizing global regulatory expectations and moving to closed 2D systems can lower costs, de-risk production, and bring life-changing therapies to more patients worldwide.
  • Network or Nowhere: Lindsay calls out the myth of the lone innovator, championing the crucial role of strategic networking, partnership models, including “sweat equity”, and early regulatory engagement as keys to avoiding the common commercialization pitfalls that stall so many promising ATMPs.

Wondering how to navigate the twin challenges of process control and commercial viability in ATMP development? This episode offers a rare, candid roadmap from the front lines.

Connect with Lindsay Davis:

LinkedIn: www.linkedin.com/in/lindsay-c-davies

Website: www.nextcellpharma.com

If you're interested in breakthroughs in cell therapy, here's what some of our previous guests have shared from the front lines of innovation:

  • Episodes 105-106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer
  • Episodes 109-110: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier Detournay
  • Episodes 125-126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

🧬 Ready to eliminate CMC chaos and hit your IND timeline with absolute certainty? Get the complete Notion CMC Dashboard at https://stan.store/SmartBiotech/p/cmc-dashboard-for-biotech-founders - the proven roadmap that's guided successful mAb programs to hit their IND submission deadlines.

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17628930 Thu, 14 Aug 2025 05:00:00 +0200 1560 180 full false 179: How Mesenchymal Stromal Cells Are Transforming Care for Diabetes and Autoimmune Diseases with Lindsay Davies - Part 1 179: How Mesenchymal Stromal Cells Are Transforming Care for Diabetes and Autoimmune Diseases with Lindsay Davies - Part 1 The key to conquering autoimmune diseases and type 1 diabetes may lie not in replacing lost cells, but in retraining the immune system using cells already within the body.

Biotech is increasingly exploring stem cell therapies, but a quieter revolution is brewing: stromal cell therapy. These master “coordinators” aren’t about rebuilding tissues molecule by molecule - instead, they orchestrate an anti-inflammatory response, offering new hope for conditions once considered incurable.

In this episode of the Smart Biotech Scientist Podcast, host David Brühlmann speaks with Lindsay Davies, a leading expert in advanced therapies. She is the CSO at NextCell Pharma, consultant at CellTherEx, and co-founder of QVance, a QC analytics provider for ATMPs. Recently elected Vice President Elect for Europe at ISCT, Lindsay also chairs its European Industry Committee and serves on multiple task forces. With over 20 years bridging academia and industry, she’s helped shape the full lifecycle of cell-based therapies, from development to commercialization.

Here are three reasons why you can’t miss this episode:

  • Stromal Cells - The Unsung Heroes: Discover the essential distinction between stem cells (the “builders”) and stromal cells (the “coordinators”), and how harnessing the latter’s unique immune-modulatory powers is unlocking treatments for diabetes, COVID-19, and autoimmune diseases.
  • A Manufacturing Mindset Shift: Lindsay explains why scaling out cell therapies defies the “plug-and-play” approaches of traditional biologics manufacturing. With cell quality so sensitive to environmental shifts, the key lies in process simplicity, early regulatory collaboration, and deep biological understanding - especially when donor variability enters the mix.
  • Allogeneic Therapies Made Real: Thanks to umbilical cord-derived stromal cells, treatments can be manufactured at scale, stored frozen, and delivered on demand - no patient matching required. The result? Outpatient infusions, no side effects, and effects lasting up to five years, dramatically simplifying lives for those with chronic inflammatory conditions.

Ready to rethink how cell therapies are changing medicine - and what it could mean for your bioprocessing strategy? Hit play and find out how Lindsay Davis is redefining what’s possible in advanced therapy manufacturing.

Connect with Lindsay Davis:

LinkedIn: www.linkedin.com/in/lindsay-c-davies

Website: www.nextcellpharma.com

If you're interested in breakthroughs in cell therapy, here's what some of our previous guests have shared from the front lines of innovation:

  • Episodes 105-106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer
  • Episodes 109-110: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier Detournay
  • Episodes 125-126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

🧬 Ready to eliminate CMC chaos and hit your IND timeline with absolute certainty? Get the complete Notion CMC Dashboard at https://stan.store/SmartBiotech/p/cmc-dashboard-for-biotech-founders - the proven roadmap that's guided successful mAb programs to hit their IND submission deadlines.

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> The key to conquering autoimmune diseases and type 1 diabetes may lie not in replacing lost cells, but in retraining the immune system using cells already within the body.

Biotech is increasingly exploring stem cell therapies, but a quieter revolution is brewing: stromal cell therapy. These master “coordinators” aren’t about rebuilding tissues molecule by molecule - instead, they orchestrate an anti-inflammatory response, offering new hope for conditions once considered incurable.

In this episode of the Smart Biotech Scientist Podcast, host David Brühlmann speaks with Lindsay Davies, a leading expert in advanced therapies. She is the CSO at NextCell Pharma, consultant at CellTherEx, and co-founder of QVance, a QC analytics provider for ATMPs. Recently elected Vice President Elect for Europe at ISCT, Lindsay also chairs its European Industry Committee and serves on multiple task forces. With over 20 years bridging academia and industry, she’s helped shape the full lifecycle of cell-based therapies, from development to commercialization.

Here are three reasons why you can’t miss this episode:

  • Stromal Cells - The Unsung Heroes: Discover the essential distinction between stem cells (the “builders”) and stromal cells (the “coordinators”), and how harnessing the latter’s unique immune-modulatory powers is unlocking treatments for diabetes, COVID-19, and autoimmune diseases.
  • A Manufacturing Mindset Shift: Lindsay explains why scaling out cell therapies defies the “plug-and-play” approaches of traditional biologics manufacturing. With cell quality so sensitive to environmental shifts, the key lies in process simplicity, early regulatory collaboration, and deep biological understanding - especially when donor variability enters the mix.
  • Allogeneic Therapies Made Real: Thanks to umbilical cord-derived stromal cells, treatments can be manufactured at scale, stored frozen, and delivered on demand - no patient matching required. The result? Outpatient infusions, no side effects, and effects lasting up to five years, dramatically simplifying lives for those with chronic inflammatory conditions.

Ready to rethink how cell therapies are changing medicine - and what it could mean for your bioprocessing strategy? Hit play and find out how Lindsay Davis is redefining what’s possible in advanced therapy manufacturing.

Connect with Lindsay Davis:

LinkedIn: www.linkedin.com/in/lindsay-c-davies

Website: www.nextcellpharma.com

If you're interested in breakthroughs in cell therapy, here's what some of our previous guests have shared from the front lines of innovation:

  • Episodes 105-106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer
  • Episodes 109-110: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier Detournay
  • Episodes 125-126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

🧬 Ready to eliminate CMC chaos and hit your IND timeline with absolute certainty? Get the complete Notion CMC Dashboard at https://stan.store/SmartBiotech/p/cmc-dashboard-for-biotech-founders - the proven roadmap that's guided successful mAb programs to hit their IND submission deadlines.

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17628899 Tue, 12 Aug 2025 05:00:00 +0200 1361 179 full false 178: Rethinking Cultivated Meat Production: Scale and Media Optimization Strategies Slashing Manufacturing Costs with Richard Alldread - Part 2 178: Rethinking Cultivated Meat Production: Scale and Media Optimization Strategies Slashing Manufacturing Costs with Richard Alldread - Part 2 The promise of cultured food is undeniable: delicious, sustainable meat and fish grown without the need for traditional farming. But the journey from lab bench to supermarket shelf is filled with complex regulatory, technological, and consumer acceptance challenges. The big question: how do we transform small-scale breakthroughs into global food production realities?

In this episode of the Smart Biotech Scientist Podcast, host David Brühlmann sits down with Richard Alldread, CTO of The Cultured Hub - a unique joint venture between Givaudan, Bühler, and Migros - positioned at the intersection of flavor, food processing, and retail expertise.

Richard Alldread has led process and technology development across the biopharmaceutical sector, with roles at major biotech corporations and brings decades of experience from the biopharma world into the food tech sphere, helping innovative startups bridge the gap from promising lab results to economically and technically scalable food products.

Here are three reasons to keep listening:

  • Scaling Up, Not Just Out: Richard exposes why many food startups stumble: overly complex, non-scalable processes and the misapplication of biopharma’s single-use equipment. Instead, the food industry is reigniting interest in robust stainless steel facilities to meet the vastly greater scale and lower margins of food versus pharma.
  • From Bench to Market: The Cultured Hub isn’t just about tanks and tech; it’s a one-stop shop where startups gain hands-on access to commercial-scale bioreactors, regulatory expertise, and direct links to the whole value chain, from flavor development to supermarket shelves.
  • Consumer Acceptance Is (Still) King: No matter how flawless the process or affordable the meat, Richard emphasizes that success hinges on consumer adoption. The industry’s greatest test isn’t technological, it’s shifting perceptions of cultured foods to turn curiosity into routine repeat purchases.

Ready to hear what it really takes to transition cultured food from niche curiosity to supermarket staple? Dive into this episode and discover the hard truths, emerging solutions, and industry insights driving the next food revolution.

Connect with Richard Alldread:

LinkedIn: www.linkedin.com/in/richard-alldread-01923644

Website: www.theculturedhub.com

Want to hear more perspectives on the future of cell-based food? Don’t miss these previous episodes:

  • Episodes 55-56: Cultivated Meat: A Promising Future or an Inevitable Bubble? with Steven Lang
  • Episodes 45-46: From Lab to Table: The Science Behind Cultivated Meat with Petra Hanga
  • Episodes 15-16: Bacon Without Pigs? Innovations in Cultivated Meat Manufacturing with Beat Thalmann

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

🧬 Ready to eliminate CMC chaos and hit your IND timeline with absolute certainty? Get the complete Notion CMC Dashboard at https://stan.store/SmartBiotech/p/cmc-dashboard-for-biotech-founders - the proven CMC roadmap for IND submission.

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> The promise of cultured food is undeniable: delicious, sustainable meat and fish grown without the need for traditional farming. But the journey from lab bench to supermarket shelf is filled with complex regulatory, technological, and consumer acceptance challenges. The big question: how do we transform small-scale breakthroughs into global food production realities?

In this episode of the Smart Biotech Scientist Podcast, host David Brühlmann sits down with Richard Alldread, CTO of The Cultured Hub - a unique joint venture between Givaudan, Bühler, and Migros - positioned at the intersection of flavor, food processing, and retail expertise.

Richard Alldread has led process and technology development across the biopharmaceutical sector, with roles at major biotech corporations and brings decades of experience from the biopharma world into the food tech sphere, helping innovative startups bridge the gap from promising lab results to economically and technically scalable food products.

Here are three reasons to keep listening:

  • Scaling Up, Not Just Out: Richard exposes why many food startups stumble: overly complex, non-scalable processes and the misapplication of biopharma’s single-use equipment. Instead, the food industry is reigniting interest in robust stainless steel facilities to meet the vastly greater scale and lower margins of food versus pharma.
  • From Bench to Market: The Cultured Hub isn’t just about tanks and tech; it’s a one-stop shop where startups gain hands-on access to commercial-scale bioreactors, regulatory expertise, and direct links to the whole value chain, from flavor development to supermarket shelves.
  • Consumer Acceptance Is (Still) King: No matter how flawless the process or affordable the meat, Richard emphasizes that success hinges on consumer adoption. The industry’s greatest test isn’t technological, it’s shifting perceptions of cultured foods to turn curiosity into routine repeat purchases.

Ready to hear what it really takes to transition cultured food from niche curiosity to supermarket staple? Dive into this episode and discover the hard truths, emerging solutions, and industry insights driving the next food revolution.

Connect with Richard Alldread:

LinkedIn: www.linkedin.com/in/richard-alldread-01923644

Website: www.theculturedhub.com

Want to hear more perspectives on the future of cell-based food? Don’t miss these previous episodes:

  • Episodes 55-56: Cultivated Meat: A Promising Future or an Inevitable Bubble? with Steven Lang
  • Episodes 45-46: From Lab to Table: The Science Behind Cultivated Meat with Petra Hanga
  • Episodes 15-16: Bacon Without Pigs? Innovations in Cultivated Meat Manufacturing with Beat Thalmann

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

🧬 Ready to eliminate CMC chaos and hit your IND timeline with absolute certainty? Get the complete Notion CMC Dashboard at https://stan.store/SmartBiotech/p/cmc-dashboard-for-biotech-founders - the proven CMC roadmap for IND submission.

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17500718 Thu, 07 Aug 2025 05:00:00 +0200 1213 178 full false 177: Rethinking Cultivated Meat Production: Scale and Media Optimization Strategies Slashing Manufacturing Costs with Richard Alldread - Part 1 177: Rethinking Cultivated Meat Production: Scale and Media Optimization Strategies Slashing Manufacturing Costs with Richard Alldread - Part 1 What if the secrets to feeding the planet - and democratizing access to future protein - were hiding in the core toolkit of biopharma?

The worlds of biopharmaceuticals and cultured food may seem galaxies apart, but at their heart, both rely on remarkably similar technology: media, bioreactors, and cell processing. Yet, as demand grows for sustainable, affordable protein for the masses, innovators are confronting a challenge bigger than scale.

This week, host David Brühlmann welcomes Richard Alldread, Chief Technology Officer at The Cultured Hub, a groundbreaking joint venture between three Swiss industry leaders that specializes in developing and scaling cell culture processes for cultivated foods.

Most of Richard’s career has been dedicated to leading process and technology development initiatives within the biopharmaceutical industry. He has held key roles at major biotech organizations. He now leads the charge in applying high-tech bioprocessing to the ultimate scale-up: cultivated food. His journey from pioneering life-saving biologics to reimagining food production offers a rare insider’s view of biotech’s next frontier.

Here are three reasons you can’t miss this episode:

  • Bioprocessing’s Universal Blueprint: Richard breaks down the striking similarities between pharmaceuticals and food - media, bioreactors, sterility - but reveals why the economics and scale make cultivated food an entirely new beast.
  • From Clinic to Kitchen: Discover how the shift from producing grams of life-saving drugs for the West to tons of affordable protein for global tables flips traditional priorities, pushing innovation in cost reduction, media development, and facility design.
  • The Art of Keeping it Simple: Richard shares a contrarian philosophy: the best processes need fewer high-tech analytics, not more. He weighs in on where digital tools, modeling, and even AI fit into building robust, scalable bioprocesses for the food industry.

Curious about how the lessons of biopharma might feed the world? Dive into this episode to uncover the biggest technical, economic, and biological hurdles - and why the next big leap in bioprocessing may end up on our dinner plates.

Connect with Richard Alldread:

LinkedIn: www.linkedin.com/in/richard-alldread-01923644

Website: www.theculturedhub.com

Want to hear more perspectives on the future of cell-based food? Don’t miss these previous episodes:

  • Episodes 55-56: Cultivated Meat: A Promising Future or an Inevitable Bubble? with Steven Lang
  • Episodes 45-46: From Lab to Table: The Science Behind Cultivated Meat with Petra Hanga
  • Episodes 15-16: Bacon Without Pigs? Innovations in Cultivated Meat Manufacturing with Beat Thalmann

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

🧬 Ready to eliminate CMC chaos and hit your IND timeline with absolute certainty? Get the complete Notion CMC Dashboard at https://stan.store/SmartBiotech/p/cmc-dashboard-for-biotech-founders - the proven CMC roadmap for IND submission.

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> What if the secrets to feeding the planet - and democratizing access to future protein - were hiding in the core toolkit of biopharma?

The worlds of biopharmaceuticals and cultured food may seem galaxies apart, but at their heart, both rely on remarkably similar technology: media, bioreactors, and cell processing. Yet, as demand grows for sustainable, affordable protein for the masses, innovators are confronting a challenge bigger than scale.

This week, host David Brühlmann welcomes Richard Alldread, Chief Technology Officer at The Cultured Hub, a groundbreaking joint venture between three Swiss industry leaders that specializes in developing and scaling cell culture processes for cultivated foods.

Most of Richard’s career has been dedicated to leading process and technology development initiatives within the biopharmaceutical industry. He has held key roles at major biotech organizations. He now leads the charge in applying high-tech bioprocessing to the ultimate scale-up: cultivated food. His journey from pioneering life-saving biologics to reimagining food production offers a rare insider’s view of biotech’s next frontier.

Here are three reasons you can’t miss this episode:

  • Bioprocessing’s Universal Blueprint: Richard breaks down the striking similarities between pharmaceuticals and food - media, bioreactors, sterility - but reveals why the economics and scale make cultivated food an entirely new beast.
  • From Clinic to Kitchen: Discover how the shift from producing grams of life-saving drugs for the West to tons of affordable protein for global tables flips traditional priorities, pushing innovation in cost reduction, media development, and facility design.
  • The Art of Keeping it Simple: Richard shares a contrarian philosophy: the best processes need fewer high-tech analytics, not more. He weighs in on where digital tools, modeling, and even AI fit into building robust, scalable bioprocesses for the food industry.

Curious about how the lessons of biopharma might feed the world? Dive into this episode to uncover the biggest technical, economic, and biological hurdles - and why the next big leap in bioprocessing may end up on our dinner plates.

Connect with Richard Alldread:

LinkedIn: www.linkedin.com/in/richard-alldread-01923644

Website: www.theculturedhub.com

Want to hear more perspectives on the future of cell-based food? Don’t miss these previous episodes:

  • Episodes 55-56: Cultivated Meat: A Promising Future or an Inevitable Bubble? with Steven Lang
  • Episodes 45-46: From Lab to Table: The Science Behind Cultivated Meat with Petra Hanga
  • Episodes 15-16: Bacon Without Pigs? Innovations in Cultivated Meat Manufacturing with Beat Thalmann

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

🧬 Ready to eliminate CMC chaos and hit your IND timeline with absolute certainty? Get the complete Notion CMC Dashboard at https://stan.store/SmartBiotech/p/cmc-dashboard-for-biotech-founders - the proven CMC roadmap for IND submission.

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17500715 Tue, 05 Aug 2025 05:00:00 +0200 1386 177 full false 176: How Virtual Reality Training Solves Europe's Bioproduction Talent Shortage with Sandrine Lemoine - Part 2 176: How Virtual Reality Training Solves Europe's Bioproduction Talent Shortage with Sandrine Lemoine - Part 2 What if the missing link to resilient European bioproduction is not just another breakthrough technology, but the ability to continuously learn, adapt, and collaborate?

In a rapidly shifting biotech landscape, innovation isn’t only driven by technical prowess. Behind every robust production process and every cutting-edge therapy, there’s a team empowered with both technical expertise and the soft skills necessary to thrive.

In this episode, host David Brühlmann explores the human side of bioproduction with Sandrine Lemoine, CEO of Immerscio.bio, who has dedicated her career to transforming talent development in the industry. Sandrine Lemoine brings a unique perspective to biotech training: as both an executive coach and a veteran of pharmaceutical leadership roles, she founded Immerscio.bio to bridge the gap between innovation and workforce development. Her work focuses on immersive, flexible training that prepares biotech professionals - new and experienced alike - for the evolving demands of modern bioproduction, keeping Europe’s talent future-ready.

Here are three reasons why you shouldn’t miss this episode:

  • Soft Skills as a Catalyst: Sandrine reveals why leadership, collaboration, and a “co-construction” approach are critical to effective innovation in bioproduction, not just as buzzwords, but as real drivers of successful project delivery.
  • Continuous Learning as a Strategy: Discover how Immerscio.bio’s adaptable training modules keep professionals ahead of the curve in a field defined by fast regulatory shifts, automation, and new therapies - arming teams for every transition, from immunology pivots to advanced manufacturing technologies.
  • Resilience through Workforce Development: As Europe faces unprecedented talent shortages and global competition, Sandrine explains how investing in people and fostering a habit of lifelong learning is key to healthcare sovereignty and the industrialization of scientific progress.

Ready to upgrade your own bioprocessing career or build a future-ready team? This conversation will inspire you to see training not as a checkbox, but as your greatest tool for impact in biotech.

Connect with Sandrine Lemoine:

LinkedIn: www.linkedin.com/in/sandrine-lemoine-ba244a58

Website: https://immerscio.bio

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing development and manufacturing: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Support the show

]]> What if the missing link to resilient European bioproduction is not just another breakthrough technology, but the ability to continuously learn, adapt, and collaborate?

In a rapidly shifting biotech landscape, innovation isn’t only driven by technical prowess. Behind every robust production process and every cutting-edge therapy, there’s a team empowered with both technical expertise and the soft skills necessary to thrive.

In this episode, host David Brühlmann explores the human side of bioproduction with Sandrine Lemoine, CEO of Immerscio.bio, who has dedicated her career to transforming talent development in the industry. Sandrine Lemoine brings a unique perspective to biotech training: as both an executive coach and a veteran of pharmaceutical leadership roles, she founded Immerscio.bio to bridge the gap between innovation and workforce development. Her work focuses on immersive, flexible training that prepares biotech professionals - new and experienced alike - for the evolving demands of modern bioproduction, keeping Europe’s talent future-ready.

Here are three reasons why you shouldn’t miss this episode:

  • Soft Skills as a Catalyst: Sandrine reveals why leadership, collaboration, and a “co-construction” approach are critical to effective innovation in bioproduction, not just as buzzwords, but as real drivers of successful project delivery.
  • Continuous Learning as a Strategy: Discover how Immerscio.bio’s adaptable training modules keep professionals ahead of the curve in a field defined by fast regulatory shifts, automation, and new therapies - arming teams for every transition, from immunology pivots to advanced manufacturing technologies.
  • Resilience through Workforce Development: As Europe faces unprecedented talent shortages and global competition, Sandrine explains how investing in people and fostering a habit of lifelong learning is key to healthcare sovereignty and the industrialization of scientific progress.

Ready to upgrade your own bioprocessing career or build a future-ready team? This conversation will inspire you to see training not as a checkbox, but as your greatest tool for impact in biotech.

Connect with Sandrine Lemoine:

LinkedIn: www.linkedin.com/in/sandrine-lemoine-ba244a58

Website: https://immerscio.bio

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing development and manufacturing: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17500398 Thu, 31 Jul 2025 05:00:00 +0200 869 176 full false 175: How Virtual Reality Training Solves Europe's Bioproduction Talent Shortage with Sandrine Lemoine - Part 1 175: How Virtual Reality Training Solves Europe's Bioproduction Talent Shortage with Sandrine Lemoine - Part 1 What if the road to bioproduction mastery started not in the lab, but with how you train your people?

Traditional biotech education often ends at theory, leaving graduates unprepared for the fast-paced world of manufacturing. But what if the key to faster, safer, and more scalable bioprocessing is digital immersion, letting scientists train in a virtual facility before they ever enter a real one?

This week, David Brühlmann welcomes Sandrine Lemoine, CEO of Immerscio.bio, to the Smart Biotech Scientist Podcast. With over 25 years spanning R&D, manufacturing strategy, and executive coaching, Sandrine has seen firsthand the widening gap between academic training and the urgent needs of industry. Now, she’s tackling the bioproduction talent shortage head-on through digital modules, built for skills, not just knowledge. From international team leadership to championing hands-on, immersive learning, Sandrine’s mission is to future-proof the workforce our industry desperately needs.

Here are three reasons you should queue up this episode:

  • Immersive Digital Training Meets Industry Demand: Sandrine explains how 100% digital courses - leveraging 3D simulations, serious games, and virtual reality - are bridging the gap between academic theory and operational reality.
  • Collaborating With Industry, Evolving With Technology: Immerscio.bio’s modules aren’t static. Developed by a consortium of major pharma and biotech companies, they’re constantly updated through direct feedback and partnership to keep pace with ever-changing technology and regulations - ensuring every learner gains relevant, up-to-date skills.
  • Beyond Technical Skills: Building the Right Mindset: Technical expertise alone won’t cut it. Sandrine shares how soft skills like critical thinking, autonomy, and quality mindset are intentionally woven into training, preparing new hires and career-changers for the demands of a high-stakes, rapidly evolving field.

Curious how digital and AI-supported training could accelerate your team’s readiness and your career? Listen in to discover how Immerscio.bio is redefining workforce development, and get inspired to rethink your own approach to learning.

Connect with Sandrine Lemoine:

LinkedIn: www.linkedin.com/in/sandrine-lemoine-ba244a58

Website: https://immerscio.bio

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing development and manufacturing: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Support the show

]]> What if the road to bioproduction mastery started not in the lab, but with how you train your people?

Traditional biotech education often ends at theory, leaving graduates unprepared for the fast-paced world of manufacturing. But what if the key to faster, safer, and more scalable bioprocessing is digital immersion, letting scientists train in a virtual facility before they ever enter a real one?

This week, David Brühlmann welcomes Sandrine Lemoine, CEO of Immerscio.bio, to the Smart Biotech Scientist Podcast. With over 25 years spanning R&D, manufacturing strategy, and executive coaching, Sandrine has seen firsthand the widening gap between academic training and the urgent needs of industry. Now, she’s tackling the bioproduction talent shortage head-on through digital modules, built for skills, not just knowledge. From international team leadership to championing hands-on, immersive learning, Sandrine’s mission is to future-proof the workforce our industry desperately needs.

Here are three reasons you should queue up this episode:

  • Immersive Digital Training Meets Industry Demand: Sandrine explains how 100% digital courses - leveraging 3D simulations, serious games, and virtual reality - are bridging the gap between academic theory and operational reality.
  • Collaborating With Industry, Evolving With Technology: Immerscio.bio’s modules aren’t static. Developed by a consortium of major pharma and biotech companies, they’re constantly updated through direct feedback and partnership to keep pace with ever-changing technology and regulations - ensuring every learner gains relevant, up-to-date skills.
  • Beyond Technical Skills: Building the Right Mindset: Technical expertise alone won’t cut it. Sandrine shares how soft skills like critical thinking, autonomy, and quality mindset are intentionally woven into training, preparing new hires and career-changers for the demands of a high-stakes, rapidly evolving field.

Curious how digital and AI-supported training could accelerate your team’s readiness and your career? Listen in to discover how Immerscio.bio is redefining workforce development, and get inspired to rethink your own approach to learning.

Connect with Sandrine Lemoine:

LinkedIn: www.linkedin.com/in/sandrine-lemoine-ba244a58

Website: https://immerscio.bio

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing development and manufacturing: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17500393 Tue, 29 Jul 2025 05:00:00 +0200 1180 175 full false 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey - Part 2 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey - Part 2 How do you transform hybrid model digital twins from promising lab concepts into commercial bioprocessing game-changers that actually deliver ROI?

As biotech companies race to implement Industry 4.0 technologies, the critical challenge isn't just developing sophisticated hybrid models - it's deploying them strategically to create user-friendly, cost-effective solutions that genuinely accelerate your path to commercial bioprocessing success.

In Part 2 of this essential conversation, David Brühlmann continues his deep dive with Krist Gernaey, Professor of Industrial Fermentation Technology at the Technical University of Denmark. Krist reveals the strategic framework for moving beyond digital twin hype to build hybrid modeling capabilities that scale from lab validation to commercial manufacturing reality.

Three Strategic Insights for Commercial Implementation:

  • Digital Twins That Deliver Business Value: Krist cuts through the marketing buzz to define what makes digital twins commercially viable - revealing why true value comes from two-way data exchange and predictive capabilities, not just virtual process copies. Learn the validation strategies that separate successful implementations from expensive pilot projects.
  • Modular Strategy Over Technology Complexity: Forget the "silver bullet" mentality. Krist advocates for strategic building blocks: start with site comparisons and predictive maintenance, then systematically add hybrid modeling complexity as your organization develops the technical capacity and team skills for sustainable commercial success.
  • User-Centric Models for Operational Excellence: The biggest commercial wins aren't always about optimizing yields - they're about creating transparency, robust documentation, and operator-friendly tools that reduce complexity rather than adding it. Discover how to design hybrid model digital twins that empower your manufacturing teams instead of overwhelming them.

Ready to develop a strategic roadmap for implementing hybrid model digital twins that drive commercial bioprocessing success? Tune in for Krist's proven framework for avoiding "cauliflower complexity" while building sustainable digital transformation capabilities that scale.

Connect with Krist Gernaey:

LinkedIn: www.linkedin.com/in/krist-gernaey-591748

Website: www.orbit.dtu.dk/en/persons/krist-v-gernaey

If you’re intrigued by the evolving frontier of bioprocessing, don’t miss these enlightening episodes:

  • Episodes 85-86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli
  • Episodes 153-154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos
  • Episodes 05-06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> How do you transform hybrid model digital twins from promising lab concepts into commercial bioprocessing game-changers that actually deliver ROI?

As biotech companies race to implement Industry 4.0 technologies, the critical challenge isn't just developing sophisticated hybrid models - it's deploying them strategically to create user-friendly, cost-effective solutions that genuinely accelerate your path to commercial bioprocessing success.

In Part 2 of this essential conversation, David Brühlmann continues his deep dive with Krist Gernaey, Professor of Industrial Fermentation Technology at the Technical University of Denmark. Krist reveals the strategic framework for moving beyond digital twin hype to build hybrid modeling capabilities that scale from lab validation to commercial manufacturing reality.

Three Strategic Insights for Commercial Implementation:

  • Digital Twins That Deliver Business Value: Krist cuts through the marketing buzz to define what makes digital twins commercially viable - revealing why true value comes from two-way data exchange and predictive capabilities, not just virtual process copies. Learn the validation strategies that separate successful implementations from expensive pilot projects.
  • Modular Strategy Over Technology Complexity: Forget the "silver bullet" mentality. Krist advocates for strategic building blocks: start with site comparisons and predictive maintenance, then systematically add hybrid modeling complexity as your organization develops the technical capacity and team skills for sustainable commercial success.
  • User-Centric Models for Operational Excellence: The biggest commercial wins aren't always about optimizing yields - they're about creating transparency, robust documentation, and operator-friendly tools that reduce complexity rather than adding it. Discover how to design hybrid model digital twins that empower your manufacturing teams instead of overwhelming them.

Ready to develop a strategic roadmap for implementing hybrid model digital twins that drive commercial bioprocessing success? Tune in for Krist's proven framework for avoiding "cauliflower complexity" while building sustainable digital transformation capabilities that scale.

Connect with Krist Gernaey:

LinkedIn: www.linkedin.com/in/krist-gernaey-591748

Website: www.orbit.dtu.dk/en/persons/krist-v-gernaey

If you’re intrigued by the evolving frontier of bioprocessing, don’t miss these enlightening episodes:

  • Episodes 85-86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli
  • Episodes 153-154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos
  • Episodes 05-06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17500353 Thu, 24 Jul 2025 05:00:00 +0200 1181 174 full false 173: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey - Part 1 173: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist Gernaey - Part 1 Are you struggling to bridge the gap between lab-scale models and commercial bioprocessing reality? For many biotech innovators, the promise of digital twins meets harsh industrial constraints - where hybrid models that excel in controlled lab environments must prove themselves in the complexity of large-scale manufacturing.

This week on the Smart Biotech Scientist Podcast, host David Brühlmann welcomes Krist Gernaey, Professor of Industrial Fermentation Technology at the Technical University of Denmark. With expertise spanning measurement technology development and two decades pioneering hybrid model digital twins for bioprocess applications, Krist reveals the critical gap between digitalization hype and industrial implementation reality.

Here are three key reasons this episode will level up your hybrid modelling and digital twin approaches.

  • From Data Overload to Intelligent Control: Raw sensor data means nothing without the right models to interpret it. Krist demonstrates how hybrid model digital twins convert complex bioprocess measurements into actionable control strategies - showing why sophisticated algorithms need simple, robust sensors to succeed at commercial scale.
  • From Individual Genius to Team Implementation: The most elegant digital twin fails without operator buy-in. Krist shares why successful commercial bioprocessing depends on bridging academic innovation with frontline manufacturing expertise - revealing the human factors that make or break advanced modeling initiatives.
  • From Lab Perfection to Commercial Pragmatism: Discover why the most promising hybrid modeling approaches must balance mechanistic understanding with data-driven adaptation. Krist provides a reality check on electrochemical sensors, validation challenges, and the strategic decisions that determine whether digital twins deliver commercial value or remain expensive experiments.

Ready to master the art of scaling hybrid model digital twins from promising lab tools to commercial bioprocessing game-changers? Tune in to discover Krist Gernaey's battle-tested strategies for navigating the complex journey from academic innovation to industrial impact.

Connect with Krist Gernaey:

LinkedIn: www.linkedin.com/in/krist-gernaey-591748

Website: www.orbit.dtu.dk/en/persons/krist-v-gernaey

If you’re intrigued by the evolving frontier of bioprocessing, don’t miss these enlightening episodes:

  • Episodes 85-86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli
  • Episodes 153-154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos
  • Episodes 05-06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Are you struggling to bridge the gap between lab-scale models and commercial bioprocessing reality? For many biotech innovators, the promise of digital twins meets harsh industrial constraints - where hybrid models that excel in controlled lab environments must prove themselves in the complexity of large-scale manufacturing.

This week on the Smart Biotech Scientist Podcast, host David Brühlmann welcomes Krist Gernaey, Professor of Industrial Fermentation Technology at the Technical University of Denmark. With expertise spanning measurement technology development and two decades pioneering hybrid model digital twins for bioprocess applications, Krist reveals the critical gap between digitalization hype and industrial implementation reality.

Here are three key reasons this episode will level up your hybrid modelling and digital twin approaches.

  • From Data Overload to Intelligent Control: Raw sensor data means nothing without the right models to interpret it. Krist demonstrates how hybrid model digital twins convert complex bioprocess measurements into actionable control strategies - showing why sophisticated algorithms need simple, robust sensors to succeed at commercial scale.
  • From Individual Genius to Team Implementation: The most elegant digital twin fails without operator buy-in. Krist shares why successful commercial bioprocessing depends on bridging academic innovation with frontline manufacturing expertise - revealing the human factors that make or break advanced modeling initiatives.
  • From Lab Perfection to Commercial Pragmatism: Discover why the most promising hybrid modeling approaches must balance mechanistic understanding with data-driven adaptation. Krist provides a reality check on electrochemical sensors, validation challenges, and the strategic decisions that determine whether digital twins deliver commercial value or remain expensive experiments.

Ready to master the art of scaling hybrid model digital twins from promising lab tools to commercial bioprocessing game-changers? Tune in to discover Krist Gernaey's battle-tested strategies for navigating the complex journey from academic innovation to industrial impact.

Connect with Krist Gernaey:

LinkedIn: www.linkedin.com/in/krist-gernaey-591748

Website: www.orbit.dtu.dk/en/persons/krist-v-gernaey

If you’re intrigued by the evolving frontier of bioprocessing, don’t miss these enlightening episodes:

  • Episodes 85-86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli
  • Episodes 153-154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos
  • Episodes 05-06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17476548 Tue, 22 Jul 2025 05:00:00 +0200 1316 173 full false 172: Reimagining Chromatography for Advanced Therapies: From Diffusion to Convection with Scott Wheelwright - Part 2 172: Reimagining Chromatography for Advanced Therapies: From Diffusion to Convection with Scott Wheelwright - Part 2 Downstream processing remains one of the most complex and critical steps in biomanufacturing, especially as new therapeutic modalities like cell and gene therapies push current technologies to their limits. The industry faces ongoing pressure to innovate, reduce costs, and improve efficiency, while still ensuring robust and reliable results.

In this practical, energetic episode, host David Brühlmann welcomes Scott Wheelwright, Chairman, CTO and Co-Founder of BioChromatographix International (BCI). With a career spanning continents - Asia, Europe, and North America - Scott's perspective is forged from hands-on manufacturing, technology transfer, and building high-growth companies from scratch. He’s not just innovating the science behind chromatography; he’s lived the manufacturing realities, spanning everything from precision antibodies to complex gene therapies, and now leads a team solving the tough purification puzzles holding progress back.

Here are three reasons why this episode is a must-listen:

  • Continuous Innovation in Chromatography: Despite a hundred-year legacy, chromatography still holds tremendous untapped potential, especially with new materials and continuous processing, as Scott highlighted with real examples from gene and cell therapy applications.
  • Bridging Lab to Market Needs Customer Focus: Getting new technology into commercial use requires not just technical innovation, but deep user engagement, robust feedback loops, and iterative improvement, plus ongoing education to help users understand new benefits.
  • Embrace Experimentation and Global Collaboration: Whether building companies in Asia, Europe, or the U.S., Scott reminds us that learning from failure, being open to international collaboration, and not being afraid to try new things are essential for long-term growth (and enjoying the biotech journey along the way!).

If you’re passionate about downstream processing, tech innovation, or just want to hear inspiring leadership lessons, check out the full episode and connect with Scott Wheelwright or visit the company’s website to follow his team’s advancements.

Connect with Scott Wheelwright:

LinkedIn: www.linkedin.com/in/scottmwheelwright

Website: www.biochromatographix.com

Curious about chromatography? Tune in to hear what our previous guests had to say!

  • Episodes 119-120: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian Guo
  • Episodes 61-62: Magnetic Bead Technology: The New Era in Downstream Processing with Nils Brechmann
  • Episodes 37-38: How to Master Downstream: A Deep Dive Into Bioprocessing Purification with Wei Zhang

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Support the show

]]> Downstream processing remains one of the most complex and critical steps in biomanufacturing, especially as new therapeutic modalities like cell and gene therapies push current technologies to their limits. The industry faces ongoing pressure to innovate, reduce costs, and improve efficiency, while still ensuring robust and reliable results.

In this practical, energetic episode, host David Brühlmann welcomes Scott Wheelwright, Chairman, CTO and Co-Founder of BioChromatographix International (BCI). With a career spanning continents - Asia, Europe, and North America - Scott's perspective is forged from hands-on manufacturing, technology transfer, and building high-growth companies from scratch. He’s not just innovating the science behind chromatography; he’s lived the manufacturing realities, spanning everything from precision antibodies to complex gene therapies, and now leads a team solving the tough purification puzzles holding progress back.

Here are three reasons why this episode is a must-listen:

  • Continuous Innovation in Chromatography: Despite a hundred-year legacy, chromatography still holds tremendous untapped potential, especially with new materials and continuous processing, as Scott highlighted with real examples from gene and cell therapy applications.
  • Bridging Lab to Market Needs Customer Focus: Getting new technology into commercial use requires not just technical innovation, but deep user engagement, robust feedback loops, and iterative improvement, plus ongoing education to help users understand new benefits.
  • Embrace Experimentation and Global Collaboration: Whether building companies in Asia, Europe, or the U.S., Scott reminds us that learning from failure, being open to international collaboration, and not being afraid to try new things are essential for long-term growth (and enjoying the biotech journey along the way!).

If you’re passionate about downstream processing, tech innovation, or just want to hear inspiring leadership lessons, check out the full episode and connect with Scott Wheelwright or visit the company’s website to follow his team’s advancements.

Connect with Scott Wheelwright:

LinkedIn: www.linkedin.com/in/scottmwheelwright

Website: www.biochromatographix.com

Curious about chromatography? Tune in to hear what our previous guests had to say!

  • Episodes 119-120: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian Guo
  • Episodes 61-62: Magnetic Bead Technology: The New Era in Downstream Processing with Nils Brechmann
  • Episodes 37-38: How to Master Downstream: A Deep Dive Into Bioprocessing Purification with Wei Zhang

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17476536 Thu, 17 Jul 2025 05:00:00 +0200 1184 172 full false 171: Reimagining Chromatography for Advanced Therapies: From Diffusion to Convection with Scott Wheelwright - Part 1 171: Reimagining Chromatography for Advanced Therapies: From Diffusion to Convection with Scott Wheelwright - Part 1 For decades, chromatographic purification has made use of bead-based diffusion - a reliable but limiting approach, especially as new modalities like gene therapies, mRNA, and viruses push the boundaries of what’s possible. But what if the future of downstream processing lies not in incremental improvement, but in a dramatic reimagining - from slow diffusion to rapid convection?

In this episode, David Brühlmann meets Scott Wheelwright, Chairman, CTO and Co-Founder of BioChromatographix International (BCI). Scott brings decades of expertise in biopharmaceutical development and manufacturing. Prior to BCI, he co-founded Biolnno Bioscience, a leading CDMO, and co-founded Innovent Biologics, one of China’s foremost biotechnology companies.

Here are three compelling reasons to tune into this episode:

  • Breaking the Mold of Purification: BCI’s AXISFLOW™ Platform moves beyond bead-based processes, using advanced 3D-printed monoliths that enable convective flow, making purification of large biomolecules and viruses faster, more efficient, and better suited for next-generation therapies.
  • Innovation Starts with Imagination (and Measurement): True progress in bioprocessing often hinges not on what we can make, but on what we can accurately measure and imagine. Scott reminds us that advances in analytical testing and creative thinking are the real engines of change.
  • Biotech Demands More than Great Science: Success isn’t just about inventing; it’s about building with the end-user in mind. Scott’s journey highlights the critical role of customer-centric product development, cross-disciplinary teamwork, and regulatory strategy - especially in a conservative, risk-averse industry.

Curious how shifting from diffusion to convection could reshape your purification workflow? Listen to this episode and discover how to unlock efficiency, cut costs, and deliver therapies that might otherwise remain out of reach.

Connect with Scott Wheelwright:

LinkedIn: www.linkedin.com/in/scottmwheelwright

Website: www.biochromatographix.com

Curious about chromatography? Tune in to hear what our previous guests had to say!

  • Episodes 119-120: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian Guo
  • Episodes 61-62: Magnetic Bead Technology: The New Era in Downstream Processing with Nils Brechmann
  • Episodes 37-38: How to Master Downstream: A Deep Dive Into Bioprocessing Purification with Wei Zhang

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Support the show

]]> For decades, chromatographic purification has made use of bead-based diffusion - a reliable but limiting approach, especially as new modalities like gene therapies, mRNA, and viruses push the boundaries of what’s possible. But what if the future of downstream processing lies not in incremental improvement, but in a dramatic reimagining - from slow diffusion to rapid convection?

In this episode, David Brühlmann meets Scott Wheelwright, Chairman, CTO and Co-Founder of BioChromatographix International (BCI). Scott brings decades of expertise in biopharmaceutical development and manufacturing. Prior to BCI, he co-founded Biolnno Bioscience, a leading CDMO, and co-founded Innovent Biologics, one of China’s foremost biotechnology companies.

Here are three compelling reasons to tune into this episode:

  • Breaking the Mold of Purification: BCI’s AXISFLOW™ Platform moves beyond bead-based processes, using advanced 3D-printed monoliths that enable convective flow, making purification of large biomolecules and viruses faster, more efficient, and better suited for next-generation therapies.
  • Innovation Starts with Imagination (and Measurement): True progress in bioprocessing often hinges not on what we can make, but on what we can accurately measure and imagine. Scott reminds us that advances in analytical testing and creative thinking are the real engines of change.
  • Biotech Demands More than Great Science: Success isn’t just about inventing; it’s about building with the end-user in mind. Scott’s journey highlights the critical role of customer-centric product development, cross-disciplinary teamwork, and regulatory strategy - especially in a conservative, risk-averse industry.

Curious how shifting from diffusion to convection could reshape your purification workflow? Listen to this episode and discover how to unlock efficiency, cut costs, and deliver therapies that might otherwise remain out of reach.

Connect with Scott Wheelwright:

LinkedIn: www.linkedin.com/in/scottmwheelwright

Website: www.biochromatographix.com

Curious about chromatography? Tune in to hear what our previous guests had to say!

  • Episodes 119-120: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian Guo
  • Episodes 61-62: Magnetic Bead Technology: The New Era in Downstream Processing with Nils Brechmann
  • Episodes 37-38: How to Master Downstream: A Deep Dive Into Bioprocessing Purification with Wei Zhang

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17452649 Tue, 15 Jul 2025 05:00:00 +0200 1235 171 full false 170: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo Jain - Part 2 170: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo Jain - Part 2 For years, disease diagnosis and treatment have focused on a few biomarkers, overlooking thousands of vital biological signals. Despite biotech advances, most therapies are still based on limited data, missing countless breakthroughs.

Multiomics changes that. By analyzing tens of thousands of proteins, metabolites, and lipids, it reveals hidden insights, paving the way for smarter, faster, and more effective medical discoveries.

In this must-listen episode, David Brühlmann welcomes Mo Jain, founder and CSO of Sapient, a pioneering force in bringing multiomic platforms out of academia and into the heart of drug development. A physician-scientist by training and a visionary entrepreneur by choice, Mo’s journey spans decades at the cutting edge of analytical technologies, culminating in the creation of ultra-high-throughput systems that analyze up to 20,000 biomarkers in a single run for real-world impact.

Here are three reasons why this episode needs to be on your playlist:

  • Multiomics at Scale: Mo shares how his team at Sapient turbocharged mass spectrometry, enabling simultaneous measurement of thousands of molecules, transforming routine diagnostics and making previously unimaginable insights accessible to scientists everywhere.
  • Turning Data into Action: Generating vast data is only half the battle. Mo explains how Sapient developed advanced biocomputational teams and frameworks to extract actionable answers, guiding drug developers to faster, smarter decisions and helping avoid the pitfalls that cripple so many omics projects.
  • The Future Is Personalized and Sooner Than You Think: From dramatically earlier disease detection to truly personalized therapies, Mo paints an optimistic picture of a coming era where AI, multiomics, and new therapeutic modalities rapidly accelerate both discovery and delivery, reshaping how biotech companies tackle even the toughest diseases.

Ready to break out of the 20-biomarker rut and see what 20,000 data points can reveal? Tune in to discover how you can harness multiomics in your own research and hear Mo’s advice for scientists and entrepreneurs venturing beyond the bench.

Connect with Mo Jain:

LinkedIn: www.linkedin.com/in/mo-jain-md-phd-373895ba

Website: www.sapient.bio

Company LinkedIn Page: https://www.linkedin.com/company/sapientbio

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> For years, disease diagnosis and treatment have focused on a few biomarkers, overlooking thousands of vital biological signals. Despite biotech advances, most therapies are still based on limited data, missing countless breakthroughs.

Multiomics changes that. By analyzing tens of thousands of proteins, metabolites, and lipids, it reveals hidden insights, paving the way for smarter, faster, and more effective medical discoveries.

In this must-listen episode, David Brühlmann welcomes Mo Jain, founder and CSO of Sapient, a pioneering force in bringing multiomic platforms out of academia and into the heart of drug development. A physician-scientist by training and a visionary entrepreneur by choice, Mo’s journey spans decades at the cutting edge of analytical technologies, culminating in the creation of ultra-high-throughput systems that analyze up to 20,000 biomarkers in a single run for real-world impact.

Here are three reasons why this episode needs to be on your playlist:

  • Multiomics at Scale: Mo shares how his team at Sapient turbocharged mass spectrometry, enabling simultaneous measurement of thousands of molecules, transforming routine diagnostics and making previously unimaginable insights accessible to scientists everywhere.
  • Turning Data into Action: Generating vast data is only half the battle. Mo explains how Sapient developed advanced biocomputational teams and frameworks to extract actionable answers, guiding drug developers to faster, smarter decisions and helping avoid the pitfalls that cripple so many omics projects.
  • The Future Is Personalized and Sooner Than You Think: From dramatically earlier disease detection to truly personalized therapies, Mo paints an optimistic picture of a coming era where AI, multiomics, and new therapeutic modalities rapidly accelerate both discovery and delivery, reshaping how biotech companies tackle even the toughest diseases.

Ready to break out of the 20-biomarker rut and see what 20,000 data points can reveal? Tune in to discover how you can harness multiomics in your own research and hear Mo’s advice for scientists and entrepreneurs venturing beyond the bench.

Connect with Mo Jain:

LinkedIn: www.linkedin.com/in/mo-jain-md-phd-373895ba

Website: www.sapient.bio

Company LinkedIn Page: https://www.linkedin.com/company/sapientbio

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17413063 Thu, 10 Jul 2025 05:00:00 +0200 1412 170 full false 169: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo Jain - Part 1 169: Why Your DNA Is a Terrible Disease Predictor (And How Multi-Omics Changes Everything) with Mo Jain - Part 1 What if the secret to truly personalized precision medicine lies not in your genetic code, but in your zip code?

For years, biotech has focused on genomics to explain disease and drug response, but DNA only accounts for a fraction of the story. The real breakthrough? Multi-omics: the large-scale analysis of proteins, metabolites, and lipids, powered by advanced mass spectrometry and AI, offering a fuller picture of human health.

In this episode, David Brühlmann meets Mo Jain, founder and CSO of Sapient, a leader in multi-omics analytics. With over two decades of experience across physiology, biomedicine, and computational biology, Mo has been at the forefront of developing scalable multi-omics technologies that are changing the way we predict, diagnose, and treat disease. From leading an academic lab to building a pioneering biotech company, Mo’s journey reflects a passion for uncovering the hidden 80–90% of disease risk that lies beyond our genes.

Here are three reasons you’ll want to listen to this episode:

  • Your Environment Matters More Than Your Genes: Mo explains why your zip code is a stronger predictor of your health than your genetic code, challenging the industry’s long-held beliefs and opening new avenues for disease prevention and risk assessment.
  • Multi-omics Disrupts Drug Development: Discover how integrating thousands of biological data points can revolutionize drug discovery by identifying novel targets, better predicting drug response, and accelerating therapeutic breakthroughs that were previously out of reach.
  • Big Data Finally Becomes Actionable: Thanks to rapid advances in mass spectrometry and computational power, scientists can now make sense of overwhelming volumes of multi-omic data, turning what was once information overload into actionable insights for diagnostics and drug development.

Ready to think beyond your genes? The biotech revolution is here, and it starts in your neighborhood.

Connect with Mo Jain:

LinkedIn: www.linkedin.com/in/mo-jain-md-phd-373895ba

Website: www.sapient.bio

Company LinkedIn Page: https://www.linkedin.com/company/sapientbio

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> What if the secret to truly personalized precision medicine lies not in your genetic code, but in your zip code?

For years, biotech has focused on genomics to explain disease and drug response, but DNA only accounts for a fraction of the story. The real breakthrough? Multi-omics: the large-scale analysis of proteins, metabolites, and lipids, powered by advanced mass spectrometry and AI, offering a fuller picture of human health.

In this episode, David Brühlmann meets Mo Jain, founder and CSO of Sapient, a leader in multi-omics analytics. With over two decades of experience across physiology, biomedicine, and computational biology, Mo has been at the forefront of developing scalable multi-omics technologies that are changing the way we predict, diagnose, and treat disease. From leading an academic lab to building a pioneering biotech company, Mo’s journey reflects a passion for uncovering the hidden 80–90% of disease risk that lies beyond our genes.

Here are three reasons you’ll want to listen to this episode:

  • Your Environment Matters More Than Your Genes: Mo explains why your zip code is a stronger predictor of your health than your genetic code, challenging the industry’s long-held beliefs and opening new avenues for disease prevention and risk assessment.
  • Multi-omics Disrupts Drug Development: Discover how integrating thousands of biological data points can revolutionize drug discovery by identifying novel targets, better predicting drug response, and accelerating therapeutic breakthroughs that were previously out of reach.
  • Big Data Finally Becomes Actionable: Thanks to rapid advances in mass spectrometry and computational power, scientists can now make sense of overwhelming volumes of multi-omic data, turning what was once information overload into actionable insights for diagnostics and drug development.

Ready to think beyond your genes? The biotech revolution is here, and it starts in your neighborhood.

Connect with Mo Jain:

LinkedIn: www.linkedin.com/in/mo-jain-md-phd-373895ba

Website: www.sapient.bio

Company LinkedIn Page: https://www.linkedin.com/company/sapientbio

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17413057 Tue, 08 Jul 2025 05:00:00 +0200 1585 169 full false 168: How Generative AI Is Revolutionizing Biotech Regulatory Compliance with Abhijeet Satwekar - Part 2 168: How Generative AI Is Revolutionizing Biotech Regulatory Compliance with Abhijeet Satwekar - Part 2 The promise of generative AI in pharma and biotech is huge, but it's also fraught with complexity, especially when it comes to integrating these systems into highly regulated environments. From monitoring evolving guidelines to balancing operational efficiency and data integrity, the journey from hype to real-world impact is filled with both opportunity and skepticism.

In this episode, David Brühlmann sits down with Abhijeet Satwekar, Innovation Manager at Merck Healthcare’s Global Analytical Development. Abhijeet has spent years on the front lines of digital transformation in the biotech sector, and his current mission: implementing generative AI for regulatory guideline monitoring, without giving the quality team a collective heart attack. He offers a no-nonsense roadmap for biotech leaders looking to streamline compliance, harness AI potential, and future-proof their operations.

Here are three reasons you should hit play on this episode:

  • From Proof of Concept to Real-World Implementation: Discover how Abhijeet’s team moved beyond early excitement to tackle regulatory, IT, and data privacy requirements, carving a safe and compliant path for bringing generative AI tools into GxP and GMP-adjacent workflows.
  • Human-in-the-Loop Isn’t Optional: Learn why user training, prompt engineering, and close collaboration between scientists and AI are essential for extracting meaningful (and accurate) insights, especially in environments where routine and regulation reign supreme.
  • ROI and Regulation - The Balancing Act: Hear candid perspectives on measuring the return on investment for new digital tools, addressing skeptics closer to manufacturing, and why the real game-changer might just be a community-driven, industry-wide approach to regulatory acceptance.

Wondering how to unlock GenAI’s full potential - or just avoid the common pitfalls? Dive into this episode for practical strategies, cautionary tales, and actionable insights from someone who’s actually navigated the compliance minefield.

Bring AI into your pipeline with confidence, clarity, and compliance.

Connect with Abhijeet Satwekar:

LinkedIn: https://www.linkedin.com/in/abhijeetsatwekar

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing development: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> The promise of generative AI in pharma and biotech is huge, but it's also fraught with complexity, especially when it comes to integrating these systems into highly regulated environments. From monitoring evolving guidelines to balancing operational efficiency and data integrity, the journey from hype to real-world impact is filled with both opportunity and skepticism.

In this episode, David Brühlmann sits down with Abhijeet Satwekar, Innovation Manager at Merck Healthcare’s Global Analytical Development. Abhijeet has spent years on the front lines of digital transformation in the biotech sector, and his current mission: implementing generative AI for regulatory guideline monitoring, without giving the quality team a collective heart attack. He offers a no-nonsense roadmap for biotech leaders looking to streamline compliance, harness AI potential, and future-proof their operations.

Here are three reasons you should hit play on this episode:

  • From Proof of Concept to Real-World Implementation: Discover how Abhijeet’s team moved beyond early excitement to tackle regulatory, IT, and data privacy requirements, carving a safe and compliant path for bringing generative AI tools into GxP and GMP-adjacent workflows.
  • Human-in-the-Loop Isn’t Optional: Learn why user training, prompt engineering, and close collaboration between scientists and AI are essential for extracting meaningful (and accurate) insights, especially in environments where routine and regulation reign supreme.
  • ROI and Regulation - The Balancing Act: Hear candid perspectives on measuring the return on investment for new digital tools, addressing skeptics closer to manufacturing, and why the real game-changer might just be a community-driven, industry-wide approach to regulatory acceptance.

Wondering how to unlock GenAI’s full potential - or just avoid the common pitfalls? Dive into this episode for practical strategies, cautionary tales, and actionable insights from someone who’s actually navigated the compliance minefield.

Bring AI into your pipeline with confidence, clarity, and compliance.

Connect with Abhijeet Satwekar:

LinkedIn: https://www.linkedin.com/in/abhijeetsatwekar

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing development: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17367899 Thu, 03 Jul 2025 05:00:00 +0200 1543 168 full false 167: How Generative AI Is Revolutionizing Biotech Regulatory Compliance with Abhijeet Satwekar - Part 1 167: How Generative AI Is Revolutionizing Biotech Regulatory Compliance with Abhijeet Satwekar - Part 1 Ever feel like you’re drowning in an ocean of constantly shifting regulatory guidelines? The world of biotech is a whirlwind of evolving standards, making compliance not just a headache, but sometimes the stumbling block between life-changing therapies and the patients who need them. But what if artificial intelligence could turn regulatory chaos into your biggest competitive advantage?

In this episode, David Brühlmann sits down with Abhijeet Satwekar, Innovation Manager at Merck KGaA’s Global Analytical Development. Abhijeet shares how he’s pioneering the use of generative AI, not as a hype machine, but as a practical, transformative tool for regulatory compliance in biotech. With over a decade navigating analytics, digitalization, and collaborative tech adoption at a major pharma leader, Abhijeet knows what it takes to connect industry stakeholders, harness new technologies, and turn business operations into streamlined, value-generating systems.

Here are three reasons you won’t want to miss this episode:

  • Generative AI as a Compliance Powerhouse: Discover how AI is being harnessed to analyze, extract, and compare complex regulatory requirements across different countries, cutting through ambiguous language and shifting specifications - so you don’t have to.
  • Reducing Regulatory Bottlenecks: The days of manually reconciling guideline documents and updating baselines with every regulatory change are numbered. Learn how generative AI accelerates multi-guideline comparison, saving teams countless hours and reducing the risk of costly errors and delays.
  • A Blueprint for Digital Transformation: Abhijeet reveals how Merck is moving from proof-of-concept to operational reality, building collaborative teams that bridge IT, analytics, regulatory, and quality to bring valuable digital tools into daily practice.

Curious if your team could automate away regulatory headaches? Listen in and get inspired to tackle your toughest compliance challenges - before your competitors do.

Connect with Abhijeet Satwekar:

LinkedIn: https://www.linkedin.com/in/abhijeetsatwekar

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing development: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Ever feel like you’re drowning in an ocean of constantly shifting regulatory guidelines? The world of biotech is a whirlwind of evolving standards, making compliance not just a headache, but sometimes the stumbling block between life-changing therapies and the patients who need them. But what if artificial intelligence could turn regulatory chaos into your biggest competitive advantage?

In this episode, David Brühlmann sits down with Abhijeet Satwekar, Innovation Manager at Merck KGaA’s Global Analytical Development. Abhijeet shares how he’s pioneering the use of generative AI, not as a hype machine, but as a practical, transformative tool for regulatory compliance in biotech. With over a decade navigating analytics, digitalization, and collaborative tech adoption at a major pharma leader, Abhijeet knows what it takes to connect industry stakeholders, harness new technologies, and turn business operations into streamlined, value-generating systems.

Here are three reasons you won’t want to miss this episode:

  • Generative AI as a Compliance Powerhouse: Discover how AI is being harnessed to analyze, extract, and compare complex regulatory requirements across different countries, cutting through ambiguous language and shifting specifications - so you don’t have to.
  • Reducing Regulatory Bottlenecks: The days of manually reconciling guideline documents and updating baselines with every regulatory change are numbered. Learn how generative AI accelerates multi-guideline comparison, saving teams countless hours and reducing the risk of costly errors and delays.
  • A Blueprint for Digital Transformation: Abhijeet reveals how Merck is moving from proof-of-concept to operational reality, building collaborative teams that bridge IT, analytics, regulatory, and quality to bring valuable digital tools into daily practice.

Curious if your team could automate away regulatory headaches? Listen in and get inspired to tackle your toughest compliance challenges - before your competitors do.

Connect with Abhijeet Satwekar:

LinkedIn: https://www.linkedin.com/in/abhijeetsatwekar

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing development: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17367894 Tue, 01 Jul 2025 05:00:00 +0200 862 167 full false 166: Why Your Funding Pitches Fail Despite Brilliant Science (And How to Fix It) - Part 2 166: Why Your Funding Pitches Fail Despite Brilliant Science (And How to Fix It) - Part 2 Have you ever presented a major scientific breakthrough, only to be met with blank stares and distracted executives? You're not alone. In this episode, David Brühlmann shares how he went from drowning in data to winning an innovation contest, not through better tech, but through the power of scientific storytelling.

Many scientists default to methods and data, but as David notes, “it’s like being fluent in a language nobody else in the room speaks.” Without a clear link to human impact, even the most brilliant work can go unnoticed.

Key insights from the episode that could transform your next presentation:

  • The Three-Act Structure: Storytelling That Resonates - David shows how Apple’s iPhone launch used this classic structure, and how scientists can do the same. Start with “why” (impact), then move to “how” (the science) to keep your audience engaged without losing rigor.
  • Turning Your Audience Into the Hero: Adapting Donald Miller’s framework, David flips the script: your audience is the hero, and your innovation is their guide. It’s about speaking to their needs, not just showcasing your work.
  • Why Storytelling Works: The Neuroscience Edge: Stories release dopamine (focus), oxytocin (trust), and endorphins (emotion) - activating how we naturally learn and remember. It’s not fluff; it’s brain science.

Decision-makers won’t remember your chromatogram, but they will remember the story and its impact. The real test of your pitch? Whether it drives action: follow-up meetings or funding.

You don’t need to simplify your science. You need to spotlight what matters most to your audience. With a strong narrative, your work stops being overlooked potential and starts becoming real-world impact.

Ready to revolutionize your next presentation? Lean into the power of storytelling - your data, your career, and the lives you touch will thank you.

Listen to the full episode to explore the straightforward storytelling structure David uses to bring scientific ideas to life.

🔗 Book a free 20-minute consultation with Brühlmann Consulting to answer any questions you may have about how to craft a compelling scientific story that connects and inspires. https://bruehlmann-consulting.com/call/

🔗 Turn Your Science into Funding Success. Book a 30-minute strategy session to transform your technical pitch into a compelling story that gets funded. Limited spots available. Schedule now at https://stan.store/SmartBiotech/p/turn-science-into-funding-a-pitch-that-sells

Support the show

]]> Have you ever presented a major scientific breakthrough, only to be met with blank stares and distracted executives? You're not alone. In this episode, David Brühlmann shares how he went from drowning in data to winning an innovation contest, not through better tech, but through the power of scientific storytelling.

Many scientists default to methods and data, but as David notes, “it’s like being fluent in a language nobody else in the room speaks.” Without a clear link to human impact, even the most brilliant work can go unnoticed.

Key insights from the episode that could transform your next presentation:

  • The Three-Act Structure: Storytelling That Resonates - David shows how Apple’s iPhone launch used this classic structure, and how scientists can do the same. Start with “why” (impact), then move to “how” (the science) to keep your audience engaged without losing rigor.
  • Turning Your Audience Into the Hero: Adapting Donald Miller’s framework, David flips the script: your audience is the hero, and your innovation is their guide. It’s about speaking to their needs, not just showcasing your work.
  • Why Storytelling Works: The Neuroscience Edge: Stories release dopamine (focus), oxytocin (trust), and endorphins (emotion) - activating how we naturally learn and remember. It’s not fluff; it’s brain science.

Decision-makers won’t remember your chromatogram, but they will remember the story and its impact. The real test of your pitch? Whether it drives action: follow-up meetings or funding.

You don’t need to simplify your science. You need to spotlight what matters most to your audience. With a strong narrative, your work stops being overlooked potential and starts becoming real-world impact.

Ready to revolutionize your next presentation? Lean into the power of storytelling - your data, your career, and the lives you touch will thank you.

Listen to the full episode to explore the straightforward storytelling structure David uses to bring scientific ideas to life.

🔗 Book a free 20-minute consultation with Brühlmann Consulting to answer any questions you may have about how to craft a compelling scientific story that connects and inspires. https://bruehlmann-consulting.com/call/

🔗 Turn Your Science into Funding Success. Book a 30-minute strategy session to transform your technical pitch into a compelling story that gets funded. Limited spots available. Schedule now at https://stan.store/SmartBiotech/p/turn-science-into-funding-a-pitch-that-sells

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17340463 Thu, 26 Jun 2025 05:00:00 +0200 1022 166 full false 165: Why Your Funding Pitches Fail Despite Brilliant Science (And How to Fix It) - Part 1 165: Why Your Funding Pitches Fail Despite Brilliant Science (And How to Fix It) - Part 1 Have you ever poured months of research into a brilliant innovation, only to watch executives’ eyes glaze over during your presentation? You’re not alone. In this episode, host David Brühlmann describes a familiar frustration: scientists are trained to perfect data, not to sell ideas. But in today’s fast-paced biotech landscape, even the most groundbreaking technology risks fading into obscurity if it isn’t communicated effectively.

Here’s what you’ll learn in this episode:

  • Why Good Science Needs Great Storytelling: David Brühlmann shows that the most funded projects are often the best-communicated, because even experts remember stories, not raw data. A thrift-store experiment proves the point: stories can increase value by over 6,000%.
  • Neuroscience: The Biology Behind the Narrative: Neuroscience shows that suspense, empathy, and humor trigger brain chemicals that boost attention, trust, and memory. That’s why even experts remember stories far more than data dumps.
  • Bridging Science and Story, Without Sacrificing Integrity: Many scientists fear storytelling undermines rigor, but David argues the opposite: story is the map, data the landmarks. Emotion doesn’t weaken science, it makes it resonate and stick.

Listen to the full episode to explore the straightforward storytelling structure David uses to bring scientific ideas to life.

Don’t let your breakthrough ideas get buried in jargon and dense slides. Your science deserves to be heard—and you already have what it takes to tell a story that sticks. Need help with an upcoming presentation?

🔗 Book a free 20-minute consultation with Brühlmann Consulting to answer any questions you may have about how to craft a compelling scientific story that connects and inspires. https://bruehlmann-consulting.com/call/

🔗 Turn Your Science into Funding Success. Book a 30-minute strategy session to transform your technical pitch into a compelling story that gets funded. Limited spots available. Schedule now at https://stan.store/SmartBiotech/p/turn-science-into-funding-a-pitch-that-sells

Support the show

]]> Have you ever poured months of research into a brilliant innovation, only to watch executives’ eyes glaze over during your presentation? You’re not alone. In this episode, host David Brühlmann describes a familiar frustration: scientists are trained to perfect data, not to sell ideas. But in today’s fast-paced biotech landscape, even the most groundbreaking technology risks fading into obscurity if it isn’t communicated effectively.

Here’s what you’ll learn in this episode:

  • Why Good Science Needs Great Storytelling: David Brühlmann shows that the most funded projects are often the best-communicated, because even experts remember stories, not raw data. A thrift-store experiment proves the point: stories can increase value by over 6,000%.
  • Neuroscience: The Biology Behind the Narrative: Neuroscience shows that suspense, empathy, and humor trigger brain chemicals that boost attention, trust, and memory. That’s why even experts remember stories far more than data dumps.
  • Bridging Science and Story, Without Sacrificing Integrity: Many scientists fear storytelling undermines rigor, but David argues the opposite: story is the map, data the landmarks. Emotion doesn’t weaken science, it makes it resonate and stick.

Listen to the full episode to explore the straightforward storytelling structure David uses to bring scientific ideas to life.

Don’t let your breakthrough ideas get buried in jargon and dense slides. Your science deserves to be heard—and you already have what it takes to tell a story that sticks. Need help with an upcoming presentation?

🔗 Book a free 20-minute consultation with Brühlmann Consulting to answer any questions you may have about how to craft a compelling scientific story that connects and inspires. https://bruehlmann-consulting.com/call/

🔗 Turn Your Science into Funding Success. Book a 30-minute strategy session to transform your technical pitch into a compelling story that gets funded. Limited spots available. Schedule now at https://stan.store/SmartBiotech/p/turn-science-into-funding-a-pitch-that-sells

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17340448 Tue, 24 Jun 2025 05:00:00 +0200 1124 165 full false 164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf - Part 2 164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf - Part 2 From lab curiosity to commercial reality. Here's what happens when moss meets the brutal economics of bioprocessing.

In Part 1, you've heard the science behind moss-based protein production. Now comes the real test: Can it survive the gauntlet of regulatory scrutiny, cost pressures, and manufacturing scale-up that crushes most biotech innovations?

In Part 2 of this groundbreaking conversation, David Brühlmann and Andreas Schaaf, Managing Director and CSO of Eleva, dive into the nuts and bolts of what it actually takes to commercialize a revolutionary production platform. Andreas doesn't just theorize—he's lived through 15+ years of transforming Eleva from startup concept to clinical-stage reality, navigating every regulatory hurdle and economic challenge along the way.

Three game-changing advantages that caught our attention:

  • Process Robustness That Actually Works: While CHO cells throw tantrums over minor parameter shifts, moss maintains consistent product quality even when your bioprocess isn't behaving perfectly; a lifeline for manufacturing teams dealing with real-world variability.
  • Economics That Make CFOs Smile: Forget expensive viral filtration steps and costly human pathogen testing. Moss's plant heritage eliminates these animal-system burdens, directly impacting your bottom line in ways that matter.
  • Operational Simplicity: Variability in process ingredients and streamlined cell banking contribute to long-term cost and operational efficiencies that compound over time.

Andreas shares hard-won insights about what it really takes to challenge entrenched bioprocessing orthodoxy, including the regulatory conversations, the economic realities, and his advice for scientists brave enough to pursue game-changing innovations.

Ready to understand how disruptive biotechnology actually makes it from bench to bedside?

Connect with Andreas Schaaf:

LinkedIn: www.linkedin.com/in/andreas-schaaf-b3797716

Website: www.elevabiologics.com

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at www.bruehlmann-consulting.com/call/

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> From lab curiosity to commercial reality. Here's what happens when moss meets the brutal economics of bioprocessing.

In Part 1, you've heard the science behind moss-based protein production. Now comes the real test: Can it survive the gauntlet of regulatory scrutiny, cost pressures, and manufacturing scale-up that crushes most biotech innovations?

In Part 2 of this groundbreaking conversation, David Brühlmann and Andreas Schaaf, Managing Director and CSO of Eleva, dive into the nuts and bolts of what it actually takes to commercialize a revolutionary production platform. Andreas doesn't just theorize—he's lived through 15+ years of transforming Eleva from startup concept to clinical-stage reality, navigating every regulatory hurdle and economic challenge along the way.

Three game-changing advantages that caught our attention:

  • Process Robustness That Actually Works: While CHO cells throw tantrums over minor parameter shifts, moss maintains consistent product quality even when your bioprocess isn't behaving perfectly; a lifeline for manufacturing teams dealing with real-world variability.
  • Economics That Make CFOs Smile: Forget expensive viral filtration steps and costly human pathogen testing. Moss's plant heritage eliminates these animal-system burdens, directly impacting your bottom line in ways that matter.
  • Operational Simplicity: Variability in process ingredients and streamlined cell banking contribute to long-term cost and operational efficiencies that compound over time.

Andreas shares hard-won insights about what it really takes to challenge entrenched bioprocessing orthodoxy, including the regulatory conversations, the economic realities, and his advice for scientists brave enough to pursue game-changing innovations.

Ready to understand how disruptive biotechnology actually makes it from bench to bedside?

Connect with Andreas Schaaf:

LinkedIn: www.linkedin.com/in/andreas-schaaf-b3797716

Website: www.elevabiologics.com

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at www.bruehlmann-consulting.com/call/

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17324320 Thu, 19 Jun 2025 05:00:00 +0200 1208 164 full false 163: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf - Part 1 163: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas Schaaf - Part 1 What if the future of "impossible" protein therapeutics is hiding in your backyard?

For decades, CHO cells have ruled the biotech kingdom as the undisputed champions of complex protein production. But here's the uncomfortable truth: countless breakthrough therapies are gathering dust on laboratory shelves—not because the science failed, but because traditional hosts can’t produce them.

Enter moss. Yes, moss. That humble green organism clinging to rocks and trees might just be the biotech industry's best-kept secret.

In this eye-opening episode, David Brühlmann sits down with Andreas Schaaf, Managing Director and CSO of Eleva, who's spent over 20 years turning the "impossible" into reality. Andreas didn't just stumble upon moss; he co-developed Eleva's revolutionary moss-based platform from wild concept to commercial-scale game-changer, propelling the company into clinical trials.

Here are three reasons why this episode is worth listening to:

  • Moss as a Game Changer: More than a plant, moss is a higher eukaryote with mammalian-like protein production, including post-translational modifications and human-compatible glycosylation.
  • Overcoming Bioprocessing Barriers: CHO cells are the industry gold standard, especially for monoclonal antibodies. But what about the therapeutic proteins that CHO can’t handle? Many promising candidates end up shelved—not because the science isn't sound, but because existing production platforms hit their limits.
  • Bioprocessing, Simplified: Moss grows in standard bioreactors using familiar workflows—just with a whole organism instead of suspended cells.

Curious about how plant-based systems could solve your protein production challenges? Dive into this episode to discover how moss could revolutionize your approach to challenging proteins; and let us know about your own production hurdles.

Connect with Andreas Schaaf:

LinkedIn: www.linkedin.com/in/andreas-schaaf-b3797716

Website: www.elevabiologics.com

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at www.bruehlmann-consulting.com/call/

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> What if the future of "impossible" protein therapeutics is hiding in your backyard?

For decades, CHO cells have ruled the biotech kingdom as the undisputed champions of complex protein production. But here's the uncomfortable truth: countless breakthrough therapies are gathering dust on laboratory shelves—not because the science failed, but because traditional hosts can’t produce them.

Enter moss. Yes, moss. That humble green organism clinging to rocks and trees might just be the biotech industry's best-kept secret.

In this eye-opening episode, David Brühlmann sits down with Andreas Schaaf, Managing Director and CSO of Eleva, who's spent over 20 years turning the "impossible" into reality. Andreas didn't just stumble upon moss; he co-developed Eleva's revolutionary moss-based platform from wild concept to commercial-scale game-changer, propelling the company into clinical trials.

Here are three reasons why this episode is worth listening to:

  • Moss as a Game Changer: More than a plant, moss is a higher eukaryote with mammalian-like protein production, including post-translational modifications and human-compatible glycosylation.
  • Overcoming Bioprocessing Barriers: CHO cells are the industry gold standard, especially for monoclonal antibodies. But what about the therapeutic proteins that CHO can’t handle? Many promising candidates end up shelved—not because the science isn't sound, but because existing production platforms hit their limits.
  • Bioprocessing, Simplified: Moss grows in standard bioreactors using familiar workflows—just with a whole organism instead of suspended cells.

Curious about how plant-based systems could solve your protein production challenges? Dive into this episode to discover how moss could revolutionize your approach to challenging proteins; and let us know about your own production hurdles.

Connect with Andreas Schaaf:

LinkedIn: www.linkedin.com/in/andreas-schaaf-b3797716

Website: www.elevabiologics.com

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at www.bruehlmann-consulting.com/call/

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17324307 Tue, 17 Jun 2025 05:00:00 +0200 1480 163 full false 162: How to Achieve 85%+ Cell Recovery Without DMSO's Toxic Side Effects with Jeffrey Allen - Part 2 162: How to Achieve 85%+ Cell Recovery Without DMSO's Toxic Side Effects with Jeffrey Allen - Part 2 The world of cell therapy is changing rapidly, with revolutionary advancements in cryopreservation and bioprocessing protocols leading the way. In a recent episode of the Smart Biotech Scientist Podcast, host David Brühlmann sat down with Jeffrey Allen, Chairman and CEO of Evia Bio, to dive deep into the “how” of implementing cutting-edge techniques in the lab and the strategic mindset needed to move therapies from concept to clinic successfully.

Jeffrey Allen is a passionate leader with a diverse background in shaping strategy, building high-performing teams, and driving exceptional results across public and private equity-backed organizations. With extensive C-level and international experience in the life sciences sector, Jeffrey has a proven track record of transforming performance and delivering profitable growth in various market environments.

Here are three key takeaways for anyone passionate about advancing biotech:

  • The four-step audit: bridging best practices and real-world results: Depending on client needs, the audit is performed either at the client’s laboratory or at Evia Bio’s own facility, ensuring real-world practices are scrutinized and optimized.
  • Protocols matter and so does execution: Even the best-written protocols can falter if not followed meticulously. Regular process audits, sometimes conducted onsite by external partners, help identify “protocol creep” and ensure teams are consistently implementing best practices.
  • Culture fuels innovation: Jeffrey’s leadership advice resonated-aligning on strategy, fostering unified company culture, and surrounding yourself with talented people accelerates growth. Passion for the mission, combined with a strong, diverse team, can deliver both exceptional results and lasting employee engagement.

Curious how these insights could save you months of frustration and millions in development costs? Tune in to the full episode, or get in touch to discuss how process optimization can empower your cell therapy journey!

Connect with Jeffrey Allen:

LinkedIn: www.linkedin.com/in/jeffreydallen2

Website: www.eviabio.com

Email: jeffrey.allen@eviabio.com

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at www.bruehlmann-consulting.com/call/

Support the show

]]> The world of cell therapy is changing rapidly, with revolutionary advancements in cryopreservation and bioprocessing protocols leading the way. In a recent episode of the Smart Biotech Scientist Podcast, host David Brühlmann sat down with Jeffrey Allen, Chairman and CEO of Evia Bio, to dive deep into the “how” of implementing cutting-edge techniques in the lab and the strategic mindset needed to move therapies from concept to clinic successfully.

Jeffrey Allen is a passionate leader with a diverse background in shaping strategy, building high-performing teams, and driving exceptional results across public and private equity-backed organizations. With extensive C-level and international experience in the life sciences sector, Jeffrey has a proven track record of transforming performance and delivering profitable growth in various market environments.

Here are three key takeaways for anyone passionate about advancing biotech:

  • The four-step audit: bridging best practices and real-world results: Depending on client needs, the audit is performed either at the client’s laboratory or at Evia Bio’s own facility, ensuring real-world practices are scrutinized and optimized.
  • Protocols matter and so does execution: Even the best-written protocols can falter if not followed meticulously. Regular process audits, sometimes conducted onsite by external partners, help identify “protocol creep” and ensure teams are consistently implementing best practices.
  • Culture fuels innovation: Jeffrey’s leadership advice resonated-aligning on strategy, fostering unified company culture, and surrounding yourself with talented people accelerates growth. Passion for the mission, combined with a strong, diverse team, can deliver both exceptional results and lasting employee engagement.

Curious how these insights could save you months of frustration and millions in development costs? Tune in to the full episode, or get in touch to discuss how process optimization can empower your cell therapy journey!

Connect with Jeffrey Allen:

LinkedIn: www.linkedin.com/in/jeffreydallen2

Website: www.eviabio.com

Email: jeffrey.allen@eviabio.com

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at www.bruehlmann-consulting.com/call/

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17258042 Thu, 12 Jun 2025 05:00:00 +0200 935 162 full false 161: How to Achieve 85%+ Cell Recovery Without DMSO's Toxic Side Effects with Jeffrey Allen - Part 1 161: How to Achieve 85%+ Cell Recovery Without DMSO's Toxic Side Effects with Jeffrey Allen - Part 1 If you’ve ever worked in a cell therapy lab or handled biologics, you’ve probably experienced the pitfalls of cryopreservation. We’ve all mourned the loss of precious samples after a freeze-thaw cycle gone wrong or watched viability figures plummet, wondering where it all went awry.

In this episode of The Smart Biotech Scientist Podcast, Jeffrey Allen, Chairman and CEO of Evia Bio, shares how nature-inspired solutions are changing the cell preservation game. With a background spanning finance, operations, and leadership across the biotech landscape, Jeffrey brings a unique perspective on bridging science and practical manufacturing needs.

Inspired by the survival strategies of Minnesota’s frozen forests, a new wave of biotech innovation is transforming the way we freeze, store, and ship life-saving cells for therapies - and it all starts with a better understanding of nature.

Here are the top three takeaways from this podcast episode:

  • Cryopreservation shouldn’t be an afterthought: Building optimal cryopreservation strategies into your process development from day one can avoid costly setbacks and delays.
  • Beyond cell viability - function matters: It’s not just about how many cells survive the freeze/thaw cycle, but whether those cells remain fully functional. Evia Bio’s new DMSO-free formulations are delivering >85% recovery on MSCs without compromising cell function.
  • One size doesn't fit all: Every cell type has unique needs for freezing, thawing, and formulation. Leveraging tailored algorithms and customized protocols can drastically improve yield and reproducibility, potentially reducing the need for costly overfilling in manufacturing.

If you’ve ever lost precious cell samples to a freeze-thaw mishap or questioned why you’re stuck with outdated, toxic cryopreservation methods, this episode is for you!

Connect with Jeffrey Allen:

LinkedIn: www.linkedin.com/in/jeffreydallen2

Website: www.eviabio.com

Email: jeffrey.allen@eviabio.com

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at www.bruehlmann-consulting.com/call/

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> If you’ve ever worked in a cell therapy lab or handled biologics, you’ve probably experienced the pitfalls of cryopreservation. We’ve all mourned the loss of precious samples after a freeze-thaw cycle gone wrong or watched viability figures plummet, wondering where it all went awry.

In this episode of The Smart Biotech Scientist Podcast, Jeffrey Allen, Chairman and CEO of Evia Bio, shares how nature-inspired solutions are changing the cell preservation game. With a background spanning finance, operations, and leadership across the biotech landscape, Jeffrey brings a unique perspective on bridging science and practical manufacturing needs.

Inspired by the survival strategies of Minnesota’s frozen forests, a new wave of biotech innovation is transforming the way we freeze, store, and ship life-saving cells for therapies - and it all starts with a better understanding of nature.

Here are the top three takeaways from this podcast episode:

  • Cryopreservation shouldn’t be an afterthought: Building optimal cryopreservation strategies into your process development from day one can avoid costly setbacks and delays.
  • Beyond cell viability - function matters: It’s not just about how many cells survive the freeze/thaw cycle, but whether those cells remain fully functional. Evia Bio’s new DMSO-free formulations are delivering >85% recovery on MSCs without compromising cell function.
  • One size doesn't fit all: Every cell type has unique needs for freezing, thawing, and formulation. Leveraging tailored algorithms and customized protocols can drastically improve yield and reproducibility, potentially reducing the need for costly overfilling in manufacturing.

If you’ve ever lost precious cell samples to a freeze-thaw mishap or questioned why you’re stuck with outdated, toxic cryopreservation methods, this episode is for you!

Connect with Jeffrey Allen:

LinkedIn: www.linkedin.com/in/jeffreydallen2

Website: www.eviabio.com

Email: jeffrey.allen@eviabio.com

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at www.bruehlmann-consulting.com/call/

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17258029 Tue, 10 Jun 2025 05:00:00 +0200 1604 161 full false 160: The Ultimate Guide to Accelerating Perfusion Process Development Using 96-Deep-Well Plates with Tom Valentin - Part 2 160: The Ultimate Guide to Accelerating Perfusion Process Development Using 96-Deep-Well Plates with Tom Valentin - Part 2 In this concluding episode of our deep dive into miniaturized perfusion systems, we tackle the most challenging aspect: implementing meaningful process analytical technology (PAT) at microscale while keeping costs realistic for high-throughput applications.

Tom Valentin, group leader at CSEM for Automated Sample Handling, continues sharing CSEM's pioneering work in automated sample handling, revealing both the breakthrough opportunities and stubborn technical barriers that define the current state of small-scale perfusion development.

Critical insights you'll gain from this episode:

  • The PAT miniaturization challenge is about more than size: While optical density sensors work reasonably well for microbial cultures, mammalian cell applications demand more sophisticated solutions. Tom explains why viable cell density remains the "holy grail"—and how promising technologies from companies like IMEC and Inspec are pushing the boundaries, though cost-effective 96-well implementation remains elusive
  • Smart compromises can unlock practical solutions: Tom reveals why the industry may need to accept hybrid approaches—real-time pH and DO monitoring combined with once-daily viable cell density sampling. He also explains the unique challenges of sensor positioning in shaking deep-well plates where liquid dynamics create measurement complexities
  • Partnership models that actually work for biotech innovation: Beyond the technical discussion, Tom outlines CSEM's proven collaboration approaches, including how Innoswiss funding can provide 50% cost reduction for development projects and why their 70% proposal success rate makes them an attractive R&D partner for both startups and established pharma companies

Discover how bioprocessing is evolving - from high-throughput screening to digital twins and continuous manufacturing- in these expert-led episodes.

  • Episode 155: From Process Bottlenecks to Seamless Production: How Continuous Bioprocessing Changes Everything
  • Episodes 153-154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos
  • Episodes 85-86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli
  • Episodes 73-74: Bead-Based Assays: The Power of High-Throughput Screening with Sebastian Giehring

Connect with Tom Valentin:

LinkedIn: www.linkedin.com/in/tom-valentin-5bb9091b

Website: www.csem.ch/en

Email: thomas.valentin@csem.ch

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at www.bruehlmann-consulting.com/call/

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> In this concluding episode of our deep dive into miniaturized perfusion systems, we tackle the most challenging aspect: implementing meaningful process analytical technology (PAT) at microscale while keeping costs realistic for high-throughput applications.

Tom Valentin, group leader at CSEM for Automated Sample Handling, continues sharing CSEM's pioneering work in automated sample handling, revealing both the breakthrough opportunities and stubborn technical barriers that define the current state of small-scale perfusion development.

Critical insights you'll gain from this episode:

  • The PAT miniaturization challenge is about more than size: While optical density sensors work reasonably well for microbial cultures, mammalian cell applications demand more sophisticated solutions. Tom explains why viable cell density remains the "holy grail"—and how promising technologies from companies like IMEC and Inspec are pushing the boundaries, though cost-effective 96-well implementation remains elusive
  • Smart compromises can unlock practical solutions: Tom reveals why the industry may need to accept hybrid approaches—real-time pH and DO monitoring combined with once-daily viable cell density sampling. He also explains the unique challenges of sensor positioning in shaking deep-well plates where liquid dynamics create measurement complexities
  • Partnership models that actually work for biotech innovation: Beyond the technical discussion, Tom outlines CSEM's proven collaboration approaches, including how Innoswiss funding can provide 50% cost reduction for development projects and why their 70% proposal success rate makes them an attractive R&D partner for both startups and established pharma companies

Discover how bioprocessing is evolving - from high-throughput screening to digital twins and continuous manufacturing- in these expert-led episodes.

  • Episode 155: From Process Bottlenecks to Seamless Production: How Continuous Bioprocessing Changes Everything
  • Episodes 153-154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos
  • Episodes 85-86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli
  • Episodes 73-74: Bead-Based Assays: The Power of High-Throughput Screening with Sebastian Giehring

Connect with Tom Valentin:

LinkedIn: www.linkedin.com/in/tom-valentin-5bb9091b

Website: www.csem.ch/en

Email: thomas.valentin@csem.ch

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at www.bruehlmann-consulting.com/call/

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17242028 Thu, 05 Jun 2025 05:00:00 +0200 1151 160 full false 159: The Ultimate Guide to Accelerating Perfusion Process Development Using 96-Deep-Well Plates with Tom Valentin - Part 1 159: The Ultimate Guide to Accelerating Perfusion Process Development Using 96-Deep-Well Plates with Tom Valentin - Part 1 In bioprocess development, the ability to rapidly screen conditions and predict scale-up performance can mean the difference between a successful therapy launch and costly delays. Today's Smart Biotech Scientist episode features Tom Valentin from CSEM, who's pioneering revolutionary approaches to miniaturized perfusion systems that could transform how we develop biologics.

Tom is a group leader at CSEM for Automated Sample Handling within the Life Sciences and Industry 4.0 business unit. As a mechanical and biomedical engineer, he brings a unique cross-disciplinary perspective to solving bioprocessing's most challenging miniaturization problems.

What makes this conversation essential listening:

  • 96-deep-well plates are revolutionizing perfusion development: Tom reveals how CSEM's innovative fluidic lids enable continuous medium exchange in 300-microliter volumes, potentially allowing up to 96 parallel perfusion experiments with automated liquid handlers and shaker incubators
  • Three critical barriers still need solving: Despite the promise, Tom identifies the key technical challenges that must be overcome: ultra-low flow rate liquid handling (imagine exchanging 300 μL over 24 hours), effective cell retention in miniaturized systems, and cost-effective real-time biomonitoring that fits within well plate constraints
  • The future of process development is automated and intelligent: From pressure-over-liquid systems to advanced sensor integration, Tom outlines how companies can achieve near-autonomous perfusion screening—but warns that current sensing limitations mean viable cell density monitoring remains the "holy grail" of small-scale perfusion

This isn't just about smaller equipment—it's about fundamentally changing how we approach process development. If you're working in cell culture optimization, process scale-up, or bioprocess automation, Tom's insights reveal both the tremendous opportunities and practical realities of implementing next-generation perfusion systems.

For biotech professionals, staying ahead means embracing these high-throughput, data-rich models, allowing smarter, faster, and more predictive process development for the therapies of tomorrow.

Discover how bioprocessing is evolving - from high-throughput screening to digital twins and continuous manufacturing- in these expert-led episodes.

  • Episode 155: From Process Bottlenecks to Seamless Production: How Continuous Bioprocessing Changes Everything
  • Episodes 153-154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos
  • Episodes 85-86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli
  • Episodes 73-74: Bead-Based Assays: The Power of High-Throughput Screening with Sebastian Giehring

Connect with Tom Valentin:

LinkedIn: www.linkedin.com/in/tom-valentin-5bb9091b

Website: www.csem.ch/en

Email: thomas.valentin@csem.ch

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at www.bruehlmann-consulting.com/call/

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> In bioprocess development, the ability to rapidly screen conditions and predict scale-up performance can mean the difference between a successful therapy launch and costly delays. Today's Smart Biotech Scientist episode features Tom Valentin from CSEM, who's pioneering revolutionary approaches to miniaturized perfusion systems that could transform how we develop biologics.

Tom is a group leader at CSEM for Automated Sample Handling within the Life Sciences and Industry 4.0 business unit. As a mechanical and biomedical engineer, he brings a unique cross-disciplinary perspective to solving bioprocessing's most challenging miniaturization problems.

What makes this conversation essential listening:

  • 96-deep-well plates are revolutionizing perfusion development: Tom reveals how CSEM's innovative fluidic lids enable continuous medium exchange in 300-microliter volumes, potentially allowing up to 96 parallel perfusion experiments with automated liquid handlers and shaker incubators
  • Three critical barriers still need solving: Despite the promise, Tom identifies the key technical challenges that must be overcome: ultra-low flow rate liquid handling (imagine exchanging 300 μL over 24 hours), effective cell retention in miniaturized systems, and cost-effective real-time biomonitoring that fits within well plate constraints
  • The future of process development is automated and intelligent: From pressure-over-liquid systems to advanced sensor integration, Tom outlines how companies can achieve near-autonomous perfusion screening—but warns that current sensing limitations mean viable cell density monitoring remains the "holy grail" of small-scale perfusion

This isn't just about smaller equipment—it's about fundamentally changing how we approach process development. If you're working in cell culture optimization, process scale-up, or bioprocess automation, Tom's insights reveal both the tremendous opportunities and practical realities of implementing next-generation perfusion systems.

For biotech professionals, staying ahead means embracing these high-throughput, data-rich models, allowing smarter, faster, and more predictive process development for the therapies of tomorrow.

Discover how bioprocessing is evolving - from high-throughput screening to digital twins and continuous manufacturing- in these expert-led episodes.

  • Episode 155: From Process Bottlenecks to Seamless Production: How Continuous Bioprocessing Changes Everything
  • Episodes 153-154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos
  • Episodes 85-86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli
  • Episodes 73-74: Bead-Based Assays: The Power of High-Throughput Screening with Sebastian Giehring

Connect with Tom Valentin:

LinkedIn: www.linkedin.com/in/tom-valentin-5bb9091b

Website: www.csem.ch/en

Email: thomas.valentin@csem.ch

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at www.bruehlmann-consulting.com/call/

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17241613 Tue, 03 Jun 2025 05:00:00 +0200 1402 159 full false 158: How to Detect Endotoxins Without Bleeding a Single Horseshoe Crab with Anika Hoffmann - Part 2 158: How to Detect Endotoxins Without Bleeding a Single Horseshoe Crab with Anika Hoffmann - Part 2 In this concluding episode of our series on revolutionary endotoxin detection, we continue our conversation with Anika Hoffmann about transitioning from theory to practice in the quest for more reliable, sustainable testing methods. Anika is a postdoctoral researcher in analytical chemistry at HES-SO Valais-Wallis, Switzerland.

Having established why traditional LAL testing falls short in Part 1, we now explore how Anika's innovative KDO-based chemical analytical approach compares in real-world applications:

  • Greater accuracy you can trust: The new method delivers impressive 5-10% coefficient variation (compared to LAL's 25%), works across broader pH and formulation conditions, but is still working toward the sensitivity targets needed for all pharmaceutical applications
  • Clear path to regulatory acceptance: Anika outlines how companies can validate alternative methods against established standards like LAL, recombinant Factor C, or monocyte activation tests to gain approval from authorities
  • Sustainable testing strategy: Health authorities and customers are increasingly demanding sustainable alternatives as horseshoe crab populations decline while testing demand rises—adopt ethical, animal-free methods now before they become an industry requirement

Most excitingly, Anika reveals her entrepreneurial journey from accidental discovery to startup founder. Her passion for solving this critical industry challenge exemplifies how scientists can transform technical innovations into practical solutions that benefit both industry and the environment.

Whether you're a bioprocess scientist struggling with endotoxin testing, a quality assurance professional seeking more reliable methods, or someone interested in sustainable alternatives to animal-based testing, this episode provides a clear path toward a future where patient safety doesn't rely on horseshoe crab blood.

Listen now to discover how you can implement smarter endotoxin testing at your organization – and reach out to Anika via the links in our show notes if you want to be among the first to access this groundbreaking technology.

Connect with Anika Hoffmann:

LinkedIn: www.linkedin.com/in/anika-hoffmann-652ab0196/

Email: anika.hoffmann@hevs.ch

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at www.bruehlmann-consulting.com/call/

Support the show

]]> In this concluding episode of our series on revolutionary endotoxin detection, we continue our conversation with Anika Hoffmann about transitioning from theory to practice in the quest for more reliable, sustainable testing methods. Anika is a postdoctoral researcher in analytical chemistry at HES-SO Valais-Wallis, Switzerland.

Having established why traditional LAL testing falls short in Part 1, we now explore how Anika's innovative KDO-based chemical analytical approach compares in real-world applications:

  • Greater accuracy you can trust: The new method delivers impressive 5-10% coefficient variation (compared to LAL's 25%), works across broader pH and formulation conditions, but is still working toward the sensitivity targets needed for all pharmaceutical applications
  • Clear path to regulatory acceptance: Anika outlines how companies can validate alternative methods against established standards like LAL, recombinant Factor C, or monocyte activation tests to gain approval from authorities
  • Sustainable testing strategy: Health authorities and customers are increasingly demanding sustainable alternatives as horseshoe crab populations decline while testing demand rises—adopt ethical, animal-free methods now before they become an industry requirement

Most excitingly, Anika reveals her entrepreneurial journey from accidental discovery to startup founder. Her passion for solving this critical industry challenge exemplifies how scientists can transform technical innovations into practical solutions that benefit both industry and the environment.

Whether you're a bioprocess scientist struggling with endotoxin testing, a quality assurance professional seeking more reliable methods, or someone interested in sustainable alternatives to animal-based testing, this episode provides a clear path toward a future where patient safety doesn't rely on horseshoe crab blood.

Listen now to discover how you can implement smarter endotoxin testing at your organization – and reach out to Anika via the links in our show notes if you want to be among the first to access this groundbreaking technology.

Connect with Anika Hoffmann:

LinkedIn: www.linkedin.com/in/anika-hoffmann-652ab0196/

Email: anika.hoffmann@hevs.ch

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at www.bruehlmann-consulting.com/call/

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17179921 Thu, 29 May 2025 05:00:00 +0200 985 158 full false 157: How to Detect Endotoxins Without Bleeding a Single Horseshoe Crab with Anika Hoffmann - Part 1 157: How to Detect Endotoxins Without Bleeding a Single Horseshoe Crab with Anika Hoffmann - Part 1 In biopharmaceutical manufacturing, endotoxins represent a silent but deadly threat – bacterial fragments capable of triggering severe immune responses at picogram levels, potentially leading to septic shock, organ failure, or even death in patients.

In this eye-opening first episode, we speak with Anika Hoffmann, a postdoctoral researcher in analytical chemistry at HES-SO Valais-Wallis, Switzerland, who's challenging the decades-old status quo of endotoxin testing. For nearly 50 years, the industry has relied on horseshoe crab blood (LAL assay) despite its significant limitations and sustainability concerns.

Anika reveals the troubling truth about traditional testing methods:

  • The LAL reliability problem: With acceptable recovery rates ranging from 50-200% and high variability, can we truly trust our current methods?
  • The "low endotoxin recovery" phenomenon: How common pharmaceutical ingredients can mask dangerous endotoxins, creating false negatives
  • The horseshoe crab sustainability crisis: Rising testing demand threatens declining horseshoe crab populations

Most importantly, Anika introduces her groundbreaking alternative: a chemical analytical method targeting KDO, a unique sugar molecule present in all endotoxins. This approach eliminates reliance on enzymes or animal products while providing more consistent results across different pharmaceutical formulations.

With regulatory limits as strict as 0.25 EU/mL for water for injection, reliable detection isn't just a quality issue – it's a patient safety imperative. If you're developing biologics, managing bioprocess quality, or navigating regulatory compliance, this episode reveals why rethinking endotoxin testing could be your most important decision.

Listen to Part 1 to discover why smarter endotoxin testing is possible without relying on horseshoe crab blood, and stay tuned for Part 2 where we'll explore the practical implementation of this revolutionary approach.

Connect with Anika Hoffmann:

LinkedIn: www.linkedin.com/in/anika-hoffmann-652ab0196/

Email: anika.hoffmann@hevs.ch

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at www.bruehlmann-consulting.com/call/

Support the show

]]> In biopharmaceutical manufacturing, endotoxins represent a silent but deadly threat – bacterial fragments capable of triggering severe immune responses at picogram levels, potentially leading to septic shock, organ failure, or even death in patients.

In this eye-opening first episode, we speak with Anika Hoffmann, a postdoctoral researcher in analytical chemistry at HES-SO Valais-Wallis, Switzerland, who's challenging the decades-old status quo of endotoxin testing. For nearly 50 years, the industry has relied on horseshoe crab blood (LAL assay) despite its significant limitations and sustainability concerns.

Anika reveals the troubling truth about traditional testing methods:

  • The LAL reliability problem: With acceptable recovery rates ranging from 50-200% and high variability, can we truly trust our current methods?
  • The "low endotoxin recovery" phenomenon: How common pharmaceutical ingredients can mask dangerous endotoxins, creating false negatives
  • The horseshoe crab sustainability crisis: Rising testing demand threatens declining horseshoe crab populations

Most importantly, Anika introduces her groundbreaking alternative: a chemical analytical method targeting KDO, a unique sugar molecule present in all endotoxins. This approach eliminates reliance on enzymes or animal products while providing more consistent results across different pharmaceutical formulations.

With regulatory limits as strict as 0.25 EU/mL for water for injection, reliable detection isn't just a quality issue – it's a patient safety imperative. If you're developing biologics, managing bioprocess quality, or navigating regulatory compliance, this episode reveals why rethinking endotoxin testing could be your most important decision.

Listen to Part 1 to discover why smarter endotoxin testing is possible without relying on horseshoe crab blood, and stay tuned for Part 2 where we'll explore the practical implementation of this revolutionary approach.

Connect with Anika Hoffmann:

LinkedIn: www.linkedin.com/in/anika-hoffmann-652ab0196/

Email: anika.hoffmann@hevs.ch

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at www.bruehlmann-consulting.com/call/

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17179916 Tue, 27 May 2025 05:00:00 +0200 1358 157 full false 156: The Hidden Economics of Continuous Processing That Most Biotech Companies Overlook 156: The Hidden Economics of Continuous Processing That Most Biotech Companies Overlook The world of biologics manufacturing is undergoing a major transformation. Once dominated by traditional batch processes, the industry is now experiencing a marked shift toward continuous bioprocessing.

But as companies contemplate this transition, two questions dominate strategic discussions: Will regulators accept continuous manufacturing? And, perhaps more pressingly, Does the business case justify making the switch?

In this podcast episode of the Smart Biotech Scientist Podcast, David Brühlmann dives into these pivotal topics - drawing insights from real-world case studies, regulatory updates, and economic analyses.

Top three takeaways:

  • Regulators Are On Board: The FDA, EMA, and global agencies now actively support continuous processing when robust controls and monitoring are in place.
  • Real Economic Wins: Cost of goods reductions of up to 35% are possible at certain production scales, with much smaller facilities and lower risk of batch failure.
  • Hybrid & Phased Approaches Work: Companies are finding success by first investing in enabling technologies and gradually transitioning, rather than making sudden changes.

Continuous bioprocessing is no longer an experimental promise - it’s an evolving standard. With regulatory bodies championing the shift, real-world implementations proving technical and economic viability, and strong financial incentives for the right manufacturers, the transition becomes not a question of “if,” but “when.”

Curious how continuous manufacturing can fit into your strategy? Listen to this episode and share your thoughts or questions!

Next step:

Transform your bioprocess development strategy with a complimentary consultation. Schedule your expert session: https://bruehlmann-consulting.com/call

Ready to scale up? Join our exclusive 1:1 Strategy Call and learn proven methods to reduce development and manufacturing costs while maintaining product quality. Our bioprocess experts will help you navigate complex bioprocessing challenges and regulatory requirements. Limited spots available: https://stan.store/SmartBiotech

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> The world of biologics manufacturing is undergoing a major transformation. Once dominated by traditional batch processes, the industry is now experiencing a marked shift toward continuous bioprocessing.

But as companies contemplate this transition, two questions dominate strategic discussions: Will regulators accept continuous manufacturing? And, perhaps more pressingly, Does the business case justify making the switch?

In this podcast episode of the Smart Biotech Scientist Podcast, David Brühlmann dives into these pivotal topics - drawing insights from real-world case studies, regulatory updates, and economic analyses.

Top three takeaways:

  • Regulators Are On Board: The FDA, EMA, and global agencies now actively support continuous processing when robust controls and monitoring are in place.
  • Real Economic Wins: Cost of goods reductions of up to 35% are possible at certain production scales, with much smaller facilities and lower risk of batch failure.
  • Hybrid & Phased Approaches Work: Companies are finding success by first investing in enabling technologies and gradually transitioning, rather than making sudden changes.

Continuous bioprocessing is no longer an experimental promise - it’s an evolving standard. With regulatory bodies championing the shift, real-world implementations proving technical and economic viability, and strong financial incentives for the right manufacturers, the transition becomes not a question of “if,” but “when.”

Curious how continuous manufacturing can fit into your strategy? Listen to this episode and share your thoughts or questions!

Next step:

Transform your bioprocess development strategy with a complimentary consultation. Schedule your expert session: https://bruehlmann-consulting.com/call

Ready to scale up? Join our exclusive 1:1 Strategy Call and learn proven methods to reduce development and manufacturing costs while maintaining product quality. Our bioprocess experts will help you navigate complex bioprocessing challenges and regulatory requirements. Limited spots available: https://stan.store/SmartBiotech

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17179907 Thu, 22 May 2025 05:00:00 +0200 1597 156 full false 155: From Process Bottlenecks to Seamless Production: How Continuous Bioprocessing Changes Everything 155: From Process Bottlenecks to Seamless Production: How Continuous Bioprocessing Changes Everything In this episode of the Smart Biotech Scientist Podcast, host David Brühlmann dives into continuous bioprocessing - a major shift in biologics manufacturing that's turning traditional batch processes into streamlined, real-time operations.

Imagine running your biologics process non-stop for 30 days, with smart monitoring and smaller, more efficient systems replacing massive reactors. It’s not just possible - it’s already happening across the industry, from Amgen’s 80% smaller facility to Sanofi’s modular "Factory of the Future."

David explores how companies - big and small - are increasing productivity, cutting costs, and reducing waste through continuous strategies. You'll also hear about enabling technologies, phased implementation approaches, and the challenges teams are navigating as they make the shift.

Top 3 Takeaways:

  • Efficiency & Cost Savings Are Real: Amgen’s results speak volumes: 80% smaller footprint, faster deployment, and cost reductions of over 60% per gram of protein.
  • It’s Not Just for Big Pharma: Small and mid-sized biotechs are embracing continuous processes to stay competitive - gaining speed, flexibility, and lowering production costs without massive infrastructure.
  • You Don’t Have to Go All In: Challenges like cost, complexity, and workforce readiness exist - but many companies are succeeding with hybrid models, applying continuous techniques step-by-step.

What’s your take on continuous manufacturing? Tune in, share your thoughts, and join the conversation about the future of biotech production.

Next step:

Transform your bioprocess development strategy with a complimentary consultation. Schedule your expert session: https://bruehlmann-consulting.com/call

Ready to scale up? Join our exclusive 1:1 Strategy Call and learn proven methods to reduce development and manufacturing costs while maintaining product quality. Our bioprocess experts will help you navigate complex bioprocessing challenges and regulatory requirements. Limited spots available: https://stan.store/SmartBiotech

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> In this episode of the Smart Biotech Scientist Podcast, host David Brühlmann dives into continuous bioprocessing - a major shift in biologics manufacturing that's turning traditional batch processes into streamlined, real-time operations.

Imagine running your biologics process non-stop for 30 days, with smart monitoring and smaller, more efficient systems replacing massive reactors. It’s not just possible - it’s already happening across the industry, from Amgen’s 80% smaller facility to Sanofi’s modular "Factory of the Future."

David explores how companies - big and small - are increasing productivity, cutting costs, and reducing waste through continuous strategies. You'll also hear about enabling technologies, phased implementation approaches, and the challenges teams are navigating as they make the shift.

Top 3 Takeaways:

  • Efficiency & Cost Savings Are Real: Amgen’s results speak volumes: 80% smaller footprint, faster deployment, and cost reductions of over 60% per gram of protein.
  • It’s Not Just for Big Pharma: Small and mid-sized biotechs are embracing continuous processes to stay competitive - gaining speed, flexibility, and lowering production costs without massive infrastructure.
  • You Don’t Have to Go All In: Challenges like cost, complexity, and workforce readiness exist - but many companies are succeeding with hybrid models, applying continuous techniques step-by-step.

What’s your take on continuous manufacturing? Tune in, share your thoughts, and join the conversation about the future of biotech production.

Next step:

Transform your bioprocess development strategy with a complimentary consultation. Schedule your expert session: https://bruehlmann-consulting.com/call

Ready to scale up? Join our exclusive 1:1 Strategy Call and learn proven methods to reduce development and manufacturing costs while maintaining product quality. Our bioprocess experts will help you navigate complex bioprocessing challenges and regulatory requirements. Limited spots available: https://stan.store/SmartBiotech

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17173153 Tue, 20 May 2025 05:00:00 +0200 1501 155 full false 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos - Part 2 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos - Part 2 In this episode, Tiago Matos, Associate Principal Scientist/Associate Director in Bioprocess Drug Substance and Commercialization at Merck & Co., shares a critical insight: continuous manufacturing in biologics currently demands 2–3x more time and FTEs than traditional fed-batch approaches. This highlights both the complexity of the shift - and the urgency for smarter digital tools and cross-functional collaboration.

With over a decade of experience and a strong track record in biologics and smart manufacturing, Tiago brings a balanced view of the promise and practical challenges of digital transformation in bioprocessing.

Top 3 Takeaways:

  • Continuous Manufacturing is Coming - But Slowly: The infrastructure and tools aren’t fully ready. Progress depends on better-integrated solutions and stronger collaboration across industry, equipment providers, and regulators.
  • Collaboration is Key: No one drives transformation alone. Digital, automation, modeling, and process experts must work together - like building a functional protein from diverse amino acids.
  • Digital Twins and AI Will Bridge the Gap: AI, soft sensors, and digital twins will help streamline control strategies. The goal isn’t perfect models, but reliable, adaptive systems that improve in real time.

Tiago’s vision is both realistic and inspiring: the future of biologics manufacturing lies in openness, teamwork, and continuous learning.

What challenges or questions do you face in the shift to digital bioprocessing?

Here is what other guests had to say on this topic:

  • Episodes 5-6: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov;
  • Episodes 85-86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli;
  • Episodes 121-122: The Transformative World of Digital Solutions in Bioprocessing with Simon Wieninger.

Connect with Tiago Matos:

LinkedIn: www.linkedin.com/in/tiagobmatos

Merck & Co.: www.merck.com

Next step:

Transform your bioprocess development strategy with a complimentary consultation. Schedule your expert session: https://bruehlmann-consulting.com/call

Ready to scale up? Join our exclusive 1:1 Strategy Call and learn proven methods to reduce development and manufacturing costs while maintaining product quality. Our bioprocess experts will help you navigate complex bioprocessing challenges and regulatory requirements. Limited spots available: https://stan.store/SmartBiotech

Support the show

]]> In this episode, Tiago Matos, Associate Principal Scientist/Associate Director in Bioprocess Drug Substance and Commercialization at Merck & Co., shares a critical insight: continuous manufacturing in biologics currently demands 2–3x more time and FTEs than traditional fed-batch approaches. This highlights both the complexity of the shift - and the urgency for smarter digital tools and cross-functional collaboration.

With over a decade of experience and a strong track record in biologics and smart manufacturing, Tiago brings a balanced view of the promise and practical challenges of digital transformation in bioprocessing.

Top 3 Takeaways:

  • Continuous Manufacturing is Coming - But Slowly: The infrastructure and tools aren’t fully ready. Progress depends on better-integrated solutions and stronger collaboration across industry, equipment providers, and regulators.
  • Collaboration is Key: No one drives transformation alone. Digital, automation, modeling, and process experts must work together - like building a functional protein from diverse amino acids.
  • Digital Twins and AI Will Bridge the Gap: AI, soft sensors, and digital twins will help streamline control strategies. The goal isn’t perfect models, but reliable, adaptive systems that improve in real time.

Tiago’s vision is both realistic and inspiring: the future of biologics manufacturing lies in openness, teamwork, and continuous learning.

What challenges or questions do you face in the shift to digital bioprocessing?

Here is what other guests had to say on this topic:

  • Episodes 5-6: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov;
  • Episodes 85-86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli;
  • Episodes 121-122: The Transformative World of Digital Solutions in Bioprocessing with Simon Wieninger.

Connect with Tiago Matos:

LinkedIn: www.linkedin.com/in/tiagobmatos

Merck & Co.: www.merck.com

Next step:

Transform your bioprocess development strategy with a complimentary consultation. Schedule your expert session: https://bruehlmann-consulting.com/call

Ready to scale up? Join our exclusive 1:1 Strategy Call and learn proven methods to reduce development and manufacturing costs while maintaining product quality. Our bioprocess experts will help you navigate complex bioprocessing challenges and regulatory requirements. Limited spots available: https://stan.store/SmartBiotech

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17077627 Thu, 15 May 2025 05:00:00 +0200 976 154 full false 153: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos - Part 1 153: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago Matos - Part 1 As the biotechnology sector races toward digital transformation, the buzz around Industry 4.0 - with its promise of interconnected systems, automation, and data-driven operations - has never been louder. But is the industry truly ready?

In this episode, we speak with Tiago Matos, Associate Principal Scientist/Associate Director in Bioprocess Drug Substance and Commercialization at Merck & Co., who brings a grounded, insider view. Despite the hype, he says most of biopharma is still operating at an “Industry 3.2” level.

With over a decade of experience in biologics and vaccines, Tiago leads teams pushing digital innovation forward - through tools like digital twins, advanced control strategies, and smart manufacturing platforms.

Key takeaways from this episode:

  • Biotech is slowly transitioning toward true Industry 4.0, through collaboration and strategic leadership.
  • Digital twins aren’t for everything. Focused use in platform processes yields the best return - broad implementation can be costly and complex.
  • Regulators are ready. Far from being a barrier, they’re encouraging innovation and open to new ideas.

Curious to learn more? Check out the full blog post for deeper insights, and let us know your thoughts in the comments - how close do you think biomanufacturing is to a true digital revolution?

Here is what other guests had to say on this topic:

  • Episodes 5-6: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov;
  • Episodes 85-86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli;
  • Episodes 121-122: The Transformative World of Digital Solutions in Bioprocessing with Simon Wieninger.

Connect with Tiago Matos:

LinkedIn: www.linkedin.com/in/tiagobmatos

Merck & Co.: www.merck.com

Next step:

Transform your bioprocess development strategy with a complimentary consultation. Schedule your expert session: https://bruehlmann-consulting.com/call

Ready to scale up? Join our exclusive 1:1 Strategy Call and learn proven methods to reduce development and manufacturing costs while maintaining product quality. Our bioprocess experts will help you navigate complex bioprocessing challenges and regulatory requirements. Limited spots available: https://stan.store/SmartBiotech

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> As the biotechnology sector races toward digital transformation, the buzz around Industry 4.0 - with its promise of interconnected systems, automation, and data-driven operations - has never been louder. But is the industry truly ready?

In this episode, we speak with Tiago Matos, Associate Principal Scientist/Associate Director in Bioprocess Drug Substance and Commercialization at Merck & Co., who brings a grounded, insider view. Despite the hype, he says most of biopharma is still operating at an “Industry 3.2” level.

With over a decade of experience in biologics and vaccines, Tiago leads teams pushing digital innovation forward - through tools like digital twins, advanced control strategies, and smart manufacturing platforms.

Key takeaways from this episode:

  • Biotech is slowly transitioning toward true Industry 4.0, through collaboration and strategic leadership.
  • Digital twins aren’t for everything. Focused use in platform processes yields the best return - broad implementation can be costly and complex.
  • Regulators are ready. Far from being a barrier, they’re encouraging innovation and open to new ideas.

Curious to learn more? Check out the full blog post for deeper insights, and let us know your thoughts in the comments - how close do you think biomanufacturing is to a true digital revolution?

Here is what other guests had to say on this topic:

  • Episodes 5-6: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov;
  • Episodes 85-86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli;
  • Episodes 121-122: The Transformative World of Digital Solutions in Bioprocessing with Simon Wieninger.

Connect with Tiago Matos:

LinkedIn: www.linkedin.com/in/tiagobmatos

Merck & Co.: www.merck.com

Next step:

Transform your bioprocess development strategy with a complimentary consultation. Schedule your expert session: https://bruehlmann-consulting.com/call

Ready to scale up? Join our exclusive 1:1 Strategy Call and learn proven methods to reduce development and manufacturing costs while maintaining product quality. Our bioprocess experts will help you navigate complex bioprocessing challenges and regulatory requirements. Limited spots available: https://stan.store/SmartBiotech

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17077616 Tue, 13 May 2025 05:00:00 +0200 1790 153 full false 152: Is an Indian CDMO the Right Move for Your Biologics Pipeline? with Abdelaziz Toumi - Part 2 152: Is an Indian CDMO the Right Move for Your Biologics Pipeline? with Abdelaziz Toumi - Part 2 Is an Indian CDMO the right move for your biologics CMC development?

Pulling back the curtain on what might be your next strategic manufacturing advantage, this episode reveals the hidden capabilities emerging from India that leading biotech companies are racing to access. As supply chain vulnerabilities continue to expose risks in traditional manufacturing models, could the solution lie halfway around the world?

Joining us to reveal the inside story is Abdelaziz Toumi, CEO of Lupin Manufacturing Solutions and veteran of global pharma giants like Bayer, Merck and Lonza. With over 20 years in biotech, Abdelaziz brings unique insights on when and why you might want to look beyond traditional Western manufacturing partners. Our host, David Brühlmann, leverages his 15+ years of biotech industry experience to extract the practical insights you need to make informed decisions about your manufacturing strategy.

In this second segment, we'll dive deeper into the Indian CDMO and biomanufacturing landscape. Then we'll explore Lupin's specialized capabilities and finally extract Abdelaziz's most valuable leadership insight from his role as a CEO.

Key insights from this episode:

  • The One-Stop Solution Advantage: Discover how Lupin is building rare end-to-end manufacturing capabilities for complex modalities like Antibody-Drug Conjugates (ADCs) - potentially eliminating the headache of managing multiple manufacturing partners across continents.
  • Beyond Labor Cost Advantages: "Digitalization plays a key role, especially if you are operating in a cost-competitive space," explains Abdelaziz. Learn how Indian CDMOs are strategically automating key processes to drive both efficiency and quality, challenging Western perceptions.
  • Leadership Across Cultures: "Listen, listen, listen," emphasizes Abdelaziz when discussing cross-cultural leadership. Understand the subtle communication dynamics that can make or break a global manufacturing partnership, especially when navigating hierarchy-sensitive cultures.

Whether you're actively evaluating Indian manufacturing options or simply preparing for the shifting global biotech landscape, these next several minutes deliver insights you can't afford to miss.

Listen to the full episode to extract the specific capability indicators that will help you determine if and when an Indian CDMO partnership makes strategic sense for your unique biologics pipeline.

Want to find out more about the CDMO selection? Here’s what one of our distinguished guests had to say about it:

  • Episodes 103-104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma Mostafa

Connect with Abdelaziz Toumi:

LinkedIn: www.linkedin.com/in/abdelaziztoumi

Lupin Manufacturing Solutions: www.lupin.com

Next step:

Transform your process development strategy with a complimentary consultation. Schedule your expert session: https://bruehlmann-consulting.com/call

Ready to scale up? Join our exclusive 1:1 Strategy Call and learn proven methods to reduce development and manufacturing costs while maintaining product quality. Our bioprocess experts will help you navigate complex bioprocessing challenges and regulatory requirements. Limited spots available: https://stan.store/SmartBiotech

Support the show

]]> Is an Indian CDMO the right move for your biologics CMC development?

Pulling back the curtain on what might be your next strategic manufacturing advantage, this episode reveals the hidden capabilities emerging from India that leading biotech companies are racing to access. As supply chain vulnerabilities continue to expose risks in traditional manufacturing models, could the solution lie halfway around the world?

Joining us to reveal the inside story is Abdelaziz Toumi, CEO of Lupin Manufacturing Solutions and veteran of global pharma giants like Bayer, Merck and Lonza. With over 20 years in biotech, Abdelaziz brings unique insights on when and why you might want to look beyond traditional Western manufacturing partners. Our host, David Brühlmann, leverages his 15+ years of biotech industry experience to extract the practical insights you need to make informed decisions about your manufacturing strategy.

In this second segment, we'll dive deeper into the Indian CDMO and biomanufacturing landscape. Then we'll explore Lupin's specialized capabilities and finally extract Abdelaziz's most valuable leadership insight from his role as a CEO.

Key insights from this episode:

  • The One-Stop Solution Advantage: Discover how Lupin is building rare end-to-end manufacturing capabilities for complex modalities like Antibody-Drug Conjugates (ADCs) - potentially eliminating the headache of managing multiple manufacturing partners across continents.
  • Beyond Labor Cost Advantages: "Digitalization plays a key role, especially if you are operating in a cost-competitive space," explains Abdelaziz. Learn how Indian CDMOs are strategically automating key processes to drive both efficiency and quality, challenging Western perceptions.
  • Leadership Across Cultures: "Listen, listen, listen," emphasizes Abdelaziz when discussing cross-cultural leadership. Understand the subtle communication dynamics that can make or break a global manufacturing partnership, especially when navigating hierarchy-sensitive cultures.

Whether you're actively evaluating Indian manufacturing options or simply preparing for the shifting global biotech landscape, these next several minutes deliver insights you can't afford to miss.

Listen to the full episode to extract the specific capability indicators that will help you determine if and when an Indian CDMO partnership makes strategic sense for your unique biologics pipeline.

Want to find out more about the CDMO selection? Here’s what one of our distinguished guests had to say about it:

  • Episodes 103-104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma Mostafa

Connect with Abdelaziz Toumi:

LinkedIn: www.linkedin.com/in/abdelaziztoumi

Lupin Manufacturing Solutions: www.lupin.com

Next step:

Transform your process development strategy with a complimentary consultation. Schedule your expert session: https://bruehlmann-consulting.com/call

Ready to scale up? Join our exclusive 1:1 Strategy Call and learn proven methods to reduce development and manufacturing costs while maintaining product quality. Our bioprocess experts will help you navigate complex bioprocessing challenges and regulatory requirements. Limited spots available: https://stan.store/SmartBiotech

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17005354 Thu, 08 May 2025 05:00:00 +0200 1281 152 full false 151: Is an Indian CDMO the Right Move for Your Biologics Pipeline? with Abdelaziz Toumi - Part 1 151: Is an Indian CDMO the Right Move for Your Biologics Pipeline? with Abdelaziz Toumi - Part 1 Is an Indian CDMO the right move for your biologics pipeline?

As Western biotech companies seek new strategic advantages, one question keeps surfacing: Is India truly becoming the next biotech manufacturing powerhouse? And what hidden capabilities are emerging that leading companies are racing to access?

In this episode of the Smart Biotech Scientist Podcast, Abdelaziz Toumi, CEO of Lupin Manufacturing Solutions and veteran of global pharma giants like Bayer, Merck, and Lonza, joins host David Brühlmann to reveal the inside story on when and why you might want to look beyond traditional Western manufacturing partners.

Here are three key insights from their conversation:

  • The Post-Pandemic Manufacturing Revelation: "During the pandemic, we realized how vulnerable our supply chain truly is," explains Abdelaziz. Discover why diversifying manufacturing partnerships isn't just smart—it's becoming essential for resilience in an unpredictable world.
  • Beyond the Cost Advantage: While Indian CDMOs can deliver up to 80% cost savings compared to Western counterparts, Abdelaziz reveals the unexpected advantages that make the most strategic partnerships about far more than budget considerations.
  • The Trust Factor: "This is a business of trust," emphasizes Abdelaziz. Learn the critical questions that separate world-class Indian CDMOs from the rest, and the cultural nuances that can make or break your manufacturing partnership.

Ready to discover if Indian CDMOs could be the missing piece in your biologics development strategy? Tune in for expert insights on IP protection, talent access, and how to navigate the cultural dynamics that determine success in this emerging manufacturing powerhouse.

Listen to the full episode to unlock the strategic advantage that could transform your pipeline's journey from lab to market.

Want to find out more about the CDMO selection? Here’s what one of our distinguished guests had to say about it:

  • Episodes 103-104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma Mostafa

Connect with Abdelaziz Toumi:

LinkedIn: www.linkedin.com/in/abdelaziztoumi

Lupin Manufacturing Solutions: www.lupin.com

Next step:

Transform your process development strategy with a complimentary consultation. Schedule your expert session: https://bruehlmann-consulting.com/call

Ready to scale up? Join our exclusive 1:1 Strategy Call and learn proven methods to reduce development and manufacturing costs while maintaining product quality. Our bioprocess experts will help you navigate complex bioprocessing challenges and regulatory requirements. Limited spots available: https://stan.store/SmartBiotech

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Is an Indian CDMO the right move for your biologics pipeline?

As Western biotech companies seek new strategic advantages, one question keeps surfacing: Is India truly becoming the next biotech manufacturing powerhouse? And what hidden capabilities are emerging that leading companies are racing to access?

In this episode of the Smart Biotech Scientist Podcast, Abdelaziz Toumi, CEO of Lupin Manufacturing Solutions and veteran of global pharma giants like Bayer, Merck, and Lonza, joins host David Brühlmann to reveal the inside story on when and why you might want to look beyond traditional Western manufacturing partners.

Here are three key insights from their conversation:

  • The Post-Pandemic Manufacturing Revelation: "During the pandemic, we realized how vulnerable our supply chain truly is," explains Abdelaziz. Discover why diversifying manufacturing partnerships isn't just smart—it's becoming essential for resilience in an unpredictable world.
  • Beyond the Cost Advantage: While Indian CDMOs can deliver up to 80% cost savings compared to Western counterparts, Abdelaziz reveals the unexpected advantages that make the most strategic partnerships about far more than budget considerations.
  • The Trust Factor: "This is a business of trust," emphasizes Abdelaziz. Learn the critical questions that separate world-class Indian CDMOs from the rest, and the cultural nuances that can make or break your manufacturing partnership.

Ready to discover if Indian CDMOs could be the missing piece in your biologics development strategy? Tune in for expert insights on IP protection, talent access, and how to navigate the cultural dynamics that determine success in this emerging manufacturing powerhouse.

Listen to the full episode to unlock the strategic advantage that could transform your pipeline's journey from lab to market.

Want to find out more about the CDMO selection? Here’s what one of our distinguished guests had to say about it:

  • Episodes 103-104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma Mostafa

Connect with Abdelaziz Toumi:

LinkedIn: www.linkedin.com/in/abdelaziztoumi

Lupin Manufacturing Solutions: www.lupin.com

Next step:

Transform your process development strategy with a complimentary consultation. Schedule your expert session: https://bruehlmann-consulting.com/call

Ready to scale up? Join our exclusive 1:1 Strategy Call and learn proven methods to reduce development and manufacturing costs while maintaining product quality. Our bioprocess experts will help you navigate complex bioprocessing challenges and regulatory requirements. Limited spots available: https://stan.store/SmartBiotech

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17005933 Tue, 06 May 2025 05:00:00 +0200 1669 151 full false 150: How to Leverage AI in Media Development Without Sacrificing Process Understanding with Tom Fletcher - Part 2 150: How to Leverage AI in Media Development Without Sacrificing Process Understanding with Tom Fletcher - Part 2 As biotech labs rush to adopt AI tools for cell culture media development, a critical question emerges: Are we creating a generation of scientists who know which buttons to push but not why they're pushing them? The automation trap that once transformed laboratory workflows now threatens to fundamentally alter how we understand the complex dynamics of culture media composition and performance.

In this second part of our conversation with Tom Fletcher, R&D Director at Fujifilm Irvine Scientific, host David Brühlmann explores the practical challenges of implementing AI in cell culture media development while preserving the scientific thinking that drives true innovation.

Key Insights from Their Conversation:

  • The Knowledge Generation Imperative: "Don't just think of your job as picking winners out of random experiments," Tom warns. He emphasizes that scientists must prioritize understanding why a specific media formulation works, not just that it works—a distinction that becomes critical as AI makes high-throughput media screening increasingly accessible.
  • Bridging Disciplinary Divides: As teams become more diverse—incorporating data scientists, automation specialists, and traditional bioprocess experts—success depends on creating a collaborative culture where specialists learn to leverage each other's strengths without expecting everyone to have the same foundation in cell culture fundamentals.
  • The Future Bioprocessing Landscape: Tom predicts that while platform media will dominate for speed to clinic, human roles will evolve toward managing automated, digitalized processes with fewer but more technically specialized staff. The media developers who thrive will be those who can maintain scientific rigor while harnessing the power of automation.

For biotech leaders navigating this technological transition, Tom's advice is clear: "Embrace AI because I think we all believe it's valuable, but don't allow lazy science to creep in... if you don't resist it, people are going to get lazy and just say 'I've got this supercomputer and I know which buttons to push.' That's not good enough."

If you enjoyed this conversation, be sure to explore how it all began:

  • Episodes 1-2: Unlock the Power of Rational Media Design in Bioprocessing with Tom Fletcher

Connect with Tom Fletcher:

LinkedIn: www.linkedin.com/in/tomfletcher2

FUJIFILM Irvine Scientific: www.irvinesci.com

The views and opinions expressed by Tom Fletcher are his own and do not necessarily reflect those of Fujifilm Irvine Scientific or its affiliates.

Next step:

Transform your cell culture media development strategy with a complimentary consultation. Schedule your expert session: https://bruehlmann-consulting.com/call

Ready to scale up? Join our exclusive 1:1 Strategy Call and learn proven methods to reduce development and manufacturing costs while maintaining product quality. Our bioprocess experts will help you navigate complex bioprocessing challenges and regulatory requirements. Limited spots available: https://stan.store/SmartBiotech

Note: These are Tom’s personal opinions and not his company’s.

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> As biotech labs rush to adopt AI tools for cell culture media development, a critical question emerges: Are we creating a generation of scientists who know which buttons to push but not why they're pushing them? The automation trap that once transformed laboratory workflows now threatens to fundamentally alter how we understand the complex dynamics of culture media composition and performance.

In this second part of our conversation with Tom Fletcher, R&D Director at Fujifilm Irvine Scientific, host David Brühlmann explores the practical challenges of implementing AI in cell culture media development while preserving the scientific thinking that drives true innovation.

Key Insights from Their Conversation:

  • The Knowledge Generation Imperative: "Don't just think of your job as picking winners out of random experiments," Tom warns. He emphasizes that scientists must prioritize understanding why a specific media formulation works, not just that it works—a distinction that becomes critical as AI makes high-throughput media screening increasingly accessible.
  • Bridging Disciplinary Divides: As teams become more diverse—incorporating data scientists, automation specialists, and traditional bioprocess experts—success depends on creating a collaborative culture where specialists learn to leverage each other's strengths without expecting everyone to have the same foundation in cell culture fundamentals.
  • The Future Bioprocessing Landscape: Tom predicts that while platform media will dominate for speed to clinic, human roles will evolve toward managing automated, digitalized processes with fewer but more technically specialized staff. The media developers who thrive will be those who can maintain scientific rigor while harnessing the power of automation.

For biotech leaders navigating this technological transition, Tom's advice is clear: "Embrace AI because I think we all believe it's valuable, but don't allow lazy science to creep in... if you don't resist it, people are going to get lazy and just say 'I've got this supercomputer and I know which buttons to push.' That's not good enough."

If you enjoyed this conversation, be sure to explore how it all began:

  • Episodes 1-2: Unlock the Power of Rational Media Design in Bioprocessing with Tom Fletcher

Connect with Tom Fletcher:

LinkedIn: www.linkedin.com/in/tomfletcher2

FUJIFILM Irvine Scientific: www.irvinesci.com

The views and opinions expressed by Tom Fletcher are his own and do not necessarily reflect those of Fujifilm Irvine Scientific or its affiliates.

Next step:

Transform your cell culture media development strategy with a complimentary consultation. Schedule your expert session: https://bruehlmann-consulting.com/call

Ready to scale up? Join our exclusive 1:1 Strategy Call and learn proven methods to reduce development and manufacturing costs while maintaining product quality. Our bioprocess experts will help you navigate complex bioprocessing challenges and regulatory requirements. Limited spots available: https://stan.store/SmartBiotech

Note: These are Tom’s personal opinions and not his company’s.

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17005343 Thu, 01 May 2025 05:00:00 +0200 1496 150 full false 149: How to Leverage AI in Media Development Without Sacrificing Process Understanding with Tom Fletcher - Part 1 149: How to Leverage AI in Media Development Without Sacrificing Process Understanding with Tom Fletcher - Part 1 From closely-guarded secrets to complex chemical interactions, cell culture media development has transformed from an afterthought to a critical competitive advantage in modern bioprocessing. But as AI and automation revolutionize the field, are we at risk of gaining speed while losing understanding?

In this eye-opening episode of the Smart Biotech Scientist Podcast, host David Brühlmann speaks with Tom Fletcher, R&D Director at Fujifilm Irvine Scientific, who brings over 30 years of experience and a unique perspective on balancing technological innovation with scientific rigor.

Key Insights from Their Conversation:

  • The Evolution of Media Formulations: Tom traces the remarkable journey from basic serum supplements to today's chemically defined media with 60-70+ precisely balanced components, transforming what was once "just that stuff you bought" into one of bioprocessing's most closely guarded competitive advantages.
  • The Collaborative Intelligence Framework: The most powerful approach combines artificial intelligence with human intelligence (AI + HI = CI), where technology enhances rather than replaces scientific thinking to generate not just data, but genuine process understanding.
  • Avoiding the Automation Trap: "Don't get lazy with technology," Tom warns, emphasizing that the goal remains generating knowledge about why processes work, not just identifying which conditions perform best—a crucial mindset as companies increasingly adopt powerful AI tools.

If you enjoyed this conversation, be sure to explore how it all began:

  • Episodes 1-2: Unlock the Power of Rational Media Design in Bioprocessing with Tom Fletcher

Connect with Tom Fletcher:

LinkedIn: www.linkedin.com/in/tomfletcher2

FUJIFILM Irvine Scientific: www.irvinesci.com

The views and opinions expressed by Tom Fletcher are his own and do not necessarily reflect those of Fujifilm Irvine Scientific or its affiliates.

Next step:

Transform your cell culture media development strategy with a complimentary consultation. Schedule your expert session: https://bruehlmann-consulting.com/call

Ready to scale up? Join our exclusive 1:1 Strategy Call and learn proven methods to reduce development and manufacturing costs while maintaining product quality. Our bioprocess experts will help you navigate complex bioprocessing challenges and regulatory requirements. Limited spots available: https://stan.store/SmartBiotech

Support the show

]]> From closely-guarded secrets to complex chemical interactions, cell culture media development has transformed from an afterthought to a critical competitive advantage in modern bioprocessing. But as AI and automation revolutionize the field, are we at risk of gaining speed while losing understanding?

In this eye-opening episode of the Smart Biotech Scientist Podcast, host David Brühlmann speaks with Tom Fletcher, R&D Director at Fujifilm Irvine Scientific, who brings over 30 years of experience and a unique perspective on balancing technological innovation with scientific rigor.

Key Insights from Their Conversation:

  • The Evolution of Media Formulations: Tom traces the remarkable journey from basic serum supplements to today's chemically defined media with 60-70+ precisely balanced components, transforming what was once "just that stuff you bought" into one of bioprocessing's most closely guarded competitive advantages.
  • The Collaborative Intelligence Framework: The most powerful approach combines artificial intelligence with human intelligence (AI + HI = CI), where technology enhances rather than replaces scientific thinking to generate not just data, but genuine process understanding.
  • Avoiding the Automation Trap: "Don't get lazy with technology," Tom warns, emphasizing that the goal remains generating knowledge about why processes work, not just identifying which conditions perform best—a crucial mindset as companies increasingly adopt powerful AI tools.

If you enjoyed this conversation, be sure to explore how it all began:

  • Episodes 1-2: Unlock the Power of Rational Media Design in Bioprocessing with Tom Fletcher

Connect with Tom Fletcher:

LinkedIn: www.linkedin.com/in/tomfletcher2

FUJIFILM Irvine Scientific: www.irvinesci.com

The views and opinions expressed by Tom Fletcher are his own and do not necessarily reflect those of Fujifilm Irvine Scientific or its affiliates.

Next step:

Transform your cell culture media development strategy with a complimentary consultation. Schedule your expert session: https://bruehlmann-consulting.com/call

Ready to scale up? Join our exclusive 1:1 Strategy Call and learn proven methods to reduce development and manufacturing costs while maintaining product quality. Our bioprocess experts will help you navigate complex bioprocessing challenges and regulatory requirements. Limited spots available: https://stan.store/SmartBiotech

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-17005332 Tue, 29 Apr 2025 05:00:00 +0200 1108 149 full false 148: Lab-Grown Blood: How Stem Cells Transform Transfusions with Ari Gargir - Part 2 148: Lab-Grown Blood: How Stem Cells Transform Transfusions with Ari Gargir - Part 2 In the wake of the COVID-19 pandemic, the fragility of global blood supply systems became undeniably clear. Recognizing the urgent need for a more reliable and universal solution, Ari Gargir and his team at RedC Biotech are leading an ambitious effort to transform blood supply as we know it. Their mission? To develop lab-grown red blood cells that not only address chronic shortages but also overcome blood type compatibility - an innovation with the potential to reshape modern medicine.

As the CEO and founder of RedC Biotech, Ari brings a powerful personal story to this mission. After a near-fatal paragliding accident, a life-saving transfusion ignited his determination to create a scalable, donor-free blood alternative. Now, through pioneering bioprocessing techniques, he and his team are working to produce universal red blood cells that could serve nearly anyone, anywhere.

In this episode, we explore:

  • Bioprocessing Breakthroughs: How RedC Biotech transforms stem cells into red blood cells - scaling from lab flasks to industrial bioreactors - and the key challenges in making this process scalable and cost-effective.
  • Quality and Cost Challenges: The rigorous standards for safety, efficacy, and affordability, and how RedC Bioteh is tackling them to produce viable blood units at scale.
  • Why Now? - Ari shares why this moment is uniquely suited for breakthroughs in blood biotech, thanks to recent advancements in Induced pluripotent stem cell (iPSC) technology and hard lessons learned from COVID-19.

Listen to the full episode for Ari’s insights and advice for biotech entrepreneurs navigating bold, high-impact innovations.

Connect with Ari Gargir:

LinkedIn: www.linkedin.com/in/ari-gargir-7107035

RedC Biotech: www.redcbiotech.com

Next step:

Transform your bioprocess development strategy with a complimentary consultation. Schedule your expert session: https://bruehlmann-consulting.com/call

Ready to scale up? Join our exclusive 1:1 Strategy Call and learn proven methods to reduce development and manufacturing costs while maintaining product quality. Our bioprocess experts will help you navigate complex bioprocessing challenges and regulatory requirements. Limited spots available: https://stan.store/SmartBiotech

Support the show

]]> In the wake of the COVID-19 pandemic, the fragility of global blood supply systems became undeniably clear. Recognizing the urgent need for a more reliable and universal solution, Ari Gargir and his team at RedC Biotech are leading an ambitious effort to transform blood supply as we know it. Their mission? To develop lab-grown red blood cells that not only address chronic shortages but also overcome blood type compatibility - an innovation with the potential to reshape modern medicine.

As the CEO and founder of RedC Biotech, Ari brings a powerful personal story to this mission. After a near-fatal paragliding accident, a life-saving transfusion ignited his determination to create a scalable, donor-free blood alternative. Now, through pioneering bioprocessing techniques, he and his team are working to produce universal red blood cells that could serve nearly anyone, anywhere.

In this episode, we explore:

  • Bioprocessing Breakthroughs: How RedC Biotech transforms stem cells into red blood cells - scaling from lab flasks to industrial bioreactors - and the key challenges in making this process scalable and cost-effective.
  • Quality and Cost Challenges: The rigorous standards for safety, efficacy, and affordability, and how RedC Bioteh is tackling them to produce viable blood units at scale.
  • Why Now? - Ari shares why this moment is uniquely suited for breakthroughs in blood biotech, thanks to recent advancements in Induced pluripotent stem cell (iPSC) technology and hard lessons learned from COVID-19.

Listen to the full episode for Ari’s insights and advice for biotech entrepreneurs navigating bold, high-impact innovations.

Connect with Ari Gargir:

LinkedIn: www.linkedin.com/in/ari-gargir-7107035

RedC Biotech: www.redcbiotech.com

Next step:

Transform your bioprocess development strategy with a complimentary consultation. Schedule your expert session: https://bruehlmann-consulting.com/call

Ready to scale up? Join our exclusive 1:1 Strategy Call and learn proven methods to reduce development and manufacturing costs while maintaining product quality. Our bioprocess experts will help you navigate complex bioprocessing challenges and regulatory requirements. Limited spots available: https://stan.store/SmartBiotech

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-16982810 Thu, 24 Apr 2025 05:00:00 +0200 977 148 full false 147: Lab-Grown Blood: How Stem Cells Transform Transfusions with Ari Gargir - Part 1 147: Lab-Grown Blood: How Stem Cells Transform Transfusions with Ari Gargir - Part 1 Blood is critical to global healthcare - vital for surgeries, trauma care, cancer treatment, and maternal health. Yet despite 120 million donations each year, a 100 million unit shortfall means nearly half the world’s needs go unmet.

One person who understands this crisis firsthand is Ari Gargir, CEO & Founder of RedC Biotech. After surviving a paragliding accident thanks to a life-saving transfusion, he set out to tackle the global blood shortage. His team is now developing universal, lab-grown red blood cells, eliminating the need for donors.

The added transitional phrase creates a smoother flow between the global problem and the personal story that follows.

Don’t miss these key insights from the full conversation:

  • The Global Crisis: Ari painted a vivid picture of the current state of blood supply. The problem is multifaceted - logistical issues, biological challenges, and socio-economic disparities in blood distribution exacerbate this shortage. Developed nations possess more blood resources, but low-income countries, where donation rates are staggeringly low, continually grapple with severe shortages.
  • Innovative Solutions: We learned about the groundbreaking technology Ari is developing at RedC Biotech. Using stem cells, they aim to create unlimited, universal, and donor-free red blood cells. This could be a game-changer, not only for transfusions but also for advanced therapeutic uses.
  • Impact on Healthcare: Ari is a strong advocate for O-negative blood, which can be used for up to 98% of people. But he’s especially focused on vulnerable patients - those with sickle cell disease, thalassemia, and complex immune conditions - who may need frequent transfusions.

Our conversation with Ari underscores the importance of innovation in biotechnology to address critical global healthcare issues. By creating a reliable, scalable supply of red blood cells, RedC Biotech holds the promise of saving countless lives and improving the quality of life for those dependent on regular blood transfusions.

Tune in to hear how Ari and RedC Biotech are shaping the future of transfusion medicine.

Connect with Ari Gargir:

LinkedIn: www.linkedin.com/in/ari-gargir-7107035

RedC Biotech: www.redcbiotech.com

Next step:

Transform your bioprocess development strategy with a complimentary consultation. Schedule your expert session: https://bruehlmann-consulting.com/call

Ready to scale up? Join our exclusive 1:1 Strategy Call and learn proven methods to reduce development and manufacturing costs while maintaining product quality. Our bioprocess experts will help you navigate complex bioprocessing challenges and regulatory requirements. Limited spots available: https://stan.store/SmartBiotech

Support the show

]]> Blood is critical to global healthcare - vital for surgeries, trauma care, cancer treatment, and maternal health. Yet despite 120 million donations each year, a 100 million unit shortfall means nearly half the world’s needs go unmet.

One person who understands this crisis firsthand is Ari Gargir, CEO & Founder of RedC Biotech. After surviving a paragliding accident thanks to a life-saving transfusion, he set out to tackle the global blood shortage. His team is now developing universal, lab-grown red blood cells, eliminating the need for donors.

The added transitional phrase creates a smoother flow between the global problem and the personal story that follows.

Don’t miss these key insights from the full conversation:

  • The Global Crisis: Ari painted a vivid picture of the current state of blood supply. The problem is multifaceted - logistical issues, biological challenges, and socio-economic disparities in blood distribution exacerbate this shortage. Developed nations possess more blood resources, but low-income countries, where donation rates are staggeringly low, continually grapple with severe shortages.
  • Innovative Solutions: We learned about the groundbreaking technology Ari is developing at RedC Biotech. Using stem cells, they aim to create unlimited, universal, and donor-free red blood cells. This could be a game-changer, not only for transfusions but also for advanced therapeutic uses.
  • Impact on Healthcare: Ari is a strong advocate for O-negative blood, which can be used for up to 98% of people. But he’s especially focused on vulnerable patients - those with sickle cell disease, thalassemia, and complex immune conditions - who may need frequent transfusions.

Our conversation with Ari underscores the importance of innovation in biotechnology to address critical global healthcare issues. By creating a reliable, scalable supply of red blood cells, RedC Biotech holds the promise of saving countless lives and improving the quality of life for those dependent on regular blood transfusions.

Tune in to hear how Ari and RedC Biotech are shaping the future of transfusion medicine.

Connect with Ari Gargir:

LinkedIn: www.linkedin.com/in/ari-gargir-7107035

RedC Biotech: www.redcbiotech.com

Next step:

Transform your bioprocess development strategy with a complimentary consultation. Schedule your expert session: https://bruehlmann-consulting.com/call

Ready to scale up? Join our exclusive 1:1 Strategy Call and learn proven methods to reduce development and manufacturing costs while maintaining product quality. Our bioprocess experts will help you navigate complex bioprocessing challenges and regulatory requirements. Limited spots available: https://stan.store/SmartBiotech

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-16982790 Tue, 22 Apr 2025 05:00:00 +0200 1322 147 full false 146: Beyond ELISA: The 10-Minute Immunoassay Enabling Real-Time Bioprocess Control with Bruno Oesch - Part 2 146: Beyond ELISA: The 10-Minute Immunoassay Enabling Real-Time Bioprocess Control with Bruno Oesch - Part 2 Stuck with outdated analytics while trying to develop cutting-edge therapies? Part 2 of our conversation with Bruno Oesch, CEO and founder of Elionova, reveals how biotech scientists can finally break free from incremental improvements and embrace the revolutionary immunoassay technology that's transforming bioprocessing workflows worldwide.

For years, ELISA (Enzyme-Linked Immunosorbent Assay) has been vital in biotechnology, but its time-consuming protocols and complex washing steps slow bioprocess development, creating bottlenecks in advancing therapies.

Bruno's team is transforming the field of immunoassays with an innovative technology that delivers quantitative results in just 10 minutes—without the need for washing steps.

Here are three key takeaways from the conversation:

  • Market Introduction Strategy: Bruno emphasizes the importance of placing the product directly in the hands of potential customers. By offering free trials, users can experience its value firsthand, creating a strong incentive for continued use.
  • Building an Open Community: Elionova fosters a collaborative environment where users can develop and share assays. Their vision follows an app store model, encouraging innovation and knowledge exchange within the biotech space.
  • Vision for the Future: Beginning with research labs, Elionova aims to expand into diagnostics, particularly in veterinary medicine, due to lower regulatory hurdles. Their long-term goal is to make a significant impact in point-of-care diagnostics, offering rapid results crucial for emergency medical scenarios.

If you're a biotech professional looking to streamline bioprocess workflows and drive innovation, Bruno Oesch’s transformative approach may provide the inspiration you need. Stay ahead of industry advancements by tuning into this episode to learn more about connecting with Oesch and exploring Elionova’s novel technology.

Connect with Bruno Oesch:

LinkedIn: www.linkedin.com/in/bruno-oesch

Elionova: www.elionova.com

Next step:

Ready to revolutionize your bioprocess workflows? Book a free consultation at https://bruehlmann-consulting.com/call to discover how real-time analytics can transform your development timeline.

Support the show

]]> Stuck with outdated analytics while trying to develop cutting-edge therapies? Part 2 of our conversation with Bruno Oesch, CEO and founder of Elionova, reveals how biotech scientists can finally break free from incremental improvements and embrace the revolutionary immunoassay technology that's transforming bioprocessing workflows worldwide.

For years, ELISA (Enzyme-Linked Immunosorbent Assay) has been vital in biotechnology, but its time-consuming protocols and complex washing steps slow bioprocess development, creating bottlenecks in advancing therapies.

Bruno's team is transforming the field of immunoassays with an innovative technology that delivers quantitative results in just 10 minutes—without the need for washing steps.

Here are three key takeaways from the conversation:

  • Market Introduction Strategy: Bruno emphasizes the importance of placing the product directly in the hands of potential customers. By offering free trials, users can experience its value firsthand, creating a strong incentive for continued use.
  • Building an Open Community: Elionova fosters a collaborative environment where users can develop and share assays. Their vision follows an app store model, encouraging innovation and knowledge exchange within the biotech space.
  • Vision for the Future: Beginning with research labs, Elionova aims to expand into diagnostics, particularly in veterinary medicine, due to lower regulatory hurdles. Their long-term goal is to make a significant impact in point-of-care diagnostics, offering rapid results crucial for emergency medical scenarios.

If you're a biotech professional looking to streamline bioprocess workflows and drive innovation, Bruno Oesch’s transformative approach may provide the inspiration you need. Stay ahead of industry advancements by tuning into this episode to learn more about connecting with Oesch and exploring Elionova’s novel technology.

Connect with Bruno Oesch:

LinkedIn: www.linkedin.com/in/bruno-oesch

Elionova: www.elionova.com

Next step:

Ready to revolutionize your bioprocess workflows? Book a free consultation at https://bruehlmann-consulting.com/call to discover how real-time analytics can transform your development timeline.

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-16921980 Thu, 17 Apr 2025 05:00:00 +0200 1089 146 full false 145: Beyond ELISA: The 10-Minute Immunoassay Enabling Real-Time Bioprocess Control with Bruno Oesch - Part 1 145: Beyond ELISA: The 10-Minute Immunoassay Enabling Real-Time Bioprocess Control with Bruno Oesch - Part 1 Tired of waiting overnight for ELISA results? Serial entrepreneur Bruno Oesch reveals how his groundbreaking 10-minute immunoassay technology is eliminating the biggest bottleneck in bioprocessing workflows.

From contributing to Nobel Prize-winning prion research to founding Prionics (the first commercial BSE test) and now revolutionizing immunoassays with Elionova, Bruno transforms high-end science into practical solutions that work for everyday labs.

Here are three takeaways from this podcast episode:

  • ELISA - The Lab Workhorse That Still Matters: Since the 1970s, ELISA assays have been a cornerstone of bioprocessing and diagnostics. As Bruno Oesch puts it, they remain the "workhorses of biochemical labs." Despite requiring over four hours of binding and washing steps, ELISA remains widely used for its affordability and reliability. However, its slow, linear workflow calls for innovation.
  • ElioDX - The Next-Gen Immunoassay: While Elionova didn’t invent evanescence, they’ve made it accessible and practical. Instead of lengthy washes, a laser-generated evanescent field enables real-time detection, delivering results in just 10 minutes by measuring signal changes dynamically.
  • The Future of Real-Time Bioprocessing: This breakthrough eliminates bottlenecks in biotech workflows. By integrating real-time analysis, ElioDX enhances efficiency, decision-making, and continuous bioprocessing, ensuring precise insights exactly when they’re needed.

As David and Bruno highlight, the future of immunoassays isn’t just about innovation - it’s about making these advancements practical and transformative across the industry.

By bridging science and accessibility, leaders like Bruno Oesch play a crucial role in demystifying bioprocessing, sparking impactful discussions, and driving real change in the scientific community.

Listen to the full discussion to explore how this real-time approach can streamline bioprocessing and transform your workflows.

Connect with Bruno Oesch:

LinkedIn: www.linkedin.com/in/bruno-oesch

Elionova: www.elionova.com

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Tired of waiting overnight for ELISA results? Serial entrepreneur Bruno Oesch reveals how his groundbreaking 10-minute immunoassay technology is eliminating the biggest bottleneck in bioprocessing workflows.

From contributing to Nobel Prize-winning prion research to founding Prionics (the first commercial BSE test) and now revolutionizing immunoassays with Elionova, Bruno transforms high-end science into practical solutions that work for everyday labs.

Here are three takeaways from this podcast episode:

  • ELISA - The Lab Workhorse That Still Matters: Since the 1970s, ELISA assays have been a cornerstone of bioprocessing and diagnostics. As Bruno Oesch puts it, they remain the "workhorses of biochemical labs." Despite requiring over four hours of binding and washing steps, ELISA remains widely used for its affordability and reliability. However, its slow, linear workflow calls for innovation.
  • ElioDX - The Next-Gen Immunoassay: While Elionova didn’t invent evanescence, they’ve made it accessible and practical. Instead of lengthy washes, a laser-generated evanescent field enables real-time detection, delivering results in just 10 minutes by measuring signal changes dynamically.
  • The Future of Real-Time Bioprocessing: This breakthrough eliminates bottlenecks in biotech workflows. By integrating real-time analysis, ElioDX enhances efficiency, decision-making, and continuous bioprocessing, ensuring precise insights exactly when they’re needed.

As David and Bruno highlight, the future of immunoassays isn’t just about innovation - it’s about making these advancements practical and transformative across the industry.

By bridging science and accessibility, leaders like Bruno Oesch play a crucial role in demystifying bioprocessing, sparking impactful discussions, and driving real change in the scientific community.

Listen to the full discussion to explore how this real-time approach can streamline bioprocessing and transform your workflows.

Connect with Bruno Oesch:

LinkedIn: www.linkedin.com/in/bruno-oesch

Elionova: www.elionova.com

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocessing analytics: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-16921973 Tue, 15 Apr 2025 05:00:00 +0200 1691 145 full false 144: The Future of Biotech: Making Biotherapeutics More Accessible Faster 144: The Future of Biotech: Making Biotherapeutics More Accessible Faster Imagine a future where every patient can access life-saving therapies and sustainable, high-quality food is within everyone’s reach. In this episode of the Smart Biotech Scientist, David Brühlmann explores how innovative biotech developments are making this vision a reality.

Here’s a sneak peek of the breakthroughs covered:

  • AI-Powered Picoliter Scale Testing: Discover how companies like Triple Bar Bio are pushing the boundaries of what's possible with their innovative microfluidic technology that screens individual cells. Their approach enables rapid identification the best cell producers, paving the way for more efficient and precise bio-manufacturing.
  • Hybrid Models for Process Prediction: Learn about DataHow's cutting-edge hybrid models that predicts process outcomes and improves product quality. Their models have demonstrated the potential to reduce the number of experiments by up to 80%.
  • Unconventional Bioreactor Approaches: Explore an intriguing proposition – could tomorrow's bioreactors be living organisms like goats? BioSourcing is exploring the potential of transgenic goats to produce biopharmaceuticals more affordably, a concept that could dramatically lower production costs and enhance accessibility.

The future of biotech is not just about technological advancement; it’s about embracing the impact these innovations can have globally. As David urges, the challenge is no longer about if these changes will happen, but how quickly we can achieve them.

Stay curious, keep innovating, and be part of this exciting transformation in biotech. Your contributions and feedback could shape the next generation of breakthroughs.

Listen, learn, and let us know what you think about these advancements. We can’t wait to hear from you!

If you enjoyed this, here are some episodes worth listening:

  • Episode 135: Beyond Breakthroughs: Making Biotherapeutics Affordable for All
  • Episode 136: 5 Roadblocks to Affordable Biologics (And How to Overcome Them)
  • Episodes 127-128: The 7 Hidden Innovation Habits That Top Biotech Scientists Use Daily
  • Episode 87: The Hidden Pitfalls of Bioprocess Development: Lessons from the Trenches
  • Episodes 41-42: Revealing the Disciplined Pursuit of Less in Bioprocessing

Next step:

Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free consultation to propel your success: https://bruehlmann-consulting.com/call

Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech

Support the show

]]> Imagine a future where every patient can access life-saving therapies and sustainable, high-quality food is within everyone’s reach. In this episode of the Smart Biotech Scientist, David Brühlmann explores how innovative biotech developments are making this vision a reality.

Here’s a sneak peek of the breakthroughs covered:

  • AI-Powered Picoliter Scale Testing: Discover how companies like Triple Bar Bio are pushing the boundaries of what's possible with their innovative microfluidic technology that screens individual cells. Their approach enables rapid identification the best cell producers, paving the way for more efficient and precise bio-manufacturing.
  • Hybrid Models for Process Prediction: Learn about DataHow's cutting-edge hybrid models that predicts process outcomes and improves product quality. Their models have demonstrated the potential to reduce the number of experiments by up to 80%.
  • Unconventional Bioreactor Approaches: Explore an intriguing proposition – could tomorrow's bioreactors be living organisms like goats? BioSourcing is exploring the potential of transgenic goats to produce biopharmaceuticals more affordably, a concept that could dramatically lower production costs and enhance accessibility.

The future of biotech is not just about technological advancement; it’s about embracing the impact these innovations can have globally. As David urges, the challenge is no longer about if these changes will happen, but how quickly we can achieve them.

Stay curious, keep innovating, and be part of this exciting transformation in biotech. Your contributions and feedback could shape the next generation of breakthroughs.

Listen, learn, and let us know what you think about these advancements. We can’t wait to hear from you!

If you enjoyed this, here are some episodes worth listening:

  • Episode 135: Beyond Breakthroughs: Making Biotherapeutics Affordable for All
  • Episode 136: 5 Roadblocks to Affordable Biologics (And How to Overcome Them)
  • Episodes 127-128: The 7 Hidden Innovation Habits That Top Biotech Scientists Use Daily
  • Episode 87: The Hidden Pitfalls of Bioprocess Development: Lessons from the Trenches
  • Episodes 41-42: Revealing the Disciplined Pursuit of Less in Bioprocessing

Next step:

Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free consultation to propel your success: https://bruehlmann-consulting.com/call

Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-16814688 Thu, 10 Apr 2025 05:00:00 +0200 775 144 full false 143: Bioprocess Breakthroughs: How Smart Bioprocessing Is Democratizing Life-Saving Treatments 143: Bioprocess Breakthroughs: How Smart Bioprocessing Is Democratizing Life-Saving Treatments In the rapidly evolving world of biotechnology, innovation is not just happening at the molecular level. Industry leaders are making groundbreaking advancements in bioprocessing - a crucial component in making life-saving therapies more accessible and affordable.

The journey to affordable therapies starts with the production process itself. In this podcast episode, David Brühlmann sheds light on innovations in bioprocess design that are setting new standards in efficiency and efficacy. At the heart of this transformation is the shift from traditional process formats like fed-batch to continuous process formats, quality by design approaches, and the implementation of breakthrough technologies.

Here's a quick rundown of the key takeaways:

  • Revolutionary Process Designs: Industry leaders are enhancing bioprocess designs—from antibody production enhancements to integrating perfusion mode. One case study highlighted a dramatic increase in viable cell density and protein titers through intensified processes.
  • Quality Control Innovations: Companies like Cyto-Facto are pioneering quality by design in the challenging cell and gene therapy space. By leveraging sophisticated PAT systems, they can monitor critical process parameters in real-time, ensuring consistent quality even in complex bioprocesses.
  • Metabolite Shifts and Efficacy: A surprising discovery revealed the power of metabolite shifts induced by cell culture media design, inspired by an intriguing study on cyclists, to enhance antibody efficacy and stability. This opens new possibilities for engineering the quality of biopharmaceuticals through simple modifications in the culturing process.

The innovations discussed in the Smart Biotech Scientist illustrate a pivotal transformation in bioprocessing. By rethinking process designs and committing to quality control, the biotech industry is paving the way for groundbreaking therapies that are not just dreams but realities - realities that are tangibly more accessible to patients worldwide.

As we anticipate more developments in this field, the promise of biotech becomes increasingly certain: a future where life-saving treatments are affordable and available to all who need them.

Catch the full episode to explore how these innovations are not just improving efficiency but making life-saving therapies more accessible globally.

If you enjoyed this, here are some episodes worth listening:

  • Episode 135: Beyond Breakthroughs: Making Biotherapeutics Affordable for All
  • Episode 136: 5 Roadblocks to Affordable Biologics (And How to Overcome Them)
  • Episodes 127-128: The 7 Hidden Innovation Habits That Top Biotech Scientists Use Daily
  • Episode 87: The Hidden Pitfalls of Bioprocess Development: Lessons from the Trenches
  • Episodes 41-42: Revealing the Disciplined Pursuit of Less in Bioprocessing

Next step:

Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free consultation to propel your success: https://bruehlmann-consulting.com/call

Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech

Support the show

]]> In the rapidly evolving world of biotechnology, innovation is not just happening at the molecular level. Industry leaders are making groundbreaking advancements in bioprocessing - a crucial component in making life-saving therapies more accessible and affordable.

The journey to affordable therapies starts with the production process itself. In this podcast episode, David Brühlmann sheds light on innovations in bioprocess design that are setting new standards in efficiency and efficacy. At the heart of this transformation is the shift from traditional process formats like fed-batch to continuous process formats, quality by design approaches, and the implementation of breakthrough technologies.

Here's a quick rundown of the key takeaways:

  • Revolutionary Process Designs: Industry leaders are enhancing bioprocess designs—from antibody production enhancements to integrating perfusion mode. One case study highlighted a dramatic increase in viable cell density and protein titers through intensified processes.
  • Quality Control Innovations: Companies like Cyto-Facto are pioneering quality by design in the challenging cell and gene therapy space. By leveraging sophisticated PAT systems, they can monitor critical process parameters in real-time, ensuring consistent quality even in complex bioprocesses.
  • Metabolite Shifts and Efficacy: A surprising discovery revealed the power of metabolite shifts induced by cell culture media design, inspired by an intriguing study on cyclists, to enhance antibody efficacy and stability. This opens new possibilities for engineering the quality of biopharmaceuticals through simple modifications in the culturing process.

The innovations discussed in the Smart Biotech Scientist illustrate a pivotal transformation in bioprocessing. By rethinking process designs and committing to quality control, the biotech industry is paving the way for groundbreaking therapies that are not just dreams but realities - realities that are tangibly more accessible to patients worldwide.

As we anticipate more developments in this field, the promise of biotech becomes increasingly certain: a future where life-saving treatments are affordable and available to all who need them.

Catch the full episode to explore how these innovations are not just improving efficiency but making life-saving therapies more accessible globally.

If you enjoyed this, here are some episodes worth listening:

  • Episode 135: Beyond Breakthroughs: Making Biotherapeutics Affordable for All
  • Episode 136: 5 Roadblocks to Affordable Biologics (And How to Overcome Them)
  • Episodes 127-128: The 7 Hidden Innovation Habits That Top Biotech Scientists Use Daily
  • Episode 87: The Hidden Pitfalls of Bioprocess Development: Lessons from the Trenches
  • Episodes 41-42: Revealing the Disciplined Pursuit of Less in Bioprocessing

Next step:

Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free consultation to propel your success: https://bruehlmann-consulting.com/call

Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-16814677 Tue, 08 Apr 2025 05:00:00 +0200 932 143 full false 142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor - Part 2 142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor - Part 2 What if we could revolutionize biotechnology by slashing antibody production costs by 70%? In a world where traditional mammalian cell cultures struggle with scalability and cost-effectiveness, an unexpected hero emerges from the depths of our oceans - microalgae.

The use of microalgae in biotechnology is not just a novelty but a necessity, given the current demands for more efficient and cost-effective production methods. Muriel Bardor, co-founder, CEO and CSO of Alga Biologics, highlights a particularly startling statistic: microalgae can reduce the cost of antibody production by an impressive 70%. This innovation could revolutionize the biotechnology industry by making life-saving therapies more accessible.

Here are 3 key takeaways from this podcast episode:

  • Quality and Safety Assurance: By collaborating with virology experts and using advanced techniques like mass spectrometry, they ensure that their processes are virus-free and free from host-cell protein contamination. The company is paving the way for future developments despite the challenges of not having standard ELISA kits commercially available.
  • Regulation and Industry Perception: Launching such transformative technology inevitably entwines with regulatory landscapes. Muriel and her company have begun discussions with the French regulatory agency, drawing optimism from the fact that similar plant-based products, such as glucocerebrosidase, have already paved the way in the market. This indicates a growing acceptance within regulatory bodies of alternative bioprocessing platforms, inspiring hope for microalgae's future in antibody production.
  • Future Vision: Muriel hopes to break conservative barriers within pharmaceutical companies and promote the adoption of microalgae production. This offers not only cost-effective solutions but also holds potential for new treatment options, like for neuroblastoma.

Check out the episode to hear Muriel's advice for aspiring scientists and the general public alike regarding the future of research and the well-being of our planet.

Connect with Muriel Bardor:

LinkedIn: www.linkedin.com/in/muriel-bardor-47953024

Email: muriel.bardor@univ-rouen.fr

Alga Biologics: www.algabiologics.com

Next step:

Book a free consultation to refine your CMC strategy to propel your success: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Support the show

]]> What if we could revolutionize biotechnology by slashing antibody production costs by 70%? In a world where traditional mammalian cell cultures struggle with scalability and cost-effectiveness, an unexpected hero emerges from the depths of our oceans - microalgae.

The use of microalgae in biotechnology is not just a novelty but a necessity, given the current demands for more efficient and cost-effective production methods. Muriel Bardor, co-founder, CEO and CSO of Alga Biologics, highlights a particularly startling statistic: microalgae can reduce the cost of antibody production by an impressive 70%. This innovation could revolutionize the biotechnology industry by making life-saving therapies more accessible.

Here are 3 key takeaways from this podcast episode:

  • Quality and Safety Assurance: By collaborating with virology experts and using advanced techniques like mass spectrometry, they ensure that their processes are virus-free and free from host-cell protein contamination. The company is paving the way for future developments despite the challenges of not having standard ELISA kits commercially available.
  • Regulation and Industry Perception: Launching such transformative technology inevitably entwines with regulatory landscapes. Muriel and her company have begun discussions with the French regulatory agency, drawing optimism from the fact that similar plant-based products, such as glucocerebrosidase, have already paved the way in the market. This indicates a growing acceptance within regulatory bodies of alternative bioprocessing platforms, inspiring hope for microalgae's future in antibody production.
  • Future Vision: Muriel hopes to break conservative barriers within pharmaceutical companies and promote the adoption of microalgae production. This offers not only cost-effective solutions but also holds potential for new treatment options, like for neuroblastoma.

Check out the episode to hear Muriel's advice for aspiring scientists and the general public alike regarding the future of research and the well-being of our planet.

Connect with Muriel Bardor:

LinkedIn: www.linkedin.com/in/muriel-bardor-47953024

Email: muriel.bardor@univ-rouen.fr

Alga Biologics: www.algabiologics.com

Next step:

Book a free consultation to refine your CMC strategy to propel your success: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-16858010 Thu, 03 Apr 2025 05:00:00 +0200 1026 142 full false 141: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor - Part 1 141: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel Bardor - Part 1 The world of biologics manufacturing is about to be transformed by a breakthrough that slashes antibody production costs by 70%. This revolutionary approach leverages the untapped potential of microalgae to deliver a sustainable, cost-effective solution that could make life-saving therapeutics more accessible than ever before. Enter microalgae, the star of this groundbreaking development.

In this episode of the Smart Biotech Scientist, Muriel Bardor, the co-founder, CEO and CSO of Alga Biologics, shared insights into how her team's pioneering work with microalgae could redefine the landscape of immunotherapy.

Here are some takeaways from her conversation with David Brühlmann:

  • Green Revolution in Bioprocessing: Discover how microalgae can slash production costs by 70% and offer a sustainable alternative to traditional antibody manufacturing. Muriel explains how these photosynthetic organisms capture 7 tons of CO2 per kilogram of product - transforming antibody manufacturing both economically and environmentally.
  • Rethinking Antibody Production: Learn why the conventional use of mammalian cells in antibody production is being challenged and how microalgae overcome the limitations of traditional methods, bringing life-saving drugs within reach for more people globally.
  • Sustainable Impact: With a process that mirrors nature, Muriel’s approach sets a new standard for eco-friendly biotech production. Find out how microalgae are changing not just the industry, but our world.

We invite you to listen to this insightful conversation and explore how you can apply these groundbreaking ideas to your own work. Has Muriel’s innovative approach inspired you? Share your thoughts or questions with us - we'd love to hear from you!

If you are interested in antibody production, here is another episode worth listening:

  • Episodes 47-48: Mastering Process Economics: Driving Down Costs in Antibody Production with Brian Kelley

Connect with Muriel Bardor:

LinkedIn: www.linkedin.com/in/muriel-bardor-47953024

Email: muriel.bardor@univ-rouen.fr

Alga Biologics: www.algabiologics.com

Next step:

Book a free consultation to refine your CMC strategy to propel your success: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> The world of biologics manufacturing is about to be transformed by a breakthrough that slashes antibody production costs by 70%. This revolutionary approach leverages the untapped potential of microalgae to deliver a sustainable, cost-effective solution that could make life-saving therapeutics more accessible than ever before. Enter microalgae, the star of this groundbreaking development.

In this episode of the Smart Biotech Scientist, Muriel Bardor, the co-founder, CEO and CSO of Alga Biologics, shared insights into how her team's pioneering work with microalgae could redefine the landscape of immunotherapy.

Here are some takeaways from her conversation with David Brühlmann:

  • Green Revolution in Bioprocessing: Discover how microalgae can slash production costs by 70% and offer a sustainable alternative to traditional antibody manufacturing. Muriel explains how these photosynthetic organisms capture 7 tons of CO2 per kilogram of product - transforming antibody manufacturing both economically and environmentally.
  • Rethinking Antibody Production: Learn why the conventional use of mammalian cells in antibody production is being challenged and how microalgae overcome the limitations of traditional methods, bringing life-saving drugs within reach for more people globally.
  • Sustainable Impact: With a process that mirrors nature, Muriel’s approach sets a new standard for eco-friendly biotech production. Find out how microalgae are changing not just the industry, but our world.

We invite you to listen to this insightful conversation and explore how you can apply these groundbreaking ideas to your own work. Has Muriel’s innovative approach inspired you? Share your thoughts or questions with us - we'd love to hear from you!

If you are interested in antibody production, here is another episode worth listening:

  • Episodes 47-48: Mastering Process Economics: Driving Down Costs in Antibody Production with Brian Kelley

Connect with Muriel Bardor:

LinkedIn: www.linkedin.com/in/muriel-bardor-47953024

Email: muriel.bardor@univ-rouen.fr

Alga Biologics: www.algabiologics.com

Next step:

Book a free consultation to refine your CMC strategy to propel your success: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call: The quickest and easiest way to excel biotech technology development. Book your call at https://stan.store/SmartBiotech

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-16857987 Tue, 01 Apr 2025 05:00:00 +0200 1567 141 full false 140: Regulatory Secrets Revealed: Why Your CMC Strategy Could Make or Break Your Biotech Startup with Rivka Zaibel - Part 2 140: Regulatory Secrets Revealed: Why Your CMC Strategy Could Make or Break Your Biotech Startup with Rivka Zaibel - Part 2 In this episode, we explore the important steps in preparing for regulatory meetings, address the dangers of cross-contamination in biotechnology facilities, and debunk common misconceptions that could derail your CMC development strategy.

As the founder and president of ADRES - Advanced Regulatory Services Ltd., Rivka Zaibel brings over 36 years of industry experience and practical strategies to help navigate the intricacies of CMC development and regulatory compliance.

Here are three key takeaways:

  • Risk Assessment is Paramount: Start risk assessments in parallel with facility design to prevent cross contamination. Remember, areas for both mammalian and microbial cells should be segregated to ensure safety.
  • Early Engagement with Regulatory Agencies: Don’t wait until everything is finalized before consulting with regulatory bodies. Engaging them early can ensure your plans align with their requirements and might even spark valuable advice you hadn’t considered.
  • Understand and Plan Your Product Journey: Have a clear vision of your final product from the start, and plan backwards. This approach ensures all supporting processes are adequately addressed, saving time and preventing costly mistakes down the line.

Ultimately, successful biologics development hinges on thorough understanding and strategic planning. This includes comprehensive risk assessments, early regulatory engagement, and a commitment to continuous training and facility validation.

Rivka's insights offer a roadmap for navigating this complex landscape, aiming to deliver groundbreaking therapies with precision and compliance. By following these expert strategies, biotech professionals can streamline their processes, avoid common pitfalls, and ensure the successful introduction of their products to the market.

Connect with Rivka Zaibel:

LinkedIn: www.linkedin.com/in/rivka-zaibel/

ADRES - Advanced Regulatory Services Ltd.: www.adres.bio

Email: tanya@adres.bio

Next step:

Book a free consultation to refine your CMC strategy to propel your success: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech

Support the show

]]> In this episode, we explore the important steps in preparing for regulatory meetings, address the dangers of cross-contamination in biotechnology facilities, and debunk common misconceptions that could derail your CMC development strategy.

As the founder and president of ADRES - Advanced Regulatory Services Ltd., Rivka Zaibel brings over 36 years of industry experience and practical strategies to help navigate the intricacies of CMC development and regulatory compliance.

Here are three key takeaways:

  • Risk Assessment is Paramount: Start risk assessments in parallel with facility design to prevent cross contamination. Remember, areas for both mammalian and microbial cells should be segregated to ensure safety.
  • Early Engagement with Regulatory Agencies: Don’t wait until everything is finalized before consulting with regulatory bodies. Engaging them early can ensure your plans align with their requirements and might even spark valuable advice you hadn’t considered.
  • Understand and Plan Your Product Journey: Have a clear vision of your final product from the start, and plan backwards. This approach ensures all supporting processes are adequately addressed, saving time and preventing costly mistakes down the line.

Ultimately, successful biologics development hinges on thorough understanding and strategic planning. This includes comprehensive risk assessments, early regulatory engagement, and a commitment to continuous training and facility validation.

Rivka's insights offer a roadmap for navigating this complex landscape, aiming to deliver groundbreaking therapies with precision and compliance. By following these expert strategies, biotech professionals can streamline their processes, avoid common pitfalls, and ensure the successful introduction of their products to the market.

Connect with Rivka Zaibel:

LinkedIn: www.linkedin.com/in/rivka-zaibel/

ADRES - Advanced Regulatory Services Ltd.: www.adres.bio

Email: tanya@adres.bio

Next step:

Book a free consultation to refine your CMC strategy to propel your success: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-16840455 Thu, 27 Mar 2025 05:00:00 +0100 1242 140 full false 139: Regulatory Secrets Revealed: Why Your CMC Strategy Could Make or Break Your Biotech Startup with Rivka Zaibel - Part 1 139: Regulatory Secrets Revealed: Why Your CMC Strategy Could Make or Break Your Biotech Startup with Rivka Zaibel - Part 1 In biotherapeutic drug development, the journey from discovery to clinic involves navigating a labyrinth of regulatory requirements and strategic considerations, particularly in Chemistry, Manufacturing, and Control (CMC).

In this episode of the Smart Biotech Scientist, host David Brühlmann engaged with Rivka Zaibel, President and Founder of ADRES - Advanced Regulatory Services Ltd. - to demystify the regulatory intricacies of biologics development and provide actionable insights for biotech leaders.

With over three decades of experience in the biopharmaceutical industry, Rivka Zaibel highlights that understanding the regulatory landscape is crucial for the success of biologics development.

Here are three key takeaways from this episode:

  • Prioritize CMC Development Early: CMC (Chemistry, Manufacturing, and Controls) development is crucial in biologics. Rivka emphasizes starting early and engaging with regulatory agencies to avoid costly delays and streamline the bioprocessing journey.
  • Understand Regulatory Differences: Different agencies (FDA vs. EMA) may have varied interpretations of guidelines. Familiarize yourself with ICH guidelines and the specific requirements of each agency to align your strategy effectively.
  • Leverage Existing Resources: Before developing your own product pathway, explore existing European Public Assessment Reports (EPARs) and summary bases of approval for comparable products. This research can provide valuable insights into regulatory expectations and streamline your approach.

For startups navigating the complexities of CMC development, Rivka highlights three critical quality and regulatory considerations essential for reaching Phase 1 trials. By embracing these key insights, biotech professionals can streamline the path to delivering innovative therapies to patients safely and efficiently.

In conclusion, as you continue your journey within the biopharmaceutical industry, let the Smart Biotech Scientist serve as your guide, demystifying the complexities and empowering you with the tools needed to thrive. Stay informed, stay proactive!

Connect with Rivka Zaibel:

LinkedIn: www.linkedin.com/in/rivka-zaibel/

ADRES - Advanced Regulatory Services Ltd.: www.adres.bio

Email: tanya@adres.bio

Next step:

Book a free consultation to refine your CMC strategy to propel your success: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> In biotherapeutic drug development, the journey from discovery to clinic involves navigating a labyrinth of regulatory requirements and strategic considerations, particularly in Chemistry, Manufacturing, and Control (CMC).

In this episode of the Smart Biotech Scientist, host David Brühlmann engaged with Rivka Zaibel, President and Founder of ADRES - Advanced Regulatory Services Ltd. - to demystify the regulatory intricacies of biologics development and provide actionable insights for biotech leaders.

With over three decades of experience in the biopharmaceutical industry, Rivka Zaibel highlights that understanding the regulatory landscape is crucial for the success of biologics development.

Here are three key takeaways from this episode:

  • Prioritize CMC Development Early: CMC (Chemistry, Manufacturing, and Controls) development is crucial in biologics. Rivka emphasizes starting early and engaging with regulatory agencies to avoid costly delays and streamline the bioprocessing journey.
  • Understand Regulatory Differences: Different agencies (FDA vs. EMA) may have varied interpretations of guidelines. Familiarize yourself with ICH guidelines and the specific requirements of each agency to align your strategy effectively.
  • Leverage Existing Resources: Before developing your own product pathway, explore existing European Public Assessment Reports (EPARs) and summary bases of approval for comparable products. This research can provide valuable insights into regulatory expectations and streamline your approach.

For startups navigating the complexities of CMC development, Rivka highlights three critical quality and regulatory considerations essential for reaching Phase 1 trials. By embracing these key insights, biotech professionals can streamline the path to delivering innovative therapies to patients safely and efficiently.

In conclusion, as you continue your journey within the biopharmaceutical industry, let the Smart Biotech Scientist serve as your guide, demystifying the complexities and empowering you with the tools needed to thrive. Stay informed, stay proactive!

Connect with Rivka Zaibel:

LinkedIn: www.linkedin.com/in/rivka-zaibel/

ADRES - Advanced Regulatory Services Ltd.: www.adres.bio

Email: tanya@adres.bio

Next step:

Book a free consultation to refine your CMC strategy to propel your success: https://bruehlmann-consulting.com/call

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-16840441 Tue, 25 Mar 2025 05:00:00 +0100 1573 139 full false 138: Skip 90% of Bioreactor Runs: The In Silico Revolution in Bioprocess Development with Yossi Quint - Part 2 138: Skip 90% of Bioreactor Runs: The In Silico Revolution in Bioprocess Development with Yossi Quint - Part 2 In the fast-evolving world of biotechnology, the pursuit of efficiency and faster development has never been more critical. The computational tools and models currently being integrated into bioprocessing present a groundbreaking approach that promises radical shifts in drug development timelines and capabilities.

In the second part of our conversation, Yossi Quint, founder and CEO of Ark, shows us that the horizon of bioprocessing is lined with possibilities that could revolutionize biotherapeutics accessibility, cost, and speed in pharmaceutical innovations.

Here are three key takeaways you don't want to miss:

  • De-risking with Simulation: Yossi shared how simulation models can drastically reduce risks by running many scenarios before actual implementation. This approach optimizes processes, lowers costs, and speeds up the development cycle.
  • Transfer Learning in Bioprocessing: Discover the potential of leveraging data across different types of molecules! Although challenging, the ultimate goal is to apply data learnings from one process to others, maximizing efficiency and success rates.
  • Patient Impact & Cost Reduction: At the heart of these innovations is the goal of quicker, more affordable drug production. By slicing down on both time and costs, computational tools not only help drugs reach the market faster but also make them more accessible to patients globally.

With innovation at its core, the modern trajectory of bioprocessing is not simply about reaching scientific milestones but about profoundly transforming patient care and accessibility. This synergistic blend of technology and purpose crafts a future in which the biotechnology sector not only grows but also enriches countless lives around the globe.

If you are interested in this topic, here are a few standout conversations on AI’s impact on bioprocessing with some incredible experts:

  • Episodes 131-132: Combining AI and Biomanufacturing for Sustainable, Cost-Effective Therapeutics with Reza Farahani
  • Episodes 115-116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti
  • Episodes 111-112: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén
  • Episodes 107-108: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David Schönauer
  • Episodes 95-96: AI in Bioprocess Development: The Game-Changer You Can't Ignore with Belma Alispahic

Connect with Yossi Quint:

LinkedIn: https://www.linkedin.com/in/yossi-quint

Ark: https://www.ark-biotech.com

Next step:

Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech

Support the show

]]> In the fast-evolving world of biotechnology, the pursuit of efficiency and faster development has never been more critical. The computational tools and models currently being integrated into bioprocessing present a groundbreaking approach that promises radical shifts in drug development timelines and capabilities.

In the second part of our conversation, Yossi Quint, founder and CEO of Ark, shows us that the horizon of bioprocessing is lined with possibilities that could revolutionize biotherapeutics accessibility, cost, and speed in pharmaceutical innovations.

Here are three key takeaways you don't want to miss:

  • De-risking with Simulation: Yossi shared how simulation models can drastically reduce risks by running many scenarios before actual implementation. This approach optimizes processes, lowers costs, and speeds up the development cycle.
  • Transfer Learning in Bioprocessing: Discover the potential of leveraging data across different types of molecules! Although challenging, the ultimate goal is to apply data learnings from one process to others, maximizing efficiency and success rates.
  • Patient Impact & Cost Reduction: At the heart of these innovations is the goal of quicker, more affordable drug production. By slicing down on both time and costs, computational tools not only help drugs reach the market faster but also make them more accessible to patients globally.

With innovation at its core, the modern trajectory of bioprocessing is not simply about reaching scientific milestones but about profoundly transforming patient care and accessibility. This synergistic blend of technology and purpose crafts a future in which the biotechnology sector not only grows but also enriches countless lives around the globe.

If you are interested in this topic, here are a few standout conversations on AI’s impact on bioprocessing with some incredible experts:

  • Episodes 131-132: Combining AI and Biomanufacturing for Sustainable, Cost-Effective Therapeutics with Reza Farahani
  • Episodes 115-116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti
  • Episodes 111-112: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén
  • Episodes 107-108: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David Schönauer
  • Episodes 95-96: AI in Bioprocess Development: The Game-Changer You Can't Ignore with Belma Alispahic

Connect with Yossi Quint:

LinkedIn: https://www.linkedin.com/in/yossi-quint

Ark: https://www.ark-biotech.com

Next step:

Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-16766907 Thu, 20 Mar 2025 05:00:00 +0100 1216 138 full false 137: Skip 90% of Bioreactor Runs: The In Silico Revolution in Bioprocess Development with Yossi Quint - Part 1 137: Skip 90% of Bioreactor Runs: The In Silico Revolution in Bioprocess Development with Yossi Quint - Part 1 The integration of AI into drug discovery has already led to groundbreaking advancements, uncovering patterns in vast datasets that were previously invisible to human researchers. Now, AI is set to revolutionize bioprocessing as well.

In this episode of the Smart Biotech Scientist Podcast, Yossi Quint, founder and CEO of Ark, and David Brühlmann explore how AI and computational tools are reshaping bioprocess development. Yossi envisions a future where 90% of bioreactor experiments could be replaced by in silico simulations, dramatically accelerating time to market and increasing throughput.

Key takeaways from the conversation with Yossi Quint:

  • AI’s Role in Drug Discovery & Bioprocessing: AI is already transforming drug discovery by identifying intricate patterns across millions of data points. Now, bioprocessing is undergoing a similar revolution, as computational tools simplify and streamline complex workflows.
  • The Power of Hybrid Models: Yossi highlights the synergy between mechanistic models and AI-driven approaches, emphasizing how AI can fill gaps where traditional models struggle—especially in understanding complex cellular behaviors.
  • Empowering Bioprocess Teams with AI: As AI accelerates drug discovery, bioprocessing must evolve to keep pace. Yossi discusses the importance of digital transformation in ensuring bioprocess teams can meet increasing demands and drive innovation forward.

With AI-driven models, hybrid simulations, and increased digitization, the bioprocessing industry stands at the cusp of a new era. The convergence of data, science, and technology promises not only greater efficiency and accuracy but also a faster path to life-saving treatments for patients in need.

If you want to learn more, here are a few standout conversations on AI’s impact on bioprocessing with some incredible experts:

  • Episodes 131-132: Combining AI and Biomanufacturing for Sustainable, Cost-Effective Therapeutics with Reza Farahani
  • Episodes 115-116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti
  • Episodes 111-112: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén
  • Episodes 107-108: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David Schönauer
  • Episodes 95-96: AI in Bioprocess Development: The Game-Changer You Can't Ignore with Belma Alispahic

Connect with Yossi Quint:

LinkedIn: https://www.linkedin.com/in/yossi-quint

Ark: https://www.ark-biotech.com

Next step:

Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech

Support the show

]]> The integration of AI into drug discovery has already led to groundbreaking advancements, uncovering patterns in vast datasets that were previously invisible to human researchers. Now, AI is set to revolutionize bioprocessing as well.

In this episode of the Smart Biotech Scientist Podcast, Yossi Quint, founder and CEO of Ark, and David Brühlmann explore how AI and computational tools are reshaping bioprocess development. Yossi envisions a future where 90% of bioreactor experiments could be replaced by in silico simulations, dramatically accelerating time to market and increasing throughput.

Key takeaways from the conversation with Yossi Quint:

  • AI’s Role in Drug Discovery & Bioprocessing: AI is already transforming drug discovery by identifying intricate patterns across millions of data points. Now, bioprocessing is undergoing a similar revolution, as computational tools simplify and streamline complex workflows.
  • The Power of Hybrid Models: Yossi highlights the synergy between mechanistic models and AI-driven approaches, emphasizing how AI can fill gaps where traditional models struggle—especially in understanding complex cellular behaviors.
  • Empowering Bioprocess Teams with AI: As AI accelerates drug discovery, bioprocessing must evolve to keep pace. Yossi discusses the importance of digital transformation in ensuring bioprocess teams can meet increasing demands and drive innovation forward.

With AI-driven models, hybrid simulations, and increased digitization, the bioprocessing industry stands at the cusp of a new era. The convergence of data, science, and technology promises not only greater efficiency and accuracy but also a faster path to life-saving treatments for patients in need.

If you want to learn more, here are a few standout conversations on AI’s impact on bioprocessing with some incredible experts:

  • Episodes 131-132: Combining AI and Biomanufacturing for Sustainable, Cost-Effective Therapeutics with Reza Farahani
  • Episodes 115-116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti
  • Episodes 111-112: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén
  • Episodes 107-108: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David Schönauer
  • Episodes 95-96: AI in Bioprocess Development: The Game-Changer You Can't Ignore with Belma Alispahic

Connect with Yossi Quint:

LinkedIn: https://www.linkedin.com/in/yossi-quint

Ark: https://www.ark-biotech.com

Next step:

Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-16766893 Tue, 18 Mar 2025 05:00:00 +0100 1315 137 full false 136: 5 Roadblocks to Affordable Biologics (And How to Overcome Them) 136: 5 Roadblocks to Affordable Biologics (And How to Overcome Them) Sickle cell disease affects thousands with severe daily pain. While FDA-approved gene therapies exist, their $2.2 million cost per treatment makes them largely inaccessible.

In this episode of the Smart Biotech Scientist Podcast, David Brühlmann explores five key challenges facing the bioprocessing industry in making these therapies more accessible:

Moving Away from Platform Technologies

Traditional bioprocessing relies on platform technologies for antibody production. However, new therapies require more flexible, adaptable systems that can accommodate novel modalities.

Increased Personalization and Smaller Batch Sizes

Personalized medicine, especially autologous cell therapy, demands highly customized approaches. With batch sizes of one patient, traditional automation becomes challenging, requiring new methodologies.

Cultivating Sensitive Cells

Modern cell types need gentler handling than traditional CHO cells. Companies are developing innovative bioreactor technologies, from acoustic wave systems to stress-free cultivation methods.

The Cell as the Product

Cell-based products are billion times more complex than antibodies, requiring sophisticated production, monitoring, and quality control processes.

Accessibility and Cost Challenges

High treatment costs remain the biggest barrier. For example, only 21,000 of 900,000 eligible patients have received CAR T cell therapy due to financial constraints.

Moving Forward

Industry leaders across academia and pharma are collaborating to overcome these challenges through innovation and cost reduction. Every improvement brings us closer to making these treatments accessible to more patients.

Join us on the Smart Biotech Scientist Podcast as we explore innovative solutions to these challenges.

Next step:

Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech

Support the show

]]> Sickle cell disease affects thousands with severe daily pain. While FDA-approved gene therapies exist, their $2.2 million cost per treatment makes them largely inaccessible.

In this episode of the Smart Biotech Scientist Podcast, David Brühlmann explores five key challenges facing the bioprocessing industry in making these therapies more accessible:

Moving Away from Platform Technologies

Traditional bioprocessing relies on platform technologies for antibody production. However, new therapies require more flexible, adaptable systems that can accommodate novel modalities.

Increased Personalization and Smaller Batch Sizes

Personalized medicine, especially autologous cell therapy, demands highly customized approaches. With batch sizes of one patient, traditional automation becomes challenging, requiring new methodologies.

Cultivating Sensitive Cells

Modern cell types need gentler handling than traditional CHO cells. Companies are developing innovative bioreactor technologies, from acoustic wave systems to stress-free cultivation methods.

The Cell as the Product

Cell-based products are billion times more complex than antibodies, requiring sophisticated production, monitoring, and quality control processes.

Accessibility and Cost Challenges

High treatment costs remain the biggest barrier. For example, only 21,000 of 900,000 eligible patients have received CAR T cell therapy due to financial constraints.

Moving Forward

Industry leaders across academia and pharma are collaborating to overcome these challenges through innovation and cost reduction. Every improvement brings us closer to making these treatments accessible to more patients.

Join us on the Smart Biotech Scientist Podcast as we explore innovative solutions to these challenges.

Next step:

Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-16717660 Thu, 13 Mar 2025 05:00:00 +0100 808 136 full false 135: Beyond Breakthroughs: Making Biotherapeutics Affordable for All 135: Beyond Breakthroughs: Making Biotherapeutics Affordable for All In a world of rapid advancements in medical science and biotechnology, bioprocessing is at the forefront of healthcare innovation. Yet, despite remarkable progress, life-saving biotherapeutics remain out of reach for much of the global population.

A staggering 80% of patients worldwide lack access to the biotherapeutics they need. While bioprocessing has made impressive strides, the high cost and slow development of these treatments create significant barriers. Addressing these challenges is critical to making innovative therapies widely available.

David Brühlmann is launching a special four-part series based on his keynote at the Amphacademy, exploring bioprocessing’s revolutionary journey - from the early days of recombinant insulin to today’s groundbreaking therapies. This series will also highlight strategies to make these innovations more accessible to patients worldwide.

From Standardization to Personalization

One major challenge is the shift away from platform technologies. Traditionally, antibodies were produced using standardized CHO cell templates and purification steps, but this approach falls short for new modalities.

Personalized therapies further complicate the landscape. Autologous cell therapies, for example, require isolating, cultivating, and reinfusing a patient’s own cells. These small-batch processes are labor-intensive, less automated, and often reliant on outdated, paper-driven workflows.

Innovations in Bioreactor Design

With the rise of sensitive cell therapies, bioreactor design must evolve. Unlike CHO cells, these delicate cells require gentler handling environments. Innovations like acoustic wave bioreactors, bionic bioreactors, and specialized cell screws are emerging to optimize cell growth and improve efficiency.

The Complexity and Cost of Cell-Based Products

New bioprocessing modalities bring greater complexity. Cell-based therapies and cultivated meats are far more intricate than traditional antibody proteins, making scaling production and ensuring quality especially challenging.

High production costs further limit access. Even in regions where these therapies are approved, pricing remains a major barrier. Lowering manufacturing costs is essential to democratizing these life-saving treatments.

The shift from basic recombinant proteins to complex cell-based therapeutics is just the beginning. Overcoming these challenges - scaling production, reducing costs, and managing complexity - is key to making breakthrough therapies accessible to all.

Next step:

Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech

Support the show

]]> In a world of rapid advancements in medical science and biotechnology, bioprocessing is at the forefront of healthcare innovation. Yet, despite remarkable progress, life-saving biotherapeutics remain out of reach for much of the global population.

A staggering 80% of patients worldwide lack access to the biotherapeutics they need. While bioprocessing has made impressive strides, the high cost and slow development of these treatments create significant barriers. Addressing these challenges is critical to making innovative therapies widely available.

David Brühlmann is launching a special four-part series based on his keynote at the Amphacademy, exploring bioprocessing’s revolutionary journey - from the early days of recombinant insulin to today’s groundbreaking therapies. This series will also highlight strategies to make these innovations more accessible to patients worldwide.

From Standardization to Personalization

One major challenge is the shift away from platform technologies. Traditionally, antibodies were produced using standardized CHO cell templates and purification steps, but this approach falls short for new modalities.

Personalized therapies further complicate the landscape. Autologous cell therapies, for example, require isolating, cultivating, and reinfusing a patient’s own cells. These small-batch processes are labor-intensive, less automated, and often reliant on outdated, paper-driven workflows.

Innovations in Bioreactor Design

With the rise of sensitive cell therapies, bioreactor design must evolve. Unlike CHO cells, these delicate cells require gentler handling environments. Innovations like acoustic wave bioreactors, bionic bioreactors, and specialized cell screws are emerging to optimize cell growth and improve efficiency.

The Complexity and Cost of Cell-Based Products

New bioprocessing modalities bring greater complexity. Cell-based therapies and cultivated meats are far more intricate than traditional antibody proteins, making scaling production and ensuring quality especially challenging.

High production costs further limit access. Even in regions where these therapies are approved, pricing remains a major barrier. Lowering manufacturing costs is essential to democratizing these life-saving treatments.

The shift from basic recombinant proteins to complex cell-based therapeutics is just the beginning. Overcoming these challenges - scaling production, reducing costs, and managing complexity - is key to making breakthrough therapies accessible to all.

Next step:

Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop bioprocessing technologies better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-16717653 Tue, 11 Mar 2025 05:00:00 +0100 766 135 full false 134: Seamless Seed Trains: Simplify Without Sacrificing Quality with François Carruzzo - Part 2 134: Seamless Seed Trains: Simplify Without Sacrificing Quality with François Carruzzo - Part 2 The biotechnology industry is on a transformative path. With emerging technologies and innovative ideas, bioprocessing professionals are poised to revolutionize how therapies are developed and delivered. In this episode of the Smart Biotech Scientist Podcast, host David Brühlmann continues his conversation with François Carruzzo, the CTO of Bioscibex, as they delve into the challenges and opportunities present in the biotech landscape.

Bioprocess automation boosts efficiency and scalability in therapeutic production. François Carruzzo explores how automation and sensors simplify processes, cut costs, and enhance reliability - key to making biologics more accessible worldwide.

Here are some key lessons Carruzzo learned on his entrepreneurial journey:

  • Seeking and Leveraging Advice as a Startup: For biotechnology entrepreneurs, seeking the right advice is a cornerstone for success. Carruzzo discusses the significance of having a scientific advisor. He highlights the value of external perspectives in helping startups navigate strategic decisions, addressing complex challenges, and innovating effectively.
  • The Role of Networking and Ecosystems: Startup ecosystems and networks play an indispensable role in propelling innovations within the biotech industry. Situated in Lausanne, Switzerland, Bioscibex is well-positioned within a dynamic biopharma ecosystem. Utilizing incubators and networking events, Carruzzo underscores the importance of connecting with other innovative organizations and experts, which can accelerate product development and industry relevance.
  • Customer Engagement as a Key Driver for Innovation: Understanding and integrating the voice of the customer is pivotal in product development. Carruzzo emphasizes starting customer interactions early in the development process. Engaging with potential users before launching a prototype allows companies to tailor products that meet user needs and align with market demands.

Carruzzo advises biotech entrepreneurs to validate their ideas through market research and pursue them with commitment. He highlights the challenges of innovation but emphasizes its invaluable rewards. By streamlining processes and prioritizing innovation, the biotech industry can drive progress that benefits both companies and patients worldwide.

This episode highlights how breakthrough biotech innovations require strategy, regulatory expertise, and customer focus. Bioscibex’s journey exemplifies technology’s transformative power in the industry.

Want to dive deeper into the startup journey and gain insights from entrepreneurs?

  • Episodes 119-120: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian Guo
  • Episodes 107-108: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David Schönauer
  • Episodes 83-84: The Hidden Potential of Shake Flasks: What Every Biotech Scientist Needs to Know with Jens Bayer
  • Episodes 81-82: Regenerating Muscles: The Future of Autologous Cell-based Therapy with Deana Mohr

Connect with François Carruzzo:

LinkedIn: https://www.linkedin.com/in/francois-carruzzo

Bioscibex: https://bioscibex.com

Next step:

Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Support the show

]]> The biotechnology industry is on a transformative path. With emerging technologies and innovative ideas, bioprocessing professionals are poised to revolutionize how therapies are developed and delivered. In this episode of the Smart Biotech Scientist Podcast, host David Brühlmann continues his conversation with François Carruzzo, the CTO of Bioscibex, as they delve into the challenges and opportunities present in the biotech landscape.

Bioprocess automation boosts efficiency and scalability in therapeutic production. François Carruzzo explores how automation and sensors simplify processes, cut costs, and enhance reliability - key to making biologics more accessible worldwide.

Here are some key lessons Carruzzo learned on his entrepreneurial journey:

  • Seeking and Leveraging Advice as a Startup: For biotechnology entrepreneurs, seeking the right advice is a cornerstone for success. Carruzzo discusses the significance of having a scientific advisor. He highlights the value of external perspectives in helping startups navigate strategic decisions, addressing complex challenges, and innovating effectively.
  • The Role of Networking and Ecosystems: Startup ecosystems and networks play an indispensable role in propelling innovations within the biotech industry. Situated in Lausanne, Switzerland, Bioscibex is well-positioned within a dynamic biopharma ecosystem. Utilizing incubators and networking events, Carruzzo underscores the importance of connecting with other innovative organizations and experts, which can accelerate product development and industry relevance.
  • Customer Engagement as a Key Driver for Innovation: Understanding and integrating the voice of the customer is pivotal in product development. Carruzzo emphasizes starting customer interactions early in the development process. Engaging with potential users before launching a prototype allows companies to tailor products that meet user needs and align with market demands.

Carruzzo advises biotech entrepreneurs to validate their ideas through market research and pursue them with commitment. He highlights the challenges of innovation but emphasizes its invaluable rewards. By streamlining processes and prioritizing innovation, the biotech industry can drive progress that benefits both companies and patients worldwide.

This episode highlights how breakthrough biotech innovations require strategy, regulatory expertise, and customer focus. Bioscibex’s journey exemplifies technology’s transformative power in the industry.

Want to dive deeper into the startup journey and gain insights from entrepreneurs?

  • Episodes 119-120: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian Guo
  • Episodes 107-108: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David Schönauer
  • Episodes 83-84: The Hidden Potential of Shake Flasks: What Every Biotech Scientist Needs to Know with Jens Bayer
  • Episodes 81-82: Regenerating Muscles: The Future of Autologous Cell-based Therapy with Deana Mohr

Connect with François Carruzzo:

LinkedIn: https://www.linkedin.com/in/francois-carruzzo

Bioscibex: https://bioscibex.com

Next step:

Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-16717643 Thu, 06 Mar 2025 05:00:00 +0100 1013 134 full false 133: Seamless Seed Trains: Simplify Without Sacrificing Quality with François Carruzzo - Part 1 133: Seamless Seed Trains: Simplify Without Sacrificing Quality with François Carruzzo - Part 1 Biologics manufacturing relies heavily on optimizing various stages, yet the seed train step - often overlooked - plays a critical role in determining overall efficiency. The seed train involves expanding cells from a small working cell bank to scales suitable for production bioreactors.

Francois Carruzzo, Co-founder and CTO of Bioscibex, is rethinking how this process can be simplified, streamlined, and made more reliable, using a fully automated, closed system. However, the complexity of scaling introduces several risks, including handling errors, contamination, and delays that could derail production timelines.

Today, seed train processes involve multiple vessels, open handling, and labor-intensive steps, all of which complicate operations. François identified two prominent challenges:

  • Contamination Risks: Multiple open steps, such as using spin tubes, shake flasks, and wave systems, result in a heightened potential for contamination.
  • Operational Complexity: With multiple campaigns and products running simultaneously, accommodating different media types and containers can become overwhelming.

Bioscibex is on the verge of revolutionizing seed train operations with its innovative single-use bioreactor system. François shared how this system addresses traditional shortcomings:

  • Wide Turndown Ratio: Capable of scaling from 30 mL all the way to 30 L within the same vessel, Bioscibex's rocking motion reactor eliminates multiple intermediary steps.
  • Closed Workflow: By maintaining a fully enclosed environment, the system dramatically lowers contamination risks, making bioprocessing more reliable.
  • Continuous Cell Expansion: Unlike traditional methods that involve batch dilutions, Bioscibex supports continuous cell expansion, ensuring optimal growth conditions with reduced downtime.

Innovation in seed train processes extends far beyond mere operational efficiency. It lays the groundwork for scalable, consistent biologics production, ensuring therapies can reliably reach clinics faster.

By simplifying the mundane yet critical seed train step, his innovation offers a glimpse into the future of stress-free, scalable cell expansion - a vision we’re excited to see unfold.

Interested in finding out more about the progress made in cell culture? Take a listen to what our previous guests had to say about it:

  • Episodes 117-118 - Critical Bottlenecks and Breakthroughs in Cell Line Development with Andrea Gough
  • Episodes 113-114: Weighing of Single-Use Bag Systems: Why Traditional Load Cells Are Holding You Back with Anders Tvegaard
  • Episodes 109-110: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier Detournay

Connect with François Carruzzo:

LinkedIn: https://www.linkedin.com/in/francois-carruzzo

Bioscibex: https://bioscibex.com

Next step:

Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Support the show

]]> Biologics manufacturing relies heavily on optimizing various stages, yet the seed train step - often overlooked - plays a critical role in determining overall efficiency. The seed train involves expanding cells from a small working cell bank to scales suitable for production bioreactors.

Francois Carruzzo, Co-founder and CTO of Bioscibex, is rethinking how this process can be simplified, streamlined, and made more reliable, using a fully automated, closed system. However, the complexity of scaling introduces several risks, including handling errors, contamination, and delays that could derail production timelines.

Today, seed train processes involve multiple vessels, open handling, and labor-intensive steps, all of which complicate operations. François identified two prominent challenges:

  • Contamination Risks: Multiple open steps, such as using spin tubes, shake flasks, and wave systems, result in a heightened potential for contamination.
  • Operational Complexity: With multiple campaigns and products running simultaneously, accommodating different media types and containers can become overwhelming.

Bioscibex is on the verge of revolutionizing seed train operations with its innovative single-use bioreactor system. François shared how this system addresses traditional shortcomings:

  • Wide Turndown Ratio: Capable of scaling from 30 mL all the way to 30 L within the same vessel, Bioscibex's rocking motion reactor eliminates multiple intermediary steps.
  • Closed Workflow: By maintaining a fully enclosed environment, the system dramatically lowers contamination risks, making bioprocessing more reliable.
  • Continuous Cell Expansion: Unlike traditional methods that involve batch dilutions, Bioscibex supports continuous cell expansion, ensuring optimal growth conditions with reduced downtime.

Innovation in seed train processes extends far beyond mere operational efficiency. It lays the groundwork for scalable, consistent biologics production, ensuring therapies can reliably reach clinics faster.

By simplifying the mundane yet critical seed train step, his innovation offers a glimpse into the future of stress-free, scalable cell expansion - a vision we’re excited to see unfold.

Interested in finding out more about the progress made in cell culture? Take a listen to what our previous guests had to say about it:

  • Episodes 117-118 - Critical Bottlenecks and Breakthroughs in Cell Line Development with Andrea Gough
  • Episodes 113-114: Weighing of Single-Use Bag Systems: Why Traditional Load Cells Are Holding You Back with Anders Tvegaard
  • Episodes 109-110: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier Detournay

Connect with François Carruzzo:

LinkedIn: https://www.linkedin.com/in/francois-carruzzo

Bioscibex: https://bioscibex.com

Next step:

Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-16717627 Tue, 04 Mar 2025 05:00:00 +0100 1350 133 full false 132: Combining AI and Biomanufacturing for Sustainable, Cost-Effective Therapeutics with Reza Farahani - Part 2 132: Combining AI and Biomanufacturing for Sustainable, Cost-Effective Therapeutics with Reza Farahani - Part 2 Artificial Intelligence (AI) is transforming industries worldwide, and biotechnology is no exception. In bioprocess development, AI is proving to be a game-changer, accelerating workflows, optimizing processes, and driving innovation. On the Smart Biotech Scientist Podcast, Reza Farahani, founder and CEO of Catalyze AI, shares his insights on how AI is reshaping biomanufacturing and the future of the industry.

As AI continues to integrate into bioprocessing, the role of scientists is evolving. Farahani envisions a future where scientists collaborate with AI to enhance efficiency. One of Catalyze AI’s exciting innovations is an agentic root cause analysis tool, designed to automate troubleshooting. Instead of spending hours on manual analysis, scientists will receive AI-generated reports outlining probable causes of failures—allowing them to focus on high-level decision-making.

What you’ll learn in this episode:

  • Exciting Advances in AI: Farahani highlights the potential of Artificial General Intelligence (AGI)—AI that can generate ideas through analogy, much like humans do. Imagine an AI system recognizing a successful method in the petroleum industry and applying those principles to biomanufacturing. This kind of cross-disciplinary innovation could unlock groundbreaking efficiencies.
  • Leadership Principles in AI-Driven Biotech Startups: Farahani takes an unconventional approach to leadership. Unlike corporate environments where avoiding mistakes is crucial, he encourages his team to embrace failure early on. "I want to see you make a mistake in the first month," he tells new hires. By removing the fear of failure, his team can experiment, think creatively, and drive true innovation—an essential mindset for biotech startups breaking new ground.
  • Advice for Aspiring Biotech Entrepreneurs: Farahani’s advice is simple: find a problem, develop a unique solution, and take action. He urges scientists to identify small inefficiencies that can be scaled and optimized. Equally important is being open to failure and iterating quickly to refine solutions. Success comes from starting, adapting, and continuously improving.

As we stand on the brink of a biomanufacturing revolution, the real opportunity lies in combining AI with biologics. While AI often dominates the conversation, Farahani emphasizes that biologics remain underhyped. The true breakthroughs will come from leveraging AI to solve real-world challenges in biomanufacturing, leading to significant efficiencies and industry-wide advancements.

For those passionate about this field, staying connected with thought leaders like Reza Farahani and keeping up with the latest innovations is key. As AI and biologics continue to converge, the future of bioprocessing holds unprecedented potential for transformation and progress.

Curious about how AI is transforming bioprocessing? Discover how industry experts are driving innovation to shape the future of this field.

  • Episodes 111 and 112: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén
  • Episodes 107 and 108: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David Schönauer

Connect with Reza Farahani

LinkedIn: https://www.linkedin.com/in/reza-farahani-/

Catalyze AI: https://www.catalyzeai.com/

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/Sma

Support the show

]]> Artificial Intelligence (AI) is transforming industries worldwide, and biotechnology is no exception. In bioprocess development, AI is proving to be a game-changer, accelerating workflows, optimizing processes, and driving innovation. On the Smart Biotech Scientist Podcast, Reza Farahani, founder and CEO of Catalyze AI, shares his insights on how AI is reshaping biomanufacturing and the future of the industry.

As AI continues to integrate into bioprocessing, the role of scientists is evolving. Farahani envisions a future where scientists collaborate with AI to enhance efficiency. One of Catalyze AI’s exciting innovations is an agentic root cause analysis tool, designed to automate troubleshooting. Instead of spending hours on manual analysis, scientists will receive AI-generated reports outlining probable causes of failures—allowing them to focus on high-level decision-making.

What you’ll learn in this episode:

  • Exciting Advances in AI: Farahani highlights the potential of Artificial General Intelligence (AGI)—AI that can generate ideas through analogy, much like humans do. Imagine an AI system recognizing a successful method in the petroleum industry and applying those principles to biomanufacturing. This kind of cross-disciplinary innovation could unlock groundbreaking efficiencies.
  • Leadership Principles in AI-Driven Biotech Startups: Farahani takes an unconventional approach to leadership. Unlike corporate environments where avoiding mistakes is crucial, he encourages his team to embrace failure early on. "I want to see you make a mistake in the first month," he tells new hires. By removing the fear of failure, his team can experiment, think creatively, and drive true innovation—an essential mindset for biotech startups breaking new ground.
  • Advice for Aspiring Biotech Entrepreneurs: Farahani’s advice is simple: find a problem, develop a unique solution, and take action. He urges scientists to identify small inefficiencies that can be scaled and optimized. Equally important is being open to failure and iterating quickly to refine solutions. Success comes from starting, adapting, and continuously improving.

As we stand on the brink of a biomanufacturing revolution, the real opportunity lies in combining AI with biologics. While AI often dominates the conversation, Farahani emphasizes that biologics remain underhyped. The true breakthroughs will come from leveraging AI to solve real-world challenges in biomanufacturing, leading to significant efficiencies and industry-wide advancements.

For those passionate about this field, staying connected with thought leaders like Reza Farahani and keeping up with the latest innovations is key. As AI and biologics continue to converge, the future of bioprocessing holds unprecedented potential for transformation and progress.

Curious about how AI is transforming bioprocessing? Discover how industry experts are driving innovation to shape the future of this field.

  • Episodes 111 and 112: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén
  • Episodes 107 and 108: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David Schönauer

Connect with Reza Farahani

LinkedIn: https://www.linkedin.com/in/reza-farahani-/

Catalyze AI: https://www.catalyzeai.com/

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/Sma

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-16630812 Thu, 27 Feb 2025 05:00:00 +0100 897 132 full false 131: Combining AI and Biomanufacturing for Sustainable, Cost-Effective Therapeutics with Reza Farahani - Part 1 131: Combining AI and Biomanufacturing for Sustainable, Cost-Effective Therapeutics with Reza Farahani - Part 1 The real-world applications of AI in biomanufacturing are transformative. From reducing drug development timelines to optimizing production yields, AI is making biomanufacturing more efficient and cost-effective. This, in turn, enhances global access to life-saving therapies. As AI continues to evolve, its potential to drive even greater innovations in biologics manufacturing becomes increasingly promising.

In the latest episode of the Smart Biotech Scientist Podcast, David Brühlmann speaks with Reza Farahani, founder and CEO of Catalyze AI, about the profound impact of AI on biomanufacturing. They discuss how AI is reshaping drug development, reducing costs, and simplifying complex biomanufacturing processes - bringing us closer to a future where life-saving drugs are as accessible as smartphones.

Why You Should Tune In:

  • AI’s Role in Democratizing Biomanufacturing: One of the core missions of Catalyze AI is to democratize the sophisticated knowledge that currently resides mostly within top pharmaceutical companies. By leveraging AI to improve bioprocess development, Farahani aims to bridge the knowledge gap between academia and industry, thereby reducing the cost and accelerating the development of new therapeutics. This democratization of bioprocess knowledge could potentially revolutionize the accessibility and affordability of life-saving drugs.
  • How AI Optimizes Bioprocess Development: AI has the unique ability to manage and analyze complex, convoluted data sets much more efficiently than humans. Reza explains how transformer models—similar to the ones used in natural language processing tasks by ChatGPT—can be utilized to predict and optimize various steps in the biomanufacturing process. These models can learn and make predictions based on past data, enabling a significant reduction in the time and resources required for process development.
  • Solving the Scale-Up Challenge: Scale-up remains one of the most challenging aspects of bioprocess development, often plagued by delays and inefficiencies. AI can immensely help by leveraging data from both small and large-scale biomanufacturing processes to predict optimal conditions. However, given the complexity and high cost associated with scale-up experiments, Reza envisions a future where distributed, small-scale biomanufacturing units could replace large-scale facilities. This would not only reduce costs but also enhance flexibility and resilience against process failures.

AI is not just accelerating drug development—it’s reshaping the entire biomanufacturing landscape. Don’t miss this insightful conversation on how AI is driving the future of biotech.

As we stand at the intersection of AI and biomanufacturing, the possibilities are limitless. With continued advancements, we may soon witness a paradigm shift where drug production becomes more decentralized, efficient, and tailored to global healthcare needs. The future of biotech is being written now—are you ready to be part of it?

Interested in exploring more about AI’s impact on bioprocessing? Check out what other experts in the field are doing to drive innovation in this space.

  • Episodes 119 and 120: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian Guo
  • Episodes 115 and 116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti

Connect with Reza Farahani

LinkedIn: https://www.linkedin.com/in/reza-farahani-/

Catalyze AI: https://www.catalyzeai.com/

Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biotherapeutics better, fa

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> The real-world applications of AI in biomanufacturing are transformative. From reducing drug development timelines to optimizing production yields, AI is making biomanufacturing more efficient and cost-effective. This, in turn, enhances global access to life-saving therapies. As AI continues to evolve, its potential to drive even greater innovations in biologics manufacturing becomes increasingly promising.

In the latest episode of the Smart Biotech Scientist Podcast, David Brühlmann speaks with Reza Farahani, founder and CEO of Catalyze AI, about the profound impact of AI on biomanufacturing. They discuss how AI is reshaping drug development, reducing costs, and simplifying complex biomanufacturing processes - bringing us closer to a future where life-saving drugs are as accessible as smartphones.

Why You Should Tune In:

  • AI’s Role in Democratizing Biomanufacturing: One of the core missions of Catalyze AI is to democratize the sophisticated knowledge that currently resides mostly within top pharmaceutical companies. By leveraging AI to improve bioprocess development, Farahani aims to bridge the knowledge gap between academia and industry, thereby reducing the cost and accelerating the development of new therapeutics. This democratization of bioprocess knowledge could potentially revolutionize the accessibility and affordability of life-saving drugs.
  • How AI Optimizes Bioprocess Development: AI has the unique ability to manage and analyze complex, convoluted data sets much more efficiently than humans. Reza explains how transformer models—similar to the ones used in natural language processing tasks by ChatGPT—can be utilized to predict and optimize various steps in the biomanufacturing process. These models can learn and make predictions based on past data, enabling a significant reduction in the time and resources required for process development.
  • Solving the Scale-Up Challenge: Scale-up remains one of the most challenging aspects of bioprocess development, often plagued by delays and inefficiencies. AI can immensely help by leveraging data from both small and large-scale biomanufacturing processes to predict optimal conditions. However, given the complexity and high cost associated with scale-up experiments, Reza envisions a future where distributed, small-scale biomanufacturing units could replace large-scale facilities. This would not only reduce costs but also enhance flexibility and resilience against process failures.

AI is not just accelerating drug development—it’s reshaping the entire biomanufacturing landscape. Don’t miss this insightful conversation on how AI is driving the future of biotech.

As we stand at the intersection of AI and biomanufacturing, the possibilities are limitless. With continued advancements, we may soon witness a paradigm shift where drug production becomes more decentralized, efficient, and tailored to global healthcare needs. The future of biotech is being written now—are you ready to be part of it?

Interested in exploring more about AI’s impact on bioprocessing? Check out what other experts in the field are doing to drive innovation in this space.

  • Episodes 119 and 120: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian Guo
  • Episodes 115 and 116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti

Connect with Reza Farahani

LinkedIn: https://www.linkedin.com/in/reza-farahani-/

Catalyze AI: https://www.catalyzeai.com/

Wondering how to develop biomanufacturing processes with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biotherapeutics better, fa

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-16630802 Tue, 25 Feb 2025 05:00:00 +0100 1667 131 full false 130: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason Foster - Part 2 130: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason Foster - Part 2 The intricacies of tech transfer and the challenges of scaling manufacturing processes are often underestimated in the biotechnology industry. Understanding these complexities is crucial for translating innovative scientific breakthroughs into commercially viable products.

In the second part of the conversation with Jason Foster, CEO of Ori Biotech, host David Brühlmann explores the complexities of cell therapy manufacturing. Their discussion highlights key challenges, including tech transfer, scale-out strategies, and the crucial role of commercial strategy alongside scientific excellence.

Jason also revealed a groundbreaking approach in the cell therapy space. He detailed how Ori's IRO® platform can process multiple patient doses simultaneously, enabling treatment for 30 patients in parallel within just 1,000 square feet of clean room space. This innovative method drastically reduces clean room requirements by about 95% and facility sizes by approximately 50%, significantly cutting costs associated with building and operating large-scale facilities.

As Jason emphasized, this shift not only accelerates access to groundbreaking therapies but also provides a sustainable model for scaling cell therapy production.

Key Points to Remember:

  • Integrated Approach: Scientists should look beyond their specialized areas and understand the requirements of subsequent bioprocessing stages to maximize patient impact.
  • Technological Evolution: Advancing distributed manufacturing and enhancing in-line analytics are essential steps to revolutionize the biotech landscape.
  • Commercial Viability: Prioritizing commercial feasibility alongside safety and efficacy in preclinical development can prevent costly late-stage setbacks.

This episode of the Smart Biotech Scientist underscores the complexities and transformative potential of cell therapy manufacturing. As the industry continues to innovate, integrating commercial viability, flexibility, and advanced manufacturing solutions will be critical. By breaking down silos and fostering collaboration, we can accelerate the development of life-saving therapies—ensuring they reach patients faster and more efficiently.

Connect with Jason Foster

LinkedIn: https://www.linkedin.com/in/jasoncfoster

Oribiotech: https://oribiotech.com

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Support the show

]]> The intricacies of tech transfer and the challenges of scaling manufacturing processes are often underestimated in the biotechnology industry. Understanding these complexities is crucial for translating innovative scientific breakthroughs into commercially viable products.

In the second part of the conversation with Jason Foster, CEO of Ori Biotech, host David Brühlmann explores the complexities of cell therapy manufacturing. Their discussion highlights key challenges, including tech transfer, scale-out strategies, and the crucial role of commercial strategy alongside scientific excellence.

Jason also revealed a groundbreaking approach in the cell therapy space. He detailed how Ori's IRO® platform can process multiple patient doses simultaneously, enabling treatment for 30 patients in parallel within just 1,000 square feet of clean room space. This innovative method drastically reduces clean room requirements by about 95% and facility sizes by approximately 50%, significantly cutting costs associated with building and operating large-scale facilities.

As Jason emphasized, this shift not only accelerates access to groundbreaking therapies but also provides a sustainable model for scaling cell therapy production.

Key Points to Remember:

  • Integrated Approach: Scientists should look beyond their specialized areas and understand the requirements of subsequent bioprocessing stages to maximize patient impact.
  • Technological Evolution: Advancing distributed manufacturing and enhancing in-line analytics are essential steps to revolutionize the biotech landscape.
  • Commercial Viability: Prioritizing commercial feasibility alongside safety and efficacy in preclinical development can prevent costly late-stage setbacks.

This episode of the Smart Biotech Scientist underscores the complexities and transformative potential of cell therapy manufacturing. As the industry continues to innovate, integrating commercial viability, flexibility, and advanced manufacturing solutions will be critical. By breaking down silos and fostering collaboration, we can accelerate the development of life-saving therapies—ensuring they reach patients faster and more efficiently.

Connect with Jason Foster

LinkedIn: https://www.linkedin.com/in/jasoncfoster

Oribiotech: https://oribiotech.com

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-16589107 Thu, 20 Feb 2025 05:00:00 +0100 1215 130 full false 129: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason Foster - Part 1 129: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason Foster - Part 1 One of the most urgent challenges in modern medicine is making cell and gene therapies widely accessible. These therapies, while groundbreaking in their safety and efficacy, often fall short when it comes to reaching patients. The reasons are manifold—high manufacturing costs, logistical complexities, and inefficiencies in the production pipeline.

We're joined by Jason Foster, CEO and Executive Director of Ori Biotech, a company that's revolutionizing cell and gene therapy manufacturing through automation and innovative approaches.

Jason sheds light on the technical bottlenecks that limit patient access to life-saving therapies and discusses how an integrated, holistic view of the development chain could make a significant difference. From the complexities of centralized manufacturing and the interconnectedness of the supply chain, to specific technical solutions Ori Biotech has developed, we explore the multi-faceted issues and potential solutions in making these advanced therapies more reachable.

Here are three key takeaways from our conversation:

  • Holistic Development Chain: Jason emphasizes the importance of integrating all stakeholders in the development chain, ensuring everyone understands what happens before and what needs to happen next to improve the overall process.
  • Technical Bottlenecks & Solutions: We delved into various technical bottlenecks, including centralized manufacturing and logistical complexities. Jason highlighted how Ori Biotech is addressing these issues through automation and reducing manual labor, which can cut manufacturing costs by 50%.
  • Impact on Accessibility: It's alarming that only 3-5% of patients who need CAR-T therapies have access to them. Jason's mission with Ori Biotech is to transform this narrative by enabling widespread access to these life-saving therapies through innovative manufacturing solutions.

As cell and gene therapies stand poised to revolutionize cancer and rare disease treatment, the focus must shift toward overcoming manufacturing constraints. By integrating automation and aiming for decentralized models, companies like Ori Biotech offer a glimpse into a future where these revolutionary treatments are accessible to all who need them.

Fascinated by Cell Therapy? Hear from top experts in these two episodes!

  • Episodes 11 and 12: From Lab to Patient: Steve Oh’s Guide to Mastering Cell Therapy Process Development
  • Episodes 21 and 22: Unleashing Effective QbD Strategies to Master Cell Therapy with Shin Kawamata

Connect with Jason Foster

LinkedIn: https://www.linkedin.com/in/jasoncfoster

Oribiotech: https://oribiotech.com

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Support the show

]]> One of the most urgent challenges in modern medicine is making cell and gene therapies widely accessible. These therapies, while groundbreaking in their safety and efficacy, often fall short when it comes to reaching patients. The reasons are manifold—high manufacturing costs, logistical complexities, and inefficiencies in the production pipeline.

We're joined by Jason Foster, CEO and Executive Director of Ori Biotech, a company that's revolutionizing cell and gene therapy manufacturing through automation and innovative approaches.

Jason sheds light on the technical bottlenecks that limit patient access to life-saving therapies and discusses how an integrated, holistic view of the development chain could make a significant difference. From the complexities of centralized manufacturing and the interconnectedness of the supply chain, to specific technical solutions Ori Biotech has developed, we explore the multi-faceted issues and potential solutions in making these advanced therapies more reachable.

Here are three key takeaways from our conversation:

  • Holistic Development Chain: Jason emphasizes the importance of integrating all stakeholders in the development chain, ensuring everyone understands what happens before and what needs to happen next to improve the overall process.
  • Technical Bottlenecks & Solutions: We delved into various technical bottlenecks, including centralized manufacturing and logistical complexities. Jason highlighted how Ori Biotech is addressing these issues through automation and reducing manual labor, which can cut manufacturing costs by 50%.
  • Impact on Accessibility: It's alarming that only 3-5% of patients who need CAR-T therapies have access to them. Jason's mission with Ori Biotech is to transform this narrative by enabling widespread access to these life-saving therapies through innovative manufacturing solutions.

As cell and gene therapies stand poised to revolutionize cancer and rare disease treatment, the focus must shift toward overcoming manufacturing constraints. By integrating automation and aiming for decentralized models, companies like Ori Biotech offer a glimpse into a future where these revolutionary treatments are accessible to all who need them.

Fascinated by Cell Therapy? Hear from top experts in these two episodes!

  • Episodes 11 and 12: From Lab to Patient: Steve Oh’s Guide to Mastering Cell Therapy Process Development
  • Episodes 21 and 22: Unleashing Effective QbD Strategies to Master Cell Therapy with Shin Kawamata

Connect with Jason Foster

LinkedIn: https://www.linkedin.com/in/jasoncfoster

Oribiotech: https://oribiotech.com

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-16589089 Tue, 18 Feb 2025 05:00:00 +0100 1330 129 full false 128: The 7 Hidden Innovation Habits That Top Biotech Scientists Use Daily - Part 2 128: The 7 Hidden Innovation Habits That Top Biotech Scientists Use Daily - Part 2 The world of bioprocess development in biotechnology is evolving at an unprecedented pace, driven by the quest for breakthrough innovations. While new technologies play a significant role, what truly sets successful innovators apart are fundamental habits that foster an environment ripe for groundbreaking discoveries.

In today's discussion, we'll delve into three essential habits that, when combined with the four habits previously discussed, can redefine your approach to bioprocess development. Additionally, we'll wrap up with a bonus tip that has the potential to revolutionize your career.

  1. Challenge the Status Quo - In any scientific endeavor, particularly in biotech, a common pitfall is accepting established processes as the best or only methods. The fifth habit to cultivate is the continuous challenging of the status quo. When was the last time you scrutinized your standard operating procedures and wondered why they are the way they are?
  2. Embrace Continuous Learning - Innovation in biotech is characterized by rapid advancements, and staying ahead demands continuous learning. According to a 2023 EDX survey, nearly half of today's workplace skills will be obsolete by 2025, primarily due to AI advancements. Hence, the sixth habit is to never stop learning.
  3. Harness the Power of Passion - At the core of every great innovation is passion. The seventh habit revolves around the deep sense of purpose that drives scientific pursuits. Beyond the routine aspects of bioprocess development, what truly fuels your ambition?

Finally, a game-changing career strategy known as Strategic Cross-Pollination Networking can significantly enhance your innovative capabilities. This goes beyond traditional networking, focusing on building connections across various domains to foster innovative solutions.

Innovation in bioprocess development is not about daily eureka moments but about the consistent application of these habits. Small, persistent efforts can cumulatively lead to transformative results in this rapidly evolving field.

If you found these insights valuable, share them with your colleagues. Ready to fast-track your product and technology development? As a strategic advisor to biotech leaders, we can help you eliminate costly delays and optimize your path to market.

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Support the show

]]> The world of bioprocess development in biotechnology is evolving at an unprecedented pace, driven by the quest for breakthrough innovations. While new technologies play a significant role, what truly sets successful innovators apart are fundamental habits that foster an environment ripe for groundbreaking discoveries.

In today's discussion, we'll delve into three essential habits that, when combined with the four habits previously discussed, can redefine your approach to bioprocess development. Additionally, we'll wrap up with a bonus tip that has the potential to revolutionize your career.

  1. Challenge the Status Quo - In any scientific endeavor, particularly in biotech, a common pitfall is accepting established processes as the best or only methods. The fifth habit to cultivate is the continuous challenging of the status quo. When was the last time you scrutinized your standard operating procedures and wondered why they are the way they are?
  2. Embrace Continuous Learning - Innovation in biotech is characterized by rapid advancements, and staying ahead demands continuous learning. According to a 2023 EDX survey, nearly half of today's workplace skills will be obsolete by 2025, primarily due to AI advancements. Hence, the sixth habit is to never stop learning.
  3. Harness the Power of Passion - At the core of every great innovation is passion. The seventh habit revolves around the deep sense of purpose that drives scientific pursuits. Beyond the routine aspects of bioprocess development, what truly fuels your ambition?

Finally, a game-changing career strategy known as Strategic Cross-Pollination Networking can significantly enhance your innovative capabilities. This goes beyond traditional networking, focusing on building connections across various domains to foster innovative solutions.

Innovation in bioprocess development is not about daily eureka moments but about the consistent application of these habits. Small, persistent efforts can cumulatively lead to transformative results in this rapidly evolving field.

If you found these insights valuable, share them with your colleagues. Ready to fast-track your product and technology development? As a strategic advisor to biotech leaders, we can help you eliminate costly delays and optimize your path to market.

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-16540264 Thu, 13 Feb 2025 05:00:00 +0100 1062 128 full false 127: The 7 Hidden Innovation Habits That Top Biotech Scientists Use Daily - Part 1 127: The 7 Hidden Innovation Habits That Top Biotech Scientists Use Daily - Part 1 In the fast-paced and highly regulated world of biotech development, maintaining an innovative spirit can sometimes feel like a Herculean task. Between optimizing cell culture processes and navigating strict regulatory requirements, it’s no wonder many scientists feel the weight of daily operations pressing down on their creativity. However, fostering innovation is crucial for breakthroughs in our field.

David Brühlmann shares practices that have transformed how scientists approach complex challenges in our field.

Here are the first four habits that can reshape your approach to bioprocess development.

  1. Cultivate Deep Curiosity: Curiosity is the cornerstone of scientific discovery. However, it’s not just about a broad interest in science. The type of curiosity that drives innovation is the kind that goes beyond initial observations. It's the kind that makes you question what's happening inside the cell culture and strive to understand phenomena at a fundamental level.
  2. Connect the Dots: Innovation often comes from connecting seemingly unrelated ideas. Drawing connections between different facts or events can lead to a better understanding and new approaches to complex challenges.
  3. Embrace Calculated Risks: In a GMP environment, risk-taking may sound contradictory. However, calculated risks are essential for innovation. It's about carefully evaluating opportunities and understanding their potential impact before acting.
  4. Practice Persistence: Persistence is a key ingredient for innovation, especially during challenging times. Experimentation often involves setbacks and unexpected results, but each failure is a learning opportunity.

Fostering innovation in biotech development is a multifaceted process that requires curiosity, the ability to connect dots, calculated risks, persistence, collaboration, digital tools, and continuous learning. By integrating these habits into your work routine, you can unlock new potentials and drive breakthroughs in the biotech field. Remember, breakthroughs often come from embracing the complex nature of bioprocess development and continuously exploring, questioning, and innovating.

Don't miss our next episode, where we’ll reveal the final three habits!

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Support the show

]]> In the fast-paced and highly regulated world of biotech development, maintaining an innovative spirit can sometimes feel like a Herculean task. Between optimizing cell culture processes and navigating strict regulatory requirements, it’s no wonder many scientists feel the weight of daily operations pressing down on their creativity. However, fostering innovation is crucial for breakthroughs in our field.

David Brühlmann shares practices that have transformed how scientists approach complex challenges in our field.

Here are the first four habits that can reshape your approach to bioprocess development.

  1. Cultivate Deep Curiosity: Curiosity is the cornerstone of scientific discovery. However, it’s not just about a broad interest in science. The type of curiosity that drives innovation is the kind that goes beyond initial observations. It's the kind that makes you question what's happening inside the cell culture and strive to understand phenomena at a fundamental level.
  2. Connect the Dots: Innovation often comes from connecting seemingly unrelated ideas. Drawing connections between different facts or events can lead to a better understanding and new approaches to complex challenges.
  3. Embrace Calculated Risks: In a GMP environment, risk-taking may sound contradictory. However, calculated risks are essential for innovation. It's about carefully evaluating opportunities and understanding their potential impact before acting.
  4. Practice Persistence: Persistence is a key ingredient for innovation, especially during challenging times. Experimentation often involves setbacks and unexpected results, but each failure is a learning opportunity.

Fostering innovation in biotech development is a multifaceted process that requires curiosity, the ability to connect dots, calculated risks, persistence, collaboration, digital tools, and continuous learning. By integrating these habits into your work routine, you can unlock new potentials and drive breakthroughs in the biotech field. Remember, breakthroughs often come from embracing the complex nature of bioprocess development and continuously exploring, questioning, and innovating.

Don't miss our next episode, where we’ll reveal the final three habits!

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-16540247 Tue, 11 Feb 2025 05:00:00 +0100 953 127 full false 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei - Part 2 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei - Part 2 As biotechnology rapidly evolves, cell therapies are emerging as a groundbreaking frontier with the potential to transform medicine. In this episode of the Smart Biotech Scientist Podcast, host David Brühlmann speaks with Armon Sharei, founder and CEO of Portal Bio, about the complexities, challenges, and future of cell therapies.

Cell therapies could revolutionize medicine in ways similar to antibiotics and vaccines. However, the current manufacturing process is costly and time-consuming.

Armon Sharei envisions a future where point-of-care production makes these therapies more accessible, even at the patient's bedside. This approach could not only benefit developed countries but also emerging markets.

Armon suggests that cell therapies could be as transformative as antibiotics and vaccines, with the potential to address complex diseases like cancer and autoimmune disorders. These therapies could precisely target tumors, correct dysfunctions in autoimmune diseases, and regenerate tissues in conditions like Parkinson's.

Key Takeaways:

  • Cell Therapies as the Future: Armon emphasizes that cell therapies, like antibiotics and vaccines, offer high efficacy with minimal toxicity. They can address complex diseases such as tumors and autoimmune disorders.
  • Simplifying Manufacturing: Current manufacturing methods are expensive and slow. Portal Bio’s point-of-care approach could streamline production, reducing both time and costs.
  • Expanding Accessibility: Making cell therapies more accessible requires technological advances as well as changes in regulatory and quality standards to lower costs and make treatments available globally.

As technology advances, the future of cell therapies looks promising. Armon believes point-of-care cell therapies will bring sophisticated treatments directly to patients, transforming healthcare.

Connect with Armon Sharei

LinkedIn: https://www.linkedin.com/in/armonsharei/

Portal: https://www.portal.bio

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Support the show

]]> As biotechnology rapidly evolves, cell therapies are emerging as a groundbreaking frontier with the potential to transform medicine. In this episode of the Smart Biotech Scientist Podcast, host David Brühlmann speaks with Armon Sharei, founder and CEO of Portal Bio, about the complexities, challenges, and future of cell therapies.

Cell therapies could revolutionize medicine in ways similar to antibiotics and vaccines. However, the current manufacturing process is costly and time-consuming.

Armon Sharei envisions a future where point-of-care production makes these therapies more accessible, even at the patient's bedside. This approach could not only benefit developed countries but also emerging markets.

Armon suggests that cell therapies could be as transformative as antibiotics and vaccines, with the potential to address complex diseases like cancer and autoimmune disorders. These therapies could precisely target tumors, correct dysfunctions in autoimmune diseases, and regenerate tissues in conditions like Parkinson's.

Key Takeaways:

  • Cell Therapies as the Future: Armon emphasizes that cell therapies, like antibiotics and vaccines, offer high efficacy with minimal toxicity. They can address complex diseases such as tumors and autoimmune disorders.
  • Simplifying Manufacturing: Current manufacturing methods are expensive and slow. Portal Bio’s point-of-care approach could streamline production, reducing both time and costs.
  • Expanding Accessibility: Making cell therapies more accessible requires technological advances as well as changes in regulatory and quality standards to lower costs and make treatments available globally.

As technology advances, the future of cell therapies looks promising. Armon believes point-of-care cell therapies will bring sophisticated treatments directly to patients, transforming healthcare.

Connect with Armon Sharei

LinkedIn: https://www.linkedin.com/in/armonsharei/

Portal: https://www.portal.bio

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-16508753 Thu, 06 Feb 2025 05:00:00 +0100 1231 126 full false 125: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei - Part 1 125: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon Sharei - Part 1 Intracellular delivery is essential for advancing research and clinical applications, yet it presents unique challenges when working with different cell types and biomolecules.

In a recent episode of the Smart Biotech Scientist podcast, David Brühlmann spoke with Armon Sharei, the founder and CEO of Portal Bio, about the future of cell therapy, the hurdles of intracellular delivery, and groundbreaking innovations in drug screening.

Armon’s journey began at MIT, where his initial focus on chemical engineering evolved into a passion for cell engineering. While exploring innovative methods for introducing materials into cells, he discovered a novel mechanism: squeezing cells to temporarily disrupt their membranes, allowing materials to diffuse in.

Armon explained that optimizing delivery parameters - such as pore size and the speed at which cells pass through specialized membranes - can significantly enhance efficiency. "If you've optimized it, one time is enough," he noted. "We can get above 80% delivery and viability pretty easily for most cell types." He emphasized the importance of tailoring pore sizes to specific cell types, such as smaller pores for T cells compared to stem cells. Additionally, the flow speed of cells through the membrane is critical; moving too slowly renders the process ineffective, while moving too quickly can damage the cells.

Tune in to this episode to find out more about:

  • Addressing Intracellular Delivery Challenges: Portal Bio’s breakthrough technology uses mechanical deformation to open a cell’s lipid bilayer, allowing materials to diffuse in. This approach overcomes the limitations of traditional methods like electroporation or nanoparticle-mediated delivery, which often depend on molecular charge or risk damaging cells.
  • Delivering a Wide Range of Molecules: Portal Bio’s technology is versatile, capable of delivering DNA, RNA, peptides, proteins, and more. Unlike methods tailored to specific molecules, this platform supports diverse applications. For instance, RNA operates in the cytoplasm, making delivery straightforward, while CRISPR complexes require nuclear localization sequences to enable gene editing in the nucleus.
  • Streamlining Drug Screening: Portal Bio’s technology also revolutionizes drug screening. Traditional approaches often struggle with impermeable small molecules, leading to lengthy and uncertain drug development processes. By enabling high-throughput screening, Portal Bio accelerates the evaluation of numerous drug candidates, identifying promising options before chemical modifications are necessary.

As bioprocesses grow more advanced, the demand for efficient and versatile intracellular delivery methods becomes increasingly critical. Armon’s insights underscore a transformative shift in the technologies and processes shaping the future of cell therapy and bioprocessing.

Connect with Armon Sharei

LinkedIn: https://www.linkedin.com/in/armonsharei

Portal: https://www.portal.bio

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Support the show

]]> Intracellular delivery is essential for advancing research and clinical applications, yet it presents unique challenges when working with different cell types and biomolecules.

In a recent episode of the Smart Biotech Scientist podcast, David Brühlmann spoke with Armon Sharei, the founder and CEO of Portal Bio, about the future of cell therapy, the hurdles of intracellular delivery, and groundbreaking innovations in drug screening.

Armon’s journey began at MIT, where his initial focus on chemical engineering evolved into a passion for cell engineering. While exploring innovative methods for introducing materials into cells, he discovered a novel mechanism: squeezing cells to temporarily disrupt their membranes, allowing materials to diffuse in.

Armon explained that optimizing delivery parameters - such as pore size and the speed at which cells pass through specialized membranes - can significantly enhance efficiency. "If you've optimized it, one time is enough," he noted. "We can get above 80% delivery and viability pretty easily for most cell types." He emphasized the importance of tailoring pore sizes to specific cell types, such as smaller pores for T cells compared to stem cells. Additionally, the flow speed of cells through the membrane is critical; moving too slowly renders the process ineffective, while moving too quickly can damage the cells.

Tune in to this episode to find out more about:

  • Addressing Intracellular Delivery Challenges: Portal Bio’s breakthrough technology uses mechanical deformation to open a cell’s lipid bilayer, allowing materials to diffuse in. This approach overcomes the limitations of traditional methods like electroporation or nanoparticle-mediated delivery, which often depend on molecular charge or risk damaging cells.
  • Delivering a Wide Range of Molecules: Portal Bio’s technology is versatile, capable of delivering DNA, RNA, peptides, proteins, and more. Unlike methods tailored to specific molecules, this platform supports diverse applications. For instance, RNA operates in the cytoplasm, making delivery straightforward, while CRISPR complexes require nuclear localization sequences to enable gene editing in the nucleus.
  • Streamlining Drug Screening: Portal Bio’s technology also revolutionizes drug screening. Traditional approaches often struggle with impermeable small molecules, leading to lengthy and uncertain drug development processes. By enabling high-throughput screening, Portal Bio accelerates the evaluation of numerous drug candidates, identifying promising options before chemical modifications are necessary.

As bioprocesses grow more advanced, the demand for efficient and versatile intracellular delivery methods becomes increasingly critical. Armon’s insights underscore a transformative shift in the technologies and processes shaping the future of cell therapy and bioprocessing.

Connect with Armon Sharei

LinkedIn: https://www.linkedin.com/in/armonsharei

Portal: https://www.portal.bio

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biotherapeutics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-16508749 Tue, 04 Feb 2025 05:00:00 +0100 1295 125 full false 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein - Part 2 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein - Part 2 In part two of our insightful conversation, Dr. Susan Sharfstein builds on our previous discussion of developability assessment to explore how AI is revolutionizing protein manufacturability predictions.

As a Professor of Nanoscale Science and Engineering at the University of Albany, she shares groundbreaking insights from her collaboration with DeepSeq AI, demonstrating how artificial intelligence is transforming our ability to assess and predict protein manufacturability early in development.

Key Takeaways:

  • Discover how AI tools are enhancing traditional developability assessments by predicting protein expression and stability before entering the lab
  • Learn why integration of experimental validation with AI predictions is crucial for successful manufacturability assessment, and how industry partnerships are making this possible at unprecedented scale
  • Understand how the synergy between AI, DNA synthesis capabilities, and robotics is creating a "positive spiral" that will accelerate protein manufacturing innovation

Whether you're involved in candidate selection, process development, or curious about AI's impact on developability assessment, this episode offers valuable insights into the future of protein manufacturing. Plus, Dr. Sharfstein shares invaluable career advice for emerging biotech scientists.

Join us to explore how AI is reshaping developability assessment and learn why this field continues to offer life-changing possibilities for patients worldwide.

Connect with Susan Sharfstein:

LinkedIn: https://www.linkedin.com/in/susan-sharfstein-b7552111/

College of Nanotechnology, Science, and Engineering, University at Albany: https://www.albany.edu/cnse

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Support the show

]]> In part two of our insightful conversation, Dr. Susan Sharfstein builds on our previous discussion of developability assessment to explore how AI is revolutionizing protein manufacturability predictions.

As a Professor of Nanoscale Science and Engineering at the University of Albany, she shares groundbreaking insights from her collaboration with DeepSeq AI, demonstrating how artificial intelligence is transforming our ability to assess and predict protein manufacturability early in development.

Key Takeaways:

  • Discover how AI tools are enhancing traditional developability assessments by predicting protein expression and stability before entering the lab
  • Learn why integration of experimental validation with AI predictions is crucial for successful manufacturability assessment, and how industry partnerships are making this possible at unprecedented scale
  • Understand how the synergy between AI, DNA synthesis capabilities, and robotics is creating a "positive spiral" that will accelerate protein manufacturing innovation

Whether you're involved in candidate selection, process development, or curious about AI's impact on developability assessment, this episode offers valuable insights into the future of protein manufacturing. Plus, Dr. Sharfstein shares invaluable career advice for emerging biotech scientists.

Join us to explore how AI is reshaping developability assessment and learn why this field continues to offer life-changing possibilities for patients worldwide.

Connect with Susan Sharfstein:

LinkedIn: https://www.linkedin.com/in/susan-sharfstein-b7552111/

College of Nanotechnology, Science, and Engineering, University at Albany: https://www.albany.edu/cnse

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-16454462 Thu, 30 Jan 2025 05:00:00 +0100 1052 124 full false 123: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein - Part 1 123: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan Sharfstein - Part 1 In this eye-opening episode, we dive deep into the critical yet often overlooked world of protein manufacturability with Dr. Susan Sharfstein, Professor of Nanoscale Science and Engineering at the University of Albany. As part of the broader developability assessment process, manufacturability evaluation helps determine whether a therapeutic candidate can be successfully produced at commercial scale.

Drawing from her extensive experience in bioprocessing and cell culture technology, Dr. Sharfstein reveals why seemingly promising protein candidates can fail during manufacturing—and how to spot these issues early.

Key Takeaways:

  • Discover why efficacy isn't enough: Learn how to evaluate protein candidates beyond clinical performance to ensure manufacturing success
  • Master early-stage assessment: Understand the critical parameters that can make or break successful scale-up, from cell line selection to protein folding
  • Future-proof your development: Gain insights into how AI is transforming protein manufacturability assessment and what this means for process development

Whether you're selecting protein candidates or optimizing your bioprocess, this episode offers invaluable guidance for making smarter decisions earlier in development. Join us to learn how to bridge the gap between discovery and manufacturing success.

Listen now to transform how you approach protein manufacturability and save valuable time and resources in your development journey.

Connect with Susan Sharfstein:

LinkedIn: https://www.linkedin.com/in/susan-sharfstein-b7552111/

College of Nanotechnology, Science, and Engineering, University at Albany: https://www.albany.edu/cnse

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Support the show

]]> In this eye-opening episode, we dive deep into the critical yet often overlooked world of protein manufacturability with Dr. Susan Sharfstein, Professor of Nanoscale Science and Engineering at the University of Albany. As part of the broader developability assessment process, manufacturability evaluation helps determine whether a therapeutic candidate can be successfully produced at commercial scale.

Drawing from her extensive experience in bioprocessing and cell culture technology, Dr. Sharfstein reveals why seemingly promising protein candidates can fail during manufacturing—and how to spot these issues early.

Key Takeaways:

  • Discover why efficacy isn't enough: Learn how to evaluate protein candidates beyond clinical performance to ensure manufacturing success
  • Master early-stage assessment: Understand the critical parameters that can make or break successful scale-up, from cell line selection to protein folding
  • Future-proof your development: Gain insights into how AI is transforming protein manufacturability assessment and what this means for process development

Whether you're selecting protein candidates or optimizing your bioprocess, this episode offers invaluable guidance for making smarter decisions earlier in development. Join us to learn how to bridge the gap between discovery and manufacturing success.

Listen now to transform how you approach protein manufacturability and save valuable time and resources in your development journey.

Connect with Susan Sharfstein:

LinkedIn: https://www.linkedin.com/in/susan-sharfstein-b7552111/

College of Nanotechnology, Science, and Engineering, University at Albany: https://www.albany.edu/cnse

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-16454392 Tue, 28 Jan 2025 05:00:00 +0100 1355 123 full false 122: The Transformative World of Digital Solutions in Bioprocessing with Simon Wieninger - Part 2 122: The Transformative World of Digital Solutions in Bioprocessing with Simon Wieninger - Part 2 In the second part of this conversation on digital solutions in bioprocessing, David Brühlmann and Simon Wieninger, Business Manager Digital Solutions at Eppendorf Group, discuss real-world examples of labs revolutionizing their workflows through smart digitalization. From real-time data monitoring to intercontinental data sharing, Simon highlights the practical benefits and exciting future potential of digital technologies in bioprocessing.

Missed Part 1? In the previous episode, Simon Wieninger from Eppendorf Group addressed data silos, cloud technology, and security in biotech. Catch up on that episode before diving into Part 2!

Key highlights from the episode:

  • Choosing the Right Tools: Simon emphasized the importance of selecting the right digital tools and technologies to focus on what brings the most value, particularly in the bioreactor space. Real-time data access, even from your mobile device while walking your dog, is now possible!
  • Data Sharing Across Sites: Simon shared a fascinating case where a U.S.-based biotech company and their CDMO in Germany shared real-time data through the cloud, breaking down silos and enabling collaborative analysis. Imagine the possibilities for your company!
  • Looking to the Future: We explored the exciting potential of integrating bioprocessing data with clinical outcomes, particularly in cell and gene therapy. This holistic approach can revolutionize patient care and therapy development.

As Simon succinctly puts it, scientists should focus on what they do best - biology. The burden of managing digital technologies should not overshadow their primary research and development activities. With specialized tools and expert support, biotechnologists can achieve greater efficiency and innovation without getting bogged down by technological complexities.

The conversation between Simon Wieninger and David Brühlmann illuminates the transformative potential of digital tools in bioprocessing. From real-time monitoring to data harmonization and cross-site collaboration, these technologies are paving the way for more efficient and innovative bioprocessing practices.

By strategically adopting these tools, scientists can focus on groundbreaking research, ultimately accelerating the development and delivery of life-saving therapies.

Connect with Simon Wieninger:

LinkedIn: https://www.linkedin.com/in/dr-simon-wieninger-45b546182

Eppendorf Group: https://www.eppendorf.com

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Support the show

]]> In the second part of this conversation on digital solutions in bioprocessing, David Brühlmann and Simon Wieninger, Business Manager Digital Solutions at Eppendorf Group, discuss real-world examples of labs revolutionizing their workflows through smart digitalization. From real-time data monitoring to intercontinental data sharing, Simon highlights the practical benefits and exciting future potential of digital technologies in bioprocessing.

Missed Part 1? In the previous episode, Simon Wieninger from Eppendorf Group addressed data silos, cloud technology, and security in biotech. Catch up on that episode before diving into Part 2!

Key highlights from the episode:

  • Choosing the Right Tools: Simon emphasized the importance of selecting the right digital tools and technologies to focus on what brings the most value, particularly in the bioreactor space. Real-time data access, even from your mobile device while walking your dog, is now possible!
  • Data Sharing Across Sites: Simon shared a fascinating case where a U.S.-based biotech company and their CDMO in Germany shared real-time data through the cloud, breaking down silos and enabling collaborative analysis. Imagine the possibilities for your company!
  • Looking to the Future: We explored the exciting potential of integrating bioprocessing data with clinical outcomes, particularly in cell and gene therapy. This holistic approach can revolutionize patient care and therapy development.

As Simon succinctly puts it, scientists should focus on what they do best - biology. The burden of managing digital technologies should not overshadow their primary research and development activities. With specialized tools and expert support, biotechnologists can achieve greater efficiency and innovation without getting bogged down by technological complexities.

The conversation between Simon Wieninger and David Brühlmann illuminates the transformative potential of digital tools in bioprocessing. From real-time monitoring to data harmonization and cross-site collaboration, these technologies are paving the way for more efficient and innovative bioprocessing practices.

By strategically adopting these tools, scientists can focus on groundbreaking research, ultimately accelerating the development and delivery of life-saving therapies.

Connect with Simon Wieninger:

LinkedIn: https://www.linkedin.com/in/dr-simon-wieninger-45b546182

Eppendorf Group: https://www.eppendorf.com

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-16292997 Thu, 23 Jan 2025 05:00:00 +0100 1078 122 full false 121: The Transformative World of Digital Solutions in Bioprocessing with Simon Wieninger - Part 1 121: The Transformative World of Digital Solutions in Bioprocessing with Simon Wieninger - Part 1 Digital transformation is reshaping industries worldwide, and biotech is no exception. With the integration of cloud technologies, AI, and data harmonization, bioprocessing is becoming smarter, more efficient, and more innovative. Catching up with digital revolutions in other sectors, biotech now stands at the threshold of tremendous change.

In this episode of the Smart Biotech Scientist Podcast, David Brühlmann sat down with Simon Wieninger, Business Manager Digital Solutions at Eppendorf Group, to discuss the digital revolution sweeping through bioprocessing labs. From bioreactors to data lakes, Simon sheds light on the urgent need for a data-driven approach in biotech and how digital transformation is set to reshape the industry.

Here are the top three key takeaways:

  • Breaking Down Silos: The importance of consolidating data in one place to facilitate better analysis and collaboration across departments.
  • Leveraging Cloud Technology: Simon emphasized that the biotech industry is ready to embrace cloud technologies for enhanced data management.
  • Data Security Concerns: Addressing the common misconception about cloud security, Simon reassured that robust measures are in place to protect bioprocess data, making it as secure as banking data.

The move towards centralized data storage, the integration of AI, and strategic collaborations are critical steps in this journey. The industry is poised for transformation, and as Simon aptly put it, “step by step,” we can harness the full potential of these digital solutions. As biotech continues to evolve, the fusion of technology and biological science will undoubtedly lead to groundbreaking advancements, streamlining processes, and unlocking new possibilities in the field.

Connect with Simon Wieninger

LinkedIn: https://www.linkedin.com/in/dr-simon-wieninger-45b546182

Eppendorf Group: https://www.eppendorf.com

Enjoyed this episode? Don’t miss these related discussions:

  • Episode 100: From Raw Data to Actionable Insights: Unlocking the Power of Process Models with Fabian Feidl, co-founder and CTO of DataHow
  • Episode 05: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov, the co-founder and COO of DataHow

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t


Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Digital transformation is reshaping industries worldwide, and biotech is no exception. With the integration of cloud technologies, AI, and data harmonization, bioprocessing is becoming smarter, more efficient, and more innovative. Catching up with digital revolutions in other sectors, biotech now stands at the threshold of tremendous change.

In this episode of the Smart Biotech Scientist Podcast, David Brühlmann sat down with Simon Wieninger, Business Manager Digital Solutions at Eppendorf Group, to discuss the digital revolution sweeping through bioprocessing labs. From bioreactors to data lakes, Simon sheds light on the urgent need for a data-driven approach in biotech and how digital transformation is set to reshape the industry.

Here are the top three key takeaways:

  • Breaking Down Silos: The importance of consolidating data in one place to facilitate better analysis and collaboration across departments.
  • Leveraging Cloud Technology: Simon emphasized that the biotech industry is ready to embrace cloud technologies for enhanced data management.
  • Data Security Concerns: Addressing the common misconception about cloud security, Simon reassured that robust measures are in place to protect bioprocess data, making it as secure as banking data.

The move towards centralized data storage, the integration of AI, and strategic collaborations are critical steps in this journey. The industry is poised for transformation, and as Simon aptly put it, “step by step,” we can harness the full potential of these digital solutions. As biotech continues to evolve, the fusion of technology and biological science will undoubtedly lead to groundbreaking advancements, streamlining processes, and unlocking new possibilities in the field.

Connect with Simon Wieninger

LinkedIn: https://www.linkedin.com/in/dr-simon-wieninger-45b546182

Eppendorf Group: https://www.eppendorf.com

Enjoyed this episode? Don’t miss these related discussions:

  • Episode 100: From Raw Data to Actionable Insights: Unlocking the Power of Process Models with Fabian Feidl, co-founder and CTO of DataHow
  • Episode 05: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael Sokolov, the co-founder and COO of DataHow

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t


Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-16315320 Tue, 21 Jan 2025 05:00:00 +0100 1437 121 full false 120: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian Guo - Part 2 120: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian Guo - Part 2 In the ever-evolving world of biotechnology, the integration of artificial intelligence (AI) and synthetic biology is driving unprecedented advancements. This transformative power was the focus of this podcast episode of the Smart Biotech Scientist, where host David Brühlmann engaged in a thought-provoking conversation with Haotian Guo, CEO and Founder of Ailurus on the role of AI in bioprocessing, the significance of wet lab validation, and the exciting future of programmable biology.

The conversation with Haotian Guo sheds light on the profound impact AI is having on the field of biotechnology. AI's role as a "co-pilot" in scientific endeavors has enabled researchers to tackle complex problems with greater efficiency and accuracy. Haotian Guo shares: "AI helps us tremendously with tasks that are tedious and time-consuming for humans, such as reading and summarizing vast amounts of scientific literature. This capability allows scientists to focus on higher-order thinking and problem-solving."

Key insights for this conversation:

  • AI as Co-Pilot: Discover how Ailurus leverages AI to enhance research workflows. Haotian emphasizes using AI to read and analyze massive amounts of scientific literature, making it an invaluable co-pilot in the lab.
  • Synthetic Biology Meets AI: Learn how synthetic biology combined with AI-driven models is opening new horizons for developing DNA designs and optimizing protein engineering. This fusion of biology and technology is proving to be a game-changer.
  • Challenges in Biotech: Haotian candidly discusses the ongoing challenges, such as the need for wet lab validation and the high costs associated with data generation. Despite these hurdles, the potential for AI to streamline processes is immense.

While the integration of AI and synthetic biology offers tremendous opportunities, Haotian Guo advises caution, particularly for those considering venturing into a biotech startup. He acknowledges the high-risk nature of startups, especially in an unpredictable economic landscape.

However, he also underscores the importance of perseverance and preparedness, qualities crucial for navigating the biotech industry's challenges.

In conclusion, Haotian Guo's insights paint a compelling picture of the future. The synergy between AI and biotech holds the promise of smarter, more efficient, and more accessible scientific research. By leveraging the strengths of both computational and experimental approaches, the biotech community is poised to achieve remarkable breakthroughs, transforming the landscape of healthcare and beyond.

Connect with Haotian Guo:

LinkedIn: www.linkedin.com/in/haotian-guo

Ailurus: www.ailurus.bio

Next Steps:

Wondering how to develop bioprocesses with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Support the show

]]> In the ever-evolving world of biotechnology, the integration of artificial intelligence (AI) and synthetic biology is driving unprecedented advancements. This transformative power was the focus of this podcast episode of the Smart Biotech Scientist, where host David Brühlmann engaged in a thought-provoking conversation with Haotian Guo, CEO and Founder of Ailurus on the role of AI in bioprocessing, the significance of wet lab validation, and the exciting future of programmable biology.

The conversation with Haotian Guo sheds light on the profound impact AI is having on the field of biotechnology. AI's role as a "co-pilot" in scientific endeavors has enabled researchers to tackle complex problems with greater efficiency and accuracy. Haotian Guo shares: "AI helps us tremendously with tasks that are tedious and time-consuming for humans, such as reading and summarizing vast amounts of scientific literature. This capability allows scientists to focus on higher-order thinking and problem-solving."

Key insights for this conversation:

  • AI as Co-Pilot: Discover how Ailurus leverages AI to enhance research workflows. Haotian emphasizes using AI to read and analyze massive amounts of scientific literature, making it an invaluable co-pilot in the lab.
  • Synthetic Biology Meets AI: Learn how synthetic biology combined with AI-driven models is opening new horizons for developing DNA designs and optimizing protein engineering. This fusion of biology and technology is proving to be a game-changer.
  • Challenges in Biotech: Haotian candidly discusses the ongoing challenges, such as the need for wet lab validation and the high costs associated with data generation. Despite these hurdles, the potential for AI to streamline processes is immense.

While the integration of AI and synthetic biology offers tremendous opportunities, Haotian Guo advises caution, particularly for those considering venturing into a biotech startup. He acknowledges the high-risk nature of startups, especially in an unpredictable economic landscape.

However, he also underscores the importance of perseverance and preparedness, qualities crucial for navigating the biotech industry's challenges.

In conclusion, Haotian Guo's insights paint a compelling picture of the future. The synergy between AI and biotech holds the promise of smarter, more efficient, and more accessible scientific research. By leveraging the strengths of both computational and experimental approaches, the biotech community is poised to achieve remarkable breakthroughs, transforming the landscape of healthcare and beyond.

Connect with Haotian Guo:

LinkedIn: www.linkedin.com/in/haotian-guo

Ailurus: www.ailurus.bio

Next Steps:

Wondering how to develop bioprocesses with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-16395794 Thu, 16 Jan 2025 05:00:00 +0100 1283 120 full false 119: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian Guo - Part 1 119: Innovating Protein Purification Using Synthetic Organelles and AI with Haotian Guo - Part 1 Biotechnology is rapidly evolving as innovation addresses real-world needs. At the cutting edge of this evolution, synthetic biology and AI-driven protein design are revolutionizing our approach to complex processes like protein purification.

In this episode of the Smart Biotech Scientist podcast, host David Brühlmann talks with Haotian Guo, CEO and Founder of Ailurus, about the modern advancements in synthetic organelles and their transformative impact on protein purification.

Haotian Guo introduces a groundbreaking approach inspired by nature’s processes. Instead of relying solely on chromatography, synthetic biology mimics how organelles in cells, like beta cells purifying insulin, naturally segregate and process proteins. This innovation simplifies and optimizes bioprocessing, offering a more efficient alternative to traditional techniques.

Key takeaways from this conversation:

  • Revolutionary Advances in Protein Purification: Haotian discusses the innovative use of synthetic membrane-less organelles to simplify and enhance protein purification processes, drawing inspiration from natural cellular mechanisms.
  • Combining AI with Synthetic Biology: Learn how the integration of AI and biotechnology can accelerate advancements and create more efficient bioprocesses, unlocking potential for rapid development in biologics.
  • Scalability and Practical Applications: Insight into how these new technologies are being scaled from lab environments to industrial applications, maintaining high purity and yield, and the potential roadblocks and solutions encountered along the way.

Through innovation rooted in imitation of natural processes and amplified by the power of AI, the future of protein purification looks drastically simplified, more efficient, and scalable. Synthetic organelles represent a leap forward, challenging the age-old techniques that have long dominated the field.

Companies like Ailurus are not just contributing new tools but reshaping the roadmap for bioprocess development. As we stand on the brink of these technological advancements, the collaborative synergy between synthetic biology and artificial intelligence is setting the stage for revolutionary impacts across the biotech landscape.

This podcast episode is filled with eye-opening insights and practical takeaways for anyone in the biotech or pharmaceutical industries. Whether you're an academic, a seasoned industry professional, or simply curious about the field, you'll find valuable perspectives to explore.

Connect with Haotian Guo:

LinkedIn: www.linkedin.com/in/haotian-guo

Ailurus: www.ailurus.bio

Next Steps:

Wondering how to develop bioprocesses with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Support the show

]]> Biotechnology is rapidly evolving as innovation addresses real-world needs. At the cutting edge of this evolution, synthetic biology and AI-driven protein design are revolutionizing our approach to complex processes like protein purification.

In this episode of the Smart Biotech Scientist podcast, host David Brühlmann talks with Haotian Guo, CEO and Founder of Ailurus, about the modern advancements in synthetic organelles and their transformative impact on protein purification.

Haotian Guo introduces a groundbreaking approach inspired by nature’s processes. Instead of relying solely on chromatography, synthetic biology mimics how organelles in cells, like beta cells purifying insulin, naturally segregate and process proteins. This innovation simplifies and optimizes bioprocessing, offering a more efficient alternative to traditional techniques.

Key takeaways from this conversation:

  • Revolutionary Advances in Protein Purification: Haotian discusses the innovative use of synthetic membrane-less organelles to simplify and enhance protein purification processes, drawing inspiration from natural cellular mechanisms.
  • Combining AI with Synthetic Biology: Learn how the integration of AI and biotechnology can accelerate advancements and create more efficient bioprocesses, unlocking potential for rapid development in biologics.
  • Scalability and Practical Applications: Insight into how these new technologies are being scaled from lab environments to industrial applications, maintaining high purity and yield, and the potential roadblocks and solutions encountered along the way.

Through innovation rooted in imitation of natural processes and amplified by the power of AI, the future of protein purification looks drastically simplified, more efficient, and scalable. Synthetic organelles represent a leap forward, challenging the age-old techniques that have long dominated the field.

Companies like Ailurus are not just contributing new tools but reshaping the roadmap for bioprocess development. As we stand on the brink of these technological advancements, the collaborative synergy between synthetic biology and artificial intelligence is setting the stage for revolutionary impacts across the biotech landscape.

This podcast episode is filled with eye-opening insights and practical takeaways for anyone in the biotech or pharmaceutical industries. Whether you're an academic, a seasoned industry professional, or simply curious about the field, you'll find valuable perspectives to explore.

Connect with Haotian Guo:

LinkedIn: www.linkedin.com/in/haotian-guo

Ailurus: www.ailurus.bio

Next Steps:

Wondering how to develop bioprocesses with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Support the show

]]> David Brühlmann - CMC Development Leader, Biotech C-level Advisor, Business Strategist Buzzsprout-16395777 Tue, 14 Jan 2025 05:00:00 +0100 1195 119 full false 118: Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea Gough - Part 2 118: Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea Gough - Part 2 In the second part of our conversation with Andrea Gough, Senior Director for Advanced Instruments’ Solentim Portfolio, we’ll explore how AI and machine learning have, in recent years, begun to transform various aspects of biotechnology, including cell line development (CLD). Andrea shares insights into how these cutting-edge technologies are being applied to the early stages of clone selection.

AI's capability to analyze images and classify clone viability is another breakthrough. Feeding thousands of images into AI systems allows for efficient and accurate decision-making, reducing the workload on scientists.

Here are three key takeaways from our conversation:

  • Leverage AI and Machine Learning: Integrate AI to streamline clone selection and optimize cell line development processes. AI can identify key phenotypic identifiers and predict the best clones, driving efficiency and productivity.
  • Diversify Expression Systems: While CHO cells dominate the protein therapy space, exploring alternative systems like HEK cells, MSCs, IPSCs, and even insect cells can offer unique benefits and improve gene therapy productions.
  • Maintain Comprehensive Documentation: Ensure rigorous tracking and documentation of all processes. From certificates of analysis to raw image data, having meticulous records will safeguard your development process and aid compliance with regulatory standards.

Tune in to the full episode for more insights on overcoming challenges in cell line development and tips for setting up successful bioprocessing workflows!

Connect with Andrea Gough

LinkedIn: www.linkedin.com/in/andrea-gough-72915282

Advanced Instruments: www.aicompanies.com

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Support the show

]]> In the second part of our conversation with Andrea Gough, Senior Director for Advanced Instruments’ Solentim Portfolio, we’ll explore how AI and machine learning have, in recent years, begun to transform various aspects of biotechnology, including cell line development (CLD). Andrea shares insights into how these cutting-edge technologies are being applied to the early stages of clone selection.

AI's capability to analyze images and classify clone viability is another breakthrough. Feeding thousands of images into AI systems allows for efficient and accurate decision-making, reducing the workload on scientists.

Here are three key takeaways from our conversation:

  • Leverage AI and Machine Learning: Integrate AI to streamline clone selection and optimize cell line development processes. AI can identify key phenotypic identifiers and predict the best clones, driving efficiency and productivity.
  • Diversify Expression Systems: While CHO cells dominate the protein therapy space, exploring alternative systems like HEK cells, MSCs, IPSCs, and even insect cells can offer unique benefits and improve gene therapy productions.
  • Maintain Comprehensive Documentation: Ensure rigorous tracking and documentation of all processes. From certificates of analysis to raw image data, having meticulous records will safeguard your development process and aid compliance with regulatory standards.

Tune in to the full episode for more insights on overcoming challenges in cell line development and tips for setting up successful bioprocessing workflows!

Connect with Andrea Gough

LinkedIn: www.linkedin.com/in/andrea-gough-72915282

Advanced Instruments: www.aicompanies.com

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-16327415 Thu, 09 Jan 2025 05:00:00 +0100 916 118 full false 117: Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea Gough - Part 1 117: Cell Line Development Secrets: Eliminating Critical Bottlenecks for Faster Timelines with Andrea Gough - Part 1 Cell line development (CLD) is a cornerstone of biologics production. This intricate process involves establishing a cell line capable of consistently producing a desired product, such as a therapeutic protein. While advancing science has refined numerous aspects of CLD, bottlenecks still exist, perpetuating challenges for scientists and industry professionals.

In this episode of the Smart Biotech Scientist Podcast, Andrea Gough, Senior Director for Advanced Instruments’ Solentim Portfolio, shared her extensive insights into the critical bottlenecks and innovative breakthroughs in cell line development.

Here are three key takeaways from this episode:

  • Understanding the DNA Integration Complexity: Andrea discusses the pros and cons of random integration, highlighting how it can become a bottleneck. She emphasizes the importance of choosing the right methodology from the very beginning to avoid the "needle in a haystack" scenario when searching for a good clone.
  • Modern Tools for Ensuring Clonality: Technologies like imaging devices and single-cell dispensers have revolutionized the process. Learn about the shift from traditional limiting dilution methods to more sophisticated and efficient tools that provide better evidence for regulatory approval.
  • Innovative Approaches to Accelerate Development: Discover how semi-targeted integration methods like transposon technology can significantly shorten timelines and improve clone stability. Andrea also explores the use of bulk pools to generate initial products quickly for pre-clinical and initial clinical studies.

Developing cell lines is a complex process, but with advanced tools and innovative approaches, challenges can become opportunities. As biotechnology progresses, the ability to stay informed and flexible will remain essential for success.

Catch the full episode to gain deeper insights and practical advice for advancing your cell line development projects!

Join us for the next episode featuring Andrea Gough, as we explore how AI and machine learning are being integrated into the early stages of clone selection. This groundbreaking approach is transforming key areas of biotechnology, including cell line development (CLD).

Connect with Andrea Gough:

LinkedIn: www.linkedin.com/in/andrea-gough-72915282

Advanced Instruments: www.aicompanies.com

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Cell line development (CLD) is a cornerstone of biologics production. This intricate process involves establishing a cell line capable of consistently producing a desired product, such as a therapeutic protein. While advancing science has refined numerous aspects of CLD, bottlenecks still exist, perpetuating challenges for scientists and industry professionals.

In this episode of the Smart Biotech Scientist Podcast, Andrea Gough, Senior Director for Advanced Instruments’ Solentim Portfolio, shared her extensive insights into the critical bottlenecks and innovative breakthroughs in cell line development.

Here are three key takeaways from this episode:

  • Understanding the DNA Integration Complexity: Andrea discusses the pros and cons of random integration, highlighting how it can become a bottleneck. She emphasizes the importance of choosing the right methodology from the very beginning to avoid the "needle in a haystack" scenario when searching for a good clone.
  • Modern Tools for Ensuring Clonality: Technologies like imaging devices and single-cell dispensers have revolutionized the process. Learn about the shift from traditional limiting dilution methods to more sophisticated and efficient tools that provide better evidence for regulatory approval.
  • Innovative Approaches to Accelerate Development: Discover how semi-targeted integration methods like transposon technology can significantly shorten timelines and improve clone stability. Andrea also explores the use of bulk pools to generate initial products quickly for pre-clinical and initial clinical studies.

Developing cell lines is a complex process, but with advanced tools and innovative approaches, challenges can become opportunities. As biotechnology progresses, the ability to stay informed and flexible will remain essential for success.

Catch the full episode to gain deeper insights and practical advice for advancing your cell line development projects!

Join us for the next episode featuring Andrea Gough, as we explore how AI and machine learning are being integrated into the early stages of clone selection. This groundbreaking approach is transforming key areas of biotechnology, including cell line development (CLD).

Connect with Andrea Gough:

LinkedIn: www.linkedin.com/in/andrea-gough-72915282

Advanced Instruments: www.aicompanies.com

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our 1:1 Strategy Call. Book your call at https://stan.store/SmartBiotech/p/book-a-11-call-with-me-j4vhuo6t

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-16327231 Tue, 07 Jan 2025 05:00:00 +0100 1465 117 full false 116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti - Part 2 116: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti - Part 2 The intersection of artificial intelligence and biology presents immense opportunities for transforming bioprocess development. As the biotech industry continues to evolve, data-driven innovations are critical to optimizing biologics manufacturing. High-quality datasets stand at the forefront of this transformation, empowering researchers to make informed predictions and advance therapeutic discoveries. As AI tools become more commoditized, the focus shifts toward generating robust and extensive datasets to maximize the potential of machine learning in biological applications.

Miniaturization has emerged as a vital enabler in this data-driven approach. Miniaturized systems allow researchers to conduct thousands of tests in an area no larger than the palm of your hand. This drastic reduction in material and resource requirements makes high-throughput screening feasible, economical, and scalable.

Traditional liquid handling robots can manage thousands of tests per day, but each test requires considerable amounts of material, usually leading to high costs. Conventional systems can cost anywhere from $10 to $100 to get a single genotype sequence from discovery to sequencing. Miniaturization can bring these costs down to mere pennies per data point, making it possible to scale the dataset size exponentially.

Key takeaways from our discussion:

  • The future of AI in biology relies heavily on large, well-annotated datasets. Without them, the full potential of AI remains untapped. High-quality data enables more accurate predictions of protein structures and functions.
  • Success in bioprocess development often involves collaboration with partners across the value chain. By working together, companies can leverage their unique strengths and expertise to overcome barriers and innovate more efficiently.
  • Advancements in miniaturization technology allow for high throughput screening at reduced costs. This shift makes it viable to generate large datasets, speeding up the pace of discovery and making AI-driven predictions more accessible.

This episode is essential for anyone eager to explore the transformative fusion of AI and biotechnology. Jeremy Agresti highlights the future of bioprocessing at the intersection of high-throughput screening, miniaturization, and AI, revealing how these innovations are solving complex challenges, driving breakthroughs, and shaping the future of science and medicine.

Connect with Jeremy Agresti:

LinkedIn: www.linkedin.com/in/jeremy-agresti-88546850/

Triplebar: www.triplebar.com

Next Steps:

Overwhelmed by complex bioprocess development decisions? Get strategic guidance to avoid costly mistakes and stay ahead: https://bruehlmann-consulting.com

Are soaring manufacturing costs keeping your lifesaving therapies out of reach for patients? Book your free assessment at: https://bruehlmann-consulting.com/assessment

Support the show

]]> The intersection of artificial intelligence and biology presents immense opportunities for transforming bioprocess development. As the biotech industry continues to evolve, data-driven innovations are critical to optimizing biologics manufacturing. High-quality datasets stand at the forefront of this transformation, empowering researchers to make informed predictions and advance therapeutic discoveries. As AI tools become more commoditized, the focus shifts toward generating robust and extensive datasets to maximize the potential of machine learning in biological applications.

Miniaturization has emerged as a vital enabler in this data-driven approach. Miniaturized systems allow researchers to conduct thousands of tests in an area no larger than the palm of your hand. This drastic reduction in material and resource requirements makes high-throughput screening feasible, economical, and scalable.

Traditional liquid handling robots can manage thousands of tests per day, but each test requires considerable amounts of material, usually leading to high costs. Conventional systems can cost anywhere from $10 to $100 to get a single genotype sequence from discovery to sequencing. Miniaturization can bring these costs down to mere pennies per data point, making it possible to scale the dataset size exponentially.

Key takeaways from our discussion:

  • The future of AI in biology relies heavily on large, well-annotated datasets. Without them, the full potential of AI remains untapped. High-quality data enables more accurate predictions of protein structures and functions.
  • Success in bioprocess development often involves collaboration with partners across the value chain. By working together, companies can leverage their unique strengths and expertise to overcome barriers and innovate more efficiently.
  • Advancements in miniaturization technology allow for high throughput screening at reduced costs. This shift makes it viable to generate large datasets, speeding up the pace of discovery and making AI-driven predictions more accessible.

This episode is essential for anyone eager to explore the transformative fusion of AI and biotechnology. Jeremy Agresti highlights the future of bioprocessing at the intersection of high-throughput screening, miniaturization, and AI, revealing how these innovations are solving complex challenges, driving breakthroughs, and shaping the future of science and medicine.

Connect with Jeremy Agresti:

LinkedIn: www.linkedin.com/in/jeremy-agresti-88546850/

Triplebar: www.triplebar.com

Next Steps:

Overwhelmed by complex bioprocess development decisions? Get strategic guidance to avoid costly mistakes and stay ahead: https://bruehlmann-consulting.com

Are soaring manufacturing costs keeping your lifesaving therapies out of reach for patients? Book your free assessment at: https://bruehlmann-consulting.com/assessment

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-16271864 Thu, 19 Dec 2024 05:00:00 +0100 1003 115 full false 115: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti - Part 1 115: Revolutionizing Biologics Development with Hyper Throughput Screening and AI with Jeremy Agresti - Part 1 Bioprocess development is transforming the biotech industry, driving innovations in life-changing therapies. Success hinges on simplifying complex mechanisms and adopting advanced technologies. By integrating high-throughput screening and artificial intelligence, we can streamline workflows, reduce trial-and-error, and speed up biologics development. Embracing cutting-edge tools empowers scientists to maximize biology's potential, delivering efficient and impactful biotech solutions.

In this episode of The Smart Biotech Scientist Podcast, host David Brühlmann explores these transformative methodologies with Jeremy Agresti, CTO and founder of Triplebar.

Jeremy highlights the future of bioprocessing at the intersection of high-throughput screening, miniaturization, and AI. With tools that enhance predictability, scalability, and efficiency, Triplebar is set to transform biotechnology. By reimagining traditional methods, improving inputs, and leveraging modern technology, companies like Triplebar are driving a new era in bioprocessing, offering innovative solutions to complex biological challenges.

Key Takeaways:

Jeremy challenges the traditional view of scale-up issues, emphasizing that many problems can be solved at a smaller scale with better engineered strains and cell lines.

By creating tiny bioreactors of droplets, Triplebar is able to perform high throughput screening, testing millions of mutations quickly and efficiently, and providing robust solutions for complex biological functions.

The integration of massive data sets with AI allows for improved enzyme and protein design, unlocking the potential to innovate even when foundational understanding is limited.

Ready to dive deeper? Join the journey of transforming bioprocess development with smart insights and pioneering spirit. Catch up with Jeremy’s full story via the latest episode of the Smart Biotech Scientist podcast.

Connect with Jeremy Agresti:

LinkedIn: www.linkedin.com/in/jeremy-agresti-88546850/

Triplebar: www.triplebar.com

Next Steps:

Overwhelmed by complex bioprocess development decisions? Get strategic guidance to avoid costly mistakes and stay ahead: https://bruehlmann-consulting.com

Are soaring manufacturing costs keeping your lifesaving therapies out of reach for patients? Book your free assessment at: https://bruehlmann-consulting.com/assessment

Support the show

]]> Bioprocess development is transforming the biotech industry, driving innovations in life-changing therapies. Success hinges on simplifying complex mechanisms and adopting advanced technologies. By integrating high-throughput screening and artificial intelligence, we can streamline workflows, reduce trial-and-error, and speed up biologics development. Embracing cutting-edge tools empowers scientists to maximize biology's potential, delivering efficient and impactful biotech solutions.

In this episode of The Smart Biotech Scientist Podcast, host David Brühlmann explores these transformative methodologies with Jeremy Agresti, CTO and founder of Triplebar.

Jeremy highlights the future of bioprocessing at the intersection of high-throughput screening, miniaturization, and AI. With tools that enhance predictability, scalability, and efficiency, Triplebar is set to transform biotechnology. By reimagining traditional methods, improving inputs, and leveraging modern technology, companies like Triplebar are driving a new era in bioprocessing, offering innovative solutions to complex biological challenges.

Key Takeaways:

Jeremy challenges the traditional view of scale-up issues, emphasizing that many problems can be solved at a smaller scale with better engineered strains and cell lines.

By creating tiny bioreactors of droplets, Triplebar is able to perform high throughput screening, testing millions of mutations quickly and efficiently, and providing robust solutions for complex biological functions.

The integration of massive data sets with AI allows for improved enzyme and protein design, unlocking the potential to innovate even when foundational understanding is limited.

Ready to dive deeper? Join the journey of transforming bioprocess development with smart insights and pioneering spirit. Catch up with Jeremy’s full story via the latest episode of the Smart Biotech Scientist podcast.

Connect with Jeremy Agresti:

LinkedIn: www.linkedin.com/in/jeremy-agresti-88546850/

Triplebar: www.triplebar.com

Next Steps:

Overwhelmed by complex bioprocess development decisions? Get strategic guidance to avoid costly mistakes and stay ahead: https://bruehlmann-consulting.com

Are soaring manufacturing costs keeping your lifesaving therapies out of reach for patients? Book your free assessment at: https://bruehlmann-consulting.com/assessment

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-16271856 Tue, 17 Dec 2024 05:00:00 +0100 1189 115 full false 114: Weighing of Single-Use Bag Systems: Why Traditional Load Cells Are Holding You Back with Anders Tvegaard - Part 2 114: Weighing of Single-Use Bag Systems: Why Traditional Load Cells Are Holding You Back with Anders Tvegaard - Part 2 Is your bioprocess facility wasting precious time and resources on traditional weighing system calibrations? In this eye-opening episode, Anders Tvegaard, COO of Eilersen Electric, reveals how digital load cell innovation is revolutionizing bioprocess monitoring and validation.

Discover why weighing systems aren't the commodity technology you might think they are, and how choosing the right solution can dramatically reduce deviations and maintenance costs. Anders shares groundbreaking insights about Eilersen's water-free calibration system, which has helped customers save over a million liters of water and 700 man-hours in tank calibration time.

Key takeaways:

  • Why a single weighing system deviation can cost facilities $10,000+ in quality management alone
  • How new digital load cell technology enables continuous monitoring during mobile vessel transport
  • The game-changing advantages of water-free calibration for single-use systems

Ready to transform your bioprocess monitoring strategy? Listen now to learn how modern weighing technology can protect your products and streamline your operations.

Connect with Anders Tvegaard:

LinkedIn: https://www.linkedin.com/in/anders-tvegaard-3305a1

Eilerson: https://eilersen.com

Next Steps:

Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Learn more at https://bruehlmann-consulting.com

Support the show

]]> Is your bioprocess facility wasting precious time and resources on traditional weighing system calibrations? In this eye-opening episode, Anders Tvegaard, COO of Eilersen Electric, reveals how digital load cell innovation is revolutionizing bioprocess monitoring and validation.

Discover why weighing systems aren't the commodity technology you might think they are, and how choosing the right solution can dramatically reduce deviations and maintenance costs. Anders shares groundbreaking insights about Eilersen's water-free calibration system, which has helped customers save over a million liters of water and 700 man-hours in tank calibration time.

Key takeaways:

  • Why a single weighing system deviation can cost facilities $10,000+ in quality management alone
  • How new digital load cell technology enables continuous monitoring during mobile vessel transport
  • The game-changing advantages of water-free calibration for single-use systems

Ready to transform your bioprocess monitoring strategy? Listen now to learn how modern weighing technology can protect your products and streamline your operations.

Connect with Anders Tvegaard:

LinkedIn: https://www.linkedin.com/in/anders-tvegaard-3305a1

Eilerson: https://eilersen.com

Next Steps:

Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Learn more at https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-16251314 Thu, 12 Dec 2024 05:00:00 +0100 1088 114 full false 113: Weighing of Single-Use Bag Systems: Why Traditional Load Cells Are Holding You Back with Anders Tvegaard - Part 1 113: Weighing of Single-Use Bag Systems: Why Traditional Load Cells Are Holding You Back with Anders Tvegaard - Part 1 What do furniture manufacturing and bioprocess weighing have in common? In this fascinating episode, Anders Tvegaard, COO of Eilersen Electric Digital Systems shares the remarkable story of how his company evolved from solving a furniture maker's wood humidity measurement problems to revolutionizing pharmaceutical manufacturing.

Fifty years ago, a simple request to build a more robust scale for weighing wood in sofa production led to the development of groundbreaking contactless load cell technology.

Key takeaways for bioprocess professionals:

  • Discover how a furniture problem sparked innovation in bioprocess weighing technology
  • Learn why traditional strain gauge technology may be compromising your mobile vessel operations
  • Understand how contactless load cells eliminate costly calibration deviations and production stops

From humble beginnings in a Danish basement to transforming modern bioprocessing, this episode reveals how cross-industry innovation is reshaping pharmaceutical manufacturing. Whether you're managing mixing tanks, mobile vessels, or single-use systems, you'll gain valuable insights into improving your bioprocess reliability.

Ready to discover how furniture-inspired technology is solving today's bioprocessing challenges? Tune in now.

Connect with Anders Tvegaard:

LinkedIn: https://www.linkedin.com/in/anders-tvegaard-3305a1

Eilerson: https://eilersen.com

Next Steps:

Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Learn more at https://bruehlmann-consulting.com

Support the show

]]> What do furniture manufacturing and bioprocess weighing have in common? In this fascinating episode, Anders Tvegaard, COO of Eilersen Electric Digital Systems shares the remarkable story of how his company evolved from solving a furniture maker's wood humidity measurement problems to revolutionizing pharmaceutical manufacturing.

Fifty years ago, a simple request to build a more robust scale for weighing wood in sofa production led to the development of groundbreaking contactless load cell technology.

Key takeaways for bioprocess professionals:

  • Discover how a furniture problem sparked innovation in bioprocess weighing technology
  • Learn why traditional strain gauge technology may be compromising your mobile vessel operations
  • Understand how contactless load cells eliminate costly calibration deviations and production stops

From humble beginnings in a Danish basement to transforming modern bioprocessing, this episode reveals how cross-industry innovation is reshaping pharmaceutical manufacturing. Whether you're managing mixing tanks, mobile vessels, or single-use systems, you'll gain valuable insights into improving your bioprocess reliability.

Ready to discover how furniture-inspired technology is solving today's bioprocessing challenges? Tune in now.

Connect with Anders Tvegaard:

LinkedIn: https://www.linkedin.com/in/anders-tvegaard-3305a1

Eilerson: https://eilersen.com

Next Steps:

Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Learn more at https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-16232389 Tue, 10 Dec 2024 05:00:00 +0100 1342 113 full false 112: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén - Part 2 112: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén - Part 2 Can artificial intelligence revolutionize drug development and reduce the staggering 90% failure rate in clinical trials? In this insightful episode, Lars Brandén, Director of Biology at Kolibri, shares his vision for the future of personalized medicine.

Drawing from his extensive experience bridging academia and industry, Lars explores how AI models could transform our understanding of human disease by simulating body-wide cell signaling. He reveals an innovative approach to drug delivery using receptor ligand combinations that could dramatically reduce side effects and improve treatment efficacy.

Key takeaways:

  • Learn why maintaining "youthful naivety" in biotech innovation can lead to breakthroughs others deemed impossible
  • Discover how combining AI with deep biological understanding could reduce clinical trial failure rates from 90% to potentially 15%
  • Understand why interdisciplinary collaboration between biologists, software engineers, and other experts is crucial for advancing personalized medicine

Ready to dive deeper into the future of biotech innovation? Listen now to unlock Lars Brandén's insights on scaling therapies, navigating cross-functional teams, and maintaining scientific creativity in the face of challenges.

Connect with Lars Brandén:

LinkedIn: https://www.linkedin.com/in/larsbranden

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Can artificial intelligence revolutionize drug development and reduce the staggering 90% failure rate in clinical trials? In this insightful episode, Lars Brandén, Director of Biology at Kolibri, shares his vision for the future of personalized medicine.

Drawing from his extensive experience bridging academia and industry, Lars explores how AI models could transform our understanding of human disease by simulating body-wide cell signaling. He reveals an innovative approach to drug delivery using receptor ligand combinations that could dramatically reduce side effects and improve treatment efficacy.

Key takeaways:

  • Learn why maintaining "youthful naivety" in biotech innovation can lead to breakthroughs others deemed impossible
  • Discover how combining AI with deep biological understanding could reduce clinical trial failure rates from 90% to potentially 15%
  • Understand why interdisciplinary collaboration between biologists, software engineers, and other experts is crucial for advancing personalized medicine

Ready to dive deeper into the future of biotech innovation? Listen now to unlock Lars Brandén's insights on scaling therapies, navigating cross-functional teams, and maintaining scientific creativity in the face of challenges.

Connect with Lars Brandén:

LinkedIn: https://www.linkedin.com/in/larsbranden

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-16175393 Thu, 05 Dec 2024 05:00:00 +0100 1473 112 full false 111: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén - Part 1 111: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén - Part 1 In this episode, we explore the delicate dance between artificial intelligence and biological research with Lars Brandén, Director of Biology at Kolibri. From his early fascination with gene therapy to pioneering high-throughput screening centers at prestigious institutions, Lars shares invaluable insights on bridging the gap between academic innovation and industrial application.

What sets this conversation apart is Lars' compelling perspective on why the popular "agile development" model doesn't always translate smoothly to bioprocess development – and why that matters for the future of drug development. His journey from the Karolinska Institute to leading cutting-edge biological research offers a unique lens on the evolution of biotech.

Key takeaways for listeners:

  • Learn why scientists must develop broader cross-disciplinary knowledge to effectively leverage AI tools in research
  • Discover how AI could dramatically reduce drug development timelines and costs within the next five years
  • Understand the potential for AI to democratize access to cell and gene therapies through optimized production methods

Join us for this fascinating exploration of how domain expertise and artificial intelligence can work in harmony to accelerate breakthrough therapies. Whether you're a biotech professional or simply curious about the future of medicine, this episode offers valuable insights into the transformation of drug development in the AI era.

Listen now to discover how the intersection of human expertise and artificial intelligence is reshaping the future of personalized medicine.

Connect with Lars Brandén:

LinkedIn: https://www.linkedin.com/in/larsbranden

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Support the show

]]> In this episode, we explore the delicate dance between artificial intelligence and biological research with Lars Brandén, Director of Biology at Kolibri. From his early fascination with gene therapy to pioneering high-throughput screening centers at prestigious institutions, Lars shares invaluable insights on bridging the gap between academic innovation and industrial application.

What sets this conversation apart is Lars' compelling perspective on why the popular "agile development" model doesn't always translate smoothly to bioprocess development – and why that matters for the future of drug development. His journey from the Karolinska Institute to leading cutting-edge biological research offers a unique lens on the evolution of biotech.

Key takeaways for listeners:

  • Learn why scientists must develop broader cross-disciplinary knowledge to effectively leverage AI tools in research
  • Discover how AI could dramatically reduce drug development timelines and costs within the next five years
  • Understand the potential for AI to democratize access to cell and gene therapies through optimized production methods

Join us for this fascinating exploration of how domain expertise and artificial intelligence can work in harmony to accelerate breakthrough therapies. Whether you're a biotech professional or simply curious about the future of medicine, this episode offers valuable insights into the transformation of drug development in the AI era.

Listen now to discover how the intersection of human expertise and artificial intelligence is reshaping the future of personalized medicine.

Connect with Lars Brandén:

LinkedIn: https://www.linkedin.com/in/larsbranden

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-16175375 Tue, 03 Dec 2024 05:00:00 +0100 1148 111 full false 110: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier Detournay - Part 2 110: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier Detournay - Part 2 Could Earth's gentle movements hold the key to scaling up cell therapy production? In this fascinating episode, cellular biologist and entrepreneur Olivier Detournay (CSO of Cellura) reveals how his groundbreaking bioreactor design, inspired by geophysics, is transforming difficult cell culture processes.

By mimicking natural planetary motions, his team at Celura has developed a low-shear stress bioreactor that elegantly solves common scale-up challenges.

Key takeaways for biotech professionals:

  • Discover how reducing rotational speed in larger volumes (from 70 RPM at 150ml to just 4 RPM at 200L) enables seamless scale-up
  • Learn why simplifying bioreactor design leads to better control over shear stress and mixing quality
  • Explore how nature-inspired solutions could make cell therapy manufacturing more accessible and cost-effective

Whether you're working in process development or manufacturing, this episode offers invaluable insights into the future of bioprocessing.

Listen now to uncover how looking to nature might help solve your toughest scale-up challenges.

Connect with Olivier Detournay:

LinkedIn: https://www.linkedin.com/in/olivier-detournay-5b157417

Cellura: https://cellura.io

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO/CSO services. Curious? Learn more at https://bruehlmann-consulting.com

Support the show

]]> Could Earth's gentle movements hold the key to scaling up cell therapy production? In this fascinating episode, cellular biologist and entrepreneur Olivier Detournay (CSO of Cellura) reveals how his groundbreaking bioreactor design, inspired by geophysics, is transforming difficult cell culture processes.

By mimicking natural planetary motions, his team at Celura has developed a low-shear stress bioreactor that elegantly solves common scale-up challenges.

Key takeaways for biotech professionals:

  • Discover how reducing rotational speed in larger volumes (from 70 RPM at 150ml to just 4 RPM at 200L) enables seamless scale-up
  • Learn why simplifying bioreactor design leads to better control over shear stress and mixing quality
  • Explore how nature-inspired solutions could make cell therapy manufacturing more accessible and cost-effective

Whether you're working in process development or manufacturing, this episode offers invaluable insights into the future of bioprocessing.

Listen now to uncover how looking to nature might help solve your toughest scale-up challenges.

Connect with Olivier Detournay:

LinkedIn: https://www.linkedin.com/in/olivier-detournay-5b157417

Cellura: https://cellura.io

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO/CSO services. Curious? Learn more at https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-16125762 Thu, 28 Nov 2024 05:00:00 +0100 984 110 full false 109: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier Detournay - Part 1 109: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier Detournay - Part 1 What if the secret to growing sensitive cells lies in mimicking Earth's own movement? In this fascinating episode, cellular biologist Olivier Detournay, CSO of Cellura, reveals how studying planetary motion led to a groundbreaking bioreactor design that could transform cell therapy manufacturing.

Drawing inspiration from geophysics research on magma flows, Olivier and his colleagues developed a revolutionary impeller-free bioreactor that creates gentle, uniform mixing through precise rotation and tilt angles.

Key takeaways for bioprocess scientists:

  • Learn how natural planetary movements can inspire gentler cell cultivation methods
  • Discover an innovative approach to scaling up sensitive cell production without shear stress
  • Understand why traditional impeller-based systems may limit the future of bioprocessing

Whether you're working with stem cells, immunotherapy, or cultivated meat, this episode offers fresh perspectives on overcoming bioprocessing challenges. Join us to explore how nature-inspired solutions could make life-saving cell therapies more accessible.

Connect with Olivier Detournay:

LinkedIn: https://www.linkedin.com/in/olivier-detournay-5b157417

Cellura: https://cellura.io

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO/CSO services. Curious? Learn more at https://bruehlmann-consulting.com

Support the show

]]> What if the secret to growing sensitive cells lies in mimicking Earth's own movement? In this fascinating episode, cellular biologist Olivier Detournay, CSO of Cellura, reveals how studying planetary motion led to a groundbreaking bioreactor design that could transform cell therapy manufacturing.

Drawing inspiration from geophysics research on magma flows, Olivier and his colleagues developed a revolutionary impeller-free bioreactor that creates gentle, uniform mixing through precise rotation and tilt angles.

Key takeaways for bioprocess scientists:

  • Learn how natural planetary movements can inspire gentler cell cultivation methods
  • Discover an innovative approach to scaling up sensitive cell production without shear stress
  • Understand why traditional impeller-based systems may limit the future of bioprocessing

Whether you're working with stem cells, immunotherapy, or cultivated meat, this episode offers fresh perspectives on overcoming bioprocessing challenges. Join us to explore how nature-inspired solutions could make life-saving cell therapies more accessible.

Connect with Olivier Detournay:

LinkedIn: https://www.linkedin.com/in/olivier-detournay-5b157417

Cellura: https://cellura.io

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO/CSO services. Curious? Learn more at https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-16125749 Tue, 26 Nov 2024 05:00:00 +0100 1167 109 full false 108: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David Schönauer - Part 2 108: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David Schönauer - Part 2 In this captivating episode, we dive deep into the groundbreaking intersection of artificial intelligence and enzyme engineering with David Schönauer, founder and CEO of Aminoverse.

From university lab benches to pioneering AI-driven enzyme discovery, David shares how his startup is transforming the biotech landscape by making enzyme development faster, more predictable, and increasingly efficient.

Highlights:

  • Discover how AI is revolutionizing enzyme prediction and design, potentially reducing development time from years to weeks
  • Learn why high-quality wet lab data remains crucial for AI success in biotech, and how Aminoverse's unique approach combines both worlds
  • Gain insights into building a profitable biotech startup without massive venture capital funding, proving that sustainable growth is possible in deep tech

David's journey from academic researcher to biotech entrepreneur offers invaluable lessons for scientists considering the entrepreneurial path. His practical approach to combining cutting-edge AI with traditional wet lab techniques demonstrates how modern biotechnology can solve real-world problems while maintaining scientific rigor.

Ready to explore the future of biotech? Listen now to learn how AI is transforming enzyme engineering and what it means for the future of sustainable technology, pharmaceuticals, and more.

Connect with David Schönauer:

LinkedIn: https://www.linkedin.com/in/david-schönauer

Aminoverse: https://www.aminoverse.com

Next Steps:

Wondering how to develop biologics with clarity and precision? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Ready to revolutionize your biologics development? Our Fractional CTO services help you develop better, faster, and more cost-effectively. Leverage your full potential today — book a free consultation at https://bruehlmann-consulting.com and let's accelerate your success!

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> In this captivating episode, we dive deep into the groundbreaking intersection of artificial intelligence and enzyme engineering with David Schönauer, founder and CEO of Aminoverse.

From university lab benches to pioneering AI-driven enzyme discovery, David shares how his startup is transforming the biotech landscape by making enzyme development faster, more predictable, and increasingly efficient.

Highlights:

  • Discover how AI is revolutionizing enzyme prediction and design, potentially reducing development time from years to weeks
  • Learn why high-quality wet lab data remains crucial for AI success in biotech, and how Aminoverse's unique approach combines both worlds
  • Gain insights into building a profitable biotech startup without massive venture capital funding, proving that sustainable growth is possible in deep tech

David's journey from academic researcher to biotech entrepreneur offers invaluable lessons for scientists considering the entrepreneurial path. His practical approach to combining cutting-edge AI with traditional wet lab techniques demonstrates how modern biotechnology can solve real-world problems while maintaining scientific rigor.

Ready to explore the future of biotech? Listen now to learn how AI is transforming enzyme engineering and what it means for the future of sustainable technology, pharmaceuticals, and more.

Connect with David Schönauer:

LinkedIn: https://www.linkedin.com/in/david-schönauer

Aminoverse: https://www.aminoverse.com

Next Steps:

Wondering how to develop biologics with clarity and precision? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Ready to revolutionize your biologics development? Our Fractional CTO services help you develop better, faster, and more cost-effectively. Leverage your full potential today — book a free consultation at https://bruehlmann-consulting.com and let's accelerate your success!

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-16105869 Thu, 21 Nov 2024 05:00:00 +0100 1646 108 full false 107: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David Schönauer - Part 1 107: From 1 Billion to 100: How AI is Cracking the Enzyme Discovery Code with David Schönauer - Part 1 Ever wondered how scientists find the perfect enzyme among billions of possibilities? In this fascinating episode of the Smart Biotech Scientist podcast, host David Brühlmann sits down with David Schönauer, CEO of Aminoverse, who's revolutionizing enzyme engineering through artificial intelligence.

As a biotech entrepreneur who transformed his academic passion into a groundbreaking startup, Schönauer shares how his company is solving one of biotechnology's biggest challenges: efficiently identifying the right enzyme for specific applications, from pharmaceutical manufacturing to sustainable consumer products.

Key Takeaways:

  • Discover how Aminoverse's innovative platform navigates through more than one billion enzyme sequences to identify the most promising candidates
  • Learn why the perfect balance between AI-powered screening and traditional lab testing is crucial for successful enzyme engineering
  • Understand how engineered enzymes are transforming industries, from mRNA vaccine production to eco-friendly laundry detergents

Whether you're a biotech professional or simply curious about the intersection of AI and biotechnology, this episode reveals how cutting-edge technology is accelerating the discovery of nature's molecular workers.

Ready to explore the future of enzyme engineering? Tune in now to hear how AI is transforming biotech innovation, one enzyme at a time.

Connect with David Schönauer:

LinkedIn: https://www.linkedin.com/in/david-schönauer

Aminoverse: https://www.aminoverse.com

Next Steps:

Wondering how to develop biologics with clarity and precision? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Ready to revolutionize your biologics development? Our Fractional CTO services help you develop better, faster, and more cost-effectively. Leverage your full potential today — book a free consultation at https://bruehlmann-consulting.com and let's accelerate your success!

Support the show

]]> Ever wondered how scientists find the perfect enzyme among billions of possibilities? In this fascinating episode of the Smart Biotech Scientist podcast, host David Brühlmann sits down with David Schönauer, CEO of Aminoverse, who's revolutionizing enzyme engineering through artificial intelligence.

As a biotech entrepreneur who transformed his academic passion into a groundbreaking startup, Schönauer shares how his company is solving one of biotechnology's biggest challenges: efficiently identifying the right enzyme for specific applications, from pharmaceutical manufacturing to sustainable consumer products.

Key Takeaways:

  • Discover how Aminoverse's innovative platform navigates through more than one billion enzyme sequences to identify the most promising candidates
  • Learn why the perfect balance between AI-powered screening and traditional lab testing is crucial for successful enzyme engineering
  • Understand how engineered enzymes are transforming industries, from mRNA vaccine production to eco-friendly laundry detergents

Whether you're a biotech professional or simply curious about the intersection of AI and biotechnology, this episode reveals how cutting-edge technology is accelerating the discovery of nature's molecular workers.

Ready to explore the future of enzyme engineering? Tune in now to hear how AI is transforming biotech innovation, one enzyme at a time.

Connect with David Schönauer:

LinkedIn: https://www.linkedin.com/in/david-schönauer

Aminoverse: https://www.aminoverse.com

Next Steps:

Wondering how to develop biologics with clarity and precision? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Ready to revolutionize your biologics development? Our Fractional CTO services help you develop better, faster, and more cost-effectively. Leverage your full potential today — book a free consultation at https://bruehlmann-consulting.com and let's accelerate your success!

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-16105860 Tue, 19 Nov 2024 05:00:00 +0100 1151 107 full false 106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer - Part 2 106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer - Part 2 In this insightful episode, Technical Development Leader at Flagship Pioneering Oliver Kraemer reveals why developing Advanced Therapy Medicinal Products (ATMPs) require a fundamental shift in thinking from traditional biologics development.

Drawing from his extensive experience across Boehringer Ingelheim, Sanofi, and BMS, Kraemer challenges conventional wisdom about process development timing and demonstrates why early integration of process considerations is crucial for ATMP success.

You will learn:

  • Rethink Development Timing: Learn why incorporating process development earlier in ATMP programs dramatically reduces failure rates and prevents costly repetition
  • Master Complexity: Understand the unique challenges of cell therapy development, including biological fitness and the critical interplay between cell lines, media, and processes
  • Navigate Cost Implications: Discover strategies for managing the unexpectedly high development costs of ATMPs and making informed early decisions that impact commercial success

Ready to transform your approach to ATMP development? Join us for this must-listen episode as we demystify the path from bench to bedside in cell and gene therapy.

Connect with Oliver Kraemer:

LinkedIn: https://www.linkedin.com/in/oliver-kraemer

Next Steps:

Overwhelmed by complex CGT development decisions? Get strategic guidance to avoid costly mistakes and stay ahead: https://bruehlmann-consulting.com

Are soaring manufacturing costs keeping your lifesaving cell and gene therapies out of reach for patients? Book your free assessment at: https://bruehlmann-consulting.com/assessment

Support the show

]]> In this insightful episode, Technical Development Leader at Flagship Pioneering Oliver Kraemer reveals why developing Advanced Therapy Medicinal Products (ATMPs) require a fundamental shift in thinking from traditional biologics development.

Drawing from his extensive experience across Boehringer Ingelheim, Sanofi, and BMS, Kraemer challenges conventional wisdom about process development timing and demonstrates why early integration of process considerations is crucial for ATMP success.

You will learn:

  • Rethink Development Timing: Learn why incorporating process development earlier in ATMP programs dramatically reduces failure rates and prevents costly repetition
  • Master Complexity: Understand the unique challenges of cell therapy development, including biological fitness and the critical interplay between cell lines, media, and processes
  • Navigate Cost Implications: Discover strategies for managing the unexpectedly high development costs of ATMPs and making informed early decisions that impact commercial success

Ready to transform your approach to ATMP development? Join us for this must-listen episode as we demystify the path from bench to bedside in cell and gene therapy.

Connect with Oliver Kraemer:

LinkedIn: https://www.linkedin.com/in/oliver-kraemer

Next Steps:

Overwhelmed by complex CGT development decisions? Get strategic guidance to avoid costly mistakes and stay ahead: https://bruehlmann-consulting.com

Are soaring manufacturing costs keeping your lifesaving cell and gene therapies out of reach for patients? Book your free assessment at: https://bruehlmann-consulting.com/assessment

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-16077470 Thu, 14 Nov 2024 05:00:00 +0100 1191 106 full false 105: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer - Part 1 105: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver Kraemer - Part 1 In this eye-opening episode, we explore the intricate landscape of Advanced Therapy Medicinal Products (ATMPs) with Oliver Kraemer, a technical development leader at Flagship Pioneering.

Drawing from his extensive experience at industry giants like BMS, Sanofi, and Boehringer Ingelheim, Oliver challenges conventional wisdom about automation in cell and gene therapy while illuminating the crucial differences between biologics and ATMPs.

Key Takeaways for Biotech Scientists:

  • Discover why automation isn't the ultimate solution for advancing CGT development right now, and what this means for your process development strategy
  • Learn how ATMP development requires a fundamental rethinking of the traditional research-to-development pipeline
  • Understand the critical early-stage decisions in cell therapy development that can make or break your project timeline

Join us as Oliver shares invaluable insights from his journey from traditional biologics to cutting-edge cell therapies, including both iPSC-derived and donor-derived approaches. Whether you're a bioprocess developer, cell therapy researcher, or biotech professional, this episode offers practical wisdom for navigating the complex landscape of ATMP development.

Ready to transform your understanding of cell therapy development? Listen now to gain insights that could save you months or even years in your development timeline.

Connect with Oliver Kraemer:

LinkedIn: https://www.linkedin.com/in/oliver-kraemer

Next Steps:

Overwhelmed by complex CGT development decisions? Get strategic guidance to avoid costly mistakes and stay ahead: https://bruehlmann-consulting.com

Are soaring manufacturing costs keeping your lifesaving cell and gene therapies out of reach for patients? Book your free assessment at: https://bruehlmann-consulting.com/assessment

Support the show

]]> In this eye-opening episode, we explore the intricate landscape of Advanced Therapy Medicinal Products (ATMPs) with Oliver Kraemer, a technical development leader at Flagship Pioneering.

Drawing from his extensive experience at industry giants like BMS, Sanofi, and Boehringer Ingelheim, Oliver challenges conventional wisdom about automation in cell and gene therapy while illuminating the crucial differences between biologics and ATMPs.

Key Takeaways for Biotech Scientists:

  • Discover why automation isn't the ultimate solution for advancing CGT development right now, and what this means for your process development strategy
  • Learn how ATMP development requires a fundamental rethinking of the traditional research-to-development pipeline
  • Understand the critical early-stage decisions in cell therapy development that can make or break your project timeline

Join us as Oliver shares invaluable insights from his journey from traditional biologics to cutting-edge cell therapies, including both iPSC-derived and donor-derived approaches. Whether you're a bioprocess developer, cell therapy researcher, or biotech professional, this episode offers practical wisdom for navigating the complex landscape of ATMP development.

Ready to transform your understanding of cell therapy development? Listen now to gain insights that could save you months or even years in your development timeline.

Connect with Oliver Kraemer:

LinkedIn: https://www.linkedin.com/in/oliver-kraemer

Next Steps:

Overwhelmed by complex CGT development decisions? Get strategic guidance to avoid costly mistakes and stay ahead: https://bruehlmann-consulting.com

Are soaring manufacturing costs keeping your lifesaving cell and gene therapies out of reach for patients? Book your free assessment at: https://bruehlmann-consulting.com/assessment

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-16077465 Tue, 12 Nov 2024 05:00:00 +0100 1312 105 full false 104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma Mostafa - Part 2 104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma Mostafa - Part 2 Want to peek behind the curtain of a leading Contract Development and Manufacturing Organization (CDMO)? In this inspiring episode, KBI Biopharma's Chief Scientific Officer Sigma Mostafa reveals the intricate world of bioprocess development and manufacturing.

Sigma shares game-changing insights into accelerating biologics development without compromising quality. She also unveils how KBI is leveraging AI and machine learning to revolutionize everything from protein sequence analysis to formulation development.

Key Takeaways:

  • Learn how to master the art of seamless tech transfer
  • Discover how to slash development timelines using innovative cell line technology and parallel processing
  • Learn how AI and machine learning are transforming CDMO operations, from predicting developability challenges to automating lab processes

Ready to transform your bioprocess development journey? Tune in to hear Sigma's vision for the future of CDMOs and get actionable insights for your next project.

Connect with Sigma Mostafa:

Linkedin: https://www.linkedin.com/in/sigma-mostafa-79180817

KBI: https://www.kbibiopharma.com

Next Steps:

Wondering how to fast-track bioprocess CMC development? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Support the show

]]> Want to peek behind the curtain of a leading Contract Development and Manufacturing Organization (CDMO)? In this inspiring episode, KBI Biopharma's Chief Scientific Officer Sigma Mostafa reveals the intricate world of bioprocess development and manufacturing.

Sigma shares game-changing insights into accelerating biologics development without compromising quality. She also unveils how KBI is leveraging AI and machine learning to revolutionize everything from protein sequence analysis to formulation development.

Key Takeaways:

  • Learn how to master the art of seamless tech transfer
  • Discover how to slash development timelines using innovative cell line technology and parallel processing
  • Learn how AI and machine learning are transforming CDMO operations, from predicting developability challenges to automating lab processes

Ready to transform your bioprocess development journey? Tune in to hear Sigma's vision for the future of CDMOs and get actionable insights for your next project.

Connect with Sigma Mostafa:

Linkedin: https://www.linkedin.com/in/sigma-mostafa-79180817

KBI: https://www.kbibiopharma.com

Next Steps:

Wondering how to fast-track bioprocess CMC development? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-16026452 Thu, 07 Nov 2024 05:00:00 +0100 1037 104 full false 103: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma Mostafa - Part 1 103: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma Mostafa - Part 1 In this insightful episode, we're joined by Sigma Mostafa, Chief Scientific Officer at KBI Biopharma, who shares crucial insights on selecting the right CDMO partner for biotech development.

Sigma brings a unique blend of scientific rigor and practical experience to the discussion, having worked on both sides of the CDMO relationship.

Key Takeaways:

  • Why harvest steps deserve more attention in bioprocess development
  • The truth about one-stop-shop CDMOs versus specialized partners
  • Critical factors in cell line and media selection that impact long-term success

Sigma emphasizes that successful CDMO partnerships hinge on transparent communication and cultural alignment, not just technical capabilities. She reveals that while one-stop shops seem convenient, partnering with specialized CDMOs who excel in specific areas often yields better results - as long as there's strong project coordination.

Whether you're a startup navigating your first CDMO relationship or an established biotech company looking to optimize your partnerships, this episode provides actionable insights for making informed decisions that will impact your project's success for years to come.

Listen now to transform your approach to CDMO selection and avoid costly pitfalls in your bioprocess development journey.

Connect with Sigma Mostafa:

Linkedin: https://www.linkedin.com/in/sigma-mostafa-79180817

KBI: https://www.kbibiopharma.com

Next Steps:

Wondering how to fast-track bioprocess CMC development? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> In this insightful episode, we're joined by Sigma Mostafa, Chief Scientific Officer at KBI Biopharma, who shares crucial insights on selecting the right CDMO partner for biotech development.

Sigma brings a unique blend of scientific rigor and practical experience to the discussion, having worked on both sides of the CDMO relationship.

Key Takeaways:

  • Why harvest steps deserve more attention in bioprocess development
  • The truth about one-stop-shop CDMOs versus specialized partners
  • Critical factors in cell line and media selection that impact long-term success

Sigma emphasizes that successful CDMO partnerships hinge on transparent communication and cultural alignment, not just technical capabilities. She reveals that while one-stop shops seem convenient, partnering with specialized CDMOs who excel in specific areas often yields better results - as long as there's strong project coordination.

Whether you're a startup navigating your first CDMO relationship or an established biotech company looking to optimize your partnerships, this episode provides actionable insights for making informed decisions that will impact your project's success for years to come.

Listen now to transform your approach to CDMO selection and avoid costly pitfalls in your bioprocess development journey.

Connect with Sigma Mostafa:

Linkedin: https://www.linkedin.com/in/sigma-mostafa-79180817

KBI: https://www.kbibiopharma.com

Next Steps:

Wondering how to fast-track bioprocess CMC development? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-16026418 Tue, 05 Nov 2024 05:00:00 +0100 1493 103 full false 102: PAT Revolution: Decoding Your Bioprocess Like Never Before with Katharina Dahlmann - Part 2 102: PAT Revolution: Decoding Your Bioprocess Like Never Before with Katharina Dahlmann - Part 2 Struggling to unravel the complexities of your bioprocess? Prepare for a paradigm shift as we dive into the world of Process Analytical Technology (PAT) with Katharina Dahlmann who is Application and PAT Expert at Hamilton.

This eye-opening episode dissects how PAT is redefining biologics manufacturing, balancing its immense potential against real-world implementation hurdles. Katharina navigates us through the intricate journey of scaling up, from micro-bioreactors to large-scale bioreactors, unveiling the hidden gems of early PAT adoption. Whether you're a startup scientist or a seasoned biotech veteran, this episode is packed with insights to elevate your bioprocessing game.

Tune in to uncover:

  1. Strategies for overcoming PAT implementation challenges
  2. Expert tips on scaling up your processes with confidence
  3. A fresh perspective on cross-disciplinary collaboration in biotech

Don't let bioprocess complexity hold you back – listen now and harness the power of PAT to decode your processes like never before!

Connect with Katharina Dahlmann:

LinkedIn: https://www.linkedin.com/in/dr-katharina-dahlmann-616790180

Hamilton: https://www.hamiltoncompany.com

Next Steps:

Wondering how to develop biologics with clarity and precision? Schedule your free consultation to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

Support the show

]]> Struggling to unravel the complexities of your bioprocess? Prepare for a paradigm shift as we dive into the world of Process Analytical Technology (PAT) with Katharina Dahlmann who is Application and PAT Expert at Hamilton.

This eye-opening episode dissects how PAT is redefining biologics manufacturing, balancing its immense potential against real-world implementation hurdles. Katharina navigates us through the intricate journey of scaling up, from micro-bioreactors to large-scale bioreactors, unveiling the hidden gems of early PAT adoption. Whether you're a startup scientist or a seasoned biotech veteran, this episode is packed with insights to elevate your bioprocessing game.

Tune in to uncover:

  1. Strategies for overcoming PAT implementation challenges
  2. Expert tips on scaling up your processes with confidence
  3. A fresh perspective on cross-disciplinary collaboration in biotech

Don't let bioprocess complexity hold you back – listen now and harness the power of PAT to decode your processes like never before!

Connect with Katharina Dahlmann:

LinkedIn: https://www.linkedin.com/in/dr-katharina-dahlmann-616790180

Hamilton: https://www.hamiltoncompany.com

Next Steps:

Wondering how to develop biologics with clarity and precision? Schedule your free consultation to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15962577 Thu, 31 Oct 2024 05:00:00 +0100 917 102 full false 101: PAT Revolution: Decoding Your Bioprocess Like Never Before with Katharina Dahlmann - Part 1 101: PAT Revolution: Decoding Your Bioprocess Like Never Before with Katharina Dahlmann - Part 1 Unlock the hidden potential of your bioprocess! In this eye-opening episode, David Brühlmann sits down with Katharina Dahlmann, Application and PAT Expert at Hamilton, to explore the game-changing world of Process Analytical Technology (PAT).

Discover how PAT is revolutionizing biotech by providing unprecedented insights into cell behavior and process dynamics. Katharina challenges conventional wisdom, revealing that what we think we know about our processes may just be the tip of the iceberg. Learn how combining multiple PAT signals can extract meaningful knowledge, leading to more reproducible and efficient processes.

You will gain valuable insights on:

  1. Leveraging PAT to optimize feeding strategies and reduce process time
  2. Balancing inline and offline measurements for comprehensive process understanding
  3. The future of PAT, including self-evaluating sensors and data modeling

Ready to take your bioprocessing game to the next level? Tune in now and transform your approach to bioprocess monitoring and control!

Connect with Katharina Dahlmann:

LinkedIn: https://www.linkedin.com/in/dr-katharina-dahlmann-616790180

Hamilton: https://www.hamiltoncompany.com

Next Steps:

Wondering how to develop biologics with clarity and precision? Schedule your free consultation to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Unlock the hidden potential of your bioprocess! In this eye-opening episode, David Brühlmann sits down with Katharina Dahlmann, Application and PAT Expert at Hamilton, to explore the game-changing world of Process Analytical Technology (PAT).

Discover how PAT is revolutionizing biotech by providing unprecedented insights into cell behavior and process dynamics. Katharina challenges conventional wisdom, revealing that what we think we know about our processes may just be the tip of the iceberg. Learn how combining multiple PAT signals can extract meaningful knowledge, leading to more reproducible and efficient processes.

You will gain valuable insights on:

  1. Leveraging PAT to optimize feeding strategies and reduce process time
  2. Balancing inline and offline measurements for comprehensive process understanding
  3. The future of PAT, including self-evaluating sensors and data modeling

Ready to take your bioprocessing game to the next level? Tune in now and transform your approach to bioprocess monitoring and control!

Connect with Katharina Dahlmann:

LinkedIn: https://www.linkedin.com/in/dr-katharina-dahlmann-616790180

Hamilton: https://www.hamiltoncompany.com

Next Steps:

Wondering how to develop biologics with clarity and precision? Schedule your free consultation to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15941483 Tue, 29 Oct 2024 05:00:00 +0100 1444 101 full false 100: From Raw Data to Actionable Insights: Unlocking the Power of Process Models with Fabian Feidl - Part 2 100: From Raw Data to Actionable Insights: Unlocking the Power of Process Models with Fabian Feidl - Part 2 Imagine predicting your bioprocess outcomes as easily as checking the weather forecast. Sound impossible? Not anymore. In this insightful episode, we dive deep into the world of digital twins and process models with Fabian Feidl, co-founder and CTO of DataHow.

Discover how these cutting-edge tools are reshaping the biotech landscape, from simplifying complex processes to enabling personalized medicine. Fabian shares invaluable insights on implementing data-driven approaches, even for smaller companies with limited resources.

Key takeaways:

  1. Learn how to start small and build powerful process models that drive real results
  2. Discover the game-changing potential of combining AI with bioprocess expertise
  3. Explore the future of personalized medicine through advanced data analytics

Ready to revolutionize your biotech workflow? Tune in now and unlock the secrets to smarter, more efficient bioprocessing!

Connect with Fabian Feidl:

LinkedIn: https://www.linkedin.com/in/fabian-feidl-a52b36b3

DataHow: https://datahow.ch

Next Steps:

Wondering how to develop biologics with clarity and precision? Schedule your free consultation to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

Support the show

]]> Imagine predicting your bioprocess outcomes as easily as checking the weather forecast. Sound impossible? Not anymore. In this insightful episode, we dive deep into the world of digital twins and process models with Fabian Feidl, co-founder and CTO of DataHow.

Discover how these cutting-edge tools are reshaping the biotech landscape, from simplifying complex processes to enabling personalized medicine. Fabian shares invaluable insights on implementing data-driven approaches, even for smaller companies with limited resources.

Key takeaways:

  1. Learn how to start small and build powerful process models that drive real results
  2. Discover the game-changing potential of combining AI with bioprocess expertise
  3. Explore the future of personalized medicine through advanced data analytics

Ready to revolutionize your biotech workflow? Tune in now and unlock the secrets to smarter, more efficient bioprocessing!

Connect with Fabian Feidl:

LinkedIn: https://www.linkedin.com/in/fabian-feidl-a52b36b3

DataHow: https://datahow.ch

Next Steps:

Wondering how to develop biologics with clarity and precision? Schedule your free consultation to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15909363 Thu, 24 Oct 2024 05:00:00 +0200 1081 100 full false 99: From Raw Data to Actionable Insights: Unlocking the Power of Process Models with Fabian Feidl - Part 1 99: From Raw Data to Actionable Insights: Unlocking the Power of Process Models with Fabian Feidl - Part 1 Are you ready to decode the future of bioprocessing? In this eye-opening episode, we dive deep into the world of digital bioprocess development with Fabian Feidl, co-founder and CTO of DataHow.

Discover how cutting-edge process models are transforming the biotech industry, bridging the gap between raw data and actionable insights.

Key takeaways:

  1. Learn how process models can streamline development, reduce costs, and accelerate time-to-market for groundbreaking therapies.
  2. Explore the game-changing potential of personalized medicine through predictive modeling in CAR T-cell therapy.
  3. Uncover strategies to overcome organizational and technological barriers in adopting digital technologies for bioprocessing.

From optimizing experimental design to enabling data-driven decision-making, this episode is packed with invaluable insights for biotech scientists and leaders. Tune in now to unlock the future of bioprocessing and take your research to the next level!

Connect with Fabian Feidl:

LinkedIn: https://www.linkedin.com/in/fabian-feidl-a52b36b3

DataHow: https://datahow.ch

Next Steps:

Wondering how to develop biologics with clarity and precision? Schedule your free consultation to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

Support the show

]]> Are you ready to decode the future of bioprocessing? In this eye-opening episode, we dive deep into the world of digital bioprocess development with Fabian Feidl, co-founder and CTO of DataHow.

Discover how cutting-edge process models are transforming the biotech industry, bridging the gap between raw data and actionable insights.

Key takeaways:

  1. Learn how process models can streamline development, reduce costs, and accelerate time-to-market for groundbreaking therapies.
  2. Explore the game-changing potential of personalized medicine through predictive modeling in CAR T-cell therapy.
  3. Uncover strategies to overcome organizational and technological barriers in adopting digital technologies for bioprocessing.

From optimizing experimental design to enabling data-driven decision-making, this episode is packed with invaluable insights for biotech scientists and leaders. Tune in now to unlock the future of bioprocessing and take your research to the next level!

Connect with Fabian Feidl:

LinkedIn: https://www.linkedin.com/in/fabian-feidl-a52b36b3

DataHow: https://datahow.ch

Next Steps:

Wondering how to develop biologics with clarity and precision? Schedule your free consultation to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15909324 Tue, 22 Oct 2024 05:00:00 +0200 1320 99 full false 98: The Biomanufacturing Revolution: Bringing Game-changing Products to Market with James Ryall - Part 2 98: The Biomanufacturing Revolution: Bringing Game-changing Products to Market with James Ryall - Part 2 Are you ready to dive into the cutting-edge world of biomanufacturing? In this episode, strategic consultant James Ryall unveils the staggering potential of bio-based products to revolutionize industries. From cultured meat to human breast milk, discover how cells are becoming the ultimate manufacturing facilities.

James shares invaluable insights on scaling challenges, regulatory hurdles, and the critical importance of early preparation for biotech startups. Learn why biomanufacturing is poised to transform up to 60% of consumer goods and how to stay ahead in this rapidly evolving field.

Gain expert strategies to:

  1. Navigate scaling and regulatory challenges with confidence
  2. Create bio-based products that outperform traditional alternatives
  3. Tap into the immense opportunities in non-clinical biomanufacturing

Whether you're a seasoned bioprocessing expert or a curious entrepreneur, this episode will ignite your passion for the biotech revolution. Tune in now and discover how to ride the wave of biomanufacturing innovation!

Connect with James Ryall:

LinkedIn: https://www.linkedin.com/in/james-ryall

Website: https://www.jamesryall.com

Next Steps:

Wondering how to develop biologics with clarity and precision? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

Support the show

]]> Are you ready to dive into the cutting-edge world of biomanufacturing? In this episode, strategic consultant James Ryall unveils the staggering potential of bio-based products to revolutionize industries. From cultured meat to human breast milk, discover how cells are becoming the ultimate manufacturing facilities.

James shares invaluable insights on scaling challenges, regulatory hurdles, and the critical importance of early preparation for biotech startups. Learn why biomanufacturing is poised to transform up to 60% of consumer goods and how to stay ahead in this rapidly evolving field.

Gain expert strategies to:

  1. Navigate scaling and regulatory challenges with confidence
  2. Create bio-based products that outperform traditional alternatives
  3. Tap into the immense opportunities in non-clinical biomanufacturing

Whether you're a seasoned bioprocessing expert or a curious entrepreneur, this episode will ignite your passion for the biotech revolution. Tune in now and discover how to ride the wave of biomanufacturing innovation!

Connect with James Ryall:

LinkedIn: https://www.linkedin.com/in/james-ryall

Website: https://www.jamesryall.com

Next Steps:

Wondering how to develop biologics with clarity and precision? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15866956 Thu, 17 Oct 2024 05:00:00 +0200 1079 98 full false 97: The Biomanufacturing Revolution: Bringing Game-changing Products to Market with James Ryall - Part 1 97: The Biomanufacturing Revolution: Bringing Game-changing Products to Market with James Ryall - Part 1 In this captivating episode, host David Brühlmann welcomes James Ryall, a strategic consultant with over two decades of experience in cell biology and regenerative medicine. From his groundbreaking work in skeletal muscle research to revolutionizing cultured meat production, James shares his fascinating journey through academia and industry.

Discover how he's now helping biotech startups align their technical strategies with commercial outcomes, accelerating their path to market.

You will gain invaluable insights on:

  1. Navigating the transition from academia to industry
  2. Scaling cell production from lab quantities to industrial volumes
  3. Identifying and pivoting to the right target market for biotech innovations

Don't miss this eye-opening discussion on simplifying bioprocessing and bringing game-changing products to life. Tune in now to supercharge your biotech career!

Connect with James Ryall:

LinkedIn: https://www.linkedin.com/in/james-ryall

Website: https://www.jamesryall.com

Next Steps:

Wondering how to develop biologics with clarity and precision? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> In this captivating episode, host David Brühlmann welcomes James Ryall, a strategic consultant with over two decades of experience in cell biology and regenerative medicine. From his groundbreaking work in skeletal muscle research to revolutionizing cultured meat production, James shares his fascinating journey through academia and industry.

Discover how he's now helping biotech startups align their technical strategies with commercial outcomes, accelerating their path to market.

You will gain invaluable insights on:

  1. Navigating the transition from academia to industry
  2. Scaling cell production from lab quantities to industrial volumes
  3. Identifying and pivoting to the right target market for biotech innovations

Don't miss this eye-opening discussion on simplifying bioprocessing and bringing game-changing products to life. Tune in now to supercharge your biotech career!

Connect with James Ryall:

LinkedIn: https://www.linkedin.com/in/james-ryall

Website: https://www.jamesryall.com

Next Steps:

Wondering how to develop biologics with clarity and precision? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15866949 Tue, 15 Oct 2024 05:00:00 +0200 1516 97 full false 96: AI in Bioprocess Development: The Game-Changer You Can't Ignore with Belma Alispahic - Part 2 96: AI in Bioprocess Development: The Game-Changer You Can't Ignore with Belma Alispahic - Part 2 Are you ready to revolutionize your bioprocess development? Join David Brühlmann as he interviews Belma Alispahic, Chief Scientific Officer and Co-Founder of AnalysisMode, who unveils the game-changing potential of AI in biopharma.

Discover how AI is transforming the industry, from drug discovery to manufacturing, and learn why it's no longer optional but essential for success.

Key takeaways:

  1. Leverage AI to streamline experiments, reduce costs, and accelerate your path to market
  2. Gain insights into emerging AI technologies reshaping biopharma's future
  3. Learn practical steps to integrate AI into your workflow, even with limited resources

Don't miss this opportunity to stay ahead of the curve and unlock the full potential of your biotech projects. Tune in now to empower your scientific journey and simplify complex bioprocessing challenges with AI-driven solutions.

Connect with Belma Alispahic:

LinkedIn: https://www.linkedin.com/in/balispahic

Analysis Mode: https://analysismode.com

Next Steps:

Wondering how to develop biologics with clarity and precision? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

Support the show

]]> Are you ready to revolutionize your bioprocess development? Join David Brühlmann as he interviews Belma Alispahic, Chief Scientific Officer and Co-Founder of AnalysisMode, who unveils the game-changing potential of AI in biopharma.

Discover how AI is transforming the industry, from drug discovery to manufacturing, and learn why it's no longer optional but essential for success.

Key takeaways:

  1. Leverage AI to streamline experiments, reduce costs, and accelerate your path to market
  2. Gain insights into emerging AI technologies reshaping biopharma's future
  3. Learn practical steps to integrate AI into your workflow, even with limited resources

Don't miss this opportunity to stay ahead of the curve and unlock the full potential of your biotech projects. Tune in now to empower your scientific journey and simplify complex bioprocessing challenges with AI-driven solutions.

Connect with Belma Alispahic:

LinkedIn: https://www.linkedin.com/in/balispahic

Analysis Mode: https://analysismode.com

Next Steps:

Wondering how to develop biologics with clarity and precision? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15831311 Thu, 10 Oct 2024 05:00:00 +0200 1193 96 full false 95: AI in Bioprocess Development: The Game-Changer You Can't Ignore with Belma Alispahic - Part 1 95: AI in Bioprocess Development: The Game-Changer You Can't Ignore with Belma Alispahic - Part 1 Is AI the secret weapon biotech scientists have been waiting for? In this eye-opening episode, we dive deep into the world of AI-driven bioprocess development with Belma Alispahic, Chief Scientific Officer and Co-Founder of AnalysisMode. Discover how AI is transforming the biotech landscape, from reducing downtime by 50% to unlocking unprecedented levels of precision in process optimization.

Key takeaways:

  1. Learn how AI can slash experiment time by up to 80%, saving you valuable resources
  2. Uncover the power of digital twins in fine-tuning your bioprocesses with unparalleled accuracy
  3. Gain insights on overcoming data challenges to harness AI's full potential in your lab

Don't miss this game-changing discussion that could revolutionize your approach to bioprocess development. Tune in now and stay ahead of the curve in the rapidly evolving world of biotech!

Connect with Belma Alispahic:

LinkedIn: https://www.linkedin.com/in/balispahic

Analysis Mode: https://analysismode.com

Next Steps:

Wondering how to develop biologics with clarity and precision? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

Support the show

]]> Is AI the secret weapon biotech scientists have been waiting for? In this eye-opening episode, we dive deep into the world of AI-driven bioprocess development with Belma Alispahic, Chief Scientific Officer and Co-Founder of AnalysisMode. Discover how AI is transforming the biotech landscape, from reducing downtime by 50% to unlocking unprecedented levels of precision in process optimization.

Key takeaways:

  1. Learn how AI can slash experiment time by up to 80%, saving you valuable resources
  2. Uncover the power of digital twins in fine-tuning your bioprocesses with unparalleled accuracy
  3. Gain insights on overcoming data challenges to harness AI's full potential in your lab

Don't miss this game-changing discussion that could revolutionize your approach to bioprocess development. Tune in now and stay ahead of the curve in the rapidly evolving world of biotech!

Connect with Belma Alispahic:

LinkedIn: https://www.linkedin.com/in/balispahic

Analysis Mode: https://analysismode.com

Next Steps:

Wondering how to develop biologics with clarity and precision? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15831309 Tue, 08 Oct 2024 05:00:00 +0200 1237 95 full false 94: From Lab Coat to LinkedIn: Benjamin McLeod's Journey to Cell and Gene Therapy Influencer - Part 2 94: From Lab Coat to LinkedIn: Benjamin McLeod's Journey to Cell and Gene Therapy Influencer - Part 2 In this electrifying episode, we dive deep into the future of biotech with biotech influencer Benjamin McLeod. From quantum AI mapping cellular interactions to the game-changing potential of process analytical technology, Ben, who is also a Cell & Gene Therapy Segment Lead at NanoMosaic, unveils how artificial intelligence is set to transform the cell and gene therapy landscape.

Discover why LinkedIn is becoming the new frontier for biotech networking and career advancement. Learn how combining AI with PAT could slash production costs and boost yields in ways you've never imagined.

You will gain invaluable insights on:

  1. Leveraging AI to optimize bioprocesses and reduce costs
  2. The evolving landscape of viral and non-viral gene therapies
  3. Strategies for breaking into the cell and gene therapy field

Don't miss this opportunity to stay ahead of the curve in biotech innovation. Tune in now and revolutionize your approach to bioprocessing!

Connect with Benjamin McLeod:

LinkedIn: https://www.linkedin.com/in/benjamin-mcleod

NanoMosaic: https://www.nanomosaicllc.com

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Support the show

]]> In this electrifying episode, we dive deep into the future of biotech with biotech influencer Benjamin McLeod. From quantum AI mapping cellular interactions to the game-changing potential of process analytical technology, Ben, who is also a Cell & Gene Therapy Segment Lead at NanoMosaic, unveils how artificial intelligence is set to transform the cell and gene therapy landscape.

Discover why LinkedIn is becoming the new frontier for biotech networking and career advancement. Learn how combining AI with PAT could slash production costs and boost yields in ways you've never imagined.

You will gain invaluable insights on:

  1. Leveraging AI to optimize bioprocesses and reduce costs
  2. The evolving landscape of viral and non-viral gene therapies
  3. Strategies for breaking into the cell and gene therapy field

Don't miss this opportunity to stay ahead of the curve in biotech innovation. Tune in now and revolutionize your approach to bioprocessing!

Connect with Benjamin McLeod:

LinkedIn: https://www.linkedin.com/in/benjamin-mcleod

NanoMosaic: https://www.nanomosaicllc.com

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15791361 Thu, 03 Oct 2024 05:00:00 +0200 1171 94 full false 93: From Lab Coat to LinkedIn: Benjamin McLeod's Journey to Cell and Gene Therapy Influencer - Part 1 93: From Lab Coat to LinkedIn: Benjamin McLeod's Journey to Cell and Gene Therapy Influencer - Part 1 Discover how a failed optometry dream led Benjamin McLeod to become a leading voice in cell and gene therapy. In this eye-opening episode, Ben, who is a Cell & Gene Therapy Segment Lead at NanoMosaic, shares his unconventional path from lab work to LinkedIn stardom, revealing how he bridges the gap between R&D and marketing in biotech.

Learn how Ben's weekly science memes evolved into valuable content that attracts both lab techs and CEOs alike.

Key takeaways:

  1. Gain insider tips on communicating complex science effectively
  2. Learn how to leverage social media to build industry credibility
  3. Discover the power of continuous learning in fast-paced biotech fields

Whether you're a seasoned scientist or biotech enthusiast, this episode offers invaluable insights into the art of scientific communication. Tune in now to transform your approach to biotech development and communicating science.

Connect with Benjamin McLeod:

LinkedIn: https://www.linkedin.com/in/benjamin-mcleod

NanoMosaic: https://www.nanomosaicllc.com

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Discover how a failed optometry dream led Benjamin McLeod to become a leading voice in cell and gene therapy. In this eye-opening episode, Ben, who is a Cell & Gene Therapy Segment Lead at NanoMosaic, shares his unconventional path from lab work to LinkedIn stardom, revealing how he bridges the gap between R&D and marketing in biotech.

Learn how Ben's weekly science memes evolved into valuable content that attracts both lab techs and CEOs alike.

Key takeaways:

  1. Gain insider tips on communicating complex science effectively
  2. Learn how to leverage social media to build industry credibility
  3. Discover the power of continuous learning in fast-paced biotech fields

Whether you're a seasoned scientist or biotech enthusiast, this episode offers invaluable insights into the art of scientific communication. Tune in now to transform your approach to biotech development and communicating science.

Connect with Benjamin McLeod:

LinkedIn: https://www.linkedin.com/in/benjamin-mcleod

NanoMosaic: https://www.nanomosaicllc.com

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15791353 Tue, 01 Oct 2024 05:00:00 +0200 1496 93 full false 92: Mass Transfer Secrets: Mastering Bubbles and kLa from Bench to Large-Scale Production with Lars Puiman & Rik Volger - Part 2 92: Mass Transfer Secrets: Mastering Bubbles and kLa from Bench to Large-Scale Production with Lars Puiman & Rik Volger - Part 2 Ever wondered why your perfectly optimized lab process falls apart at industrial scale?

Mass transfer experts Lars Puiman and Rik Volger from the University of Delft reveal the hidden world of oxygen transfer and aeration that can make or break your production.

Dive into the crucial differences between lab-scale and industrial-scale bioreactors, and discover why your DO sensor might be fooling you. Learn how CFD simulations and innovative downscaling techniques can revolutionize your scale-up strategy.

In this episode, you'll gain:

  1. Insider tips for predicting and managing concentration gradients in large-scale reactors
  2. Cutting-edge methods to measure kLa accurately in industrial settings
  3. Strategies to leverage microfluidics for cost-effective process development

From the basics of bubble behavior to the latest in AI and machine learning, this episode is packed with practical insights to enhance your bioprocess efficiency and product quality. Don't miss out on these game-changing mass transfer secrets – tune in now and take your bioprocessing skills to the next level!

Connect with our guests:

Lars Puiman: https://www.linkedin.com/in/larspuiman

Rik Volger:  https://www.linkedin.com/in/rikvolger

Next Step:

Enhance your bioprocess development strategy! Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Additional Resources:

Bubbles and Broth: A review on the impact of broth composition on bubble column bioreactor hydrodynamics

Read the review paper at https://doi.org/10.1016/j.bej.2023.109124

Support the show

]]> Ever wondered why your perfectly optimized lab process falls apart at industrial scale?

Mass transfer experts Lars Puiman and Rik Volger from the University of Delft reveal the hidden world of oxygen transfer and aeration that can make or break your production.

Dive into the crucial differences between lab-scale and industrial-scale bioreactors, and discover why your DO sensor might be fooling you. Learn how CFD simulations and innovative downscaling techniques can revolutionize your scale-up strategy.

In this episode, you'll gain:

  1. Insider tips for predicting and managing concentration gradients in large-scale reactors
  2. Cutting-edge methods to measure kLa accurately in industrial settings
  3. Strategies to leverage microfluidics for cost-effective process development

From the basics of bubble behavior to the latest in AI and machine learning, this episode is packed with practical insights to enhance your bioprocess efficiency and product quality. Don't miss out on these game-changing mass transfer secrets – tune in now and take your bioprocessing skills to the next level!

Connect with our guests:

Lars Puiman: https://www.linkedin.com/in/larspuiman

Rik Volger:  https://www.linkedin.com/in/rikvolger

Next Step:

Enhance your bioprocess development strategy! Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Additional Resources:

Bubbles and Broth: A review on the impact of broth composition on bubble column bioreactor hydrodynamics

Read the review paper at https://doi.org/10.1016/j.bej.2023.109124

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15767522 Thu, 26 Sep 2024 05:00:00 +0200 989 92 full false 91: Mass Transfer Secrets: Mastering Bubbles and kLa from Bench to Large-Scale Production with Lars Puiman & Rik Volger - Part 1 91: Mass Transfer Secrets: Mastering Bubbles and kLa from Bench to Large-Scale Production with Lars Puiman & Rik Volger - Part 1 Unlock the mysteries of oxygen transfer in bioreactors with mass transfer experts Lars Puiman and Rik Volger from the University of Delft. In this eye-opening episode, dive deep into the crucial world of kLa (oxygen mass transfer coefficient) and its impact on bioprocess scale-up.

Discover why understanding kLa is essential for optimizing cell growth and product formation in bioreactors. Learn practical strategies to enhance oxygen transfer, from manipulating bubble size to leveraging unexpected allies like ethanol. Our experts reveal:

  1. How to increase mass transfer efficiency without breaking the bank
  2. The surprising effects of broth composition on oxygen transfer rates
  3. Cutting-edge sparger technologies for optimal aeration

Whether you're a seasoned bioprocess engineer or a curious scientist, this episode will revolutionize your approach to oxygen transfer in bioprocessing.

Don't miss these game-changing insights – tune in now!

Connect with our guests:

Lars Puiman: https://www.linkedin.com/in/larspuiman

Rik Volger:  https://www.linkedin.com/in/rikvolger

Next Step:

Enhance your bioprocess development strategy! Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Additional Resources:

Bubbles and Broth: A review on the impact of broth composition on bubble column bioreactor hydrodynamics

Read the review paper at https://doi.org/10.1016/j.bej.2023.109124

Support the show

]]> Unlock the mysteries of oxygen transfer in bioreactors with mass transfer experts Lars Puiman and Rik Volger from the University of Delft. In this eye-opening episode, dive deep into the crucial world of kLa (oxygen mass transfer coefficient) and its impact on bioprocess scale-up.

Discover why understanding kLa is essential for optimizing cell growth and product formation in bioreactors. Learn practical strategies to enhance oxygen transfer, from manipulating bubble size to leveraging unexpected allies like ethanol. Our experts reveal:

  1. How to increase mass transfer efficiency without breaking the bank
  2. The surprising effects of broth composition on oxygen transfer rates
  3. Cutting-edge sparger technologies for optimal aeration

Whether you're a seasoned bioprocess engineer or a curious scientist, this episode will revolutionize your approach to oxygen transfer in bioprocessing.

Don't miss these game-changing insights – tune in now!

Connect with our guests:

Lars Puiman: https://www.linkedin.com/in/larspuiman

Rik Volger:  https://www.linkedin.com/in/rikvolger

Next Step:

Enhance your bioprocess development strategy! Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Additional Resources:

Bubbles and Broth: A review on the impact of broth composition on bubble column bioreactor hydrodynamics

Read the review paper at https://doi.org/10.1016/j.bej.2023.109124

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15767508 Tue, 24 Sep 2024 05:00:00 +0200 997 91 full false 90: Scale-Up Secrets: Cracking the Code of AAV Production with Ahmed Youssef - Part 2 90: Scale-Up Secrets: Cracking the Code of AAV Production with Ahmed Youssef - Part 2 Dive into the cutting-edge world of gene therapy as we unravel the complexities of AAV production. In this insightful episode, Ahmed Youssef, a seasoned AAV expert and Senior Process Development Manager at Ascend, explains how you can navigate the complex world of AAV scale-up and learn why thinking outside the box is crucial for success.

Key takeaways:

  1. Leverage early expert advice to ensure your therapeutic's long-term viability
  2. Explore innovative technologies like doggy bone DNA to reduce impurities
  3. Gain insights from industry pioneers to revolutionize your AAV production process

From plasmid alternatives to cutting-edge CDMO strategies, this episode is packed with game-changing information. Don't miss out on these invaluable scale-up secrets that could transform your gene therapy projects.

Tune in now and take your AAV production skills to the next level!

Connect with Ahmed Youssef:

LinkedIn: https://www.linkedin.com/in/ahmed-samir-youssef

Ascend: https://www.ascend-adv.com

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Dive into the cutting-edge world of gene therapy as we unravel the complexities of AAV production. In this insightful episode, Ahmed Youssef, a seasoned AAV expert and Senior Process Development Manager at Ascend, explains how you can navigate the complex world of AAV scale-up and learn why thinking outside the box is crucial for success.

Key takeaways:

  1. Leverage early expert advice to ensure your therapeutic's long-term viability
  2. Explore innovative technologies like doggy bone DNA to reduce impurities
  3. Gain insights from industry pioneers to revolutionize your AAV production process

From plasmid alternatives to cutting-edge CDMO strategies, this episode is packed with game-changing information. Don't miss out on these invaluable scale-up secrets that could transform your gene therapy projects.

Tune in now and take your AAV production skills to the next level!

Connect with Ahmed Youssef:

LinkedIn: https://www.linkedin.com/in/ahmed-samir-youssef

Ascend: https://www.ascend-adv.com

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15719394 Thu, 19 Sep 2024 05:00:00 +0200 1566 90 full false 89: Scale-Up Secrets: Cracking the Code of AAV Production with Ahmed Youssef - Part 1 89: Scale-Up Secrets: Cracking the Code of AAV Production with Ahmed Youssef - Part 1 Unlock the mysteries of AAV manufacturing in this eye-opening episode! Ahmed, a seasoned AAV expert and Senior Process Development Manager at Ascend, reveals insider strategies for biotech scientists navigating the complex world of gene therapy production.

Discover why quality is the cornerstone of successful AAV development and how to avoid costly missteps in the journey from lab to clinic.

Key takeaways:

  1. Learn to design a robust AAV manufacturing process that stands up to regulatory scrutiny
  2. Master the art of balancing yield and quality for economically viable production
  3. Gain insights into cutting-edge analytical tools that ensure your AAV's efficacy

From cell line selection to plasmid optimization, Ahmed breaks down the critical factors that can make or break your AAV project. Whether you're a biotech novice or a seasoned pro, this episode is packed with actionable advice to elevate your gene therapy game.

Ready to revolutionize your approach to AAV production? Tune in now!

Connect with Ahmed Youssef:

LinkedIn: https://www.linkedin.com/in/ahmed-samir-youssef

Ascend: https://www.ascend-adv.com

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Support the show

]]> Unlock the mysteries of AAV manufacturing in this eye-opening episode! Ahmed, a seasoned AAV expert and Senior Process Development Manager at Ascend, reveals insider strategies for biotech scientists navigating the complex world of gene therapy production.

Discover why quality is the cornerstone of successful AAV development and how to avoid costly missteps in the journey from lab to clinic.

Key takeaways:

  1. Learn to design a robust AAV manufacturing process that stands up to regulatory scrutiny
  2. Master the art of balancing yield and quality for economically viable production
  3. Gain insights into cutting-edge analytical tools that ensure your AAV's efficacy

From cell line selection to plasmid optimization, Ahmed breaks down the critical factors that can make or break your AAV project. Whether you're a biotech novice or a seasoned pro, this episode is packed with actionable advice to elevate your gene therapy game.

Ready to revolutionize your approach to AAV production? Tune in now!

Connect with Ahmed Youssef:

LinkedIn: https://www.linkedin.com/in/ahmed-samir-youssef

Ascend: https://www.ascend-adv.com

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15719374 Tue, 17 Sep 2024 05:00:00 +0200 1208 88 full false 88: The Swiss Army Knife of Biotech: Unleashing the Power of Fractional Expertise 88: The Swiss Army Knife of Biotech: Unleashing the Power of Fractional Expertise Unlock the secret weapon of biotech success! In this eye-opening episode, host David Brühlmann reveals how fractional CTOs are revolutionizing drug development, inspired by Michael Jordan's approach to greatness. Learn how this innovative strategy can slash timelines, mitigate risks, and give your biotech company a competitive edge.

Discover the game-changing benefits of fractional expertise:

  1. Gain rapid access to broad biotech knowledge, navigating complex challenges with ease.
  2. Slash costs while tapping into C-level strategic guidance for critical growth phases.
  3. Accelerate business development through valuable industry connections and insights.

Ready to transform your biotech journey? Tune in to explore how harnessing fractional expertise could be the catalyst your company needs.

Don't miss this opportunity to level up your drug development game – listen now and stay ahead in the fast-paced world of biotech innovation!

Next Steps:

Schedule your free call at https://bruehlmann-consulting.com/assessment to discover how you can develop biologics better, faster, at a fraction of the cost with our Fractional CTO services.

Support the show

]]> Unlock the secret weapon of biotech success! In this eye-opening episode, host David Brühlmann reveals how fractional CTOs are revolutionizing drug development, inspired by Michael Jordan's approach to greatness. Learn how this innovative strategy can slash timelines, mitigate risks, and give your biotech company a competitive edge.

Discover the game-changing benefits of fractional expertise:

  1. Gain rapid access to broad biotech knowledge, navigating complex challenges with ease.
  2. Slash costs while tapping into C-level strategic guidance for critical growth phases.
  3. Accelerate business development through valuable industry connections and insights.

Ready to transform your biotech journey? Tune in to explore how harnessing fractional expertise could be the catalyst your company needs.

Don't miss this opportunity to level up your drug development game – listen now and stay ahead in the fast-paced world of biotech innovation!

Next Steps:

Schedule your free call at https://bruehlmann-consulting.com/assessment to discover how you can develop biologics better, faster, at a fraction of the cost with our Fractional CTO services.

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15719363 Thu, 12 Sep 2024 05:00:00 +0200 998 88 full false 87: The Hidden Pitfalls of Bioprocess Development: Lessons from the Trenches 87: The Hidden Pitfalls of Bioprocess Development: Lessons from the Trenches Unlock the secrets of successful bioprocess development with host David Brühlmann as he shares hard-won lessons from his 15+ years of experience leading technology transfers and technology innovation projects.

Discover why prioritizing process development is crucial for transforming groundbreaking science into life-changing therapies. In this eye-opening episode, you'll learn:

  1. How to avoid costly mistakes in technology transfer and scale-up, saving you time and resources
  2. Strategies for balancing investor expectations with regulatory hurdles, keeping your project on track
  3. Tips for building a robust risk management strategy that impresses investors and navigates challenges

From selecting the right cell lines to mastering the delicate dance of speed and quality, David unveils the hidden pitfalls that can derail even the most promising biotech innovations.

Whether you're a seasoned scientist or a curious entrepreneur, this episode is packed with actionable insights to supercharge your bioprocess development. Don't miss out – tune in now and take your biotech game to the next level!

Next Steps:

Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Support the show

]]> Unlock the secrets of successful bioprocess development with host David Brühlmann as he shares hard-won lessons from his 15+ years of experience leading technology transfers and technology innovation projects.

Discover why prioritizing process development is crucial for transforming groundbreaking science into life-changing therapies. In this eye-opening episode, you'll learn:

  1. How to avoid costly mistakes in technology transfer and scale-up, saving you time and resources
  2. Strategies for balancing investor expectations with regulatory hurdles, keeping your project on track
  3. Tips for building a robust risk management strategy that impresses investors and navigates challenges

From selecting the right cell lines to mastering the delicate dance of speed and quality, David unveils the hidden pitfalls that can derail even the most promising biotech innovations.

Whether you're a seasoned scientist or a curious entrepreneur, this episode is packed with actionable insights to supercharge your bioprocess development. Don't miss out – tune in now and take your biotech game to the next level!

Next Steps:

Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15683074 Tue, 10 Sep 2024 05:00:00 +0200 1014 87 full false 86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli - Part 2 86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli - Part 2 What if your biomanufacturing facility could run itself, optimize its own processes, and operate non-stop? This isn't science fiction – it's the cutting-edge reality Professor Massimo Morbidelli is helping to create.

In this captivating episode, the bioprocessing pioneer unveils how AI, continuous manufacturing, and revolutionary machine learning techniques are transforming the industry landscape.

As a Professor Emeritus at ETH Zurich and Politecnico di Milano, and a co-founder of ChromaCon (now YMC) and DataHow, Massimo Morbidelli has been at the forefront of bioprocess innovation. He is currently the recipient of the ERC Advanced Grant Continuous Digitalisation of Bioprocesses (CoDiBio) at the Aristotle University of Thessaloniki.

Discover how transfer learning is revolutionizing process development across molecules and scales, dramatically reducing time-to-market for new biologics. Learn why the integration of computer science and biology is crucial for staying competitive in the rapidly evolving biopharma landscape.

You will gain invaluable insights on

  1. Slashing development costs,
  2. Maximizing productivity through 24/7 operations
  3. Leveraging interdisciplinary knowledge to solve complex bioprocessing challenges

All are essential skills for thriving in the next era of biomanufacturing.

Tune in now and revolutionize your approach to biopharma innovation!

Connect with Massimo Morbidelli:

Email: massimo “dot” morbidelli “at” polimi “dot” it

Next Steps:

Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> What if your biomanufacturing facility could run itself, optimize its own processes, and operate non-stop? This isn't science fiction – it's the cutting-edge reality Professor Massimo Morbidelli is helping to create.

In this captivating episode, the bioprocessing pioneer unveils how AI, continuous manufacturing, and revolutionary machine learning techniques are transforming the industry landscape.

As a Professor Emeritus at ETH Zurich and Politecnico di Milano, and a co-founder of ChromaCon (now YMC) and DataHow, Massimo Morbidelli has been at the forefront of bioprocess innovation. He is currently the recipient of the ERC Advanced Grant Continuous Digitalisation of Bioprocesses (CoDiBio) at the Aristotle University of Thessaloniki.

Discover how transfer learning is revolutionizing process development across molecules and scales, dramatically reducing time-to-market for new biologics. Learn why the integration of computer science and biology is crucial for staying competitive in the rapidly evolving biopharma landscape.

You will gain invaluable insights on

  1. Slashing development costs,
  2. Maximizing productivity through 24/7 operations
  3. Leveraging interdisciplinary knowledge to solve complex bioprocessing challenges

All are essential skills for thriving in the next era of biomanufacturing.

Tune in now and revolutionize your approach to biopharma innovation!

Connect with Massimo Morbidelli:

Email: massimo “dot” morbidelli “at” polimi “dot” it

Next Steps:

Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15673637 Thu, 05 Sep 2024 05:00:00 +0200 1433 86 full false 85: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli - Part 1 85: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo Morbidelli - Part 1 Imagine a world where biologic drugs are produced faster, cheaper, and with unprecedented precision.

In this episode, we dive into that future with Professor Massimo Morbidelli, a trailblazer in bioprocessing innovation. As a Professor Emeritus at ETH Zurich and Politecnico di Milano, and a co-founder of ChromaCon (now YMC) and DataHow, Massimo Morbidelli has been at the forefront of bioprocess innovation. He is currently the recipient of the ERC Advanced Grant Continuous Digitalisation of Bioprocesses (CoDiBio) at the Aristotle University of Thessaloniki.

From his groundbreaking work in continuous chromatography to spearheading AI-driven manufacturing, Morbidelli's 25-year journey has reshaped the biotech landscape.

Discover how initial industry skepticism transformed into widespread adoption of continuous processing and machine learning. Prof. Morbidelli shares insights on his current project: a fully automated, end-to-end manufacturing process for plasmid DNA production.

You will gain invaluable insights into:

  1. The evolution of continuous bioprocessing and its impact on productivity and yield
  2. How digitalization and machine learning are optimizing process development and manufacturing
  3. The potential of transfer learning to dramatically reduce time-to-market for new biologics

Don't miss this opportunity to learn from a true visionary in the field.

Tune in now to unlock the secrets of next-generation biomanufacturing and stay ahead of the curve in this rapidly evolving industry.

Connect with Massimo Morbidelli:

Email: massimo “dot” morbidelli “at” polimi “dot” it

Next Steps:

Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Imagine a world where biologic drugs are produced faster, cheaper, and with unprecedented precision.

In this episode, we dive into that future with Professor Massimo Morbidelli, a trailblazer in bioprocessing innovation. As a Professor Emeritus at ETH Zurich and Politecnico di Milano, and a co-founder of ChromaCon (now YMC) and DataHow, Massimo Morbidelli has been at the forefront of bioprocess innovation. He is currently the recipient of the ERC Advanced Grant Continuous Digitalisation of Bioprocesses (CoDiBio) at the Aristotle University of Thessaloniki.

From his groundbreaking work in continuous chromatography to spearheading AI-driven manufacturing, Morbidelli's 25-year journey has reshaped the biotech landscape.

Discover how initial industry skepticism transformed into widespread adoption of continuous processing and machine learning. Prof. Morbidelli shares insights on his current project: a fully automated, end-to-end manufacturing process for plasmid DNA production.

You will gain invaluable insights into:

  1. The evolution of continuous bioprocessing and its impact on productivity and yield
  2. How digitalization and machine learning are optimizing process development and manufacturing
  3. The potential of transfer learning to dramatically reduce time-to-market for new biologics

Don't miss this opportunity to learn from a true visionary in the field.

Tune in now to unlock the secrets of next-generation biomanufacturing and stay ahead of the curve in this rapidly evolving industry.

Connect with Massimo Morbidelli:

Email: massimo “dot” morbidelli “at” polimi “dot” it

Next Steps:

Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? Contact us at https://bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15673629 Tue, 03 Sep 2024 05:00:00 +0200 1496 85 full false 84: The Hidden Potential of Shake Flasks: What Every Biotech Scientist Needs to Know with Jens Bayer - Part 2 84: The Hidden Potential of Shake Flasks: What Every Biotech Scientist Needs to Know with Jens Bayer - Part 2 Are your shake flasks holding back your bioprocess development? Discover how to transform them into smart bioreactors! In this game-changing episode, we talk with Jens Bayer about the groundbreaking DOTS platform. He is a deep tech entrepreneur and seasoned commercial leader, currently serving as Chief Commercial Officer at Scientific Bioprocessing.

Jens reveals how this cutting-edge technology is bridging the gap between simple shake flasks and complex bioreactors, offering scientists unprecedented control and data insights.

Learn how to:

  1. Generate real-time growth curves and monitor key parameters without invasive sampling
  2. Run fed-batch experiments in shake flasks, mimicking bioreactor conditions
  3. Optimize your processes for better scalability and reproducibility

Whether you're a startup scientist or working in Big Pharma, this episode will revolutionize your approach to early-stage bioprocessing. Don't miss Jens' invaluable tips for designing successful shake flask experiments and his inspiring journey as a biotech entrepreneur.

Ready to supercharge your bioprocess development? Tune in now and unlock the hidden potential of your shake flasks!

Connect with Jens Bayer:

LinkedIn: https://www.linkedin.com/in/jens-bayer-65a46350

Scientific Bioprocessing: https://www.scientificbio.com

Next Steps:

Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Are your shake flasks holding back your bioprocess development? Discover how to transform them into smart bioreactors! In this game-changing episode, we talk with Jens Bayer about the groundbreaking DOTS platform. He is a deep tech entrepreneur and seasoned commercial leader, currently serving as Chief Commercial Officer at Scientific Bioprocessing.

Jens reveals how this cutting-edge technology is bridging the gap between simple shake flasks and complex bioreactors, offering scientists unprecedented control and data insights.

Learn how to:

  1. Generate real-time growth curves and monitor key parameters without invasive sampling
  2. Run fed-batch experiments in shake flasks, mimicking bioreactor conditions
  3. Optimize your processes for better scalability and reproducibility

Whether you're a startup scientist or working in Big Pharma, this episode will revolutionize your approach to early-stage bioprocessing. Don't miss Jens' invaluable tips for designing successful shake flask experiments and his inspiring journey as a biotech entrepreneur.

Ready to supercharge your bioprocess development? Tune in now and unlock the hidden potential of your shake flasks!

Connect with Jens Bayer:

LinkedIn: https://www.linkedin.com/in/jens-bayer-65a46350

Scientific Bioprocessing: https://www.scientificbio.com

Next Steps:

Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15570519 Thu, 29 Aug 2024 05:00:00 +0200 1449 84 full false 83: The Hidden Potential of Shake Flasks: What Every Biotech Scientist Needs to Know with Jens Bayer - Part 1 83: The Hidden Potential of Shake Flasks: What Every Biotech Scientist Needs to Know with Jens Bayer - Part 1 Are shake flasks outdated relics or untapped goldmines of bioprocess development? In this eye-opening episode, we dive deep with Jens Bayer, a deep tech entrepreneur and seasoned commercial leader, currently serving as Chief Commercial Officer at Scientific Bioprocessing.

Jens shatters common misconceptions about shake flasks, revealing why they remain indispensable tools in both industry and research settings.

Discover:

  1. Why shake flasks are irreplaceable for rapid, cost-effective experimentation
  2. How to overcome the "black box" challenge and extract crucial data
  3. Strategies to optimize shake flask processes for better scalability

From startups to Big Pharma, learn how mastering shake flask techniques can accelerate your bioprocess development and save precious resources. Whether you're a seasoned biotech pro or just starting out, this episode will transform how you approach early-stage bioprocessing.

Ready to revolutionize your lab work? Tune in now and unlock the hidden potential of shake flasks!

Connect with Jens Bayer:

LinkedIn: https://www.linkedin.com/in/jens-bayer-65a46350

Scientific Bioprocessing: https://www.scientificbio.com

Next Steps:

Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Support the show

]]> Are shake flasks outdated relics or untapped goldmines of bioprocess development? In this eye-opening episode, we dive deep with Jens Bayer, a deep tech entrepreneur and seasoned commercial leader, currently serving as Chief Commercial Officer at Scientific Bioprocessing.

Jens shatters common misconceptions about shake flasks, revealing why they remain indispensable tools in both industry and research settings.

Discover:

  1. Why shake flasks are irreplaceable for rapid, cost-effective experimentation
  2. How to overcome the "black box" challenge and extract crucial data
  3. Strategies to optimize shake flask processes for better scalability

From startups to Big Pharma, learn how mastering shake flask techniques can accelerate your bioprocess development and save precious resources. Whether you're a seasoned biotech pro or just starting out, this episode will transform how you approach early-stage bioprocessing.

Ready to revolutionize your lab work? Tune in now and unlock the hidden potential of shake flasks!

Connect with Jens Bayer:

LinkedIn: https://www.linkedin.com/in/jens-bayer-65a46350

Scientific Bioprocessing: https://www.scientificbio.com

Next Steps:

Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15513058 Tue, 27 Aug 2024 05:00:00 +0200 1105 83 full false 82: Regenerating Muscles: The Future of Autologous Cell-based Therapy with Deana Mohr - Part 2 82: Regenerating Muscles: The Future of Autologous Cell-based Therapy with Deana Mohr - Part 2 Dive into the cutting-edge world of autologous cell-based therapy with Deana Mohr, CEO and co-founder of MUVON Therapeutics, spin-off from the University of Zurich. In this eye-opening episode, discover how MUVON Therapeutics’ innovative approach to muscle regeneration is revolutionizing treatments for stress urinary incontinence and beyond.

Learn how her team is tackling the challenges of bringing personalized medicine to market at scale, from navigating complex regulations to automating production processes.

Listeners will gain invaluable insights on:

  1. Strategies for engaging with regulatory bodies to advance novel therapies
  2. The crucial role of automation in making cell therapies accessible and affordable
  3. Building successful partnerships to accelerate biotech innovation

Whether you're a scientist, investor, or healthcare professional, this episode offers a fascinating glimpse into the future of regenerative medicine. Tune in to explore how Deana's vision of "copy-paste" therapy production could transform millions of lives and reshape the biotech landscape!

Connect with Deana Mohr:

LinkedIn: https://www.linkedin.com/in/deana-mohr-haralampieva-95a9a5a4

MUVON Therapeutics: https://www.muvon-therapeutics.com

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Support the show

]]> Dive into the cutting-edge world of autologous cell-based therapy with Deana Mohr, CEO and co-founder of MUVON Therapeutics, spin-off from the University of Zurich. In this eye-opening episode, discover how MUVON Therapeutics’ innovative approach to muscle regeneration is revolutionizing treatments for stress urinary incontinence and beyond.

Learn how her team is tackling the challenges of bringing personalized medicine to market at scale, from navigating complex regulations to automating production processes.

Listeners will gain invaluable insights on:

  1. Strategies for engaging with regulatory bodies to advance novel therapies
  2. The crucial role of automation in making cell therapies accessible and affordable
  3. Building successful partnerships to accelerate biotech innovation

Whether you're a scientist, investor, or healthcare professional, this episode offers a fascinating glimpse into the future of regenerative medicine. Tune in to explore how Deana's vision of "copy-paste" therapy production could transform millions of lives and reshape the biotech landscape!

Connect with Deana Mohr:

LinkedIn: https://www.linkedin.com/in/deana-mohr-haralampieva-95a9a5a4

MUVON Therapeutics: https://www.muvon-therapeutics.com

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15570491 Thu, 22 Aug 2024 05:00:00 +0200 1078 82 full false 81: Regenerating Muscles: The Future of Autologous Cell-based Therapy with Deana Mohr - Part 1 81: Regenerating Muscles: The Future of Autologous Cell-based Therapy with Deana Mohr - Part 1 Discover how scientists are transforming lives through innovative muscle regeneration therapy. In this captivating episode, Deana Mohr, CEO and co-founder of MUVON Therapeutics, spin-off from the University of Zurich, unveils her groundbreaking autologous muscle regeneration technology for treating stress urinary incontinence.

Learn how this minimally invasive treatment harnesses the power of a patient's own cells to restore muscle function, offering hope to millions. Diana shares her journey from PhD research to clinical trials, revealing the challenges of translating cutting-edge science into real-world treatments.

Listeners will gain insights on:

  1. The potential of autologous muscle tissue regeneration and the hurdles of medical innovation.
  2. Navigating the complex path from lab to clinic
  3. Key differences between muscle-based and CAR-T cell therapies

Whether you're a scientist, investor, or simply curious about medical innovations, this episode offers a fascinating glimpse into the future of regenerative medicine. Tune in to explore the forefront of biotech entrepreneurship!

Connect with Deana Mohr:

LinkedIn: https://www.linkedin.com/in/deana-mohr-haralampieva-95a9a5a4

MUVON Therapeutics: https://www.muvon-therapeutics.com

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Support the show

]]> Discover how scientists are transforming lives through innovative muscle regeneration therapy. In this captivating episode, Deana Mohr, CEO and co-founder of MUVON Therapeutics, spin-off from the University of Zurich, unveils her groundbreaking autologous muscle regeneration technology for treating stress urinary incontinence.

Learn how this minimally invasive treatment harnesses the power of a patient's own cells to restore muscle function, offering hope to millions. Diana shares her journey from PhD research to clinical trials, revealing the challenges of translating cutting-edge science into real-world treatments.

Listeners will gain insights on:

  1. The potential of autologous muscle tissue regeneration and the hurdles of medical innovation.
  2. Navigating the complex path from lab to clinic
  3. Key differences between muscle-based and CAR-T cell therapies

Whether you're a scientist, investor, or simply curious about medical innovations, this episode offers a fascinating glimpse into the future of regenerative medicine. Tune in to explore the forefront of biotech entrepreneurship!

Connect with Deana Mohr:

LinkedIn: https://www.linkedin.com/in/deana-mohr-haralampieva-95a9a5a4

MUVON Therapeutics: https://www.muvon-therapeutics.com

Next Steps:

Wondering how to develop cell and gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15570476 Tue, 20 Aug 2024 05:00:00 +0200 1355 81 full false 80: Think Before You Build: Holistic Approaches to Biotech Facility Design with Alfredo Martínez Mogarra - Part 2 80: Think Before You Build: Holistic Approaches to Biotech Facility Design with Alfredo Martínez Mogarra - Part 2 Ever wondered why some biotech facilities thrive while others struggle Alfredo Martínez Mogarra, a Bioprocess Engineer with over 30 years of experience and Chief Operations Manager at VIVEbiotech, reveals the secrets to successful biotech manufacturing.

In this eye-opening episode, Alfredo shares critical insights on bridging the gap between lab-scale processes and industrial production.

You will get:

  1. Strategies for seamless scale-up and risk mitigation in bioprocess development
  2. Tips for fostering crucial interdepartmental collaboration in biotech facilities
  3. Guidance on leveraging automation and AI for enhanced process control and predictability

Whether you're a biotech scientist, engineer, or industry professional, this episode is packed with invaluable wisdom to elevate your facility design and operations.

Don't miss Alfredo's golden rule: "Think very well before starting doing things." Tune in now and learn how to build a foundation for biotech success!

Connect with Alfredo Martínez Mogarra:

LinkedIn: https://www.linkedin.com/in/alfredo-martínez-mogarra-a381087

Biotech Academy in Rome: https://www.biotechacademy.eu

Next Steps:

Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Support the show

]]> Ever wondered why some biotech facilities thrive while others struggle Alfredo Martínez Mogarra, a Bioprocess Engineer with over 30 years of experience and Chief Operations Manager at VIVEbiotech, reveals the secrets to successful biotech manufacturing.

In this eye-opening episode, Alfredo shares critical insights on bridging the gap between lab-scale processes and industrial production.

You will get:

  1. Strategies for seamless scale-up and risk mitigation in bioprocess development
  2. Tips for fostering crucial interdepartmental collaboration in biotech facilities
  3. Guidance on leveraging automation and AI for enhanced process control and predictability

Whether you're a biotech scientist, engineer, or industry professional, this episode is packed with invaluable wisdom to elevate your facility design and operations.

Don't miss Alfredo's golden rule: "Think very well before starting doing things." Tune in now and learn how to build a foundation for biotech success!

Connect with Alfredo Martínez Mogarra:

LinkedIn: https://www.linkedin.com/in/alfredo-martínez-mogarra-a381087

Biotech Academy in Rome: https://www.biotechacademy.eu

Next Steps:

Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15537922 Thu, 15 Aug 2024 05:00:00 +0200 1214 80 full false 79: Think Before You Build: Holistic Approaches to Biotech Facility Design with Alfredo Martínez Mogarra - Part 1 79: Think Before You Build: Holistic Approaches to Biotech Facility Design with Alfredo Martínez Mogarra - Part 1 Ever wondered what it takes to build a large-scale biotech manufacturing facility? Alfredo Martínez Mogarra, a seasoned Bioprocess Engineer with over 30 years of experience and Chief Operations Manager at VIVEbiotech, reveals the secrets behind successful biotech facility design and scale-up. He has been at the forefront of transforming bench processes into industrial realities.

In this eye-opening episode, Alfredo shares critical insights on navigating the complex world of biotech manufacturing. Listeners will gain:

  1. A deep understanding of the key factors in designing efficient biotech facilities
  2. Strategies to mitigate risks when scaling up processes
  3. Tips for fostering successful interdisciplinary collaboration

Whether you're a biotech scientist, engineer, or industry professional, this episode is packed with invaluable wisdom to elevate your bioprocessing game.

Tune in now and learn how to think holistically about biotech facility design.

Connect with Alfredo Martínez Mogarra:

LinkedIn: https://www.linkedin.com/in/alfredo-martínez-mogarra-a381087

Biotech Academy in Rome: https://www.biotechacademy.eu

Next Steps:

Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Ever wondered what it takes to build a large-scale biotech manufacturing facility? Alfredo Martínez Mogarra, a seasoned Bioprocess Engineer with over 30 years of experience and Chief Operations Manager at VIVEbiotech, reveals the secrets behind successful biotech facility design and scale-up. He has been at the forefront of transforming bench processes into industrial realities.

In this eye-opening episode, Alfredo shares critical insights on navigating the complex world of biotech manufacturing. Listeners will gain:

  1. A deep understanding of the key factors in designing efficient biotech facilities
  2. Strategies to mitigate risks when scaling up processes
  3. Tips for fostering successful interdisciplinary collaboration

Whether you're a biotech scientist, engineer, or industry professional, this episode is packed with invaluable wisdom to elevate your bioprocessing game.

Tune in now and learn how to think holistically about biotech facility design.

Connect with Alfredo Martínez Mogarra:

LinkedIn: https://www.linkedin.com/in/alfredo-martínez-mogarra-a381087

Biotech Academy in Rome: https://www.biotechacademy.eu

Next Steps:

Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15537912 Tue, 13 Aug 2024 05:00:00 +0200 1516 79 full false 78: Cell Factories Explained: How Synthetic Biology and AI Revolutionize Protein Production with Mauro Torres - Part 2 78: Cell Factories Explained: How Synthetic Biology and AI Revolutionize Protein Production with Mauro Torres - Part 2 Unlock the secrets of cell factories and discover how cutting-edge technologies are revolutionizing biopharmaceutical production. In this episode, we welcome Mauro Torres, a postdoctoral researcher at the University of Manchester, who takes us on a fascinating journey through the complex world of protein manufacturing.

Mauro Torres explains the intricate steps involved in the secretory pathway, from gene expression to protein export, likening it to a sophisticated car manufacturing process. He then delves into how omics technologies and systems-level approaches are enhancing our understanding of cell physiology and improving production effectiveness.

Listeners will gain valuable insights into:

  1. The potential of AI and machine learning to navigate vast amounts of bioprocess data
  2. How synthetic biology is creating cells with new functionalities and improved adaptability
  3. The exciting future of biopharmaceutical production as technologies converge

Discover how these advancements are paving the way for more predictable, affordable, and robust medicine production, promising a brighter future for patients worldwide.

Connect with Mauro Torres:

Linkedin: https://www.linkedin.com/in/mauro-torres-seb

Next Steps:

Book a free assessment to help you develop biologics with peace of mind: https://bruehlmann-consulting.com

Support the show

]]> Unlock the secrets of cell factories and discover how cutting-edge technologies are revolutionizing biopharmaceutical production. In this episode, we welcome Mauro Torres, a postdoctoral researcher at the University of Manchester, who takes us on a fascinating journey through the complex world of protein manufacturing.

Mauro Torres explains the intricate steps involved in the secretory pathway, from gene expression to protein export, likening it to a sophisticated car manufacturing process. He then delves into how omics technologies and systems-level approaches are enhancing our understanding of cell physiology and improving production effectiveness.

Listeners will gain valuable insights into:

  1. The potential of AI and machine learning to navigate vast amounts of bioprocess data
  2. How synthetic biology is creating cells with new functionalities and improved adaptability
  3. The exciting future of biopharmaceutical production as technologies converge

Discover how these advancements are paving the way for more predictable, affordable, and robust medicine production, promising a brighter future for patients worldwide.

Connect with Mauro Torres:

Linkedin: https://www.linkedin.com/in/mauro-torres-seb

Next Steps:

Book a free assessment to help you develop biologics with peace of mind: https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15513055 Thu, 08 Aug 2024 05:00:00 +0200 1090 78 full false 77: Cell Factories Explained: How Synthetic Biology and AI Revolutionize Protein Production with Mauro Torres - Part 1 77: Cell Factories Explained: How Synthetic Biology and AI Revolutionize Protein Production with Mauro Torres - Part 1 Unlock the secrets of cell factories with Mauro Torres, a postdoctoral researcher at the University of Manchester who brings cutting-edge insights into protein production. Discover how the concept of cell factories has evolved from basic insulin extraction to groundbreaking treatments for genetic disorders and cancer. We reveal the challenges faced by biotech scientists in bioprocess development and offers a fascinating analogy between car manufacturing and cellular protein assembly.

Learn how recent advancements in synthetic biology, genetic editing, and AI-driven process optimization are transforming the biopharmaceutical industry. From transposon technology to microfluidics and hybrid modeling, We explore the game-changing innovations that are accelerating cell line development and enhancing protein secretion.

Gain valuable insights into:

  1. The evolution of cell factories
  2. Cutting-edge technologies revolutionizing bioprocessing
  3. Strategies for reprogramming cells for enhanced protein production

Don't miss this episode packed with expert knowledge on the future of biomanufacturing.

Connect with Mauro Torres:

Linkedin: https://www.linkedin.com/in/mauro-torres-seb

Next Steps:

Book a free assessment to help you develop biologics with peace of mind: https://bruehlmann-consulting.com

Support the show

]]> Unlock the secrets of cell factories with Mauro Torres, a postdoctoral researcher at the University of Manchester who brings cutting-edge insights into protein production. Discover how the concept of cell factories has evolved from basic insulin extraction to groundbreaking treatments for genetic disorders and cancer. We reveal the challenges faced by biotech scientists in bioprocess development and offers a fascinating analogy between car manufacturing and cellular protein assembly.

Learn how recent advancements in synthetic biology, genetic editing, and AI-driven process optimization are transforming the biopharmaceutical industry. From transposon technology to microfluidics and hybrid modeling, We explore the game-changing innovations that are accelerating cell line development and enhancing protein secretion.

Gain valuable insights into:

  1. The evolution of cell factories
  2. Cutting-edge technologies revolutionizing bioprocessing
  3. Strategies for reprogramming cells for enhanced protein production

Don't miss this episode packed with expert knowledge on the future of biomanufacturing.

Connect with Mauro Torres:

Linkedin: https://www.linkedin.com/in/mauro-torres-seb

Next Steps:

Book a free assessment to help you develop biologics with peace of mind: https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15513461 Tue, 06 Aug 2024 05:00:00 +0200 1380 77 full false 76: Transforming Single-Cell Analysis With Impedance Flow Cytometry w/ Furkan Gökçe - Part 2 76: Transforming Single-Cell Analysis With Impedance Flow Cytometry w/ Furkan Gökçe - Part 2 Curious about the latest innovations in cell analysis technology? Join us in this episode with Furkan Gökçe, New Business Development Manager at Amphasys, as we delve into the fascinating world of Impedance Flow Cytometry (IFC).

Furkan shares how IFC is revolutionizing single-cell analysis by providing faster, more precise, and high-resolution data.

Key Takeaways:

  1. Real-Time Precision: Discover how IFC allows for real-time, label-free assessments of cells, providing detailed insights into their natural state.
  2. Enhanced Process Control: Learn how IFC can detect early signs of nutrient deficiencies and contaminants, leading to timely interventions and improved bioreactor outcomes.
  3. Versatile Applications: Hear about practical applications, from brewing to protein production, where IFC has significantly boosted yields and process efficiency.

Tune in to uncover how IFC is set to transform the landscape of bioprocessing, ensuring better quality and sustainability in biologics production.

Connect with Furkan Gökçe:

LinkedIn: https://www.linkedin.com/in/furkangokce

Amphasys: https://amphasys.com/bioprocessing

Next Steps:

Book a free assessment to help you get started with the implementation of new technologies in your manufacturing processes: https://bruehlmann-consulting.com

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Curious about the latest innovations in cell analysis technology? Join us in this episode with Furkan Gökçe, New Business Development Manager at Amphasys, as we delve into the fascinating world of Impedance Flow Cytometry (IFC).

Furkan shares how IFC is revolutionizing single-cell analysis by providing faster, more precise, and high-resolution data.

Key Takeaways:

  1. Real-Time Precision: Discover how IFC allows for real-time, label-free assessments of cells, providing detailed insights into their natural state.
  2. Enhanced Process Control: Learn how IFC can detect early signs of nutrient deficiencies and contaminants, leading to timely interventions and improved bioreactor outcomes.
  3. Versatile Applications: Hear about practical applications, from brewing to protein production, where IFC has significantly boosted yields and process efficiency.

Tune in to uncover how IFC is set to transform the landscape of bioprocessing, ensuring better quality and sustainability in biologics production.

Connect with Furkan Gökçe:

LinkedIn: https://www.linkedin.com/in/furkangokce

Amphasys: https://amphasys.com/bioprocessing

Next Steps:

Book a free assessment to help you get started with the implementation of new technologies in your manufacturing processes: https://bruehlmann-consulting.com

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15453557 Thu, 01 Aug 2024 05:00:00 +0200 1461 76 full false 75: Transforming Single-Cell Analysis With Impedance Flow Cytometry w/ Furkan Gökçe - Part 1 75: Transforming Single-Cell Analysis With Impedance Flow Cytometry w/ Furkan Gökçe - Part 1 Ever wondered how single-cell analysis could revolutionize bioprocessing? Join us in this episode as we delve into the cutting-edge world of impedance flow cytometry.

Furkan Gökçe, New Business Development Manager at Amphasys, shares his insights on the transformative power of this technology in the biotech industry. With a background in engineering and physics, Furkan provides a unique perspective on tackling the complexities of biological systems.

Key Takeaways:

  1. Enhanced Process Control: Learn how impedance flow cytometry offers high-resolution, label-free analysis of individual cells, ensuring optimal growth conditions and quality production.
  2. Understanding Cell Heterogeneity: Discover the importance of single-cell analysis in revealing critical variations within cell populations that bulk measurements often miss.
  3. Innovation in Bioprocessing: Explore the advancements in microfabrication techniques that make real-time, high-throughput cell analysis possible, revolutionizing bioprocessing efficiency and accuracy.

Tune in to gain valuable knowledge on how this innovative technology can enhance your bioprocess development and manufacturing strategies!

Connect with Furkan Gökçe:

LinkedIn: https://www.linkedin.com/in/furkangokce

Amphasys: https://amphasys.com/bioprocessing

Next Steps:

Book a free assessment to help you get started with the implementation of new technologies in your manufacturing processes: https://bruehlmann-consulting.com

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Support the show

]]> Ever wondered how single-cell analysis could revolutionize bioprocessing? Join us in this episode as we delve into the cutting-edge world of impedance flow cytometry.

Furkan Gökçe, New Business Development Manager at Amphasys, shares his insights on the transformative power of this technology in the biotech industry. With a background in engineering and physics, Furkan provides a unique perspective on tackling the complexities of biological systems.

Key Takeaways:

  1. Enhanced Process Control: Learn how impedance flow cytometry offers high-resolution, label-free analysis of individual cells, ensuring optimal growth conditions and quality production.
  2. Understanding Cell Heterogeneity: Discover the importance of single-cell analysis in revealing critical variations within cell populations that bulk measurements often miss.
  3. Innovation in Bioprocessing: Explore the advancements in microfabrication techniques that make real-time, high-throughput cell analysis possible, revolutionizing bioprocessing efficiency and accuracy.

Tune in to gain valuable knowledge on how this innovative technology can enhance your bioprocess development and manufacturing strategies!

Connect with Furkan Gökçe:

LinkedIn: https://www.linkedin.com/in/furkangokce

Amphasys: https://amphasys.com/bioprocessing

Next Steps:

Book a free assessment to help you get started with the implementation of new technologies in your manufacturing processes: https://bruehlmann-consulting.com

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15453535 Tue, 30 Jul 2024 05:00:00 +0200 1044 75 full false 74: Bead-Based Assays: The Power of High-Throughput Screening w/ Sebastian Giehring - Part 2 74: Bead-Based Assays: The Power of High-Throughput Screening w/ Sebastian Giehring - Part 2 Dive into the transformative world of bead-based assays with Sebastian Giehring, CEO and founder of PAIA Biotech, where high-throughput screening meets cutting-edge biotechnological advancements.

Join us as we chat with Sebastian, a seasoned scientist and entrepreneur who has revolutionized the workflow of high-throughput screening of titer, glycosylation, and aggregation with innovative bead-based assays.

Key Takeaways:

  1. Streamlined Workflow: Learn how a simplified sample prep can enhance efficiency and accuracy in glycosylation and aggregation screenings.
  2. Optimized Experiment Design: Discover the critical do's and don'ts in designing robust experiments that yield meaningful results.
  3. Future of Screening: Explore how AI and machine learning are set to revolutionize the biotechnological landscape, driving better drug development and process optimization.

Tune in to uncover how these insights can transform your lab's capabilities and drive groundbreaking discoveries!

Connect with Sebastian Giehring:

LinkedIn: https://www.linkedin.com/in/sebastian-giehring-6ba1992

PAIA Biotech: https://www.paiabio.com

Next Steps:

Book a free assessment to help you get started with the design of your next experiment at https://bruehlmann-consulting.com

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Support the show

]]> Dive into the transformative world of bead-based assays with Sebastian Giehring, CEO and founder of PAIA Biotech, where high-throughput screening meets cutting-edge biotechnological advancements.

Join us as we chat with Sebastian, a seasoned scientist and entrepreneur who has revolutionized the workflow of high-throughput screening of titer, glycosylation, and aggregation with innovative bead-based assays.

Key Takeaways:

  1. Streamlined Workflow: Learn how a simplified sample prep can enhance efficiency and accuracy in glycosylation and aggregation screenings.
  2. Optimized Experiment Design: Discover the critical do's and don'ts in designing robust experiments that yield meaningful results.
  3. Future of Screening: Explore how AI and machine learning are set to revolutionize the biotechnological landscape, driving better drug development and process optimization.

Tune in to uncover how these insights can transform your lab's capabilities and drive groundbreaking discoveries!

Connect with Sebastian Giehring:

LinkedIn: https://www.linkedin.com/in/sebastian-giehring-6ba1992

PAIA Biotech: https://www.paiabio.com

Next Steps:

Book a free assessment to help you get started with the design of your next experiment at https://bruehlmann-consulting.com

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15428641 Thu, 25 Jul 2024 05:00:00 +0200 1037 74 full false 73: Bead-Based Assays: The Power of High-Throughput Screening w/ Sebastian Giehring - Part 1 73: Bead-Based Assays: The Power of High-Throughput Screening w/ Sebastian Giehring - Part 1 Ready to revolutionize your lab work? Join us as we dive deep into bead-based assays with Sebastian Giehring, CEO and founder of PAIA Biotech.

Discover how these tiny beads are making a massive impact on biotech research and development — for titer, glycan, and aggreation screening — and how this developability screening platform can enhance your antibody discovery, antibody engineering and lead optimization.

In this episode, you’ll learn:

  1. Speed and Simplicity: How bead-based assays offer unmatched throughput and ease of use, allowing you to analyze hundreds of samples in just a few steps.
  2. Versatile Applications: The diverse applications of bead-based assays in cell development, bioprocessing, and antibody discovery, helping streamline workflows and enhance innovation.
  3. Early Screening Advantages: The benefits of bead-based assays in early-stage process development, enabling quick decision-making with less detailed but rapid results.

Tune in to uncover how these assays can transform your biotech research and push the boundaries of what's possible!

Connect with Sebastian Giehring:

LinkedIn: https://www.linkedin.com/in/sebastian-giehring-6ba1992

PAIA Biotech: https://www.paiabio.com

Next Steps:

Book a free assessment to help you get started with the design of your next experiment at https://bruehlmann-consulting.com

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Support the show

]]> Ready to revolutionize your lab work? Join us as we dive deep into bead-based assays with Sebastian Giehring, CEO and founder of PAIA Biotech.

Discover how these tiny beads are making a massive impact on biotech research and development — for titer, glycan, and aggreation screening — and how this developability screening platform can enhance your antibody discovery, antibody engineering and lead optimization.

In this episode, you’ll learn:

  1. Speed and Simplicity: How bead-based assays offer unmatched throughput and ease of use, allowing you to analyze hundreds of samples in just a few steps.
  2. Versatile Applications: The diverse applications of bead-based assays in cell development, bioprocessing, and antibody discovery, helping streamline workflows and enhance innovation.
  3. Early Screening Advantages: The benefits of bead-based assays in early-stage process development, enabling quick decision-making with less detailed but rapid results.

Tune in to uncover how these assays can transform your biotech research and push the boundaries of what's possible!

Connect with Sebastian Giehring:

LinkedIn: https://www.linkedin.com/in/sebastian-giehring-6ba1992

PAIA Biotech: https://www.paiabio.com

Next Steps:

Book a free assessment to help you get started with the design of your next experiment at https://bruehlmann-consulting.com

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15428635 Tue, 23 Jul 2024 05:00:00 +0200 1158 73 full false 72: Effective Outsourcing: How Small Biotech Companies Can Thrive w/ Mark Melville - Part 2 72: Effective Outsourcing: How Small Biotech Companies Can Thrive w/ Mark Melville - Part 2 How do small biotech companies make strategic decisions with limited resources? This episode dives deep into the art of prioritization and outsourcing to achieve success.

Join us as we speak with Mark Melville, Vice President of CMC, Biologics at Cullinan Therapeutics, a seasoned biotech scientist with years of experience in both large and small biotech companies. Mark shares his invaluable insights on navigating the complexities of bioprocess development and outsourcing.

In this episode, we explore:

  1. Discover the secrets to prioritizing projects for maximum impact
  2. Leverage outsourcing for flexibility and expertise
  3. Learn to build strong relationships with external vendors to ensure top-notch quality and regulatory compliance.

Connect with Mark Melville:

LinkedIn: https://www.linkedin.com/in/mark-melville-a9a43b2

Next Steps:

Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Support the show

]]> How do small biotech companies make strategic decisions with limited resources? This episode dives deep into the art of prioritization and outsourcing to achieve success.

Join us as we speak with Mark Melville, Vice President of CMC, Biologics at Cullinan Therapeutics, a seasoned biotech scientist with years of experience in both large and small biotech companies. Mark shares his invaluable insights on navigating the complexities of bioprocess development and outsourcing.

In this episode, we explore:

  1. Discover the secrets to prioritizing projects for maximum impact
  2. Leverage outsourcing for flexibility and expertise
  3. Learn to build strong relationships with external vendors to ensure top-notch quality and regulatory compliance.

Connect with Mark Melville:

LinkedIn: https://www.linkedin.com/in/mark-melville-a9a43b2

Next Steps:

Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15397058 Thu, 18 Jul 2024 05:00:00 +0200 1319 72 full false 71: Effective Outsourcing: How Small Biotech Companies Can Thrive w/ Mark Melville - Part 1 71: Effective Outsourcing: How Small Biotech Companies Can Thrive w/ Mark Melville - Part 1 Are you navigating the complex world of bioprocess CMC development and manufacturing in a small biotech company?

Our latest episode is a must-listen! Join us as we sit down with Mark Melville, Vice President of CMC, Biologics at Cullinan Therapeutics, who shares invaluable insights on overcoming the unique challenges faced by small biotech firms.

In this episode, we explore:

  1. The critical communication strategies needed for successful outsourcing to CDMOs.
  2. How small biotechs can leverage their agility to make fast, impactful decisions.
  3. The surprising benefits of wearing multiple hats and fostering cross-functional expertise.

Tune in to discover how mastering these areas can help your small biotech thrive and stay ahead in a competitive market.

Don't miss this opportunity to gain practical advice and turn your challenges into advantages!

Connect with Mark Melville:

LinkedIn: https://www.linkedin.com/in/mark-melville-a9a43b2

Next Steps:

Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Support the show

]]> Are you navigating the complex world of bioprocess CMC development and manufacturing in a small biotech company?

Our latest episode is a must-listen! Join us as we sit down with Mark Melville, Vice President of CMC, Biologics at Cullinan Therapeutics, who shares invaluable insights on overcoming the unique challenges faced by small biotech firms.

In this episode, we explore:

  1. The critical communication strategies needed for successful outsourcing to CDMOs.
  2. How small biotechs can leverage their agility to make fast, impactful decisions.
  3. The surprising benefits of wearing multiple hats and fostering cross-functional expertise.

Tune in to discover how mastering these areas can help your small biotech thrive and stay ahead in a competitive market.

Don't miss this opportunity to gain practical advice and turn your challenges into advantages!

Connect with Mark Melville:

LinkedIn: https://www.linkedin.com/in/mark-melville-a9a43b2

Next Steps:

Wondering how to develop biologics with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15397049 Tue, 16 Jul 2024 05:00:00 +0200 1112 71 full false 70: Glycoanalytics Explained: Analysing and Designing Better Biopharmaceutical Drugs w/ Róisín O’Flaherty - Part 2 70: Glycoanalytics Explained: Analysing and Designing Better Biopharmaceutical Drugs w/ Róisín O’Flaherty - Part 2 In this insightful episode, we explore the cutting-edge field of glycoengineering and its transformative impact on biopharmaceutical drug design. Join us as we chat with Róisín O’Flaherty, Assistant Professor in the Department of Chemistry at Maynooth University, to uncover the nuances of chemoenzymatic glycogen engineering and its potential to revolutionize therapeutics.

Key Takeaways:

  1. Understanding Glycoengineering: Discover the three main approaches—genetic, metabolomic, and chemoenzymatic—for modifying glycosylation and enhancing drug properties.
  2. Real-World Applications: Learn how industry giants are leveraging glycoengineering to innovate cancer treatments and other therapies.
  3. Future of Glycoanalytics: Explore how AI and machine learning are poised to further advance the precision and efficiency of glycoengineering.

Don't miss this deep dive into how glycoanalytics is paving the way for more effective and personalized biopharmaceutical drugs. Tune in to understand the future of drug design and the exciting possibilities it holds.

Connect with Róisín O’Flaherty:

LinkedIn: https://www.linkedin.com/in/roisin-o-flaherty-a67a2b8a

Twitter: https://x.com/irishglycogirl

Next Steps:

Book a free assessment to help you get started with glycoanalytics and glycoengineering at https://bruehlmann-consulting.com

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Support the show

]]> In this insightful episode, we explore the cutting-edge field of glycoengineering and its transformative impact on biopharmaceutical drug design. Join us as we chat with Róisín O’Flaherty, Assistant Professor in the Department of Chemistry at Maynooth University, to uncover the nuances of chemoenzymatic glycogen engineering and its potential to revolutionize therapeutics.

Key Takeaways:

  1. Understanding Glycoengineering: Discover the three main approaches—genetic, metabolomic, and chemoenzymatic—for modifying glycosylation and enhancing drug properties.
  2. Real-World Applications: Learn how industry giants are leveraging glycoengineering to innovate cancer treatments and other therapies.
  3. Future of Glycoanalytics: Explore how AI and machine learning are poised to further advance the precision and efficiency of glycoengineering.

Don't miss this deep dive into how glycoanalytics is paving the way for more effective and personalized biopharmaceutical drugs. Tune in to understand the future of drug design and the exciting possibilities it holds.

Connect with Róisín O’Flaherty:

LinkedIn: https://www.linkedin.com/in/roisin-o-flaherty-a67a2b8a

Twitter: https://x.com/irishglycogirl

Next Steps:

Book a free assessment to help you get started with glycoanalytics and glycoengineering at https://bruehlmann-consulting.com

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15339322 Thu, 11 Jul 2024 05:00:00 +0200 931 70 full false 69: Glycoanalytics Explained: Analysing and Designing Better Biopharmaceutical Drugs w/ Róisín O’Flaherty - Part 1 69: Glycoanalytics Explained: Analysing and Designing Better Biopharmaceutical Drugs w/ Róisín O’Flaherty - Part 1 Uncover the hidden science behind creating safer, more effective biological drugs! Dive into glycoanalytics and glycoengineering, the secret weapons revolutionizing biopharma.

Join us as we talk with Róisín O’Flaherty, Assistant Professor in the Department of Chemistry at Maynooth University, who breaks down the complexities of glycosylation and its pivotal role in drug development.

Key Takeaways:

  1. Critical Quality Attributes: Understand how glycans influence the function and structure of biopharmaceutical products, enhancing their efficacy and safety.
  2. Analytical Techniques: Learn about the three major approaches—native glycoprotein analysis, glycopeptide analysis, and released glycan analysis—each providing unique insights into glycosylation.
  3. Future Trends: Discover how automation, AI, and advanced mass spectrometry are revolutionizing glycoanalytics, making it more accessible and precise.

Tune in to explore how glycoanalytics is driving the next generation of safer, more effective biopharmaceuticals!

Connect with Róisín O’Flaherty:

LinkedIn: https://www.linkedin.com/in/roisin-o-flaherty-a67a2b8a

Twitter: https://x.com/irishglycogirl

Next Steps:

Book a free assessment to help you get started with glycoanalytics and glycoengineering at https://bruehlmann-consulting.com

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Support the show

]]> Uncover the hidden science behind creating safer, more effective biological drugs! Dive into glycoanalytics and glycoengineering, the secret weapons revolutionizing biopharma.

Join us as we talk with Róisín O’Flaherty, Assistant Professor in the Department of Chemistry at Maynooth University, who breaks down the complexities of glycosylation and its pivotal role in drug development.

Key Takeaways:

  1. Critical Quality Attributes: Understand how glycans influence the function and structure of biopharmaceutical products, enhancing their efficacy and safety.
  2. Analytical Techniques: Learn about the three major approaches—native glycoprotein analysis, glycopeptide analysis, and released glycan analysis—each providing unique insights into glycosylation.
  3. Future Trends: Discover how automation, AI, and advanced mass spectrometry are revolutionizing glycoanalytics, making it more accessible and precise.

Tune in to explore how glycoanalytics is driving the next generation of safer, more effective biopharmaceuticals!

Connect with Róisín O’Flaherty:

LinkedIn: https://www.linkedin.com/in/roisin-o-flaherty-a67a2b8a

Twitter: https://x.com/irishglycogirl

Next Steps:

Book a free assessment to help you get started with glycoanalytics and glycoengineering at https://bruehlmann-consulting.com

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at hello@bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15339317 Tue, 09 Jul 2024 05:00:00 +0200 1089 69 full false 68: How Process Mapping Transforms Knowledge Management in Biotech w/ Irwin Hirsh - Part 2 68: How Process Mapping Transforms Knowledge Management in Biotech w/ Irwin Hirsh - Part 2 Join us as we explore the pivotal role of process mapping in biotech knowledge management. Our guest, Irwin Hirsh, a seasoned biotech consultant concentrating on enhancing business efficiency and effectiveness, shares invaluable insights into leveraging technology to streamline operations.

Key Insights:

  1. Identifying Critical Process Knowledge: Learn strategies to identify and manage vital process knowledge essential for optimal performance.
  2. Transitioning from Implicit to Explicit Knowledge: Discover why converting hidden, tribal wisdom into structured, accessible information is crucial for scalability and continuity.
  3. Harnessing Digital Tools: Explore effective approaches to digital transformation, ensuring seamless integration and collaboration across teams and time zones.

Join us as Irwin uncovers actionable steps to enhance efficiency and innovation in biotech through strategic process mapping.

Connect with Irwin Hirsh:

LinkedIn: https://www.linkedin.com/in/ishirsh

Q-Specialists AB: https://www.qspecialists.com

Next Steps:

Wondering how to develop biologics and cell & gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Join us as we explore the pivotal role of process mapping in biotech knowledge management. Our guest, Irwin Hirsh, a seasoned biotech consultant concentrating on enhancing business efficiency and effectiveness, shares invaluable insights into leveraging technology to streamline operations.

Key Insights:

  1. Identifying Critical Process Knowledge: Learn strategies to identify and manage vital process knowledge essential for optimal performance.
  2. Transitioning from Implicit to Explicit Knowledge: Discover why converting hidden, tribal wisdom into structured, accessible information is crucial for scalability and continuity.
  3. Harnessing Digital Tools: Explore effective approaches to digital transformation, ensuring seamless integration and collaboration across teams and time zones.

Join us as Irwin uncovers actionable steps to enhance efficiency and innovation in biotech through strategic process mapping.

Connect with Irwin Hirsh:

LinkedIn: https://www.linkedin.com/in/ishirsh

Q-Specialists AB: https://www.qspecialists.com

Next Steps:

Wondering how to develop biologics and cell & gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15267703 Thu, 04 Jul 2024 05:00:00 +0200 1784 68 full false 67: How Process Mapping Transforms Knowledge Management in Biotech w/ Irwin Hirsh - Part 1 67: How Process Mapping Transforms Knowledge Management in Biotech w/ Irwin Hirsh - Part 1 Want to turn your biotech chaos into streamlined success? Learn from expert Irwin Hirsh, a seasoned biotech consultant concentrating on enhancing business efficiency and effectiveness, on how process mapping can transform your knowledge management and elevate your business performance.

Key Takeaways:

  1. Eliminate Scope Creep: Learn how to maintain focus in projects despite shifts and changes, improving productivity and reducing frustration.
  2. Bridge Experience Gaps: Understand how process mapping creates a common language, enabling seamless knowledge transfer between seasoned experts and newcomers.
  3. Enhance Systematic Approach: Discover the power of standardization and continuous improvement to boost overall business performance.

Tune in to uncover practical strategies that can transform your knowledge management practices and drive your biotech endeavors to new heights.

Connect with Irwin Hirsh:

LinkedIn: https://www.linkedin.com/in/ishirsh

Q-Specialists AB: https://www.qspecialists.com

Next Steps:

Wondering how to develop biologics and cell & gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Support the show

]]> Want to turn your biotech chaos into streamlined success? Learn from expert Irwin Hirsh, a seasoned biotech consultant concentrating on enhancing business efficiency and effectiveness, on how process mapping can transform your knowledge management and elevate your business performance.

Key Takeaways:

  1. Eliminate Scope Creep: Learn how to maintain focus in projects despite shifts and changes, improving productivity and reducing frustration.
  2. Bridge Experience Gaps: Understand how process mapping creates a common language, enabling seamless knowledge transfer between seasoned experts and newcomers.
  3. Enhance Systematic Approach: Discover the power of standardization and continuous improvement to boost overall business performance.

Tune in to uncover practical strategies that can transform your knowledge management practices and drive your biotech endeavors to new heights.

Connect with Irwin Hirsh:

LinkedIn: https://www.linkedin.com/in/ishirsh

Q-Specialists AB: https://www.qspecialists.com

Next Steps:

Wondering how to develop biologics and cell & gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15267698 Tue, 02 Jul 2024 05:00:00 +0200 862 67 full false 66: Freezing and Thawing Cells: the Science Behind Cryopreservation w/ Mark Davison - Part 2 66: Freezing and Thawing Cells: the Science Behind Cryopreservation w/ Mark Davison - Part 2 Get ready to dive into the fascinating world of cryopreservation!

In this episode, we welcome Mark Davison, an experienced entrepreneur and CEO of Grant Instruments, leaders in laboratory equipment, to explore the intricate science of freezing and thawing cells.

Mark brings his wealth of experience to demystify this crucial process, revealing how cutting-edge technology ensures precision and reliability in preserving biological samples.

Key Takeaways:

  1. Mastering Precision: Learn how data acquisition and controlled rate freezing are essential to maintaining the integrity of your samples.
  2. Technological Advancements: Discover the latest innovations transforming laboratory practices, from analog to digital conversions to remote monitoring.
  3. Entrepreneurial Insights: Gain valuable advice on leveraging support systems and cultivating a collaborative culture to succeed in scientific entrepreneurship.

Tune in for an insightful conversation that blends technical expertise with practical advice, perfect for scientists and entrepreneurs alike!

Connect with Mark Davison:

LinkedIn: https://www.linkedin.com/in/markdavison100

The Big Experiment podcast: https://thebigexperiment.buzzsprout.com

Grant Instruments: https://www.grantinstruments.com

Next Steps:

Wondering how to develop biologics and cell & gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Support the show

]]> Get ready to dive into the fascinating world of cryopreservation!

In this episode, we welcome Mark Davison, an experienced entrepreneur and CEO of Grant Instruments, leaders in laboratory equipment, to explore the intricate science of freezing and thawing cells.

Mark brings his wealth of experience to demystify this crucial process, revealing how cutting-edge technology ensures precision and reliability in preserving biological samples.

Key Takeaways:

  1. Mastering Precision: Learn how data acquisition and controlled rate freezing are essential to maintaining the integrity of your samples.
  2. Technological Advancements: Discover the latest innovations transforming laboratory practices, from analog to digital conversions to remote monitoring.
  3. Entrepreneurial Insights: Gain valuable advice on leveraging support systems and cultivating a collaborative culture to succeed in scientific entrepreneurship.

Tune in for an insightful conversation that blends technical expertise with practical advice, perfect for scientists and entrepreneurs alike!

Connect with Mark Davison:

LinkedIn: https://www.linkedin.com/in/markdavison100

The Big Experiment podcast: https://thebigexperiment.buzzsprout.com

Grant Instruments: https://www.grantinstruments.com

Next Steps:

Wondering how to develop biologics and cell & gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15267683 Thu, 27 Jun 2024 05:00:00 +0200 968 66 full false 65: Freezing and Thawing Cells: the Science Behind Cryopreservation w/ Mark Davison - Part 1 65: Freezing and Thawing Cells: the Science Behind Cryopreservation w/ Mark Davison - Part 1 Picture a world where we can freeze cells and bring them back to life perfectly intact.

In this episode, we're joined by Mark Davison, a leading expert in cryopreservation and CEO of Grant Instruments to uncover the intricate science of freezing and thawing cells. From basic principles to advanced techniques, we delve into how cryopreservation is revolutionizing biotechnology and cell therapies.

Key Takeaways:

  1. Cell Survival Secrets: Discover why water is both a friend and foe in preserving cell viability, and how precise control over freezing rates can prevent cell damage.
  2. Advanced Techniques: Learn about cutting-edge technologies that ensure safe and effective cryopreservation, minimizing risks associated with traditional methods like liquid nitrogen.
  3. Automation in Cryopreservation: Understand the future of lab workflows with automation, reducing human error and increasing reproducibility in cell-based experiments.

Tune in to explore how cryopreservation is shaping the future of biotech!

Connect with Mark Davison:

LinkedIn: https://www.linkedin.com/in/markdavison100

The Big Experiment podcast: https://thebigexperiment.buzzsprout.com

Grant Instruments: https://www.grantinstruments.com

Next Steps:

Wondering how to develop biologics and cell & gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Picture a world where we can freeze cells and bring them back to life perfectly intact.

In this episode, we're joined by Mark Davison, a leading expert in cryopreservation and CEO of Grant Instruments to uncover the intricate science of freezing and thawing cells. From basic principles to advanced techniques, we delve into how cryopreservation is revolutionizing biotechnology and cell therapies.

Key Takeaways:

  1. Cell Survival Secrets: Discover why water is both a friend and foe in preserving cell viability, and how precise control over freezing rates can prevent cell damage.
  2. Advanced Techniques: Learn about cutting-edge technologies that ensure safe and effective cryopreservation, minimizing risks associated with traditional methods like liquid nitrogen.
  3. Automation in Cryopreservation: Understand the future of lab workflows with automation, reducing human error and increasing reproducibility in cell-based experiments.

Tune in to explore how cryopreservation is shaping the future of biotech!

Connect with Mark Davison:

LinkedIn: https://www.linkedin.com/in/markdavison100

The Big Experiment podcast: https://thebigexperiment.buzzsprout.com

Grant Instruments: https://www.grantinstruments.com

Next Steps:

Wondering how to develop biologics and cell & gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15267675 Tue, 25 Jun 2024 05:00:00 +0200 1506 65 full false 64: Why Sound Waves Are the Future of Gene Therapy Bioreactors w/ Gabriel Dumy - Part 2 64: Why Sound Waves Are the Future of Gene Therapy Bioreactors w/ Gabriel Dumy - Part 2 Could sound waves be the revolutionary key to gene therapy manufacturing? In this episode, Gabriel Dumy, CTO and Co-founder at Kolibri, reveals how acoustic waves are set to transform cell harvesting and gene transfection processes, making biomanufacturing more efficient and less damaging to cells.

Kolibri is a company revolutionizing the way we grow and engineer cells at scale using acoustic waves.

Key Takeaways:

  1. Real-Time Cell Harvesting: Discover how reconfigurable acoustic waves enable non-damaging, precise cell harvesting without the need for harsh chemicals.
  2. Enhanced Gene Transfection: Learn about breakthrough methods to make cell membranes more permeable, dramatically improving the efficiency of gene delivery.
  3. Scalable Bioproduction: Understand the scalable potential of acoustic waves in bioreactors, offering innovative solutions for complex tissue engineering and fragile cell growth.

Join us to explore how these advancements could revolutionize the future of gene therapy and beyond!

Connect with Gabriel Dumy

LinkedIn: https://www.linkedin.com/in/gabrieldumy

Kolibri: https://www.kolibrilab.com

Next Steps:

Wondering how to develop biologics and cell & gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Support the show

]]> Could sound waves be the revolutionary key to gene therapy manufacturing? In this episode, Gabriel Dumy, CTO and Co-founder at Kolibri, reveals how acoustic waves are set to transform cell harvesting and gene transfection processes, making biomanufacturing more efficient and less damaging to cells.

Kolibri is a company revolutionizing the way we grow and engineer cells at scale using acoustic waves.

Key Takeaways:

  1. Real-Time Cell Harvesting: Discover how reconfigurable acoustic waves enable non-damaging, precise cell harvesting without the need for harsh chemicals.
  2. Enhanced Gene Transfection: Learn about breakthrough methods to make cell membranes more permeable, dramatically improving the efficiency of gene delivery.
  3. Scalable Bioproduction: Understand the scalable potential of acoustic waves in bioreactors, offering innovative solutions for complex tissue engineering and fragile cell growth.

Join us to explore how these advancements could revolutionize the future of gene therapy and beyond!

Connect with Gabriel Dumy

LinkedIn: https://www.linkedin.com/in/gabrieldumy

Kolibri: https://www.kolibrilab.com

Next Steps:

Wondering how to develop biologics and cell & gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15196709 Thu, 20 Jun 2024 05:00:00 +0200 1312 64 full false 63: Why Sound Waves Are the Future of Gene Therapy Bioreactors w/ Gabriel Dumy - Part 1 63: Why Sound Waves Are the Future of Gene Therapy Bioreactors w/ Gabriel Dumy - Part 1 Are sound waves the key to revolutionizing gene therapy? In this groundbreaking episode, we sit down with Gabriel Dumy, CTO and Co-founder at Kolibri, a company revolutionizing the way we grow and engineer cells at scale using acoustic waves.

Gabriel shares the challenges facing modern bioproduction and unveils an exciting solution that's setting the stage for the future of gene therapy.

Key Takeaways:

  1. Enhanced Cell Productivity: Discover how acoustic waves minimize shear stress, significantly boosting mammalian cell productivity and density.
  2. Versatile Bioreactor Design: Learn about a cell-agnostic technology that seamlessly adapts to various cell lines, simplifying process development.
  3. Scalable Innovation: Understand the potential of this scalable tech to maintain consistent microenvironments, paving the way for large-scale gene therapy production.

Tune in to find out how acoustic waves could be the breakthrough gene therapy has been waiting for!

Connect with Gabriel Dumy

LinkedIn: https://www.linkedin.com/in/gabrieldumy

Kolibri: https://www.kolibrilab.com

Next Steps:

Wondering how to develop biologics and cell & gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Are sound waves the key to revolutionizing gene therapy? In this groundbreaking episode, we sit down with Gabriel Dumy, CTO and Co-founder at Kolibri, a company revolutionizing the way we grow and engineer cells at scale using acoustic waves.

Gabriel shares the challenges facing modern bioproduction and unveils an exciting solution that's setting the stage for the future of gene therapy.

Key Takeaways:

  1. Enhanced Cell Productivity: Discover how acoustic waves minimize shear stress, significantly boosting mammalian cell productivity and density.
  2. Versatile Bioreactor Design: Learn about a cell-agnostic technology that seamlessly adapts to various cell lines, simplifying process development.
  3. Scalable Innovation: Understand the potential of this scalable tech to maintain consistent microenvironments, paving the way for large-scale gene therapy production.

Tune in to find out how acoustic waves could be the breakthrough gene therapy has been waiting for!

Connect with Gabriel Dumy

LinkedIn: https://www.linkedin.com/in/gabrieldumy

Kolibri: https://www.kolibrilab.com

Next Steps:

Wondering how to develop biologics and cell & gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Develop biologics better, faster, at a fraction of the cost with our Fractional CTO services. Curious? DM us at https://bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15147406 Tue, 18 Jun 2024 05:00:00 +0200 1579 63 full false 62: Magnetic Bead Technology: The New Era in Downstream Processing w/ Nils Brechmann - Part 2 62: Magnetic Bead Technology: The New Era in Downstream Processing w/ Nils Brechmann - Part 2 Dive into the future of bioprocessing with Nils Brechmann, Marketing Manager at MAGic BioProcessing and co-inventor of the process applications, as we explore how magnetic bead technology is transforming downstream processing.

MAGic BioProcessing is a biotech company from Uppsala, Sweden, that develops magnetic-based recovery of biologicals.

Key Takeaways:

  1. Streamlined Purification: Discover how magnetic beads enable simultaneous clarification and capture, boosting efficiency.
  2. Cost Savings: Learn about significant cost reductions by integrating steps and improving process economics.
  3. Scalable Solutions: Understand the potential for large-scale applications, making magnetic bead technology a versatile option for biomanufacturing.

Join us for an in-depth look at the benefits and innovations of magnetic bead technology in modern bioprocessing.

Connect with Nils Brechmann:

LinkedIn: https://www.linkedin.com/in/nils-brechmann-ph-d-44205114a

MAGic BioProcessing: https://magicbioprocessing.com

Next Step:

Enhance your bioprocess development strategy! Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Support the show

]]> Dive into the future of bioprocessing with Nils Brechmann, Marketing Manager at MAGic BioProcessing and co-inventor of the process applications, as we explore how magnetic bead technology is transforming downstream processing.

MAGic BioProcessing is a biotech company from Uppsala, Sweden, that develops magnetic-based recovery of biologicals.

Key Takeaways:

  1. Streamlined Purification: Discover how magnetic beads enable simultaneous clarification and capture, boosting efficiency.
  2. Cost Savings: Learn about significant cost reductions by integrating steps and improving process economics.
  3. Scalable Solutions: Understand the potential for large-scale applications, making magnetic bead technology a versatile option for biomanufacturing.

Join us for an in-depth look at the benefits and innovations of magnetic bead technology in modern bioprocessing.

Connect with Nils Brechmann:

LinkedIn: https://www.linkedin.com/in/nils-brechmann-ph-d-44205114a

MAGic BioProcessing: https://magicbioprocessing.com

Next Step:

Enhance your bioprocess development strategy! Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15144225 Thu, 13 Jun 2024 05:00:00 +0200 916 62 full false 61: Magnetic Bead Technology: The New Era in Downstream Processing w/ Nils Brechmann - Part 1 61: Magnetic Bead Technology: The New Era in Downstream Processing w/ Nils Brechmann - Part 1 Dive into the latest episode as we explore how magnetic bead technology is revolutionizing downstream processing, promising higher yields and greater purity.

Our guest, Nils Brechmann, Marketing Manager at MAGic BioProcessing and co-inventor of the process applications, shares his insights on overcoming industry challenges and the future of purification. MAGic BioProcessing is a biotech company from Uppsala, Sweden, that develops magnetic-based recovery of biologicals.

Key Takeaways:

  1. Discover how magnetic beads integrate cell clarification and capture, reducing processing steps and mechanical stress.
  2. Learn about the remarkable efficiency of magnetic beads in achieving low Host Cell Protein (HCP) levels right from the start.
  3. Understand the economic benefits of this technology, from cost savings to increased throughput in large-scale facilities.

Ready to elevate your bioprocessing game? Tune in now and harness the power of magnetic bead technology.

Connect with Nils Brechmann:

LinkedIn: https://www.linkedin.com/in/nils-brechmann-ph-d-44205114a

MAGic BioProcessing: https://magicbioprocessing.com

Next Step:

Enhance your bioprocess development strategy! Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Support the show

]]> Dive into the latest episode as we explore how magnetic bead technology is revolutionizing downstream processing, promising higher yields and greater purity.

Our guest, Nils Brechmann, Marketing Manager at MAGic BioProcessing and co-inventor of the process applications, shares his insights on overcoming industry challenges and the future of purification. MAGic BioProcessing is a biotech company from Uppsala, Sweden, that develops magnetic-based recovery of biologicals.

Key Takeaways:

  1. Discover how magnetic beads integrate cell clarification and capture, reducing processing steps and mechanical stress.
  2. Learn about the remarkable efficiency of magnetic beads in achieving low Host Cell Protein (HCP) levels right from the start.
  3. Understand the economic benefits of this technology, from cost savings to increased throughput in large-scale facilities.

Ready to elevate your bioprocessing game? Tune in now and harness the power of magnetic bead technology.

Connect with Nils Brechmann:

LinkedIn: https://www.linkedin.com/in/nils-brechmann-ph-d-44205114a

MAGic BioProcessing: https://magicbioprocessing.com

Next Step:

Enhance your bioprocess development strategy! Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15144204 Tue, 11 Jun 2024 05:00:00 +0200 1162 61 full false 60: Next-Generation Sequencing: Transforming Science and Medicine w/ Jonathon Hill - Part 2 60: Next-Generation Sequencing: Transforming Science and Medicine w/ Jonathon Hill - Part 2 Unlock the future of epigenetics and join us for an insightful conversation with Jonathon Hill as he delves into the groundbreaking world of next-generation sequencing (NGS) and its transformative impact on science and medicine. Jonathon Hill is the VP of Science and Technology and a co-founder of Wasatch BioLabs and Associate Professor of Cell Biology and Physiology at Brigham Young University.

Discover how cutting-edge nanopore technology is overcoming the limitations of traditional methods and revolutionizing epigenetic research.

Key Takeaways:

  1. Unparalleled Accuracy: Learn how nanopore technology achieves 99.6% accuracy in methylation calls, eliminating PCR and bisulfite conversion noise.
  2. Comprehensive Insights: Understand the benefits of whole-molecule sequencing for detailed methylation analysis, providing a clearer, more precise picture of genetic data.
  3. Future of Diagnostics: Explore the future of NGS in clinical settings, with genomic and epigenetic data integration into electronic health records guiding personalized treatments.

Don't miss this episode packed with innovative insights and the future landscape of genomic technology.

Connect with Jonathon Hill:

LinkedIn: https://www.linkedin.com/in/jonathon-t-hill

Wasatch BioLabs: https://www.wasatchbiolabs.com

Next Steps:

Schedule your free assessment to take process development to the next level now at https://bruehlmann-consulting.com/assessment

Support the show

]]> Unlock the future of epigenetics and join us for an insightful conversation with Jonathon Hill as he delves into the groundbreaking world of next-generation sequencing (NGS) and its transformative impact on science and medicine. Jonathon Hill is the VP of Science and Technology and a co-founder of Wasatch BioLabs and Associate Professor of Cell Biology and Physiology at Brigham Young University.

Discover how cutting-edge nanopore technology is overcoming the limitations of traditional methods and revolutionizing epigenetic research.

Key Takeaways:

  1. Unparalleled Accuracy: Learn how nanopore technology achieves 99.6% accuracy in methylation calls, eliminating PCR and bisulfite conversion noise.
  2. Comprehensive Insights: Understand the benefits of whole-molecule sequencing for detailed methylation analysis, providing a clearer, more precise picture of genetic data.
  3. Future of Diagnostics: Explore the future of NGS in clinical settings, with genomic and epigenetic data integration into electronic health records guiding personalized treatments.

Don't miss this episode packed with innovative insights and the future landscape of genomic technology.

Connect with Jonathon Hill:

LinkedIn: https://www.linkedin.com/in/jonathon-t-hill

Wasatch BioLabs: https://www.wasatchbiolabs.com

Next Steps:

Schedule your free assessment to take process development to the next level now at https://bruehlmann-consulting.com/assessment

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15134720 Thu, 06 Jun 2024 05:00:00 +0200 1237 60 full false 59: Next-Generation Sequencing: Transforming Science and Medicine w/ Jonathon Hill - Part 1 59: Next-Generation Sequencing: Transforming Science and Medicine w/ Jonathon Hill - Part 1 Curious about the latest advancements in next-generation sequencing (NGS) and how they are revolutionizing science and medicine?

In this episode, we delve into the cutting-edge developments of NGS with our expert guest, Jonathon Hill, VP of Science and Technology and a co-founder of Wasatch BioLabs and Associate Professor of Cell Biology and Physiology at Brigham Young University, who has been at the forefront of this transformative field.

Key Takeaways:

  1. Discover how NGS is empowering scientists to explore new frontiers in research with groundbreaking tools and technologies.
  2. Learn about the incredible advancements in long-read sequencing and their impact on genome assembly and understanding complex diseases.
  3. Understand how NGS is unlocking the potential of epigenetics, revolutionizing drug development, and enhancing diagnostic accuracy for personalized medicine.

Join us to get an insider's view on how NGS is not only changing the landscape of research but also making a profound impact on human health. Don't miss this informative conversation with a leading expert in the field!

Connect with Jonathon Hill:

LinkedIn: https://www.linkedin.com/in/jonathon-t-hill

Wasatch BioLabs: https://www.wasatchbiolabs.com

Next Steps:

Schedule your free assessment to take process development to the next level now at https://bruehlmann-consulting.com/assessment

Support the show

]]> Curious about the latest advancements in next-generation sequencing (NGS) and how they are revolutionizing science and medicine?

In this episode, we delve into the cutting-edge developments of NGS with our expert guest, Jonathon Hill, VP of Science and Technology and a co-founder of Wasatch BioLabs and Associate Professor of Cell Biology and Physiology at Brigham Young University, who has been at the forefront of this transformative field.

Key Takeaways:

  1. Discover how NGS is empowering scientists to explore new frontiers in research with groundbreaking tools and technologies.
  2. Learn about the incredible advancements in long-read sequencing and their impact on genome assembly and understanding complex diseases.
  3. Understand how NGS is unlocking the potential of epigenetics, revolutionizing drug development, and enhancing diagnostic accuracy for personalized medicine.

Join us to get an insider's view on how NGS is not only changing the landscape of research but also making a profound impact on human health. Don't miss this informative conversation with a leading expert in the field!

Connect with Jonathon Hill:

LinkedIn: https://www.linkedin.com/in/jonathon-t-hill

Wasatch BioLabs: https://www.wasatchbiolabs.com

Next Steps:

Schedule your free assessment to take process development to the next level now at https://bruehlmann-consulting.com/assessment

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15134714 Tue, 04 Jun 2024 05:00:00 +0200 1006 59 full false 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls w/ Matthias Müllner - Part 2 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls w/ Matthias Müllner - Part 2 Dive into the realm of biotech with our latest episode as we unravel the enigma of Quality by Design (QbD) with Matthias Müllner, CEO of & Co-Founder bespark*bio, a company empowering viral vector-based medicines.

Discover how integrating QbD principles early in your development cycle can revolutionize your approach to producing safe, high-quality products consistently. From understanding critical quality attributes to designing robust manufacturing processes, we illuminate the transformative potential of QbD.

Key Takeaways:

  1. Harnessing QbD principles empowers biotech companies to design quality into processes, fostering a deeper understanding of critical parameters and ensuring product consistency—a game-changer in the industry's quest for reliability.
  2. By adopting a phased approach to process development rooted in QbD, companies can streamline experimentation, minimize resource expenditure, and accelerate time-to-market, amplifying efficiency by up to 40%.
  3. Embracing innovation, such as machine learning and digitalization, holds the key to unlocking new horizons in CMC development, paving the way for a future where creativity and regulatory compliance converge seamlessly.

Tune in to learn how a solid CMC strategy can be the cornerstone of your biotech product's success and ensure you avoid common mistakes that could derail your project.

Connect with Matthias Müllner:

LinkedIn: https://www.linkedin.com/in/matthias-muellner

Next Step:

Enhance your bioprocess development strategy! Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Support the show

]]> Dive into the realm of biotech with our latest episode as we unravel the enigma of Quality by Design (QbD) with Matthias Müllner, CEO of & Co-Founder bespark*bio, a company empowering viral vector-based medicines.

Discover how integrating QbD principles early in your development cycle can revolutionize your approach to producing safe, high-quality products consistently. From understanding critical quality attributes to designing robust manufacturing processes, we illuminate the transformative potential of QbD.

Key Takeaways:

  1. Harnessing QbD principles empowers biotech companies to design quality into processes, fostering a deeper understanding of critical parameters and ensuring product consistency—a game-changer in the industry's quest for reliability.
  2. By adopting a phased approach to process development rooted in QbD, companies can streamline experimentation, minimize resource expenditure, and accelerate time-to-market, amplifying efficiency by up to 40%.
  3. Embracing innovation, such as machine learning and digitalization, holds the key to unlocking new horizons in CMC development, paving the way for a future where creativity and regulatory compliance converge seamlessly.

Tune in to learn how a solid CMC strategy can be the cornerstone of your biotech product's success and ensure you avoid common mistakes that could derail your project.

Connect with Matthias Müllner:

LinkedIn: https://www.linkedin.com/in/matthias-muellner

Next Step:

Enhance your bioprocess development strategy! Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15079708 Thu, 30 May 2024 05:00:00 +0200 1148 58 full false 57: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls w/ Matthias Müllner - Part 1 57: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls w/ Matthias Müllner - Part 1 Join us for an insightful episode as we dive into the world of bioprocess CMC development strategies with Matthias Müllner, CEO of & Co-Founder bespark*bio, a company empowering viral vector-based medicines.

Matthias shares his wealth of knowledge on avoiding common pitfalls in developing robust Chemistry, Manufacturing, and Controls (CMC) strategies. He also emphasizes the critical elements that ensure your biotech product's success.

Key Takeaways:

  1. Start Strong: Establishing a comprehensive CMC plan early can prevent costly and time-consuming issues later.
  2. Leverage Expertise: Bringing in external CMC consultants early on can bridge knowledge gaps and streamline the development process.
  3. Build Internally: Gradually develop in-house CMC capabilities to enhance long-term project viability and attract investor confidence.

Tune in to learn how a solid CMC strategy can be the cornerstone of your biotech product's success and ensure you avoid common mistakes that could derail your project.

Connect with Matthias Müllner:

LinkedIn: https://www.linkedin.com/in/matthias-muellner

Next Step:

Enhance your bioprocess development strategy! Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Support the show

]]> Join us for an insightful episode as we dive into the world of bioprocess CMC development strategies with Matthias Müllner, CEO of & Co-Founder bespark*bio, a company empowering viral vector-based medicines.

Matthias shares his wealth of knowledge on avoiding common pitfalls in developing robust Chemistry, Manufacturing, and Controls (CMC) strategies. He also emphasizes the critical elements that ensure your biotech product's success.

Key Takeaways:

  1. Start Strong: Establishing a comprehensive CMC plan early can prevent costly and time-consuming issues later.
  2. Leverage Expertise: Bringing in external CMC consultants early on can bridge knowledge gaps and streamline the development process.
  3. Build Internally: Gradually develop in-house CMC capabilities to enhance long-term project viability and attract investor confidence.

Tune in to learn how a solid CMC strategy can be the cornerstone of your biotech product's success and ensure you avoid common mistakes that could derail your project.

Connect with Matthias Müllner:

LinkedIn: https://www.linkedin.com/in/matthias-muellner

Next Step:

Enhance your bioprocess development strategy! Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15079680 Tue, 28 May 2024 05:00:00 +0200 1034 57 full false 56: Cultivated Meat: A Promising Future or an Inevitable Bubble? w/ Steven Lang - Part 2 56: Cultivated Meat: A Promising Future or an Inevitable Bubble? w/ Steven Lang - Part 2 Is cultivated meat the food of tomorrow or just a passing trend? In this episode, we dive deep with Steven Lang, an expert in the field of cultivated meat. Steven sheds light on the intricate process of creating meat in the lab, the challenges faced, and the potential future of this innovative industry.

Key Takeaways:

  1. Precision in Analytics: Discover how cutting-edge sensory analytics are crucial for developing cultivated meat that mimics traditional meat's texture and taste.
  2. Regulatory Innovation: Learn why the regulatory landscape for cultivated meat is set to revolutionize, benefiting not just food tech but also the biopharmaceutical industry.
  3. Future Prospects: Understand the potential pitfalls and the exciting innovations on the horizon, making cultivated meat a game-changer for food and biotech sectors.

Tune in to explore whether cultivated meat is the future we’ve been waiting for or just a bubble waiting to burst.

Connect with Steven Lang:

LinkedIn: https://www.linkedin.com/in/steven-lang-b003406

Next Step:

Don't miss out on boosting your bioprocess development strategy! Schedule your complimentary assessment to propel your success: https://bruehlmann-consulting.com/assessment

Support the show

]]> Is cultivated meat the food of tomorrow or just a passing trend? In this episode, we dive deep with Steven Lang, an expert in the field of cultivated meat. Steven sheds light on the intricate process of creating meat in the lab, the challenges faced, and the potential future of this innovative industry.

Key Takeaways:

  1. Precision in Analytics: Discover how cutting-edge sensory analytics are crucial for developing cultivated meat that mimics traditional meat's texture and taste.
  2. Regulatory Innovation: Learn why the regulatory landscape for cultivated meat is set to revolutionize, benefiting not just food tech but also the biopharmaceutical industry.
  3. Future Prospects: Understand the potential pitfalls and the exciting innovations on the horizon, making cultivated meat a game-changer for food and biotech sectors.

Tune in to explore whether cultivated meat is the future we’ve been waiting for or just a bubble waiting to burst.

Connect with Steven Lang:

LinkedIn: https://www.linkedin.com/in/steven-lang-b003406

Next Step:

Don't miss out on boosting your bioprocess development strategy! Schedule your complimentary assessment to propel your success: https://bruehlmann-consulting.com/assessment

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15079643 Thu, 23 May 2024 05:00:00 +0200 906 56 full false 55: Cultivated Meat: A Promising Future or an Inevitable Bubble? /w Steven Lang - Part 1 55: Cultivated Meat: A Promising Future or an Inevitable Bubble? /w Steven Lang - Part 1 How can you create an environment suitable for shear-stress-sensitive cells that results in higher cell concentrations and superior quality? Essentially, bionic bioreactors revolutionize this process, changing the game rules with their ability to facilitate bubble-free gas exchange.

Join us in this episode as we unravel the groundbreaking innovations in bioreactor technology with our guest, Patrick Bongartz, CEO of BioThrust and the visionary mind behind stress-free cell cultivation.

Key Highlights:

  1. Discover how bionic bioreactors defy conventional limitations, doubling cell densities even in sensitive cultures like insect cells, promising a paradigm shift in bioproduction efficiency.
  2. Unveil the game-changing membrane stirrer technology that not only enhances oxygen transfer but also facilitates precise pH control, revolutionizing process optimization and scalability.
  3. Embrace the challenge of disrupting conservative mindsets in the biotech industry.

Embark on a journey of scientific breakthroughs and entrepreneurial resilience in this episode.

Connect with Patrick Bongartz:

Website: https://biothrust.de

Linkedin BioThrust: https://www.linkedin.com/company/biothrust-de

Instagram: https://www.instagram.com/biothrust

Patrick’s LinkedIn: https://www.linkedin.com/in/patrick-bongartz-1106/

Next Step:

Wondering how to develop biologics and cell & gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Support the show

]]> How can you create an environment suitable for shear-stress-sensitive cells that results in higher cell concentrations and superior quality? Essentially, bionic bioreactors revolutionize this process, changing the game rules with their ability to facilitate bubble-free gas exchange.

Join us in this episode as we unravel the groundbreaking innovations in bioreactor technology with our guest, Patrick Bongartz, CEO of BioThrust and the visionary mind behind stress-free cell cultivation.

Key Highlights:

  1. Discover how bionic bioreactors defy conventional limitations, doubling cell densities even in sensitive cultures like insect cells, promising a paradigm shift in bioproduction efficiency.
  2. Unveil the game-changing membrane stirrer technology that not only enhances oxygen transfer but also facilitates precise pH control, revolutionizing process optimization and scalability.
  3. Embrace the challenge of disrupting conservative mindsets in the biotech industry.

Embark on a journey of scientific breakthroughs and entrepreneurial resilience in this episode.

Connect with Patrick Bongartz:

Website: https://biothrust.de

Linkedin BioThrust: https://www.linkedin.com/company/biothrust-de

Instagram: https://www.instagram.com/biothrust

Patrick’s LinkedIn: https://www.linkedin.com/in/patrick-bongartz-1106/

Next Step:

Wondering how to develop biologics and cell & gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-15066130 Tue, 21 May 2024 05:00:00 +0200 1365 55 full false 54: Bionic Bioreactors: The Key to Stress-Free Cell Cultivation w/ Patrick Bongartz - Part 2 54: Bionic Bioreactors: The Key to Stress-Free Cell Cultivation w/ Patrick Bongartz - Part 2 How can you create an environment suitable for shear-stress-sensitive cells that results in higher cell concentrations and superior quality? Essentially, bionic bioreactors revolutionize this process, changing the game rules with their ability to facilitate bubble-free gas exchange.

Join us in this episode as we unravel the groundbreaking innovations in bioreactor technology with our guest, Patrick Bongartz, CEO of BioThrust and the visionary mind behind stress-free cell cultivation.

Key Highlights:

  1. Discover how bionic bioreactors defy conventional limitations, doubling cell densities even in sensitive cultures like insect cells, promising a paradigm shift in bioproduction efficiency.
  2. Unveil the game-changing membrane stirrer technology that not only enhances oxygen transfer but also facilitates precise pH control, revolutionizing process optimization and scalability.
  3. Embrace the challenge of disrupting conservative mindsets in the biotech industry.

Embark on a journey of scientific breakthroughs and entrepreneurial resilience in this episode.


Connect with Patrick Bongartz:

Website: https://biothrust.de

Linkedin BioThrust https://www.linkedin.com/company/biothrust-de

Instagram: https://www.instagram.com/biothrust

Patrick’s LinkedIn: https://www.linkedin.com/in/patrick-bongartz-1106/

Next Step:

Wondering how to develop biologics and cell & gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Support the show

]]> How can you create an environment suitable for shear-stress-sensitive cells that results in higher cell concentrations and superior quality? Essentially, bionic bioreactors revolutionize this process, changing the game rules with their ability to facilitate bubble-free gas exchange.

Join us in this episode as we unravel the groundbreaking innovations in bioreactor technology with our guest, Patrick Bongartz, CEO of BioThrust and the visionary mind behind stress-free cell cultivation.

Key Highlights:

  1. Discover how bionic bioreactors defy conventional limitations, doubling cell densities even in sensitive cultures like insect cells, promising a paradigm shift in bioproduction efficiency.
  2. Unveil the game-changing membrane stirrer technology that not only enhances oxygen transfer but also facilitates precise pH control, revolutionizing process optimization and scalability.
  3. Embrace the challenge of disrupting conservative mindsets in the biotech industry.

Embark on a journey of scientific breakthroughs and entrepreneurial resilience in this episode.


Connect with Patrick Bongartz:

Website: https://biothrust.de

Linkedin BioThrust https://www.linkedin.com/company/biothrust-de

Instagram: https://www.instagram.com/biothrust

Patrick’s LinkedIn: https://www.linkedin.com/in/patrick-bongartz-1106/

Next Step:

Wondering how to develop biologics and cell & gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14988845 Thu, 16 May 2024 05:00:00 +0200 1159 54 full false 53: Bionic Bioreactors: The Key to Stress-Free Cell Cultivation w/ Patrick Bongartz - Part 1 53: Bionic Bioreactors: The Key to Stress-Free Cell Cultivation w/ Patrick Bongartz - Part 1 How can you provide stress-free cultivation conditions to achieve higher cell concentrations and quality? In a nutshell, bionic bioreactors and thus change bubble-free gas exchange change the game.

Join us as we delve into the future of biotech with our guest, Patrick Bongartz, CEO of BioThrust and an expert in innovative bioreactor design.

Key Highlights:

  1. Unveil the groundbreaking "artificial lung," a marvel of engineering that decouples mixing and gas transfer, enabling stress-free cell growth at unprecedented densities.
  2. From scaling issues to cell sensitivity, discover the hurdles that demand ingenious solutions.
  3. Explore the critical factors when handling sensitive cell types driving bioreactor evolution.

Discover how bionic bioreactors are paving the way for a stress-free future in cell cultivation.

Connect with Patrick Bongartz:

Website: https://biothrust.de

Linkedin BioThrust https://www.linkedin.com/company/biothrust-de

Instagram: https://www.instagram.com/biothrust

Patrick’s LinkedIn: https://www.linkedin.com/in/patrick-bongartz-1106/

Next Step:

Wondering how to develop biologics and cell & gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Support the show

]]> How can you provide stress-free cultivation conditions to achieve higher cell concentrations and quality? In a nutshell, bionic bioreactors and thus change bubble-free gas exchange change the game.

Join us as we delve into the future of biotech with our guest, Patrick Bongartz, CEO of BioThrust and an expert in innovative bioreactor design.

Key Highlights:

  1. Unveil the groundbreaking "artificial lung," a marvel of engineering that decouples mixing and gas transfer, enabling stress-free cell growth at unprecedented densities.
  2. From scaling issues to cell sensitivity, discover the hurdles that demand ingenious solutions.
  3. Explore the critical factors when handling sensitive cell types driving bioreactor evolution.

Discover how bionic bioreactors are paving the way for a stress-free future in cell cultivation.

Connect with Patrick Bongartz:

Website: https://biothrust.de

Linkedin BioThrust https://www.linkedin.com/company/biothrust-de

Instagram: https://www.instagram.com/biothrust

Patrick’s LinkedIn: https://www.linkedin.com/in/patrick-bongartz-1106/

Next Step:

Wondering how to develop biologics and cell & gene therapies with peace of mind? Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14988836 Tue, 14 May 2024 05:00:00 +0200 1100 53 full false 52: Unraveling the Complexity of Commercializing Cell and Gene Therapies w/ Wajiha Ali - Part 2 52: Unraveling the Complexity of Commercializing Cell and Gene Therapies w/ Wajiha Ali - Part 2 Does the process of commercializing cell and gene therapies seem complex and unclear to you?

Dive deep into the groundbreaking world of cell and gene therapies with our guest, Wajiha Ali, a strategy expert who believes in bridging the gap between research and commercialization with data, as we unravel the complexities of bringing life-saving therapies to patients.

From cutting-edge technologies to innovative collaboration models, we explore the future landscape of these transformative treatments.

You’ll get:

  1. An understanding of how partnerships between academic centers, pharma companies, and regulators can decrease development costs and simplify commercialization, resulting in wider accessibility.
  2. An investigation into how data analytics, AI, and machine learning can transform supply chains, target selection, commercialization strategies, and regulatory frameworks.
  3. A discovery of new methods for equitable therapy access, such as outcome-based pricing, local manufacturing, and the growing role of digital platforms in patient advocacy.

Join us on this insightful journey into the future of cell and gene therapies.

Connect with Wajiha Ali:

LinkedIn: https://www.linkedin.com/in/wajiha-ali-6468454

X (Twitter): https://twitter.com/Wajihaali

Next Step:

Develop biologics and cell & gene therapies with peace of mind. Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Does the process of commercializing cell and gene therapies seem complex and unclear to you?

Dive deep into the groundbreaking world of cell and gene therapies with our guest, Wajiha Ali, a strategy expert who believes in bridging the gap between research and commercialization with data, as we unravel the complexities of bringing life-saving therapies to patients.

From cutting-edge technologies to innovative collaboration models, we explore the future landscape of these transformative treatments.

You’ll get:

  1. An understanding of how partnerships between academic centers, pharma companies, and regulators can decrease development costs and simplify commercialization, resulting in wider accessibility.
  2. An investigation into how data analytics, AI, and machine learning can transform supply chains, target selection, commercialization strategies, and regulatory frameworks.
  3. A discovery of new methods for equitable therapy access, such as outcome-based pricing, local manufacturing, and the growing role of digital platforms in patient advocacy.

Join us on this insightful journey into the future of cell and gene therapies.

Connect with Wajiha Ali:

LinkedIn: https://www.linkedin.com/in/wajiha-ali-6468454

X (Twitter): https://twitter.com/Wajihaali

Next Step:

Develop biologics and cell & gene therapies with peace of mind. Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14981832 Thu, 09 May 2024 05:00:00 +0200 1592 52 full false 51: Unraveling the Complexity of Commercializing Cell and Gene Therapies w/ Wajiha Ali - Part 1 51: Unraveling the Complexity of Commercializing Cell and Gene Therapies w/ Wajiha Ali - Part 1 Are you finding the path to commercializing cell and gene therapies complex and uncertain?

Join us as we explore this intricate landscape with our guest, Wajiha Ali. As a strategy expert who believes in bridging the gap between research and commericalization with data who she will guide us through the challenges, victories, and vital strategies for successfully bringing these cutting-edge therapies to market.

Key Highlights:

  1. Discover the amplified complexity of cell and gene therapies, from patient referral hurdles to manufacturing site regulations.
  2. Explore the crucial commercialization strategies, infrastructure requirements, and the delicate balance between innovation and necessity.
  3. Unveil the regulatory scrutiny and stakeholder management intricacies, paving the way for safer, more accessible therapies.

Tune in as we navigate the journey from scientific breakthroughs to real-world application, unraveling the complexities shaping the future of healthcare.

Connect with Wajiha Ali:

LinkedIn: https://www.linkedin.com/in/wajiha-ali-6468454

X (Twitter): https://twitter.com/Wajihaali

Next Step:

Develop biologics and cell & gene therapies with peace of mind. Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Support the show

]]> Are you finding the path to commercializing cell and gene therapies complex and uncertain?

Join us as we explore this intricate landscape with our guest, Wajiha Ali. As a strategy expert who believes in bridging the gap between research and commericalization with data who she will guide us through the challenges, victories, and vital strategies for successfully bringing these cutting-edge therapies to market.

Key Highlights:

  1. Discover the amplified complexity of cell and gene therapies, from patient referral hurdles to manufacturing site regulations.
  2. Explore the crucial commercialization strategies, infrastructure requirements, and the delicate balance between innovation and necessity.
  3. Unveil the regulatory scrutiny and stakeholder management intricacies, paving the way for safer, more accessible therapies.

Tune in as we navigate the journey from scientific breakthroughs to real-world application, unraveling the complexities shaping the future of healthcare.

Connect with Wajiha Ali:

LinkedIn: https://www.linkedin.com/in/wajiha-ali-6468454

X (Twitter): https://twitter.com/Wajihaali

Next Step:

Develop biologics and cell & gene therapies with peace of mind. Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14981824 Tue, 07 May 2024 05:00:00 +0200 1166 51 full true 50: Decode Bioprocess Success: The Art of Stakeholder Management - Part 2 50: Decode Bioprocess Success: The Art of Stakeholder Management - Part 2 In the second part of "Decode Bioprocess Success: The Art of Stakeholder Management," we delve deeper into the strategies for effective stakeholder management in bioprocess development.

Through a step-by-step approach, we explore how to identify, classify, and engage with stakeholders to ensure project success.

Key highlights:

  1. Learn how to create a stakeholder management plan tailored to the unique needs and interests of each stakeholder group.
  2. Discover the power interest grid, a valuable tool for categorizing stakeholders based on their level of influence and interest in the project.
  3. Gain insights into developing communication plans that align with stakeholders' preferences and needs.

Join us as we uncover the art of stakeholder management and its transformative impact on bioprocess development success. Don't miss out on this episode filled with practical advice and actionable strategies for mastering stakeholder engagement in bioprocess projects.

Next Step:

Boost your bioprocess strategy! Book your free assessment for success: https://bruehlmann-consulting.com/assessment

Support the show

]]> In the second part of "Decode Bioprocess Success: The Art of Stakeholder Management," we delve deeper into the strategies for effective stakeholder management in bioprocess development.

Through a step-by-step approach, we explore how to identify, classify, and engage with stakeholders to ensure project success.

Key highlights:

  1. Learn how to create a stakeholder management plan tailored to the unique needs and interests of each stakeholder group.
  2. Discover the power interest grid, a valuable tool for categorizing stakeholders based on their level of influence and interest in the project.
  3. Gain insights into developing communication plans that align with stakeholders' preferences and needs.

Join us as we uncover the art of stakeholder management and its transformative impact on bioprocess development success. Don't miss out on this episode filled with practical advice and actionable strategies for mastering stakeholder engagement in bioprocess projects.

Next Step:

Boost your bioprocess strategy! Book your free assessment for success: https://bruehlmann-consulting.com/assessment

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14877205 Thu, 02 May 2024 05:00:00 +0200 668 50 full false 49: Decode Bioprocess Success: The Art of Stakeholder Management - Part 1 49: Decode Bioprocess Success: The Art of Stakeholder Management - Part 1 In this episode, we embark on a journey to uncover the essential strategies for navigating stakeholder relationships in bioprocess CMC development projects.

We delve into the critical role of stakeholders in bioprocess development and how their engagement can determine the success or failure of a project. Drawing from real-life experiences and insights, we explore the importance of understanding stakeholder needs, interests, and power dynamics.

Discover why stakeholder management is not just a skill but an art form essential for unlocking bioprocess success. Join us as we unravel the complexities of stakeholder engagement and provide actionable tips for mastering this crucial aspect of bioprocess development.

Tune in to learn how decoding the dynamics of stakeholder management can lead to triumph in bioprocess projects.

Next Step:

Boost your bioprocess strategy! Book your free assessment for success: https://bruehlmann-consulting.com/assessment

Support the show

]]> In this episode, we embark on a journey to uncover the essential strategies for navigating stakeholder relationships in bioprocess CMC development projects.

We delve into the critical role of stakeholders in bioprocess development and how their engagement can determine the success or failure of a project. Drawing from real-life experiences and insights, we explore the importance of understanding stakeholder needs, interests, and power dynamics.

Discover why stakeholder management is not just a skill but an art form essential for unlocking bioprocess success. Join us as we unravel the complexities of stakeholder engagement and provide actionable tips for mastering this crucial aspect of bioprocess development.

Tune in to learn how decoding the dynamics of stakeholder management can lead to triumph in bioprocess projects.

Next Step:

Boost your bioprocess strategy! Book your free assessment for success: https://bruehlmann-consulting.com/assessment

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14877195 Tue, 30 Apr 2024 05:00:00 +0200 1030 49 full false 48: Mastering Process Economics: Driving Down Costs in Antibody Production w/ Brian Kelley - Part 2 48: Mastering Process Economics: Driving Down Costs in Antibody Production w/ Brian Kelley - Part 2 Unlock the secrets to cost-efficient antibody therapeutics with Brian Kelley, Senior Vice President of Process Development at VIR Biotechnology.

In this illuminating episode, industry expert Brian Kelley shares invaluable insights into driving down manufacturing costs while maintaining quality and accessibility. From optimizing batch sizes to maximizing titers, discover practical strategies to streamline the process economics of antibody development.

Key Takeaways:

  1. Scale Matters: Learn how economies of scale play a pivotal role in minimizing manufacturing costs, paving the way for global accessibility of life-saving therapies.
  2. Titer Triumphs: Dive deep into the significance of maximizing titers to achieve substantial reductions in batch requirements and cost of goods, revolutionizing antibody production efficiency.
  3. Focus Innovation: Gain clarity on where to direct innovation efforts, balancing established manufacturing practices with groundbreaking developments in emerging modalities like cell and gene therapies.

Join us as we unravel the future landscape of antibody production, where simplicity and innovation converge to shape the next frontier of healthcare solutions. Tune in now for actionable strategies and visionary perspectives on mastering process economics in antibody therapeutics.

Connect with Brian Kelley:

LinkedIn: https://www.linkedin.com/in/brian-kelley-3389375

Next Step:

Enhance your bioprocess development strategy! Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Support the show

]]> Unlock the secrets to cost-efficient antibody therapeutics with Brian Kelley, Senior Vice President of Process Development at VIR Biotechnology.

In this illuminating episode, industry expert Brian Kelley shares invaluable insights into driving down manufacturing costs while maintaining quality and accessibility. From optimizing batch sizes to maximizing titers, discover practical strategies to streamline the process economics of antibody development.

Key Takeaways:

  1. Scale Matters: Learn how economies of scale play a pivotal role in minimizing manufacturing costs, paving the way for global accessibility of life-saving therapies.
  2. Titer Triumphs: Dive deep into the significance of maximizing titers to achieve substantial reductions in batch requirements and cost of goods, revolutionizing antibody production efficiency.
  3. Focus Innovation: Gain clarity on where to direct innovation efforts, balancing established manufacturing practices with groundbreaking developments in emerging modalities like cell and gene therapies.

Join us as we unravel the future landscape of antibody production, where simplicity and innovation converge to shape the next frontier of healthcare solutions. Tune in now for actionable strategies and visionary perspectives on mastering process economics in antibody therapeutics.

Connect with Brian Kelley:

LinkedIn: https://www.linkedin.com/in/brian-kelley-3389375

Next Step:

Enhance your bioprocess development strategy! Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14877187 Thu, 25 Apr 2024 05:00:00 +0200 1134 48 full false 47: Mastering Process Economics: Driving Down Costs in Antibody Production w/ Brian Kelley - Part 1 47: Mastering Process Economics: Driving Down Costs in Antibody Production w/ Brian Kelley - Part 1 Join us in this enlightening episode as we explore process economics with industry expert Brian Kelley. He is the Senior Vice President of Process Development at VIR Biotechnology.

Unraveling the mysteries of cost management in antibody therapeutics, Brian sheds light on the intricate challenges faced by biotech scientists and engineers.

Key Highlights:

  1. Discover the nuanced interplay between technical and cultural obstacles in process development.
  2. Navigate the labyrinth of cost drivers in antibody manufacturing, from raw materials to labor expenses.
  3. Learn the art of balancing speed, quality, and cost-effectiveness in bringing therapeutics to market.

Tune in for a masterclass in maximizing efficiency and driving down costs in the dynamic landscape of biologics production.

Connect with Brian Kelley:

LinkedIn: https://www.linkedin.com/in/brian-kelley-3389375

Next Step:

Enhance your bioprocess development strategy! Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Support the show

]]> Join us in this enlightening episode as we explore process economics with industry expert Brian Kelley. He is the Senior Vice President of Process Development at VIR Biotechnology.

Unraveling the mysteries of cost management in antibody therapeutics, Brian sheds light on the intricate challenges faced by biotech scientists and engineers.

Key Highlights:

  1. Discover the nuanced interplay between technical and cultural obstacles in process development.
  2. Navigate the labyrinth of cost drivers in antibody manufacturing, from raw materials to labor expenses.
  3. Learn the art of balancing speed, quality, and cost-effectiveness in bringing therapeutics to market.

Tune in for a masterclass in maximizing efficiency and driving down costs in the dynamic landscape of biologics production.

Connect with Brian Kelley:

LinkedIn: https://www.linkedin.com/in/brian-kelley-3389375

Next Step:

Enhance your bioprocess development strategy! Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14877175 Tue, 23 Apr 2024 05:00:00 +0200 1015 47 full false 46: From Lab to Table: The Science Behind Cultivated Meat w/ Petra Hanga - Part 2 46: From Lab to Table: The Science Behind Cultivated Meat w/ Petra Hanga - Part 2 Dive into the future of food with our latest episode, "From Lab to Table: The Science Behind Cultivated Meat." With our guest, Petra Hanga, a Lecturer in Biochemical Engineering at University College London and Chief Scientific Officer of Quest Meat Ltd., we unravel the secrets behind this groundbreaking technology.

Key highlights:

1. Discover how stem cells revolutionize the production of cultivated meat, providing a scalable solution for creating muscle, fat, and connective tissues.

2. Explore the intricate balance of nutrients, growth factors, and environmental conditions crucial for maximizing cell growth and quality.

3. Understand the challenges and breakthroughs in scaling up bioreactor processes for efficient meat production.

Join us for an informative discussion on the cutting edge of food technology. Gain valuable insights into the process of transforming lab-grown cells into delectable dishes on your table.

Don't miss out on this compelling episode!

Connect with Petra Hanga:

LinkedIn: https://www.linkedin.com/in/petrahanga/

Twitter: @PetraHanga

Next Step:

Enhance your bioprocess development strategy! Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Dive into the future of food with our latest episode, "From Lab to Table: The Science Behind Cultivated Meat." With our guest, Petra Hanga, a Lecturer in Biochemical Engineering at University College London and Chief Scientific Officer of Quest Meat Ltd., we unravel the secrets behind this groundbreaking technology.

Key highlights:

1. Discover how stem cells revolutionize the production of cultivated meat, providing a scalable solution for creating muscle, fat, and connective tissues.

2. Explore the intricate balance of nutrients, growth factors, and environmental conditions crucial for maximizing cell growth and quality.

3. Understand the challenges and breakthroughs in scaling up bioreactor processes for efficient meat production.

Join us for an informative discussion on the cutting edge of food technology. Gain valuable insights into the process of transforming lab-grown cells into delectable dishes on your table.

Don't miss out on this compelling episode!

Connect with Petra Hanga:

LinkedIn: https://www.linkedin.com/in/petrahanga/

Twitter: @PetraHanga

Next Step:

Enhance your bioprocess development strategy! Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14877148 Thu, 18 Apr 2024 05:00:00 +0200 1606 46 full false 45: From Lab to Table: The Science Behind Cultivated Meat w/ Petra Hanga - Part 1 45: From Lab to Table: The Science Behind Cultivated Meat w/ Petra Hanga - Part 1 Dive into the fascinating world of cultivated meat with our guest, Petra Hanga, Lecturer in Biochemical Engineering – Cellular Agriculture at University College London and the Chief Scientific Officer of Quest Meat Ltd.

In this episode, Petra sheds light on the intricacies of developing cultivated meat and reveals the key hurdles biotech scientists face.

Highlights:

  1. Learn how scientists tackle the complexity of replicating animal meat, ensuring a truly authentic taste and texture for future meat alternatives.
  2. Gain insight into the innovative solutions shaping the future of sustainable protein sources.
  3. Discover the potential of cultivated meat to revolutionize our food system.

Join us as we explore the promising landscape of cultivated meat, where science and innovation converge to shape a more sustainable future.

Enjoy your listening!

Connect with Petra Hanga:

LinkedIn: https://www.linkedin.com/in/petrahanga/

Twitter: @PetraHanga

Next Step:

Enhance your bioprocess development strategy! Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Support the show

]]> Dive into the fascinating world of cultivated meat with our guest, Petra Hanga, Lecturer in Biochemical Engineering – Cellular Agriculture at University College London and the Chief Scientific Officer of Quest Meat Ltd.

In this episode, Petra sheds light on the intricacies of developing cultivated meat and reveals the key hurdles biotech scientists face.

Highlights:

  1. Learn how scientists tackle the complexity of replicating animal meat, ensuring a truly authentic taste and texture for future meat alternatives.
  2. Gain insight into the innovative solutions shaping the future of sustainable protein sources.
  3. Discover the potential of cultivated meat to revolutionize our food system.

Join us as we explore the promising landscape of cultivated meat, where science and innovation converge to shape a more sustainable future.

Enjoy your listening!

Connect with Petra Hanga:

LinkedIn: https://www.linkedin.com/in/petrahanga/

Twitter: @PetraHanga

Next Step:

Enhance your bioprocess development strategy! Schedule your free assessment to propel your success: https://bruehlmann-consulting.com/assessment

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14846976 Tue, 16 Apr 2024 05:00:00 +0200 866 45 full false 44: Mastering the Art and Science of Glycan Engineering in Drug Development w/ Henning von Horsten - Part 2 44: Mastering the Art and Science of Glycan Engineering in Drug Development w/ Henning von Horsten - Part 2 Does uncovering the secrets of glycan engineering feel like navigating a maze of molecular complexity?

In this captivating continuation of our exploration into the world of glycan engineering, we delve deeper into groundbreaking innovations and the crucial role of analytics in ensuring consistent quality.

Henning von Horsten, Professor of Industrial Bioengineering at HTW Berlin (University of Applied Sciences in Berlin), shares the fascinating story behind a groundbreaking technology designed to modulate antibody-dependent cell-mediated cytotoxicity (ADCC).

You’ll get:

  1. Learn how advancements in high-throughput techniques are streamlining analytics for quicker insights and data-driven optimizations.
  2. Explore the future of glycan engineering, which may lead to more effective therapeutics.
  3. Understand why glycans matter across various fields of biotechnology, including monoclonal antibodies and vaccines, and discover their pivotal role in shaping the future of healthcare.

Connect with Henning von Horsten:

Next Step:

Elevate your bioprocess development strategy — Schedule your free assessment now: https://bruehlmann-consulting.com/assessment

Support the show

]]> Does uncovering the secrets of glycan engineering feel like navigating a maze of molecular complexity?

In this captivating continuation of our exploration into the world of glycan engineering, we delve deeper into groundbreaking innovations and the crucial role of analytics in ensuring consistent quality.

Henning von Horsten, Professor of Industrial Bioengineering at HTW Berlin (University of Applied Sciences in Berlin), shares the fascinating story behind a groundbreaking technology designed to modulate antibody-dependent cell-mediated cytotoxicity (ADCC).

You’ll get:

  1. Learn how advancements in high-throughput techniques are streamlining analytics for quicker insights and data-driven optimizations.
  2. Explore the future of glycan engineering, which may lead to more effective therapeutics.
  3. Understand why glycans matter across various fields of biotechnology, including monoclonal antibodies and vaccines, and discover their pivotal role in shaping the future of healthcare.

Connect with Henning von Horsten:

Next Step:

Elevate your bioprocess development strategy — Schedule your free assessment now: https://bruehlmann-consulting.com/assessment

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14796655 Thu, 11 Apr 2024 05:00:00 +0200 1106 44 full false 43: Mastering the Art and Science of Glycan Engineering in Drug Development w/ Henning von Horsten - Part 1 43: Mastering the Art and Science of Glycan Engineering in Drug Development w/ Henning von Horsten - Part 1 Does unlocking the secrets of glycan engineering seem like navigating a labyrinth of molecular complexity?

In this episode, we delve into the pivotal role of glycans as critical quality attributes (CQAs) in biotherapeutics.

Henning von Horsten, Professor of Industrial Bioengineering at HTW Berlin (University of Applied Sciences in Berlin), sheds light on the art and science of glycan engineering and analysis.

Key highlights:

  1. Discover various methods scientists are utilizing to improve glycan profiles.
  2. Get insights into the challenges and solutions of off-target effects and cellular metabolic adjustments.
  3. Learn about the exciting advancements in synthesizing ideal glycans outside living cells.

Connect with Henning von Horsten:

Next Step:

Elevate your bioprocess development strategy — Schedule your free assessment now: https://bruehlmann-consulting.com/assessment

Support the show

]]> Does unlocking the secrets of glycan engineering seem like navigating a labyrinth of molecular complexity?

In this episode, we delve into the pivotal role of glycans as critical quality attributes (CQAs) in biotherapeutics.

Henning von Horsten, Professor of Industrial Bioengineering at HTW Berlin (University of Applied Sciences in Berlin), sheds light on the art and science of glycan engineering and analysis.

Key highlights:

  1. Discover various methods scientists are utilizing to improve glycan profiles.
  2. Get insights into the challenges and solutions of off-target effects and cellular metabolic adjustments.
  3. Learn about the exciting advancements in synthesizing ideal glycans outside living cells.

Connect with Henning von Horsten:

Next Step:

Elevate your bioprocess development strategy — Schedule your free assessment now: https://bruehlmann-consulting.com/assessment

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14796521 Tue, 09 Apr 2024 05:00:00 +0200 1359 43 full false 42: Revealing the Disciplined Pursuit of Less in Bioprocessing - Part 2 42: Revealing the Disciplined Pursuit of Less in Bioprocessing - Part 2 Hey, fellow scientists! Do you find yourself buried under an avalanche of tasks, unsure which one truly matters? If you're tired of the chaos and want to reclaim control of your time and energy, stick around.

Today, we're unlocking the secrets of Essentialism, tailor-made for busy biotech scientists like you. We discuss the importance of focusing on the vital few tasks that contribute significantly to your goals, celebrating small wins, and protecting your time.

We also share a powerful story that illustrates the potential of Essentialism. Discover how Essentialism is not about doing more, but doing the right things, and how this disciplined approach can lead you to significant breakthroughs in your bioprocess CMC development activities. This episode is a must-listen for any scientist and engineer who feels overcommitted, overloaded, or overworked.

Tune in to learn how to navigate the complex world of biotech process development in a more strategic, efficient, and successful way.

Next Step:

Elevate your bioprocess development strategy — Schedule your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> Hey, fellow scientists! Do you find yourself buried under an avalanche of tasks, unsure which one truly matters? If you're tired of the chaos and want to reclaim control of your time and energy, stick around.

Today, we're unlocking the secrets of Essentialism, tailor-made for busy biotech scientists like you. We discuss the importance of focusing on the vital few tasks that contribute significantly to your goals, celebrating small wins, and protecting your time.

We also share a powerful story that illustrates the potential of Essentialism. Discover how Essentialism is not about doing more, but doing the right things, and how this disciplined approach can lead you to significant breakthroughs in your bioprocess CMC development activities. This episode is a must-listen for any scientist and engineer who feels overcommitted, overloaded, or overworked.

Tune in to learn how to navigate the complex world of biotech process development in a more strategic, efficient, and successful way.

Next Step:

Elevate your bioprocess development strategy — Schedule your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14738442 Thu, 04 Apr 2024 05:00:00 +0200 794 42 full false 41: Revealing the Disciplined Pursuit of Less in Bioprocessing - Part 1 41: Revealing the Disciplined Pursuit of Less in Bioprocessing - Part 1 Hey, fellow scientists! Do you find yourself buried under an avalanche of tasks, unsure which one truly matters? If you're tired of the chaos and want to reclaim control of your time and energy, stick around.

Today, we're unlocking the secrets of Essentialism, tailor-made for busy biotech scientists like you. We discuss the importance of focusing on the vital few tasks that contribute significantly to your goals, celebrating small wins, and protecting your time.

We also share a powerful story that illustrates the potential of Essentialism. Discover how Essentialism is not about doing more, but doing the right things, and how this disciplined approach can lead you to significant breakthroughs in your bioprocess CMC development activities. This episode is a must-listen for any scientist and engineer who feels overcommitted, overloaded, or overworked.

Tune in to learn how to navigate the complex world of biotech process development in a more strategic, efficient, and successful way.

Next Step:

Elevate your bioprocess development strategy — Schedule your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> Hey, fellow scientists! Do you find yourself buried under an avalanche of tasks, unsure which one truly matters? If you're tired of the chaos and want to reclaim control of your time and energy, stick around.

Today, we're unlocking the secrets of Essentialism, tailor-made for busy biotech scientists like you. We discuss the importance of focusing on the vital few tasks that contribute significantly to your goals, celebrating small wins, and protecting your time.

We also share a powerful story that illustrates the potential of Essentialism. Discover how Essentialism is not about doing more, but doing the right things, and how this disciplined approach can lead you to significant breakthroughs in your bioprocess CMC development activities. This episode is a must-listen for any scientist and engineer who feels overcommitted, overloaded, or overworked.

Tune in to learn how to navigate the complex world of biotech process development in a more strategic, efficient, and successful way.

Next Step:

Elevate your bioprocess development strategy — Schedule your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14738421 Tue, 02 Apr 2024 05:00:00 +0200 902 41 full false 40: Balancing Perfusion Process Development and Sustainability w/ Jochen Sieck - Part 2 40: Balancing Perfusion Process Development and Sustainability w/ Jochen Sieck - Part 2 Explore the intricate world of perfusion and its sustainability challenges in the part 2 of this episode. Dive into the operational side of managing vast quantities of media production and storage, and discover smart strategies to address these challenges.

Jochen Sieck, Director of Cell Culture Media and Process Development at Merck Life Science, discusses the distinction between facility designs for batch and perfusion bioreactors, shedding light on the need for extensive tank farms to support perfusion.

Key Insights:

  1. Explore the success of automated perfusion media preparation at the lab scale and its scaling up to a 500L capacity.
  2. Discover how advancements in small-scale perfusion operations are supercharging the perfusion process development.
  3. Get practical steps for developing a cost-efficient perfusion process.

Tune in to discover how perfusion processes are revolutionizing the biotech industry and contributing to a more sustainable future.

Connect with Jochen Sieck:

LinkedIn: https://www.linkedin.com/in/jochenbsieck

ACTIP Fellowship award: https://www.actip.org/fellowship

Resources:

Perfusion Cell Culture Processes for Biopharmaceuticals by Moritz Wolf, Jean-Marc Bielser, and Massimo Morbidelli: https://www.cambridge.org/core/books/perfusion-cell-culture-processes-for-biopharmaceuticals/5C650AD26D52B2435E7796D382ECE5DA

Next Step:

Elevate your biologics development strategy — Schedule your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> Explore the intricate world of perfusion and its sustainability challenges in the part 2 of this episode. Dive into the operational side of managing vast quantities of media production and storage, and discover smart strategies to address these challenges.

Jochen Sieck, Director of Cell Culture Media and Process Development at Merck Life Science, discusses the distinction between facility designs for batch and perfusion bioreactors, shedding light on the need for extensive tank farms to support perfusion.

Key Insights:

  1. Explore the success of automated perfusion media preparation at the lab scale and its scaling up to a 500L capacity.
  2. Discover how advancements in small-scale perfusion operations are supercharging the perfusion process development.
  3. Get practical steps for developing a cost-efficient perfusion process.

Tune in to discover how perfusion processes are revolutionizing the biotech industry and contributing to a more sustainable future.

Connect with Jochen Sieck:

LinkedIn: https://www.linkedin.com/in/jochenbsieck

ACTIP Fellowship award: https://www.actip.org/fellowship

Resources:

Perfusion Cell Culture Processes for Biopharmaceuticals by Moritz Wolf, Jean-Marc Bielser, and Massimo Morbidelli: https://www.cambridge.org/core/books/perfusion-cell-culture-processes-for-biopharmaceuticals/5C650AD26D52B2435E7796D382ECE5DA

Next Step:

Elevate your biologics development strategy — Schedule your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14674785 Thu, 28 Mar 2024 05:00:00 +0100 897 40 full false 39: Balancing Perfusion Process Development and Sustainability w/ Jochen Sieck - Part 1 39: Balancing Perfusion Process Development and Sustainability w/ Jochen Sieck - Part 1 Explore perfusion processes and sustainability with our guest, Jochen Sieck, Director of Cell Culture Media and Process Development at Merck Life Science.

Learn about the evolution of perfusion methodologies, its historical roots in addressing product stability, and its recent return to continuous and integrated manufacturing.

Jochen discusses the economic and strategic reasons behind perfusion's resurgence, emphasizing the need for flexible, smaller-scale facilities.

Key Learnings:

  1. Gain insight into the environmental impact of traditional facilities and the potential benefits of alternatives.
  2. Dive deep into the balance of cost, productivity, and sustainability in media consumption.
  3. Discover strategies for optimizing perfusion rates and sustainability.

Get ready to expand your understanding of perfusion processes, sustainability, and the delicate dance between economics and environmental consciousness.

Connect with Jochen Sieck:

LinkedIn: https://www.linkedin.com/in/jochenbsieck

ACTIP Fellowship award: https://www.actip.org/fellowship

Resources:

Perfusion Cell Culture Processes for Biopharmaceuticals by Moritz Wolf, Jean-Marc Bielser, and Massimo Morbidelli: https://www.cambridge.org/core/books/perfusion-cell-culture-processes-for-biopharmaceuticals/5C650AD26D52B2435E7796D382ECE5DA

Next Step:

Elevate your biologics development strategy — Schedule your free assessment now: https://bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Explore perfusion processes and sustainability with our guest, Jochen Sieck, Director of Cell Culture Media and Process Development at Merck Life Science.

Learn about the evolution of perfusion methodologies, its historical roots in addressing product stability, and its recent return to continuous and integrated manufacturing.

Jochen discusses the economic and strategic reasons behind perfusion's resurgence, emphasizing the need for flexible, smaller-scale facilities.

Key Learnings:

  1. Gain insight into the environmental impact of traditional facilities and the potential benefits of alternatives.
  2. Dive deep into the balance of cost, productivity, and sustainability in media consumption.
  3. Discover strategies for optimizing perfusion rates and sustainability.

Get ready to expand your understanding of perfusion processes, sustainability, and the delicate dance between economics and environmental consciousness.

Connect with Jochen Sieck:

LinkedIn: https://www.linkedin.com/in/jochenbsieck

ACTIP Fellowship award: https://www.actip.org/fellowship

Resources:

Perfusion Cell Culture Processes for Biopharmaceuticals by Moritz Wolf, Jean-Marc Bielser, and Massimo Morbidelli: https://www.cambridge.org/core/books/perfusion-cell-culture-processes-for-biopharmaceuticals/5C650AD26D52B2435E7796D382ECE5DA

Next Step:

Elevate your biologics development strategy — Schedule your free assessment now: https://bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14674776 Tue, 26 Mar 2024 05:00:00 +0100 1484 39 full false 38: How to Master Downstream: A Deep Dive Into Bioprocessing Purification w/ Wei Zhang - Part 2 38: How to Master Downstream: A Deep Dive Into Bioprocessing Purification w/ Wei Zhang - Part 2 In part 2 of this insightful episode, we embark on a journey into the intricate world of biotech purification processes. Our guest, Wei Zhang, DSP Group Head at A*STAR Bioprocessing Technology Institute, delves into three key modalities, shedding light on the challenges and advancements in virus, RNA, and traditional vaccine purification.

You will learn:

  1. Learn how to master the purification of viruses
  2. Get an overview of the advancements in RNA purification techniques: the evolution from simple RNA structures to long-stranded messenger RNA (mRNA)
  3. How to improve separation efficiency and simplify scale-up to meet increasing demands

Tune in as we unravel the complexities of downstream processing and glean valuable insights to excel in the dynamic field of bioprocessing purification.

Connect with Wei Zhang:

LinkedIn: https://www.linkedin.com/in/wei-zhang-a6539845

Next Step:

Elevate your bioprocess development capabilities — Schedule your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> In part 2 of this insightful episode, we embark on a journey into the intricate world of biotech purification processes. Our guest, Wei Zhang, DSP Group Head at A*STAR Bioprocessing Technology Institute, delves into three key modalities, shedding light on the challenges and advancements in virus, RNA, and traditional vaccine purification.

You will learn:

  1. Learn how to master the purification of viruses
  2. Get an overview of the advancements in RNA purification techniques: the evolution from simple RNA structures to long-stranded messenger RNA (mRNA)
  3. How to improve separation efficiency and simplify scale-up to meet increasing demands

Tune in as we unravel the complexities of downstream processing and glean valuable insights to excel in the dynamic field of bioprocessing purification.

Connect with Wei Zhang:

LinkedIn: https://www.linkedin.com/in/wei-zhang-a6539845

Next Step:

Elevate your bioprocess development capabilities — Schedule your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14697196 Thu, 21 Mar 2024 05:00:00 +0100 1001 38 full false 37: How to Master Downstream: A Deep Dive Into Bioprocessing Purification w/ Wei Zhang - Part 1 37: How to Master Downstream: A Deep Dive Into Bioprocessing Purification w/ Wei Zhang - Part 1 In this episode, Wei Zhang, DSP Group Head at A*STAR Bioprocessing Technology Institute, delves into the complexities of purification. Wei’s team pioneers bioprocessing processes for diverse biotherapeutics.

You will gain valuable insights into the intricate challenges and innovative solutions in bioprocessing purification.

You will learn:

  1. Master scale-up challenges
  2. Understand how you can ensure product stability
  3. Get an overview of the advancements in purification techniques

The conversation unravels the evolving landscape of bioprocessing, where the emergence of complex drug modalities necessitates continuous advancements in purification techniques and tools.

Connect with Wei Zhang:

LinkedIn: https://www.linkedin.com/in/wei-zhang-a6539845

Next Step:

Elevate your bioprocess development capabilities — Schedule your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> In this episode, Wei Zhang, DSP Group Head at A*STAR Bioprocessing Technology Institute, delves into the complexities of purification. Wei’s team pioneers bioprocessing processes for diverse biotherapeutics.

You will gain valuable insights into the intricate challenges and innovative solutions in bioprocessing purification.

You will learn:

  1. Master scale-up challenges
  2. Understand how you can ensure product stability
  3. Get an overview of the advancements in purification techniques

The conversation unravels the evolving landscape of bioprocessing, where the emergence of complex drug modalities necessitates continuous advancements in purification techniques and tools.

Connect with Wei Zhang:

LinkedIn: https://www.linkedin.com/in/wei-zhang-a6539845

Next Step:

Elevate your bioprocess development capabilities — Schedule your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14697184 Tue, 19 Mar 2024 05:00:00 +0100 1178 37 full false 36: Smart Biotech Development Strategies for Adherent Cell Culture w/ Joel Eichmann - Part 2 36: Smart Biotech Development Strategies for Adherent Cell Culture w/ Joel Eichmann - Part 2 Welcome back to the second part of our insightful interview with Joel Eichmann, Managing Director of Green Elephant Biotech.

In this episode, we delve deeper into the technical aspects of adherent cell expansion systems, explore sustainable biotech practices, and discuss key considerations for cost-efficient and environmentally friendly bioprocessing.

Key Insights:

  • How to adopt a strategic approach to adherent cell culture development
  • Delve into the intricacies of scaling up adherent cell culture, understanding the challenges associated with transitioning from T-flasks to larger, dynamic environments
  • Discover sustainable biotech practices to reducing your carbon footprint

Whether you're a seasoned professional or a curious enthusiast, this episode provides a wealth of knowledge for those passionate about advancing biotech process develoment.

Contact Joel Eichmann:

LinkedIn: https://www.linkedin.com/in/joel-eichmann

Website: https://www.greenelephantbiotech.com

Next Step:

Elevate your biologics development strategy — Schedule your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> Welcome back to the second part of our insightful interview with Joel Eichmann, Managing Director of Green Elephant Biotech.

In this episode, we delve deeper into the technical aspects of adherent cell expansion systems, explore sustainable biotech practices, and discuss key considerations for cost-efficient and environmentally friendly bioprocessing.

Key Insights:

  • How to adopt a strategic approach to adherent cell culture development
  • Delve into the intricacies of scaling up adherent cell culture, understanding the challenges associated with transitioning from T-flasks to larger, dynamic environments
  • Discover sustainable biotech practices to reducing your carbon footprint

Whether you're a seasoned professional or a curious enthusiast, this episode provides a wealth of knowledge for those passionate about advancing biotech process develoment.

Contact Joel Eichmann:

LinkedIn: https://www.linkedin.com/in/joel-eichmann

Website: https://www.greenelephantbiotech.com

Next Step:

Elevate your biologics development strategy — Schedule your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14644834 Thu, 14 Mar 2024 11:00:00 +0100 1050 36 full false 35: Smart Biotech Development Strategies for Adherent Cell Culture w/ Joel Eichmann - Part 1 35: Smart Biotech Development Strategies for Adherent Cell Culture w/ Joel Eichmann - Part 1 Get ready for a deep dive into the world of bioprocess development as Joel Eichmann, Managing Director of Green Elephant Biotech, shares his expertise on smart strategies for adherent cell culture .

Join us as we unravel the intricacies of adherent cell culture and discover the innovative strategies shaping the future of bioprocess development.

You’ll get:

  1. Acquire a comprehensive understanding of the key challenges in developing an adherent cell culture process.
  2. Gain a fresh perspective on the role of microcarriers and explore alternative options for adherent cell cultures.
  3. Uncover the unique inspiration behind Joel's bioreactor for adherent cells and how childhood experiences can spark groundbreaking ideas.

Join us for an insightful conversation and invaluable insights for biotech professionals, researchers, and enthusiasts like you looking to navigate the complexities of adherent cell culture and bioprocess development.

Contact Joel Eichmann:

LinkedIn: https://www.linkedin.com/in/joel-eichmann

Website: https://www.greenelephantbiotech.com

Next Step:

Elevate your biologics development strategy — Schedule your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> Get ready for a deep dive into the world of bioprocess development as Joel Eichmann, Managing Director of Green Elephant Biotech, shares his expertise on smart strategies for adherent cell culture .

Join us as we unravel the intricacies of adherent cell culture and discover the innovative strategies shaping the future of bioprocess development.

You’ll get:

  1. Acquire a comprehensive understanding of the key challenges in developing an adherent cell culture process.
  2. Gain a fresh perspective on the role of microcarriers and explore alternative options for adherent cell cultures.
  3. Uncover the unique inspiration behind Joel's bioreactor for adherent cells and how childhood experiences can spark groundbreaking ideas.

Join us for an insightful conversation and invaluable insights for biotech professionals, researchers, and enthusiasts like you looking to navigate the complexities of adherent cell culture and bioprocess development.

Contact Joel Eichmann:

LinkedIn: https://www.linkedin.com/in/joel-eichmann

Website: https://www.greenelephantbiotech.com

Next Step:

Elevate your biologics development strategy — Schedule your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14644820 Tue, 12 Mar 2024 05:00:00 +0100 1126 35 full false 34: The 7 Habits of Highly Successful Innovators - Part 2 34: The 7 Habits of Highly Successful Innovators - Part 2 Uncover the secrets of successful innovators, including Steve Jobs, Elon Musk, and Thomas Edison, in this enlightening episode of our podcast. We dive deep into the habits that set these trailblazers apart and fuel their innovative spirit.

Key learnings include:

  1. The power of curiosity and how it leads to groundbreaking ideas and improvements.
  2. The importance of connecting the dots to gain new insights and see invisible relationships.
  3. The role of risk-taking in pushing boundaries and experimenting with new ideas.

These insights provide a roadmap to developing your own innovative mindset and achieving success. Don't miss out on these valuable insights that could ignite your innovative spirit. Tune in now!

Next Step:

Elevate your biologics development strategy — Grab your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> Uncover the secrets of successful innovators, including Steve Jobs, Elon Musk, and Thomas Edison, in this enlightening episode of our podcast. We dive deep into the habits that set these trailblazers apart and fuel their innovative spirit.

Key learnings include:

  1. The power of curiosity and how it leads to groundbreaking ideas and improvements.
  2. The importance of connecting the dots to gain new insights and see invisible relationships.
  3. The role of risk-taking in pushing boundaries and experimenting with new ideas.

These insights provide a roadmap to developing your own innovative mindset and achieving success. Don't miss out on these valuable insights that could ignite your innovative spirit. Tune in now!

Next Step:

Elevate your biologics development strategy — Grab your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14599898 Thu, 07 Mar 2024 05:00:00 +0100 674 34 full false 33: The 7 Habits of Highly Successful Innovators - Part 1 33: The 7 Habits of Highly Successful Innovators - Part 1 Uncover the secrets of successful innovators, including Steve Jobs, Elon Musk, and Thomas Edison, in this enlightening episode of our podcast. We dive deep into the habits that set these trailblazers apart and fuel their innovative spirit.

Key learnings include:

  1. The power of curiosity and how it leads to groundbreaking ideas and improvements.
  2. The importance of connecting the dots to gain new insights and see invisible relationships.
  3. The role of risk-taking in pushing boundaries and experimenting with new ideas.

These insights provide a roadmap to developing your own innovative mindset and achieving success. Don't miss out on these valuable insights that could ignite your innovative spirit. Tune in now!

Next Step:

Elevate your biologics development strategy — Grab your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> Uncover the secrets of successful innovators, including Steve Jobs, Elon Musk, and Thomas Edison, in this enlightening episode of our podcast. We dive deep into the habits that set these trailblazers apart and fuel their innovative spirit.

Key learnings include:

  1. The power of curiosity and how it leads to groundbreaking ideas and improvements.
  2. The importance of connecting the dots to gain new insights and see invisible relationships.
  3. The role of risk-taking in pushing boundaries and experimenting with new ideas.

These insights provide a roadmap to developing your own innovative mindset and achieving success. Don't miss out on these valuable insights that could ignite your innovative spirit. Tune in now!

Next Step:

Elevate your biologics development strategy — Grab your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14599890 Tue, 05 Mar 2024 05:00:00 +0100 688 33 full false 32: The Future of Glycoengineering: Trends Unveiled w/ Thomas Rexer - Part 2 32: The Future of Glycoengineering: Trends Unveiled w/ Thomas Rexer - Part 2 Discover the hurdles and breakthroughs in glycoengineering, including the high costs of activated sugars.

Thomas Rexer, CTO of eversyn, a spin-off of the Max Planck Institute Magdeburg, unveils eversyn's multi-step biocatalysis process, designed to significantly drive down costs and make in vitro glycoengineering more accessible on a large scale.

Key Insights:

  1. Uncover the power of multistep biocatalysis in driving down costs and making in vitro glycoengineering more accessible.
  2. Bridge the Gap between academia and industry in glycoengineering and thus ensure a smoother integration of groundbreaking glycoengineering technologies into the industrial landscape.
  3. Gain valuable insights into the challenges and triumphs of transitioning from pure science to entrepreneurship, offering aspiring scientists a roadmap to navigate the unknown.

Connect with Thomas Rexer:

LinkedIn: https://www.linkedin.com/in/thomas-rexer

Website: www.eversyn.de

Next Step:

Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> Discover the hurdles and breakthroughs in glycoengineering, including the high costs of activated sugars.

Thomas Rexer, CTO of eversyn, a spin-off of the Max Planck Institute Magdeburg, unveils eversyn's multi-step biocatalysis process, designed to significantly drive down costs and make in vitro glycoengineering more accessible on a large scale.

Key Insights:

  1. Uncover the power of multistep biocatalysis in driving down costs and making in vitro glycoengineering more accessible.
  2. Bridge the Gap between academia and industry in glycoengineering and thus ensure a smoother integration of groundbreaking glycoengineering technologies into the industrial landscape.
  3. Gain valuable insights into the challenges and triumphs of transitioning from pure science to entrepreneurship, offering aspiring scientists a roadmap to navigate the unknown.

Connect with Thomas Rexer:

LinkedIn: https://www.linkedin.com/in/thomas-rexer

Website: www.eversyn.de

Next Step:

Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14565433 Thu, 29 Feb 2024 05:00:00 +0100 1049 32 full false 31: The Future of Glycoengineering: Trends Unveiled w/ Thomas Rexer - Part 1 31: The Future of Glycoengineering: Trends Unveiled w/ Thomas Rexer - Part 1 Get ready for a crash course in glycoengineering as Thomas Rexer, CTO of eversyn, a spin-off of the Max Planck Institute Magdeburg, breaks down the significance of modifying glycans in biopharmaceuticals.

Explore the science behind glycoengineering and its potential to enhance the properties of therapeutic proteins.

Key Insights:

  1. Unlock new frontiers in glycoengineering
  2. Explore the potential of glycoengineering to revolutionize biopharmaceuticals
  3. Ensure seamless integration of glycoengineering into production processes

Don't miss this episode as Thomas unveils the trends that will shape the future of glycoengineering, offering actionable insights for scientists, entrepreneurs, and biotech enthusiasts alike.

Connect with Thomas Rexer:

LinkedIn: https://www.linkedin.com/in/thomas-rexer

Website: www.eversyn.de

Next Step:

Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> Get ready for a crash course in glycoengineering as Thomas Rexer, CTO of eversyn, a spin-off of the Max Planck Institute Magdeburg, breaks down the significance of modifying glycans in biopharmaceuticals.

Explore the science behind glycoengineering and its potential to enhance the properties of therapeutic proteins.

Key Insights:

  1. Unlock new frontiers in glycoengineering
  2. Explore the potential of glycoengineering to revolutionize biopharmaceuticals
  3. Ensure seamless integration of glycoengineering into production processes

Don't miss this episode as Thomas unveils the trends that will shape the future of glycoengineering, offering actionable insights for scientists, entrepreneurs, and biotech enthusiasts alike.

Connect with Thomas Rexer:

LinkedIn: https://www.linkedin.com/in/thomas-rexer

Website: www.eversyn.de

Next Step:

Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14559919 Tue, 27 Feb 2024 05:00:00 +0100 1106 31 full false 30: From Monoclonals to Gene Therapy: Tips for Biopharma Process Development w/ Neil Templeton - Part 2 30: From Monoclonals to Gene Therapy: Tips for Biopharma Process Development w/ Neil Templeton - Part 2 In our insightful second part of the conversation, we broaden our perspective to delve into the various modalities within the biotech industry, highlighting the unique and shared aspects of process development and scale-up.

Neil Templeton, the Director of Upstream Process Development at Solid Biosciences, passionately articulates his commitment towards making gene therapy more accessible. He does this by outlining strategic solutions to reduce the costs of development and manufacturing.

You will gain:

  1. A comprehensive understanding of process development's similarities and differences across biologics, vaccines, and cell and gene therapy manufacturing.
  2. Effective strategies aimed at reducing the costs associated with gene therapy development and manufacturing.
  3. Insights into how capitalizing on the expertise from the biologics sector can positively impact other fields.

To connect with Neil Templeton and learn more about his work, visit his LinkedIn profile.

LinkedIn: https://www.linkedin.com/in/neil-templeton

Next Step:

Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> In our insightful second part of the conversation, we broaden our perspective to delve into the various modalities within the biotech industry, highlighting the unique and shared aspects of process development and scale-up.

Neil Templeton, the Director of Upstream Process Development at Solid Biosciences, passionately articulates his commitment towards making gene therapy more accessible. He does this by outlining strategic solutions to reduce the costs of development and manufacturing.

You will gain:

  1. A comprehensive understanding of process development's similarities and differences across biologics, vaccines, and cell and gene therapy manufacturing.
  2. Effective strategies aimed at reducing the costs associated with gene therapy development and manufacturing.
  3. Insights into how capitalizing on the expertise from the biologics sector can positively impact other fields.

To connect with Neil Templeton and learn more about his work, visit his LinkedIn profile.

LinkedIn: https://www.linkedin.com/in/neil-templeton

Next Step:

Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14502669 Thu, 22 Feb 2024 05:00:00 +0100 896 30 full false 29: From Monoclonals to Gene Therapy: Tips for Biopharma Process Development w/ Neil Templeton - Part 1 29: From Monoclonals to Gene Therapy: Tips for Biopharma Process Development w/ Neil Templeton - Part 1 In this enlightening episode, we're joined by Neil Templeton, Director in Upstream Process Development at Solid Biosciences, who pulls back the curtain on the intricate world of bioprocess development and manufacturing.

Neil delves into the shifting paradigms of the industry, sharing his expert insights on overcoming the unique challenges that surface when transitioning from R&D to GMP production. This episode is packed full of invaluable knowledge that's crucial for anyone looking to succeed in this field.

Key points we discuss include:

  1. Strategies and solutions for overcoming the obstacles faced when transitioning from R&D to GMP production.
  2. The importance and application of Design of Experiment (DOE) approaches, and their role in understanding critical process parameters.
  3. The role of metabolite analysis in optimizing processes and ensuring their robustness.

Get connected with Neil Templeton:

LinkedIn: https://www.linkedin.com/in/neil-templeton

Next Step:

Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> In this enlightening episode, we're joined by Neil Templeton, Director in Upstream Process Development at Solid Biosciences, who pulls back the curtain on the intricate world of bioprocess development and manufacturing.

Neil delves into the shifting paradigms of the industry, sharing his expert insights on overcoming the unique challenges that surface when transitioning from R&D to GMP production. This episode is packed full of invaluable knowledge that's crucial for anyone looking to succeed in this field.

Key points we discuss include:

  1. Strategies and solutions for overcoming the obstacles faced when transitioning from R&D to GMP production.
  2. The importance and application of Design of Experiment (DOE) approaches, and their role in understanding critical process parameters.
  3. The role of metabolite analysis in optimizing processes and ensuring their robustness.

Get connected with Neil Templeton:

LinkedIn: https://www.linkedin.com/in/neil-templeton

Next Step:

Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14502656 Tue, 20 Feb 2024 05:00:00 +0100 1449 29 full false 28: How to Simplify Project Management in Bioprocess Development - Part 2 28: How to Simplify Project Management in Bioprocess Development - Part 2 Tackling bioprocess development and scale-up can be complex. While the science might be challenging, project management within biotech doesn't have to be.

In this engaging episode, we'll guide you on how to streamline your CMC development, demystifying the complexities of project planning and execution.

Here's what you'll gain:

  1. Discover the secret to 'Successful Planning,' - a strategy to ensure your projects are well-organised, resource-smart, and timely delivered.
  2. Understand the crucial role of 'Assessing Scalability Potential,' and why it's a game-changer for your project's long-term success.
  3. Unleash the 'Power of a High-Performance Team,' and learn how effective leadership can enable your team to excel and achieve outstanding results.

Don't allow complexity to impede your progress - join us for these insights and beyond!

Next Step:

Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> Tackling bioprocess development and scale-up can be complex. While the science might be challenging, project management within biotech doesn't have to be.

In this engaging episode, we'll guide you on how to streamline your CMC development, demystifying the complexities of project planning and execution.

Here's what you'll gain:

  1. Discover the secret to 'Successful Planning,' - a strategy to ensure your projects are well-organised, resource-smart, and timely delivered.
  2. Understand the crucial role of 'Assessing Scalability Potential,' and why it's a game-changer for your project's long-term success.
  3. Unleash the 'Power of a High-Performance Team,' and learn how effective leadership can enable your team to excel and achieve outstanding results.

Don't allow complexity to impede your progress - join us for these insights and beyond!

Next Step:

Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14448412 Thu, 15 Feb 2024 05:00:00 +0100 760 28 full false 27: How to Simplify Project Management in Bioprocess Development - Part 1 27: How to Simplify Project Management in Bioprocess Development - Part 1 Bioprocess development and scale-up are complex. Science may give you headaches, but biotech project management should not.

In this riveting episode, you'll learn how to simplify your CMC development, guiding you through the maze of project planning and execution.

Key Takeaways:

  1. Uncover how to "Plan for Success," ensuring your projects are well-structured, resource-efficient, and delivered on time.
  2. Learn the importance of "Evaluating the Scalability Potential," and why it's crucial for the long-term success of your project.
  3. Discover the power of "Building a High-Performing Team," and how the right leadership can empower your team and skyrocket results.

Don't let complexity hold you back - tune in for these insights and more!

Next Step:

Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> Bioprocess development and scale-up are complex. Science may give you headaches, but biotech project management should not.

In this riveting episode, you'll learn how to simplify your CMC development, guiding you through the maze of project planning and execution.

Key Takeaways:

  1. Uncover how to "Plan for Success," ensuring your projects are well-structured, resource-efficient, and delivered on time.
  2. Learn the importance of "Evaluating the Scalability Potential," and why it's crucial for the long-term success of your project.
  3. Discover the power of "Building a High-Performing Team," and how the right leadership can empower your team and skyrocket results.

Don't let complexity hold you back - tune in for these insights and more!

Next Step:

Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14448403 Tue, 13 Feb 2024 05:00:00 +0100 948 27 full false 26: 9 Critical Steps for a Seamless Transition to Large-Scale Production - Part 2 26: 9 Critical Steps for a Seamless Transition to Large-Scale Production - Part 2 In this riveting episode of the Smart Biotech Scientist podcast, we navigate the intricate labyrinth of biotech scale-ups. We distill the process down to 9 essential steps for a smooth transition from laboratory to large-scale production.

Key Insights:

  • Acquire Comprehensive Process Understanding: Bolster your decision-making and problem-solving skills with an in-depth understanding of your process, molecule, and expertise at your disposal.
  • Span the Technology Gaps: Tackle obstacles and boost efficiency by utilizing appropriate technology and strategic risk mitigation techniques.
  • Develop a Detailed, Sequential Roadmap: Alleviate confusion and ensure a fluid scale-up process with a precise, well-defined roadmap.

Equip yourself with the knowledge to not just endure tech transfers, but to excel.

Transform the tumult of tech transfer into a harmonious symphony with our expert guidance!

Next Step:

Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> In this riveting episode of the Smart Biotech Scientist podcast, we navigate the intricate labyrinth of biotech scale-ups. We distill the process down to 9 essential steps for a smooth transition from laboratory to large-scale production.

Key Insights:

  • Acquire Comprehensive Process Understanding: Bolster your decision-making and problem-solving skills with an in-depth understanding of your process, molecule, and expertise at your disposal.
  • Span the Technology Gaps: Tackle obstacles and boost efficiency by utilizing appropriate technology and strategic risk mitigation techniques.
  • Develop a Detailed, Sequential Roadmap: Alleviate confusion and ensure a fluid scale-up process with a precise, well-defined roadmap.

Equip yourself with the knowledge to not just endure tech transfers, but to excel.

Transform the tumult of tech transfer into a harmonious symphony with our expert guidance!

Next Step:

Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14404591 Thu, 08 Feb 2024 05:00:00 +0100 761 26 full false 25: 9 Critical Steps for a Seamless Transition to Large-Scale Production - Part 1 25: 9 Critical Steps for a Seamless Transition to Large-Scale Production - Part 1 In this enlightening episode of the Smart Biotech Scientist podcast, we delve into the complex world of biotech scale-ups. We break down the 9 crucial steps to ensure a seamless transition from lab to large-scale production.

Top 3 Takeaways:

  • Gain Comprehensive Process Understanding: Enhance your decision-making and problem-solving abilities by thoroughly understanding your process, molecule, and available expertise.
  • Bridge the Technology Gaps: Overcome challenges and increase efficiency by leveraging suitable technology and strategic risk mitigation methodologies.
  • Create a Clear, Step-by-Step Roadmap: Reduce confusion and facilitate a smooth scale-up process with a clear, detailed roadmap.

You will be armed with the knowledge to not just survive tech transfers, but to thrive.

Turn the tech transfer chaos into a well-orchestrated symphony with our expert insights!

Next Step:

Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> In this enlightening episode of the Smart Biotech Scientist podcast, we delve into the complex world of biotech scale-ups. We break down the 9 crucial steps to ensure a seamless transition from lab to large-scale production.

Top 3 Takeaways:

  • Gain Comprehensive Process Understanding: Enhance your decision-making and problem-solving abilities by thoroughly understanding your process, molecule, and available expertise.
  • Bridge the Technology Gaps: Overcome challenges and increase efficiency by leveraging suitable technology and strategic risk mitigation methodologies.
  • Create a Clear, Step-by-Step Roadmap: Reduce confusion and facilitate a smooth scale-up process with a clear, detailed roadmap.

You will be armed with the knowledge to not just survive tech transfers, but to thrive.

Turn the tech transfer chaos into a well-orchestrated symphony with our expert insights!

Next Step:

Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14404555 Tue, 06 Feb 2024 05:00:00 +0100 1125 25 full false 24: Strategies for Success: Master CMC Development with Gene Lee - Part 2 24: Strategies for Success: Master CMC Development with Gene Lee - Part 2 If you've ever wondered how to seamlessly transition from R&D to process development, this is your golden ticket. Uncover practical strategies and expert advice that can be your compass through the intricate landscape of mastering CMC development.

Uncover the challenges and tactics to seamlessly navigate this critical phase.

  1. Conduct Early Developability Assessments: By assessing productivity, aggregation propensity, and manufacturability early on, you can strategically avoid future roadblocks.
  2. Use a Platform: A platform approach facilitates swift and cost-effective transitions to clinical trials, reducing pre-proof of concept investment.
  3. Bridge the R&D and Process Development Gap: Navigating this intricate phase successfully leads to seamless collaboration, promoting a unified approach and shared understanding among team members.

Connect with Gene Lee:

LinkedIn: www.linkedin.com/in/gene-w-lee-phd-0318b83

Website: www.altrubio.com

Next Step:

Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> If you've ever wondered how to seamlessly transition from R&D to process development, this is your golden ticket. Uncover practical strategies and expert advice that can be your compass through the intricate landscape of mastering CMC development.

Uncover the challenges and tactics to seamlessly navigate this critical phase.

  1. Conduct Early Developability Assessments: By assessing productivity, aggregation propensity, and manufacturability early on, you can strategically avoid future roadblocks.
  2. Use a Platform: A platform approach facilitates swift and cost-effective transitions to clinical trials, reducing pre-proof of concept investment.
  3. Bridge the R&D and Process Development Gap: Navigating this intricate phase successfully leads to seamless collaboration, promoting a unified approach and shared understanding among team members.

Connect with Gene Lee:

LinkedIn: www.linkedin.com/in/gene-w-lee-phd-0318b83

Website: www.altrubio.com

Next Step:

Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14381873 Thu, 01 Feb 2024 05:00:00 +0100 1354 24 full false 23: Strategies for Success: Master CMC Development with Gene Lee - Part 1 23: Strategies for Success: Master CMC Development with Gene Lee - Part 1 Embark on a journey into the intricate world of CMC development with our latest episode, unraveling the challenges that often baffle biotech scientists. The complexity of CMC development is a formidable hurdle, and in this insightful discussion, we delve into strategies to master this critical process.

Key Takeaways:

  1. Start Early: Learn how starting CMC development early, even without a complete understanding of your drug, can reduce risks and prepare you better for clinical milestones.
  2. Collaborate: CMC development should not work in isolation but integrate insights from diverse teams for a comprehensive drug development strategy.
  3. Adopt a Platform Approach: Understand the role of platform processes in speeding up drug development and how they facilitate multiple attempts for cost-efficient progression from discovery to clinical trials, particularly in biologics.

Your journey to mastering CMC development starts here.

Connect with Gene Lee:

LinkedIn: www.linkedin.com/in/gene-w-lee-phd-0318b83

Website: www.altrubio.com

Next Step:

Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> Embark on a journey into the intricate world of CMC development with our latest episode, unraveling the challenges that often baffle biotech scientists. The complexity of CMC development is a formidable hurdle, and in this insightful discussion, we delve into strategies to master this critical process.

Key Takeaways:

  1. Start Early: Learn how starting CMC development early, even without a complete understanding of your drug, can reduce risks and prepare you better for clinical milestones.
  2. Collaborate: CMC development should not work in isolation but integrate insights from diverse teams for a comprehensive drug development strategy.
  3. Adopt a Platform Approach: Understand the role of platform processes in speeding up drug development and how they facilitate multiple attempts for cost-efficient progression from discovery to clinical trials, particularly in biologics.

Your journey to mastering CMC development starts here.

Connect with Gene Lee:

LinkedIn: www.linkedin.com/in/gene-w-lee-phd-0318b83

Website: www.altrubio.com

Next Step:

Elevate your bioprocess development strategy — Grab your free assessment now: https://bruehlmann-consulting.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14376437 Tue, 30 Jan 2024 05:00:00 +0100 1108 23 full false 22: Unleashing Effective QbD Strategies to Master Cell Therapy with Shin Kawamata - Part 2 22: Unleashing Effective QbD Strategies to Master Cell Therapy with Shin Kawamata - Part 2 Are you looking for advanced strategies to enhance the quality and efficiency of cell therapy manufacturing processes?

In this episode with Shin Kawamata, CEO of Cyto-Facto Inc., we dive into the transformative power of digitization in cell therapy manufacturing and explore strategies to enhance efficiency and reduce costs.

Actionable Takeaways:

  1. Initiate Digital Transformation: Take the first step toward transforming your manufacturing processes by incorporating robust data business practices, ensuring a maturation of the cell therapy industry.
  2. Leverage AI and Metabolome Sensors: Discover actionable insights into harnessing the power of AI for navigating cell therapy complexities. Implement metabolome sensors to actively monitor cell culture, gathering essential data for quality control and elevating your therapy development strategies.
  3. Cultivate Collaborative Ecosystems: Shin shares practical insights into building comprehensive ecosystems and collaborating with various stakeholders.

Join us as we uncover the latest advancements, challenges, and Shin's vision for the future of the cell therapy industry.

Connect with Shin:

Get Cell and Gene Therapy Training:

Support the show

]]> Are you looking for advanced strategies to enhance the quality and efficiency of cell therapy manufacturing processes?

In this episode with Shin Kawamata, CEO of Cyto-Facto Inc., we dive into the transformative power of digitization in cell therapy manufacturing and explore strategies to enhance efficiency and reduce costs.

Actionable Takeaways:

  1. Initiate Digital Transformation: Take the first step toward transforming your manufacturing processes by incorporating robust data business practices, ensuring a maturation of the cell therapy industry.
  2. Leverage AI and Metabolome Sensors: Discover actionable insights into harnessing the power of AI for navigating cell therapy complexities. Implement metabolome sensors to actively monitor cell culture, gathering essential data for quality control and elevating your therapy development strategies.
  3. Cultivate Collaborative Ecosystems: Shin shares practical insights into building comprehensive ecosystems and collaborating with various stakeholders.

Join us as we uncover the latest advancements, challenges, and Shin's vision for the future of the cell therapy industry.

Connect with Shin:

Get Cell and Gene Therapy Training:

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14325241 Thu, 25 Jan 2024 05:00:00 +0100 1114 22 full false 21: Unleashing Effective QbD Strategies to Master Cell Therapy with Shin Kawamata - Part 1 21: Unleashing Effective QbD Strategies to Master Cell Therapy with Shin Kawamata - Part 1 Are the escalating costs and intricate technical hurdles of cell therapy development causing you stress?

Tune into this insightful podcast episode featuring Shin Kawamata, CEO of Cyto-Facto Inc. in Kobe, Japan, who shares his expertise and innovative solutions to these pressing issues in the cell therapy industry.

Discover how to streamline your manufacturing processes, reduce costs, and enhance product quality, transforming the way you approach cell therapy development.

Key Takeaways:

  1. Revolutionize Cell Manufacturing: Shin outlines how Cyto-Facto is pioneering a new business model, merging public sector support with commercial viability. Learn how this shift can accelerate the growth of the cell therapy industry.
  2. Leverage QbD in Living Systems: Discover why Quality by Design (QbD) strategies are imperative for cell therapy manufacturing.
  3. Scale Up Efficiently: Shin shares valuable insights on the challenges in scaling up cell therapies and the importance of automation, digitalization, and QbD in streamlining manufacturing processes, reducing costs, and enhancing product quality.

Join us as we uncover the latest advancements, challenges, and Shin's vision for the future of the cell therapy industry.

Connect with Shin:

Get Cell and Gene Therapy Training:

Support the show

]]> Are the escalating costs and intricate technical hurdles of cell therapy development causing you stress?

Tune into this insightful podcast episode featuring Shin Kawamata, CEO of Cyto-Facto Inc. in Kobe, Japan, who shares his expertise and innovative solutions to these pressing issues in the cell therapy industry.

Discover how to streamline your manufacturing processes, reduce costs, and enhance product quality, transforming the way you approach cell therapy development.

Key Takeaways:

  1. Revolutionize Cell Manufacturing: Shin outlines how Cyto-Facto is pioneering a new business model, merging public sector support with commercial viability. Learn how this shift can accelerate the growth of the cell therapy industry.
  2. Leverage QbD in Living Systems: Discover why Quality by Design (QbD) strategies are imperative for cell therapy manufacturing.
  3. Scale Up Efficiently: Shin shares valuable insights on the challenges in scaling up cell therapies and the importance of automation, digitalization, and QbD in streamlining manufacturing processes, reducing costs, and enhancing product quality.

Join us as we uncover the latest advancements, challenges, and Shin's vision for the future of the cell therapy industry.

Connect with Shin:

Get Cell and Gene Therapy Training:

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14324883 Tue, 23 Jan 2024 05:00:00 +0100 1330 21 full false 20: How to Take Your Molecule From the Lab to Clinical Trials w/ Bernardo Estupiñán Gaisbauer - Part 2 20: How to Take Your Molecule From the Lab to Clinical Trials w/ Bernardo Estupiñán Gaisbauer - Part 2 Welcome to Part 2 of our conversation with Bernardo Estupiñán Gaisbauer, Principal at Drug Biologics Consulting.

In this insightful episode, we dive into the complex world of taking a molecule from the lab to clinical trials. Our guest shares invaluable insights into outsourcing strategies for biotech companies.

Key Learnings:

  • Strategic Outsourcing: Discover when and why outsourcing is crucial for biotech companies, particularly in areas like analytical work and process development. Learn how it can be a game-changer for companies of all sizes.
  • Critical Outsourcing Steps: Understand the pivotal role of analytics in confirming lab results and ensuring a robust process. Explore the importance of choosing the right outsourcing partner for scalability, from small bioreactors to larger manufacturing stages.
  • Balancing Control and Expertise: Uncover the delicate balance between keeping in-house control and leveraging the expertise of outsourcing partners. Gain insights into finding the sweet spot to achieve process understanding and cost efficiency.

Join us for a deep dive into the outsourcing landscape, unraveling the intricacies of selecting the right partner and ensuring a successful collaboration. Tune in and elevate your biotech game!

Connect with Bernardo Estupiñán Gaisbauer:

Website: www.drugbiologics.com/cdmoadvisor

Article: In Search Of The Unicorn: Do End-To-End C(x)DMOs Really Exist?: www.bioprocessonline.com/doc/in-search-of-the-unicorn-do-end-to-end-c-x-dmos-really-exist-0001

Support the show

]]> Welcome to Part 2 of our conversation with Bernardo Estupiñán Gaisbauer, Principal at Drug Biologics Consulting.

In this insightful episode, we dive into the complex world of taking a molecule from the lab to clinical trials. Our guest shares invaluable insights into outsourcing strategies for biotech companies.

Key Learnings:

  • Strategic Outsourcing: Discover when and why outsourcing is crucial for biotech companies, particularly in areas like analytical work and process development. Learn how it can be a game-changer for companies of all sizes.
  • Critical Outsourcing Steps: Understand the pivotal role of analytics in confirming lab results and ensuring a robust process. Explore the importance of choosing the right outsourcing partner for scalability, from small bioreactors to larger manufacturing stages.
  • Balancing Control and Expertise: Uncover the delicate balance between keeping in-house control and leveraging the expertise of outsourcing partners. Gain insights into finding the sweet spot to achieve process understanding and cost efficiency.

Join us for a deep dive into the outsourcing landscape, unraveling the intricacies of selecting the right partner and ensuring a successful collaboration. Tune in and elevate your biotech game!

Connect with Bernardo Estupiñán Gaisbauer:

Website: www.drugbiologics.com/cdmoadvisor

Article: In Search Of The Unicorn: Do End-To-End C(x)DMOs Really Exist?: www.bioprocessonline.com/doc/in-search-of-the-unicorn-do-end-to-end-c-x-dmos-really-exist-0001

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14178674 Thu, 18 Jan 2024 05:00:00 +0100 1034 20 full false 19: How to Take Your Molecule From the Lab to Clinical Trials w/ Bernardo Estupiñán Gaisbauer - Part 1 19: How to Take Your Molecule From the Lab to Clinical Trials w/ Bernardo Estupiñán Gaisbauer - Part 1 Are you ready to unlock the secrets of taking your molecule from the lab to clinical trials?

Join us in an exclusive interview with Bernardo Estupiñán Gaisbauer, a seasoned expert and principal at Drug Biologics Consulting, as he reveals the crucial steps and strategies necessary for a successful journey in CMC development.

Biotech scientists often underestimate the challenges of transitioning a molecule from the lab into large-scale production. Bernardo emphasizes the critical importance of addressing Developability and Manufacturability early on.

Key Learnings:

  • Consider Developability and Manufacturability: The success of your biotech asset hinges on developing a scalable process and ensuring cost-effective manufacturing. Assessing these aspects early guides strategic decision-making.
  • Start Early: Bernardo stresses the need to consider crucial milestones from the moment you conceive a promising molecule. Avoid costly delays by initiating conversations with potential partners and service providers at the earliest stages.
  • Find a Balance for Regulatory Aspects: While regulatory considerations are crucial, Bernardo advises against premature obsession. Prioritize good laboratory and manufacturing practices initially, saving detailed regulatory planning for later stages.
Discover how to overcome challenges, optimize manufacturing, and navigate regulatory requirements. Don't miss out on this valuable opportunity to accelerate your biotech success!

Connect with Bernardo Estupiñán Gaisbauer:

Website: www.drugbiologics.com/cdmoadvisor

Article: In Search Of The Unicorn: Do End-To-End C(x)DMOs Really Exist?: www.bioprocessonline.com/doc/in-search-of-the-unicorn-do-end-to-end-c-x-dmos-really-exist-0001

Support the show

]]> Are you ready to unlock the secrets of taking your molecule from the lab to clinical trials?

Join us in an exclusive interview with Bernardo Estupiñán Gaisbauer, a seasoned expert and principal at Drug Biologics Consulting, as he reveals the crucial steps and strategies necessary for a successful journey in CMC development.

Biotech scientists often underestimate the challenges of transitioning a molecule from the lab into large-scale production. Bernardo emphasizes the critical importance of addressing Developability and Manufacturability early on.

Key Learnings:

  • Consider Developability and Manufacturability: The success of your biotech asset hinges on developing a scalable process and ensuring cost-effective manufacturing. Assessing these aspects early guides strategic decision-making.
  • Start Early: Bernardo stresses the need to consider crucial milestones from the moment you conceive a promising molecule. Avoid costly delays by initiating conversations with potential partners and service providers at the earliest stages.
  • Find a Balance for Regulatory Aspects: While regulatory considerations are crucial, Bernardo advises against premature obsession. Prioritize good laboratory and manufacturing practices initially, saving detailed regulatory planning for later stages.
Discover how to overcome challenges, optimize manufacturing, and navigate regulatory requirements. Don't miss out on this valuable opportunity to accelerate your biotech success!

Connect with Bernardo Estupiñán Gaisbauer:

Website: www.drugbiologics.com/cdmoadvisor

Article: In Search Of The Unicorn: Do End-To-End C(x)DMOs Really Exist?: www.bioprocessonline.com/doc/in-search-of-the-unicorn-do-end-to-end-c-x-dmos-really-exist-0001

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14178666 Tue, 16 Jan 2024 05:00:00 +0100 1177 19 full false 18: How Extracting Gold From Your Data Accelerates Process Development w/ Ioscani Jiménez del Val - Part 2 18: How Extracting Gold From Your Data Accelerates Process Development w/ Ioscani Jiménez del Val - Part 2 In part 2 of this interview with Ioscani, Assistant Professor at the School of Chemical & Bioprocess Engineering, University College Dublin, we delve into the art and science of accelerating process development through the strategic extraction of valuable insights from data.

Our guest, a seasoned expert in computational modeling, unfolds the intricate dance between quality by design principles and data-driven approaches.

Key takeaways from this insightful conversation include:

  • Optimizing with Confidence: Understand the input-output relationships qualitatively and quantitatively. Frame confidence spaces and align them with the design space for robust models.
  • Strategic Experimentation: Uncover the fine line between modeling and experimental work. Learn how to use computational models to design optimally informative experiments, saving both time and resources.
  • Balancing Act with Data: Navigate the delicate balance between adding value to model development programs and not overwhelming companies with excessive data demands.

Join us as we explore the transformative power of computational models in the biopharma sector, unlocking new possibilities for process optimization and efficiency.

Contact Ioscani Jiménez del Val:

Twitter: @UcdCell

LinkedIn: https://www.linkedin.com/in/ioscanij

Website: https://people.ucd.ie/ioscani.jimenezdelval

Support the show

]]> In part 2 of this interview with Ioscani, Assistant Professor at the School of Chemical & Bioprocess Engineering, University College Dublin, we delve into the art and science of accelerating process development through the strategic extraction of valuable insights from data.

Our guest, a seasoned expert in computational modeling, unfolds the intricate dance between quality by design principles and data-driven approaches.

Key takeaways from this insightful conversation include:

  • Optimizing with Confidence: Understand the input-output relationships qualitatively and quantitatively. Frame confidence spaces and align them with the design space for robust models.
  • Strategic Experimentation: Uncover the fine line between modeling and experimental work. Learn how to use computational models to design optimally informative experiments, saving both time and resources.
  • Balancing Act with Data: Navigate the delicate balance between adding value to model development programs and not overwhelming companies with excessive data demands.

Join us as we explore the transformative power of computational models in the biopharma sector, unlocking new possibilities for process optimization and efficiency.

Contact Ioscani Jiménez del Val:

Twitter: @UcdCell

LinkedIn: https://www.linkedin.com/in/ioscanij

Website: https://people.ucd.ie/ioscani.jimenezdelval

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14173468 Thu, 11 Jan 2024 05:00:00 +0100 838 18 full false 17: How Extracting Gold From Your Data Accelerates Process Development w/ Ioscani Jiménez del Val - Part 1 17: How Extracting Gold From Your Data Accelerates Process Development w/ Ioscani Jiménez del Val - Part 1 Join us as we unravel the complexities of computational methods in bioprocessing, featuring cutting-edge research on glycosylation and process development.

Ioscani Jiménez del Val, Assistant Professor at the School of Chemical & Bioprocess Engineering, University College Dublin, explores the intricacies of creating computational models, closing the loop, and optimizing with numerical methods.

Discover the two broad flavors of modeling – kinetic and metabolic models – and how they contribute to understanding cellular processes in bioreactors.

Key Learnings:

  • Closed Loop Optimization: Learn how closing the computational loop enhances model robustness, generating experimental data to refine kinetic parameters.
  • Modeling Variety: Explore different computational models, including kinetic models, metabolic models, and the rising trend of data-driven approaches for efficient bioprocess monitoring.
  • Hybrid Modeling: Uncover the power of hybrid models, combining mechanistic and data-driven approaches for a comprehensive understanding of your production process.

Experience the journey of innovation as we explore how the revolutionary process of extracting valuable insights from your data is transforming the field of bioprocessing. Tune in now for an enlightening conversation with our esteemed expert guest.

Contact Ioscani Jiménez del Val:

Twitter: @UcdCell

LinkedIn: https://www.linkedin.com/in/ioscanij

Website: https://people.ucd.ie/ioscani.jimenezdelval

Support the show

]]> Join us as we unravel the complexities of computational methods in bioprocessing, featuring cutting-edge research on glycosylation and process development.

Ioscani Jiménez del Val, Assistant Professor at the School of Chemical & Bioprocess Engineering, University College Dublin, explores the intricacies of creating computational models, closing the loop, and optimizing with numerical methods.

Discover the two broad flavors of modeling – kinetic and metabolic models – and how they contribute to understanding cellular processes in bioreactors.

Key Learnings:

  • Closed Loop Optimization: Learn how closing the computational loop enhances model robustness, generating experimental data to refine kinetic parameters.
  • Modeling Variety: Explore different computational models, including kinetic models, metabolic models, and the rising trend of data-driven approaches for efficient bioprocess monitoring.
  • Hybrid Modeling: Uncover the power of hybrid models, combining mechanistic and data-driven approaches for a comprehensive understanding of your production process.

Experience the journey of innovation as we explore how the revolutionary process of extracting valuable insights from your data is transforming the field of bioprocessing. Tune in now for an enlightening conversation with our esteemed expert guest.

Contact Ioscani Jiménez del Val:

Twitter: @UcdCell

LinkedIn: https://www.linkedin.com/in/ioscanij

Website: https://people.ucd.ie/ioscani.jimenezdelval

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14173431 Tue, 09 Jan 2024 05:00:00 +0100 1163 17 full false 16: Bacon Without Pigs? Innovations in Cultivated Meat Manufacturing with Beat Thalmann - Part 2 16: Bacon Without Pigs? Innovations in Cultivated Meat Manufacturing with Beat Thalmann - Part 2 In part 2, we explore the details of cost reduction in cultivated meat manufacturing, with a focus on two important factors: media and simplified bioreactors.

Beat Thalmann, a passionate innovator and serial entrepreneur specializing in the development of animal-free cell culture systems, highlights the strategic importance of selecting the right cells and advocates for a streamlined process that incorporates plant-based structures. This approach offers a cost-effective entry point for supermarkets.

Key Learnings:

  • Discover the challenges of adapting adherent media for meat cells in suspension culture.
  • Find out the most cost-effective approach that enables competitive pricing of cultivated meat products.
  • Understand why the future of cultivated meat lies in niche products, which offer additional options alongside traditional meat and plant-based alternatives.

Don't miss this engaging conversation that unlocks the future of sustainable and innovative meat production.

Connect with Beat Thalmann:

LinkedIn: https://www.linkedin.com/in/beatthalmann

Website: www.scinora.com

Support the show

]]> In part 2, we explore the details of cost reduction in cultivated meat manufacturing, with a focus on two important factors: media and simplified bioreactors.

Beat Thalmann, a passionate innovator and serial entrepreneur specializing in the development of animal-free cell culture systems, highlights the strategic importance of selecting the right cells and advocates for a streamlined process that incorporates plant-based structures. This approach offers a cost-effective entry point for supermarkets.

Key Learnings:

  • Discover the challenges of adapting adherent media for meat cells in suspension culture.
  • Find out the most cost-effective approach that enables competitive pricing of cultivated meat products.
  • Understand why the future of cultivated meat lies in niche products, which offer additional options alongside traditional meat and plant-based alternatives.

Don't miss this engaging conversation that unlocks the future of sustainable and innovative meat production.

Connect with Beat Thalmann:

LinkedIn: https://www.linkedin.com/in/beatthalmann

Website: www.scinora.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14147526 Thu, 21 Dec 2023 05:00:00 +0100 1196 16 full false 15: Bacon Without Pigs? Innovations in Cultivated Meat Manufacturing with Beat Thalmann - Part 1 15: Bacon Without Pigs? Innovations in Cultivated Meat Manufacturing with Beat Thalmann - Part 1 Is bacon without pigs the future? In this episode, join us as Beat Thalmann, a passionate innovator and serial entrepreneur specializing in the development of animal-free cell culture systems, unveils the exciting possibilities.

Discover how he overcomes the challenges of production and envisions a future where cultivated steak competes on price. Beat Thalmann provides an insider's perspective on the complexities of cell lines and production processes, exploring the intersection of biopharmaceuticals and cultivated meat.

Explore the innovative techniques companies are adopting, from rethinking bioreactors to recycling media, in their quest to bring affordable and sustainable alternatives to our plates.

You will Learn:

  1. Overcoming production challenges: Learn how you can tackle the hurdles in the development and scaling of cultivated meat production processes.
  2. Innovative techniques: Discover the cutting-edge approaches being employed by companies in the field, such as reimagining bioreactors and adopting media recycling practices.
  3. Strategies for Cost-Effective Scaling: Get a roadmap to achieving cost-effective processes, making cultivated meat a viable and affordable option for the future.

Tune in now to explore the future of bacon, steaks, and more – all without the need for traditional farming. It's a fascinating journey into the world of cultivated meat technology.

Connect with Beat Thalmann:

LinkedIn: https://www.linkedin.com/in/beatthalmann

Website: www.scinora.com

Support the show

]]> Is bacon without pigs the future? In this episode, join us as Beat Thalmann, a passionate innovator and serial entrepreneur specializing in the development of animal-free cell culture systems, unveils the exciting possibilities.

Discover how he overcomes the challenges of production and envisions a future where cultivated steak competes on price. Beat Thalmann provides an insider's perspective on the complexities of cell lines and production processes, exploring the intersection of biopharmaceuticals and cultivated meat.

Explore the innovative techniques companies are adopting, from rethinking bioreactors to recycling media, in their quest to bring affordable and sustainable alternatives to our plates.

You will Learn:

  1. Overcoming production challenges: Learn how you can tackle the hurdles in the development and scaling of cultivated meat production processes.
  2. Innovative techniques: Discover the cutting-edge approaches being employed by companies in the field, such as reimagining bioreactors and adopting media recycling practices.
  3. Strategies for Cost-Effective Scaling: Get a roadmap to achieving cost-effective processes, making cultivated meat a viable and affordable option for the future.

Tune in now to explore the future of bacon, steaks, and more – all without the need for traditional farming. It's a fascinating journey into the world of cultivated meat technology.

Connect with Beat Thalmann:

LinkedIn: https://www.linkedin.com/in/beatthalmann

Website: www.scinora.com

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14147494 Tue, 19 Dec 2023 05:00:00 +0100 1087 15 full false 14: Digital Transformation in Biomanufacturing: A Rapidly Moving Tech Frontier w/ Abhijeet Satwekar - Part 2 14: Digital Transformation in Biomanufacturing: A Rapidly Moving Tech Frontier w/ Abhijeet Satwekar - Part 2 Are you struggling to unlock the full potential of Process Analytical Technology (PAT) in biomanufacturing?

Look no further!

Join us for a game-changing conversation with Abhijeet Satwekar, an Innovation Manager at Merck Guidonia-Rome, Italy.

Discover how PAT can revolutionize your decision-making, accelerate development timelines, and propel your biotech company to new heights.

Key Learnings:

  1. Decoding PAT's Impact: Abhijeet provides unprecedented insights into how PAT technologies revolutionize decision-making in real-time, ensuring unparalleled control over manufacturing processes. Discover the race towards achieving real-time release and initiatives propelling patient-centric value.
  2. Fast-Tracking Development Timelines: Explore the potential of PAT in risk reduction by gaining step-by-step insights into process evolution. Uncover how comprehensive data capture can slash Quality Control testing lead times, potentially transforming weeks into mere days.
  3. Mastering PAT Implementation Strategies: Abhijeet advocates for simplicity in adopting PAT, commencing with a strategic voice-of-customer approach. Delve into critical process points, select PAT tools judiciously, and establish equivalence with traditional methods for seamless integration.

Get ready to harness the power of PAT and gain a competitive edge in the digital transformation of biomanufacturing.

Don't miss out on this opportunity to become a PAT expert and unlock endless possibilities for success!

Connect with Abhijeet Satwekar:

LinkedIn: https://www.linkedin.com/in/abhijeetsatwekar/

Support the show

]]> Are you struggling to unlock the full potential of Process Analytical Technology (PAT) in biomanufacturing?

Look no further!

Join us for a game-changing conversation with Abhijeet Satwekar, an Innovation Manager at Merck Guidonia-Rome, Italy.

Discover how PAT can revolutionize your decision-making, accelerate development timelines, and propel your biotech company to new heights.

Key Learnings:

  1. Decoding PAT's Impact: Abhijeet provides unprecedented insights into how PAT technologies revolutionize decision-making in real-time, ensuring unparalleled control over manufacturing processes. Discover the race towards achieving real-time release and initiatives propelling patient-centric value.
  2. Fast-Tracking Development Timelines: Explore the potential of PAT in risk reduction by gaining step-by-step insights into process evolution. Uncover how comprehensive data capture can slash Quality Control testing lead times, potentially transforming weeks into mere days.
  3. Mastering PAT Implementation Strategies: Abhijeet advocates for simplicity in adopting PAT, commencing with a strategic voice-of-customer approach. Delve into critical process points, select PAT tools judiciously, and establish equivalence with traditional methods for seamless integration.

Get ready to harness the power of PAT and gain a competitive edge in the digital transformation of biomanufacturing.

Don't miss out on this opportunity to become a PAT expert and unlock endless possibilities for success!

Connect with Abhijeet Satwekar:

LinkedIn: https://www.linkedin.com/in/abhijeetsatwekar/

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14115839 Thu, 14 Dec 2023 05:00:00 +0100 1028 14 full false 13: Digital Transformation in Biomanufacturing: A Rapidly Moving Tech Frontier w/ Abhijeet Satwekar - Part 1 13: Digital Transformation in Biomanufacturing: A Rapidly Moving Tech Frontier w/ Abhijeet Satwekar - Part 1 Wondering how you can leverage the immense potential of the rapidly evolving world of digital transformation in biomanufacturing?

Join us as we explore the frontiers of technology and innovation with Abhijeet Satwekar, Innovation Manager at Merck Healthcare.

Discover how cutting-edge digital technologies are revolutionizing bioprocesses, optimizing efficiency, and ensuring consistent product quality.

Key Learnings:

  1. Process Optimization: Discover the transformative impact of digital technologies on optimizing processes from small-scale studies to large-scale manufacturing, ensuring robustness and consistent product quality.
  2. Digital Twin and Efficiency: Explore the realm of digital twins, simulations, and business intelligence tools that revolutionize batch scheduling, planning, and overall bio-manufacturing efficiency.
  3. Balancing Innovation and Regulation: Understand the delicate balance between embracing new technologies and satisfying regulatory requirements. Abhijeet provides insights into maintaining confidence through a hybrid model that combines digital insights with traditional process analytical technology.

Tune in for a wealth of knowledge that transcends the boundaries of traditional and digital realms in the quest for groundbreaking biologics.

Connect with Abhijeet Satwekar:

LinkedIn: https://www.linkedin.com/in/abhijeetsatwekar/

Support the show

]]> Wondering how you can leverage the immense potential of the rapidly evolving world of digital transformation in biomanufacturing?

Join us as we explore the frontiers of technology and innovation with Abhijeet Satwekar, Innovation Manager at Merck Healthcare.

Discover how cutting-edge digital technologies are revolutionizing bioprocesses, optimizing efficiency, and ensuring consistent product quality.

Key Learnings:

  1. Process Optimization: Discover the transformative impact of digital technologies on optimizing processes from small-scale studies to large-scale manufacturing, ensuring robustness and consistent product quality.
  2. Digital Twin and Efficiency: Explore the realm of digital twins, simulations, and business intelligence tools that revolutionize batch scheduling, planning, and overall bio-manufacturing efficiency.
  3. Balancing Innovation and Regulation: Understand the delicate balance between embracing new technologies and satisfying regulatory requirements. Abhijeet provides insights into maintaining confidence through a hybrid model that combines digital insights with traditional process analytical technology.

Tune in for a wealth of knowledge that transcends the boundaries of traditional and digital realms in the quest for groundbreaking biologics.

Connect with Abhijeet Satwekar:

LinkedIn: https://www.linkedin.com/in/abhijeetsatwekar/

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14115796 Tue, 12 Dec 2023 05:00:00 +0100 1032 13 full false 12: From Lab to Patient: Steve Oh’s Guide to Mastering Cell Therapy Process Development - Part 2 12: From Lab to Patient: Steve Oh’s Guide to Mastering Cell Therapy Process Development - Part 2 Welcome back to the second part of our exclusive interview with Steve Oh, former Institute Professor at the Bioprocessing Technology Institute (BTI) at the Agency for Science and Technology (A*STAR) and now Scientific Advisor to several international companies.

In this episode, Steve dives deep into the challenges of manufacturing different cell types, sharing insights gained from his groundbreaking research. From preventing spontaneous differentiation to optimizing multi-stage processes, Steve unveils the complexities of mastering cell therapy development.

Key Takeaways:

  • Controlled Differentiation: Learn how Steve tackled the challenge of directed differentiation in a dynamic environment, ensuring cells follow the desired path without spontaneous deviations.
  • Scaling Up Strategies: Explore Steve's expertise in choosing the right culture conditions for cultivating various cell types at scale, emphasizing the importance of microcarriers and their impact on maintaining stable states.
  • Harvesting and Preservation: Delve into the critical aspects of harvesting cells and preserving their functionality. Discover innovative enzyme-based harvesting methods and the evolving landscape of cryopreservation beyond traditional DMSO.

Join us as Steve shares invaluable insights into the intricate world of cell therapy, offering a roadmap for developers and industry leaders alike. Don't miss this episode packed with expertise and practical advice.

Currently, Steve is an Scientific Advisor to several international companies involved in lentivirus & AAV manufacturing, cryopreservation solutions, biodegradable/edible microcarriers, novel gene delivery methods, cultured meat and stem cell manufacturing.

Connect with Steve Oh:

LinkedIn: https://www.linkedin.com/in/steve-oh-4946261/

Support the show

]]> Welcome back to the second part of our exclusive interview with Steve Oh, former Institute Professor at the Bioprocessing Technology Institute (BTI) at the Agency for Science and Technology (A*STAR) and now Scientific Advisor to several international companies.

In this episode, Steve dives deep into the challenges of manufacturing different cell types, sharing insights gained from his groundbreaking research. From preventing spontaneous differentiation to optimizing multi-stage processes, Steve unveils the complexities of mastering cell therapy development.

Key Takeaways:

  • Controlled Differentiation: Learn how Steve tackled the challenge of directed differentiation in a dynamic environment, ensuring cells follow the desired path without spontaneous deviations.
  • Scaling Up Strategies: Explore Steve's expertise in choosing the right culture conditions for cultivating various cell types at scale, emphasizing the importance of microcarriers and their impact on maintaining stable states.
  • Harvesting and Preservation: Delve into the critical aspects of harvesting cells and preserving their functionality. Discover innovative enzyme-based harvesting methods and the evolving landscape of cryopreservation beyond traditional DMSO.

Join us as Steve shares invaluable insights into the intricate world of cell therapy, offering a roadmap for developers and industry leaders alike. Don't miss this episode packed with expertise and practical advice.

Currently, Steve is an Scientific Advisor to several international companies involved in lentivirus & AAV manufacturing, cryopreservation solutions, biodegradable/edible microcarriers, novel gene delivery methods, cultured meat and stem cell manufacturing.

Connect with Steve Oh:

LinkedIn: https://www.linkedin.com/in/steve-oh-4946261/

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14070878 Thu, 07 Dec 2023 05:00:00 +0100 1044 12 full false 11: From Lab to Patient: Steve Oh’s Guide to Mastering Cell Therapy Process Development - Part 1 11: From Lab to Patient: Steve Oh’s Guide to Mastering Cell Therapy Process Development - Part 1 Dive into the world of cell therapy process development with Steve Oh, former Institute Professor at the Bioprocessing Technology Institute (BTI) at the Agency for Science and Technology (A*STAR) and now Scientific Advisor to several international companies, as he shares thought-provoking perspectives and predictions on technologies that will impact the biotech industry.

In this riveting conversation, Steve Oh unveils secrets to consistent bioproducts and forecasts the future of cell and gene therapy.

Gain a deeper understanding of the evolving landscape and the challenges and opportunities it presents.

Key Takeaways:

  1. The Power of Open Mindsets: Discover why carefully orchestrated listening ears lay the foundation for developing solutions in bioprocess development. Learn how avoiding predetermined views enhances the quality of conversations.
  2. Beyond Short-Term Goals: Uncover the downside of short-term thinking and how prioritizing long-term improvements can lead to substantial productivity gains. Steve delves into the balance between meeting financial deliverables and achieving lasting advancements.
  3. Process Development as a Pillar: Gain insights into why process development is a critical pillar in every biotech company's journey towards scaling. Steve emphasizes the significance of manufacturing consistent biological products and the need to educate scientists on the process's pivotal role.

Join the conversation as Steve Oh unfolds the intricate world of cell therapy process development, offering a roadmap from lab exploration to patient impact.

Currently, Steve is an Scientific Advisor to several international companies involved in lentivirus & AAV manufacturing, cryopreservation solutions, biodegradable/edible microcarriers, novel gene delivery methods, cultured meat and stem cell manufacturing.

Connect with Steve Oh:

LinkedIn: https://www.linkedin.com/in/steve-oh-4946261/

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Dive into the world of cell therapy process development with Steve Oh, former Institute Professor at the Bioprocessing Technology Institute (BTI) at the Agency for Science and Technology (A*STAR) and now Scientific Advisor to several international companies, as he shares thought-provoking perspectives and predictions on technologies that will impact the biotech industry.

In this riveting conversation, Steve Oh unveils secrets to consistent bioproducts and forecasts the future of cell and gene therapy.

Gain a deeper understanding of the evolving landscape and the challenges and opportunities it presents.

Key Takeaways:

  1. The Power of Open Mindsets: Discover why carefully orchestrated listening ears lay the foundation for developing solutions in bioprocess development. Learn how avoiding predetermined views enhances the quality of conversations.
  2. Beyond Short-Term Goals: Uncover the downside of short-term thinking and how prioritizing long-term improvements can lead to substantial productivity gains. Steve delves into the balance between meeting financial deliverables and achieving lasting advancements.
  3. Process Development as a Pillar: Gain insights into why process development is a critical pillar in every biotech company's journey towards scaling. Steve emphasizes the significance of manufacturing consistent biological products and the need to educate scientists on the process's pivotal role.

Join the conversation as Steve Oh unfolds the intricate world of cell therapy process development, offering a roadmap from lab exploration to patient impact.

Currently, Steve is an Scientific Advisor to several international companies involved in lentivirus & AAV manufacturing, cryopreservation solutions, biodegradable/edible microcarriers, novel gene delivery methods, cultured meat and stem cell manufacturing.

Connect with Steve Oh:

LinkedIn: https://www.linkedin.com/in/steve-oh-4946261/

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14070787 Tue, 05 Dec 2023 05:00:00 +0100 1572 11 full false 10: Revolutionizing Cell-Line Development: Unleashing the Power of Nanopens and Microenvironments w/ Tanner Nevill - Part 2 10: Revolutionizing Cell-Line Development: Unleashing the Power of Nanopens and Microenvironments w/ Tanner Nevill - Part 2 Unlock the secrets of cell-line development with Tanner Nevill, the SVP of Applications at Bruker Cellular Analysis and one of the primary inventors and developers of the Beacon Optofluidic Platform.

In this interview, Tanner delves into the transformative power of nanopens and microenvironments in cell-line development.

Key Takeaways:

  1. Nanopens Redefining Norms: Tanner introduces the game-changing nanopens, disrupting traditional cell line development. Learn how these innovative tools are reshaping the landscape and ushering in a new era of efficiency.
  2. AI's Impact on In Silico Discovery: Explore the future of cell-line development as Tanner discusses the integration of AI. Uncover how in silico discovery and engineering are poised to revolutionize processes, prompting a shift towards early functional testing and accelerated throughput.
  3. Strategies for Small Players: Gain insights into practical strategies for smaller companies seeking to enhance throughput and reduce cell-line development durations. Tanner emphasizes the importance of understanding cost dynamics and leveraging data-driven decision-making.

Join us as Tanner Nevill navigates the dynamic intersection of technology and life sciences, offering a glimpse into the evolving landscape of cell-line development.

Connect with Tanner Nevill:

For more on Tanner's insights and the revolutionary Beacon Optofluidic Platform, connect with him on LinkedIn or search for "beacon, CLD or CLD beacon."

LinkedIn: www.linkedin.com/in/tannernevill

Website: https://brukercellularanalysis.com/products/workflows/cell-line-development

Support the show

]]> Unlock the secrets of cell-line development with Tanner Nevill, the SVP of Applications at Bruker Cellular Analysis and one of the primary inventors and developers of the Beacon Optofluidic Platform.

In this interview, Tanner delves into the transformative power of nanopens and microenvironments in cell-line development.

Key Takeaways:

  1. Nanopens Redefining Norms: Tanner introduces the game-changing nanopens, disrupting traditional cell line development. Learn how these innovative tools are reshaping the landscape and ushering in a new era of efficiency.
  2. AI's Impact on In Silico Discovery: Explore the future of cell-line development as Tanner discusses the integration of AI. Uncover how in silico discovery and engineering are poised to revolutionize processes, prompting a shift towards early functional testing and accelerated throughput.
  3. Strategies for Small Players: Gain insights into practical strategies for smaller companies seeking to enhance throughput and reduce cell-line development durations. Tanner emphasizes the importance of understanding cost dynamics and leveraging data-driven decision-making.

Join us as Tanner Nevill navigates the dynamic intersection of technology and life sciences, offering a glimpse into the evolving landscape of cell-line development.

Connect with Tanner Nevill:

For more on Tanner's insights and the revolutionary Beacon Optofluidic Platform, connect with him on LinkedIn or search for "beacon, CLD or CLD beacon."

LinkedIn: www.linkedin.com/in/tannernevill

Website: https://brukercellularanalysis.com/products/workflows/cell-line-development

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14048248 Thu, 30 Nov 2023 05:00:00 +0100 951 10 full false 09: Revolutionizing Cell-Line Development: Unleashing the Power of Nanopens and Microenvironments w/ Tanner Nevill - Part 1 09: Revolutionizing Cell-Line Development: Unleashing the Power of Nanopens and Microenvironments w/ Tanner Nevill - Part 1 In this episode, Tanner Nevill, the SVP of Applications at Bruker Cellular Analysis and one of the primary inventors and developers of the Beacon Optofluidic Platform, shares insights into revolutionizing cell-line development through nanopens and microenvironments.

Key Takeaways:

  1. Challenging the Status Quo: Tanner challenges conventional thinking, highlighting the limitations of planar cell cultures and the shortcomings of traditional approaches in the field. His perspective sparks a conversation about the need for innovative thinking in bioprocess development.
  2. The Multidisciplinary Nature of Cell-Line Development: Tanner emphasizes the importance of multidisciplinary collaboration in the industry. He stresses that success in bioprocess development requires not only scientific expertise but also effective communication and teamwork across diverse disciplines.
  3. Critical Aspects for High Productivity Clones: The discussion explores the significance of microenvironments in cell-line development. Tanner introduces the concept of nanopens—tiny chambers that mimic bioreactor conditions, enabling precise screening and optimization for high productivity clones.

Join us as we uncover the dynamic intersection of science and engineering, challenging the norms in cell-line development.

Connect with Tanner Nevill:

LinkedIn: www.linkedin.com/in/tannernevill

Website: https://brukercellularanalysis.com/products/workflows/cell-line-development

Support the show

]]> In this episode, Tanner Nevill, the SVP of Applications at Bruker Cellular Analysis and one of the primary inventors and developers of the Beacon Optofluidic Platform, shares insights into revolutionizing cell-line development through nanopens and microenvironments.

Key Takeaways:

  1. Challenging the Status Quo: Tanner challenges conventional thinking, highlighting the limitations of planar cell cultures and the shortcomings of traditional approaches in the field. His perspective sparks a conversation about the need for innovative thinking in bioprocess development.
  2. The Multidisciplinary Nature of Cell-Line Development: Tanner emphasizes the importance of multidisciplinary collaboration in the industry. He stresses that success in bioprocess development requires not only scientific expertise but also effective communication and teamwork across diverse disciplines.
  3. Critical Aspects for High Productivity Clones: The discussion explores the significance of microenvironments in cell-line development. Tanner introduces the concept of nanopens—tiny chambers that mimic bioreactor conditions, enabling precise screening and optimization for high productivity clones.

Join us as we uncover the dynamic intersection of science and engineering, challenging the norms in cell-line development.

Connect with Tanner Nevill:

LinkedIn: www.linkedin.com/in/tannernevill

Website: https://brukercellularanalysis.com/products/workflows/cell-line-development

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14031043 Tue, 28 Nov 2023 05:00:00 +0100 846 9 full false 08: Unveiling the Power of Microcarriers: Scaling Up Adherent Cell Cultures in Bioprocessing w/ Payar Radfar - Part 2 08: Unveiling the Power of Microcarriers: Scaling Up Adherent Cell Cultures in Bioprocessing w/ Payar Radfar - Part 2 In the second part of our insightful interview with Payar Radfar, CEO of Smart MCs, we delve into the practical steps of developing adherence cell cultures for bioprocessing scalability.

Payar emphasizes the critical need for patience and a methodical approach, recounting how many clients rush into large-scale cultures prematurely. The key takeaways include:

1. Start Small, Stay Patient: Begin with small cultures and test various microcarriers. Patience is crucial; rushing can lead to ambiguous results and hinder long-term success.

2. Role of Modeling: Payar discusses the potential of AI modeling in scaling up processes. While AI can save time, he emphasizes the importance of a cautious, step-by-step approach.

3. Avoid Pitfalls: Highlighting the diverse nature of cell types, microcarriers, and bioreactors, Payar warns against assuming uniformity. Each component plays a crucial role, requiring careful consideration and gradual adjustments.

Join us as we explore future trends in bioprocessing, where Payar anticipates breakthroughs in media formulation and the use of novel technologies like microfluidics. Discover the broad applications beyond cellular therapies and cultivated meat, reaching into vaccine production and other cell-dependent fields.

Tune in now to gain invaluable insights into the dynamic world of adherence cell cultures and the promising future of bioprocessing innovation.

Connect with Payar Radfar:

Website: https://smartmcs.com.au/

LinkedIn: linkedin.com/company/smart-mcs

Twitter: twitter.com/SmartMCsPTYLTD

Support the show

]]> In the second part of our insightful interview with Payar Radfar, CEO of Smart MCs, we delve into the practical steps of developing adherence cell cultures for bioprocessing scalability.

Payar emphasizes the critical need for patience and a methodical approach, recounting how many clients rush into large-scale cultures prematurely. The key takeaways include:

1. Start Small, Stay Patient: Begin with small cultures and test various microcarriers. Patience is crucial; rushing can lead to ambiguous results and hinder long-term success.

2. Role of Modeling: Payar discusses the potential of AI modeling in scaling up processes. While AI can save time, he emphasizes the importance of a cautious, step-by-step approach.

3. Avoid Pitfalls: Highlighting the diverse nature of cell types, microcarriers, and bioreactors, Payar warns against assuming uniformity. Each component plays a crucial role, requiring careful consideration and gradual adjustments.

Join us as we explore future trends in bioprocessing, where Payar anticipates breakthroughs in media formulation and the use of novel technologies like microfluidics. Discover the broad applications beyond cellular therapies and cultivated meat, reaching into vaccine production and other cell-dependent fields.

Tune in now to gain invaluable insights into the dynamic world of adherence cell cultures and the promising future of bioprocessing innovation.

Connect with Payar Radfar:

Website: https://smartmcs.com.au/

LinkedIn: linkedin.com/company/smart-mcs

Twitter: twitter.com/SmartMCsPTYLTD

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-14003337 Thu, 23 Nov 2023 05:00:00 +0100 792 8 full false 07: Unveiling the Power of Microcarriers: Scaling Up Adherent Cell Cultures in Bioprocessing w/ Payar Radfar - Part 1 07: Unveiling the Power of Microcarriers: Scaling Up Adherent Cell Cultures in Bioprocessing w/ Payar Radfar - Part 1 In this episode, we explore the world of adherent cell cultures with Payar Radfar, CEO of Smart MCs. Smart MCs specializes in customized biomaterials and microfluidic solutions. Payar shares his unique journey in the biotech industry, driven by his passion for improving people's health.

Key Takeaways:

1. Revolutionizing Bioprocessing: Payar discusses the challenges scientists face when transitioning from lab-scale to industrial-scale production. He emphasizes the importance of a multidisciplinary approach and envisions his company playing a crucial role in simplifying and enhancing bioprocessing technologies.

2. Cost Challenges in Cellular Therapies: Payar addresses the high costs associated with cellular therapies and explores the barriers to wider distribution. He highlights the role of competition and regulations in reducing costs and increasing accessibility to these therapies.

3. The Power of Microcarriers: The technical discussion focuses on microcarriers and their vital role in adherent cell cultures. Payar explains how these microscopic spheres enable efficient scaling up of cell production in bioreactors, offering a glimpse into the future of bioprocessing.

Are you curious about the transformative potential of microcarriers and the future of bioprocessing?

Join us in this insightful conversation with Payar Radfar as we uncover the secrets behind scaling up adherent cell cultures and their profound impact on the biotech industry.

Connect with Payar Radfar:

Website: https://smartmcs.com.au/

LinkedIn: linkedin.com/company/smart-mcs

Twitter: twitter.com/SmartMCsPTYLTD

Support the show

]]> In this episode, we explore the world of adherent cell cultures with Payar Radfar, CEO of Smart MCs. Smart MCs specializes in customized biomaterials and microfluidic solutions. Payar shares his unique journey in the biotech industry, driven by his passion for improving people's health.

Key Takeaways:

1. Revolutionizing Bioprocessing: Payar discusses the challenges scientists face when transitioning from lab-scale to industrial-scale production. He emphasizes the importance of a multidisciplinary approach and envisions his company playing a crucial role in simplifying and enhancing bioprocessing technologies.

2. Cost Challenges in Cellular Therapies: Payar addresses the high costs associated with cellular therapies and explores the barriers to wider distribution. He highlights the role of competition and regulations in reducing costs and increasing accessibility to these therapies.

3. The Power of Microcarriers: The technical discussion focuses on microcarriers and their vital role in adherent cell cultures. Payar explains how these microscopic spheres enable efficient scaling up of cell production in bioreactors, offering a glimpse into the future of bioprocessing.

Are you curious about the transformative potential of microcarriers and the future of bioprocessing?

Join us in this insightful conversation with Payar Radfar as we uncover the secrets behind scaling up adherent cell cultures and their profound impact on the biotech industry.

Connect with Payar Radfar:

Website: https://smartmcs.com.au/

LinkedIn: linkedin.com/company/smart-mcs

Twitter: twitter.com/SmartMCsPTYLTD

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-13972803 Tue, 21 Nov 2023 05:00:00 +0100 983 7 full true 06: Hybrid Modeling: The Key to Smarter Bioprocessing w/ Michael Sokolov - Part 2 06: Hybrid Modeling: The Key to Smarter Bioprocessing w/ Michael Sokolov - Part 2 In the second part of our conversation with Michael Sokolov, the co-founder and COO of DataHow, we dive into practical insights on leveraging hybrid modeling in bioprocessing.

You will discover:

1. Starting Small, Dreaming Big: Even in smaller companies, you can start with a minimal number of reactors and still leverage hybrid modeling effectively. Whether it's just a few shakers or a handful of bioreactors, you can begin the journey to process improvement.

2. The Power of Digital Twins: Michael sheds light on the concept of digital twins, which involves creating a real-time model of your bioprocess. It not only helps optimize the process but also enables feedback control, reducing manual operations and adapting to changes on the fly.

3. Regulatory Acceptance: While the pharmaceutical industry is known for its conservatism, regulators are becoming more receptive to innovative technologies like hybrid modeling. Health authorities are encouraging the use of promising tools in process development and are not imposing specific technologies. As more companies adopt these tools and gather data on their effectiveness, they are likely to play a more prominent role in regulatory filings.

Don't miss out on this insightful discussion with Michael Sokolov as he unravels the potential of hybrid modeling in bioprocessing. If you're looking to simplify and streamline your bioprocessing journey, this episode is a must-listen.

Connect with Michael Sokolov:

Website: www.datahow.ch

Support the show

]]> In the second part of our conversation with Michael Sokolov, the co-founder and COO of DataHow, we dive into practical insights on leveraging hybrid modeling in bioprocessing.

You will discover:

1. Starting Small, Dreaming Big: Even in smaller companies, you can start with a minimal number of reactors and still leverage hybrid modeling effectively. Whether it's just a few shakers or a handful of bioreactors, you can begin the journey to process improvement.

2. The Power of Digital Twins: Michael sheds light on the concept of digital twins, which involves creating a real-time model of your bioprocess. It not only helps optimize the process but also enables feedback control, reducing manual operations and adapting to changes on the fly.

3. Regulatory Acceptance: While the pharmaceutical industry is known for its conservatism, regulators are becoming more receptive to innovative technologies like hybrid modeling. Health authorities are encouraging the use of promising tools in process development and are not imposing specific technologies. As more companies adopt these tools and gather data on their effectiveness, they are likely to play a more prominent role in regulatory filings.

Don't miss out on this insightful discussion with Michael Sokolov as he unravels the potential of hybrid modeling in bioprocessing. If you're looking to simplify and streamline your bioprocessing journey, this episode is a must-listen.

Connect with Michael Sokolov:

Website: www.datahow.ch

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-13941399 Thu, 16 Nov 2023 05:00:00 +0100 1158 6 full false 05: Hybrid Modeling: The Key to Smarter Bioprocessing w/ Michael Sokolov - Part 1 05: Hybrid Modeling: The Key to Smarter Bioprocessing w/ Michael Sokolov - Part 1 In this insightful conversation, we explore how to accelerate bioprocess development and enhance manufacturing using hybrid modeling. Our guest, Michael Sokolov, COO of DataHow (a spin-off company from ETH Zurich), shares valuable insights.

Discover the three major takeaways that could transform the bioprocessing industry:

1. Unlocking the Power of Hybrid Modeling: Michael Sokolov introduces the revolutionary concept of hybrid modeling, which combines mechanistic knowledge with machine learning to expedite bioprocess development.

2. Accelerating Process Development: Learn how hybrid modeling can speed up your bioprocessing efforts, potentially allowing you to reduce the number of experiments by 60-80%, saving valuable time and resources.

3. Data-Driven Decision Making: Gain insights into how this approach enables data-driven decision making in the unpredictable world of biotech. It provides a deep understanding and empowers scientists to make informed choices.

Don't miss this episode for a comprehensive guide to smarter and more efficient bioprocessing!

Connect with Michael Sokolov:

Website: www.datahow.ch

Support the show

]]> In this insightful conversation, we explore how to accelerate bioprocess development and enhance manufacturing using hybrid modeling. Our guest, Michael Sokolov, COO of DataHow (a spin-off company from ETH Zurich), shares valuable insights.

Discover the three major takeaways that could transform the bioprocessing industry:

1. Unlocking the Power of Hybrid Modeling: Michael Sokolov introduces the revolutionary concept of hybrid modeling, which combines mechanistic knowledge with machine learning to expedite bioprocess development.

2. Accelerating Process Development: Learn how hybrid modeling can speed up your bioprocessing efforts, potentially allowing you to reduce the number of experiments by 60-80%, saving valuable time and resources.

3. Data-Driven Decision Making: Gain insights into how this approach enables data-driven decision making in the unpredictable world of biotech. It provides a deep understanding and empowers scientists to make informed choices.

Don't miss this episode for a comprehensive guide to smarter and more efficient bioprocessing!

Connect with Michael Sokolov:

Website: www.datahow.ch

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-13941341 Tue, 14 Nov 2023 05:00:00 +0100 1017 5 full false 04: How to Master Biotech Scale-up Without Guesswork w/ Leonardo Sibilio - Part 2 04: How to Master Biotech Scale-up Without Guesswork w/ Leonardo Sibilio - Part 2 In today's episode, we continue our fascinating conversation with Leonardo Sibilio, CEO of Biotech Academy and CSO at BetaPro Consulting. We delve into the pivotal role of structured training in the dynamic biotech industry.

In this episode, you'll discover:

- Foundation of Success: Leonardo emphasizes the importance of a strong foundation in GMP and an understanding of biotech facility operations. Whether you're an aspiring employee or a seasoned professional, a solid knowledge base in these areas is the cornerstone of a successful career.

- Broaden Your Horizons: Biotech is a multifaceted industry. Leonardo advises listeners to be curious and embrace a wide range of skills. You'll thrive by gaining expertise in both upstream and downstream processes, as well as analytical methods. This adaptability is key to succeeding in today's rapidly evolving biotech landscape.

- Continuous Learning: In the ever-changing world of biotech, continuous learning is vital. Leonardo recommends staying updated with technical literature, online courses, and hands-on training. To excel, it's crucial to master the practical aspects of bioreactor assembly, autoclaving, and equipment operation.

Join Leonardo as he explores the exciting opportunities in biotech, and find out how to enhance your expertise.

If you're passionate about biotech and eager to take your career to new heights, this episode is a must-listen! Don't miss out on the valuable insights Leonardo shares on mastering biotech scale-up. Tune in now!

Connect with Leonardo Sibilio:

LinkedIn: www.linkedin.com/in/leonardo-sibilio-9bb26320

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> In today's episode, we continue our fascinating conversation with Leonardo Sibilio, CEO of Biotech Academy and CSO at BetaPro Consulting. We delve into the pivotal role of structured training in the dynamic biotech industry.

In this episode, you'll discover:

- Foundation of Success: Leonardo emphasizes the importance of a strong foundation in GMP and an understanding of biotech facility operations. Whether you're an aspiring employee or a seasoned professional, a solid knowledge base in these areas is the cornerstone of a successful career.

- Broaden Your Horizons: Biotech is a multifaceted industry. Leonardo advises listeners to be curious and embrace a wide range of skills. You'll thrive by gaining expertise in both upstream and downstream processes, as well as analytical methods. This adaptability is key to succeeding in today's rapidly evolving biotech landscape.

- Continuous Learning: In the ever-changing world of biotech, continuous learning is vital. Leonardo recommends staying updated with technical literature, online courses, and hands-on training. To excel, it's crucial to master the practical aspects of bioreactor assembly, autoclaving, and equipment operation.

Join Leonardo as he explores the exciting opportunities in biotech, and find out how to enhance your expertise.

If you're passionate about biotech and eager to take your career to new heights, this episode is a must-listen! Don't miss out on the valuable insights Leonardo shares on mastering biotech scale-up. Tune in now!

Connect with Leonardo Sibilio:

LinkedIn: www.linkedin.com/in/leonardo-sibilio-9bb26320

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-13926791 Thu, 09 Nov 2023 05:00:00 +0100 833 4 full false 03: How to Master Biotech Scale-up Without Guesswork w/ Leonardo Sibilio - Part 1 03: How to Master Biotech Scale-up Without Guesswork w/ Leonardo Sibilio - Part 1 In this captivating episode, we delve into the world of biotech scale-up with the seasoned expert, Leonardo Sibilio, CSO at BetaPro Consulting and CEO of the Biotech Academy in Rome.

Discover how mastering the art of biotech scale-up can transform your journey from doubt to dominance.

Key Takeaways:

1. Early Planning is Paramount: Leonardo emphasizes the importance of initiating the scale-up process as early as possible. Waiting until later phases can lead to challenges and hinder progress. Early planning, including characterizing the cell line and ensuring stability, is key to a seamless transition from R&D to large-scale production.

2. Mindset Shift is Crucial: Successful scale-up requires a shift in mindset, especially for startups originating from academia. Transitioning from research to regulated environments demands precision, rigorous documentation, and an unwavering focus on producing life-changing medicines.

3. Embrace Learning and Structured Processes: Leonardo encourages the use of structured methodologies and tools like R or Python for better data analysis and visualization. Structured documentation and reporting are critical for regulatory compliance and efficient tech transfer.

Join us as we explore the challenges, pitfalls, and strategies of biotech scale-up, unlocking the secrets to mastering it without guesswork.

Whether you're a seasoned professional or new to the field, this episode provides valuable insights for anyone interested in bioprocess scale-up and commercialization.

Connect with Leonardo Sibilio:

LinkedIn: www.linkedin.com/in/leonardo-sibilio-9bb26320

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> In this captivating episode, we delve into the world of biotech scale-up with the seasoned expert, Leonardo Sibilio, CSO at BetaPro Consulting and CEO of the Biotech Academy in Rome.

Discover how mastering the art of biotech scale-up can transform your journey from doubt to dominance.

Key Takeaways:

1. Early Planning is Paramount: Leonardo emphasizes the importance of initiating the scale-up process as early as possible. Waiting until later phases can lead to challenges and hinder progress. Early planning, including characterizing the cell line and ensuring stability, is key to a seamless transition from R&D to large-scale production.

2. Mindset Shift is Crucial: Successful scale-up requires a shift in mindset, especially for startups originating from academia. Transitioning from research to regulated environments demands precision, rigorous documentation, and an unwavering focus on producing life-changing medicines.

3. Embrace Learning and Structured Processes: Leonardo encourages the use of structured methodologies and tools like R or Python for better data analysis and visualization. Structured documentation and reporting are critical for regulatory compliance and efficient tech transfer.

Join us as we explore the challenges, pitfalls, and strategies of biotech scale-up, unlocking the secrets to mastering it without guesswork.

Whether you're a seasoned professional or new to the field, this episode provides valuable insights for anyone interested in bioprocess scale-up and commercialization.

Connect with Leonardo Sibilio:

LinkedIn: www.linkedin.com/in/leonardo-sibilio-9bb26320

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-13886852 Tue, 07 Nov 2023 05:00:00 +0100 1058 3 full false 02: Unlock the Power of Rational Media Design in Bioprocessing w/ Tom Fletcher - Part 2 02: Unlock the Power of Rational Media Design in Bioprocessing w/ Tom Fletcher - Part 2 Welcome to a fascinating Smart Biotech Scientist episode! In this conversation, we dive deep into the nuts and bolts of rational media development with our guest, Tom Fletcher, R&D Director, Process development, Fujifilm Irvine Scientific.

Together, we explore the immense potential of Rational Media Design and how it's transforming the industry.

Here are three major takeaways from this episode:

1. Define Your Goals: Tom emphasizes the importance of clearly defining your bioprocessing goals. Whether it's boosting cell growth or enhancing product quality, understanding your specific needs is the first crucial step.

2. Gain Process Understanding: Learn how to identify limiting factors in your process and generate hypotheses. Tom discusses how thinking through biochemical pathways and potential bottlenecks is key to achieving your goals.

3. Leverage Automation: Discover the future of bioprocessing with automated, closed systems that eliminate human intervention and ensure consistent, sterile media preparation. Tom shares insights into groundbreaking innovations that simplify and streamline the process.

Join us in unraveling the science behind bioprocessing and unlock the power of rational media design in this episode.

Don't miss out on the knowledge that could revolutionize your bioprocessing journey!

Connect with Tom Fletcher:

LinkedIn: https://www.linkedin.com/in/tomfletcher2

Fujifilm Irvine Scientific: https://www.irvinesci.com

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> Welcome to a fascinating Smart Biotech Scientist episode! In this conversation, we dive deep into the nuts and bolts of rational media development with our guest, Tom Fletcher, R&D Director, Process development, Fujifilm Irvine Scientific.

Together, we explore the immense potential of Rational Media Design and how it's transforming the industry.

Here are three major takeaways from this episode:

1. Define Your Goals: Tom emphasizes the importance of clearly defining your bioprocessing goals. Whether it's boosting cell growth or enhancing product quality, understanding your specific needs is the first crucial step.

2. Gain Process Understanding: Learn how to identify limiting factors in your process and generate hypotheses. Tom discusses how thinking through biochemical pathways and potential bottlenecks is key to achieving your goals.

3. Leverage Automation: Discover the future of bioprocessing with automated, closed systems that eliminate human intervention and ensure consistent, sterile media preparation. Tom shares insights into groundbreaking innovations that simplify and streamline the process.

Join us in unraveling the science behind bioprocessing and unlock the power of rational media design in this episode.

Don't miss out on the knowledge that could revolutionize your bioprocessing journey!

Connect with Tom Fletcher:

LinkedIn: https://www.linkedin.com/in/tomfletcher2

Fujifilm Irvine Scientific: https://www.irvinesci.com

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-13886819 Tue, 07 Nov 2023 05:00:00 +0100 1040 2 full false 01: Unlock the Power of Rational Media Design in Bioprocessing w/ Tom Fletcher - Part 1 01: Unlock the Power of Rational Media Design in Bioprocessing w/ Tom Fletcher - Part 1 In this episode with Tom Fletcher, R&D Director, Process development, Fujifilm Irvine Scientific, we delve into the world of bioprocessing. Tom shares insights into the transformative power of rational media design.

From the complexities of bioprocess development to the game-changing potential of AI, this interview is a treasure trove of knowledge for both scientists and engineers.

You will learn:

- Learn about the evolution of priorities during bioprocess development, from speed to reliability, and how scientists must adapt accordingly.

- Discover the importance of a thoughtful, hypothesis-driven approach compared to a blind, random one, and how it can reveal valuable process knowledge.

- Explore the exciting future of bioprocessing, including the role of AI and in silico models, and the importance of combining technology with human reasoning.

Tune in to gain a deeper understanding of the critical role that rational media design plays in advancing the biotech industry.

Connect with Tom Fletcher:

LinkedIn: https://www.linkedin.com/in/tomfletcher2

Fujifilm Irvine Scientific: https://www.irvinesci.com

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> In this episode with Tom Fletcher, R&D Director, Process development, Fujifilm Irvine Scientific, we delve into the world of bioprocessing. Tom shares insights into the transformative power of rational media design.

From the complexities of bioprocess development to the game-changing potential of AI, this interview is a treasure trove of knowledge for both scientists and engineers.

You will learn:

- Learn about the evolution of priorities during bioprocess development, from speed to reliability, and how scientists must adapt accordingly.

- Discover the importance of a thoughtful, hypothesis-driven approach compared to a blind, random one, and how it can reveal valuable process knowledge.

- Explore the exciting future of bioprocessing, including the role of AI and in silico models, and the importance of combining technology with human reasoning.

Tune in to gain a deeper understanding of the critical role that rational media design plays in advancing the biotech industry.

Connect with Tom Fletcher:

LinkedIn: https://www.linkedin.com/in/tomfletcher2

Fujifilm Irvine Scientific: https://www.irvinesci.com

Next step:

Book a free consultation to help you get started on any questions you may have about bioprocess development: https://bruehlmann-consulting.com/call

Free 5-day email course, The CMC Failure Chain: the five recurring CMC mistakes that put your promising program at risk → Get it here

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-13863116 Tue, 07 Nov 2023 05:00:00 +0100 1106 1 full false Biotech Simplified: Your Path to Bioprocess Mastery Unveiled (Trailer) Biotech Simplified: Your Path to Bioprocess Mastery Unveiled (Trailer) Are you a busy biotech scientist, trying to navigate the complex world of bioprocessing while fueling your passion for science? Join us on the Smart Biotech Scientist Podcast, where we're about to unravel the secrets to bioprocess mastery.

Hosted by a seasoned biotech leader and entrepreneur with over 15 years in the industry, this podcast is your compass through the maze of challenges. Picture yourself in the lab, deadlines looming, feeling like you're solving a puzzle with missing pieces. We've been there, too.

In this podcast, we simplify the journey to bioprocess mastery, providing practical solutions, deep dives into analytics, and inspiring conversations with biotech leaders. Imagine gaining insights from industry experts and belonging to a supportive community that fuels your growth.

Get ready for stories that resonate, solutions that empower, and questions that pique your curiosity. Don’t miss out!

►► Subscribe now, with new episodes dropping every Tuesday and Thursday.

Reignite your passion for science as we tackle challenges and simplify bioprocessing together. Join us on this exciting adventure!

Support the show

]]> Are you a busy biotech scientist, trying to navigate the complex world of bioprocessing while fueling your passion for science? Join us on the Smart Biotech Scientist Podcast, where we're about to unravel the secrets to bioprocess mastery.

Hosted by a seasoned biotech leader and entrepreneur with over 15 years in the industry, this podcast is your compass through the maze of challenges. Picture yourself in the lab, deadlines looming, feeling like you're solving a puzzle with missing pieces. We've been there, too.

In this podcast, we simplify the journey to bioprocess mastery, providing practical solutions, deep dives into analytics, and inspiring conversations with biotech leaders. Imagine gaining insights from industry experts and belonging to a supportive community that fuels your growth.

Get ready for stories that resonate, solutions that empower, and questions that pique your curiosity. Don’t miss out!

►► Subscribe now, with new episodes dropping every Tuesday and Thursday.

Reignite your passion for science as we tackle challenges and simplify bioprocessing together. Join us on this exciting adventure!

Support the show

]]> David Brühlmann: Biotech Entrepreneur & Cell Culture Technology Innovation Aficionado Buzzsprout-13837643 Tue, 31 Oct 2023 05:00:00 +0100 154 busy biotech scientist, bioprocess mastery, biotech experts, bioprocess technology, data analytics, visionary industry leaders, industry trends, practical solutions, journey to bioprocess mastery, seasoned biotech leader, science passion, simplify biopr trailer false